<SEC-DOCUMENT>0001654954-25-000288.txt : 20250113
<SEC-HEADER>0001654954-25-000288.hdr.sgml : 20250113
<ACCEPTANCE-DATETIME>20250113161633
ACCESSION NUMBER:		0001654954-25-000288
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		86
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20250113
DATE AS OF CHANGE:		20250113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		25526551

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>cvm_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:cvm="http://cvm.com/20240930"><head><title>cvm_10k.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html"/></head><body style="text-align:justify;font:10pt times new roman"><div style="display:none;text-align:justify;font:10pt times new roman;" id="XBRLDIV"><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2023-10-01to2024-09-30" id="ixv-16398">0000725363</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2023-10-01to2024-09-30" format="ixt:booleanfalse" id="ixv-16399">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="From2023-10-01to2024-09-30" id="ixv-16400">No</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="From2023-10-01to2024-09-30" id="ixv-16401">--09-30</ix:nonNumeric><ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="From2023-10-01to2024-09-30" id="ixv-16402">No</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="From2023-10-01to2024-09-30" id="ixv-16403">FY</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="From2023-10-01to2024-09-30" id="ixv-16404">2024</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFinStmtErrorCorrectionFlag" contextRef="From2023-10-01to2024-09-30" format="ixt:booleanfalse" id="ixv-16405">false</ix:nonNumeric><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30" unitRef="USDPShares" decimals="INF" id="ixv-16406">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-09-30" unitRef="Shares" decimals="0" id="ixv-16407">600000000</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-09-30" unitRef="Shares" decimals="0" id="ixv-16408">63787104</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-09-30" unitRef="Shares" decimals="0" id="ixv-16409">47422304</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30" unitRef="USDPShares" decimals="INF" id="ixv-16410">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-09-30" unitRef="Shares" decimals="0" id="ixv-16411">200000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-09-30" unitRef="Shares" decimals="0" id="ixv-16412">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-09-30" unitRef="Shares" decimals="0" id="ixv-16413">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-09-30" unitRef="Shares" decimals="0" id="ixv-16414">0</ix:nonFraction><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-09-30" unitRef="USD" decimals="0" id="ixv-16415">250000</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-10-01to2023-09-30" unitRef="Pure" decimals="INF" id="ixv-16416">0</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-10-01to2024-09-30" unitRef="Pure" decimals="INF" id="ixv-16417">0</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-10-01to2024-09-30_cvm_OutstandingMember" unitRef="USDPShares" decimals="INF" id="ixv-16418">0</ix:nonFraction><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-10-01to2024-09-30_cvm_ExercisableMember" unitRef="USDPShares" decimals="INF" id="ixv-16419">0</ix:nonFraction><ix:nonFraction name="cvm:EmployeeContributionsToDefinedContributionPlans" contextRef="From2022-10-01to2023-09-30" unitRef="USD" decimals="0" id="ixv-16420">10000</ix:nonFraction><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2022-10-01to2023-09-30_us-gaap_LeaseAgreementsMember" unitRef="USD" decimals="0" id="ixv-16421">1800000.0</ix:nonFraction><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-10-01to2023-09-30_us-gaap_LeaseAgreementsMember" unitRef="USD" decimals="0" id="ixv-16422">1800000.0</ix:nonFraction><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-09-30_us-gaap_OperatingExpenseMember" unitRef="USD" decimals="0" id="ixv-16423">200000.0</ix:nonFraction><ix:nonFraction name="us-gaap:OtherExpenses" contextRef="From2022-10-01to2023-09-30_us-gaap_OperatingExpenseMember" unitRef="USD" decimals="0" id="ixv-16424">400000.0</ix:nonFraction><ix:nonFraction name="cvm:RestrictedCommonStockSharesIssued" contextRef="From2022-10-01to2023-09-30_cvm_OfficerAndDirectorMember" unitRef="USD" decimals="0" id="ixv-16425">0</ix:nonFraction><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-10-01to2023-09-30_cvm_OfficerAndDirectorMember" unitRef="USD" decimals="0" id="ixv-16426">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cvm-20240930.xsd"/></ix:references><ix:resources><xbrli:context id="From2023-10-01to2024-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-10-01to2024-10-18_us-gaap_SubsequentEventMember_cvm_ErgomedGroupMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ErgomedGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-12-01to2024-12-31_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-12-31_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_UnvestedRestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_UnvestedRestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_OptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_OptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_CostMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">cvm:CostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_CostMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">cvm:CostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_CostMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">cvm:CostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_CostMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">cvm:CostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_FairValueMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:FairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_FairValueMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:FairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_FairValueMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:FairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_FairValueMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:FairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_EquityProceedsFromSaleCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">cvm:EquityProceedsFromSaleCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-02-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-11-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-07-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-11-01to2023-11-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-02-01to2024-02-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_EquityProceedsFromSaleCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">cvm:EquityProceedsFromSaleCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-07-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_SeriesRRWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-05-01to2024-05-04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-07-11_cvm_CEOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:CEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_OfficerAndDirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:OfficerAndDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_OfficerAndDirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:OfficerAndDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2024-07-01to2024-07-18_cvm_CEOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:CEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-01-01to2023-01-11_cvm_LandlordMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvm:LandlordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_OperatingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_us-gaap_OperatingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_us-gaap_OperatingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_us-gaap_OperatingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_LeaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_us-gaap_LeaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_us-gaap_LeaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_us-gaap_LeaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_ErgomedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_NonQualifiedStockOptionsPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_NonQualifiedStockOptionsPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_NonQualifiedStockOptionsPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_IncentiveStockBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:IncentiveStockBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_IncentiveStockOptionPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:IncentiveStockOptionPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_NonQualifiedStockOptionsPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_StockCompensationPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:StockCompensationPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_IncentiveStockBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:IncentiveStockBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_IncentiveStockBonusPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:IncentiveStockBonusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_StockBonusPlansMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:StockBonusPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_NonVestedOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonVestedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_RestrictedStockAwardsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:RestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_RestrictedStockAwardsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:RestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_RestrictedStockAwardsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:RestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_cvm_RestrictedStockAwardsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:RestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_RestrictedStockAwardsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:RestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_ExercisableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_ExercisableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_ExercisableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_ExercisableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_cvm_ExercisableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_OutstandingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_OutstandingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_OutstandingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_OutstandingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_cvm_OutstandingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_NonEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_NonEmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_EmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_EmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_IncomeTaxMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">cvm:IncomeTaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_IncomeTaxMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">cvm:IncomeTaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_IncomeTaxMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">cvm:IncomeTaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_TopMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:TopMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_BottomMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:BottomMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_ConsultingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember_cvm_TopMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:TopMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember_cvm_TopMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:TopMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember_cvm_TwoSeptemberTwoThousendTwentyFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:TwoSeptemberTwoThousendTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember_cvm_TwoSeptemberTwoThousendTwentyFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:TwoSeptemberTwoThousendTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_SeriesSSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesSSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_ConsultantsMember_cvm_BottomMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:BottomMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_ConsultantsOneMember_cvm_TopMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:TopMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_ConsultantsOneMember_cvm_TopMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:TopMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_ConsultantsMember_cvm_BottomMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:BottomMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_ConsultantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_SeriesNNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_SeriesMMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesMMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_SeriesUUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesUUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_cvm_SeriesNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_ConsultantsOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_SeriesNNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_SeriesMMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesMMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_SeriesUUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesUUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_cvm_SeriesNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_ConsultantsMember_cvm_BottomMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:BottomMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_SeriesNNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_SeriesMMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesMMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_ConsultantsOneMember_cvm_TopMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:TopMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_ConsultantsOneMember_cvm_TopMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:TopMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_SeriesUUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesUUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_SeriesNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_ConsultantsMember_cvm_BottomMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:BottomMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_SeriesRRMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesRRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_SeriesNNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_SeriesMMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesMMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_SeriesYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_SeriesXMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_cvm_SeriesUUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesUUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_cvm_SeriesNMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-01to2022-09-30_us-gaap_PatentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2023-10-01to2024-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2022-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2022-10-01to2023-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2023-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2025-01-06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-01-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2024-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; &#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span style="font-size:18pt"><strong>FORM <ix:nonNumeric name="dei:DocumentType" contextRef="From2023-10-01to2024-09-30" id="ixv-17541">10-K</ix:nonNumeric></strong></span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Mark One)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"><ix:nonNumeric name="dei:DocumentAnnualReport" contextRef="From2023-10-01to2024-09-30" format="ixt-sec:boolballotbox" id="ixv-17542">&#9746;</ix:nonNumeric>&#160;&#160;&#160;&#160; ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the fiscal year ended <strong><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="From2023-10-01to2024-09-30" format="ixt:datemonthdayyearen" id="ixv-17543">September 30, 2024</ix:nonNumeric>.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">OR</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="From2023-10-01to2024-09-30" format="ixt-sec:boolballotbox" id="ixv-17544">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160; TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the transition period from _________ to __________.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Commission file number <strong><ix:nonNumeric name="dei:EntityFileNumber" contextRef="From2023-10-01to2024-09-30" id="ixv-17545">1-11889</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:88%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="From2023-10-01to2024-09-30" id="ixv-17546">CEL-SCI CORPORATION</ix:nonNumeric></span></strong></p></td></tr><tr style="height:15px"><td style="width:88%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Exact name of registrant as specified in its charter)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="From2023-10-01to2024-09-30" format="ixt-sec:stateprovnameen" id="ixv-17547">Colorado</ix:nonNumeric></strong></p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="From2023-10-01to2024-09-30" id="ixv-17548">84-0916344</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(State or other jurisdiction of incorporation or organization)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(I.R.S. Employer Identification No.)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="From2023-10-01to2024-09-30" id="ixv-17549">8229 Boone Blvd.</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="From2023-10-01to2024-09-30" id="ixv-17550">Suite 802</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="From2023-10-01to2024-09-30" id="ixv-17551">Vienna</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="From2023-10-01to2024-09-30" format="ixt-sec:stateprovnameen" id="ixv-17552">Virginia</ix:nonNumeric></strong></p></td><td style="width:10%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="From2023-10-01to2024-09-30" id="ixv-17553">22182</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Address of principal executive offices)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Zip Code)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Registrant's telephone number, including area code: (<ix:nonNumeric name="dei:CityAreaCode" contextRef="From2023-10-01to2024-09-30" id="ixv-17554">703</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="From2023-10-01to2024-09-30" id="ixv-17555">506-9460</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Securities registered pursuant to Section 12(b) of the Act: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Title of each class</p></td><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Trading Symbol</p></td><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:32%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Name of each exchange on which registered</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="From2023-10-01to2024-09-30" id="ixv-17556">Common Stock</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="From2023-10-01to2024-09-30" id="ixv-17557">CVM</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="From2023-10-01to2024-09-30" format="ixt-sec:exchnameen" id="ixv-17558">NYSE</ix:nonNumeric> American</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Securities registered pursuant to Section 12(g) of the Act: None</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="From2023-10-01to2024-09-30" id="ixv-17559">Yes</ix:nonNumeric> &#9746;&#160;&#160;&#160;&#160; No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="From2023-10-01to2024-09-30" id="ixv-17560">Yes</ix:nonNumeric> &#9746;&#160;&#160;&#160;&#160; No &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an &#8220;emerging growth company&#8221;. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:30%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Large accelerated filer</p></td><td style="width:20%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td><td style="width:30%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accelerated filer</p></td><td style="width:20%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="From2023-10-01to2024-09-30" format="ixt-sec:entityfilercategoryen" id="ixv-17561">Non-accelerated filer</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9746;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Smaller reporting company</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="From2023-10-01to2024-09-30" format="ixt-sec:boolballotbox" id="ixv-17562">&#9746;</ix:nonNumeric></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Emerging Growth Company</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="From2023-10-01to2024-09-30" format="ixt-sec:boolballotbox" id="ixv-17563">&#9744;</ix:nonNumeric></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" contextRef="From2023-10-01to2024-09-30" format="ixt-sec:boolballotbox" id="ixv-17564">&#9744;</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act): Yes <ix:nonNumeric name="dei:EntityShellCompany" contextRef="From2023-10-01to2024-09-30" format="ixt-sec:boolballotbox" id="ixv-17565">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160; No &#9746;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The aggregate market value of the voting stock held by non-affiliates of the Registrant, based upon the closing sale price of the registrant&#8217;s common stock on March 31, 2024, as quoted on the NYSE American, was $<ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2024-03-31" format="ixt:numdotdecimal" unitRef="USD" decimals="0" scale="0" id="ixv-17566">100,002,189</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">As of January 6, 2025, the Registrant had <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-01-06" format="ixt:numdotdecimal" unitRef="Shares" decimals="INF" id="ixv-17567">74,107,041</ix:nonFraction> issued and outstanding shares of common stock. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Documents Incorporated by Reference: None</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"/></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FORWARD-LOOKING STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">This report contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally identify these forward-looking statements by forward-looking words such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;future,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;plans,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;potential,&#8221; &#8220;continues&#8221; and similar words or expressions (as well as other words or expressions referencing future events, conditions or circumstances). These forward-looking statements involve risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements, including, but not limited to:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the progress and timing of, and the amount of expenses associated with, our research, development and commercialization activities for our product candidates, including Multikine;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our expectations regarding the timing, costs and outcome of any pending or future litigation matters, lawsuits or arbitration proceedings;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the success of our clinical studies for our product candidates;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our ability to obtain U.S. and foreign regulatory approval for our product candidates and the ability of our product candidates to meet existing or future regulatory standards;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our expectations regarding federal, state and foreign regulatory requirements;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the therapeutic benefits and effectiveness of our product candidates;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the safety profile and related adverse events of our product candidates;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our ability to manufacture sufficient amounts of Multikine or our other product candidates for use in our clinical studies or, if approved, for commercialization activities following such regulatory approvals;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our plans with respect to collaborations and licenses related to the development, manufacture or sale of our product candidates;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our expectations as to future financial performance, expense levels and liquidity sources;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our ability to compete with other companies that are or may be developing or selling products that are competitive with our product candidates;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">anticipated trends and challenges in our potential markets;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our ability to attract, retain and motivate key personnel;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our ability to continue as a going concern; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">our liquidity.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;&#160;&#160; </p><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:45px">All forward-looking statements are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained in this report speak only as of their respective dates. Except to the extent required by applicable laws and regulations, we undertake no obligation to update these forward-looking statements to reflect new information, events or circumstances or to reflect the occurrence of unanticipated events. In light of these risks and uncertainties, the forward-looking events and circumstances described in this report may not occur and actual results could differ materially from those anticipated or implied in such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PART I</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">ITEM 1. BUSINESS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">CEL-SCI&#8217;s PRODUCT CANDIDATES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI Corporation is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body&#8217;s natural defense system. CEL-SCI is currently focused on the development of the following product candidates and technologies:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">1)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">2)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology, or LEAPS, with several product candidates under development for the potential treatment of rheumatoid arthritis.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in this report as Multikine. Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review under CEL-SCI&#8217;s future anticipated regulatory submission for approval. None of CEL-SCI&#8217;s product candidates have been approved for sale, barter or exchange by the Food and Drug Administration (FDA) or any other regulatory agency for any use to treat disease in humans nor has the safety or efficacy of these products been established for any use. There can be no assurance that obtaining marketing approval from the FDA in the United States and by comparable agencies in most foreign countries will be granted.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">MULTIKINE, THE PHASE III CLINICAL TRIAL RESULTS, AND PATH FORWARD</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong><span style="text-decoration:underline">Immunotherapy is a large, high growth market.</span></strong> Immunotherapies use the patient&#8217;s own immune system to fight disease. These &#8220;targeted therapies&#8221; are at the forefront of modern cancer research. A Bloomberg report from January 2023 asserted that:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The global cancer immunotherapy market is expected to reach USD $196.45 billion by 2030, registering CAGR of 7.2% during the forecast period, according to a new report by Grand View Research, Inc. The rising adoption of immunotherapy over other therapy options for cancer owing to its targeted action is anticipated to increase the adoption during the forecast period. Moreover, increasing regulatory approvals from authoritarian establishments for novel immunotherapy used for oncology is also expected to further fuel the market growth.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Source</span>: <span style="text-decoration:underline">https://www.bloomberg.com/press-releases/2023-01-18/cancer-immunotherapy-market-worth-196-45-billion-by-2030-grand-view-research-inc</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI hopes to participate in this growing market with its lead investigational therapy Multikine&#174; (Leukocyte Interleukin, Injection). Multikine is unique among approved cancer immunotherapies because it is <em><span style="text-decoration:underline">given first</span></em><span style="text-decoration:underline">, right after diagnosis, before any other treatment including surgery</span>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Multikine has been tested in approximately 740 patients in Phase 1, 2 and 3 clinical studies conducted in the U.S., Canada, Europe, Israel and Asia. In these studies, it has been administered in multiple doses by various routes and various frequencies to determine its safety and efficacy. The data from these studies allowed CEL-SCI to determine the patient population most responsive to Multikine and most likely to benefit from it. The target population is newly diagnosed advanced primary head and neck cancer patients with no lymph node involvement (determined via PET imaging) and with low PD-L1 tumor expression (determined via biopsy), two features that physicians routinely assess at baseline as part of standard practice.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI completed a bias analysis for the target population in the 928 patient Phase III study in preparation for submission of data to regulatory agencies including the FDA for confirmatory registration study. The detailed data on parameters including patient age, sex, race, tumor locations, and staging demonstrate balance between the treatment and control arms. Therefore, no bias was found, which supports confidence in Multikine&#8217;s efficacy results.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In the target patient population CEL-SCI believes Multikine significantly extended life. In the Phase III study, CEL-SCI observed a 73% survival rate with Multikine vs. only 45% without Multikine at 5 years after treatment, and a Hazard ratio of 0.35 (95% CIs [0.19, 0.66]).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI applied to the FDA for a 212-patient randomized controlled confirmatory registration study focusing only on those patients in the target population, which accounts for approximately 100,000 patients worldwide per year. In May 2024, CEL-SCI announced that the FDA indicated CEL-SCI may move forward with a confirmatory registration study of Multikine in the target population.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong><span style="text-decoration:underline">What is Multikine and who is it for?</span></strong> Multikine is a biological medicinal immunotherapy comprised of a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment <em><span style="text-decoration:underline">before</span></em> the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikine&#8217;s rationale for use is to incite a locoregional immune response against the tumor before the local immune system has been compromised by the standard of care and/or disease progression.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Multikine target population is not yet treated adult patients with resectable locally advanced primary squamous cell carcinoma of the head and neck (SCCHN) in the oral cavity and who have:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:8%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>No lymph node involvement</strong> (via PET imaging)</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong>Low PD-L1 tumor expression</strong> (TPS<span style="text-decoration:underline">&lt;</span>10) (via biopsy)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">PD-L1 is a protein receptor on the tumor surface that helps the tumor repel cells of the immune system. CEL-SCI believes that patients with tumors having low PD-L1 would be more likely to respond to Multikine because their tumors have lower defenses against the patient&#8217;s immune system. CEL-SCI estimates that patients with tumors having low PD-L1 represent about 70% of locally advanced primary SCCHN patients.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Targeting low PD-L1 also differentiates Multikine from other immunotherapies. For example, checkpoint inhibitors like Keytruda and Opdivo appear to best serve patients having high PD-L1, because these drugs work by blocking PD1/PD-L1 receptors interaction; when this interaction (PD1/PD-L1) happens it leads to inactivation/death of the immune cells attacking the tumor. These checkpoint inhibitors appear to act best when tumors express high levels of PD-L1 receptors (usually TPS &gt;20 to TPS &gt;50). While none of these drugs are currently approved as a first-line treatment before surgery, even if such approvals were to come in the future, we believe the large majority of patients having low PD-L1 would still be expected to need Multikine.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong><span style="text-decoration:underline">CEL-SCI believes Multikine leads to longer survival with no safety issues.</span></strong> Clinical investigations of Multikine, presented at ESMO (Europe Society for Medical Oncology) in October 2023, have demonstrated in the randomized controlled Phase III trial (RCT) the following in the target population:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><strong><em><span style="text-decoration:underline">risk of death cut in half at five years</span></em></strong><strong><em> </em></strong>versus the control;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">28.6% absolute 5-year overall survival benefit versus control (p=0.0015);</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">0.349 hazard ratio vs control (95% CIs [0.18, 0.66], Wald p=0.0012);</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">&gt;35% rate of pre-surgery reductions and/or downstages (p&lt;0.01); and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">low PD-L1 tumor expression (vs high PD-L1 where Keytruda and Opdivo work best).</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">There were no demonstrable safety signals or toxicities observed in approximately 740 Multikine-treated subjects across multiple clinical trials. Adverse event (AE) and serious adverse event (SAE) incidences were not significantly different among treatment and control groups. There were no Multikine-related deaths, no Multikine-related delays of surgery, no Multikine-related interference with post-surgical treatment, and only two discontinuations. Multikine-related AEs before surgery were local and resolved after surgery. Although the literature reports that some of Multikine&#8217;s components may be toxic when administered systemically (e.g., TNF&#945;, IFN &#947;, IL-1&#946;), these toxicities did not emerge with Multikine, even at doses many times higher than those administered in the Phase III trial, primarily due to Multikine&#8217;s delivery by local injection and dosage.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI published its data as abstracts and posters at the annual conferences for the 2022 American Society of Clinical Oncology (ASCO), 2022, 2023 European Society for Medical Oncology (ESMO), the 2023 European Head and Neck Society&#8217;s (EHNS&#8217;s) annual European Conference On Head And Neck Oncology (ECHNO), the 2023 European Society for Therapeutic Radiology and Oncology (ESTRO) and the 2023 American Head and Neck society (AHNS). These publications can be accessed at <span style="text-decoration:underline"><span style="color:blue">http://www.cel-sci.com</span>.</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong><span style="text-decoration:underline">Multikine works by inducing pre-surgical responses.</span></strong> CEL-SCI observed statistically significant pre-surgical responses after Multikine treatment, and therefore CEL-SCI believes in the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#10146;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Multikine causes pre-surgical responses;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#10146;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pre-surgical responses lead to longer life;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#10146;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Therefore, selecting more patients predicted to have a pre-surgical response should lead to much better survival in the target population.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">A &#8220;pre-surgical response&#8221; is a significant change in disease before surgery. CEL-SCI saw two kinds of responses in the Phase III trial. First, there were &#8220;reductions&#8221; in the size of the tumor&#8212;a reduction of 30% or more qualified as a &#8220;pre-surgical reduction,&#8221; or &#8220;PSR&#8221; for short. Second, there were disease &#8220;downstages,&#8221; (e.g., the disease improved from Stage IV to Stage III) pre-surgery. CEL-SCI calls this a &#8220;pre-surgical downstaging&#8221; or &#8220;PSD&#8221; for short. CEL-SCI&#8217;s 2022 ESMO cancer conference presentation reported on PSR, and CEL-SCI&#8217;s new 2023 ESMO presentation reported on PSD.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Across the whole Phase III trial, PSRs were seen in 8.5% of Multikine patients compared to <em><span style="text-decoration:underline">none</span><strong> </strong></em>in the control group. PSDs were seen in 22% of Multikine patients as compared to 13% in the control group. Because Multikine was the only therapy given to these patients before surgery, it is CEL-SCI&#8217;s strong belief that Multikine had to be the cause of the higher rates of PSR and PSD.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">These data are presented visually below. The taller blue columns show PSR and PSD rates in all 529 Multikine-treated patients in the Phase III trial, and the gray columns show PSR and PSD rates for all 394 control patients.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10kimg10.jpg" alt="cvm_10kimg10.jpg"/></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">It was not enough for us to show that Multikine likely leads to PSRs and PSDs as compared to a control group, CEL-SCI also had to test if PSRs and PSDs lead to improved survival. CEL-SCI&#8217;s Phase III trial demonstrated that PSR patients were 72% likely to be alive after five years, whereas control patients were only about 49% likely to be alive after five years. Patients with PSD saw similar improvement in CEL-SCI&#8217;s Phase III trial. Their five-year chance of survival was approximately 68%. Therefore, CEL-SCI believes that the Phase III trial demonstrated that those patients who had PSR or PSD resulting from Multikine lived longer than those who were not treated with Multikine. It is important to note that these results are from the entire Phase III study population, not from a subgroup. The likelihood of living at least five years is shown in the graphic below for patients with PSR (blue), patients with PSD (orange) and control patients who did not receive Multikine (gray).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10kimg11.jpg" alt="cvm_10kimg11.jpg"/></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><strong><span style="text-decoration:underline">Multikine cut the 5-year risk of death in half in the target population.</span></strong><strong> </strong>CEL-SCI&#8217;s results show that Multikine can cut the risk of death in half at five<strong> </strong>years versus the control group in the target population. Survival increased from 45% in the control group to 73% in the Multikine group at five years. This means the risk of death fell to 27% in the Multikine group from 55% in the control, shown below.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10kimg12.jpg" alt="cvm_10kimg12.jpg"/></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Another way to see the survival benefit of Multikine in the target population is the Kaplan-Meier curve from our ESMO &#8217;23 poster, shown below. On the vertical axis is the probability of survival and the horizontal axis is time in months. The blue Multikine line is far above the green control line, meaning the chance of survival is much higher in the Multikine group at every point in time compared to the control. These results had a low (log rank) p-value of 0.0015, which is very significant as a statistical matter.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10kimg13.jpg" alt="cvm_10kimg13.jpg"/></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s physician consultants tell CEL-SCI that the early separation of these two survival curves (e.g., at 12 months) adds validation to the potential positive effects of Multikine.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Another measure of survival benefit is called the &#8220;hazard ratio,&#8221; which compares the rate of an event (chances) of dying between two different groups. Here, in the Multikine target population, the hazard ratio was 0.35, which means that deaths occurred in the Multikine group about one-third as frequently as in the control group. It is also important to note that the hazard ratio&#8217;s 95% confidence interval remained far below 1.0 (which would mean parity between the compared groups). In the case of Multikine, statistically speaking, there is a 95% chance that the hazard ratio would fall between 0.18 and 0.66 if Multikine were tested in the target population in another study. A hazard ratio of 0.66 as the &#8220;so-called worst-case scenario&#8221; (the upper limit of the 95% confidence interval - for the hazard ration - in this case) is still below (better) than the hazard ratio required for most drug approvals.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI completed a bias analysis for the target population in the Phase III study in preparation for submission of data to regulatory agencies including the FDA for confirmatory registration study. The detailed data on parameters including patient age, sex, race, tumor locations, and staging demonstrate balance between the treatment and control arms. Therefore, no bias was found, which supports confidence in Multikine&#8217;s efficacy results.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10kimg14.jpg" alt="cvm_10kimg14.jpg"/></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">These positive survival outcomes&#8212;increased overall survival, reduced risk of death, widely separated Kaplan-Meier curves with early separation, low hazard ratio, low p-values, low confidence intervals&#8212;CEL-SCI believes were driven by high PSR/PSD rates in the target population, as shown in the graphic below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10kimg15.jpg" alt="cvm_10kimg15.jpg"/></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI relies on all of these data together to support its plan to request accelerated/conditional approval in the new target population without waiting until the completion of another clinical trial. CEL-SCI&#8217;s regulatory strategy going forward is to seek approval of Multikine following full enrollment of our confirmatory study wherever possible.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI applied to the FDA for a 212-patient randomized controlled confirmatory registration study focusing only on those patients in the target population, which accounts for approximately 100,000 patients worldwide per year. In May 2024, CEL-SCI announced that the FDA indicated CEL-SCI may move forward with a confirmatory registration study of Multikine in the target population.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10kimg16.jpg" alt="cvm_10kimg16.jpg"/></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The confirmatory study will be a randomized controlled trial with two arms: Multikine treatment plus standard of care versus standard of care alone. CEL-SCI expects to initiate the confirmatory study in Q1 2025 and reach full enrollment in Q2 2026.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If approved as a pre-surgical treatment, CEL-SCI believes Multikine should be added to the standard of care for the target population in this unmet medical need.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI believes that the confirmatory study has a high likelihood of success based on the large survival benefit that has already been observed in the target population from the completed Phase III study. The planned confirmatory study will be much smaller&#8212;less than a quarter the size of the prior study&#8212; and will focus on the patients who saw the greatest survival benefit when treated with Multikine.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Why Do We Believe Our Confirmatory Study Will Be Successful?</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10kimg17.jpg" alt="cvm_10kimg17.jpg"/></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">An &#8220;unmet need&#8221; is a factor for approval considered by all major regulatory bodies worldwide. In the Multikine target population, there is also a great unmet need for improved survival. The current standard of care provides only about a 50/50 chance of surviving five years, whereas Multikine could increase that survival rate to over 70% in the target population based on the Phase III data. Chemotherapy (in addition to radiotherapy following surgery) has improved survival outcome for some head and neck patients, but chemotherapy is only indicated for high-risk patients, who are not likely to fall within the Multikine target population. Currently available immunotherapies are given after surgery or where surgery is not indicated, in contrast to Multikine, which is given before surgery to patients with resectable tumors. Available checkpoint inhibitors work best on tumors with high PD-L1 expression, whereas Multikine works best in tumors with low PD-L1 expression. Therefore, Multikine&#8217;s target population is underserved, and will continue to be underserved by current therapies. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The major regulatory bodies with whom we are working, U.S. FDA, Health Canada, European Medicine Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) all have conditional approval pathways designed for situations where the target population has not been fully tested prospectively and there is strong data supporting clinical benefit for patients. The reason is that regulators understand that in many cases patients should not have to wait for additional data before being offered the chance to benefit from a new drug, especially if the drug has shown to be safe. Every situation is different and depends on the specific facts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>IN CONCLUSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Strong survival data</strong>: Multikine-treated patients in the target population had a 73% 5-year survival vs a 45% 5-year survival in the control group who did not receive Multikine in the Phase III study. In addition, no safety signals or toxicities versus standard of care. The Hazard ratio is 0.35 with an upper limit (95% Confidence interval) of 0.66.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Addressing an unmet medical need</strong>: Multikine focuses on the 70% of patients not well served by the two leading approved drugs for head and neck cancer, Keytruda and Opdivo. Multikine&#8217;s proposed indication is a pre-surgical treatment in head &amp; neck cancer, where no drug is currently approved.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Multikine&#8217;s Target Population</strong>: The confirmatory registration study will focus on newly diagnosed locally advanced primary head and neck cancer patients with no lymph node involvement (determined via PET scan) and with low PD-L1 tumor expression (determined via biopsy).</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>FDA pathway</strong>: CEL-SCI is aiming to begin enrollment for a 212-patient confirmatory registration study in Q1 2025, with full enrollment expected in Q2 2026 with the potential to seek early approval after full enrollment.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">CORPORATE HISTORY</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI was formed as a Colorado corporation in 1983. CEL-SCI&#8217;s principal office is located at 8229 Boone Boulevard, Suite 802, Vienna, VA 22182. CEL-SCI&#8217;s telephone number is 703-506-9460 and its website is <span style="text-decoration:underline"><span style="color:blue">www.cel-sci.com</span>. CEL-SCI does not incorporate the information on its website into this report, and you should not consider it part of this report.</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI makes its electronic filings with the Securities and Exchange Commission (SEC), including its annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to these reports. These filings are available on its website free of charge as soon as practicable after they are filed or furnished to the SEC.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">MORE ABOUT MULTIKINE</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s lead investigational therapy, Multikine, is being developed as a potential therapeutic agent directed at using the immune system to produce an anti-tumor immune response. Data from CEL-SCI&#8217;s clinical trials suggest that Multikine may help the immune system &#8220;see&#8221; the tumor and then attack it, enabling the body&#8217;s own anti-tumor immune response to fight the tumor. Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to review by the FDA, in connection with CEL-SCI&#8217;s future anticipated regulatory submission for approval in the United States. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency, and neither its safety nor its efficacy have been established.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Multikine is an immunotherapy product candidate comprised of a patented defined mixture of 14 human natural cytokines. If commercial approval is obtained, CEL-SCI intends to manufacture Multikine in a proprietary manner in CEL-SCI&#8217;s manufacturing facility near Baltimore, Maryland, USA. CEL-SCI spent many years and more than $200 million developing and validating the manufacturing process for Multikine. The pro-inflammatory cytokine mixture includes interleukins, interferons, chemokines and colony-stimulating factors, which contain elements of the body&#8217;s natural mix of defenses against cancer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Multikine is designed to be used in a different way than cancer immunotherapy is generally being used. Generally, cancer immunotherapy is given to patients who have already failed other treatments such as surgery, radiation and/or chemotherapy and most of the time it is administered systemically. Multikine on the other hand is administered locally to treat tumors and their microenvironment before any other therapy has been administered because it is believed that this is the time when the immune system would be strongest and most amenable to activation against the tumor. For example, in the Phase III clinical trial, Multikine was injected locally around the tumor and near the adjacent draining lymph nodes for three weeks, five days a week as a first treatment before surgery, radiation and/or chemotherapy. The goal is to help the intact immune system recognize and kill the tumor micro metastases that usually cause recurrence of the cancer. In short, CEL-SCI believes that the local administration of Multikine before weakening of the immune system by surgery and radiation will result in better anti-tumor response than if Multikine were administered after surgery and radiation. In clinical studies of Multikine, administration of the investigational therapy to head and neck cancer patients has demonstrated the potential for lesser or no appreciable toxicity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="cvm_10kimg18.jpg" alt="cvm_10kimg18.jpg"/></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Source: Adapted from Timar et al., Journal of Clinical Oncology 23(15) May 20, 2005</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The first indication CEL-SCI is pursuing for its investigational drug product candidate Multikine is an indication for the neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck, or SCCHN (hereafter also referred to as advanced primary head and neck cancer).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In October 2023, CEL-SCI presented a poster at the European Society for Medical Oncology (EMSO) annual Congress that reported three major new advancements supporting Multikine&#8217;s approvability:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">First, Multikine is most effective in patients having tumors with low PD-L1 expression, consisting of about 70% of the study population. (It should be noted that immune checkpoint inhibitors like Keytruda and Opdivo appear to work best in patients with tumors having high PD-L1 expression).</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Second, the Multikine target population can now be readily identified upon diagnosis, prior to surgery, using tests that physicians routinely use in cancer screenings.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Third, Multikine patients in the target population saw a significant increase in 5-year overall survival, from 45% for control patients who did not receive Multikine to 73% for Multikine-treated patients.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Link to poster: <span style="text-decoration:underline">https://cel-sci.com/wp-content/uploads/2023/10/ESMO-2023-Poster_893P_FINAL.pdf</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Previously, CEL-SCI published two abstracts and presented a poster related to its pivotal Phase III Multikine head and neck cancer clinical trial at the American Society of Clinical Oncology (ASCO) in June 2022. The abstract titles and corresponding links are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>&#8220;Leukocyte interleukin injection (LI) immunotherapy extends overall survival (OS) in treatment-naive low-risk (LR) locally advanced primary squamous cell carcinoma of the head and neck: The IT-MATTERS study.&#8221; </em></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:8%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">o</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Link to abstract: <span style="text-decoration:underline">https://meetings.asco.org/abstracts-presentations/207201</span></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">o</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Link to poster: <span style="text-decoration:underline">https://cel-sci.com/wp-content/uploads/2022/06/CEL-SCI-ASCO-2022-Poster-6032-June-6-Head-and-Neck-Cancer-1.pdf</span></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>&#8220;Novel algorithm for assigning risk/disease-directed treatment (DDT) choice in locally advanced primary squamous cell carcinoma of the head and neck (SCCHN): Using pretreatment data only.&#8221; </em></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:8%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">o</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Link to abstract: <span style="text-decoration:underline">https://meetings.asco.org/abstracts-presentations/207202/</span></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Ultimately, the decision as to whether CEL-SCI&#8217;s drug product candidate is safe and effective can only be made by the FDA and/or by other regulatory authorities based upon an assessment of all of the data from an entire drug development program submitted as part of an application for marketing approval. As detailed in the Risk Factors section of this report, the completed Phase III clinical study for CEL-SCI&#8217;s investigational drug cannot be used as the pivotal study supporting a marketing application in the United States, and therefore a confirmatory study is needed to be conducted to support a marketing application in the United States. The cost of the confirmatory registration study is estimated to be approximately $30 million and is projected to begin enrollment in Q1 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Development Agreements for Multikine</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In August 2008, CEL-SCI signed an agreement with Teva Pharmaceutical Industries Ltd., or Teva, that gives Teva the exclusive right and license to market, distribute and sell Multikine, if approved, in Israel and Turkey for treatment of head and neck cancer. The agreement terminates on a country-by-country basis 10 years after the product launch in each country or upon a material breach or upon bankruptcy of either party. The agreement will automatically extend for additional two-year terms unless either party gives notice of its intent not to extend the agreement. If CEL-SCI develops Multikine for other oncology indications and Teva indicates a desire to participate, the parties have agreed to negotiate in good faith with respect to Teva&#8217;s participation and contribution in future clinical trials.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Teva has agreed to use all reasonable efforts to obtain regulatory approval to market and sell Multikine in its territory at its own cost and expense. Pursuant to the agreement, it is CEL-SCI&#8217;s responsibility to supply Multikine and Teva&#8217;s responsibility to sell Multikine, if approved by regulatory authorities in the relevant countries. Net sales will be divided 50/50 between the two parties. Teva also initially agreed to fund certain activities relating to the conduct of a clinical trial in Israel as part of the global Phase III trial for Multikine. In July 2011, Serbia and Croatia were added to Teva&#8217;s territory, pursuant to a joinder agreement between CEL-SCI and PLIVA Hrvatska d.o.o., or PLIVA, an affiliate of Teva&#8217;s, subject to similar terms as described above. In January 2012, pursuant to an assignment and assumption agreement between CEL-SCI, Teva and GCP Clinical Studies Ltd., or GCP, Teva transferred all of its rights and obligations concerning the Phase III trial in Israel to GCP. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In consideration for the rights granted by CEL-SCI to PLIVA under the joinder agreement, CEL-SCI will be paid by PLIVA (in U.S. dollars):</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">$100,000 upon EMA grant of Marketing Authorization for Multikine;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">$50,000 upon Croatia&#8217;s grant of reimbursement status for Multikine in Croatia; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">$50,000 upon Serbia&#8217;s grant of reimbursement status for Multikine in Serbia.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In November 2000, CEL-SCI signed an agreement with Orient Europharma Co., Ltd., or Orient Europharma, of Taiwan, which was amended in October 2008 and again in June 2010. Pursuant to this agreement, as amended, Orient Europharma has the exclusive marketing and distribution rights to Multikine, if approved by regulatory authorities, for head and neck cancer, naso-pharyngeal cancer and potentially cervical cancer indications in Taiwan, Singapore, Malaysia, Hong Kong, the Philippines, South Korea, Australia and New Zealand. CEL-SCI has granted Orient Europharma the first right of negotiation with respect to Thailand and China.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The agreement requires Orient Europharma to fund 10% of the cost of the clinical trials needed to obtain marketing approvals in these countries for head and neck cancer, naso-pharyngeal cancer and potentially cervical cancer. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If Multikine is approved for sale, Orient Europharma will purchase Multikine from CEL-SCI for 35% of the gross selling price in each country. Orient Europharma is obligated to use the same diligent efforts to develop, register, market, sell and distribute Multikine in its territory as with its own products or other licensed products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The agreement will terminate on a country-by-country basis 15 years after the product approval for Multikine in each country, at which point the agreement will be automatically extended for successive two-year periods, unless either party gives notice of its intent not to extend the agreement. The agreement may also be terminated upon the bankruptcy of either party or material misrepresentations that are not cured within 60 days. If the agreement ends before the 15-year term through no fault of either party, CEL-SCI will reimburse Orient Europharma for a prorated part of Orient Europhorma&#8217;s costs towards the clinical trials of Multikine. If Orient Europharma fails to make certain minimum purchases of Multikine during the term of the agreement, Orient Europhorma&#8217;s rights to the territory will become non-exclusive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has a licensing agreement with Byron Biopharma LLC, or Byron, under which CEL-SCI granted Byron an exclusive license to market and distribute Multikine in the Republic of South Africa, if approved. This license will terminate 20 years after marketing approval in South Africa or after the bankruptcy or uncured material breach by either party. After the 20-year period has expired, the agreement will be automatically extended for successive two-year periods, unless either party gives notice of its intent not to extend the agreement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Pursuant to the agreement, Byron will be responsible for registering Multikine in South Africa. If Multikine is approved for sale in South Africa, CEL-SCI will be responsible for manufacturing the product, while Byron will be responsible for sales in South Africa. Sales revenues will be divided equally between CEL-SCI and Byron.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">ABOUT LEAPS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s patented T-cell Modulation Process, referred to as LEAPS (Ligand Epitope Antigen Presentation System), uses &#8220;heteroconjugates&#8221; to direct the body to choose a specific immune response. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. LEAPS combines T-cell binding ligand peptides with small, disease associated, peptide antigens and may provide a new method to treat and prevent certain diseases.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The ability to generate a specific immune response is important because many diseases are often not combated effectively due to the body&#8217;s selection of the &#8220;inappropriate&#8221; immune response. The capability to specifically reprogram an immune response may offer a more effective approach than existing vaccines and drugs in attacking an underlying disease.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">LEAPS Candidates: CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000)</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On September 19, 2017, CEL-SCI announced that it had been awarded a Phase 2 Small Business Innovation Research (SBIR) grant in the amount of $1.5 million from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), which is part of the U.S. National Institutes of Health (NIH). This grant provided funding to allow CEL-SCI to advance its first LEAPS product candidate, CEL-4000, towards an Investigational New Drug (IND) application for a Phase 1 safety study, by funding IND enabling studies and additional mechanism of action studies, among other preclinical development activities. Work on CEL-4000 was conducted at CEL-SCI&#8217;s research laboratory and Rush University Medical Center in Chicago, Illinois in the laboratories of Tibor Glant, MD, Ph.D., Jorge O. Galante Professor of Orthopedic Surgery and Katalin Mikecz, MD, Ph.D. Professor of Orthopedic Surgery &amp; Biochemistry. The SBIR grant was awarded based on published data described below by Dr. Glant's team in collaboration with CEL-SCI showing that the administration of a proprietary peptide using CEL-SCI's LEAPS technology prevented the development, and lessened the severity, including inflammation, of experimental proteoglycan induced arthritis (PGIA or GIA) when it was administered after the disease was induced in animals. This grant has been fully expended.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As part of the follow-up to the grant funded work, CEL-SCI published a review comparing CEL-4000 and the new LEAPS peptide CEL-5000 to both the Janus kinase (JAK) inhibitors and disease modifying anti-rheumatic drugs (DMARDs) in use for RA and autoimmune arthritis. The article reviewed the mechanism of action and targets with pictorial graphics in the journal Biomedicines and can be found online at <span style="text-decoration:underline"><span style="color:blue">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772713/</span>.</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In May 2019, CEL-SCI announced that a newly discovered LEAPS conjugate acts alone and can complement CEL-4000 therapeutically when administered in combination to an animal model of Rheumatoid Arthritis (RA). This new LEAPS conjugate appears to act on T cell pathways by a new mechanism that is different from the pathways used by the CEL-4000 vaccine. The data was presented at the American Association of Immunologists 103rd Annual Meeting (Immunology 2019) by Daniel Zimmerman, Ph.D., CEL-SCI&#8217;s Senior Vice President of Research, Cellular Immunology. The work was performed in conjunction with researchers at Rush University Medical Center, Chicago, Illinois and was funded by the SBIR Phase 2 Grant.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In July 2019, one of CEL-SCI&#8217;s collaborators from Rush, Dr. Adrienn Markovics presented new LEAPS data at i-Chem2019, International Conference on Immunity and Immunochemistry. Data presented was for a new second RA conjugate discovered which acts alone and can complement the existing CEL-4000 RA vaccine in an animal model of RA. The combination of the two RA conjugates provided not only broader epitope coverage, but also a greater therapeutic effect than either conjugate alone. The LEAPS work was performed in conjunction with researchers at CEL-SCI on CEL-4000 and the newly discovered LEAPS conjugate, CEL-5000. Both conjugates were evaluated alone and in combination in the model of proteoglycan [PG] induced arthritis (PGIA) called recombinant PG G1 domain-induced arthritis (GIA), an autoimmune mouse model of RA.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In February 2017 and November 2016, CEL-SCI announced preclinical data that demonstrate its investigational new drug candidate CEL-4000 has the potential to treat rheumatoid arthritis. This study was supported in part by the SBIR Phase I Grant and was conducted in collaboration with Drs. Katalin Mikecz and Tibor Glant, and their research team at Rush University Medical Center in Chicago, IL. This work was published in an article entitled &#8220;<em>An epitope-specific DerG-PG70 LEAPS vaccine modulates T cell responses and suppresses arthritis progression in two related murine models of rheumatoid arthritis</em>&#8221; and can be found online at <span style="text-decoration:underline"><span style="color:blue">https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC5568759/</span>.</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Prior to the SBIR Phase 2 grant in 2014, CEL-SCI was awarded a Phase 1 SBIR grant in the amount of $225,000 from NIAMS. This grant funded the development of CEL-SCI&#8217;s LEAPS technology as a potential treatment for rheumatoid arthritis, an autoimmune disease of the joints. The work was conducted at Rush University Medical Center in Chicago, Illinois in the laboratories of Tibor Glant, MD, Ph.D., Katalin Mikecz, MD, Ph.D., and Allison Finnegan, Ph.D. Professor of Medicine. The grant was fully recognized in prior periods.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">With the support of these SBIR grants, CEL-SCI is developing several new drug candidates, CEL-2000 and CEL-4000, as potential rheumatoid arthritis therapeutic treatments. The data from animal studies using the CEL-2000 treatment suggests that it could be used against rheumatoid arthritis with fewer administrations than those required by other anti-rheumatoid arthritis treatments currently on the market for arthritic conditions associated with the Th17 signature cytokine TNF-a. The preclinical data indicates these peptides could be used against rheumatoid arthritis where a Th1 signature cytokine (IFN-&#947;) is dominant. CEL-2000 and CEL-4000 each have the potential to become a personalized, disease-specific therapy, that acts at an earlier step in the disease process than current therapies, and which may be useful in patients not responding to existing rheumatoid arthritis therapies. CEL-SCI believes this represents a large unmet medical need in the rheumatoid arthritis market.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In March 2015, CEL-SCI and its collaborators published a review article on vaccine therapies for rheumatoid arthritis based in part on work supported by the SBIR Phase 1 grant. The article is entitled &#8220;Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic Ligand Epitope Antigen Presentation System vaccines for models of rheumatoid arthritis&#8221; and was published in Expert Review of Vaccines 1 - 18 and can be found online at <span style="text-decoration:underline"><span style="color:blue">http://www.ncbi.nlm.nih.gov/pubmed/25787143</span>.</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Accordingly, even though the various LEAPS candidates have not yet been given to humans, they have been tested in vitro with human cells. They have induced similar cytokine responses that were seen in these animal models, which may indicate that the LEAPS technology might translate to humans. The LEAPS candidates have demonstrated protection against lethal herpes simplex virus (HSV1) and H1N1 influenza infection, as a prophylactic or therapeutic agent in animals. They have also shown some level of activity in animals in two autoimmune conditions, curtailing and sometimes preventing disease progression in arthritis and myocarditis animal models. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">None of the LEAPS investigational products have been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from the early-phase, preclinical-trials data involving these investigational products. Before obtaining marketing approval from the FDA in the United States, and by comparable agencies in most foreign countries, these product candidates must undergo rigorous preclinical and clinical testing which is costly and time consuming and subject to unanticipated delays. There can be no assurance that these approvals will be granted.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">INTELLECTUAL PROPERTY</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Patents and other proprietary rights are essential to CEL-SCI&#8217;s business. CEL-SCI files patent applications to protect its technologies, inventions and improvements that CEL-SCI considers important to the development of its business. CEL-SCI&#8217;S intellectual property portfolio covers its proprietary technologies, including Multikine and LEAPS, by multiple issued patents and pending patent applications in the United States and in key foreign markets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Composition-of-matter patents for Multikine have been issued in Japan (issued in November 2012 and currently set to expire in 2025) and three in Europe (issued in September 2015, May 2016 and October 2017, currently set to expire in 2025 and 2026). The most recent patent issued in October 2017, patent # EP 1 879 618 B1, titled &#8220;A Method for Modulating HLA Class II Tumor Cell Surface Expression With A Cytokine Mixture,&#8221; addresses Multikine&#8217;s mechanism of action to make tumors more visible to the immune system. This new patent is important because, along with the other Multikine issued patents, it addresses how Multikine enables the immune system to recognize and attack the tumor. One way tumor cells evade the immune system is by expressing human leukocyte antigens (HLA) on the tumor cell surface, thus appearing as &#8216;self&#8217; to the immune cells and therefore the tumor cells are not attacked. It is important to note that the tumors of the Multikine-treated best responders in CEL-SCI&#8217;s prior Phase II studies had no HLA Class II expressed on the cell surface following Multikine treatment as compared to controls. This points to Multikine&#8217;s ability to modulate HLA expression on the tumor cell surface, thereby allowing the immune system to recognize and attack the tumor.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In addition to the patents that offer certain protections for Multikine, the method of manufacture for Multikine, a complex biological product, is held by CEL-SCI as a trade secret. CEL-SCI considers this to be its best protection from competitors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">LEAPS is protected by patents in the United States issued between January 2019 and June 2021. The LEAPS patents, which expire between 2027 and 2032, include overlapping claims, with composition of both matter (new chemical entity), process and methods-of-use, to maximize and extend the coverage in their current format. One issued U.S. application is a joint application with Northeast Ohio Medical University (&#8220;Neoucom&#8221;) and CEL-SCI will share the ability to use the patent, unless CEL-SCI licenses the rights to the patent from Neoucom. In October 2017 and October 2020, patents were issued in Europe for LEAPS, which expire in 2029 and 2034, respectively. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has one patent applications pending in the United States for LEAPS, which, if issued, would extend protection, subject to any potential patent term extensions. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As of December 15, 2024, there were no contested proceedings and/or third-party claims with respect to CEL-SCI&#8217;s patents or patent applications.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">MANUFACTURING FACILITY</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Before starting the Phase III clinical trial, for reasons related to regulatory considerations, CEL-SCI built a dedicated manufacturing facility to produce its investigational biological product candidate Multikine. This facility produced multiple clinical lots for the Phase III clinical trial and has also passed quality systems review by a European Union Qualified Person on several occasions. CEL-SCI expanded the manufacturing facility so CEL-SCI will be able to meet the expected demand for Multikine, if approval to sell the drug is granted. This expansion was completed at the end of 2021, allowing CEL-SCI employees to return to work inside the manufacturing facility. In February 2024, CEL-SCI announced that the commissioning of the manufacturing facility had been completed, a significant milestone toward a planned Biologics License Application (BLA) with several regulatory agencies for approval of Multikine in the treatment of head and neck cancer. Since the completion of commissioning of the manufacturing facility, CEL-SCI undertook qualification of the manufacturing environment and validation of the manufacturing process in the updated manufacturing facility, aiming to complete the clinical lot in time for the initiation of the confirmatory study.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s lease on the manufacturing facility expires on October 31, 2028. At that time CEL-SCI can either purchase the facility or extend its lease. See Item 2 of this report for more information concerning the terms of this lease.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">GOVERNMENT REGULATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The FDA and other regulatory authorities at federal, state and local levels and in foreign countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing and post-approval monitoring and reporting of biologics such as those CEL-SCI is developing. CEL-SCI, along with third party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which it wishes to conduct studies or seek approval or licensure of its product candidates. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>U.S. Food and Drug Administration Regulation of Biological Products</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In the United States, the FDA regulates biological products under the Federal Food, Drug, and Cosmetic Act, or FDCA, and the Public Health Service Act, or PHSA, and their implementing regulations. The process required by the FDA before biological product candidates may be marketed in the United States generally involves the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s Good Laboratory Practice, or GLP, regulations;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">submission to the FDA of an investigational new drug application, or IND, which must become effective before clinical trials may begin and must be updated annually;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">approval by an independent Institutional Review Board, or IRB, or ethics committee at each clinical site before the trial is initiated;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">performance of adequate and well-controlled human clinical trials in compliance with Good Clinical Practice, or GCP, regulations to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">preparation of and submission to the FDA of a Biologics License Application, or BLA, after completion of clinical trials;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">satisfactory completion of an FDA Advisory Committee review, if applicable;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with current Good Manufacturing Practice, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigations to assess compliance with GCPs; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the United States.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Prior to commencing the first clinical trial with a product candidate in the U.S., CEL-SCI must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human studies. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to commence a clinical trial.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial commences at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board (DSMB) or independent data monitoring committee (IDMC), which provides recommendations for whether or not a study should move forward at designated check points based on access to certain data from the study and may suggest halting the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">For purposes of approval of a Biologics License Application, or BLA, human clinical trials are typically conducted in three or four sequential phases that may overlap.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Phase I &#8212; The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans and the side effects associated with increasing doses.</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Phase II &#8212; The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase II clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase III clinical trials.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Phase III &#8212; The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval. A confirmatory study is meant to establish an acceptable benefit/safety profile in order to gain regulatory approval for a precisely defined indication (&#8220;registration&#8221; clinical trials).</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Phase IV &#8212; In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. The FDA may also make these so-called Phase IV or post-marketing studies a condition to approval of the BLA.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Phase I, Phase II and Phase III testing may not be completed successfully within a specified period, if at all, and there can be no assurance that the data collected will support FDA approval or licensure of the product. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>BLA Submission and Review by the FDA</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of a use of the product, or from a number of alternative sources, including studies initiated by investigators.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In most cases, the submission of a BLA is subject to a substantial application user fee. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, for original BLAs, the FDA&#8217;s goal is to review the BLA within ten months after it accepts the application for filing, or, if the product relates to an unmet medical need in a serious or life-threatening indication and has received a priority review designation, six months after the FDA accepts the application for filing.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">After filing the marketing application, the FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve a biological product for marketing unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the data provided in the application, or the manufacturing process or manufacturing facilities for the product are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. The FDA also may refer applications for novel biologic candidates which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions on approval.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the biological product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete but the application is not ready for approval. A Complete Response Letter may request additional information or clarification, including new clinical studies. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the re-submitted BLA does not satisfy the criteria for approval.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If a product receives regulatory approval, such approval is limited to the conditions of use (e.g., patient population, indication) described in the application. Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings or precautions be included in the product labeling, require that post-approval trials, including Phase IV clinical trials, be conducted to further assess a product&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a Risk Evaluation and Mitigation Strategy, or REMS, plan if it determines that a REMS is necessary to ensure that the benefits of the product outweigh its risks and to assure the safe use of the biological product, which can materially affect the potential market and profitability of the product. The REMS plan could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. The FDA may prevent or limit further marketing of a product based on the results of post- marketing trials or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Expedited Review and Approval</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">A sponsor may seek approval of its product candidate under programs designed to accelerate the FDA&#8217;s review and approval of new drugs and biological products that meet certain criteria. Specifically, new drugs and biological products are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. For a fast track product, the FDA may consider sections of the BLA for review on a rolling basis before the complete application is submitted if relevant criteria are met. A fast track designated product candidate may also qualify for priority review.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Under the accelerated approval program, the FDA may approve a BLA on the basis of either a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Post-marketing studies or completion of ongoing studies after marketing approval are generally required to verify the biologic&#8217;s clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit. In addition, the Food and Drug Administration Safety and Innovation Act, or FDASIA, which was enacted and signed into law in 2012, established the new Breakthrough Therapy designation. A sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the product candidate is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Sponsors may request the FDA to designate a breakthrough therapy at the time of or any time after the submission of an IND, but ideally before an end-of-phase 2 meeting with the FDA. If the FDA designates a breakthrough therapy, it may take actions appropriate to expedite the development and review of the application, which may include holding meetings with the sponsor and the review team throughout the development of the therapy; providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the nonclinical and clinical data necessary for approval is as efficient as practicable; involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review; assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor; and considering alternative clinical trial designs when scientifically appropriate, which may result in smaller trials or more efficient trials that require less time to complete and may minimize the number of patients exposed to a potentially less efficacious treatment.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Fast Track designation, priority review and breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Post-Approval Requirements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">All therapeutic products manufactured or distributed pursuant to FDA approval or licensure are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements under the PDUFA for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications containing clinical data. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements, which impose significant procedural and documentation requirements. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements on manufacturers. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. CEL-SCI cannot be certain that it, or CEL-SCI&#8217;s present or future suppliers, will be able to comply with the cGMP regulations and other FDA regulatory requirements. If CEL-SCI is not able to comply with these requirements, the FDA may, among other things, take enforcement action or seek sanctions against use, impose restrictions on a product or its manufacturer, require CEL-SCI to recall a product from distribution, or withdraw approval of the BLA.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">fines, warning letters or holds on post-approval clinical studies;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">product seizure or detention, or refusal to permit the import or export of products;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">injunctions or the imposition of civil or criminal penalties; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">consent decrees, corporate integrity agreements, debarment, or exclusion from federal healthcare programs; or mandated modification of promotional materials and labeling and the issuance of corrective information.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The FDA closely regulates the marketing, labeling, advertising and promotion of drugs and biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of unapproved, or &#8220;off-label,&#8221; uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Orphan Drug Designation</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs or biologics intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States and there is no reasonable expectation that the cost of developing and making the drug for this type of disease or condition will be recovered from sales in the United States.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market a drug for the same indication for a period of 7 years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity. Orphan drug exclusivity also could block the approval of one of CEL-SCI&#8217;s products for seven years if a competitor obtains approval of a product before CEL-SCI does, for the same indication CEL-SCI is seeking, or if CEL-SCI&#8217;s product candidate is determined to be contained within the scope of the competitor&#8217;s product for the same indication or disease. If one of CEL-SCI&#8217;s products designated as an orphan drug receives marketing approval for an indication broader than that which is designated, it may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union has similar, but not identical, requirements and benefits.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Orphan drug designation must be requested before submitting a BLA to the FDA for review and approval. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Multikine has received Orphan Drug Status from the FDA.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Other U.S. Health Care Laws</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s sales, promotion, medical education and other activities following product approval will be subject to regulation by numerous regulatory and law enforcement authorities in the United States in addition to the FDA, including potentially the Federal Trade Commission, the Department of Justice, the Centers for Medicare and Medicaid Services, other divisions of the Department of Health and Human Services and state and local governments. CEL-SCI&#8217;s promotional and scientific/educational programs must comply with the anti-kickback provisions of the Social Security Act, the Foreign Corrupt Practices Act, the False Claims Act, the Physician Payments Sunshine Act, the Veterans Health Care Act and similar state laws.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Depending on the circumstances, failure to meet these applicable regulatory requirements can result in criminal prosecution, fines or other penalties, exclusion from government health care programs, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, private &#8220;qui tam&#8221; actions brought by individual whistleblowers under the False Claims Act in the name of the government or refusal to allow CEL-SCI to enter into supply contracts, including government contracts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Coverage, Pricing and Reimbursement in the U.S.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Sales of pharmaceutical products depend significantly on the availability of third-party coverage and reimbursement. Third-party payors include government health administrative authorities, managed care providers, private health insurers and other organizations. These third-party payors are increasingly challenging the price and examining the cost-effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare products and new drug classes, including biological products such as CEL-SCI&#8217;s product candidates. CEL-SCI may need to conduct expensive clinical studies to demonstrate the comparative cost-effectiveness of its products. The product candidates that CEL-SCI develops may not be considered cost-effective. It is time consuming and expensive for CEL-SCI to seek reimbursement from third-party payors. Reimbursement may not be available or sufficient to allow CEL-SCI to sell its products on a competitive and profitable basis.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect CEL-SCI&#8217;s ability to sell its products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Foreign Regulation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In addition to regulations in the United States, CEL-SCI will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its products to the extent CEL-SCI chooses to develop or sell any products outside of the United States. The approval process varies from country to country and the time may be longer or shorter than that required to obtain FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 1B. RISK FACTORS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The risks described below could adversely affect the price of CEL-SCI&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Risk Factor Summary</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has incurred significant losses since its inception and anticipates that it will continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI will require substantial additional capital to remain in operation. A failure to obtain this necessary capital when needed could force CEL-SCI to delay, limit, reduce or terminate the product candidates&#8217; development or commercialization efforts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The costs of the product candidates&#8217; development and clinical trials are difficult to estimate and will be very high for many years, preventing CEL-SCI from making a profit for the foreseeable future, if ever.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has not established a definite plan for the marketing of Multikine, if approved.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI depends heavily on the success of Multikine, for which Phase III results have been announced, while its other candidates are still in preclinical phases. CEL-SCI&#8217;s product candidates must undergo rigorous preclinical and clinical testing and regulatory approvals, which could be costly and time-consuming and subject CEL-SCI to unanticipated delays or prevent CEL-SCI from marketing any products. If CEL-SCI is unable to advance its product candidates in clinical development, obtain regulatory approval and ultimately commercialize its product candidates, or experience significant delays in doing so, CEL-SCI&#8217;s business will be materially harmed.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Even if CEL-SCI obtains regulatory approval for its investigational products, CEL-SCI will be subject to stringent, ongoing government regulation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial utility of an approved prescribing label, or result in significant negative consequences following marketing approval, if any.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Biologics carry unique risks and uncertainties, which could have a negative impact on future results of CEL-SCI&#8217;s operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The current and future relationships with healthcare professionals, principal investigators, consultants, potential customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable healthcare laws and regulations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s commercial success depends, in part, upon attaining significant market acceptance of its product candidates, if approved, among physicians, patients, healthcare payors and major operators of cancer clinics.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s patents might not protect its technology from competitors, in which case CEL-SCI may not have any advantage over competitors in selling any products that CEL-SCI may develop.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Much of CEL-SCI&#8217;s intellectual property is protected as trade secrets or confidential know-how, not by patents.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">You may experience future dilution as a result of future equity offerings or other equity issuances by CEL-SCI.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The price of CEL-SCI&#8217;s common stock has been volatile and is likely to continue to be volatile, which could result in substantial losses for CEL-SCI&#8217;s shareholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Risks Related to CEL-SCI</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI has incurred significant losses since its inception and anticipates that it will continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has a history of net losses, expects to incur substantial losses and have negative operating cash flow for the foreseeable future, and may never achieve or maintain profitability. Since the date of its formation and through September 30, 2024, CEL-SCI incurred net losses of approximately $514 million. CEL-SCI has relied principally upon the proceeds from the public and private sales of its securities to finance its activities to date. To date, CEL-SCI has not commercialized any products or generated any revenue from the sale of products, and CEL-SCI does not expect to generate any product revenue for the foreseeable future. CEL-SCI does not know whether or when it will generate product revenue or become profitable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is heavily dependent on the success of Multikine for which Phase III data has been announced and presented at ASCO 2022, ESMO 2022, ECHNO 2023, ESTRO 2023, ESMO 2023, IDDST 2024 and ESMO 2024. CEL-SCI cannot be certain that Multikine will receive regulatory approval or be successfully commercialized even if CEL-SCI receives regulatory approval. Multikine is the only product candidate in late-stage clinical development and CEL-SCI&#8217;s business currently depends heavily on its successful development, regulatory approval and commercialization. CEL-SCI has no drug products for sale currently and may never be able to develop approved and marketable drug products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Even if CEL-SCI succeeds in developing and commercializing one or more of its product candidates, CEL-SCI expects to continue to incur significant operating and capital expenditures as CEL-SCI:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">continues to undertake preclinical development and clinical trials for product candidates;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">seeks regulatory approvals for product candidates; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">implements additional internal systems and infrastructure.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">To become and remain profitable, CEL-SCI must succeed in developing and commercializing product candidates which must generate significant revenue. This will require CEL-SCI to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of its product candidates, discovering or acquiring additional product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling any products for which CEL-SCI may obtain regulatory approval. CEL-SCI is only in the preliminary stages of most of these activities. CEL-SCI may never succeed in these activities and, even if CEL-SCI does, may never generate revenue that is significant enough to achieve profitability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Even if CEL-SCI does achieve profitability, it may not be able to sustain or increase profitability on a quarterly or annual basis. The failure to become and remain profitable could depress the value of CEL-SCI&#8217;s common stock and could impair its ability to raise capital, expand its business, maintain research and development efforts, diversify product offerings or even continue in operation. A decline in the value of CEL-SCI&#8217;s common stock could cause its stockholders to lose all or part of their investment.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI has identified conditions and events that raise substantial doubt about its ability to continue as a going concern for more than twelve months from the date of these financial statements.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Primarily as a result of CEL-SCI&#8217;s losses incurred to date, CEL-SCI&#8217;s expected continued future losses, and the uncertainties associated with obtaining regulatory approval and ultimately commercializing its products, management has identified conditions and events that raise substantial doubt about CEL-SCI&#8217;s ability to continue as a going concern. CEL-SCI&#8217;s ability to continue as a going concern is contingent upon, among other factors, the sale of its securities or obtaining alternate financing.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI will require substantial additional capital to remain in operation. A failure to obtain this necessary capital when needed could force CEL-SCI to delay, limit, reduce or terminate the product candidates&#8217; development or commercialization efforts.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As of September 30, 2024, CEL-SCI had cash and cash equivalents of approximately $4.7 million. CEL-SCI believes that it will continue to expend substantial resources for the foreseeable future developing Multikine, LEAPS and any other product candidates or technologies that it may develop or acquire. These expenditures will include costs associated with research and development, obtaining regulatory approvals and having the products manufactured, as well as marketing and selling products approved for sale, if any. In addition, other unanticipated costs may arise. CEL-SCI cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of the product candidates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s future capital requirements depend on many factors, including:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the cost of completing a confirmatory registration study of Multikine for the treatment of certain head and neck cancers;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the results of the applications to and meetings with the FDA, the EMA and other regulatory authorities and the consequential effect on operating costs;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the cost, timing and outcome of the efforts to obtain marketing approval for Multikine in the United States, Europe and in other jurisdictions, including the preparation and filing of regulatory submissions for Multikine with the FDA, the EMA and other regulatory authorities;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the scope, progress, results and costs of additional preclinical, clinical, or other studies for additional indications for Multikine, LEAPS and other product candidates and technologies that CEL-SCI may develop or acquire;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the timing of, and the costs involved in, obtaining regulatory approvals for LEAPS if clinical studies are successful;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the cost and timing of future commercialization activities for the products, if any of the product candidates are approved for marketing, including product manufacturing, marketing, sales and distribution costs;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the revenue, if any, received from commercial sales of the product candidates for which CEL-SCI receives marketing approval;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the cost of having the product candidates manufactured for clinical trials and in preparation for commercialization;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the costs involved in preparing, filing and prosecuting patent applications and maintaining, defending and enforcing its intellectual property rights, including litigation costs, and the outcome of such litigation; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 30px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the extent to which CEL-SCI acquires or in-licenses other products or technologies.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI will need to raise additional funds in order to continue its operations and additional funds may not be available when CEL-SCI needs them on terms that are acceptable to CEL-SCI, or at all. If adequate funds are not available to CEL-SCI on a timely basis, CEL-SCI may be required to delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for Multikine, LEAPS, or any other product candidates or technologies that CEL-SCI develops or acquires, or delay, limit, reduce or terminate its sales and marketing activities that may be necessary to commercialize its product candidates. Due to recurring losses from operations and future liquidity needs, there is substantial doubt about CEL-SCI&#8217;s ability to continue as a going concern without additional capital becoming available. The substantial doubt about CEL-SCI&#8217;s ability to continue as a going concern could have an adverse impact on CEL-SCI&#8217;s ability to execute its business plan, result in the reluctance on the part of certain suppliers to do business with CEL-SCI, or adversely affect CEL-SCI&#8217;s ability to raise additional debt or equity capital.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>The costs of the product candidates&#8217; development and clinical trials are difficult to estimate and will be very high for many years, preventing CEL-SCI from making a profit for the foreseeable future, if ever.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Clinical and other studies necessary to obtain approval of a new drug or biologic can be time consuming and costly, especially in the United States, but also in foreign countries. The estimates of the costs associated with future clinical trials and research may be substantially higher than what CEL-SCI actually experiences. It is impossible to predict what CEL-SCI will face in the development of a product candidate such as Multikine. The purpose of clinical trials is to provide both CEL-SCI and regulatory authorities with safety and efficacy data in humans. The difficult and often complex steps necessary to obtain regulatory approval, especially that of the FDA and the EMA, involve significant costs and may require several years to complete. CEL-SCI expects that it will need substantial additional financing over an extended period of time in order to fund the costs of future clinical trials, related research, and general and administrative expenses.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI&#8217;s LEAPS technology may not result in a viable drug candidate</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Using CEL-SCI&#8217;s LEAPS technology, CEL-SCI is developing a LEAPS immunotherapy for the potential treatment of Rheumatoid Arthritis. However, the development of this technology is in a preliminary stage and CEL-SCI is currently focused on having Multikine approved for sale. There can be no assurance that the LEAPS technology will be successful in treating any disease. CEL-SCI&#8217;s primary focus at present is seeking the approval of Multikine for the treatment of head and neck cancer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">28</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>An adverse determination in any future legal proceedings could have a material adverse effect on CEL-SCI.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI may be the target of claims asserting violations of securities fraud and derivative actions, or other litigation or arbitration proceedings in the future. Any future litigation could result in substantial costs and divert management&#8217;s attention and resources. These legal proceedings may result in large judgments or settlements against CEL-SCI, any of which could have a material adverse effect on its business, operating results, financial condition and liquidity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Compliance with changing regulations concerning corporate governance and public disclosure may result in additional expenses.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Changing laws, regulations and standards relating to corporate governance and public disclosure may create uncertainty regarding compliance matters. New or changed laws, regulations and standards are subject to varying interpretations in many cases. As a result, their application in practice may evolve over time. CEL-SCI is committed to maintaining high standards of corporate governance and public disclosure. Complying with evolving interpretations of new or changing legal requirements may cause CEL-SCI to incur higher costs as CEL-SCI revises current practices, policies and procedures, and may divert management time and attention from potential revenue-generating activities to compliance matters. If the efforts to comply with new or changed laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, CEL-SCI&#8217;s reputation may also be harmed. Further, CEL-SCI&#8217;s board members, chief executive officer, and other executive officers could face an increased risk of personal liability in connection with the performance of their duties. As a result, CEL-SCI may have difficulty attracting and retaining qualified board members and executive officers, which could harm its business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI has not established a definite plan for the marketing of Multikine, if approved.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has not established a definitive plan for marketing Multikine nor has CEL-SCI established a price structure for any of its product candidates, if approved. However, CEL-SCI intends, if it is in a position to do so, to sell Multikine itself in certain markets where it is approved, and or to enter into written marketing agreements with various third parties with established sales forces in such markets. The sales forces in turn would, CEL-SCI believes, focus on selling Multikine to targeted cancer centers, physicians and clinics involved in the treatment of head and neck cancer. CEL-SCI has already licensed future sales of Multikine, if approved, to three companies: Teva Pharmaceutical Industries Ltd. in Israel, Turkey, Serbia and Croatia; Orient Europharma in Taiwan, Singapore, Hong Kong, Malaysia, South Korea, the Philippines, Australia and New Zealand; and Byron BioPharma, LLC in South Africa. CEL-SCI believes that these companies will have the resources to market Multikine appropriately in their respective territories, if approved, but there is no guarantee that they will. There is no assurance that CEL-SCI will be able to find qualified third-party partners to market its products in other areas, on terms that are favorable to CEL-SCI, or at all.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI may encounter problems, delays and additional expenses in developing marketing plans with third parties. In addition, even if Multikine, if approved, is cost-effective and demonstrated to increase overall patient survival, CEL-SCI may experience other limitations involving the proposed sale of Multikine, such as uncertainty of third-party coverage and reimbursement. There is no assurance that CEL-SCI can successfully market Multikine, if approved, or any other product candidates it may develop.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">29</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI hopes to expand its clinical development capabilities in the future, and any difficulties hiring or retaining key personnel or managing this growth could disrupt its operations.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is highly dependent on the principal members of its management and development staff. CEL-SCI expects to expand its clinical development and manufacturing capabilities, which will involve hiring additional employees. Future growth will require CEL-SCI to continue to implement and improve its managerial, operational and financial systems and continue to retain, recruit and train additional qualified personnel, which may impose a strain on its administrative and its operational infrastructure. The competition for qualified personnel in the biopharmaceutical field is intense. CEL-SCI is highly dependent on its ability to attract, retain and motivate highly qualified management and specialized personnel required for clinical development. Due to limited resources, CEL-SCI may not be able to effectively manage the expansion of its operations or recruit and train additional qualified personnel. If CEL-SCI is unable to retain key personnel or manage its future growth effectively, CEL-SCI may not be able to implement its business plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>If product liability or patient injury lawsuits are brought against CEL-SCI, CEL-SCI may incur substantial liabilities and may be required to limit clinical testing or future commercialization of Multikine or its other product candidates.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI faces an inherent risk of product liability as a result of the clinical testing of Multikine and other product candidates and will face an even greater risk if CEL-SCI is able to commercialize any of its product candidates. For example, CEL-SCI may be sued if its Multikine or LEAPS product candidates, or any other future product candidates, allegedly cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing or, if approved, marketing, sale or during administration to patients. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Furthermore, Multikine is made, in part, from components of human blood. There are inherent risks associated with products that involve human blood such as possible contamination with viruses, including hepatitis or HIV. Any possible contamination could cause injuries to patients who receive contaminated Multikine, or could require CEL-SCI to destroy batches of Multikine, thereby subjecting CEL-SCI to possible financial losses, lawsuits and harm to its business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If CEL-SCI cannot successfully defend itself against product liability claims, CEL-SCI may incur substantial liabilities or be required to limit or cease the clinical testing or commercialization of its product candidates, if approved. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">decreased demand for Multikine or other product candidates, if approved and commercialized, or clinical holds or suspension of the IND while the candidates are still in clinical development;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">injury to CEL-SCI&#8217;s reputation;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">withdrawal of existing, or failure to enroll additional, clinical trial participants;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">costs to defend any related litigation;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">a diversion of management&#8217;s time and resources;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">substantial monetary awards to trial participants or patients;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">recalls of approved products, withdrawal of BLA approvals or new labeling, marketing or promotional restrictions;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">loss of revenue;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">inability to commercialize Multikine or other product candidates; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">a decline in the price of CEL-SCI&#8217;s common stock.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">30</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Although CEL-SCI has product liability insurance for Multikine in the amount of $10 million, the successful prosecution of a product liability case against CEL-SCI could have a materially adverse effect upon its business if the amount of any judgment exceeds the insurance coverage. Any claim that may be brought against CEL-SCI could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by CEL-SCI&#8217;s insurance or that is in excess of the limits of the insurance coverage. CEL-SCI&#8217;s insurance policies also have various exclusions, and CEL-SCI may be subject to a claim for which CEL-SCI has no coverage. CEL-SCI may have to pay any amounts awarded by a court or negotiated in a settlement that exceed the coverage limitations or that are not covered by its insurance, and CEL-SCI may not have, or be able to obtain, sufficient capital to pay such amounts. CEL-SCI completed enrollment in the Phase III clinical trial for Multikine in September 2016. Although no claims have been brought to date, participants in the clinical trials could bring civil actions against CEL-SCI for any unanticipated harmful effects allegedly arising from the use of Multikine or any other product candidate that CEL-SCI may attempt to develop.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI&#8217;s commercial success depends, in part, upon attaining significant market acceptance of its product candidates, if approved, among physicians, patients, healthcare payors and major operators of cancer clinics.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Even if CEL-SCI obtains regulatory approval for its product candidates, any resulting product may not gain market acceptance among physicians, healthcare payors, patients and the medical community, which are critical to commercial success. Market acceptance of any product candidate for which CEL-SCI receives approval depends on a number of factors, including:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the efficacy and safety of the products as demonstrated in clinical trials;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the timing of market introduction of such product as well as competitive products;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the clinical indications for which the biological product is approved;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the approval, availability, market acceptance and reimbursement for the companion diagnostic, if appropriate or necessary;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">acceptance by physicians, major operators of cancer clinics and patients of the biologic as a safe and effective treatment;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the potential and perceived advantages of such product candidate over alternative treatments, especially with respect to patient subsets that are targeted with such product;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the safety of such product seen in a broader patient group, including its use outside the approved indications;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the cost of treatment in relation to alternative treatments;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the availability of adequate reimbursement and pricing by third-party payors and government authorities;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">relative convenience and ease of administration;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the prevalence and severity of adverse side effects; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the effectiveness of sales and marketing efforts.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If CEL-SCI&#8217;s product candidates are approved but fail to achieve an adequate level of acceptance by physicians, healthcare payors and patients, CEL-SCI will not be able to generate significant revenues, and CEL-SCI may not become or remain profitable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Any failure to meet the continued listing requirements of NYSE American could result in a delisting of CEL-SCI&#8217;s common stock.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Since October 14, 2024, CEL-SCI&#8217;s closing price on NYSE American has been below $1.00. If CEL-SCI fails to satisfy the continued listing requirements of NYSE American, such as failing the minimum closing bid price requirement, NYSE American may take steps to delist CEL-SCI&#8217;s securities. Such a delisting would likely have a negative effect on the price of CEL-SCI&#8217;s securities and would impair your ability to sell or purchase the securities when you wish to do so. In the event of a delisting, CEL-SCI can provide no assurance that any action taken by CEL-SCI to restore compliance with listing requirements would allow CEL-SCI&#8217;s securities to become listed again, stabilize the market price or improve the liquidity of CEL-SCI&#8217;s securities, prevent CEL-SCI&#8217;s securities from dropping below the NYSE American minimum bid price requirement or prevent future non-compliance with NYSE American&#8217;s listing requirements. Additionally, if CEL-SCI&#8217;s securities are not listed on, or become delisted from, NYSE American for any reason, and are quoted on the OTC Bulletin Board, an inter-dealer automated quotation system for equity securities that is not a national securities exchange, the liquidity and price of our securities may be more limited than if CEL-SCI&#8217;s securities were quoted or listed on NYSE American or another national securities exchange. You may be unable to sell your securities unless a market can be established or sustained.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">31</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Under CEL-SCI&#8217;s amended bylaws, stockholders that initiate certain proceedings may be obligated to reimburse CEL-SCI and its officers and directors for all fees, costs and expenses incurred in connection with such proceedings if the claim proves unsuccessful.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On February 18, 2015, CEL-SCI adopted new bylaws which include a fee-shifting provision in Article X for stockholder claims. Article X provides that in the event any stockholder initiates or asserts a claim against CEL-SCI, or any of its officers or directors, including any derivative claim or claim purportedly filed on CEL-SCI&#8217;s behalf, and the stockholder does not obtain a judgment on the merits that substantially achieves, in substance and amount, the full remedy sought, then the stockholder will be obligated to reimburse CEL-SCI and any of its officers or directors named in the action, for all fees, costs and expenses of every kind and description that CEL-SCI or its officers or directors may incur in connection with the claim. In adopting Article X, it is the intent that:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">all actions, including federal securities law claims, would be subject to Article X;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the phrase &#8220;a judgment on the merits&#8221; means the determination by a court of competent jurisdiction on the matters submitted to the court;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the phrase &#8220;substantially achieves, in both substance and amount&#8221; means the plaintiffs in the action would be awarded at least 90% of the relief sought;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">only persons who were stockholders at the time an action was brought would be subject to Article X; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">in addition to CEL-SCI, only the directors or officers named in the action would be allowed to recover.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The fee-shifting provision contained in Article X of the bylaws is not limited to specific types of actions, but is rather potentially applicable to the fullest extent permitted by law. Fee-shifting bylaws are relatively new and untested. The case law and potential legislative action on fee-shifting bylaws are evolving and there exists considerable uncertainty regarding the validity of, and potential judicial and legislative responses to, such bylaws. For example, it is unclear whether the ability to invoke the fee-shifting bylaw in connection with claims under the federal securities laws would be pre-empted by federal law. Similarly, it is unclear how courts might apply the standard that a claiming stockholder must obtain a judgment that substantially achieves, in substance and amount, the full remedy sought. The application of the fee-shifting bylaw in connection with such claims, if any, will depend in part on future developments of the law. CEL-SCI cannot assure its shareholders that CEL-SCI will or will not invoke the fee-shifting bylaw in any particular dispute. In addition, given the unsettled state of the law related to fee-shifting bylaws, such as CEL-SCI&#8217;s, CEL-SCI may incur significant additional costs associated with resolving disputes with respect to such bylaw, which could adversely affect CEL-SCI&#8217;s business and financial condition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If a stockholder that brings any such claim, suit, action or proceeding is unable to obtain the required judgment, the attorneys&#8217; fees and other litigation expenses that might be shifted to a claiming stockholder are potentially significant. This fee-shifting bylaw may therefore dissuade or discourage stockholders and their attorneys from initiating lawsuits or claims against CEL-SCI or its directors and officers. In addition, it may impact the fees, contingency or otherwise, required by potential plaintiffs&#8217; attorneys to represent the stockholders or otherwise discourage plaintiffs&#8217; attorneys from representing the stockholders at all. As a result, this bylaw may limit the ability of stockholders to alter CEL-SCI&#8217;s management and direction, particularly through litigation or the threat of litigation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>The provision of the amended bylaws requiring exclusive venue in the U.S. District Court for Delaware for certain types of lawsuits may have the effect of discouraging lawsuits against CEL-SCI and its directors and officers.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Article X of CEL-SCI&#8217;s amended bylaws provides that stockholder claims brought against CEL-SCI, or its officers or directors, including any derivative claim or claim purportedly filed on its behalf, must be brought in the U.S. District Court for the district of Delaware and that with respect to any such claim, the laws of Delaware will apply.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The exclusive forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum the stockholder finds favorable for disputes with CEL-SCI or its directors or officers and may have the effect of discouraging lawsuits with respect to claims that may benefit CEL-SCI or its stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">32</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>A provision in our Bylaws regarding shareholder claims may not be enforceable.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Article X of our bylaws provides that stockholder claims brought against us, or our officers or directors, including any derivative claim or claim purportedly filed on our behalf, must be brought in the U.S. District Court for the district of Delaware.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Although it is our intent that this provision applies to actions arising under the Securities Act of 1933 and the Securities Exchange Act of 1934 there is uncertainty as to whether a court would enforce this provision since Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations under the Securities Act.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In addition, since this provision in our bylaws applies to state law claims there is uncertainty as to whether any court would enforce this provision.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Risks Related to Clinical Development, Government Approvals and the Marketing of Biopharmaceutical Products</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI depends heavily on the success of Multikine, for which Phase III data has been presented, while its other candidates are still in preclinical phases. CEL-SCI&#8217;s product candidates must undergo rigorous preclinical and clinical testing and regulatory approvals, which could be costly and time-consuming and subject CEL-SCI to unanticipated delays or prevent CEL-SCI from marketing any products. If CEL-SCI is unable to advance its product candidates in clinical development, obtain regulatory approval and ultimately commercialize its product candidates, or experiences significant delays in doing so, CEL-SCI&#8217;s business will be materially harmed.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI currently has no products approved for sale and CEL-SCI cannot guarantee that it will ever have marketable products. CEL-SCI&#8217;s product candidates are subject to premarket approval from the FDA in the United States, the EMA in the European Union, and by comparable agencies in most foreign countries before they can be sold. Before obtaining marketing approval, these product candidates must undergo costly and time consuming preclinical and clinical testing which could subject CEL-SCI to unanticipated delays and may prevent CEL-SCI from marketing the product candidates in the future. There can be no assurance that such approvals will be granted on a timely basis, if at all.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of the product candidates may not be predictive of the results of later-stage clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. CEL-SCI&#8217;s current and future clinical trials may not be successful.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is in the early development stages for the candidates designed using its LEAPS technology and has not yet initiated any clinical studies for any of those product candidates. Clinical trials can be delayed for a variety of reasons, including delays related to:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the availability of financial resources needed to commence and complete the planned trials;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">obtaining regulatory approval to commence a trial;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">obtaining Institutional Review Board, or IRB, approval at each clinical trial site;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">recruiting suitable patients to participate in a trial;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">having patients complete a trial or return for post-treatment follow-up;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">clinical trial sites deviating from trial protocol or dropping out of a trial;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">adding new clinical trial sites; or</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">manufacturing sufficient quantities of the product candidate for use in clinical trials.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">33</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the competence of the CRO running the study, size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and clinicians' and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications CEL-SCI is investigating. Furthermore, CEL-SCI relies on CROs and clinical trial sites to ensure the proper and timely conduct of the clinical trials and while CEL-SCI has agreements governing their committed activities, CEL-SCI has limited influence over their actual performance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI could also encounter significant delays and/or need to terminate a development program for a product candidate if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of the product candidates while existing treatments have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by CEL-SCI, one or more of the IRBs for the institutions in which such trials are being conducted, by CEL-SCI upon a final recommendation by the Independent Data Monitoring Committee, or IDMC, with which CEL-SCI agrees for such trial, or by FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or the clinical protocols, as a result of inspection of the clinical trial operations or trial site(s) by FDA or other regulatory authorities, the imposition of a clinical hold or partial clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. The occurrence of any one or more of these events would have significant and severe material consequences for CEL-SCI and could impact CEL-SCI&#8217;s ability to continue as a going concern.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If CEL-SCI experiences termination of, or delays in the completion of, any clinical trial of its product candidates, the commercial prospects for the product candidates will be harmed, and the ability to generate product revenues will be delayed. In addition, any delays in completing the clinical trials will increase the costs, slow the product development and approval process and jeopardize the ability to commence product sales and generate revenues. Any of these occurrences may harm CEL-SCI&#8217;s business, prospects, financial condition and results of operations significantly. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to a delay or the denial of regulatory approval for the product candidates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI cannot be certain when or under what conditions it will undertake future clinical trials. Early trials for the other product candidates, or the plans for later trials, may not satisfy the requirements of regulatory authorities, such as the FDA. CEL-SCI may fail to find subjects willing to enroll in the trials. Accordingly, the clinical trials relating to the product candidates may not be completed on schedule, the FDA or foreign regulatory agencies may order CEL-SCI to stop or modify research, or these agencies may not ultimately approve any of the product candidates for commercial sale. Varying interpretations of the data obtained from pre-clinical and clinical testing could delay, limit or prevent regulatory approval of the product candidates. The data collected from the clinical trials may not be sufficient to support regulatory approval of the various product candidates, including Multikine. The failure to adequately demonstrate the safety and efficacy of any of the product candidates would delay or prevent regulatory approval of the product candidates in the United States, which could prevent CEL-SCI from achieving profitability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">34</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The development and testing of product candidates and the process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include, among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, termination of the Phase III study, warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, and payment of civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on CEL-SCI.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The requirements governing the conduct of clinical trials, manufacturing and marketing of the product candidates, including Multikine, outside the United States vary from country to country. Foreign approvals may take longer to obtain than FDA approvals and can require, among other things, additional testing and different trial designs. Foreign regulatory approval processes include all of the risks associated with the FDA approval process. Some of those agencies also must approve prices for products approved for marketing. Approval of a product by the FDA or the EMA does not ensure approval of the same product by the health authorities of other countries. In addition, changes in regulatory requirements for product approval in any country during the clinical trial process and regulatory agency review of each submitted new application may cause delays or rejections.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI has only limited experience in filing and pursuing applications necessary to gain regulatory approvals. </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">This lack of experience may impede its ability to obtain timely approvals from regulatory agencies, if at all. CEL-SCI will not be able to commercialize Multikine and other product candidates until CEL-SCI has obtained regulatory approval. In addition, regulatory authorities may also limit the types of patients to which CEL-SCI or its third-party partners may market Multikine (if approved) or the other product candidates. Any failure to obtain or any delay in obtaining required regulatory approvals may adversely affect CEL-SCI&#8217;s or its third-party partners&#8217; ability to successfully market the product candidates even if they are approved.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Even if CEL-SCI obtains regulatory approval for its investigational products, CEL-SCI will be subject to stringent, ongoing government regulation.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If CEL-SCI&#8217;s investigational products receive regulatory approval, either in the United States or internationally, those products will be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval and may contain requirements for potentially costly post-marketing testing, including Phase IV clinical trials, and surveillance of the safety and efficacy of the investigational products. CEL-SCI will continue to be subject to extensive regulatory requirements. These regulations are wide-ranging and govern, among other things:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">product design, development and manufacture;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">product application and use;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">adverse drug experience monitoring and reporting;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">product advertising and promotion;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">product manufacturing, including compliance with good manufacturing practices;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">record keeping requirements;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">registration and listing of products with the FDA, EMA and other state and national agencies;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">product storage and shipping;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">drug sampling and distribution requirements;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">electronic record and signature requirements; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">labeling changes or modifications.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">35</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI and any of its third-party manufacturers or suppliers must continually adhere to federal regulations setting forth human drug and biologic manufacturing requirements, known as current Good Manufacturing Practices, or cGMPs, and their foreign equivalents, which are enforced by the FDA, the EMA and other national regulatory bodies through their facilities inspection programs. If the facilities, or the facilities of the contract manufacturers or suppliers, cannot pass a pre-approval inspection by regulators or fail such inspections in the future, the FDA, EMA or other national regulators will not approve the marketing applications for the product candidates, or may withdraw any prior approval. In complying with cGMP and foreign regulatory requirements, CEL-SCI and any of its potential third-party manufacturers or suppliers will be obligated to expend time, money and effort in production, record-keeping and quality control to ensure that the product candidates meet applicable specifications and other requirements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If CEL-SCI does not comply with regulatory requirements at any stage, whether before or after marketing approval is obtained, CEL-SCI may be subject to, among other things, license suspension or revocation, criminal prosecution, seizure, injunction, fines, be forced to remove a product from the market or experience other adverse consequences, including restrictions or delays in obtaining regulatory marketing approval for such products or for other product candidates for which CEL-SCI seeks approval. This could materially harm CEL-SCI&#8217;s financial results, reputation and stock price. Additionally, CEL-SCI may not be able to obtain the labeling claims necessary or desirable for product promotion. If CEL-SCI or other parties identify adverse effects after any of the products are on the market, or if manufacturing problems occur, regulatory approval may be suspended or withdrawn. CEL-SCI may be required to reformulate products, conduct additional clinical trials, make changes in product labeling or indications of use, or submit additional marketing applications to support any changes. If CEL-SCI encounters any of the foregoing problems, its business and results of operations will be harmed and the market price of its common stock may decline.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The FDA and other governmental authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of CEL-SCI&#8217;s product candidates. If CEL-SCI is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if CEL-SCI is not able to maintain regulatory compliance, CEL-SCI may lose any marketing approval that it may have obtained, which would adversely affect its business, prospects and ability to achieve or sustain profitability. CEL-SCI cannot predict the extent of adverse government regulations which might arise from future legislative or administrative action. Without government approval, CEL-SCI will be unable to sell any of its product candidates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI&#8217;s product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial utility of an approved prescribing label, or result in significant negative consequences following marketing approval, if any.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Undesirable side effects caused by its product candidates could cause CEL-SCI or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Results of the clinical trials could reveal a high and unacceptable severity and/or prevalence of these or other side effects. In such an event, the trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order CEL-SCI to cease further development of, or deny approval of, the product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm CEL-SCI&#8217;s business, financial condition and prospects significantly.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">36</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Additionally, if one or more of the product candidates receives marketing approval, and CEL-SCI or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including but not limited to the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">regulatory authorities may withdraw approvals of such product or require product recalls;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">regulatory authorities may require additional warnings on the label or impose restrictions on product distribution or use;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">regulatory authorities may require CEL-SCI to conduct new post-marketing studies or clinical trials;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI could receive warning or untitled letters from the FDA or comparable notices of violations from foreign regulatory authorities;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI could be sued and held liable for harm caused to patients; and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI&#8217;s reputation may suffer.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Any of these events could prevent CEL-SCI from achieving or maintaining market acceptance of a particular product candidate, if approved, and could significantly harm its business, results of operations and prospects.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI relies on third parties to conduct its preclinical and clinical trials. If these third parties do not successfully carry out their contractual duties and meet regulatory requirements, or meet expected deadlines, CEL-SCI may not be able to obtain regulatory approval for or commercialize the product candidates and its business could be substantially harmed.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI does not have the ability to independently conduct large clinical trials. CEL-SCI has relied upon and plans to continue to rely upon third-party CROs to prepare for, conduct, monitor and manage data for its ongoing preclinical and clinical programs, including the global Phase III trial for Multikine. CEL-SCI relies on these parties for all aspects of the execution of its clinical trials and although CEL-SCI diligently oversees and carefully manages the CROs, CEL-SCI directly controls only certain aspects of their activities and relies upon them to provide timely, complete, and accurate reports on the conduct of the studies. Although such third parties provide support and represent CEL-SCI for regulatory purposes in the context of the clinical trials, ultimately CEL-SCI is responsible for ensuring that each of the studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards, and the reliance on the CROs does not relieve CEL-SCI of its regulatory responsibilities. CEL-SCI and the CROs acting on CEL-SCI&#8217;s behalf, as well as principal investigators and trial sites, are required to comply with Good Clinical Practice, or GCP, and other applicable requirements, which are implemented through regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area, or EEA, and comparable foreign regulatory authorities for all of the products in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators, and trial sites. If CEL-SCI or any of the CROs fail to comply with applicable GCPs or other applicable regulations, the clinical data generated in the clinical trials may be determined to be unreliable and CEL-SCI may therefore need to enroll additional subjects in the clinical trials, or the FDA, EMA or comparable foreign regulatory authorities may require CEL-SCI to perform an additional clinical trial or trials before approving the marketing applications. Moreover, if CEL-SCI or any of the CROs, principal investigators, or trial sites, fail to comply with applicable regulatory and GCP requirements, CEL-SCI, the CROs, principal investigators, or trial sites may be subject to enforcement actions, such as fines, warning letters, untitled letters, clinical holds, civil or criminal penalties, and/or injunctions. CEL-SCI cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of the clinical trials comply with cGCP regulations. In addition, the clinical trials must be conducted with product produced under cGMP regulations. The failure to comply with these regulations may require CEL-SCI to delay or repeat clinical trials, which would delay the regulatory approval process.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">37</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If any of the relationships with the third-party CROs terminate, CEL-SCI may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. In addition, the CROs are not CEL-SCI&#8217;s employees, and except for remedies available to CEL-SCI under the agreements with such CROs, CEL-SCI cannot control whether or not they devote sufficient time and resources to the on-going clinical, nonclinical and preclinical programs. If CROs do not successfully fulfill their regulatory obligations, carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to the clinical protocols, regulatory requirements or for other reasons, the clinical trials may be extended, delayed or terminated, and CEL-SCI may not be able to obtain regulatory approval for, or successfully commercialize, the product candidates. As a result, CEL-SCI&#8217;s results of operations and the commercial prospects for the product candidates would be harmed, the costs could increase and the ability to generate revenues could be delayed.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays may occur, which can materially impact CEL-SCI&#8217;s ability to meet the desired clinical development timelines. Though CEL-SCI diligently oversees and carefully manages its relationships with the CROs, there can be no assurance that CEL-SCI will not encounter similar challenges or delays in clinical development in the future or that these delays or challenges will not have a material adverse impact on CEL-SCI&#8217;s business, financial condition and prospects.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI has obtained orphan drug designation from the FDA for Multikine for neoadjuvant, or primary, therapy in patients with squamous cell carcinoma of the head and neck, but CEL-SCI may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biologic intended to treat a rare disease or condition, which is defined as one occurring in a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug or biologic will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Even though CEL-SCI has received orphan drug designation for Multikine for the treatment of squamous cell carcinoma of the head and neck, CEL-SCI may not be the first to obtain marketing approval of a product for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. CEL-SCI believes this to be unlikely since it does not know of any other company with a similar technology in Phase III studies. In addition, exclusive marketing rights in the United States may be limited if CEL-SCI seeks approval for an indication broader than the orphan-designated indication, or may be lost if the FDA later determines that the request for designation was materially defective or if CEL-SCI is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if CEL-SCI obtains orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different drugs with different active moieties can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve another drug with the same active moiety for the same condition if the FDA concludes that the later drug is safer, more effective, or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">38</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Statements in this report about the efficacy and pathway of approval for Multikine are based on CEL-SCI&#8217;s analysis of its Phase III trial and are speculative in nature and may ultimately prove to be inaccurate or incorrect. </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">This report contains statements about CEL-SCI&#8217;s intention to pursue accelerated and/or conditional approval in various jurisdictions for Multikine, about Multikine's demonstrated efficacy and the potential to receive such approvals based on CEL-SCI&#8217;s analysis of the results of its Phase III trial and other data. However, these statements reflect CEL-SCI&#8217;s opinions and beliefs, and although CEL-SCI believe such statements are accurate, they are speculative in nature and there is a possibility that they may be inaccurate or incorrect. There is no certainty that the results observed in CEL-SCI&#8217;s Phase III trial will be replicated in any future study or results from any future study would not vary significantly from CEL-SCI&#8217;s Phase III trial results, or that CEL-SCI&#8217;s results to date, or the results of any future study, will be sufficient to obtain accelerated and/or conditional approvals for Multikine in any jurisdiction.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI may need to conduct a &#8216;Bridging study&#8217; for the assay used in the confirmatory study to detect/determine the PD-L1 status of patients. The Bridging study will test the concordance of the PD-L1 test results between the assay used in the clinical trial with the diagnostic companion test for PD-L1; developed in collaboration with a diagnostics testing partner prior to submission for marketing approval for Multikine. If the bridging study or collaboration with CEL-SCI&#8217;s diagnostics partner is disrupted, then CEL-SCI may not be able to timely submit the marketing approval to the FDA.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">For the confirmatory study, CEL-SCI is required to perform an assay for PD-L1 to determine if patients meet the required PD-L1 selection criteria. The PD-L1 test CEL-SCI proposes to use to select patients for the confirmatory study is the same test that was used in CEL-SCI&#8217;s phase 3 trial, but is not a currently approved test for head and neck cancer. FDA agreed this test is acceptable to use for the confirmatory study, however, they also stipulated that Multikine will only be approved for commercial use in conjunction with a CDRH approved companion diagnostic test which will be used to determine PD-L1 levels in the head and neck cancer patient population for which Multikine is intended.&#160; CEL-SCI intends to select a diagnostic partner for the companion diagnostic test&#8217;s development, validation, and future submission. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">CEL-SCI will need to perform a bridging study to show that the PD-L1 assay test results CEL-SCI used for the selection of patients for the confirmatory study can be reproduced at an acceptable level of concordance using the companion diagnostic test for the testing of the same patient samples. There can be no assurance that CEL-SCI will be able to identify and collaborate with a suitable diagnostic partner on a timely basis, or at all. Even if CEL-SCI was able to establish such a collaboration, although there is a very good likelihood, there can be no complete assurance that CEL-SCI will be able to perform the bridging study successfully, on a timely basis or at all. Therefore, CEL-SCI may be unable to fulfill the criteria required to be able to submit the BLA and marketing license application to the FDA in a timely manner.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Biologics carry unique risks and uncertainties, which could have a negative impact on future results of CEL-SCI&#8217;s operations.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The successful discovery, development, manufacturing and sale of biological products such as CEL-SCI&#8217;s candidates is a long, expensive and uncertain process. There are unique risks and uncertainties with biologics. For example, access to and supply of necessary biological materials, such as cell lines, may be limited and governmental regulations restrict access to and regulate the transport and use of such materials. In addition, the development, manufacturing and sale of biologics is subject to regulations that are often more complex and extensive than the regulations applicable to other pharmaceutical products. Manufacturing biologics, especially in large quantities, is often complex and may require the use of innovative technologies. Such manufacturing also requires facilities specifically designed and validated for this purpose and sophisticated quality assurance and quality control procedures. Biologics are also frequently costly to manufacture because production inputs are derived from living animal or plant material, and some biologics cannot be made synthetically. Failure to successfully discover, develop, manufacture and sell its biological product candidates would adversely impact CEL-SCI&#8217;s business and future results of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI may face substantial competition, which may result in others discovering, developing or commercializing competing products more quickly or more successfully than CEL-SCI.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The development and commercialization of new drug and biological products is highly competitive. CEL-SCI expects to face competition with respect to any product candidates that CEL-SCI may seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Many of the companies which CEL-SCI may compete with in the future have significantly greater financial resources and expertise in research and development, manufacturing, nonclinical studies, conducting clinical trials, obtaining marketing approvals and marketing approved products than CEL-SCI. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of CEL-SCI&#8217;s potential competitors. Smaller and early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties may compete with CEL-SCI in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, CEL-SCI&#8217;s programs.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">39</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI may be unable to successfully scale-up manufacturing of its lead product candidate Multikine in sufficient quality and quantity, which would delay or prevent CEL-SCI from commercializing this product, if approved for marketing by the FDA or other regulatory agencies.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In order to commercialize its product candidates, CEL-SCI will need to manufacture them in large quantities. At the present time, CEL-SCI is manufacturing Multikine in preparation for the confirmatory registration study. CEL-SCI may be unable to successfully increase the manufacturing capacity for its lead product candidate Multikine due to issues that may arise during scale-up activities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Further, in order to release product and demonstrate stability of product candidates for future commercial use, CEL-SCI&#8217;s analytical methods must be validated in accordance with regulatory guidelines. CEL-SCI may not be able to successfully validate or maintain validation of its analytical methods during scale-up or demonstrate adequate purity, stability or comparability of its biological product candidates in a timely or cost-effective manner, or at all. Even if CEL-SCI believes its manufacturing processes meet all of the regulatory manufacturing requirements, the FDA will review those processes and the manufacturing facility as part of the review of the future BLA for Multikine when submitted. If CEL-SCI is unable to successfully scale up the manufacture of Multikine in sufficient quality and quantity, or if CEL-SCI encounters validation issues, the development, testing, and clinical trials of future product candidates, may be delayed or be infeasible, and regulatory approval or commercial launch of any resulting product, including Multikine, may be delayed or may not be successfully achieved.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>The current and future relationships with healthcare professionals, principal investigators, consultants, potential customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable healthcare laws and regulations.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Although CEL-SCI does not currently have any products on the market, if CEL-SCI begins commercializing its product candidates, CEL-SCI will be subject to additional healthcare statutory and regulatory requirements and oversight by federal and state governments as well as foreign governments in the jurisdictions in which CEL-SCI conducts its business. Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any drug candidates for which CEL-SCI obtains marketing approval. The current and future arrangements with healthcare professionals, principal investigators, consultants, potential customers and third-party payors may expose CEL-SCI to broadly applicable healthcare laws, including, without limitation:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation. In addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">40</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">federal civil and criminal false claims laws, including the federal False Claims Act, which impose criminal and civil penalties, including civil whistleblower actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a healthcare offense and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">HIPAA, which also imposes obligations on covered entities, including healthcare providers, health plans, and healthcare clearinghouses, as well as their respective business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the U.S. federal physicians payment transparency requirements, sometimes called the &#8220;Sunshine Act&#8221; and its implementing regulations, which requires certain manufacturers of drugs, devices, biologicals and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to physician payments and &#8220;other transfers of value&#8221; to physicians and teaching hospitals and, for transfers of value to other healthcare providers, as well as the ownership and investment interests held by physicians and their immediate family members;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">analogous state and foreign laws, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government which otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the U.S. federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under federal healthcare programs; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">state and foreign laws that govern the privacy and security of health information in certain circumstances, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">41</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Efforts to ensure that the future business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that the business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws. If CEL-SCI&#8217;s operations are found to be in violation of any of these laws or any other governmental regulations, CEL-SCI may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of the operations, all of which could significantly harm CEL-SCI&#8217;s business. If any of the physicians or other healthcare providers or entities with whom CEL-SCI expects to do business, including current and future collaborators, are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also adversely affect CEL-SCI&#8217;s business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Failure to obtain or maintain adequate coverage and reimbursement for the product candidates, if approved, could limit the ability to market those products and decrease CEL-SCI&#8217;s ability to generate revenue.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Sales of CEL-SCI&#8217;s product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of the approved products will be paid by health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or reimbursed by government authorities, private health insurers and other third-party payors. CEL-SCI anticipates that government authorities and other third-party payors will continue efforts to contain healthcare costs by limiting the coverage and reimbursement levels for new drugs and biologics. If coverage and reimbursement are not available, or are available only to limited levels, CEL-SCI may not be able to successfully commercialize its product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow CEL-SCI to establish or maintain pricing sufficient to realize a return on its investment. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for CEL-SCI&#8217;s product candidates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Moreover, in some countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, CEL-SCI may be required to conduct a clinical trial that compares the cost-effectiveness of its product candidate to other available therapies. If reimbursement of its products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, CEL-SCI&#8217;s business could be harmed, possibly materially.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Even if any product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If CEL-SCI&#8217;s product candidates do not achieve an adequate level of acceptance, CEL-SCI may not generate significant product revenues and CEL-SCI may not become profitable. The degree of market acceptance of its product candidates, including Multikine if approved for commercial sale, will depend on a number of factors, including:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the timing of CEL-SCI&#8217;s receipt of any marketing approvals;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the terms of any approvals and the countries in which approvals are obtained;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">42</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the efficacy and safety and potential advantages and disadvantages compared to alternative treatments, including future alternative treatments;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the prevalence and severity of any side effects associated with CEL-SCI&#8217;s product candidates;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the indications for which its products are approved and the scope of risk information required to be included in the product labeling;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">adverse publicity about CEL-SCI&#8217;s products or favorable publicity about competing products;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the approval of other products for the same indications as CEL-SCI&#8217;s products;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">CEL-SCI&#8217;s ability to offer its products for sale at competitive prices;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the convenience and ease of administration compared to alternative treatments;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the success of CEL-SCI&#8217;s physician education programs;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the strength of CEL-SCI&#8217;s marketing and distribution support; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the availability of third-party coverage and adequate reimbursement.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If any product candidate CEL-SCI commercializes fails to achieve market acceptance, it could have a material and adverse effect on CEL-SCI&#8217;s business, financial condition, results of operation and prospects.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI currently has no marketing and sales force. If CEL-SCI is unable to establish effective sales or marketing capabilities or enter into agreements with third parties to sell or market its product candidates, CEL-SCI may not be able to effectively sell or market its product candidates, if approved, or generate product revenues.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI currently has no sales and marketing infrastructure due to the fact that all of its product candidates are still in clinical development. To achieve commercial success for any approved product candidate for which CEL-SCI retains sales and marketing responsibilities, CEL-SCI must build its sales, marketing, managerial, and other non-technical capabilities or make arrangements with third parties to perform these services. For example, CEL-SCI has entered into agreements with certain foreign distributors to commercialize Multikine, if approved, within their respective territories. However, CEL-SCI may determine that there is a need to building its own sales force in the United States for the future marketing of Multikine, if approved, rather than seeking a U.S. co-marketing partner or relying on a contracted sales force. There are risks involved with either establishing its own sales and marketing capabilities or entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which CEL-SCI recruits a sales force and establishes marketing capabilities is delayed or does not occur for any reason, CEL-SCI would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and its investment would be lost if CEL-SCI cannot retain or reposition its sales and marketing personnel.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Factors that may inhibit CEL-SCI&#8217;s efforts to commercialize its product candidates on its own include:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">CEL-SCI&#8217;s inability to recruit, hire, retain and incentivize adequate numbers of effective sales and marketing personnel;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to use and administer CEL-SCI&#8217;s future products;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">43</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the lack of complementary products to be offered by sales personnel, which may put CEL-SCI at a competitive disadvantage relative to companies with more extensive product lines; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">unforeseen costs and expenses associated with establishing an independent sales and marketing organization.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If CEL-SCI does not establish sales and marketing capabilities successfully, either on its own or in collaboration with third parties, CEL-SCI will not be successful in commercializing Multikine, if approved, or any of its other product candidates that receive marketing approval or any such commercialization may experience delays or limitations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI&#8217;s business activities may be subject to the Foreign Corrupt Practices Act and similar anti-bribery and anti-corruption laws of other countries in which CEL-SCI operates or will operate in the future.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has conducted and has ongoing studies in international locations and may in the future initiate additional studies in countries other than the United States. Moreover, CEL-SCI has entered into agreements with foreign distributors to commercialize Multikine, if approved, in various territories outside of the United States. As a result, CEL-SCI&#8217;s business activities may be subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which CEL-SCI operates. The FCPA generally prohibits offering, promising, giving or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the healthcare providers who prescribe biopharmaceuticals are employed by their government, and the purchasers of biopharmaceuticals are government entities; therefore, CEL-SCI&#8217;s dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of CEL-SCI&#8217;s employees, agents or contractors conducting business abroad will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against CEL-SCI, its officers or employees, the closing of CEL-SCI&#8217;s facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs and prohibitions on the conduct of CEL-SCI&#8217;s business. Any such violations could include prohibitions on CEL-SCI&#8217;s ability to offer its product candidates, if approved, in one or more countries and could materially damage its reputation, its brand, its future international marketing efforts, its ability to attract and retain employees and its business, prospects, operating results and financial condition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Healthcare legislative reform measures may have a material adverse effect on CEL-SCI&#8217;s business and results of operations.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of CEL-SCI&#8217;s product candidates. CEL-SCI cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If CEL-SCI is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if CEL-SCI is not able to maintain regulatory compliance, CEL-SCI may lose any marketing approval that it may have obtained and it may not achieve or sustain profitability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">44</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs that may result in more limited coverage or downward pressure on the price CEL-SCI may otherwise receive for its product candidates. For example, in March 2010, Congress passed the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, which expanded healthcare coverage through Medicaid expansion and the implementation of the individual mandate for health insurance coverage and which included changes to the coverage and reimbursement of drug products under federal healthcare programs. The ACA contains a number of provisions that affect coverage and reimbursement of drug and biological products and/or that could potentially reduce the demand for pharmaceutical products such as increasing drug rebates under state Medicaid programs for brand name prescription drugs and extending those rebates to Medicaid managed care and assessing a fee on manufacturers and importers of brand name prescription drugs reimbursed under certain government programs, including Medicare and Medicaid. Tax reform legislation was enacted at the end of 2017 that eliminates the tax penalty established under the ACA for individuals who do not maintain mandated health insurance coverage beginning in 2019. In a May 2018 report, the Congressional Budget Office estimated that, compared to 2018, the number of uninsured will increase by 3 million in 2019 and 6 million in 2028, in part due to the elimination of the individual mandate. The ACA has also been subject to judicial challenge. In December 2018, a federal district court, in a challenge brought by a number of state attorneys general, found the ACA unconstitutional in its entirety because, once Congress repealed the individual mandate provision, there was no longer a basis to rely on Congressional taxing authority to support enactment of the law. Pending appeals, which could take some time, the ACA is still operational in all respects. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In December 2022, Congress enacted amendments to the accelerated approval program as part of the Food and Drug Omnibus Reform Act (&#8220;FDORA&#8221;), expanding FDA&#8217;s authority to, among other things, use expedited withdrawal procedures if a sponsor fails to conduct a confirmatory clinical trial with due diligence and require a confirmatory trial be underway prior to granting an accelerated approval.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s industry continues to face potential changes in the legal and regulatory landscape on the federal, state and international levels. Additional legislative actions to control U.S. healthcare or other costs have passed. The Budget Control Act, as amended, resulted in the imposition of 2% reductions in Medicare (but not Medicaid) payments to providers in 2013 and will remain in effect through 2027 unless additional Congressional action is taken. There has also been increasing and considerable public and government interest in the United States with respect to specialty drug pricing practices, including proposed federal and state legislation designed to bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, put in place limits and caps on pharmaceutical prices, request rebates for certain pharmaceutical products, and reform government program reimbursement methodologies for drugs. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what biopharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. In markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and control the prices of medicinal products for human use.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI expects that current or future healthcare reform measures may result in more rigorous coverage criteria and in additional downward pressure on the price that it receives for any approved product, including Multikine if it is approved for commercialization. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent CEL-SCI from being able to generate revenue, attain profitability or commercialize its product candidates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">45</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Legislative and regulatory proposals also have been made to expand post-approval requirements and restrict sales and promotional activities for biotechnology products. CEL-SCI cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations for biological products will be changed, or what the impact of such changes on the marketing approvals of its product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval and decision-making processes may significantly delay or prevent marketing approval, as well as subject CEL-SCI to more stringent product labeling and post-marketing testing and other requirements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Foreign governments often impose strict price controls, which may adversely affect CEL-SCI&#8217;s future profitability.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI intends to seek approval to market its lead investigational product, Multikine, in both the United States and foreign jurisdictions. If CEL-SCI obtains approval in one or more foreign jurisdictions, CEL-SCI will be subject to rules and regulations in those jurisdictions relating to Multikine. In some foreign countries, particularly in the European Union, prescription drug pricing is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug candidate. Coverage and reimbursement decisions in one foreign jurisdiction may impact decisions in other countries. To obtain reimbursement or pricing approval in some countries, CEL-SCI may be required to conduct clinical trials that demonstrate the product candidate is more effective than current treatments and that compare the cost-effectiveness of Multikine to other available therapies. If reimbursement of Multikine is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, CEL-SCI may be unable to achieve or sustain profitability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>If CEL-SCI fails to comply with environmental, health and safety laws and regulations, CEL-SCI could become subject to fines or penalties or incur costs that could harm its business.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes generated in its biologic manufacturing facility. CEL-SCI cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from its use of hazardous materials, including radioactive materials used in its research laboratory, CEL-SCI could be held liable for any resulting damages, and the amount of the liability could exceed its resources. CEL-SCI also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Risks Related to Intellectual Property</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI may not be able to achieve or maintain a competitive position, and other technological developments may result in its proprietary technologies becoming uneconomical or obsolete.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is involved in a biomedical field that is undergoing rapid and significant technological change. The pace of change continues to accelerate. The successful development of product candidates from the compounds, compositions and processes, through research financed by CEL-SCI, or as a result of possible third-party licensing arrangements with pharmaceutical or other companies, is not assured. CEL-SCI may fail to apply for patents on important technologies or product candidates in a timely fashion, or at all.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">46</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Many companies are working on drugs designed to cure or treat cancer. Many of these companies have financial, research and development, and marketing resources which are much greater than CEL-SCI&#8217;s and are capable of providing significant long-term competition either by establishing in-house research groups or by forming collaborative ventures with other entities. In addition, smaller companies and non-profit institutions are active in research relating to cancer and infectious diseases. The future market share of Multikine or the other product candidates, if approved, will be reduced or eliminated if the competitors develop and obtain approval for products that are safer or more effective than CEL-SCI&#8217;S product candidates. Moreover, the patent positions of pharmaceutical companies are highly uncertain and involve complex legal and factual questions for which important legal principles are often evolving and remain unresolved. As a result, the validity and enforceability of patents cannot be predicted with certainty. In addition, CEL-SCI does not know whether:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">CEL-SCI was the first to make the inventions covered by each of its issued patents and pending patent applications;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">CEL-SCI was the first to file patent applications for these inventions;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">others will independently develop similar or alternative technologies or duplicate any of CEL-SCI&#8217;s technologies;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">any of the pending patent applications will result in issued patents;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">any of the patents will be valid or enforceable;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">any patents issued to CEL-SCI or its collaboration partners will provide CEL-SCI with any competitive advantages or will be challenged by third parties;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">CEL-SCI will be able to develop additional proprietary technologies that are patentable;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the U.S. government will exercise any of its statutory rights to CEL-SCI&#8217;s intellectual property that was developed with government funding; or</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">its business may infringe the patents or other proprietary rights of others.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI&#8217;s patents might not protect its technology from competitors, in which case CEL-SCI may not have any advantage over competitors in selling any products that CEL-SCI may develop.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s commercial success will depend in part on its ability to obtain additional patents and protect its existing patent position, as well as its ability to maintain adequate intellectual property protection for the technologies, product candidates, and any future products in the United States and other countries. If CEL-SCI does not adequately protect its technology, product candidates and future products, competitors may be able to use or practice them and erode or negate any competitive advantage CEL-SCI may have, which could harm CEL-SCI&#8217;s business and its ability to achieve profitability. The laws of some foreign countries do not protect the proprietary rights to the same extent or in the same manner as U.S. laws, and CEL-SCI may encounter significant problems in protecting and defending its proprietary rights in these countries. CEL-SCI will be able to protect its proprietary rights from unauthorized use by third parties only to the extent that its proprietary technologies, product candidates and any future products are covered by valid and enforceable patents or are effectively maintained as trade secrets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Certain aspects of CEL-SCI&#8217;s technologies are covered by U.S. and foreign patents. In addition, CEL-SCI has a number of new patent applications pending. There is no assurance that the applications which are pending or which may be filed in the future will result in the issuance of any patents. Furthermore, there is no assurance as to the breadth and degree of protection any issued patents might afford CEL-SCI. Disputes may arise between CEL-SCI and others as to the scope and validity of these or other patents. Any defense of the patents could prove costly and time consuming and there can be no assurance that CEL-SCI will be in a position, or will deem it advisable, to carry on such a defense. A suit for patent infringement could result in increasing costs, delaying or halting development, or even forcing CEL-SCI to abandon a product candidate. Other private and public concerns, including universities, may have filed applications for, may have been issued, or may obtain additional patents and other proprietary rights to technology potentially useful or necessary to CEL-SCI. CEL-SCI is not currently aware of any such patents, but the scope and validity of such patents, if any, and the cost and availability of such rights are impossible to predict.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">47</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Much of CEL-SCI&#8217;s intellectual property is protected as trade secrets or confidential know-how, not as a patent.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI considers proprietary trade secrets and/or confidential and unpatented know-how to be important to its business. Much of the intellectual property pertains to CEL-SCI&#8217;s manufacturing methodologies, certain aspects of which may not be suitable for patent filings and must be protected as trade secrets and/or confidential know-how. This type of information must be protected diligently by CEL-SCI to protect its disclosure to competitors, since legal protections after disclosure may be minimal or non-existent. Accordingly, much of the value of this intellectual property is dependent upon the ability of CEL-SCI to keep its trade secrets and know-how confidential.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">To protect this type of information against disclosure or appropriation by competitors, CEL-SCI&#8217;s policy is to require its employees, consultants, contractors and advisors to enter into confidentiality agreements with CEL-SCI. However, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose the confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Enforcing a claim that a third party obtained illegally, and is using, trade secrets and/or confidential know-how is expensive, time consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In addition, in some cases a regulator considering the application for product candidate approval may require the disclosure of some or all of the proprietary information. In such a case, CEL-SCI must decide whether to disclose the information or forego approval in a particular country. If CEL-SCI is unable to market its product candidates in key countries, CEL-SCI&#8217;s opportunities and value may suffer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Failure to obtain or maintain trade secrets and/or confidential know-how trade protection could adversely affect CEL-SCI&#8217;S competitive position. Moreover, competitors may independently develop substantially equivalent proprietary information and may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, competitors could limit the use of such trade secrets and/or confidential know-how.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI may be subject to claims challenging the inventorship or ownership of its patents and other intellectual property.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in its patents or other intellectual property. CEL-SCI may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing the product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If CEL-SCI fails in defending any such claims, in addition to paying monetary damages, CEL-SCI may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on its business. Even if CEL-SCI is successful in defending against such claims, litigation could result in substantial costs and be a distraction to CEL-SCI&#8217;s management and employees.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Risks Related to CEL-SCI&#8217;s common stock</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Future equity offerings or other equity issuances may result in dilution to existing shareholders.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI expects that significant additional capital will be needed in the future to continue its planned operations. To raise additional capital, CEL-SCI may in the future offer additional shares of its common stock or other securities convertible into or exchangeable for its common stock. To the extent CEL-SCI raises additional capital by issuing equity securities, CEL-SCI&#8217;s stockholders may experience substantial dilution. These sales may result in new investors gaining rights superior to existing stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Section 382 of the Internal Revenue Code May Limit the Use of CEL-SCI&#8217;s Net Operating Losses.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Pursuant to Section 382 of the Internal Revenue Code, or IRC, annual use of CEL-SCI&#8217;s net operating loss (NOL) carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. Such ownership change could result in annual limitations on the utilization of tax attributes, including NOL carryforwards and tax credits.&#160; CEL-SCI performed an estimated analysis to determine if any additional ownership changes occurred during the year ended September 30, 2024 and no such changes were identified. If changes in ownership occur after year end, NOL and tax credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">48</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>The exercise of outstanding warrants and options will cause dilution.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As of September 30, 2024, there were outstanding warrants which allow the holders to purchase 1,092,470 shares of common stock, with a weighted average exercise price of $3.16 per share, outstanding pre-funded warrants which allow the holders to purchase 1,450,000 shares of common stock and outstanding options which allow the holders to purchase up to 16,258,080 shares of common stock, with a weighted average exercise price of $6.88 per share. There are 1,063,031 options remaining for future issuances under our current stock option plans. The exercise of these outstanding warrants and options will cause dilution to holders of our common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Since CEL-SCI does not intend to pay dividends on its common stock, any potential return to investors will result only from any increases in the price of its common stock.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">At the present time, CEL-SCI intends to use available funds to finance its operations. Accordingly, while payment of dividends rests within the discretion of its board of directors, no common stock dividends have been declared or paid by CEL-SCI and CEL-SCI has no intention of paying any common stock dividends in the foreseeable future. Additionally, any future debt financing arrangement may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on CEL-SCI&#8217;s common stock. Any return to CEL-SCI&#8217;s shareholders will therefore be limited to appreciation in the price of its common stock, which may never occur. If CEL-SCI&#8217;s stock price does not increase, CEL-SCI&#8217;S shareholders are unlikely to receive any return on their investments in CEL-SCI&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>The price of CEL-SCI&#8217;s common stock has been volatile and is likely to continue to be volatile, which could result in substantial losses for CEL-SCI&#8217;s shareholders.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s stock price has been, and is likely to continue to be, volatile. As a result of this volatility, CEL-SCI&#8217;s shareholders may not be able to sell their shares at or above the price they paid for their shares. The market price for CEL-SCI&#8217;s common stock may be influenced by many factors, including:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">actual or anticipated fluctuations in CEL-SCI&#8217;s financial condition and operating results;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">actual or anticipated changes in CEL-SCI&#8217;s growth rate relative to competitors;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">competition from existing products or new products or product candidates that may emerge;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">development of new technologies that may make CEL-SCI&#8217;s technology less attractive;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">changes in physician, hospital or healthcare provider practices that may make CEL-SCI&#8217;s product candidates less useful;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">announcements by CEL-SCI, its partners or competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the recruitment or departure of key personnel;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">failure to meet or exceed financial estimates and projections of the investment community;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">variations in its financial results or those of companies that are perceived to be similar to CEL-SCI;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">49</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">changes to coverage and reimbursement levels by commercial third-party payors and government payors, including Medicare, and any announcements relating to reimbursement levels;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">general economic, industry and market conditions; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">the other factors described in this &#8220;Risk Factors&#8221; section.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI has identified material weaknesses in its internal control over financial reporting. Failure to achieve and maintain effective internal controls over financial reporting could adversely affect CEL-SCI&#8217;s ability to report its results of operations and financial condition accurately and in a timely manner, which could have an adverse impact on CEL-SCI&#8217;s business.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s management is responsible for establishing and maintaining adequate internal control over financial reporting designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement in an entity&#8217;s annual or interim consolidated financial statements might not be prevented or detected on a timely basis.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As described in Item 9A of this Annual Report, management noted material weaknesses in its internal control over financial reporting as of September 30, 2024. CEL-SCI&#8217;s management concluded that material weaknesses existed relating to the logical access to information technology systems that support CEL-SCI&#8217;s financial reporting process and the operating effectiveness of certain management review controls. Although these control weaknesses did not result in any material misstatement of CEL-SCI&#8217;s financial statements for the periods presented, they could lead to a material misstatement of account balances or disclosures. As a result, CEL-SCI&#8217;s management concluded that its internal controls over financial reporting were not effective as of September 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In order to remediate these material weaknesses, CEL-SCI will change certain control activities over financial reporting to include, but not limited to, the following: (i) evaluating and implementing enhanced process controls around access to information technology systems and (ii) enhancing the operating effectiveness of management&#8217;s review controls. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If CEL-SCI is unable to remediate the material weaknesses timely and sufficiently or if CEL-SCI identifies future material weaknesses in its internal control over financial reporting or is unable to comply with the requirements of Section 404 in a timely manner or assert that its internal control over financial reporting is effective, CEL-SCI may experience a loss of investor confidence in the accuracy and completeness of its financial statements, incur material misstatements in its financial statements, incur difficulty accessing capital on favorable terms, or at all, be subject to fines, penalties or judgments, incur reputational harm, and the market price of its common stock may be adversely affected.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Cybersecurity breaches could affect CEL-SCI&#8217;s operations.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Security breaches and other disruptions in CEL-SCI&#8217;S information technology systems could limit CEL-SCI&#8217;s capacity to effectively monitor and control its operations, compromise its suppliers&#8217; confidential information or otherwise adversely affect its operating results or business reputation. Any failure to effectively prevent, detect and/or recover from any such security breaches could result in legal claims or regulatory penalties under laws protecting the privacy of personal information, disrupt operations, and damage CEL-SCI&#8217;s reputation, which could adversely affect its business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 1B. <span style="text-decoration:underline">UNRESOLVED SEC COMMENTS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">None</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">50</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 1C. CYBERSECURITY</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI recognizes the importance of assessing, identifying, and managing material risks from cybersecurity threats. CEL-SCI&#8217;s policies, standards and procedures for assessing, identifying, and managing material risks from cybersecurity threats are integrated into our overall risk management system. In this regard, CEL-SCI uses various tools and processes to help prevent, identify, and resolve any identified vulnerabilities and security incidents in a timely manner. These include, but are not limited to, internal reporting, routine employee awareness updates, annual cyber security training, monthly email testing engaging experts and third-party monitoring and detection tools.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI employs third-party information technology (&#8220;IT&#8217;) consultants to manage its information technology environment and help manage and assess cybersecurity risks. The third-party IT consultants have relevant industry experience, including security solutions and data protection and recovery. Using various monitoring and detection tools implemented into CEL-SCI&#8217;s internal technology systems, they can identify cybersecurity threats and report such risks to CEL-SCI&#8217;s management team.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s management team oversees efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which includes oversight over its third-party IT consultant, monitoring systems and employee engagement. The management team is responsible for reporting any cybersecurity risks identified by CEL-SCI&#8217;s third-party IT consultant to its board of directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s board of directors is responsible for oversight over its risk management system, including review and approval of the risk management system and processes implemented by management to identify, assess, manage and mitigate cybersecurity risks. The Board is responsible for monitoring and assessing material risk exposure to cybersecurity risks, and CEL-SCI&#8217;s management is responsible for the day-to-day supervision of the material risks CEL-SCI may face.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s risks from cybersecurity threats have not affected or are reasonably not likely to materially affect its business strategy, results of operations, or financial condition.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 2. </strong><strong><span style="text-decoration:underline">PROPERTIES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI leases approximately 3,700 square feet of office space at 8229 Boone Blvd., Suite 802, Vienna, Virginia at a monthly rental of approximately $8,000. The lease on the office space expires on November 30, 2025. CEL-SCI believes this arrangement is adequate for the conduct of its present business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has a 17,900 square foot laboratory located in Baltimore, Maryland. The laboratory is leased by CEL-SCI at a cost of approximately $22,000 per month. During the period ended September 30, 2021, the laboratory lease was extended ten years and expires on February 29, 2032.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In August 2007, CEL-SCI leased a building near Baltimore, Maryland (the San Tomas lease). The building, which consists of approximately 73,000 square feet, has been remodeled in accordance with CEL-SCI&#8217;s specifications so that it can be used by CEL-SCI to manufacture Multikine for CEL-SCI&#8217;s Phase III clinical trial and sales of the drug, if approved by the FDA. The lease expires on October 31, 2028 and required annual base rent payments of approximately $2.7 million during the twelve months ended September 30, 2024. The annual base rent escalates each year at 3% beginning on November 1st. CEL-SCI is also required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities, which were approximately<strong> </strong>$76,000<strong> </strong>per month as of September 30, 2024. The lease allows CEL-SCI, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">51</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In August 2020, the Company entered into an amendment to the San Tomas lease agreement under which the landlord agreed to allow the Company to substantially upgrade the manufacturing facility in preparation for the potential commercial production of Multikine. The total cost of the upgrades was $11.1 million. The landlord agreed to finance the final $2.4 million of the costs incurred. The Company started repaying these costs on March 1, 2021 through increased lease payments which will continue over the remaining lease term. The repayment includes a base rent which escalates at 3% each year plus interest that accrues at 13.75% per year on the $2.4 million financed.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 3. </strong><strong><span style="text-decoration:underline">LEGAL PROCEEDINGS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Not applicable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 4.</strong><strong> </strong><strong><span style="text-decoration:underline">MINE SAFETY DISCLOSURES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Not applicable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 5.</strong> <strong><span style="text-decoration:underline">MARKET FOR CEL-SCI'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As of September 30, 2024, there were approximately 465 record holders of CEL-SCI&#8217;s common stock. CEL-SCI&#8217;s common stock is traded on the NYSE American under the symbol &#8220;CVM&#8221;.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Shown below are the range of high and low quotations for CEL-SCI&#8217;s common stock for the periods indicated as reported by the NYSE American.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Quarter Ending</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">High</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Low</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">12/31/2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.68</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.88</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3/31/2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.33</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.15</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">6/30/2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.94</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.86</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">9/30/2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.99</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.08</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">12/31/2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.23</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.04</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3/31/2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.08</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.63</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">6/30/2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.39</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.10</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">9/30/2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.22</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.02</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Holders of common stock are entitled to receive dividends as may be declared by CEL-SCI&#8217;s Board of Directors out of legally available funds and, in the event of liquidation, to share pro rata in any distribution of CEL-SCI&#8217;s assets after payment of liabilities. CEL-SCI&#8217;s Board of Directors is not obligated to declare a dividend. CEL-SCI has not paid any dividends on its common stock and CEL-SCI does not have any current plans to pay any common stock dividends.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The provisions in CEL-SCI&#8217;s Articles of Incorporation relating to CEL-SCI&#8217;s preferred stock allow CEL-SCI&#8217;s directors to issue preferred stock with rights to multiple votes per share and dividend rights which would have priority over any dividends paid with respect to CEL-SCI&#8217;s common stock. The issuance of preferred stock with such rights may make more difficult the removal of management even if such removal would be considered beneficial to shareholders generally, and will have the effect of limiting shareholder participation in certain transactions such as mergers or tender offers if such transactions are not favored by incumbent management.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"/></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">52</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td/></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The market price of CEL-SCI&#8217;s common stock, as well as the securities of other biopharmaceutical and biotechnology companies, have historically been highly volatile, and the market has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. Factors such as fluctuations in CEL-SCI&#8217;s operating results, announcements of technological innovations or new therapeutic products by CEL-SCI or its competitors, governmental regulation, developments in patent or other proprietary rights, public concern as to the safety of products which may be developed by CEL-SCI or other biotechnology and pharmaceutical companies, and general market conditions may have a significant effect on the market price of CEL-SCI&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 6. </strong><strong><span style="text-decoration:underline">SELECTED FINANCIAL DATA</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is a smaller reporting company as defined by Rule 12b-2 of the Securities and Exchange Commission and is not required to provide the information required under this item.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 7.</strong> <strong><span style="text-decoration:underline">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following discussion should be read in conjunction with the financial statements and the related notes thereto appearing elsewhere in this report.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Multikine (Leukocyte Interleukin, Injection) which, for simplicity, is referred to in this report as Multikine, is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject to FDA review under the Company&#8217;s future anticipated regulatory submission for approval. Multikine has not been licensed or approved by the FDA or any other regulatory agency. Neither has its safety or efficacy been established for any use.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI also owns and is developing a pre-clinical technology called LEAPS (Ligand Epitope Antigen Presentation System). CEL-SCI is using its LEAPS technology platform to investigate its lead peptide-based immunotherapy (CEL-4000) as a vaccine treatment for rheumatoid arthritis.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">All of CEL-SCI&#8217;s projects are under development. As a result, CEL-SCI cannot predict when it will be able to generate any revenue from the sale of any of its products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Since inception, CEL-SCI has financed its operations through the issuance of equity securities, convertible notes, loans and certain research grants. CEL-SCI will likely continue to generate net operating losses as it continues the development of Multikine and brings other drug candidates into clinical trials. Until such time as CEL-SCI becomes profitable, any or all of these financing vehicles or others may be utilized to assist CEL-SCI&#8217;s capital requirements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Results of Operations</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Company incurred a net operating loss of approximately $26.4 million for the twelve months ended September 30, 2024. This net operating loss consists of significant non-cash expenses accounting for approximately 30% of the operating loss. The non-cash operating expenses include approximately $4.3 million in stock-based employee compensation and approximately $4.0 million in depreciation and amortization expense.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">During the year ended September 30, 2024, research and development expenses decreased by approximately $4.3 million, or 19%, compared to the year ended September 30, 2023. Major components of this decrease include an approximately $1.6 million decrease in employee stock compensation expense and a decrease of approximately $3.3 million in costs related to its clinical study activities. These decreases were offset by an increase of approximately $0.6 million in other research and development costs.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">53</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">During the year ended September 30, 2024, general and administrative expenses decreased by approximately $0.8 million, or 9%, compared to the year ended September 30, 2023. This decrease is primarily due to a decrease in employee stock compensation expense of approximately $0.5&#160;million and a decrease in other net general and administrative expenses of approximately $0.3 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Net interest expense decreased by approximately $0.1 million for the year ended September 30, 2024 compared to the year ended September 30, 2023. This decrease is primarily due to the Company earning approximately $0.2 million less in interest income and approximately $0.1 million less in interest expense from its finance leases during the year ended September 30, 2024 compared to the year ended September 30, 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Research and Development Expenses</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s research and development efforts involved Multikine and LEAPS. The table below shows the research and development expenses associated with each project during the reporting periods.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Year ended September 30, </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Multikine</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,072,573</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,098,222</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">LEAPS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">88,878</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">373,274</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">18,161,451</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">22,471,496</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s Phase III clinical trial began in December 2010 after the completion and validation of CEL-SCI&#8217;s dedicated manufacturing facility.&#160; The Phase III clinical trial was fully enrolled in September 2016, reached its primary endpoint in April 2020 and achieved database lock in December 2020. The data was unblinded in June 2021, the primary endpoint results were announced in June 2021, additional data was presented at ASCO 2022, ESMO 2022, ECHNO 2023, ESTRO 2023, ESMO 2023, IDDST 2024 and ESMO 2024.&#160; As part of CEL-SCI&#8217;s global regulatory approval strategy, CEL-SCI concurrently plans to conduct a confirmatory registration study to support a filing for marketing authorization in the United States and pursue filings for marketing authorization in Canada, United Kingdom and Europe.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">As explained in Item 1 of this report, clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of the CEL-SCI&#8217;s clinical trials and research programs are primarily based upon the amount of capital available to CEL-SCI and the extent to which CEL-SCI has received regulatory approvals for clinical trials. The inability of CEL-SCI to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent CEL-SCI from completing the studies and research required to obtain regulatory approval for any products which CEL-SCI is developing. Without regulatory approval, CEL-SCI will be unable to sell any of its products. Since all of CEL-SCI&#8217;s projects are under development, CEL-SCI cannot predict when it will be able to generate any revenue from the sale of any of its products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Liquidity and Capital Resources&#160; </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has relied primarily upon capital generated from the public and private offerings of its common stock and convertible notes.&#160;&#160;In addition, CEL-SCI has utilized short-term loans to meet its capital requirements.&#160;&#160;Capital raised by CEL-SCI has been used to acquire an exclusive worldwide license to use, and later purchase, certain patented and unpatented proprietary technology and know-how relating to the human immunological defense system and for clinical trials.&#160;&#160;Capital has also been used for patent applications, debt repayment, research and development, administrative costs, and for CEL-SCI&#8217;s laboratory and manufacturing facilities.&#160;&#160;CEL-SCI does not anticipate realizing significant revenues until it enters into licensing arrangements regarding its technology and know-how or until it receives regulatory approval to sell its products (which could take a number of years). As a result, CEL-SCI has been dependent primarily upon the proceeds from the sale of its securities to meet all of its liquidity and capital requirements and anticipates having to do so in the future.&#160; During fiscal year 2024 and 2023, CEL-SCI raised net proceeds of approximately $21.2 million and $6.3 million, respectively, through a combination of the sale of common stock and the exercise of warrants.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">54</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In August 2007, CEL-SCI leased a building near Baltimore, Maryland.&#160; The building, which consists of approximately 73,000 square feet, has been remodeled in accordance with CEL-SCI&#8217;s specifications so that it can be used by CEL-SCI to manufacture Multikine for CEL-SCI&#8217;s Phase III clinical trials and sales of the drug if approved by the FDA. The lease expires on October 31, 2028, and required annual base rent payments of approximately $2.6 million during the twelve months ended September 30, 2024.&#160; See Item 2 of this report for more information concerning the terms of this lease.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">During the year ended September 30, 2024, 5,680,000 pre-funded warrants were exercised. During the year ended September 30, 2023, the following chart lists the warrants that were exercised and the proceeds received.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Fiscal Year 2023</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercised</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Proceeds</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,752</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,291</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">418,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">217,752</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">447,291</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">During the year ended September 30, 2024, the Company&#8217;s cash increased by approximately $0.6 million.&#160; The significant component of this increase included approximately $21.2 million of cash received from issuance of common stock, and exercise of warrants offset by cash used to fund the Company&#8217;s regular operations of approximately $18.8 million, approximately $0.1 million used to acquire research and development equipment, and approximately $1.8 million in payments on the Company&#8217;s finance leases.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">During the year ended September 30, 2023, the Company&#8217;s cash decreased by approximately $18.5 million. The significant component of this decrease included cash used to fund the Company&#8217;s regular operations of approximately $22.8 million, which includes the approximate $2.3 million deposit made to the Company&#8217;s landlord as a result of falling below certain cash requirements per the San Tomas lease.&#160; Other components of this decrease include approximately $0.4 million used to make leasehold improvements and acquire research and development equipment, and approximately $1.6 million in payments on the Company&#8217;s finance leases. These decreases were offset by approximately $5.8 million and $0.5 million of cash received from issuance of common stock and exercise of warrants, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Supplies are purchased for use in the Company&#8217;s manufacturing and R&amp;D efforts.&#160; During the year ended September 30, 2024, the supplies increased by approximately $0.2 million in support of the work to validate and prepare the manufacturing facility to produce Multikine for the confirmatory registration study and before the Company&#8217;s Biologics License Application (BLA) can be submitted to the FDA.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Primarily as a result of CEL-SCI&#8217;s losses incurred to date, its expected continued future losses, and limited cash balances, CEL-SCI has included a disclosure in its financial statements expressing substantial doubt about its ability to continue as a going concern. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">55</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Future Capital Requirements</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s material capital commitments include funding operating losses, funding its research and development program and making required lease payments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">For information on employment contracts, see Item 11 of this report.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI will need to raise additional funds, either through debt or equity financings or a partnering arrangement, to bring Multikine to market. The ability of CEL-SCI to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. However, it is possible that CEL-SCI will not be able to generate enough cash to continue operations at its current level. CEL-SCI&#8217;s management has engaged in fundraising for over 30 years and believes that the manner in which it is proceeding will produce the best possible outcome for the shareholders. There can be no assurances that CEL-SCI will be successful in raising additional funds.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of CEL-SCI&#8217;s clinical trials and research programs are primarily based upon the amount of capital available to CEL-SCI and the extent to which CEL-SCI has received regulatory approvals for clinical trials. The inability of CEL-SCI to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent CEL-SCI from completing the studies and research required to obtain regulatory approval for any products which CEL-SCI is developing. Without regulatory approval, CEL-SCI will be unable to sell any of its products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In the absence of revenues, CEL-SCI will be required to raise additional funds through the sale of securities, debt financings or other arrangements in order to continue with its research efforts. However, there can be no assurance that such financing will be available or be available on favorable terms. Ultimately, CEL-SCI must complete the development of its products, obtain appropriate regulatory approvals and obtain sufficient revenues to support its cost structure.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Since all of CEL-SCI&#8217;s projects are under development, CEL-SCI cannot predict with any certainty the funds required for future research and clinical trials, the timing of future research and development projects, or when it will be able to generate any revenue from the sale of any of its products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI's cash flow and earnings are subject to fluctuations due to changes in interest rates on its bank accounts, and, to an immaterial extent, foreign currency exchange rates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Critical Accounting Estimates</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI's significant accounting estimates are more fully described in Note 3 to the financial statements included as part of this report. However, certain accounting estimates are particularly important to the portrayal of CEL-SCI&#8217;s financial position and results of operations and require the application of significant judgments by management. As a result, the financial statements are subject to an inherent degree of uncertainty. In applying those estimates, management uses its judgment to determine the appropriate assumptions to be used in the determination of certain estimates. These estimates are based on CEL-SCI's historical experience, terms of existing contracts, observance of trends in the industry and information available from outside sources, as appropriate.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Management believes that the following critical accounting estimates require the most significant judgments and estimates with respect to the preparation of CEL-SCI&#8217;s financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;"><em>Lease Accounting </em>&#8211; The measurement of the finance and operating lease right-of-use asset and lease liabilities requires the determination of an estimated lease term and an incremental borrowing rate. The determination of the incremental borrowing rates for new and modified lease contracts is a critical accounting estimate. Significant judgment is required by management to develop inputs and assumptions used to determine the incremental borrowing rate for lease contracts. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">56</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><em>Share-based Compensation </em>&#8211;Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, <em>Compensation &#8211; Stock Compensation</em> (&#8220;ASC 718&#8221;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the &#8220;Plans&#8221;. All Plans have been approved by CEL-SCI&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, CEL-SCI has based its assumption for stock price volatility on the variance of daily closing prices of CEL-SCI&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 7A. <span style="text-decoration:underline">QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISKS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Not applicable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 8. </strong><strong><span style="text-decoration:underline">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">See the financial statements included with this report.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 9.</strong> <strong><span style="text-decoration:underline">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Not applicable</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 9A. </strong><strong><span style="text-decoration:underline">CONTROLS AND PROCEDURES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Evaluation of Disclosure Controls and Procedures</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has carried out an evaluation, under the supervision and with the participation of its Chief Executive Officer (&#8220;CEO&#8221;) and the Chief Financial and Operations Officer (&#8220;CFO/COO&#8221;), of the effectiveness of the design and operation of CEL-SCI&#8217;s disclosure controls and procedures as of the end of the period covered by this report. Disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, are controls and procedures that are designed to ensure that information required to be disclosed in CEL-SCI&#8217;s reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">57</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In designing and evaluating the disclosure controls and procedures, CEL-SCI&#8217;s management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. CEL-SCI&#8217;s disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching CEL-SCI&#8217;s desired disclosure controls objectives. Based on this evaluation, CEL-SCI&#8217;s CEO and CFO/COO concluded that the Company&#8217;s disclosure controls and procedures were not effective as of September 30, 2024 as a result of material weaknesses in CEL-SCI&#8217;s internal control over financial reporting as described below.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Management&#8217;s Report on Internal Control over Financial Reporting</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Exchange Act Rule 13a-15(f) and 15d-15(f). Under the supervision and with the participation of our management, including our CEO and CFO/COO, CEL-SCI conducted an evaluation of the effectiveness of its internal control over financial reporting based on criteria established in Internal Control &#8211; Integrated Framework (2013) published by the COSO. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI identified certain control deficiencies in the design and implementation of its internal control over financial reporting that constituted material weaknesses. A material weakness (as defined in Rule 12b-2 under the Exchange Act) is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of CEL-SCI&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis.&#160; Specifically, CEL-SCI did not design and or implement an effective control environment or control activities as further detailed below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><em>Control Environment, Risk Assessment, Information and Communication, and Monitoring</em> &#8211; CEL-SCI did not have appropriately designed controls impacting the (1) control environment, (2) risk assessment procedures, (3) identification of control activities, and (4) monitoring activities to prevent or detect material misstatements to the financial statements and assess whether the components of internal control were present and functioning.&#160; CEL-SCI did not develop and perform sufficient ongoing evaluations to ascertain whether the components of internal control were present and functioning. These deficiencies were attributed to not developing and performing sufficient ongoing evaluations to ascertain whether the components of internal control were present and functioning. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><em>Control Activities and Information and Communication</em> &#8211; Management has determined that the Company did not have adequate selection and development of effective control activities resulting in the following material weaknesses:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Management did not design and maintain effective information technology general controls in the areas of user logical access and program change management for certain information technology systems that support the Company&#8217;s financial reporting and other processes. As a result of this material weakness, certain activity level controls that are dependent on information derived from these information technology systems were deemed to be ineffective. This material weakness also resulted in segregation of duties conflicts for certain user roles relating to the review of manual journal entries.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">58</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Management did not have properly designed management review controls over certain areas. Specifically, controls are not designed to sufficiently evaluate the completeness and accuracy of data used in account analyses. Additionally, the Company&#8217;s management review controls are not operating effectively over certain areas, as sufficient evidence was not maintained to demonstrate that reviews occurred with a sufficient level of precision to detect a material misstatement.</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Remediation of the Material Weaknesses in Internal Control over Financial Reporting</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In response to the material weaknesses identified, management designed a remediation plan which was approved by the Audit Committee and Board of Directors. Management has made progress to remediate the control deficiencies contributing to the material weaknesses, as described below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;width:100%" cellpadding="2"><tbody><tr style="height:15px"><td style="padding:2px;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#9679;</p></td><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI will provide training to new and continue training existing personnel on proper execution of designed control procedures;</p></td></tr><tr style="height:15px"><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#9679;</p></td><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI has developed a preliminary hiring plan and will continue to assess our personnel needs, expertise and requirements and will hire personnel as needed.</p></td></tr><tr style="height:15px"><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">CEL-SCI will continue to develop internally and engage external resources with the appropriate depth of expertise to establish a robust financial controls governance structure, conduct a financial risk assessment, establish internal materiality thresholds, and identify key business processes.</p></td></tr><tr style="height:15px"><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">CEL-SCI will conduct process and control walkthroughs of all key processes to identify risk points and establish corresponding controls to address identified design gaps.</p></td></tr><tr style="height:15px"><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">CEL-SCI has initiated and will continue the process to document, implement and redesign controls, policies, and procedures with an appropriate level of precision to detect a material misstatement, and to retain sufficient documentation to support the operating effectiveness of the controls. The control enhancement procedures are focused on:</p></td></tr><tr style="height:15px"><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;width:4%;"/><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;width:4%;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;width:6%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">o</p></td><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Increasing the precision and specificity of CEL-SCI&#8217;s control activities, addressing completeness and accuracy of the information used in performing management review controls, as well as documenting sufficient evidence of management&#8217;s review supporting its conclusions; and</p></td></tr><tr style="height:15px"><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"/><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">o</p></td><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Modifying CEL-SCI&#8217;s journal entry operating procedures to establish a formal hierarchy of review of journal entries to enforce proper segregation of duties in advance of implementing a new general ledger system.</p></td></tr><tr style="height:15px"><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"/><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">o</p></td><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Continue to assess roles and permissions across relevant financial systems and restricting access based on job responsibilities.</p></td></tr><tr style="height:15px"><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"/><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">o</p></td><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CEL-SCI has implemented enhanced process controls around the logical access to information technology systems and will continue redesigning information technology general controls across relevant systems related to user access and change management.&#160; </p></td></tr><tr style="height:15px"><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9679;</p></td><td style="padding-bottom:2px;padding-top:2px;padding-left:2px;padding-right:2px;padding:2px;" colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">CEL-SCI will also seek to improve the process of assessing the effectiveness of the control environment.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Management is committed to the remediation of the material weaknesses described above, as well as the continued improvement of the Company&#8217;s internal control over financial reporting. The actions that CEL-SCI is taking are subject to ongoing senior management review, as well as oversight of the audit committee of our board of directors. CEL-SCI may also conclude that additional measures may be required to remediate the material weaknesses. CEL-SCI will not be able to conclude that CEL-SCI has remediated a material weakness until the applicable controls operate for a sufficient period of time and management has concluded, through formal testing, that these controls are operating effectively. CEL-SCI will continue to monitor the design and effectiveness of these and other processes, procedures and controls and make any further changes management deems appropriate.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">59</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Changes in Internal Control over Financial Reporting</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI changed certain control activities over financial reporting in order to remediate certain material weaknesses that existed as of September 30, 2024.&#160; CEL-SCI implemented the following: (i) evaluating and implementing enhanced process controls around the logical access to information technology systems and (ii) enhancing the operating effectiveness of management review controls.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Other than as described above, there have been no other changes in CEL-SCI&#8217;s internal control over financial reporting occurred during the quarter ended September 30, 2024 that has materially affected, or is reasonably likely to materially affect, CEL-SCI&#8217;s internal control over financial reporting.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 9B. <span style="text-decoration:underline">OTHER INFORMATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">During the three months ended September 30, 2024, none of the Company&#8217;s directors or officers adopted or terminated a &#8220;Rule 10b5-1 trading arrangement&#8221; or adopted or terminated a &#8220;non-Rule 10b5-1 trading arrangement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Not applicable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">60</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 10. </strong><strong><span style="text-decoration:underline">DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Officers and Directors</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:22%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:8%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Age</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Position</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Geert R. Kersten, Esq.</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">66</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director, Chief Executive and Financial Officer and Treasurer</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Patricia B. Prichep</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">73</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Financial and Operations Officer and Corporate Secretary</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Dr. Eyal Talor</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">68</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Scientific Officer</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Dr. Daniel H. Zimmerman</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">83</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Senior Vice President of Research, Cellular Immunology</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">John Cipriano</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">82</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Senior Vice President of Regulatory Affairs</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Robert Watson</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">67</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director, Chairman of the Board</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Bruno Baillavoine</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">71</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Mario Gobbo</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">71</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The directors of CEL-SCI serve in such capacity until the next annual meeting of CEL-SCI&#8217;s shareholders or until their successors have been duly elected and qualified. The officers of CEL-SCI serve at the discretion of CEL-SCI&#8217;s directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The principal occupations of CEL-SCI&#8217;s officers and directors, during the past several years, are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Geert Kersten has served in his current leadership role at CEL-SCI since 1995. Mr. Kersten has been with CEL-SCI since 1987. He has been involved in the pioneering field of cancer immunotherapy for over three decades and has successfully steered CEL-SCI through many challenging cycles in the biotechnology industry.&#160; Mr. Kersten also provides CEL-SCI with significant expertise in the fields of finance and law and has a unique vision of how CEL-SCI&#8217;s Multikine product could potentially change the way cancer is treated.&#160; Prior to joining CEL-SCI, Mr. Kersten worked at the law firm of Finley &amp; Kumble and worked at Source Capital, an investment banking firm located in McLean, VA.&#160; He is a native of Germany, graduated from high school in England, and completed his studies in the US. Mr. Kersten received his Undergraduate Degree in Accounting and an M.B.A. from George Washington University, and a law degree (J.D.) from American University in Washington, DC.&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Patricia B. Prichep has over 35 years of experience in business operations and administration. She assumed the duties of CEL-SCI's Chief Financial and Operations Officer, effective November 2024. She joined CEL-SCI in 1992 and was CEL-SCI&#8217;s Senior Vice President of Operations from March 1994 to October 2024.&#160; Between December 1992 and March 1994, Ms. Prichep was CEL-SCI&#8217;s Director of Operations.&#160; Ms. Prichep became CEL-SCI&#8217;s Corporate Secretary in May 2000.&#160; She is responsible for all day-to-day operations of CEL-SCI, including human resources and is the liaison with CEL-SCI&#8217;s independent registered public accounting firm for financial reporting.&#160; From June 1990 to December 1992, Ms. Prichep was the Manager of Quality and Productivity for the NASD&#8217;s Management, Systems and Support Department and was responsible for the internal auditing and work flow analysis of operations. Between 1982 and 1990, Ms. Prichep was Vice President and Operations Manager for Source Capital, Ltd.&#160; She handled all operations and compliance for Source Capital and was licensed as a securities broker.&#160; Ms. Prichep received her B.A. from the University of Bridgeport in Connecticut.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">61</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Eyal Talor, Ph.D. joined CEL-SCI in October 1993. In October 2009, Dr. Talor was promoted to Chief Scientific Officer. Prior to this promotion, Dr. Talor was the Senior Vice President of Research and Manufacturing. He is a clinical immunologist with over 27 years of hands-on management of clinical research and drug development for immunotherapy application; pre-clinical to Phase III clinical trials, in the biopharmaceutical industry. His expertise includes biopharmaceutical R&amp;D and Biologics product development, GMP (Good Manufacturing Practices) manufacture, Quality Control testing, and the design and building of GMP manufacturing and testing facilities. He served as Director of Clinical Laboratories (certified by the State of Maryland) and has experience in the design of pre-clinical and clinical trials (Phase I &#8211; III) and GCP (Good Clinical Practices) requirements. He also has broad experience in the different aspects of biological assay development, analytical methods validation, raw material specifications, and QC (Quality Control) tests development under FDA/GMP, USP, and ICH guidelines. He has extensive experience in the preparation of documentation for IND and other regulatory submissions. His scientific area of expertise encompasses immune response assessment. He is the author of over 25 publications and has published a number of reviews on immune regulations in relation to clinical immunology. Before coming to CEL-SCI, he was Director of R&amp;D and Clinical Development at CBL, Inc., Principal Scientist &#8211; Project Director, and Clinical Laboratory Director at SRA Technologies, Inc. Prior to that he was a full-time faculty member at The Johns Hopkins University, Medical Institutions; School of Public Health. He has invented technologies which are covered by ten issued patents on Multikine&#8217;s composition of matter and method of use in cancer and two platform Peptide technologies, Antigen Directed Apoptosis of T-cells (&#8216;Adapt&#8217;) and LEAPS, for the treatment of autoimmune diseases, asthma, allergy, transplantation rejection and infectious diseases. He also is responsible for numerous product and process inventions as well as a number of pending US and PCT patent applications. He received his Ph.D. in Microbiology and Immunology from the University of Ottawa, Ottawa, Ontario, Canada, and had post-doctoral training in clinical and cellular immunology at The Johns Hopkins University, Baltimore, Maryland, USA. He holds an Associate teaching position at the Johns Hopkins University Medical Institutions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Daniel H. Zimmerman, Ph.D. was CEL-SCI&#8217;s Senior Vice President of Research, Cellular Immunology between 1996 and December 2008 and again since November 2009.&#160; He joined CEL-SCI in January 1996 as the Vice President of Research, Cellular Immunology. Dr. Zimmerman founded CELL-MED, Inc. and was its president from 1987-1995.&#160; From 1973-1987, Dr. Zimmerman served in various positions at Electronucleonics, Inc. His positions included: Scientist, Senior Scientist, Technical Director and Program Manager. Dr. Zimmerman held various teaching positions at Montgomery College between 1987 and 1995. Dr. Zimmerman has invented technologies which are covered by over a dozen US patents as well as many foreign equivalent patents. He is the author of over 50 scientific publications in the area of immunology and infectious diseases. He has been awarded numerous grants from National Institutes of Health, or NIH, and the Department of Defense, or DOD.&#160; From 1969-1973, Dr. Zimmerman was a Senior Staff Fellow at NIH. For the following 25 years, he continued on at NIH as a&#160;guest worker. Dr. Zimmerman received a Ph.D. in Biochemistry in 1969, and a Masters in Zoology in 1966 from the University of Florida as well as a B.S. in Biology from Emory and Henry College in 1963.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">John Cipriano was CEL-SCI&#8217;s Senior Vice President of Regulatory Affairs between March 2004 and December 2008 and again since October 2009.&#160; Mr. Cipriano brings to CEL-SCI over 30 years of experience with both biotech and pharmaceutical companies. In addition, he held positions at the United States Food and Drug Administration (FDA) as Deputy Director, Division of Biologics Investigational New Drugs, Office of Biologics Research and Review and was the Deputy Director, IND Branch, Division of Biologics Evaluation, Office of Biologics.&#160; Mr. Cipriano completed his B.S. in Pharmacy from the Massachusetts College of Pharmacy in Boston, Massachusetts and his M.S. in Pharmaceutical Chemistry from Purdue University in West Lafayette, Indiana.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">62</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Bruno Baillavoine joined CEL-SCI&#8217;s board of directors in June 2015.&#160; Since 2017, Mr. Baillavoine has been the Director, Head of Pericles Group UK the subsidiary of the Paris-based leading French consulting firm Pericles Consulting Holdings SAS.&#160; Pericles is an expert in the fields of Banking, Finance, Asset Management and Insurance with over 500 institutional clients.&#160; Since November 2022, Mr. Baillavoine has been a director, initially non-executive, now executive of ESG.AI, a Canadian Company. From July 2023 to October 2024, Mr. Baillavoine was Executive Chair of Gratomic Inc., a Canadian Graphite mining company listed on the TSXV. He now works for Gratomic as a consultant.&#160; He has also been an advisor to the Board of CSL Inc., now &#8220;Combat Sport Entertainment&#8221;, a US Mixed Martial Arts company from 2017 to 2022 and retains a financial interest in the Company.&#160; Between 2010-2016, Mr. Baillavoine was a partner of Globomass Holdings Limited, a London, England based developer of renewable energy projects. He became Executive Chairmans from 2012 to 2016. Globomass was acquired by CleanBay Inc. in 2016. Mr. Baillavoine remains a significant shareholder in CleanBay Inc.&#160;&#160; Between 1978 and 1982 he was the marketing manager of Ravenhead Ltd., a manufacturer of glass tableware, and part of United Distillers Group (later acquired by Grand Metropolitan). During this time Mr. Baillavoine became the UK Business Manager where he restored market share and profit for United Distillers.&#160; From 1982 to 1986 Mr. Baillavoine was Group Corporate Planning and Group Marketing Director for Prontaprint where he expanded the number of shops to 500 locations in four years. Mr. Baillavoine was with Grand Metropolitan Plc between 1986-1988 (now Diageo Plc), a FTSE 100 beverage, food, hotel and leisure company, as director in the Special Operations division.&#160; In this capacity, he developed plans for Grand Met&#8217;s trouble-shooting division for over 20,000 Grand Met retail outlets. From 1988-1991 he was the Managing Director of Nutri Systems (UK) Ltd., a subsidiary of the US based provider of professionally supervised weight loss programs.&#160; Between 1991 and 1995, Mr. Baillavoine was Director of BET Group plc, a multinational business support services group, and in 1992, was promoted to the Managing Director for the manufacturing businesses. The &#163;2.3 billion turnaround of BET during his tenure is one of the most successful turnarounds of a top 100 FTSE company.&#160; Since 1995, Mr. Baillavoine has held a number of CEO positions across a wide range of industries and geographical locations.&#160; Mr. Baillavoine has European and American educations (US high school and University of Wisconsin Eau Claire 1972-1976).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Robert Watson has been a director of CEL-SCI since December 2017. Mr. Watson was the President and CEO of Juvare, LLC (formerly Intermedix, Inc.) from July 2017 to July 2023.&#160; At present he is a Director of Juvare, LLC. &#160;Immediately prior to joining Intermedix, now Juvare, he was the President and Chief Growth Officer of NantHealth, Inc. (Nasdaq: NH) from January 2015 to May 2017. Prior to NantHealth, he was President and CEO of Streamline Health, Inc. (Nasdaq: STRM) from January 2011 to January 2015. Mr. Watson has over 40 years of experience in the healthcare information technology industry as a CEO, board member and advisor to multiple healthcare information technology companies. He has participated in over 75 acquisitions, raised nearly $750 million in capital, completed three public offerings and successfully sold five companies. Mr. Watson holds a MBA from the Wharton School of Business at the University of Pennsylvania and a BA degree from Syracuse University. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Mario Gobbo has been a Director of CEL-SCI since April 2024. Mr. Gobbo has nearly 40 years of banking and corporate finance experience in healthcare and energy. His expertise encompasses venture capital and private equity as well as investment banking and strategic advisory services. Now quasi-retired, Mr. Gobbo is a Partner in Corporate Finance Investment Partners, a boutique NY merchant bank since September 2023, and is advising the Ministry of Finance of the Maldives on reform of state-owned enterprises since August 2024.&#160; In addition, he serves on the Supervisory Board of Cinkarna Celje, a fine chemicals company from Slovenia. As an executive director, he was on the board of Lazard Brothers, London and of Z. Triglav, the largest Slovenian insurance company.&#160; Mr. Gobbo holds a Bachelor of Arts in Organic Chemistry from Harvard College, a Master of Science in Biochemistry from the University of Colorado and an MBA, a Master of Business Economics and a PhD (Management) from the Wharton School of the University of Pennsylvania.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI believes its directors are qualified to serve as directors for the following reasons:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:25%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name</p></td><td style="width:2%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Reason</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Geert Kersten, Esq.</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Long standing relationship with CEL-SCI, relevant industry expertise and leadership experience</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Robert Watson</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Long standing relationship with CEL-SCI, relevant industry expertise and financial acumen</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Bruno Baillavoine</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Long standing relationship with CEL-SCI, diverse perspective and strong decision-making abilities</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Mario Gobbo</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;Nearly 40 years of banking and corporate finance experience in healthcare and energy</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">63</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">All of CEL-SCI&#8217;s officers devote substantially all of their time to CEL-SCI&#8217;s business.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s Board of Directors does not have a &#8220;leadership structure&#8221;, as such, since each director is entitled to introduce resolutions to be considered by the Board and each director is entitled to one vote on any resolution considered by the Board. The Chairman of CEL-SCI&#8217;s Board of Directors is Robert Watson.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s Board of Directors has the ultimate responsibility to evaluate and respond to risks facing CEL-SCI. CEL-SCI&#8217;s Board of Directors fulfills its obligations in this regard by meeting on a regular basis and communicating, when necessary, with CEL-SCI&#8217;s officers.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Bruno Baillavoine, Robert Watson, and Mario Gobbo are independent directors as that term is defined in section 803 of the listing standards of the NYSE American.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has adopted a Code of Ethics which is applicable to CEL-SCI&#8217;S principal executive, financial, and accounting officers and persons performing similar functions. The Code of Ethics is available on CEL-SCI&#8217;s website, located at <span style="text-decoration:underline"><span style="color:blue">https://cel-sci.com/new-investor-information/<em>.</em></span></span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If a violation of this code of ethics act is discovered or suspected, any person (anonymously, if desired) may send a detailed note, with relevant documents, to CEL-SCI&#8217;s Audit Committee, c/o Robert Watson at <span style="text-decoration:underline"><span style="color:blue">whistleblower@cel-sci.com</span> or to the following address:</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Compliance Officer</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Patricia Prichep</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI Corporation</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8229 Boone Boulevard</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Suite 802</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Vienna, VA 22182</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">For purposes of electing directors at its annual meeting, CEL-SCI has a Nominating and Governance Committee that is made up of CEL-SCI&#8217;s independent directors. The Nominating and Governance Committee selects the nominees to the Board of Directors which are subject to election by CEL-SCI&#8217;s shareholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI does not have any policy regarding the consideration of director candidates recommended by shareholders and under Colorado law, any shareholder can nominate a person for election as a director at the annual shareholders&#8217; meeting. However, CEL-SCI&#8217;s Board of Directors will consider candidates recommended by shareholders. To submit a candidate for the Board of Directors the shareholder should send the name, address and telephone number of the candidate, together with any relevant background or biographical information, to CEL-SCI&#8217;s Chief Executive Officer, at the address shown on the cover page of this report. The Board has not established any specific qualifications or skills a nominee must meet to serve as a director. Although the Board does not have any process for identifying and evaluating director nominees, the Board does not believe there would be any differences in the manner in which the Board evaluates nominees submitted by shareholders as opposed to nominees submitted by any other person.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI does not have a policy with regard to Board member&#8217;s attendance at annual meetings. All Board members attended the last annual shareholder&#8217;s meeting held on April 19, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">64</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Holders of CEL-SCI&#8217;s common stock can send written communications to CEL-SCI&#8217;s entire Board of Directors, or to one or more Board members, by addressing the communication to &#8220;the Board of Directors&#8221; or to one or more directors, specifying the director or directors by name, and sending the communication to CEL-SCI&#8217;s offices in Vienna, Virginia. Communications addressed to the Board of Directors as whole will be delivered to each Board member. Communications addressed to a specific director (or directors) will be delivered to the director (or directors) specified.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">A security holder communication not sent to the Board of Directors as a whole is not relayed to Board members which did not receive the communication.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 11. </strong><strong><span style="text-decoration:underline">EXECUTIVE COMPENSATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Components of Compensation &#8212; Executive Officers</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI&#8217;s executive officers are compensated through the following three components:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Base Salary</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Long-Term Incentives (&#8220;LTIs&#8221;) (stock options and/or grants of stock)</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Benefits</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">These components provide a balanced mix of base compensation and compensation that is contingent upon each executive officer&#8217;s individual performance. A goal of the compensation program is to provide executive officers with a reasonable level of security through base salary and benefits. CEL-SCI wants to ensure that the compensation programs are appropriately designed to encourage executive officer retention and motivation to create shareholder value. The Compensation Committee believes that CEL-SCI&#8217;s stockholders are best served when CEL-SCI can attract and retain talented executives by providing compensation packages that are competitive but fair.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Base Salaries</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Base salaries generally have been targeted to be competitive when compared to the salary levels of persons holding similar positions in other pharmaceutical companies and other publicly traded companies of comparable size. Each executive officer&#8217;s respective responsibilities, experience, expertise and individual performance are considered.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">A further consideration in establishing compensation for the senior employees is their long term history with CEL-SCI. Taken into consideration are factors that have helped CEL-SCI survive in times when it was financially weak, such as: willingness to accept salary cuts, willingness not to be paid at all for extended time periods, and in general an attitude that helped CEL-SCI survive during financially difficult times.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Long-Term Incentives</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Stock grants and option grants help to align the interests of CEL-SCI&#8217;s officers, directors and employees with those of its shareholders. Options and stock grants are made under CEL-SCI&#8217;s Stock Option, Incentive Stock Bonus, Stock Bonus and Stock Compensation Plans. Options are granted with exercise prices equal to the closing price of CEL-SCI&#8217;s common stock on the day immediately preceding the date of grant, with pro rata vesting at the end of each of the following three years.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI believes that grants of equity-based compensation:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Enhance the link between the creation of shareholder value and long-term executive incentive compensation;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Provide focus, motivation and retention incentive; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Provide competitive levels of total compensation.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">65</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Benefits</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In addition to cash and equity compensation programs, executive officers participate in the health and welfare benefit programs available to other employees. In a few limited circumstances, CEL-SCI provides other benefits to certain executive officers, such as car allowances.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">All executive officers are eligible to participate in CEL-SCI&#8217;s 401(k) plan on the same basis as its other employees. CEL-SCI matches 100% of each employee&#8217;s contribution up to 6% of his or her salary.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table sets forth in summary form the compensation received by (i) the Chief Executive and Financial Officer of CEL-SCI and (ii) by each other executive officer of CEL-SCI who received in excess of $100,000 during the two fiscal years ended September 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Name and </p><p style="font-size:10pt;font-family:times new roman;margin:0px">Principal Position</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Fiscal</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Year</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Salary</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(1)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Bonus</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(2)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Stock Awards (3)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Option Awards (4)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">All Other Compensation</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(5)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">$</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Geert R. Kersten,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">644,091</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">20,475</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">340,357</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">65,631</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,070,554</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Executive and Financial Officer and Treasurer</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">637,157</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">19,200</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">305,977</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">65,631</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,027,965</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patricia B. Prichep,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">289,194</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">17,160</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">227,359</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,031</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">542,744</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Senior Vice President of Operations and Secretary</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">286,145</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">17,160</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">204,392</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,031</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">516,729</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Eyal Talor, Ph.D.,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">349,612</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,600</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">247,780</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6,031</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">613,023</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Scientific Officer</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">345,849</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9,600</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">222,751</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6,031</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">584,230</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">John Cipriano,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">249,562</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">31</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">249,593</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Senior Vice President of Regulatory Affairs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">246,940</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">--</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">79,554</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">31</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">326,526</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(1)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The dollar value of base salary (cash and non-cash) earned. The officers have agreed to take less than their actual salary for the year 2024 and 2023. As of September 30, 2024, CEL-SCI owed back salaries to the following employees:</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Name</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160; Salary</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Geert Kersten</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">48,538</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patricia Prichep</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,814</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Eyal Talor, Ph.D.</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,346</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">John Cipriano</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,354</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(2)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The dollar value of bonus (cash and non-cash) earned.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(3)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">For all persons listed in the table, the shares issued as CEL-SCI's contribution on behalf of the named officer who participates in CEL-SCI's 401(k) retirement plan. The value of all stock awarded during the periods covered by the table is calculated according to ASC 718-10-30-3 which represented the grant date fair value.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">66</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(4)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The fair value of all stock options granted during the periods covered by the table are calculated on the grant date in accordance with ASC 718-10-30-3 which represented the grant date fair value.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(5)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">All other compensation received that CEL-SCI could not properly report in any other column of the table including the dollar value of any insurance premiums paid by, or on behalf of, CEL-SCI with respect to term life insurance for the benefit of the named executive officer and car allowances paid by CEL-SCI. Includes board of directors fees for Mr. Kersten.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Employee Pension, Profit Sharing or Other Retirement Plans</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has a defined contribution retirement plan, qualifying under Section 401(k) of the Internal Revenue Code and covering substantially all CEL-SCI&#8217;s employees.&#160; CEL-SCI&#8217;s contribution to the plan is made in shares of CEL-SCI's common stock. Each participant's contribution is matched by CEL-SCI with shares of common stock which have a value equal to 100% of the participant's contribution, not to exceed 6% of the participant's total compensation.&#160; CEL-SCI's contribution of common stock is valued each quarter based upon the closing price of its common stock.&#160; The fiscal 2024 expenses for this plan were approximately $5,000. Other than the 401(k) Plan, CEL-SCI does not have a defined benefit, pension plan, profit sharing or other retirement plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Compensation of Directors During Year Ended September 30, 20</span></strong><strong><span style="text-decoration:underline">24</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Name</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Fees</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Stock</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Awards (1)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Option</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Awards (2)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Geert Kersten&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">340,357</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">390,357</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Robert Watson</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">60,859</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">87,131</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">147,990</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Bruno Baillavoine</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">55,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">87,131</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">142,131</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Mario Gobbo</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,629</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">87,131</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">111,760</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(1)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The fair value of stock issued for services.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(2)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The fair value of options granted computed in accordance with ASC 718-10-30-3 on the date of grant which represents their grant date fair value.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Directors&#8217; fees paid to Geert Kersten are included in the Executive Compensation table.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Employment Contracts</span></strong>&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Geert Kersten</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On August 31, 2019, CEL-SCI entered into a four-year employment agreement with Geert Kersten, CEL-SCI&#8217;s Chief Executive Officer. The employment agreement with Mr. Kersten, which is essentially the same as Mr. Kersten&#8217;s prior employment agreement, as amended on August 30, 2016, provided that, during the term of the agreement, CEL-SCI would pay Mr. Kersten an annual salary of $559,052, plus any increases in proportion to salary increases granted to other senior executive officers of CEL-SCI, as well any increases approved by the Board of Directors during the term of the employment agreement. On October 26, 2023, CEL-SCI agreed that the term of the employment agreement would be extended to August 31, 2027. All other terms of the employment agreement remain the same.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">During the employment term, Mr. Kersten will be entitled to receive any other benefits which are provided to CEL-SCI's executive officers or other full time employees in accordance with CEL-SCI's policies and practices and subject to Mr. Kersten&#8217;s satisfaction of any applicable conditions of eligibility.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">67</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If Mr. Kersten resigns after the occurrence of any of the following events: (i) a reduction in Mr. Kersten&#8217;s salary (ii) a relocation (or demand for relocation) of Mr. Kersten&#8217;s place of employment to a location more than ten (10) miles from his current place of employment, (iii) a significant and material reduction in Mr. Kersten&#8217;s authority, job duties or level of responsibility or the imposition of significant and material limitations on Mr. Kersten&#8217;s autonomy in his position, or (iv) a Change in Control, then the employment agreement will be terminated and Mr. Kersten will be entitled to receive a lump-sum payment from CEL-SCI equal to 24 months of salary ($1,288,182) and the unvested portion of any stock options would vest immediately. For purposes of the employment agreement a change in the control of CEL-SCI means: (1) the merger of CEL-SCI with another entity if after such merger the shareholders of CEL-SCI do not own at least 50% of voting capital stock of the surviving corporation; (2) the sale of substantially all of the assets of CEL-SCI; (3) the acquisition by any person of more than 50% of CEL-SCI's common stock; or (4) a change in a majority of CEL-SCI's directors which has not been approved by the incumbent directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The employment agreement will also terminate upon the death of Mr. Kersten or Mr. Kersten&#8217;s physical or mental disability. If the employment agreement is terminated for any of these reasons, Mr. Kersten, or his legal representatives, as the case may be, will be paid the salary provided by the employment agreement through the date of termination, any options or bonus shares of CEL-SCI then held by Mr. Kersten will become fully vested and the expiration date of any options which would expire during the four year period following his termination of employment will be extended to the date which is four years after his termination of employment. The employment agreement will also terminate upon the willful misconduct, an act of fraud against CEL-SCI, or a breach of the employment agreement by Mr. Kersten, in which case Mr. Kersten will be paid the salary provided by the employment agreement through the date of termination.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Patricia B. Prichep / Eyal Talor, Ph.D.</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On August 31, 2019, CEL-SCI entered into a four-year employment agreement with Patricia B. Prichep, CEL-SCI&#8217;s Senior Vice President of Operations. The employment agreement with Ms. Prichep, which is essentially the same as Ms. Prichep&#8217;s prior employment agreement entered into on August 30, 2016 provided that, during the term of the agreement, CEL-SCI would pay Ms. Prichep an annual salary of $245,804 plus any increases approved by the Board of Directors during the period of the employment agreement. On August 31, 2023, CEL-SCI agreed that the term of the employment agreement would be extended to August 31, 2027. All other terms of the employment agreement remain the same.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On August 31, 2019, CEL-SCI entered into a four-year employment agreement with Eyal Talor, Ph.D., CEL-SCI&#8217;s Chief Scientific Officer. The employment agreement with Dr. Talor, which is essentially the same as Dr. Talor&#8217;s prior employment agreement entered into on August 30, 2016, provided that, during the term of the agreement, CEL-SCI would pay Dr. Talor an annual salary of $303,453 plus any increases approved by the Board of Directors during the period of the employment agreement. On August 31, 2023, CEL-SCI agreed that the term of the employment agreement would be extended to August 31, 2027. All other terms of the employment agreement remain the same.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">If Ms. Prichep or Dr. Talor resigns after the occurrence of any of the following events: (i) a relocation (or demand for relocation) of employee&#8217;s place of employment to a location more than ten (10) miles from the employee&#8217;s current place of employment, (ii) a significant and material reduction in the employee&#8217;s authority, job duties or level of responsibility, (iii) the imposition of significant and material limitations on the employee&#8217;s autonomy in her or his position, or (iv) there is a change in the control of CEL-SCI, the employment agreements with Ms. Prichep and Dr. Talor allow Ms. Prichep and/or Dr. Talor (as the case may be) to resign from her or his position at CEL-SCI and receive a lump-sum payment from CEL-SCI equal to 18 months of salary ($424,790 and $524,419 respectively). In addition, the unvested portion of any stock options held by the employee will vest immediately. For purposes of the employment agreements, a change in the control of CEL-SCI means: (1) the merger of CEL-SCI with another entity if after such merger the shareholders of CEL-SCI do not own at least 50% of voting capital stock of the surviving corporation; (2) the sale of substantially all of the assets of CEL-SCI; (3) the acquisition by any person of more than 50% of CEL-SCI's common stock; or (4) a change in a majority of CEL-SCI's directors which has not been approved by the incumbent directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">68</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The employment agreements with Ms. Prichep and Dr. Talor will also terminate upon the death of the employee, the employee&#8217;s physical or mental disability, willful misconduct, an act of fraud against CEL-SCI, or a breach of the employment agreement by the employee. If the employment agreement is terminated for any of these reasons the employee, or her or his legal representatives, as the case may be, will be paid the salary provided by the employment agreement through the date of termination.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Compensation Committee Interlocks and Insider Participation</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has a compensation committee comprised of Mr. Bruno Baillavoine, Mr. Robert Watson and Mr. Mario Gobbo, all of whom are independent directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">During the year ended September 30, 2024, no director of CEL-SCI was also an executive officer of another entity, which had an executive officer of CEL-SCI serving as a director of such entity or as a member of the compensation committee of such entity.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Stock Option, Bonus and Compensation Plans</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Bonus Plans, Stock Compensation Plans and an Incentive Stock Bonus Plan. All Stock Option, Bonus and Compensation Plans have been approved by CEL-SCI&#8217;s stockholders. A summary description of these Plans follows. In some cases these Plans are collectively referred to as the "Plans".</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><span style="text-decoration:underline">Incentive Stock Option Plan</span><span style="text-decoration:underline">s</span>. The Incentive Stock Option Plans authorize the issuance of shares of CEL-SCI's common stock to persons who exercise options granted pursuant to the Plans. Only CEL-SCI&#8217;s employees may be granted options pursuant to the Incentive Stock Option Plans.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Options may not be exercised until one year following the date of grant. Options granted to an employee then owning more than 10% of the common stock of CEL-SCI may not be exercisable by its terms after five years from the date of grant. Any other option granted pursuant to the Plans may not be exercisable by its terms after ten years from the date of grant.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The option exercise price is determined by CEL-SCI&#8217;s Compensation Committee but cannot be less than the fair market value of the common stock on the date of the grant of the option (or 110% of the fair market value in the case of a person owning more than 10% of CEL-SCI's outstanding shares).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><span style="text-decoration:underline">Non-Qualified Stock Option Plans</span>. The Non-Qualified Stock Option Plans authorize the issuance of shares of CEL-SCI's common stock to persons that exercise options granted pursuant to the Plans. CEL-SCI's employees, directors, officers, consultants and advisors are eligible to be granted options pursuant to the Plans, provided however that bona fide services must be rendered by such consultants or advisors and such services must not be in connection with a capital-raising transaction or promoting CEL-SCI&#8217;s common stock. The option exercise price is determined by CEL-SCI&#8217;s Compensation Committee.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><span style="text-decoration:underline">Stock Bonus Plan</span><span style="text-decoration:underline">s</span>. Under the Stock Bonus Plans shares of CEL-SCI&#8217;s common stock may be issued to CEL-SCI's employees, directors, officers, consultants and advisors, provided however that bona fide services must be rendered by consultants or advisors and such services must not be in connection with a capital-raising transaction or promoting CEL-SCI&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">69</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><span style="text-decoration:underline">Stock Compensation Plan</span><span style="text-decoration:underline">s</span>. Under the Stock Compensation Plans, shares of CEL-SCI&#8217;s common stock may be issued to CEL-SCI&#8217;s employees, directors, officers, consultants and advisors in payment of salaries, fees and other compensation owed to these persons. However, bona fide services must be rendered by consultants or advisors and such services must not be in connection with a capital-raising transaction or promoting CEL-SCI&#8217;s common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><span style="text-decoration:underline">Incentive Stock Bonus </span><span style="text-decoration:underline">Plan</span>. Under the 2014 Incentive Stock Bonus Plan, shares of CEL-SCI&#8217;s common stock may be issued to executive officers and other employees who contribute significantly to the success of CEL-SCI. The purpose of the Plan is to provide long term incentive for outstanding service to CEL-SCI and its shareholders, to assist in recruiting and retaining people of outstanding ability and initiative in executive and management positions to allow officers and employees to participate in CEL-SCI's future prosperity and growth, and to align the interests of CEL-SCI's officers and employees with those of its shareholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><span style="text-decoration:underline">Other Information Regarding the Plans</span>. The Plans are administered by CEL-SCI's Compensation Committee (&#8220;the Committee&#8221;), each member of which is a director of CEL-SCI. The members of the Committee were selected by CEL-SCI's Board of Directors and serve for a one-year tenure and until their successors are elected. A member of the Committee may be removed at any time by action of the Board of Directors. Any vacancies which may occur on the Committee will be filled by the Board of Directors. The Committee is vested with the authority to interpret the provisions of the Plans and supervise the administration of the Plans. In addition, the Committee is empowered to select those persons to whom shares or options are to be granted, to determine the number of shares subject to each grant of a stock bonus or an option and to determine when, and upon what conditions, shares or options granted under the Plans will vest or otherwise be subject to forfeiture and cancellation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In the discretion of the Committee, any option granted pursuant to the Plans may include installment exercise terms such that the option becomes fully exercisable in a series of cumulating portions. The Committee may also accelerate the date upon which any option (or any part of any options) is first exercisable. Any shares issued pursuant to the Stock Bonus Plans or Stock Compensation Plans and any options granted pursuant to the Incentive Stock Option Plans or the Non-Qualified Stock Option Plans will be forfeited if the "vesting" schedule established by the Committee administering the Plans at the time of the grant is not met. For this purpose, vesting means the period during which the employee must remain an employee of CEL-SCI or the period of time a non-employee must provide services to CEL-SCI. At the time an employee ceases working for CEL-SCI (or at the time a non-employee ceases to perform services for CEL-SCI), any shares or options not fully vested will be forfeited and cancelled. At the discretion of the Committee payment for the shares of common stock underlying options may be paid through the delivery of shares of CEL-SCI's common stock having an aggregate fair market value equal to the option price, provided such shares have been owned by the option holder for at least one year prior to such exercise. A combination of cash and shares of common stock may also be permitted at the discretion of the Committee.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Options are generally non-transferable except upon the death of the option holder. Shares issued pursuant to the Stock Bonus Plans will generally not be transferable until the person receiving the shares satisfies the vesting requirements imposed by the Committee when the shares were issued.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Board of Directors of CEL-SCI may at any time, and from time to time, amend, terminate, or suspend one or more of the Plans in any manner it deems appropriate, provided that such amendment, termination or suspension may not adversely affect rights or obligations with respect to shares or options previously granted.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">70</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Stock Options</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table shows information concerning the options granted during the fiscal year ended September 30, 2024, to the persons named below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span style="text-decoration:underline">Options Granted</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Name&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Grant Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options Granted</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise Price </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Geert Kersten</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">4/19/2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">250,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4/18/2034</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patricia Prichep</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">4/19/2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">167,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4/18/2034</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Eyal Talor</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">4/19/2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">182,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4/18/2034</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Robert Watson</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">4/19/2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4/18/2034</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Bruno Baillavoine</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">4/19/2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4/18/2034</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Mario Gobbo</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">4/19/2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4/18/2034</p></td><td style="width:1%;">&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table shows the outstanding options held by the persons named below on September 30, 2024:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares underlying unexercised</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Option which are:</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration</p></td><td>&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Name</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercisable</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Unexercisable</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Price ($)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Geert R. Kersten</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">180,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.18</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">07/27/27</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">530,121</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.45</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/30/28</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">813,180</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/10/29</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">148,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">444,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/19/30</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">592,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/13/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.48</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">11/18/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">166,667</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">83,333</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">06/12/32</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">83,334</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">166,666</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.36</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">08/07/33</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">250,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/18/34</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patricia B. Prichep</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.18</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">07/27/27</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">222,607</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.45</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/30/28</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">405,631</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/10/29</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">72,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">216,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/19/30</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">288,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/13/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.48</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">11/18/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">111,334</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">55,666</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">06/12/32</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">55,667</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">111,333</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.36</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">08/07/33</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">167,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/18/34</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Eyal Talor, Ph.D.</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.18</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">07/27/27</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">193,934</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.45</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/30/28</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.55</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">09/20/28</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">382,712</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/10/29</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">72,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">216,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/19/30</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">318,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/13/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.48</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">11/18/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">121,334</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">60,666</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">06/12/32</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">60,667</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">121,333</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.36</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">08/07/33</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">182,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/18/34</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Dan Zimmerman, Ph.D.</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">06/25/25</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">07/21/26</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.87</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">06/28/27</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.59</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">09/17/27</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">126,194</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.45</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/30/28</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">211,459</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/10/29</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/19/30</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">160,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/13/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.48</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">11/18/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">53,334</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,666</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">06/12/32</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">John Cipriano</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">90,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.18</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">07/27/27</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">148,347</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.45</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/30/28</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">206,880</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/10/29</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">120,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.93</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">04/19/30</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">130,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.61</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">05/13/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">50,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.48</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">11/18/31</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,334</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,666</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">06/12/32</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,667</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43,333</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.36</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">08/07/33</p></td><td style="width:1%;">&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">71</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"><span style="text-decoration:underline">Summary</span>. The following shows certain information as of September 30, 2024 concerning the stock options and stock bonuses granted by CEL-SCI.&#160; Each option represents the right to purchase one share of CEL-SCI's common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Name of Plan</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total Shares Reserved</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Under Plans</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:20%;vertical-align:bottom;text-align:right;">138,400</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">17,787,200</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Bonus Plans</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,283,760</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock Compensation Plans</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">634,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Bonus Plan</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">640,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Of the shares issued pursuant to CEL-SCI's Stock Bonus Plans, 567,518 shares were issued as part of CEL-SCI's contribution to its 401(k) plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table shows the weighted average exercise price of the outstanding options granted pursuant to CEL-SCI&#8217;s Incentive and Non-Qualified Stock Option Plans as of September 30, 2024, CEL-SCI&#8217;s most recent fiscal year end. CEL-SCI's Incentive and Non-Qualified Stock Option Plans have been approved by CEL-SCI's shareholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Plan category</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number of Securities</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">to be Issued Upon</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise of</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Outstanding Options</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(a)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted-Average</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Price of</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Outstanding</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number of Securities Remaining</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Available For Future Issuance Under</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Equity Compensation Plans, </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Excluding Securities </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Reflected in Column (a)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:15%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Incentive Stock Option Plans&#160;&#160; </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:15%;vertical-align:bottom;text-align:right;">40,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:15%;vertical-align:bottom;text-align:right;">2.18</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:15%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Qualified Stock Option Plans </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">16,218,080</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6.90</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,063,031</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">72</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On April 19, 2024, CEL-SCI granted options to its employees and directors, including the three persons mentioned in the following table.&#160; On April 19, 2024 and April 23, 2024, CEL-SCI issued 8-K reports disclosing material non-public information.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Name</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Grant date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number of</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">securities</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">underlying</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">the award</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">price of the</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">award ($/Sh)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Grant date</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">fair value of</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">the award</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Percentage change in the</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">closing market price of the</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">securities underlying the</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">award between the trading</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">day ending immediately</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">prior to the disclosure of</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">material nonpublic</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">information and the trading</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">day beginning immediately</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">following the disclosure of</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">material nonpublic</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">information</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Geert Kersten</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:10%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4/19/24</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:10%;vertical-align:bottom;text-align:right;">250,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:10%;vertical-align:bottom;text-align:right;">1.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:10%;vertical-align:bottom;text-align:right;">1.36</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:25%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">For the 8-K filed on April 19, 2024 +.007%. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">For the 8-K filed on April 23, 2024 &#8211;3%.</p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patricia Prichep</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4/19/24</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">167,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.50</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.36</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">For the 8-K filed on April 19, 2024 +.007%. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">For the 8-K filed on April 23, 2024 &#8211;3%.</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Eyal Talor</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4/19/24</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">182,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.50</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.36</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">For the 8-K filed on April 19, 2024 +.007%. </p><p style="font-size:10pt;font-family:times new roman;margin:0px">For the 8-K filed on April 23, 2024 &#8211;3%.</p></td><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Insider Trading Arrangements and Policies</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">CEL-SCI is committed to promoting high standards of ethical business conduct and compliance with applicable laws, rules and regulations. &#160;As part of this commitment, CEL-SCI has adopted an Insider Trading Policy governing the purchase, sale, and/or other dispositions of CEL-SCI&#8217;s securities by its directors, officers, employees and others that CEL-SCI believe is reasonably designed to promote compliance with insider trading laws, rules and regulations. &#160;A copy of CEL-SCI&#8217;s Insider Trading Policy is filed as Exhibit 19 to this Annual Report on Form 10-K.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 12. <span style="text-decoration:underline">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following table shows, as of December 20, 2024, information with respect to the only persons owning beneficially 5% or more of CEL-SCI&#8217;s outstanding common stock and the number and percentage of outstanding shares owned by each director and officer of CEL-SCI and by the officers and directors as a group. Unless otherwise indicated, each owner has sole voting and investment powers over his shares of common stock.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name and Address</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number of Shares (1)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Percent of Class (2)</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Geert R. Kersten </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">8229 Boone Blvd., Suite 802</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vienna, VA&#160; 22182</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">4,123,362</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">(3)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">5.9</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Patricia B. Prichep</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">8229 Boone Blvd., Suite 802</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vienna, VA&#160; 22182</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,245,869</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.8</td><td style="vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Eyal Talor, Ph.D.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">8229 Boone Blvd., Suite 802</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Vienna, VA&#160;&#160;22182</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,169,243</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.7</td><td style="vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Daniel H. Zimmerman, Ph.D.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">8229 Boone Blvd., Suite 802</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vienna, VA&#160; 22182</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">585,213</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">John Cipriano</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">8229 Boone Blvd., Suite 802</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vienna, VA&#160; 22182</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">613,336</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">*</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">73</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Bruno Baillavoine</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">8229 Boone Blvd., Suite 802</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vienna, VA&#160; 22182</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">379,474</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Robert Watson</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">245 N. Highland Ave. NE</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Suite 230-296</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Atlanta, GA 30307</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">370,432</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Mario Gobbo</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3531 South Logan St., </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Suite D-357</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Englewood, CO 80113</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">*</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All Officers and Directors</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">as a Group (8 persons)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,486,929</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11.61</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">*</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less than 1%</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(1)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Includes shares issuable prior to February 25, 2025 upon the exercise of options or warrants granted to the following persons:</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options or Warrants Exercisable</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Prior to February 25, 2025</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Geert R. Kersten, Esq.</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:25%;vertical-align:bottom;text-align:right;">2,918,710</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">(3)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patricia B. Prichep</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,005,798</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Eyal Talor, Ph.D.</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1,050,647</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Daniel Zimmerman, Ph.D.</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">464,987</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">John Cipriano</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">550,228</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Bruno Baillavoine</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">373,501</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Robert Watson</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">346,001</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Mario Gobbo</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(2)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Amount includes shares referred to in (1) above but excludes shares which may be issued upon the exercise of options and warrants previously issued by CEL-SCI.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(3)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Amount includes 346,421 shares and 390,928 warrants held in the de Clara Trust, of which Mr. Kersten is a trustee and beneficiary.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 13. </strong><strong><span style="text-decoration:underline">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">During the year ended September 30, 2024, officers and a director of the Company purchased 58,000 restricted shares of the Company&#8217;s common stock at an aggregate market value of approximately $80,620. During the year ended September 30, 2023, no shares of the Company&#8217;s common stock were purchased by officers or directors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">See Note 11 to the financial statements included as part of this report for additional information concerning related party transactions.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">74</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 14</strong>. <strong><span style="text-decoration:underline">PRINCIPAL ACCOUNTING FEES AND SERVICES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">BDO USA, P.C. served as CEL-SCI&#8217;s independent registered public accountant for the two years ended September 30, 2024. The following table shows the aggregate fees billed to CEL-SCI for these years by BDO USA, P.C.:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;&#160;&#160; Year Ended September 30,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Audit Fees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">656,009</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">342,287</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Audit Related Fees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Tax Fees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">All Other Fees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Audit fees represent amounts billed for professional services rendered for the audit of CEL-SCI&#8217;s annual financial statements and the reviews of the financial statements included in CEL-SCI&#8217;s 10-Q reports for the fiscal year and all regulatory filings.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Before BDO USA, P.C. was engaged by CEL-SCI to render audit or non-audit services, the engagement was approved by CEL-SCI&#8217;s audit committee. CEL-SCI&#8217;s Board of Directors is of the opinion that the audit fees charged by BDO USA, P.C. are consistent with BDO USA, P.C. maintaining its independence from CEL-SCI.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">75</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">ITEM 15.</span></strong><strong><span style="text-decoration:underline">&#160;</span></strong><strong><span style="text-decoration:underline">EXHIBITS</span></strong><strong><span style="text-decoration:underline"> AND</span></strong><strong><span style="text-decoration:underline"> FINANCIAL STATEMENT SCHEDULES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Exhibits</span></strong></p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="width:9%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3(a)</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:40%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Articles of Incorporation</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 3(a) of CEL-SCI's combined Registration Statement on Form S-1 and Post-Effective Amendment ("Registration Statement"), Registration Nos. 2-85547-D and 33-7531.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3(b)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Amended Articles</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 3(a) of CEL-SCI's Registration Statement on Form S-1, Registration Nos. 2-85547-D and 33-7531.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">3(c)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Amended Articles (Name change only)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 3(c) of CEL-SCI's Registration Statement on Form S-1 Registration Statement (No. 33-34878).</p></td></tr><tr style="height:15px;background-color:#ffffff"><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495420002630/cvm_ex3d.htm">3(d)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495420002630/cvm_ex3d.htm">Bylaws (as amended)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;Incorporated by reference to Exhibit 3(d) of CEL-SCI's Post-Effective Amendment No. 3 to Registration Statement on Form S-1 (No. 333-229295).</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495420011660/cvm_ex4.htm">4</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495420011660/cvm_ex4.htm">Shareholders Rights Agreement, as Amended</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 4&#160;filed with CEL-SCI&#8217;s 8-K report dated October 30, 2020.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495416002720/cvi_ex4b.htm">4(b)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495416002720/cvi_ex4b.htm">Incentive Stock Option Plan</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 4 (b) filed on October 7, 2016 with CEL-SCI&#8217;s registration statement on Form S&#172;8 (File number 333-214031).</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495424011346/cvm_ex4b.htm">4(c)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495424011346/cvm_ex4b.htm">Non-Qualified Stock Option Plan</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 4 (b) filed on August 30, 2024 with CEL-SCI&#8217;s registration statement on Form S&#172;8 (File number 333-281884).</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423015936/cvm_ex4c.htm">4(d)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423015936/cvm_ex4c.htm">Stock Bonus Plan</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 4 (c) filed on December 22, 2023 with CEL-SCI&#8217;s registration statement on Form S&#172;8 (File number 333-276238).</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495420000735/cvm_ex4c.htm">4(e)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495420000735/cvm_ex4c.htm">Stock Compensation Plan</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 4 (e) filed on January 24, 2020 with CEL-SCI&#8217;s registration statement on Form S&#172;8 (File number 333-236063).</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815003367/cvm_ex4f.htm">4(f)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815003367/cvm_ex4f.htm">2014 Incentive Stock Bonus Plan</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;Filed with Amendment No. 2 to CEL-SCI&#8217;s annual report on Form 10-K for the year ended September 30, 2014.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10m11-10.txt">10(l)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10m11-10.txt">First Amendment to Development Supply&#160;and Distribution Agreement with Orient&#160;Europharma.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(m)&#160;filed with CEL-SCI&#8217;s 10-K report for the&#160;year ended September 30, 2010.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10n11-10.txt">10(m)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10n11-10.txt">Exclusive License and Distribution&#160;Agreement with Teva&#160;Pharmaceutical Industries&#160;Ltd.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(n)&#160;filed with CEL-SCI&#8217;s 10-K report for the&#160;year ended September 30, 2010.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10o11-10.txt">10(n)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487810000213/exh10o11-10.txt">Lease Agreement</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(o)&#160;filed with CEL-SCI&#8217;s 10-K report for the&#160;year ended September 30, 2010.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">10(p)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Licensing Agreement with Byron&#160;Biopharma</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(i) of&#160;CEL-SCI&#8217;s report on Form 8-K dated March&#160;27, 2009</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487804000009/sept03amnd10kex10z.txt">10(z)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000100487804000009/sept03amnd10kex10z.txt">Development, Supply and Distribution&#160;Agreement with Orient Europharma</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit&#160;10(z)&#160;filed with CEL-SCI&#8217;s report on Form&#160;10-K for the year ended September 30, 2003.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10rr.htm">10 (rr)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10rr.htm">Assignment and Assumption Agreement with Teva Pharmaceutical Industries, Ltd. and GCP Clinical Studies, Ltd.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(rr) of CEL-SCI&#8217;s report on Form 10-K/A report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10ss.htm">10 (ss)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10ss.htm">Service Agreement with GCP Clinical Studies,&#160;Ltd., together with Amendment 1 thereto*</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(ss) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10tt.htm">10 (tt)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10tt.htm">Joinder Agreement with PLIVA Hrvatska d.o.o.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(tt) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10uu.htm">10 (uu)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10uu.htm">Master Service Agreement with Ergomed Clinical Research, Ltd.,&#160;&#160;and Clinical Trial Orders thereunder</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(uu) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10vv.htm">10 (vv)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10vv.htm">Co-Development and Revenue Sharing Agreement with Ergomed Clinical Research Ltd., dated April 19, 2013, as amended</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(vv) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">76</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="width:9%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10ww.htm">10 (ww)</a></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:40%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10ww.htm">Co-Development and Revenue Sharing Agreement II:&#160;&#160;Cervical Intraepithelial Neoplasia in HIV/HPV co-infected women, with Ergomed Clinical Research Ltd., dated October 10, 2013, as amended</a></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(ww) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815005519/cvm_ex10iii.htm">10 (xx)</a></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815005519/cvm_ex10iii.htm">Co-Development and Revenue Sharing Agreement III: Anal warts and anal intraepithelial neoplasia in HIV/HPV co-infected patients, with Ergomed Clinical Research Ltd., dated October 24, 2013</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(xx) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10yy.htm">10 (yy)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10yy.htm">Master Services Agreement with Aptiv Solutions, Inc.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(yy) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10zz.htm">10 (zz)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10zz.htm">Project Agreement Number 1 with Aptiv Solutions, Inc. together with Amendments 1 and 2 thereto*</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(zz) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10aaa.htm">10 (aaa)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815001817/cvm_ex10aaa.htm">Second Amendment to Development Supply and Distribution Agreement with Orient Europharma</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(aaa) of CEL-SCI&#8217;s first amendment to its Form 10-K report for the&#160;year ended September 30, 2014 dated April 17, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815005519/cvm_ex10iii.htm">10 (iii)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">\</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000135448815005519/cvm_ex10iii.htm">Amendment to Co-Development and Revenue Sharing Agreement with Ergomed Clinical Research, Ltd., dated&#160; September 15, 2015</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10 (iii)&#160;filed with CEL-SCI&#8217;s 10-K report for the&#160;year ended September 30, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495419010199/cvm_ex107.htm">10 (mmm)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495419010199/cvm_ex107.htm">Employment Agreement with Geert Kersten (2019-2023)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(10.7) of CEL-SCI&#8217;s report on Form 8-K dated August 31, 2019.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495419010199/cvm_ex108.htm">10 (nnn)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495419010199/cvm_ex108.htm">Employment Agreement with Patricia Prichep (2019-2022)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(10.8) of CEL-SCI&#8217;s report on Form 8-K dated August 31, 2019.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495419010199/cvm_ex109.htm">10 (ooo)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495419010199/cvm_ex109.htm">Employment Agreement with Eyal Taylor (2019-2022)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(10.9) of CEL-SCI&#8217;s report on Form 8-K dated August 31, 2019.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423011434/cvm_ex1010.htm">10 (ppp)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423011434/cvm_ex1010.htm">Extension of Employment Agreement with Patricia Prichep (2023-2027)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; Incorporated by reference to Exhibit 10(10.10) of CEL-SCI&#8217;s report on Form 8-K dated August 31, 2023.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423011434/cvm_ex1011.htm">10 (qqq)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423011434/cvm_ex1011.htm">Extension of Employment Agreement with Eyal Talor (2023-2027)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10(10.11) of CEL-SCI&#8217;s report on Form 8-K dated August 31, 2023.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423013555/cvm_ex1010.htm">10 (rrr)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423013555/cvm_ex1010.htm">Extension of Employment Agreement with Geert Kersten (2023-2027)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 10.10 of CEL-SCI&#8217;s report on Form 8-K dated October 26, 2023.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="cvm_ex19.htm">19</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="cvm_ex19.htm">Insider Trading Policies and Procedures</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="cvm_ex231.htm">23.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="cvm_ex231.htm">Consent of BDO USA, P.C.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="cvm_ex31.htm">31</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="cvm_ex31.htm">Rule 13a-14(a) Certifications</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="cvm_ex32.htm">32</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="cvm_ex32.htm">Section 1350 Certifications</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423015877/cvm_ex97.htm">97</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/725363/000165495423015877/cvm_ex97.htm">Policy relating to Recovery of Erroneously Awarded Compensation</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Incorporated by reference to Exhibit 97 of CEL-SCI&#8217;s 10-K report for the year ended September 30, 2023.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">* Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the Commission under Rule 24b-2 of the Securities Exchange Act of 1934. The omitted confidential material has been filed separately with the Commission. The location of the omitted confidential information is indicated in the exhibit with asterisks (*)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">77</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:35%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>CEL-SCI CORPORATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Financial Statements for the Years</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Ended September 30, </strong><strong>2024 and 2023</strong><strong>, and</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Report of Independent Registered Public Accounting Firm</strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"/></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CEL-SCI CORPORATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="Toc2">TABLE OF CONTENTS</span></strong></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Page</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a href="#re">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM&#160;(PCAOB ID: <ix:nonNumeric name="dei:AuditorFirmId" contextRef="From2023-10-01to2024-09-30" id="ixv-17568">243</ix:nonNumeric>)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">F- 2</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">FINANCIAL STATEMENTS FOR THE YEARS ENDED SEPTEMBER 30, 2024 and 2023:</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"><a href="#bs">Balance Sheets</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">F- 4</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"><a href="#so">Statements of Operations</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">F- 5</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"><a href="#sse">Statements of Stockholders&#8217; Equity</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">F- 6</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"><a href="#cs">Statements of Cash Flows</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">F- 7</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"><a href="#note">Notes to Financial Statements</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">F- 9 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-1</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><span class="atag" style="display: inline" id="re">Report of Independent Registered Public Accounting Firm</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Stockholders and Board of Directors</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI Corporation</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Vienna, Virginia</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"><strong>Opinion on the Financial Statements</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">We have audited the accompanying balance sheets of CEL-SCI Corporation (the &#8220;Company&#8221;) as of September 30, 2024 and 2023, the related statements of operations, stockholders&#8217; equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at September 30, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"><strong>Going Concern Uncertainty</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations and has future liquidity needs that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"><strong>Basis for Opinion</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0in; text-align:justify;"><strong>Critical Audit Matter</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">F-2</p></td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Classification of Pre-Funded Warrants</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">As described in Note 12 to the financial statements, on July 29, 2024, the Company sold 3,715,000 shares of common stock at an offering price of $1.00 per share, and pre-funded warrants to purchase up to 7,130,000 shares of common stock, at an offering price of $0.99 per pre-funded warrant, for proceeds of approximately $9.7 million, net of issuance costs of approximately $1.1 million. The Company determined that the Pre-Funded Warrants met all of the criteria for equity classification and recorded them as a component of additional paid-in capital upon the closing of the transaction in July 2024.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We identified the determination of the financial statement classification of the Pre-Funded Warrants as a critical audit matter. Our principal considerations included the existence of accounting complexities related to certain provisions of the warrant agreement, including settlement provisions and derivative elements in applying the accounting standard. Auditing these elements involved especially complex auditor judgment due to the terms of the applicable agreement, including the extent of specialized knowledge and skills needed.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The primary procedures we performed to address this critical audit matter included:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Evaluating the appropriateness of management&#8217;s application of the accounting guidance in determining the classification of the pre-funded warrants in the financial statement by i) reviewing the relevant terms of the pre-funded warrant agreement, (ii) evaluating the completeness and accuracy of the Company&#8217;s technical accounting analysis and the application of the relevant accounting literature.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Utilizing personnel with specialized knowledge and skills in technical accounting to assist in: (i) evaluating the terms of the warrant agreement in relation to the relevant accounting literature, and (ii) assessing the appropriateness of conclusions reached by the Company.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">/s/<ix:nonNumeric name="dei:AuditorName" contextRef="From2023-10-01to2024-09-30" id="ixv-17569">BDO USA, P.C.</ix:nonNumeric></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have served as the Company's auditor since 2005.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><ix:nonNumeric name="dei:AuditorLocation" contextRef="From2023-10-01to2024-09-30" id="ixv-17570">Potomac, Maryland</ix:nonNumeric></p><p style="font-size:10pt;font-family:times new roman;margin:0px">January 13, 2025</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-3</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="bs">CEL-SCI CORPORATION</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">BALANCE SHEETS</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">SEPTEMBER 30, 2024 and 2023</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>ASSETS</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Current assets:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2088" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,738,173</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2089" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,145,735</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Prepaid expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2090" name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">294,097</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2091" name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">520,368</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Supplies used for R&amp;D and manufacturing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2092" name="us-gaap:InventoryNet" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,019,908</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2093" name="us-gaap:InventoryNet" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,248,072</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2094" name="us-gaap:DepositsAssetsCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,500</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2095" name="us-gaap:DepositsAssetsCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,245</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2096" name="us-gaap:AssetsCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,055,678</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2097" name="us-gaap:AssetsCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,918,420</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finance lease right-of-use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2098" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,350,364</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2099" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,131,987</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating lease right-of-use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2100" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,495,937</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2101" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,698,243</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2102" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8,129,753</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2103" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,188,126</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patent costs, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2104" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">165,492</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2105" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">197,704</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2106" name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,319,101</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2107" name="us-gaap:DepositsAssetsNoncurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,319,101</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Supplies used for R&amp;D and manufacturing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2108" name="us-gaap:InventoryNoncurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,475,441</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2109" name="us-gaap:InventoryNoncurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">74,669</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2110" name="us-gaap:Assets" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">26,991,766</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2111" name="us-gaap:Assets" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">30,528,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>LIABILITIES AND STOCKHOLDERS' EQUITY</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Current Liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2114" name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,448,467</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2115" name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,009,786</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2116" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">566,042</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2117" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,049,581</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Due to employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2118" name="cvm:AmountsDueToEmployeesCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">363,306</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2119" name="cvm:AmountsDueToEmployeesCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">557,244</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Finance lease obligation, current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2120" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,010,995</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2121" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,771,804</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Operating lease obligation, current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2122" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">226,969</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2123" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">197,431</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2124" name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,615,779</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2125" name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">5,585,846</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Finance lease liabilities, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2126" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,957,925</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2127" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,949,565</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Operating lease liabilities, net of current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2128" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,425,979</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2129" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,652,949</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Other liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2130" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">125,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2131" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">125,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2132" name="us-gaap:Liabilities" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">14,124,683</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2133" name="us-gaap:Liabilities" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">17,313,360</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Commitments and contingencies</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">STOCKHOLDERS' EQUITY</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Preferred stock, $<ix:nonFraction id="fid_1456" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.01</ix:nonFraction> par value; <ix:nonFraction id="fid_1457" name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">200,000</ix:nonFraction> shares authorized; <ix:nonFraction id="fid_1458" name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">0</ix:nonFraction> shares issued and outstanding</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2136" name="us-gaap:PreferredStockValue" contextRef="AsOf2024-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2137" name="us-gaap:PreferredStockValue" contextRef="AsOf2023-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Common stock, $<ix:nonFraction id="fid_1443" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.01</ix:nonFraction> par value; <ix:nonFraction id="fid_1445" name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">600,000,000</ix:nonFraction> shares authorized; <ix:nonFraction id="fid_1446" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">63,787,104</ix:nonFraction> and <ix:nonFraction id="fid_1447" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">47,422,304</ix:nonFraction> shares issued and outstanding at September 30, 2024 and 2023, respectively</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2335" name="us-gaap:CommonStockValue" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">637,870</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2336" name="us-gaap:CommonStockValue" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">474,223</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Additional paid-in capital</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2138" name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">526,241,074</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2139" name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">499,832,063</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accumulated deficit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2140" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">514,011,861</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2141" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">487,091,396</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total stockholders' equity</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2142" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">12,867,083</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2143" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,214,890</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2144" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">26,991,766</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2145" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">30,528,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-4</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="so">CEL-SCI CORPORATION</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">STATEMENTS OF OPERATIONS</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">YEARS ENDED SEPTEMBER 30, 2024 and 2023</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research and development</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2147" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">18,161,451</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2148" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">22,471,496</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">General &amp; administrative</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2149" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8,191,023</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2150" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,004,578</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total operating expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2151" name="us-gaap:OperatingExpenses" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">26,352,474</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2152" name="us-gaap:OperatingExpenses" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">31,476,074</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2153" name="us-gaap:OperatingIncomeLoss" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">26,352,474</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2154" name="us-gaap:OperatingIncomeLoss" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">31,476,074</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Interest expense, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2155" name="us-gaap:InterestExpense" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">745,673</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2156" name="us-gaap:InterestExpense" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">675,416</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other income (expense) &#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2157" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">177,682</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2158" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">42,813</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2159" name="us-gaap:ProfitLoss" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">26,920,465</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2160" name="us-gaap:ProfitLoss" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">32,194,303</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Modification of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2161" name="cvm:ModificationOfWarrants" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">659,456</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2162" name="cvm:ModificationOfWarrants" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">171,552</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common shareholders</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2163" name="us-gaap:NetIncomeLoss" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">27,579,921</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2164" name="us-gaap:NetIncomeLoss" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">32,365,855</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss per common share &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2165" name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">0.51</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2166" name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">0.73</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average common shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2167" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">54,044,989</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2168" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">44,479,865</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-5</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="sse">CEL-SCI CORPORATION</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">STATEMENT OF STOCKHOLDERS' EQUITY</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">YEARS ENDED SEPTEMBER 30, 2024 and 2023</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Common Stock</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Additional</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Paid-In</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Accumulated</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares </p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Amount</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Capital</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Deficit</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Total</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCE, SEPTEMBER 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2246" name="us-gaap:SharesIssued" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">43,448,317</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2247" name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">434,484</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2248" name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">486,625,816</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2249" name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">454,897,093</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2250" name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">32,163,207</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrant exercises</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2251" name="cvm:StockIssuedDuringPeriodSharesStockWarrantsExercised" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">217,752</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2252" name="cvm:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,177</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2253" name="cvm:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">445,114</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2254" name="cvm:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2255" name="cvm:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">447,291</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">401(k) contributions paid in common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2256" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">97,004</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2257" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">970</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2258" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">206,623</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2259" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2260" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">207,593</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2261" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">249,997</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2262" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2263" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">563,480</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2264" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2265" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">565,980</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds from the sale of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2266" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">3,413,234</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2267" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">34,132</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2268" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,088,365</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2270" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,122,497</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2014 Incentive Stock Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2271" name="cvm:IncentiveStockForfeitedShares" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2272" name="cvm:IncentiveStockForfeitedAmount" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">40</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2273" name="cvm:IncentiveStockForfeitedAmount" contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">22,160</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2274" name="cvm:IncentiveStockForfeitedAmount" contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2275" name="cvm:IncentiveStockForfeitedAmount" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">22,200</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation - employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2276" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2277" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,308,431</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2278" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2279" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,308,431</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Share issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2280" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2281" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">383,606</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2282" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2283" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">383,606</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2284" name="us-gaap:ProfitLoss" contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2285" name="us-gaap:ProfitLoss" contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2286" name="us-gaap:ProfitLoss" contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">32,194,303</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2287" name="us-gaap:ProfitLoss" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">32,194,303</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCE, SEPTEMBER 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2288" name="us-gaap:SharesIssued" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">47,422,304</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2289" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">474,223</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2290" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">499,832,063</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2291" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">487,091,396</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2292" name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,214,890</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">401(k) contributions paid in common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2293" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">136,868</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2294" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,368</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2295" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2023-10-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">217,349</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2296" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2023-10-01to2024-09-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2297" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">218,717</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock issued to nonemployees for service</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2298" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">409,932</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2299" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,099</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2300" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-10-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">755,802</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2301" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-10-01to2024-09-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2302" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">759,901</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds from the sale of common stock and pre-funded warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2303" name="cvm:ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsShares" contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">10,080,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2304" name="cvm:ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount" contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">100,800</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2305" name="cvm:ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount" contextRef="From2023-10-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">23,417,400</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2306" name="cvm:ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount" contextRef="From2023-10-01to2024-09-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2307" name="cvm:ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">23,518,200</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercise of pre-funded warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2308" name="cvm:ExerciseOfPreFundedWarrantsShares" contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">5,680,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2309" name="cvm:ExerciseOfPreFundedWarrantsAmount" contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">56,800</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2310" name="cvm:ExerciseOfPreFundedWarrantsAmount" contextRef="From2023-10-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2311" name="cvm:ExerciseOfPreFundedWarrantsAmount" contextRef="From2023-10-01to2024-09-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2312" name="cvm:ExerciseOfPreFundedWarrantsAmount" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">56,800</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Purchase of stock by officers and directors</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2313" name="cvm:PurchaseOfStockByOfficersAndDirectorsShares" contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">58,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2314" name="cvm:PurchaseOfStockByOfficersAndDirectorsAmount" contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">580</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2315" name="cvm:PurchaseOfStockByOfficersAndDirectorsAmount" contextRef="From2023-10-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">80,040</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2316" name="cvm:PurchaseOfStockByOfficersAndDirectorsAmount" contextRef="From2023-10-01to2024-09-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2317" name="cvm:PurchaseOfStockByOfficersAndDirectorsAmount" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">80,620</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Equity based compensation - employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2318" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2319" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-10-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,270,180</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2320" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-10-01to2024-09-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2321" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,270,180</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Share issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2322" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2323" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2023-10-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,331,760</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2324" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2023-10-01to2024-09-30_us-gaap_RetainedEarningsMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2325" name="cvm:CostIncurredInIssuanceOfStock" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,331,760</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2326" name="us-gaap:ProfitLoss" contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2327" name="us-gaap:ProfitLoss" contextRef="From2023-10-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2328" name="us-gaap:ProfitLoss" contextRef="From2023-10-01to2024-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">26,920,465</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2329" name="us-gaap:ProfitLoss" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">26,920,465</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">BALANCE, SEPTEMBER 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2330" name="us-gaap:SharesIssued" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">63,787,104</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2331" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">637,870</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2332" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">526,241,074</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2333" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">514,011,861</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2334" name="us-gaap:StockholdersEquity" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">12,867,083</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-6</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="cs">CEL-SCI CORPORATION</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">STATEMENTS OF CASH FLOWS</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">YEARS ENDED SEPTEMBER 30, 2024 and 2023</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH FLOWS FROM OPERATING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2170" name="us-gaap:ProfitLoss" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">26,920,465</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2171" name="us-gaap:ProfitLoss" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">32,194,303</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Depreciation and amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2173" name="us-gaap:DepreciationAndAmortization" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,969,183</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2174" name="us-gaap:DepreciationAndAmortization" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,958,334</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Non-cash lease expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2175" name="us-gaap:OtherNoncashExpense" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,873</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2176" name="us-gaap:OtherNoncashExpense" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">15,292</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Share-based payments for services</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2177" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">858,498</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2178" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">655,740</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Equity based compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2179" name="us-gaap:ShareBasedCompensation" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,270,180</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2180" name="us-gaap:ShareBasedCompensation" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,286,231</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Common stock contributed to 401(k) plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2181" name="cvm:CommonStockContributedToEmployeeBenefitPlan" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">218,717</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2182" name="cvm:CommonStockContributedToEmployeeBenefitPlan" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">207,593</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">(Increase)/decrease in assets:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Prepaid expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2184" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">72,674</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2185" name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">151,935</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Supplies used for R&amp;D and manufacturing</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2186" name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">172,608</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2187" name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">156,727</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2188" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">745</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2189" name="us-gaap:IncreaseDecreaseInDepositOtherAssets" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,323,346</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Increase/(decrease) in liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2191" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">460,576</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2192" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">257,845</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2193" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">458,489</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2194" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">207,089</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Due to employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2195" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">193,938</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2196" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">85,756</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 60px">Net cash used in operating activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2197" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">18,811,206</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2198" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">22,848,561</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH FLOWS FROM INVESTING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Purchases of property and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2200" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">94,875</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2201" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">361,892</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Expenditures for patent costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2202" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,211</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2203" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,370</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 60px">Net cash used in investing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2204" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">108,086</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2205" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">372,262</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH FLOWS FROM FINANCING ACTIVITIES:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from issuance of common stock and pre-funded warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2207" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">23,575,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2208" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,552,497</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Payments of stock issuance costs</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2209" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,370,513</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2210" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">744,913</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from the purchase of stock by officers and directors</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2211" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">80,620</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2212" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="From2022-10-01to2023-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from the exercise of warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2213" name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2023-10-01to2024-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2214" name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">447,291</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Payments on obligations under finance leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2215" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,773,377</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2216" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,560,455</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from related party loans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2217" name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">450,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2218" name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2022-10-01to2023-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Payments of related party loans</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2219" name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">450,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2220" name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2022-10-01to2023-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 60px">Net cash provided by financing activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2221" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">19,511,730</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2222" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,694,420</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2223" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">592,438</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2224" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">18,526,403</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2225" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,145,735</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2226" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">22,672,138</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CASH AND CASH EQUIVALENTS, END OF YEAR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2227" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,738,173</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2228" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,145,735</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-7</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">CEL-SCI CORPORATION</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">STATEMENTS OF CASH FLOWS</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">YEARS ENDED SEPTEMBER 30, 2024 and 2023</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="4" style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment purchases included in current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2229" name="cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">32,954</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2230" name="cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">51,650</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Capitalized patent costs included in current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2231" name="cvm:CapitalizedIntangibleAssetsCostsIncludedInCurrentLiabilities" contextRef="From2023-10-01to2024-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2232" name="cvm:CapitalizedIntangibleAssetsCostsIncludedInCurrentLiabilities" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,211</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Assets purchased under finance leases</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2233" name="cvm:PurchaseOfAssetsUnderFinanceLeases" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">20,797</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2234" name="cvm:PurchaseOfAssetsUnderFinanceLeases" contextRef="From2022-10-01to2023-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finance lease obligation included in accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2235" name="cvm:FinanceLeaseObligationIncludedInAccountsPayable" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,320</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2236" name="cvm:FinanceLeaseObligationIncludedInAccountsPayable" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,451</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consulting services paid with issuance of common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2237" name="cvm:ConsultingServicesPaidWithIssuanceOfCommonStock" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">759,901</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2238" name="cvm:ConsultingServicesPaidWithIssuanceOfCommonStock" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">565,980</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Financing costs included in current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2239" name="cvm:FinancingCostsIncludedInCurrentLiabilities" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">38,950</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2240" name="cvm:FinancingCostsIncludedInCurrentLiabilities" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">77,703</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Accrued consulting services to be paid with common stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2241" name="cvm:AccruedConsultingServicesToBePaidUnderShareBasedPaymentArrangement" contextRef="From2023-10-01to2024-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2242" name="cvm:AccruedConsultingServicesToBePaidUnderShareBasedPaymentArrangement" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">55,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">SUPPLEMENTAL DISCLOSURE OF CASH FLOWS:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash paid for interest</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2244" name="us-gaap:InterestPaidNet" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">923,807</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2245" name="us-gaap:InterestPaidNet" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,062,564</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-8</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="note">CEL-SCI CORPORATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTES TO FINANCIAL STATEMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><ix:nonNumeric id="fid_1563" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1. ORGANIZATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">CEL-SCI Corporation (the Company) was incorporated on March 22, 1983, in the state of Colorado, to finance research and development in biomedical science and ultimately to engage in marketing and selling products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company has announced results from its Phase III study for its lead investigational therapy, Multikine&#174; (Leukocyte Interleukin, Injection), involving head and neck cancer, for which the Company has received Orphan Drug Status from the United States Food and Drug Administration (FDA). Unlike other immune therapies, Multikine is administered locally at the site of the tumor as a first line treatment right after diagnosis, before surgery and radiation. The goal is to help the intact immune system kill the micro metastases that usually cause recurrence of the cancer to improve outcomes and better overall survival rates for patients suffering from head and neck cancer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">CEL-SCI is also investigating a peptide-based immunotherapy (CEL-4000) as a vaccine for rheumatoid arthritis using its LEAPS technology platform. CEL-SCI is in the process of completing pre-IND studies for CEL-4000.&#160; </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1549" name="cvm:LiquidityDisclosureTextblock" contextRef="From2023-10-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>2</strong><strong>.</strong>&#160; <strong>LIQUIDITY </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and conducting clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine, the Company&#8217;s lead investigational therapy, to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from any regulatory agency for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase III study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Due to the Company&#8217;s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern.&#160; The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-9</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1550" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true" continuedAt="cont_d00ef8"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>3</strong><strong>. </strong><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2338" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Basis of Presentation</em> &#8211; The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1564" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1567" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1566" name="us-gaap:InventoryPolicyTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Supplies used for R&amp;D and manufacturing</em> &#8211; Supplies are consumable items kept on hand to support the Company&#8217;s R&amp;D and manufacturing operations. Supplies are recorded at the lower of cost or net realizable value and are charged to expense as they are used in operations. The Company regularly reviews the quality and utilization of supplies to determine if future use of these supplies is probable. Due to the generic use of these supplies, they can be used in multiple projects other than those currently being studied. Supplies held less than twelve months are classified as current assets and supplies held longer than twelve months are classified as non-current assets.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1568" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" contextRef="From2023-10-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Patents</em> &#8211; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (<ix:nonNumeric id="fid_1852" name="cvm:FiniteLivedIntangibleAssetsUsefulLife" contextRef="From2021-10-01to2022-09-30_us-gaap_PatentsMember" format="ixt-sec:duryear">17</ix:nonNumeric> years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1569" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Leases</em> &#8211; The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. The incremental borrowing rate reflects the rate of interest that the Company would pay on the lease commencement date to borrow an amount equal to the lease payments on a collateralized basis over a similar term in similar economic environments. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. Operating and finance lease agreements which require payments for lease and non-lease components are accounted for as a single lease component.&#160; Variable lease payments that cannot be determined at the commencement of the lease are not included in the calculation of right of use assets or lease liabilities, and are expensed as incurred.&#160; </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1571" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="From2023-10-01to2024-09-30" escape="true" continuedAt="cont_820c91"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Share-Based Compensation</em> &#8211; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, Compensation &#8211; Stock Compensation (&#8220;ASC 718&#8221;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate, and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.</p></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-10</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_d00ef8" continuedAt="cont_d2e9c8"><ix:continuation id="cont_820c91"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1572" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="From2023-10-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Research and Development Costs</em> - Research and development costs are expensed as incurred.&#160; Management accrues Clinical Research Organization (&#8220;CRO&#8221;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1573" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share. Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1574" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="From2023-10-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Concentration of Credit Risk</em> &#8211; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents.&#160; The Company maintains its cash and cash equivalents with high quality financial institutions.&#160; At times, these accounts may exceed federally insured limits.&#160; The Company has not experienced any losses in such bank accounts.&#160; The Company believes it is not exposed to significant credit risk related to cash and cash equivalents.&#160; All non-interest bearing cash balances were fully insured up to $<ix:nonFraction id="fid_1851" name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">250,000</ix:nonFraction> at September 30, 2024 and 2023. </p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-11</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_d2e9c8" continuedAt="cont_b57ac2"><ix:nonNumeric id="fid_1575" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Income Taxes</em> &#8211; The Company accounts for income taxes in accordance with the provisions of ASC 740, Income Taxes, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards.&#160; Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of September 30, 2024 and 2023.</p></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">&#160;</p><ix:nonNumeric id="fid_2060" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Impairment of long-lived assets </em>&#8211; CEL-SCI&#8217;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#8217;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1576" name="us-gaap:UseOfEstimates" contextRef="From2023-10-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, share-based compensation, useful lives for depreciation and amortization of long-lived assets, right-of-use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year.&#160; Additionally, in calculating the right-of-use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Recently Adopted Accounting Standards</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2339" name="cvm:RecentlyAdoptedAccountingStandardsPolicyPolicyTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2016-13, Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;). ASU 2016-13 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13 had no material impact on the Company&#8217;s financial position, results of operations, or cash flows.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-12</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_b57ac2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>New Accounting Pronouncements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1577" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (&#8220;ASU 2023-07&#8221;), which expands disclosures about a public entity&#8217;s reportable segments and requires more enhanced information about a reportable segment&#8217;s expenses, interim segment profit or loss, and how a public entity&#8217;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is currently evaluating the impact that this change will have on the Company&#8217;s disclosures. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In December 2023, the FASB issued Accounting Standards Update No. 2023-09, Improvements to Income Tax Disclosures, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In March 2024, the SEC issued its final climate disclosure rules, which require the disclosure of climate-related information in annual reports and registration statements. The rules require disclosure in the audited financial statements of certain effects of severe weather events and other natural conditions above certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates, if material. Under the rules as originally issued, disclosure requirements begin phasing in for fiscal years beginning on or after January 1, 2027. However, on April 4, 2024, the SEC determined to voluntarily stay the final rules pending certain legal challenges. We are currently evaluating the impact of the new rules and continue to monitor the status of the related legal challenges.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2024, the FASB issued Accounting Standards Update No. 2024-03, Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;). ASU 2024-03 will require more detailed information about the types of expenses in commonly presented income statement captions such as &#8220;Cost of sales&#8221; and &#8220;Selling, general and administrative expenses&#8221;. The new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027 with early adoption permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.</p></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1551" name="cvm:WarrantsAndNonEmployeeOptionsDisclosureTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true" continuedAt="cont_16b8a7"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>4. WARRANTS AND NON-EMPLOYEE OPTIONS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following warrants and non-employee options are outstanding at September 30, 2024:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1578" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true" continuedAt="cont_d8fbaf"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrant/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares Issuable</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of Warrants/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1864" name="cvm:Issuedate2" contextRef="From2023-10-01to2024-09-30_cvm_SeriesNMember">8/18/2008</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1881" name="cvm:SharesIssuableUponExerciseOfwarrant" contextRef="AsOf2024-09-30_cvm_SeriesNMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">85,339</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1899" name="cvm:ExercisePrice" contextRef="AsOf2024-09-30_cvm_SeriesNMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">3.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1918" name="cvm:ExpirationDate1" contextRef="From2023-10-01to2024-09-30_cvm_SeriesNMember">8/18/2026</ix:nonNumeric>&#160; </p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1855" name="cvm:Issuedate2" contextRef="From2023-10-01to2024-09-30_cvm_SeriesUUMember">6/11/2018</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1882" name="cvm:SharesIssuableUponExerciseOfwarrant" contextRef="AsOf2024-09-30_cvm_SeriesUUMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">93,603</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1900" name="cvm:ExercisePrice" contextRef="AsOf2024-09-30_cvm_SeriesUUMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.80</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1919" name="cvm:ExpirationDate1" contextRef="From2023-10-01to2024-09-30_cvm_SeriesUUMember">6/30/2026</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1867" name="cvm:Issuedate2" contextRef="From2023-10-01to2024-09-30_cvm_SeriesXMember">1/13/2016</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1883" name="cvm:SharesIssuableUponExerciseOfwarrant" contextRef="AsOf2024-09-30_cvm_SeriesXMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">120,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1902" name="cvm:ExercisePrice" contextRef="AsOf2024-09-30_cvm_SeriesXMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">9.25</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1921" name="cvm:ExpirationDate1" contextRef="From2023-10-01to2024-09-30_cvm_SeriesXMember">7/13/2026</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1868" name="cvm:Issuedate2" contextRef="From2023-10-01to2024-09-30_cvm_SeriesYMember">2/15/2016</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1884" name="cvm:SharesIssuableUponExerciseOfwarrant" contextRef="AsOf2024-09-30_cvm_SeriesYMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">26,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1903" name="cvm:ExercisePrice" contextRef="AsOf2024-09-30_cvm_SeriesYMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">12.00</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1922" name="cvm:ExpirationDate1" contextRef="From2023-10-01to2024-09-30_cvm_SeriesYMember">8/15/2026</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1869" name="cvm:Issuedate2" contextRef="From2023-10-01to2024-09-30_cvm_SeriesMMMember">6/22/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1885" name="cvm:SharesIssuableUponExerciseOfwarrant" contextRef="AsOf2024-09-30_cvm_SeriesMMMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">333,432</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1904" name="cvm:ExercisePrice" contextRef="AsOf2024-09-30_cvm_SeriesMMMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.86</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1923" name="cvm:ExpirationDate1" contextRef="From2023-10-01to2024-09-30_cvm_SeriesMMMember">6/22/2026</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1870" name="cvm:Issuedate2" contextRef="From2023-10-01to2024-09-30_cvm_SeriesNNMember">7/24/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1886" name="cvm:SharesIssuableUponExerciseOfwarrant" contextRef="AsOf2024-09-30_cvm_SeriesNNMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">200,087</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1905" name="cvm:ExercisePrice" contextRef="AsOf2024-09-30_cvm_SeriesNNMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.52</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1924" name="cvm:ExpirationDate1" contextRef="From2023-10-01to2024-09-30_cvm_SeriesNNMember">7/24/2026</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1860" name="cvm:Issuedate2" contextRef="From2023-10-01to2024-09-30_cvm_SeriesRRMember">10/30/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1887" name="cvm:SharesIssuableUponExerciseOfwarrant" contextRef="AsOf2024-09-30_cvm_SeriesRRMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">234,009</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1906" name="cvm:ExercisePrice" contextRef="AsOf2024-09-30_cvm_SeriesRRMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.65</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1925" name="cvm:ExpirationDate1" contextRef="From2023-10-01to2024-09-30_cvm_SeriesRRMember">10/30/2026</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1872" name="cvm:Issuedate2" contextRef="From2023-10-01to2024-09-30_cvm_ConsultantsMember_cvm_BottomMember">7/28/2017</ix:nonNumeric> &#8211; <ix:nonNumeric id="fid_1866" name="cvm:Issuedate2" contextRef="From2023-10-01to2024-09-30_cvm_ConsultantsOneMember_cvm_TopMember">9/2/2023</ix:nonNumeric> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1890" name="cvm:SharesIssuableUponExerciseOfwarrant" contextRef="AsOf2024-09-30_cvm_ConsultantsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">110,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;&#160; $<ix:nonFraction id="fid_1909" name="cvm:ExercisePrice" contextRef="AsOf2024-09-30_cvm_ConsultantsMember_cvm_BottomMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.39</ix:nonFraction> - $<ix:nonFraction id="fid_1901" name="cvm:ExercisePrice" contextRef="AsOf2024-09-30_cvm_ConsultantsOneMember_cvm_TopMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.18</ix:nonFraction> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1928" name="cvm:ExpirationDate1" contextRef="From2023-10-01to2024-09-30_cvm_ConsultantsMember_cvm_BottomMember">7/27/2027</ix:nonNumeric> &#8211; <ix:nonNumeric id="fid_1920" name="cvm:ExpirationDate1" contextRef="From2023-10-01to2024-09-30_cvm_ConsultantsOneMember_cvm_TopMember">9/1/2028</ix:nonNumeric></p></td><td>&#160;</td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-13</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_16b8a7" continuedAt="cont_1d99cd"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following warrants and non-employee options are outstanding at September 30, 2023:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_d8fbaf"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrant/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares Issuable</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of Warrants/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1854" name="cvm:Issuedate2" contextRef="From2022-10-01to2023-09-30_cvm_SeriesNMember">8/18/2008</ix:nonNumeric></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1873" name="cvm:SharesIssuableUponExerciseOfwarrant" contextRef="AsOf2023-09-30_cvm_SeriesNMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">85,339</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1891" name="cvm:ExercisePrice" contextRef="AsOf2023-09-30_cvm_SeriesNMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">3.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1910" name="cvm:ExpirationDate1" contextRef="From2022-10-01to2023-09-30_cvm_SeriesNMember">8/18/2024</ix:nonNumeric>&#160; </p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1865" name="cvm:Issuedate2" contextRef="From2022-10-01to2023-09-30_cvm_SeriesUUMember">6/11/2018</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1874" name="cvm:SharesIssuableUponExerciseOfwarrant" contextRef="AsOf2023-09-30_cvm_SeriesUUMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">93,603</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1892" name="cvm:ExercisePrice" contextRef="AsOf2023-09-30_cvm_SeriesUUMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.80</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1911" name="cvm:ExpirationDate1" contextRef="From2022-10-01to2023-09-30_cvm_SeriesUUMember">6/30/2024</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1856" name="cvm:Issuedate2" contextRef="From2022-10-01to2023-09-30_cvm_SeriesXMember">1/13/2016</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1875" name="cvm:SharesIssuableUponExerciseOfwarrant" contextRef="AsOf2023-09-30_cvm_SeriesXMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">120,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1893" name="cvm:ExercisePrice" contextRef="AsOf2023-09-30_cvm_SeriesXMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">9.25</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1912" name="cvm:ExpirationDate1" contextRef="From2022-10-01to2023-09-30_cvm_SeriesXMember">7/13/2024</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1857" name="cvm:Issuedate2" contextRef="From2022-10-01to2023-09-30_cvm_SeriesYMember">2/15/2016</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1876" name="cvm:SharesIssuableUponExerciseOfwarrant" contextRef="AsOf2023-09-30_cvm_SeriesYMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">26,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1894" name="cvm:ExercisePrice" contextRef="AsOf2023-09-30_cvm_SeriesYMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">12.00</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1913" name="cvm:ExpirationDate1" contextRef="From2022-10-01to2023-09-30_cvm_SeriesYMember">8/15/2024</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1858" name="cvm:Issuedate2" contextRef="From2022-10-01to2023-09-30_cvm_SeriesMMMember">6/22/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1877" name="cvm:SharesIssuableUponExerciseOfwarrant" contextRef="AsOf2023-09-30_cvm_SeriesMMMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">333,432</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1895" name="cvm:ExercisePrice" contextRef="AsOf2023-09-30_cvm_SeriesMMMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.86</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1914" name="cvm:ExpirationDate1" contextRef="From2022-10-01to2023-09-30_cvm_SeriesMMMember">6/22/2024</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1859" name="cvm:Issuedate2" contextRef="From2022-10-01to2023-09-30_cvm_SeriesNNMember">7/24/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1878" name="cvm:SharesIssuableUponExerciseOfwarrant" contextRef="AsOf2023-09-30_cvm_SeriesNNMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">200,087</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1896" name="cvm:ExercisePrice" contextRef="AsOf2023-09-30_cvm_SeriesNNMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.52</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1915" name="cvm:ExpirationDate1" contextRef="From2022-10-01to2023-09-30_cvm_SeriesNNMember">7/24/2024</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1871" name="cvm:Issuedate2" contextRef="From2022-10-01to2023-09-30_cvm_SeriesRRMember">10/30/2017</ix:nonNumeric></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1879" name="cvm:SharesIssuableUponExerciseOfwarrant" contextRef="AsOf2023-09-30_cvm_SeriesRRMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">234,009</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1897" name="cvm:ExercisePrice" contextRef="AsOf2023-09-30_cvm_SeriesRRMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.65</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1916" name="cvm:ExpirationDate1" contextRef="From2022-10-01to2023-09-30_cvm_SeriesRRMember">10/30/2024</ix:nonNumeric></p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1863" name="cvm:Issuedate2" contextRef="From2022-10-01to2023-09-30_cvm_ConsultantsMember_cvm_BottomMember">7/28/2017</ix:nonNumeric> &#8211; <ix:nonNumeric id="fid_1929" name="cvm:Issuedate2" contextRef="From2022-10-01to2023-09-30_cvm_ConsultantsOneMember_cvm_TopMember">9/2/2023</ix:nonNumeric> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2341" name="cvm:SharesIssuableUponExerciseOfwarrant" contextRef="AsOf2023-09-30_cvm_ConsultantsOneMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">110,000</ix:nonFraction></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;">$</td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;&#160; <ix:nonFraction id="fid_1898" name="cvm:ExercisePrice" contextRef="AsOf2023-09-30_cvm_ConsultantsMember_cvm_BottomMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.39</ix:nonFraction> - $<ix:nonFraction id="fid_1930" name="cvm:ExercisePrice" contextRef="AsOf2023-09-30_cvm_ConsultantsOneMember_cvm_TopMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.18</ix:nonFraction> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonNumeric id="fid_1917" name="cvm:ExpirationDate1" contextRef="From2022-10-01to2023-09-30_cvm_ConsultantsMember_cvm_BottomMember">7/27/2027</ix:nonNumeric> &#8211; <ix:nonNumeric id="fid_1931" name="cvm:ExpirationDate1" contextRef="From2022-10-01to2023-09-30_cvm_ConsultantsOneMember_cvm_TopMember">9/1/2028</ix:nonNumeric></p></td><td>&#160;</td></tr></tbody></table></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>A. Equity Warrants</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Changes in Equity Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the fiscal year ended September 30, 2024, <ix:nonFraction id="fid_2384" name="cvm:EquityWarrantsExercised" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">5,680,000</ix:nonFraction> pre-funded warrants were exercised. The following equity warrants were exercised during the year ended September 30, 2023:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1582" name="cvm:ScheduleOfEquityWarrantsWereExercisedTableTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Proceeds</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1951" name="cvm:EquityWarrantsExercised" contextRef="From2022-10-01to2023-09-30_cvm_SeriesRRMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">17,752</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1957" name="cvm:EquityWarrantsExercisePrice" contextRef="From2022-10-01to2023-09-30_cvm_SeriesRRMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.65</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1954" name="cvm:ProceedsFromEquityWarrantsExercised" contextRef="From2022-10-01to2023-09-30_cvm_SeriesRRMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">29,291</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1952" name="cvm:EquityWarrantsExercised" contextRef="From2022-10-01to2023-09-30_cvm_SeriesSSMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">200,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1958" name="cvm:EquityWarrantsExercisePrice" contextRef="From2022-10-01to2023-09-30_cvm_SeriesSSMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.09</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1955" name="cvm:ProceedsFromEquityWarrantsExercised" contextRef="From2022-10-01to2023-09-30_cvm_SeriesSSMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">418,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1961" name="cvm:EquityWarrantsExercised" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">217,752</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1960" name="cvm:ProceedsFromEquityWarrantsExercised" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">447,291</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">No warrants recorded as equity expired during the fiscal year ended September 30, 2024. On February 5, 2023, 600 Series TT warrants, with an exercise price of $<ix:nonFraction id="fid_2385" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-10-01to2024-09-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.24</ix:nonFraction>, expired.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On May 4, 2024, the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates.&#160; The incremental cost of this extension was approximately $<ix:nonFraction id="fid_2383" name="cvm:IncrementalCostDeemedDividend" contextRef="From2023-10-01to2024-09-30_cvm_SeriesRRMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">659,455</ix:nonFraction>, which was recorded as a deemed dividend. The Series N, X, MM, NN, RR and UU warrants are held by current Officers of the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><strong>B.</strong> <strong>Options and Shares Issued to Consultants</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company typically enters into consulting arrangements in exchange for common stock or stock options. During the years ended September 30, 2024 and 2023, the Company issued <ix:nonFraction id="fid_2369" name="cvm:CommonStockIssuedForServiceShares" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">409,932</ix:nonFraction> and <ix:nonFraction id="fid_2368" name="cvm:CommonStockIssuedForServiceShares" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">249,997</ix:nonFraction> shares, respectively, of common stock to consultants, all of which were restricted shares. Under these arrangements, during the periods presented, the common stock was issued with stock prices ranging from $<ix:nonFraction id="fid_2376" name="us-gaap:SharePrice" contextRef="AsOf2024-09-30_cvm_BottomMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.08</ix:nonFraction> to $<ix:nonFraction id="fid_2377" name="us-gaap:SharePrice" contextRef="AsOf2024-09-30_cvm_TopMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">3.47</ix:nonFraction> per share. The weighted average grant price was $<ix:nonFraction id="fid_2371" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-10-01to2024-09-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember_cvm_TopMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.69</ix:nonFraction> and $<ix:nonFraction id="fid_2370" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-10-01to2023-09-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember_cvm_TopMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.83</ix:nonFraction>, respectively, for stock issued during the years ended September 30, 2024 and 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the years ended September 30, 2024 and 2023, the Company recorded total expense of approximately $<ix:nonFraction id="fid_2373" name="us-gaap:CostsAndExpenses" contextRef="From2023-10-01to2024-09-30_cvm_ConsultingAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">681,000</ix:nonFraction> and $<ix:nonFraction id="fid_2372" name="us-gaap:CostsAndExpenses" contextRef="From2022-10-01to2023-09-30_cvm_ConsultingAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">656,000</ix:nonFraction>, respectively, relating to these consulting agreements, which are included in general and administrative expense on the accompanying statements of operations. At September 30, 2024 and 2023, costs of approximately $<ix:nonFraction id="fid_2374" name="cvm:PrepaidExpenses" contextRef="AsOf2024-09-30_cvm_ConsultingAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">52,000</ix:nonFraction> and $<ix:nonFraction id="fid_2375" name="cvm:PrepaidExpenses" contextRef="AsOf2022-09-30_cvm_ConsultingAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">205,000</ix:nonFraction>, respectively, are included in prepaid expenses.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-14</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_1d99cd"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">No options were issued to consultants during the year ended September 30, 2024. During the year ended September 30, 2023, the Company issued <ix:nonFraction id="fid_2378" name="cvm:StockIssuedDuringPeriodToPurchaseCommonStock" contextRef="From2023-10-01to2024-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">100,000</ix:nonFraction> options to a consultant to purchase common stock with an exercise price of $<ix:nonFraction id="fid_2379" name="cvm:StockOptionExercisePrice" contextRef="From2023-10-01to2024-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.39</ix:nonFraction>. These options vest <ix:nonFraction id="fid_2380" name="cvm:VestedOptions" contextRef="From2023-10-01to2024-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember_cvm_TwoSeptemberTwoThousendTwentyFourMember" unitRef="Pure" decimals="INF" scale="-2">50</ix:nonFraction>% on September 2, 2024 and <ix:nonFraction id="fid_2381" name="cvm:VestedOptions" contextRef="From2023-10-01to2024-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember_cvm_TwoSeptemberTwoThousendTwentyFiveMember" unitRef="Pure" decimals="INF" scale="-2">50</ix:nonFraction>% on September 2, 2025 and expire on September 1, 2028. As of September 30, 2024, <ix:nonFraction id="fid_2382" name="cvm:IssuanceOfOptionsForServices" contextRef="AsOf2024-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">110,000</ix:nonFraction> options issued to consultants as payment for services remained outstanding, all of which were issued from the Non-Qualified Stock Option Plan.</p></ix:continuation><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1552" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>5</strong><strong>. </strong><strong>PROPERTY AND </strong><strong>EQUIPMENT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Property and equipment consisted of the following at September 30:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1583" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1599" name="us-gaap:FixturesAndEquipmentGross" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,167,828</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1598" name="us-gaap:FixturesAndEquipmentGross" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,109,070</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Furniture and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1601" name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">104,593</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1600" name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">99,296</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Leasehold improvements</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1603" name="us-gaap:LeaseholdImprovementsGross" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,924,724</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1602" name="us-gaap:LeaseholdImprovementsGross" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">13,924,724</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1605" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">18,197,145</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1604" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">18,133,090</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: Accumulated depreciation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1607" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,067,392</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1606" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,944,964</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1609" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">8,129,753</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1608" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,188,126</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Depreciation expense for the years ended September 30, 2024 and 2023 totaled approximately $<ix:nonFraction id="fid_1611" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,135,000</ix:nonFraction> and $<ix:nonFraction id="fid_1610" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,114,000</ix:nonFraction>, respectively, and is included in operating expenses on the accompanying statements of operations.&#160; </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1553" name="us-gaap:IntangibleAssetsDisclosureTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>6</strong><strong>. PATENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Patents consist of the following at September 30:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1584" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1613" name="us-gaap:FiniteLivedPatentsGross" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">829,716</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1612" name="us-gaap:FiniteLivedPatentsGross" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">853,445</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: Accumulated amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1614" name="cvm:AccumulatedAmortization" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">664,224</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1615" name="cvm:AccumulatedAmortization" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">655,741</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patents, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1616" name="us-gaap:OtherIntangibleAssetsNet" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">165,492</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1617" name="us-gaap:OtherIntangibleAssetsNet" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">197,704</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">During the years ended September 30, 2024 and 2023, there was no impairment of patent costs.&#160; The weighted average remaining amortization period for patents is approximately <ix:nonNumeric id="fid_2343" name="cvm:PatentsWeightedAverageAmortizationPeriod" contextRef="From2023-10-01to2024-09-30" format="ixt-sec:duryear">8</ix:nonNumeric> years. For the years ended September 30, 2024 and 2023, amortization of patent costs totaled approximately $<ix:nonFraction id="fid_1626" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">32,000</ix:nonFraction> and $<ix:nonFraction id="fid_1625" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">38,000</ix:nonFraction>, respectively, and is included in general and administrative expense on the accompanying statements of operations.&#160; The total estimated future amortization is as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1585" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="4"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Years ending September 30, </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1620" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">29,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1621" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">25,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1622" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">22,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1618" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">19,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1619" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">16,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1623" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">54,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1624" name="cvm:TotalFiniteLivedIntangibleAssetsAmortizationExpense" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">165,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-15</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1554" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true" continuedAt="cont_251567"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>7</strong><strong>. INCOME TAXES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">At September 30, 2024 and 2023, the Company had net deferred tax assets of $<ix:nonFraction id="fid_1676" name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-09-30_cvm_IncomeTaxMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">62.5</ix:nonFraction> million and $<ix:nonFraction id="fid_1677" name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-09-30_cvm_IncomeTaxMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">60.0</ix:nonFraction> million, respectively. Due to uncertainties surrounding the Company&#8217;s ability to generate future taxable income to realize these assets, a full valuation allowance has been established to offset the net deferred tax assets. In assessing the realization of deferred tax assets, management considered whether it was more likely than not that some, or all, of the deferred tax assets will be realized.&#160; The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income.&#160; Management has considered the history of the Company&#8217;s operating losses and believes that the realization of the benefit of the deferred tax assets cannot be reasonably assured.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Pursuant to Section 382 of the Internal Revenue Code, or IRC, annual use of the Company&#8217;s <ix:nonNumeric id="fid_1674" name="cvm:CumulativeChangeInOwnershipPercentage" contextRef="From2023-10-01to2024-09-30_cvm_IncomeTaxMember">net operating loss (NOL) carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period</ix:nonNumeric>. Such ownership change could result in annual limitations on the utilization of tax attributes, including NOL carryforwards and tax credits. The Company performed an estimated analysis to determine if any additional ownership changes occurred during the year ended September 30, 2024 and no such changes were identified. If changes in ownership occur after year end, NOL and tax credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company had federal NOL carryforwards of approximately $<ix:nonFraction id="fid_1671" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-09-30_cvm_IncomeTaxMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">146.4</ix:nonFraction> million and $<ix:nonFraction id="fid_1672" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-09-30_cvm_IncomeTaxMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">123.1</ix:nonFraction> million at September 30, 2024 and 2023, respectively. <ix:nonNumeric id="fid_1675" name="us-gaap:TaxCreditCarryforwardDescription" contextRef="From2023-10-01to2024-09-30_cvm_IncomeTaxMember">Approximately $19.2 million of the NOL carryforwards begin to expire during the year ended September 30, 2024 and become fully expired by 2038 and approximately $127.2 million of NOL carryforwards</ix:nonNumeric>, which were generated after the enactment of Tax Cuts and Jobs Act, have an indefinite life.&#160; In addition, the Company has a general business credit as a result of the credit for increasing research activities (&#8220;R&amp;D credit&#8221;) of approximately $<ix:nonFraction id="fid_1669" name="cvm:ResearchAndDevelopmentCredit" contextRef="AsOf2024-09-30_cvm_IncomeTaxMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.9</ix:nonFraction> million and&#160;$<ix:nonFraction id="fid_1670" name="cvm:ResearchAndDevelopmentCredit" contextRef="AsOf2023-09-30_cvm_IncomeTaxMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.2</ix:nonFraction> million at September 30, 2024 and 2023, respectively.&#160;<ix:nonNumeric id="fid_1673" name="cvm:ResearchAndDevelopmentCreditDescription" contextRef="From2023-10-01to2024-09-30_cvm_IncomeTaxMember">The R&amp;D credit expires during the fiscal year ended 2029</ix:nonNumeric>.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Significant components of the Company&#8217;s deferred tax assets and liabilities as of September 30, 2024 and 2023 are listed below:&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1586" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">NOL carryforwards</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1628" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">34,673,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1627" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">30,829,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Capitalized R&amp;D</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1636" name="cvm:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">14,062,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1635" name="cvm:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">15,196,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1634" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">11,645,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1633" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">11,579,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1630" name="cvm:LeaseLiabilities" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,752,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1629" name="cvm:LeaseLiabilities" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,400,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">R&amp;D credit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1632" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">932,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1631" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,221,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vacation and other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1638" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">188,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1637" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">298,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fixed assets and intangibles</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1654" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">347,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1653" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">168,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total deferred tax assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1640" name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">64,599,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1639" name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">62,691,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Right-of-use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1642" name="cvm:RightOfUseAssets" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">2,095,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1641" name="cvm:RightOfUseAssets" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">2,713,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fixed assets and intangibles</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1644" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="AsOf2024-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1643" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="AsOf2023-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total deferred tax liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1646" name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,095,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1645" name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,713,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net deferred tax asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1648" name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">62,504,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1647" name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">59,978,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1650" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">62,504,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1649" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">59,978,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ending balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1652" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2024-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1651" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2023-09-30" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-16</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><ix:continuation id="cont_251567"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has no federal or state current or deferred tax expense or benefit.&#160; The Company&#8217;s effective tax rate differs from the applicable federal statutory tax rate.&#160; The reconciliation of these rates is as follows for the years ended September 30:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1587" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Federal rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1656" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-10-01to2024-09-30" unitRef="Pure" decimals="INF" scale="-2">21.00</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1655" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-10-01to2023-09-30" unitRef="Pure" decimals="INF" scale="-2">21.00</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">State rate change </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1657" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="From2023-10-01to2024-09-30" unitRef="Pure" decimals="INF" sign="-" scale="-2">11.97</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1658" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="From2022-10-01to2023-09-30" unitRef="Pure" decimals="INF" sign="-" scale="-2">1.58</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">State tax rate, net of federal benefit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1659" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2023-10-01to2024-09-30" unitRef="Pure" decimals="INF" scale="-2">2.68</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1660" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2022-10-01to2023-09-30" unitRef="Pure" decimals="INF" scale="-2">4.05</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other adjustments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1661" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2023-10-01to2024-09-30" unitRef="Pure" decimals="INF" sign="-" scale="-2">2.32</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1662" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="From2022-10-01to2023-09-30" unitRef="Pure" decimals="INF" sign="-" scale="-2">1.62</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Permanent differences</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1663" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="From2023-10-01to2024-09-30" unitRef="Pure" decimals="INF" scale="-2">0.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1664" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="From2022-10-01to2023-09-30" unitRef="Pure" decimals="INF" scale="-2">0.00</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Change in valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1665" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-10-01to2024-09-30" unitRef="Pure" decimals="INF" sign="-" scale="-2">9.39</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1666" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-10-01to2023-09-30" unitRef="Pure" decimals="INF" sign="-" scale="-2">21.85</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effective tax rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1667" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-10-01to2024-09-30" unitRef="Pure" decimals="INF" scale="-2">0.00</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1668" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-10-01to2023-09-30" unitRef="Pure" decimals="INF" scale="-2">0.00</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company applies the provisions of ASC 740, <em>Accounting for Uncertainty in Income Taxes,</em> which requires financial statement benefits to be recognized for positions taken for tax return purposes when it is more likely than not that the position will be sustained.&#160; The Company has elected to reflect any tax penalties or interest resulting from tax assessments on uncertain tax positions as a component of tax expense.&#160; The Company has generated federal net operating losses in tax years ending September 30, 1999 through 2024.&#160;&#160;The Company files income tax returns in the U.S. federal jurisdiction and various states. With few exceptions, the Company is no longer subject to U.S. federal and state income tax examinations by tax authorities for years before September 30, 2021. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1555" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true" continuedAt="cont_34ebb4"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>8</strong><strong>.</strong> <strong>EQUITY-BASED</strong><strong> COMPENSATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company recognized the following expenses for options issued or vested and restricted stock awarded during the year:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1588" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Year Ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1678" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="From2023-10-01to2024-09-30_cvm_EmployeesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,270,180</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1679" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="From2022-10-01to2023-09-30_cvm_EmployeesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">6,286,231</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1680" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="From2023-10-01to2024-09-30_cvm_NonEmployeesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">680,768</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1681" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" contextRef="From2022-10-01to2023-09-30_cvm_NonEmployeesMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">655,740</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of September 30, 2024, the total compensation cost related to non-vested options and restricted stock awarded to employees and non-employees not yet recognized was approximately $<ix:nonFraction id="fid_2072" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-10-01to2024-09-30_cvm_NonVestedOptionsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">4.5</ix:nonFraction> million and $<ix:nonFraction id="fid_2070" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-10-01to2024-09-30_cvm_RestrictedStockAwardsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.1</ix:nonFraction> million, respectively, and the weighted-average period over which it is expected to be recognized is <ix:nonNumeric id="fid_2074" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="From2023-10-01to2024-09-30_cvm_NonVestedOptionsMember" format="ixt-sec:duryear">1.9</ix:nonNumeric> and <ix:nonNumeric id="fid_2073" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" contextRef="From2023-10-01to2024-09-30_cvm_RestrictedStockAwardsMember" format="ixt-sec:duryear">0.54</ix:nonNumeric> years, respectively.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-17</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_34ebb4" continuedAt="cont_5e5d09"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the years ended September 30, 2024 and 2023, the fair value of each option grant was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1589" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected stock price volatility</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_1682" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2023-10-01to2024-09-30" unitRef="Pure" decimals="INF" scale="-2">100.89</ix:nonFraction> &#8211; <ix:nonFraction id="fid_1684" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2023-10-01to2024-09-30" unitRef="Pure" decimals="INF" scale="-2">101.66</ix:nonFraction>%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_1683" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2022-10-01to2023-09-30" unitRef="Pure" decimals="INF" scale="-2">99.18</ix:nonFraction> &#8211; <ix:nonFraction id="fid_1685" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2022-10-01to2023-09-30" unitRef="Pure" decimals="INF" scale="-2">100.18</ix:nonFraction>%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_1686" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2023-10-01to2024-09-30" unitRef="Pure" decimals="INF" scale="-2">3.77</ix:nonFraction> &#8211; <ix:nonFraction id="fid_1688" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2023-10-01to2024-09-30" unitRef="Pure" decimals="INF" scale="-2">4.58</ix:nonFraction>%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_1687" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2022-10-01to2023-09-30" unitRef="Pure" decimals="INF" scale="-2">3.41</ix:nonFraction> &#8211; <ix:nonFraction id="fid_1689" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2022-10-01to2023-09-30" unitRef="Pure" decimals="INF" scale="-2">4.25</ix:nonFraction>%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected life of options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric id="fid_1690" name="cvm:ExpectedLifeOfOptionsMin1" contextRef="From2023-10-01to2024-09-30" format="ixt-sec:duryear">9.61</ix:nonNumeric> &#8211; <ix:nonNumeric id="fid_1692" name="cvm:ExpectedLifeOfOptionsMax" contextRef="From2022-10-01to2023-09-30" format="ixt-sec:duryear">9.64</ix:nonNumeric> years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonNumeric id="fid_1691" name="cvm:ExpectedLifeOfOptionsMin1" contextRef="From2022-10-01to2023-09-30" format="ixt-sec:duryear">9.63</ix:nonNumeric> &#8211; <ix:nonNumeric id="fid_1693" name="cvm:ExpectedLifeOfOptionsMax" contextRef="From2023-10-01to2024-09-30" format="ixt-sec:duryear">9.66</ix:nonNumeric> years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Non-Qualified Stock Option Plan</span><span style="text-decoration:underline">s</span>&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the year ended September 30, 2024, the Company adopted the 2024 Non-Qualified Stock Option Plan, which provides for the issuance of up to <ix:nonFraction id="fid_1792" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2024-09-30_cvm_NonQualifiedStockOptionsPlansMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,000,000</ix:nonFraction> options to purchase shares of common stock. On April 19, 2024, the Company granted <ix:nonFraction id="fid_1782" name="cvm:PerformanceBasedStockOptionsSharesGranted" contextRef="AsOf2024-09-30_cvm_NonQualifiedStockOptionsPlansMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,962,000</ix:nonFraction> options to purchase shares of common stock from the 2024 Non-Qualified Stock Option Plan to officers, directors and employees. Each option entitles the holder to purchase one share of the Company&#8217;s common stock at a price of $<ix:nonFraction id="fid_1784" name="us-gaap:OptionIndexedToIssuersEquityStrikePrice1" contextRef="From2023-10-01to2024-09-30_cvm_NonQualifiedStockOptionsPlansMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.50</ix:nonFraction> per share, vests in three equal annual installments commencing one year after the grant date and expires on April 18, 2034.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the year ended September 30, 2023, the Company adopted the 2023 Non-Qualified Stock Option Plan, which provides for the issuance of up to <ix:nonFraction id="fid_1791" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2023-09-30_cvm_NonQualifiedStockOptionsPlansMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,000,000</ix:nonFraction> options to purchase shares of common stock. On August 8, 2023, the Company granted <ix:nonFraction id="fid_1788" name="cvm:PerformanceBasedStockOptionsSharesGranted" contextRef="AsOf2023-09-30_cvm_NonQualifiedStockOptionsPlansMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,958,500</ix:nonFraction> options to purchase shares of common stock from the 2023 Non-Qualified Stock Option Plan to officers, directors and employees. Each option entitles the holder to purchase one share of the Company&#8217;s common stock at a price of $<ix:nonFraction id="fid_1783" name="us-gaap:OptionIndexedToIssuersEquityStrikePrice1" contextRef="From2022-10-01to2023-09-30_cvm_NonQualifiedStockOptionsPlansMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.36</ix:nonFraction> per share, vests in three equal annual installments commencing one year after the grant date and expires on August 7, 2033.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">At September 30, 2024, the Company has collectively authorized the issuance of <ix:nonFraction id="fid_1777" name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-09-30_cvm_NonQualifiedStockOptionsPlansMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">17,787,200</ix:nonFraction> options to purchase shares of common stock under its Non-Qualified Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms of the options were determined by the Company&#8217;s Compensation Committee which administers the plans. The Company&#8217;s employees, directors, officers, and consultants or advisors are eligible to be granted options under the Non-Qualified Stock Option Plans.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Incentive Stock Option Plan</span><span style="text-decoration:underline">s</span> &#8211; At September 30, 2024, the Company had collectively authorized the issuance of <ix:nonFraction id="fid_1778" name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-09-30_cvm_IncentiveStockOptionPlansMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">138,400</ix:nonFraction> options to purchase shares of common stock under its Incentive Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms of the options were determined by the Company&#8217;s Compensation Committee which administers the Plans. Only the Company&#8217;s employees are eligible to be granted options under the Incentive Stock Option Plans.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Activity in the Company&#8217;s Non-Qualified and Incentive Stock Option Plans for the two years ended September 30, 2024 is summarized as follows:</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-18</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_5e5d09" continuedAt="cont_a27f70"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Non-Qualified and Incentive Stock Option Plans</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1590" name="cvm:ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="14"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Outstanding</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="14"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercisable</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Remaining Contractual Term (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Remaining Contractual Term (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1696" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-09-30_cvm_OutstandingMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">12,964,014</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1710" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_cvm_OutstandingMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">9.06</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_2409" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember" format="ixt-sec:duryear">7.35</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2075" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2022-09-30_cvm_OutstandingMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,866,240</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1697" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-09-30_cvm_ExercisableMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">7,067,617</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1711" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_cvm_ExercisableMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">6.21</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_2410" name="cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" contextRef="From2022-10-01to2023-09-30_cvm_ExercisableMember" format="ixt-sec:duryear">6.21</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2080" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2022-09-30_cvm_ExercisableMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,866,105</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1700" name="cvm:NumberOfOptionsVested" contextRef="AsOf2022-09-30_cvm_ExercisableMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">952,256</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1714" name="cvm:WeightedAverageExercisePriceVested" contextRef="AsOf2022-09-30_cvm_ExercisableMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">8.41</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Granted (a)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1736" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,065,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1741" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.37</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(213,165</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1740" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">9.19</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1705" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">58,791</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1717" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">61.05</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1706" name="cvm:NumberOfOptions" contextRef="From2022-10-01to2023-09-30_cvm_ExercisableMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0" sign="-">58,791</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1718" name="cvm:WeightedAverageExercisePriceExpired" contextRef="From2022-10-01to2023-09-30_cvm_ExercisableMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">61.05</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1698" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-09-30_cvm_OutstandingMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">14,757,558</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1712" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-09-30_cvm_OutstandingMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">7.78</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1725" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember" format="ixt-sec:duryear">6.81</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2076" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2023-09-30_cvm_OutstandingMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">0</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1699" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-09-30_cvm_ExercisableMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">7,961,082</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1713" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-09-30_cvm_ExercisableMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">6.07</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1726" name="cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" contextRef="From2022-10-01to2023-09-30_cvm_ExercisableMember" format="ixt-sec:duryear">5.60</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2082" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2023-09-30_cvm_ExercisableMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">0</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1743" name="cvm:NumberOfOptionsVested" contextRef="AsOf2023-09-30_cvm_ExercisableMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,501,583</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1745" name="cvm:WeightedAverageExercisePriceVested" contextRef="AsOf2023-09-30_cvm_ExercisableMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">4.24</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Granted (b)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1734" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-10-01to2024-09-30_cvm_OutstandingMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,969,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1739" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-10-01to2024-09-30_cvm_OutstandingMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.50</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(406,333</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1738" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2023-10-01to2024-09-30_cvm_OutstandingMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">10.01</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1707" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2023-10-01to2024-09-30_cvm_OutstandingMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">62,145</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1719" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-10-01to2024-09-30_cvm_OutstandingMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">27.35</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1708" name="cvm:NumberOfOptions" contextRef="From2023-10-01to2024-09-30_cvm_ExercisableMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0" sign="-">62,145</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1720" name="cvm:WeightedAverageExercisePriceExpired" contextRef="From2023-10-01to2024-09-30_cvm_ExercisableMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">27.35</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1732" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-09-30_cvm_OutstandingMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">16,258,080</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1737" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_cvm_OutstandingMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">6.88</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1724" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="From2023-10-01to2024-09-30_cvm_OutstandingMember" format="ixt-sec:duryear">6.25</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2078" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2024-09-30_cvm_OutstandingMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">0</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1742" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-09-30_cvm_ExercisableMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">9,400,520</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1744" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-09-30_cvm_ExercisableMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">5.64</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonNumeric id="fid_1723" name="cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" contextRef="From2023-10-01to2024-09-30_cvm_ExercisableMember" format="ixt-sec:duryear">5.19</ix:nonNumeric></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2083" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2024-09-30_cvm_ExercisableMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">0</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(a)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Includes 1,965,500 performance based options issued to officers and directors, 100,000 options issued to consultants. The weighted average grant date fair value was $1.22.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(b)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The weighted average grant date fair value was $1.36.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">A summary of the status of the Company&#8217;s unvested options for the two years ended September 30, 2024 is presented below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_2061" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Options</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Grant Date Fair Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1751" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">5,896,397</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1760" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">3.63</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1752" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">952,256</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2084" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">7.30</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1754" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,065,500</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2414" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.22</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1756" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">213,165</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2415" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">8.02</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1750" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">6,796,476</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1761" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2.25</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1753" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,501,583</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2085" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">3.73</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1755" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,969,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2412" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.36</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1757" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">406,333</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2413" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.94</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1759" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">6,857,560</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1763" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.69</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Incentive Stock Bonus Plan</span> &#8211; On September 30, 2024, <ix:nonFraction id="fid_1779" name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-09-30_cvm_IncentiveStockBonusPlanMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">610,500</ix:nonFraction> of the shares granted under the 2014 Incentive Stock Bonus Plan remain outstanding, of which <ix:nonFraction id="fid_1786" name="cvm:VestedShares" contextRef="From2023-10-01to2024-09-30_cvm_IncentiveStockBonusPlanMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">463,250</ix:nonFraction> shares are fully vested.&#160; During the year ended September 30, 2024 and 2023, there were <ix:nonFraction id="fid_2417" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="From2023-10-01to2024-09-30_cvm_IncentiveStockBonusPlanMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">0</ix:nonFraction> and <ix:nonFraction id="fid_1793" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="From2022-10-01to2023-09-30_cvm_IncentiveStockBonusPlanMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,000</ix:nonFraction> unvested shares that were forfeited, respectively. The shares are being earned upon the achievement of certain milestones leading to the commercialization of the Company&#8217;s Multikine technology, or specified increases in the market price of the Company&#8217;s stock.&#160; The fair value of the shares on the grant date was calculated using the market value on the grant-date for issuances where the attainment of performance criteria is likely and using a Monte Carlo Simulation for issuances where the attainment of performance criteria is uncertain.&#160; The grant date fair value of shares issued that remain outstanding as of September 30, 2024 was approximately $<ix:nonFraction id="fid_1785" name="cvm:RemainingOutstandingFairValueOfShares" contextRef="AsOf2024-09-30_cvm_IncentiveStockBonusPlanMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">8.6</ix:nonFraction> million.&#160; The total value of the shares, if earned, is being expensed over the requisite service periods for each milestone, provided the requisite service periods are rendered, regardless of whether the market conditions are met.&#160; No compensation cost is recognized for awards where the requisite service period is not rendered.&#160; During the years ended September 30, 2024 and 2023, the Company recorded expense relating to the issuance of restricted stock pursuant to the plan of approximately $<ix:nonFraction id="fid_1789" name="us-gaap:DeferredCompensationEquity" contextRef="AsOf2024-09-30_cvm_IncentiveStockBonusPlanMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-3" scale="3">0</ix:nonFraction> and $(22,000), respectively.&#160; As of September 30, 2023, all compensation expense related to the 2014 Incentive Stock Bonus Plan has been fully recognized. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-19</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_a27f70"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">A summary of the status of the Company&#8217;s restricted common stock issued from the Incentive Stock Bonus Plan for the two years ended September 30, 2024 is presented below: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1592" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number of</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Grant Date Fair Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unvested at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1765" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2022-09-30_cvm_RestrictedStockAwardsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">151,250</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2416" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-09-30_cvm_RestrictedStockAwardsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">13.75</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1766" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="From2022-10-01to2023-09-30_cvm_RestrictedStockAwardsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">4,000</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unvested at September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1764" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2023-09-30_cvm_RestrictedStockAwardsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">147,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1772" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-09-30_cvm_RestrictedStockAwardsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">13.75</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unvested at September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1771" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2024-09-30_cvm_RestrictedStockAwardsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">147,250</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1774" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-09-30_cvm_RestrictedStockAwardsMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">13.75</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Stock Bonus Plans</span><span style="text-decoration:underline"> </span>&#8211; As of September 30, 2024, the Company authorized to issue up to <ix:nonFraction id="fid_1780" name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-09-30_cvm_StockBonusPlansMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,283,760</ix:nonFraction> shares of common stock from the Stock Bonus Plans and has issued a total of <ix:nonFraction id="fid_1775" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-09-30_cvm_StockBonusPlansMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">649,840</ix:nonFraction> shares of common stock under its Stock Bonus Plans.&#160; All employees, directors, officers, consultants, and advisors are eligible to be granted shares.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Stock Compensation Plans</span> &#8211; On September 30, 2024, <ix:nonFraction id="fid_1781" name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-09-30_cvm_StockCompensationPlansMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">634,000</ix:nonFraction> shares were authorized for issuance pursuant to the Company&#8217;s Stock Compensation Plans, of which <ix:nonFraction id="fid_1776" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-09-30_cvm_StockCompensationPlansMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">153,195</ix:nonFraction> shares were issued and outstanding.&#160; No shares were issued from the Stock Compensation Plans during the years ended September 30, 2024 and 2023.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1556" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>9</strong><strong>. EMPLOYEE BENEFIT PLAN</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company maintains a defined contribution retirement plan, qualifying under Section 401(k) of the Internal Revenue Code, subject to the Employee Retirement Income Security Act of 1974, as amended, and covering substantially all Company employees. Each participant&#8217;s contribution is matched by the Company with shares of common stock that have a value equal to 100% of the participant&#8217;s contribution, not to exceed the lesser of $<ix:nonFraction id="fid_2344" name="cvm:EmployeeContributionsToDefinedContributionPlans" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">10,000</ix:nonFraction> or <ix:nonFraction id="fid_2345" name="cvm:PercentageOfEmployeeContributionsToDefinedContributionPlans" contextRef="From2023-10-01to2024-09-30" unitRef="Pure" decimals="INF" scale="-2">6</ix:nonFraction>% of the participant&#8217;s total compensation. The Company&#8217;s contribution of common stock is valued each quarter based upon the closing bid price of the Company&#8217;s common stock. During the year ended September 30, 2024, <ix:nonFraction id="fid_1986" name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">136,868</ix:nonFraction> shares were issued to the Company&#8217;s 401(k) plan for a cost of approximately $<ix:nonFraction id="fid_1982" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">219,000</ix:nonFraction>. During the year ended September 30, 2023, <ix:nonFraction id="fid_1987" name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">97,004</ix:nonFraction> shares were issued to the Company&#8217;s 401(k) plan for a cost of approximately $<ix:nonFraction id="fid_1983" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">208,000</ix:nonFraction>.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1557" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true" continuedAt="cont_85ad7e"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>10</strong><strong>. COMMITMENTS AND CONTINGENCIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Clinical Research Agreements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In August 2024 the Company entered into an agreement, pursuant to which the Company engaged Ergomed Clinical Research, Inc. to provide clinical development services related to the Company&#8217;s upcoming confirmatory registration study in exchange for fees. Since the Company entered into this agreement it has incurred research and development expenses of approximately $<ix:nonFraction id="fid_2008" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2023-10-01to2024-09-30_cvm_ErgomedMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.4</ix:nonFraction> million as of September 30, 2024.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Lease Agreements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#8217;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#8217;s Phase III clinical trial and sales of the drug if approved by the FDA or regulators in Canada, the UK or Europe. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. &#160;The renewal options are not included in the calculation of the right-of-use asset and lease liability because exercise of those options is not reasonably certain.&#160;&#160; </p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-20</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_85ad7e" continuedAt="cont_3c8659"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of September 30, 2024 and 2023, respectively, the net book value of the finance lease right-of-use asset is approximately $<ix:nonFraction id="fid_2018" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">7.4</ix:nonFraction> million and $<ix:nonFraction id="fid_2019" name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="AsOf2023-09-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">9.1</ix:nonFraction> million and the balance of the finance lease liability is approximately $<ix:nonFraction id="fid_2020" name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">10.0</ix:nonFraction> million and $<ix:nonFraction id="fid_2021" name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2023-09-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">11.7</ix:nonFraction> million, of which approximately $<ix:nonFraction id="fid_2022" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">2.0</ix:nonFraction> million and $<ix:nonFraction id="fid_2023" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2023-09-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.8</ix:nonFraction> million is current. These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment. During the years ended September 30, 2024 and 2023, the finance right of use assets are being depreciated using a straight-line method over the underlying lease terms and depreciation expense totaled approximately $<ix:nonFraction id="fid_2024" name="us-gaap:Depreciation" contextRef="From2023-10-01to2024-09-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.8</ix:nonFraction> million in both periods, which is included in research and development expense on the accompanying statements of operations. Total cash paid related to finance leases during the years ended September 30, 2024 and 2023, respectively, was approximately $<ix:nonFraction id="fid_2027" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2023-10-01to2024-09-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">2.7</ix:nonFraction> million and $<ix:nonFraction id="fid_2028" name="us-gaap:FinanceLeasePrincipalPayments" contextRef="From2022-10-01to2023-09-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">2.6</ix:nonFraction> million, of which approximately $<ix:nonFraction id="fid_2026" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="From2023-10-01to2024-09-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.9</ix:nonFraction> million and $<ix:nonFraction id="fid_2029" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="From2022-10-01to2023-09-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.1</ix:nonFraction> million was for interest. The total cash paid related to finance lease principal payments is included in cash flows from financing activities on the accompanying statements of cash flows. The total cash paid related to finance lease interest expense is included in cash flows from operating activities on the accompanying statements of cash flows. The weighted average discount rate of the Company&#8217;s finance leases is <ix:nonFraction id="fid_2030" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" contextRef="From2023-10-01to2024-09-30_us-gaap_LeaseAgreementsMember" unitRef="Pure" decimals="INF" scale="-2">8.46</ix:nonFraction>% and the weighted average remaining lease term is <ix:nonNumeric id="fid_2017" name="cvm:WeightedAverageMaturityYear" contextRef="From2023-10-01to2024-09-30_us-gaap_LeaseAgreementsMember" format="ixt-sec:duryear">4.09</ix:nonNumeric> years. During the years ended September 30, 2024 and 2023, total finance lease costs were approximately $<ix:nonFraction id="fid_2418" name="cvm:FinanceLeaseCosts" contextRef="From2023-10-01to2024-09-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">2.7</ix:nonFraction> million and $<ix:nonFraction id="fid_2419" name="cvm:FinanceLeaseCosts" contextRef="From2022-10-01to2023-09-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">2.9</ix:nonFraction> million, consisting of approximately $<ix:nonFraction id="fid_2420" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="From2023-10-01to2024-09-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.8</ix:nonFraction> million of lease asset amortization in both periods, and approximately $<ix:nonFraction id="fid_2422" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.9</ix:nonFraction> million and $<ix:nonFraction id="fid_2423" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.1</ix:nonFraction> million of interest on the finance lease liabilities, respectively. Variable lease expenses, such as maintenance costs, utilities, and real property taxes are not included in right of use assets or lease liabilities but rather are expensed as incurred. During the year ended September 30, 2024, there were approximately $<ix:nonFraction id="fid_2424" name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2023-10-01to2024-09-30_us-gaap_LeaseAgreementsMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.9</ix:nonFraction> million of variable finance lease costs, which are included in research and development expense on the accompanying statements of operations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On January 11, 2023, the Company was required to deposit approximately $<ix:nonFraction id="fid_2033" name="cvm:PaymentsMadeToLandlord" contextRef="From2023-01-01to2023-01-11_cvm_LandlordMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">2.3</ix:nonFraction> million to its landlord, equivalent to one year&#8217;s rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Approximate future minimum lease payments under finance leases as of September 30, 2024 are as follows:&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1593" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1989" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,747,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1990" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,838,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1991" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,929,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1996" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,021,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1988" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">255,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1993" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">11,790,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1994" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,821,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1992" name="us-gaap:FinanceLeaseLiability" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">9,969,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of finance lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1995" name="cvm:FinanceLeaseLiabilityCurrentPortion" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,011,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of finance lease obligations &#8211; non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1997" name="cvm:FinanceLeaseLiabilityNoncurrentPortion" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">7,958,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company leases two facilities under operating leases.&#160; The lease for the Company&#8217;s office headquarters will expire on November 30, 2025.&#160; The lease for its research and development laboratory and will expire on February 29, 2032. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. </p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-21</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_3c8659"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of September 30, 2024 and 2023, respectively, the net book value of the operating lease right-of-use asset is approximately $<ix:nonFraction id="fid_2041" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-09-30_us-gaap_OperatingExpenseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.5</ix:nonFraction> million and $<ix:nonFraction id="fid_2042" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-09-30_us-gaap_OperatingExpenseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.7</ix:nonFraction> million and the balance of the operating lease liability is approximately $<ix:nonFraction id="fid_2039" name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-09-30_us-gaap_OperatingExpenseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.7</ix:nonFraction> million and $<ix:nonFraction id="fid_2040" name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-09-30_us-gaap_OperatingExpenseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.9</ix:nonFraction> million, of which approximately $<ix:nonFraction id="fid_2037" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-09-30_us-gaap_OperatingExpenseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.2</ix:nonFraction> million is current in both periods. During the years ended September 30, 2024 and 2023, the Company incurred lease expense under operating leases of approximately $<ix:nonFraction id="fid_2044" name="us-gaap:OtherExpenses" contextRef="From2023-10-01to2024-09-30_us-gaap_OperatingExpenseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.4</ix:nonFraction> million in both periods, which is included in general and administrative expense on the accompanying statements of operations. Total cash paid related to operating leases during the years ended September 30, 2024 and 2023 was approximately $<ix:nonFraction id="fid_2034" name="us-gaap:OperatingLeasePayments" contextRef="From2023-10-01to2024-09-30_us-gaap_OperatingExpenseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.4</ix:nonFraction> million and $<ix:nonFraction id="fid_2035" name="us-gaap:OperatingLeasePayments" contextRef="From2022-10-01to2023-09-30_us-gaap_OperatingExpenseMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.3</ix:nonFraction> million, respectively. The total cash paid related to operating leases is included in cash flows from operating activities on the accompanying statements of cash flows. The weighted average discount rate of the Company&#8217;s operating leases is <ix:nonFraction id="fid_2036" name="cvm:WeightedAverageOperatingLeaseDiscountRate" contextRef="From2023-10-01to2024-09-30_us-gaap_OperatingExpenseMember" unitRef="Pure" decimals="INF" scale="-2">9.0</ix:nonFraction>% and the weighted average the remaining lease term is <ix:nonNumeric id="fid_2043" name="cvm:WeightedAverageOperatingLeaseMaturityYear" contextRef="From2023-10-01to2024-09-30_us-gaap_OperatingExpenseMember" format="ixt-sec:duryear">6.98</ix:nonNumeric> years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of September 30, 2024, future minimum lease payments on operating leases are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1594" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1999" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">366,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2000" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">287,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2001" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">277,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2006" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">285,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1998" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">294,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2002" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">746,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2003" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,255,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2004" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">602,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2367" name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,653,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2007" name="cvm:OperatingLeaseObligationyCurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">227,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations &#8211; non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2005" name="cvm:OperatingLeaseObligationyNoncurrent" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,426,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1558" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1</strong><strong>1</strong><strong>. </strong><strong>RELATED PARTY TRANSACTIONS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the year ended September 30, 2024, certain officers and directors purchased <ix:nonFraction id="fid_1796" name="cvm:RestrictedCommonStockSharesIssued" contextRef="From2023-10-01to2024-09-30_cvm_OfficerAndDirectorMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">58,000</ix:nonFraction> shares of restricted common stock at an aggregated fair market value of approximately $<ix:nonFraction id="fid_2354" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-10-01to2024-09-30_cvm_OfficerAndDirectorMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">81,000</ix:nonFraction>. During the year ended September 30, 2023, no restricted shares of the Company&#8217;s common stock were purchased by related parties.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On July 11, 2024, Geert Kersten, the Company&#8217;s Chief Executive Officer and a director, loaned the Company $<ix:nonFraction id="fid_2361" name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2024-07-01to2024-07-11_cvm_CEOMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">200,000</ix:nonFraction>. On July 18, 2024, Mr. Kersten loaned the Company an additional $<ix:nonFraction id="fid_2359" name="cvm:ProceedsFromAdditionalDebtFromRelatedParty" contextRef="From2024-07-01to2024-07-18_cvm_CEOMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">250,000</ix:nonFraction>. These amounts were repaid on <ix:nonNumeric id="fid_2363" name="us-gaap:DebtInstrumentMaturityDate" contextRef="From2024-07-01to2024-07-11_cvm_CEOMember" format="ixt:datemonthdayyearen">July 30, 2024</ix:nonNumeric>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On May 4, 2024, <ix:nonNumeric id="fid_2366" name="cvm:DescriptionOfModificationOfWarrants" contextRef="From2024-05-01to2024-05-04">the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates. The incremental cost of this extension was approximately $0.7 million, which was recorded as a deemed dividend</ix:nonNumeric> in the financial statements for the three months ended June 30, 2024. The Series N, X, MM, NN, RR and UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024 (Note C). The incremental cost of this extension was approximately $<ix:nonFraction id="fid_1795" name="cvm:IncrementalCostOfWarrantsExtension" contextRef="From2023-10-01to2024-09-30_cvm_SeriesRRWarrantMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">172,000</ix:nonFraction>, which was recorded as a deemed dividend.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-22</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:nonNumeric id="fid_1559" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1</strong><strong>2</strong><strong>.</strong> <strong>STOCKHOLDERS&#8217; EQUITY</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Exercise of Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the year ended September 30, 2024, <ix:nonFraction id="fid_2390" name="cvm:EquityWarrantsExercised" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">5,680,000</ix:nonFraction> pre-funded warrants were exercised. During the year ended September 30, 2023, the Company received proceeds of approximately $<ix:nonFraction id="fid_2388" name="cvm:ProceedFromIssuanceOrSaleOfEquity" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.4</ix:nonFraction> million from the exercise of warrants, as detailed in Note 4. Upon exercise, <ix:nonFraction id="fid_2389" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">217,752</ix:nonFraction> shares of common stock were issued during the year ended September 30, 2023. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Proceeds from the Sale of Common Stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On July 29, 2024, the Company sold <ix:nonFraction id="fid_2386" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-07-29" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">3,715,000</ix:nonFraction> shares of common stock at an offering price of $<ix:nonFraction id="fid_2387" name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-07-29" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.00</ix:nonFraction> per share, and pre-funded warrants to purchase up to <ix:nonFraction id="fid_2425" name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">7,130,000</ix:nonFraction> shares of common stock, at an offering price of $<ix:nonFraction id="fid_2406" name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-09-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.99</ix:nonFraction> per pre-funded warrant, for proceeds of approximately $<ix:nonFraction id="fid_2407" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-07-01to2024-07-29" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">9.7</ix:nonFraction> million, net of issuance costs of approximately $<ix:nonFraction id="fid_2408" name="cvm:NetIssuanceCosts" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.1</ix:nonFraction> million. Holders of the pre-funded warrants have exercised 5,680,000 of the pre-funded warrants as of September 30, 2024. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company determined that the pre-funded warrants sold in the July 26, 2024 offering are freestanding financial instruments because they are both legally detachable and separately exercisable from the common stock sold in the offering. As such, the Company evaluated the pre-funded warrants to determine whether they represent instruments that require liability classification pursuant to the guidance in ASC 480. However, the Company concluded that the pre-funded warrants are not a liability within the scope of ASC 480 due to their characteristics. Further, the Company determined that the pre-funded warrants do not meet the definition of a derivative under ASC 815. Accordingly, the Company assessed the pre-funded warrants relative to the guidance in ASC No. 815-40, Contracts in Entity&#8217;s Own Equity, to determine the appropriate treatment. The Company concluded that the pre-funded warrants are both indexed to its own stock and meet all other conditions for equity classification. Accordingly, the Company has classified the pre-funded warrants as permanent equity and recorded them as a component of additional paid-in capital upon the closing of the transaction in July 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In February 2024, the Company sold <ix:nonFraction id="fid_2391" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-02-29" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">3,875,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction id="fid_2392" name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-02-29" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2</ix:nonFraction>.00 per share and received proceeds of approximately $<ix:nonFraction id="fid_2393" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-02-01to2024-02-29" format="ixt:numdotdecimal" unitRef="USD" decimals="-6" scale="6">7</ix:nonFraction>.0 million, net of issuance costs of approximately $<ix:nonFraction id="fid_2394" name="cvm:NetIssuanceCosts" contextRef="From2024-02-01to2024-02-29" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.7</ix:nonFraction> million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2023, the Company sold <ix:nonFraction id="fid_2395" name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-11-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">2,490,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction id="fid_2396" name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-11-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">2</ix:nonFraction>.00 per share and received proceeds of approximately $<ix:nonFraction id="fid_2397" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-11-01to2023-11-30" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">4.5</ix:nonFraction> million, net of issuance costs of approximately $<ix:nonFraction id="fid_2398" name="cvm:NetIssuanceCosts" contextRef="From2023-11-01to2023-11-30" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.5</ix:nonFraction> million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In April 2023, the Company sold <ix:nonFraction id="fid_2399" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-10-01to2024-09-30_cvm_EquityProceedsFromSaleCommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">794,117</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction id="fid_2400" name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2024-09-30_cvm_EquityProceedsFromSaleCommonStockMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">1.70</ix:nonFraction> per share and received proceeds of approximately $<ix:nonFraction id="fid_2401" name="cvm:ProceedFromIssuanceOrSaleOfEquity" contextRef="From2023-10-01to2024-09-30_cvm_EquityProceedsFromSaleCommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">1.4</ix:nonFraction> million. The Company granted the underwriters a 30-day option to purchase up to <ix:nonFraction id="fid_2402" name="cvm:AdditionalPurchaseOfCommonStock" contextRef="From2023-10-01to2024-09-30_cvm_EquityProceedsFromSaleCommonStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">119,117</ix:nonFraction> additional shares of common stock to cover over-allotments. The underwriter fully exercised this option in May 2023, resulting in additional proceeds to the Company of approximately $<ix:nonFraction id="fid_2403" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-10-01to2024-09-30_cvm_EquityProceedsFromSaleCommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">200,000</ix:nonFraction>. The Company incurred issuance costs of approximately $<ix:nonFraction id="fid_2404" name="cvm:IssuanceCostOfCommonStock" contextRef="From2023-10-01to2024-09-30_cvm_EquityProceedsFromSaleCommonStockMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-5" scale="6">0.2</ix:nonFraction> million related to this offering.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1560" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true" continuedAt="cont_3e147e"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1</strong><strong>3</strong><strong>. FAIR VALUE MEASUREMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In accordance with the provisions of ASC 820, &#8220;Fair Value Measurements,&#8221; the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160; The Company generally applies the income approach to determine fair value.&#160; This method uses valuation techniques to convert future amounts to a single present amount.&#160; The measurement is based on the value indicated by current market expectations with respect to the future amounts.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-23</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_3e147e"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value.&#160; The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&#160; The Company classifies fair value balances based on the observability of those inputs.&#160; The three levels of the fair value hierarchy are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Level 1 &#8211; Observable inputs such as quoted prices in active markets for identical assets or liabilities</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Level 2 &#8211; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs other than quoted prices that are observable for the asset or liability are observable in active markets</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Level 3 &#8211; Unobservable inputs that reflect management&#8217;s assumptions</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement.&#160; The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company&#8217;s money market funds included in cash equivalents are measured at fair value on a recurring basis. The following tables summarize the Company&#8217;s fair value measurements and the level of inputs within the fair value hierarchy utilized to determine such fair value as of September 30:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1595" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;" colspan="13"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30, 2024</strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Description</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Level</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Cost</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fair Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2439" name="us-gaap:Cash" contextRef="AsOf2024-09-30_cvm_CostMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2438" name="us-gaap:Cash" contextRef="AsOf2024-09-30_cvm_FairValueMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,258,173</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Money market funds included in cash and cash equivalents (Note 2)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1813" name="cvm:MoneyMarketFundsIncludedInCashAndCashEquivalents" contextRef="From2023-10-01to2024-09-30_cvm_CostMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,480,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2443" name="cvm:MoneyMarketFundsIncludedInCashAndCashEquivalents" contextRef="From2023-10-01to2024-09-30_cvm_FairValueMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,480,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Total cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2454" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-09-30_cvm_CostMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">3,480,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2453" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-09-30_cvm_FairValueMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,738,173</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;" colspan="13"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30, 2023</strong></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Description</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Level</strong></p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Cost</strong></p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Fair Value</strong></p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2444" name="us-gaap:Cash" contextRef="AsOf2023-09-30_cvm_CostMember" format="ixt:zerodash" unitRef="USD" decimals="0">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2442" name="us-gaap:Cash" contextRef="AsOf2023-09-30_cvm_FairValueMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">1,895,735</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Money market funds included in cash and cash equivalents (Note 2)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2445" name="cvm:MoneyMarketFundsIncludedInCashAndCashEquivalents" contextRef="From2022-10-01to2023-09-30_cvm_CostMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,250,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2441" name="cvm:MoneyMarketFundsIncludedInCashAndCashEquivalents" contextRef="From2022-10-01to2023-09-30_cvm_FairValueMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,250,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Total cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2451" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-09-30_cvm_CostMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">2,250,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2452" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-09-30_cvm_FairValueMember" format="ixt:numdotdecimal" unitRef="USD" decimals="0">4,145,735</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1561" name="us-gaap:EarningsPerShareTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true" continuedAt="cont_d098e4"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1</strong><strong>4</strong><strong>. NET LOSS PER COMMON SHARE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed using the treasury stock method. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, common stock warrants and restricted stock&#160;are not included in the computation of diluted net loss per share&#160;if their effect&#160;would be anti-dilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The calculation of basis and diluted net loss per share includes <ix:nonFraction id="fid_2351" name="cvm:WarrantsUsedForCalculationOfEarningPerShare" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">1,450,000</ix:nonFraction> of the pre-funded warrants that remain outstanding as of September 30, 2024.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-24</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td><em><a href="#Toc2">Table of Contents</a></em></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><ix:continuation id="cont_d098e4"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following table provides a reconciliation of the numerators and denominators of the basic and diluted per-share computations: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1596" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Year ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Loss per share &#8211; basic and diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common shareholders &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2049" name="us-gaap:NetIncomeLoss" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">27,579,921</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2048" name="us-gaap:NetIncomeLoss" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USD" decimals="0" sign="-">32,365,855</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2051" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">54,044,989</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2050" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">44,479,865</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Basic and diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2053" name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">0.51</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_2052" name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF" sign="-">0.73</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In accordance with the contingently issuable shares guidance of ASC 260, <em>Earnings Per Share</em>, the calculation of diluted net loss per share excludes the following dilutive securities because their inclusion would have been anti-dilutive as of September 30: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1597" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options and warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2054" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-10-01to2024-09-30_cvm_OptionsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">17,350,550</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2055" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-10-01to2023-09-30_cvm_OptionsMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">15,850,028</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested restricted stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2056" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-10-01to2024-09-30_cvm_UnvestedRestrictedStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">147,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2057" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-10-01to2023-09-30_cvm_UnvestedRestrictedStockMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">147,250</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2059" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-10-01to2024-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">17,497,800</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_2058" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-10-01to2023-09-30" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">15,997,278</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1562" name="us-gaap:SubsequentEventsTextBlock" contextRef="From2023-10-01to2024-09-30" escape="true"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>15.&#160; SUBSEQUENT EVENTS </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On October 18, 2024, the Company entered into a Securities Purchase Agreement with Ergomed Group Limited pursuant to which the Company issued <ix:nonFraction id="fid_2437" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-10-01to2024-10-18_us-gaap_SubsequentEventMember_cvm_ErgomedGroupMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="-6" scale="6">1</ix:nonFraction> million shares of common stock in exchange for services. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On December 31, 2024, the Company sold&#160;<ix:nonFraction id="fid_2428" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2024-12-01to2024-12-31_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">7,552,500</ix:nonFraction>&#160;shares of common stock at an offering price of $<ix:nonFraction id="fid_2426" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.31</ix:nonFraction>&#160;per share, and pre-funded warrants to purchase up to&#160;<ix:nonFraction id="fid_2433" name="cvm:WarrantsToPurchaseCommonStock" contextRef="From2024-12-01to2024-12-31_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" unitRef="Shares" decimals="0">8,577,500</ix:nonFraction>&#160;shares of common stock, at an offering price of $<ix:nonFraction id="fid_2427" name="cvm:WarrantsOfferingPrice" contextRef="AsOf2024-12-31_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" unitRef="USDPShares" decimals="INF">0.3099</ix:nonFraction>&#160;per pre-funded warrant, for gross proceeds of approximately $<ix:nonFraction id="fid_2432" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-12-01to2024-12-31_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" unitRef="USD" decimals="-6" scale="6">5</ix:nonFraction>&#160;million.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">F-25</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accordance with Section 13 or 15(a) of the Securities Exchange Act of 1934, the Registrant has caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized on the 13th&#160;day of January 2025.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td>&#160;</td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CEL-SCI CORPORATION</p></td><td/></tr><tr style="height:15px"><td style="width:50%;">&#160;</td><td style="width:3%;">&#160;</td><td style="width:35%;">&#160;</td><td style="width:12%;">&#160;</td></tr><tr style="height:15px"><td/><td>By:</td><td style="BORDER-BOTTOM: black 1px solid;">/s/ Geert Kersten</td><td/></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td>Geert Kersten, Chief Executive Officer</td><td>&#160;</td></tr><tr style="height:15px"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr><tr style="height:15px"><td>&#160;</td><td>By:</td><td style="BORDER-BOTTOM: #000000 1px solid;">/s/ Patricia Prichep</td><td>&#160;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Patricia Prichep, Chief Financial</p><p style="font-size:10pt;font-family:times new roman;margin:0px">and Operations Officer</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Pursuant to the requirements of the Securities Act of l934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid;width:35%;">Signature</td><td style="width:3%;">&#160;</td><td style="BORDER-BOTTOM: black 1px solid;width:39%;">Title</td><td style="width:3%;">&#160;</td><td style="BORDER-BOTTOM: black 1px solid;width:20%;">Date</td></tr><tr style="height:15px"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid;">/s/ Geert Kersten</td><td>&#160;</td><td>Chief Executive</td><td>&#160;</td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">January 13, 2025</p></td></tr><tr style="height:15px"><td>Geert R. Kersten</td><td>&#160;</td><td>Officer and a Director</td><td>&#160;</td><td>&#160;</td></tr><tr style="height:15px"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid;">/s/ Bruno Baillavoine&#160;</td><td>&#160;</td><td>Director&#160;</td><td>&#160;</td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">January 13, 2025</p></td></tr><tr style="height:15px"><td>Bruno Baillavoine</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr><tr style="height:15px"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid;">/s/ Robert Watson&#160;</td><td>&#160;</td><td>Director&#160;</td><td>&#160;</td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">January 13, 2025</p></td></tr><tr style="height:15px"><td>Robert Watson</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ Mario Gobbo</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Director&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">January 13, 2025</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Mario Gobbo</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"/></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160; &#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CEL-SCI CORPORATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FORM 10-K</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FOR THE YEAR ENDED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SEPTEMBER 30, 2024</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EXHIBITS </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"/></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19
<SEQUENCE>2
<FILENAME>cvm_ex19.htm
<DESCRIPTION>EX-19
<TEXT>
<html><head><title>cvm_ex19.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 19</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:12pt">CEL-SCI CORPORATION</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:12pt">Insider Trading Policy</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>I. </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>PURPOSE</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="margin:0px">CEL-SCI Corporation (the &#8220;Company&#8221;) has adopted this Insider Trading Policy (this &#8220;Policy&#8221;) to help its directors and officers comply with insider trading laws, to prevent even the appearance of improper insider trading and to promote compliance with the Company&#8217;s obligation under Item 408 of Regulation S-K to publicly disclose information related to its insider trading policies and practices.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>II. </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>SCOPE</strong></p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">A.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">This Policy applies to all directors and officers of the Company, their respective family members and others in their households (collectively referred to as &#8220;Insiders&#8221;), and any other individuals the Compliance Officer (defined below) may designate as Insiders because they have access to material nonpublic information concerning the Company.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">B.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Except as set forth explicitly below, this Policy applies to any and all transactions in the Company&#8217;s securities, including transactions in common stock, options, preferred stock, restricted stock, restricted stock units, and any other type of securities that the Company may issue. This Policy applies to such securities regardless of whether they are held in a brokerage account, a 401(k) or similar account, through an employee stock purchase plan or otherwise.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong></strong>&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>III. </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>SPECIFIC GUIDANCE</strong></p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong></strong>&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>A.</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px">Generally Prohibited Activities. The prohibitions below apply to actions an Insider may take directly or indirectly through family members or other persons or entities.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><u>Trading in Company Securities</u>.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:12%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">a.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">No Insider may buy, sell, donate or otherwise transact in Company securities while aware of material nonpublic information concerning the Company.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">b.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">No Insider may buy, sell, donate or otherwise transact in Company securities during any special trading blackout period applicable to such Insider as designated by the Compliance Officer.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">2.</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><u>Tipping</u>. Providing material nonpublic information to another person who may trade or advise others to trade on the basis of that information is known as &#8220;tipping&#8221; and is illegal. Therefore, no Insider may &#8220;tip&#8221; or provide material nonpublic information concerning the Company to any person other than a director, officer or employee of the Company, unless required as part of that Insider&#8217;s regular duties for the Company and authorized by the Compliance Officer.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">3.</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><u>Giving Trading Advice</u>. No Insider may give trading advice of any kind about the Company to anyone, whether or not such Insider is aware of material nonpublic information about the Company, except that Insiders should advise other Insiders not to trade if such trading might violate the law or this Policy.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">4.</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><u>Engaging in Short Sales</u>. No Insider may engage in short sales of Company securities. A short sale is the sale of a security that the seller does not own at the time of the trade.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><u>Engaging in Derivative Transactions</u>. No Insider may engage in transactions in puts, calls or other derivative instruments that relate to or involve Company securities. Such transactions are, in effect, bets on short-term movements in the Company&#8217;s stock price and therefore create the appearance that the transaction is based on nonpublic information.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">6.</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><u>Hedging</u>. No Insider may engage in hedging transactions involving Company securities, including forward sale or purchase contracts, equity swaps, collars or exchange funds. Such transactions are speculative in nature and therefore create the appearance that the transaction is based on nonpublic information.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">7.</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><u>Trading on Margin or Pledging</u>. No Insider may place the Company&#8217;s securities as security for a margin account or pledge (or hypothecate) Company securities as collateral for a loan at a time when the Insider is aware of material nonpublic information.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">8.</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><u>Trading in Securities of Other Companies</u>. No Insider may, while in possession of material nonpublic information about any other public company gained in the course of employment with the Company, (a) buy, sell, donate or otherwise transact in the securities of the other public company, (b) &#8220;tip&#8221; or disclose such material nonpublic information concerning that company to anyone, or (c) give trading advice of any kind to anyone concerning the other public company.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>B. </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Exceptions.</strong></p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:justify;">The prohibited activities above do not apply to:</p></td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Exercises of stock options or similar equity awards or the surrender of shares to the Company in payment of the stock option exercise price or in satisfaction of any tax withholding obligations, provided that any securities acquired pursuant to such exercise may not be sold, including as part of a broker-assisted cashless exercise, while the Insider is in possession of material nonpublic information.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">2.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The vesting of restricted stock, or the exercise of a tax withhold right pursuant to which an Insider elects to have the Company withhold shares of stock to satisfy tax withholding requirements upon the vesting of any restricted stock, provided that any securities acquired pursuant to such vesting may not be sold while the Insider is in possession of material nonpublic information.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">3.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Acquisitions or dispositions of Company securities under the Company&#8217;s Equity Incentive Plan or any other individual account that are made pursuant to standing instructions entered into while the Insider is not in possession of material nonpublic information.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">4.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Other purchases of securities from the Company or sales of securities to the Company that do not involve a market transaction.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Purchases, sales or donations made pursuant to a Rule 10b5-1 plan that is adopted and operated in compliance with the terms of this Policy (see Section VII).</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong></strong>&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>IV. </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>DETERMINING WHETHER INFORMATION IS MATERIAL AND NONPUBLIC</strong></p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong></strong>&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>A. </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Definition of &#8220;Material&#8221; Information.</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">There is no bright line test for determining whether particular information is material. Such a determination depends on the facts and circumstances unique to each situation and cannot be made solely based on the potential financial impact of the information.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">2.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">In general, information about the Company should be considered &#8220;material&#8221; if:</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:12%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">A reasonable investor would consider the information significant when deciding whether to buy or sell Company securities; or</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">The information, if disclosed, could be viewed by a reasonable investor as having significantly altered the total mix of information available in the marketplace about the Company.</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">Put simply, if the information could reasonably be expected to affect the price of the Company&#8217;s stock, it should be considered material.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">3.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">It is important to remember that whether information is material will be viewed by enforcement authorities with the benefit of hindsight. In other words, if the price of the Company&#8217;s stock changed as a result of the information having been made public, it will likely be considered material by enforcement authorities.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">4.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">While it is not possible to identify every type of information that could be deemed &#8220;material,&#8221; the following matters ordinarily should be considered material:</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:12%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Projections of future earnings or losses, or other earnings guidance, or changes in projections or guidance.</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Financial performance, especially quarterly and year-end earnings or significant changes in financial performance or liquidity.</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Potential significant mergers and acquisitions or the sale of significant assets or subsidiaries.</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">New major contracts, orders, suppliers, customers, or finance sources, or the loss thereof.</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Major discoveries or significant changes or developments in products or product lines, research or technologies.</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Significant changes or developments in supplies or inventory, including significant product defects, recalls or product returns.</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Stock splits, public or private securities/debt offerings, or changes in dividend policies or amounts.</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Significant changes in senior management.</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Actual or threatened major litigation, or the resolution of such litigation.</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">An imminent change in the Company&#8217;s credit rating by a rating agency.</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">The contents of forthcoming publications that may affect the market price of Company securities.</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Significant breaches of information technology systems or other events impacting cybersecurity.</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>B. </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Definition of &#8220;Nonpublic&#8221; Information.</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td></td> <td style="vertical-align:top;"> <p style="margin:0px">Information is &#8220;nonpublic&#8221; if it has not been disseminated to investors through a widely circulated news or wire service (such as Dow Jones, Bloomberg, PR Newswire, etc.) or through a public filing with the Securities and Exchange Commission (the &#8220;SEC&#8221;).</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>C. </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Consult the Compliance Officer for Guidance.</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td></td> <td style="vertical-align:top;"> <p style="margin:0px">Any Insider who is unsure whether the information that he or she possesses is material or nonpublic should consult the Compliance Officer for guidance before trading in any Company securities.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong></strong>&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>V. </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>COMPLIANCE OFFICER</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="margin:0px">The Company has designated Patricia Prichep as the individual responsible for administration of this Policy (the &#8220;Compliance Officer&#8221;). The duties of the Compliance Officer include administering this Policy and monitoring and enforcing compliance with this Policy.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="margin:0px">The Compliance Officer may designate one or more individuals who may perform the Compliance Officer&#8217;s duties in the event that the Compliance Officer is unable or unavailable to perform such duties.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>VI. </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>RULE 10b5-1 TRADING PLANS</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="margin:0px">Under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, an individual has an affirmative defense against an allegation of insider trading if he or she demonstrates that the purchase, sale or trade in question took place pursuant to a binding contract, specific instruction or written plan that was put into place before he or she became aware of material nonpublic information. Such contracts, irrevocable instructions and plans are commonly referred to as Rule 10b5-1 plans and must satisfy several conditions set forth in Rule 10b5-1.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="margin:0px">Rule 10b5-1 plans have the obvious advantage of protecting against insider trading liability. However, they also require advance commitments regarding the amounts, prices and timing of purchases or sales of Company securities and thus limit flexibility and discretion. In addition, once a Rule 10b5-1 plan has been adopted, it is generally not permissible to amend or modify such plan without complying with new conditions and timing limitations set forth in Rule 10b5-1. Accordingly, while some individuals may find Rule 10b5-1 plans attractive, they may not be suitable for all Insiders.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>VII. </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>POST-TERMINATION TRANSACTIONS</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="margin:0px">This Policy continues to apply to transactions in the Company&#8217;s securities after termination of service to the Company. If an individual is in possession of material nonpublic information when his or her service terminates, that individual may not trade in the Company&#8217;s securities until any such material nonpublic information has become public or is no longer material.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>VIII. </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>POTENTIAL PENALTIES AND DISCIPLINARY SANCTIONS </strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>A. </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Civil and Criminal Penalties.</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td></td> <td style="vertical-align:top;"> <p style="margin:0px">The consequences of prohibited insider trading or tipping can be severe. Persons violating insider trading or tipping rules may be required to disgorge the profit made or the loss avoided by the trading, pay the loss suffered by the person who purchased securities from or sold securities to the Insider or tippee, pay significant civil and/or criminal penalties, and serve a lengthy jail term. The Company in such circumstances may also be required to pay major civil or criminal penalties.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>B. </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Company Discipline.</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td></td> <td style="vertical-align:top;"> <p style="margin:0px">Violation of this Policy or federal or state insider trading or tipping laws by any Insider may, in the case of a director, subject the director to dismissal proceedings and, in the case of an officer or employee, subject the officer or employee to disciplinary action by the Company up to and including termination for cause.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>C. </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Reporting of Violations.</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td></td> <td style="vertical-align:top;"> <p style="margin:0px">Any Insider who violates this Policy or any federal or state law governing insider trading or tipping, or knows of any such violation by any other Insider, must report the violation immediately to the Compliance Officer. Upon determining that any such violation has occurred, the Compliance Officer, in consultation with the Company&#8217;s Board of Directors, will determine whether the Company should release any material nonpublic information, and, when required by applicable law, shall cause the Company to report the violation to the SEC or other appropriate governmental authority.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong></strong>&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>IX. </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>MISCELLANEOUS</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="margin:0px">This Policy will be delivered to all Insiders upon its adoption by the Company and to all Insiders at the start of their employment or relationship with the Company. Upon first receiving a copy of this Policy or any revised versions, each Insider must sign an acknowledgment that he or she has received a copy of this Policy and agrees to comply with its terms.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Receipt and Acknowledgment </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Upon first receiving a copy of the Insider Trading Policy of CEL-SCI Corporation, or any revised version thereof, each member of the Board of Directors, each officer designated under the Policy as a &#8220;Section 16 Individual&#8221; and each individual meeting the definition of a &#8220;Key Employee&#8221; must sign and return to the Company&#8217;s Compliance Officer the following receipt and acknowledgement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, _________________, hereby acknowledge that I have received and read a copy of the Insider Trading Policy of CEL-SCI Corporation and agree to comply with its terms. I understand that violation of insider trading or tipping laws or regulations may subject me to severe civil and/or criminal penalties, and that violation of the terms of the above-titled policy may subject me to discipline by the Company up to and including termination for cause.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;width:35%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:20%;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;width:30%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:15%;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">Signature</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">Date</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">(Print Name)</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; TEXT-INDENT: 0px;">7</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>cvm_ex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head><title>cvm_ex231.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 23.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (File numbers 333-265995 and 333-282844) and Form S-8 (File numbers 333-117088, 333-140792, 333-162265, 333-179477, 333-184092, 333-198244, 333-206538, 333-214031, 333-222969, 333-228252, 333-236063, 333-237845, 333-265994, 333-276238 and 333-281884) of CEL-SCI Corporation (the Company) appearing in the Company&#8217;s Annual Report on Form 10-K for the year ended September 30, 2024.&nbsp; Our report contains an explanatory paragraph regarding the Company&#8217;s ability to continue as a going concern.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; &nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">/s/ BDO USA, P.C.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Potomac, Maryland</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">January 13, 2025</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>4
<FILENAME>cvm_ex31.htm
<DESCRIPTION>EX-31
<TEXT>
<html><head><title>cvm_ex31.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATIONS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Geert Kersten, of CEL-SCI Corporation, certify that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">I have reviewed this annual report on Form 10-K of CEL-SCI Corporation;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">2.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">3.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">designed such internal control over financial reporting, or cause such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">c)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">d)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">any fraud, whether or not material, that involves management or other employees who have significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;">January 13, 2025</td> <td style="width:3%;">By:</td> <td style="BORDER-BOTTOM: black 1px solid;width:35%;">/s/ Geert Kersten</td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td>Geert R. Kersten <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Principal Executive Officer</p></td> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATIONS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Patricia Prichep, of CEL-SCI Corporation, certify that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">I have reviewed this annual report on Form 10-K of CEL-SCI Corporation;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">2.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">3.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">4.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">designed such internal control over financial reporting, or cause such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">c)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">d)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">a)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">b)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">any fraud, whether or not material, that involves management or other employees who have significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">January 13, 2025</p></td> <td style="width:3%;">By:</td> <td style="BORDER-BOTTOM: black 1px solid;width:35%;">/s/ Patricia Prichep</td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Patricia Prichep</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Principal Financial Officer</p></td> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>5
<FILENAME>cvm_ex32.htm
<DESCRIPTION>EX-32
<TEXT>
<html><head><title>cvm_ex32.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 32</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">In connection with the Annual Report of CEL-SCI Corporation (the &#8220;Company&#8221;) on Form 10-K for the period ending September 30, 2024 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), Geert Kersten, the Chief Executive Officer of the Company and Patricia Prichep, the Chief Financial and Operations Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(1)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">(2)</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">The information contained in the Report fairly presents, in all material respects the financial condition and results of the Company.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">January 13, 2025</p></td> <td style="width:3%;">By:</td> <td style="BORDER-BOTTOM: black 1px solid;width:35%;">/s/ Geert Kersten</td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Geert Kersten, Chief Executive Officer</p></td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td>&nbsp;</td> <td>By:</td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">/s/ Patricia Prichep</p></td> <td>&nbsp;</td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">Patricia Prichep, Chief Financial and</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Operations Officer</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr></table><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cvm-20240930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 01/12/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:cvm="http://cvm.com/20240930" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cvm.com/20240930">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://cvm.com/role/Cover" id="Cover">
        <link:definition>000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/BalanceSheets" id="BalanceSheets">
        <link:definition>000002 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
        <link:definition>000003 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StatementsOfOperations" id="StatementsOfOperations">
        <link:definition>000004 - Statement - STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
        <link:definition>000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
        <link:definition>000006 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/ORGANIZATION" id="ORGANIZATION">
        <link:definition>000007 - Disclosure - ORGANIZATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/LIQUIDITY" id="LIQUIDITY">
        <link:definition>000008 - Disclosure - LIQUIDITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptions" id="WarrantsAndNonemployeeOptions">
        <link:definition>000010 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
        <link:definition>000011 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PATENTS" id="PATENTS">
        <link:definition>000012 - Disclosure - PATENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>000013 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/EquityBasedCompensation" id="EquityBasedCompensation">
        <link:definition>000014 - Disclosure - EQUITY-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/EmployeeBenefitPlan" id="EmployeeBenefitPlan">
        <link:definition>000015 - Disclosure - EMPLOYEE BENEFIT PLAN</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>000016 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>000017 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>000018 - Disclosure - STOCKHOLDERS EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>000019 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/NetLossPerCommonShare" id="NetLossPerCommonShare">
        <link:definition>000020 - Disclosure - NET LOSS PER COMMON SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>000021 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsTables" id="WarrantsAndNonemployeeOptionsTables">
        <link:definition>000023 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
        <link:definition>000024 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsTables" id="PatentsTables">
        <link:definition>000025 - Disclosure - PATENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <link:definition>000026 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/EquityBasedCompensationTables" id="EquityBasedCompensationTables">
        <link:definition>000027 - Disclosure - EQUITY-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <link:definition>000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
        <link:definition>000029 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/NetLossPerCommonShareTables" id="NetLossPerCommonShareTables">
        <link:definition>000030 - Disclosure - NET LOSS PER COMMON SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
        <link:definition>000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" id="WarrantsAndNonemployeeOptionsDetails">
        <link:definition>000032 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1" id="WarrantsAndNonemployeeOptionsDetails1">
        <link:definition>000033 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative" id="WarrantsAndNonemployeeOptionsDetailsNarrative">
        <link:definition>000034 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
        <link:definition>000035 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
        <link:definition>000036 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsDetails" id="PatentsDetails">
        <link:definition>000037 - Disclosure - PATENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsDetails1" id="PatentsDetails1">
        <link:definition>000038 - Disclosure - PATENTS (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/PatentsDetailsNarrative" id="PatentsDetailsNarrative">
        <link:definition>000039 - Disclosure - PATENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <link:definition>000040 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
        <link:definition>000041 - Disclosure - INCOME TAXES (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
        <link:definition>000042 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/EquityBasedCompensationDetails" id="EquityBasedCompensationDetails">
        <link:definition>000043 - Disclosure - EQUITY-BASED COMPENSATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/EquityBasedCompensationDetails1" id="EquityBasedCompensationDetails1">
        <link:definition>000044 - Disclosure - EQUITY-BASED COMPENSATION (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/EquityBasedCompensationDetails2" id="EquityBasedCompensationDetails2">
        <link:definition>000045 - Disclosure - EQUITY-BASED COMPENSATION (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/EquityBasedCompensationDetails3" id="EquityBasedCompensationDetails3">
        <link:definition>000046 - Disclosure - EQUITY-BASED COMPENSATION (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/EquityBasedCompensationDetails4" id="EquityBasedCompensationDetails4">
        <link:definition>000047 - Disclosure - EQUITY-BASED COMPENSATION (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/EquityBasedCompensationDetailsNarrative" id="EquityBasedCompensationDetailsNarrative">
        <link:definition>000048 - Disclosure - EQUITY-BASED COMPENSATION (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" id="EmployeeBenefitPlanDetailNarrative">
        <link:definition>000049 - Disclosure - EMPLOYEE BENEFIT PLAN (Detail Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>000050 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
        <link:definition>000051 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
        <link:definition>000052 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
        <link:definition>000053 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
        <link:definition>000054 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/FairValueMeasurementsDetails" id="FairValueMeasurementsDetails">
        <link:definition>000055 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/NetLossPerCommonShareDetails" id="NetLossPerCommonShareDetails">
        <link:definition>000056 - Disclosure - NET LOSS PER COMMON SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/NetLossPerCommonShareDetails1" id="NetLossPerCommonShareDetails1">
        <link:definition>000057 - Disclosure - NET LOSS PER COMMON SHARE (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/NetLossPerCommonShareDetailsNarrative" id="NetLossPerCommonShareDetailsNarrative">
        <link:definition>000058 - Disclosure - NET LOSS PER COMMON SHARE (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cvm.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
        <link:definition>000059 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20240930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20240930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20240930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvm-20240930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd" />
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd" />
  <import namespace="http://fasb.org/srt-roles/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd" />
  <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
  <import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
  <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
  <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <element id="cvm_AmountsDueToEmployeesCurrent" name="AmountsDueToEmployeesCurrent" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CommitmentsAndContingenciesDisclosuresAbstract" name="CommitmentsAndContingenciesDisclosuresAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ModificationOfWarrants" name="ModificationOfWarrants" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised" name="StockIssuedDuringPeriodSharesStockWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_StockIssuedDuringPeriodValueStockWarrantsExercised" name="StockIssuedDuringPeriodValueStockWarrantsExercised" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncentiveStockForfeitedShares" name="IncentiveStockForfeitedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncentiveStockForfeitedAmount" name="IncentiveStockForfeitedAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CostIncurredInIssuanceOfStock" name="CostIncurredInIssuanceOfStock" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsShares" name="ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount" name="ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExerciseOfPreFundedWarrantsShares" name="ExerciseOfPreFundedWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExerciseOfPreFundedWarrantsAmount" name="ExerciseOfPreFundedWarrantsAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PurchaseOfStockByOfficersAndDirectorsShares" name="PurchaseOfStockByOfficersAndDirectorsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PurchaseOfStockByOfficersAndDirectorsAmount" name="PurchaseOfStockByOfficersAndDirectorsAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CommonStockContributedToEmployeeBenefitPlan" name="CommonStockContributedToEmployeeBenefitPlan" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" name="PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CapitalizedIntangibleAssetsCostsIncludedInCurrentLiabilities" name="CapitalizedIntangibleAssetsCostsIncludedInCurrentLiabilities" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PurchaseOfAssetsUnderFinanceLeases" name="PurchaseOfAssetsUnderFinanceLeases" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseObligationIncludedInAccountsPayable" name="FinanceLeaseObligationIncludedInAccountsPayable" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ConsultingServicesPaidWithIssuanceOfCommonStock" name="ConsultingServicesPaidWithIssuanceOfCommonStock" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinancingCostsIncludedInCurrentLiabilities" name="FinancingCostsIncludedInCurrentLiabilities" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AccruedConsultingServicesToBePaidUnderShareBasedPaymentArrangement" name="AccruedConsultingServicesToBePaidUnderShareBasedPaymentArrangement" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LiquidityDisclosureTextblock" name="LiquidityDisclosureTextblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantsAndNonEmployeeOptionsDisclosureTextBlock" name="WarrantsAndNonEmployeeOptionsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_RecentlyAdoptedAccountingStandardsPolicyPolicyTextBlock" name="RecentlyAdoptedAccountingStandardsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock" name="ScheduleOfEquityWarrantsWereExercisedTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock" name="ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FiniteLivedIntangibleAssetsUsefulLife" name="FiniteLivedIntangibleAssetsUsefulLife" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_Issuedate2" name="Issuedate2" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_SharesIssuableUponExerciseOfwarrant" name="SharesIssuableUponExerciseOfwarrant" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExercisePrice" name="ExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExpirationDate1" name="ExpirationDate1" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_EquityWarrantsExercised" name="EquityWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ProceedsFromEquityWarrantsExercised" name="ProceedsFromEquityWarrantsExercised" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_EquityWarrantsExercisePrice" name="EquityWarrantsExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_StockIssuedDuringPeriodToPurchaseCommonStock" name="StockIssuedDuringPeriodToPurchaseCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_StockOptionExercisePrice" name="StockOptionExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_VestedOptions" name="VestedOptions" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IssuanceOfOptionsForServices" name="IssuanceOfOptionsForServices" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncrementalCostDeemedDividend" name="IncrementalCostDeemedDividend" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CommonStockIssuedForServiceShares" name="CommonStockIssuedForServiceShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PrepaidExpenses" name="PrepaidExpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AccumulatedAmortization" name="AccumulatedAmortization" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_TotalFiniteLivedIntangibleAssetsAmortizationExpense" name="TotalFiniteLivedIntangibleAssetsAmortizationExpense" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PatentsWeightedAverageAmortizationPeriod" name="PatentsWeightedAverageAmortizationPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" name="DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LeaseLiabilities" name="LeaseLiabilities" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_RightOfUseAssets" name="RightOfUseAssets" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ResearchAndDevelopmentCredit" name="ResearchAndDevelopmentCredit" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ResearchAndDevelopmentCreditDescription" name="ResearchAndDevelopmentCreditDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_CumulativeChangeInOwnershipPercentage" name="CumulativeChangeInOwnershipPercentage" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExpectedLifeOfOptionsMin1" name="ExpectedLifeOfOptionsMin1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ExpectedLifeOfOptionsMax" name="ExpectedLifeOfOptionsMax" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NumberOfOptionsVested" name="NumberOfOptionsVested" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NumberOfOptionsExercised" name="NumberOfOptionsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NumberOfOptions" name="NumberOfOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageExercisePriceVested" name="WeightedAverageExercisePriceVested" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageExercisePriceExpired" name="WeightedAverageExercisePriceExpired" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" name="WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" name="WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PerformanceBasedStockOptionsSharesGranted" name="PerformanceBasedStockOptionsSharesGranted" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_RemainingOutstandingFairValueOfShares" name="RemainingOutstandingFairValueOfShares" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_VestedShares" name="VestedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_EmployeeContributionsToDefinedContributionPlans" name="EmployeeContributionsToDefinedContributionPlans" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PercentageOfEmployeeContributionsToDefinedContributionPlans" name="PercentageOfEmployeeContributionsToDefinedContributionPlans" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseLiabilityCurrentPortion" name="FinanceLeaseLiabilityCurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseLiabilityNoncurrentPortion" name="FinanceLeaseLiabilityNoncurrentPortion" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_OperatingLeaseObligationyCurrent" name="OperatingLeaseObligationyCurrent" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_OperatingLeaseObligationyNoncurrent" name="OperatingLeaseObligationyNoncurrent" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_FinanceLeaseCosts" name="FinanceLeaseCosts" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageMaturityYear" name="WeightedAverageMaturityYear" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageOperatingLeaseDiscountRate" name="WeightedAverageOperatingLeaseDiscountRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WeightedAverageOperatingLeaseMaturityYear" name="WeightedAverageOperatingLeaseMaturityYear" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_PaymentsMadeToLandlord" name="PaymentsMadeToLandlord" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ProceedsFromAdditionalDebtFromRelatedParty" name="ProceedsFromAdditionalDebtFromRelatedParty" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_RestrictedCommonStockSharesIssued" name="RestrictedCommonStockSharesIssued" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_DescriptionOfModificationOfWarrants" name="DescriptionOfModificationOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IncrementalCostOfWarrantsExtension" name="IncrementalCostOfWarrantsExtension" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ProceedFromIssuanceOrSaleOfEquity" name="ProceedFromIssuanceOrSaleOfEquity" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_NetIssuanceCosts" name="NetIssuanceCosts" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_IssuanceCostOfCommonStock" name="IssuanceCostOfCommonStock" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_AdditionalPurchaseOfCommonStock" name="AdditionalPurchaseOfCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_MoneyMarketFundsIncludedInCashAndCashEquivalents" name="MoneyMarketFundsIncludedInCashAndCashEquivalents" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_ProfitLossPerShareBasicAndDilutedAbstract" name="ProfitLossPerShareBasicAndDilutedAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantsUsedForCalculationOfEarningPerShare" name="WarrantsUsedForCalculationOfEarningPerShare" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantsOfferingPrice" name="WarrantsOfferingPrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantsToPurchaseCommonStock" name="WarrantsToPurchaseCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_LIQUIDITYAbstract" name="LIQUIDITYAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="cvm_WarrantsAndNonemployeeOptionsAbstract" name="WarrantsAndNonemployeeOptionsAbstract" nillable="true" abstract="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element name="FairValueMember" id="cvm_FairValueMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="IncomeTaxMember" id="cvm_IncomeTaxMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesYMember" id="cvm_SeriesYMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesMMMember" id="cvm_SeriesMMMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesNNMember" id="cvm_SeriesNNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesRRMember" id="cvm_SeriesRRMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesSSMember" id="cvm_SeriesSSMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultantsMember" id="cvm_ConsultantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OutstandingMember" id="cvm_OutstandingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ExercisableMember" id="cvm_ExercisableMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="RestrictedStockAwardsMember" id="cvm_RestrictedStockAwardsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockBonusPlansMember" id="cvm_StockBonusPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="StockCompensationPlansMember" id="cvm_StockCompensationPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NonQualifiedStockOptionsPlansMember" id="cvm_NonQualifiedStockOptionsPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="IncentiveStockOptionPlansMember" id="cvm_IncentiveStockOptionPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="IncentiveStockBonusPlanMember" id="cvm_IncentiveStockBonusPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OfficerAndDirectorMember" id="cvm_OfficerAndDirectorMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OptionsMember" id="cvm_OptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ErgomedGroupMember" id="cvm_ErgomedGroupMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CEOMember" id="cvm_CEOMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesRRWarrantMember" id="cvm_SeriesRRWarrantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultingAgreementsMember" id="cvm_ConsultingAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultantMember" id="cvm_ConsultantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TwoSeptemberTwoThousendTwentyFourMember" id="cvm_TwoSeptemberTwoThousendTwentyFourMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TwoSeptemberTwoThousendTwentyFiveMember" id="cvm_TwoSeptemberTwoThousendTwentyFiveMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="UnvestedRestrictedStockMember" id="cvm_UnvestedRestrictedStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesNMember" id="cvm_SeriesNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesUUMember" id="cvm_SeriesUUMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeriesXMember" id="cvm_SeriesXMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="RestrictedStocksMember" id="cvm_RestrictedStocksMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EquityProceedsFromSaleCommonStockMember" id="cvm_EquityProceedsFromSaleCommonStockMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ErgomedMember" id="cvm_ErgomedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="LandlordMember" id="cvm_LandlordMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="BottomMember" id="cvm_BottomMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TopMember" id="cvm_TopMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ConsultantsOneMember" id="cvm_ConsultantsOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NonEmployeesMember" id="cvm_NonEmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EmployeesMember" id="cvm_EmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="CostMember" id="cvm_CostMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NonVestedOptionsMember" id="cvm_NonVestedOptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>cvm-20240930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 01/12/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Fin Stmt Error Correction Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address Address Line 2</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm Id</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl_58966d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl_58966d" xml:lang="en-US">BALANCE SHEETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl_103958" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl_103958" xml:lang="en-US">ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl_089232" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl_089232" xml:lang="en-US">Current assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_97c7b6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_97c7b6" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl_8ef51f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl_8ef51f" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl_3c11aa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl_3c11aa" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl_dea33c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl_dea33c" xml:lang="en-US">Deposits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_3559c7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl_3559c7" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl_8" xml:lang="en-US">[Assets, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl_6bc5de" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl_6bc5de" xml:lang="en-US">Finance lease right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_e2ff80" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_e2ff80" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_8a9924" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_8a9924" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_78f343" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl_78f343" xml:lang="en-US">Patent costs, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl_aaf29f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl_aaf29f" xml:lang="en-US">Deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl_13" xml:lang="en-US">[Deposits Assets, Noncurrent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNoncurrent" xlink:to="us-gaap_InventoryNoncurrent_lbl_ea663a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNoncurrent_lbl_ea663a" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNoncurrent" xlink:to="us-gaap_InventoryNoncurrent_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNoncurrent_lbl_14" xml:lang="en-US">[Inventory, Noncurrent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_0ef96b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl_0ef96b" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl_15" xml:lang="en-US">[Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_688ca3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_688ca3" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl_1162f9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl_1162f9" xml:lang="en-US">Current Liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl_69e7eb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl_69e7eb" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl_14a85e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl_14a85e" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_AmountsDueToEmployeesCurrent" xlink:label="cvm_AmountsDueToEmployeesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AmountsDueToEmployeesCurrent" xlink:to="cvm_AmountsDueToEmployeesCurrent_lbl_207f16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AmountsDueToEmployeesCurrent_lbl_207f16" xml:lang="en-US">Due to employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl_1d2afe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl_1d2afe" xml:lang="en-US">Finance lease obligation, current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_b59fb5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_b59fb5" xml:lang="en-US">Operating lease obligation, current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_f91134" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl_f91134" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl_23" xml:lang="en-US">[Liabilities, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_b0b9e6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl_b0b9e6" xml:lang="en-US">Finance lease liabilities, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_810fef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl_810fef" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl_0215fc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl_0215fc" xml:lang="en-US">Other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_7aaac3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl_7aaac3" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl_27" xml:lang="en-US">[Liabilities]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_CommitmentsAndContingenciesDisclosuresAbstract" xlink:label="cvm_CommitmentsAndContingenciesDisclosuresAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CommitmentsAndContingenciesDisclosuresAbstract" xlink:to="cvm_CommitmentsAndContingenciesDisclosuresAbstract_lbl_af43a6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CommitmentsAndContingenciesDisclosuresAbstract_lbl_af43a6" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl_3c13e8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl_3c13e8" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl_d9a87f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl_d9a87f" xml:lang="en-US">Preferred stock, $0.01 par value; 200,000 shares authorized; 0 shares issued and outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl_2b50b2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl_2b50b2" xml:lang="en-US">Common stock, $0.01 par value; 600,000,000 shares authorized; 63,787,104 and 47,422,304 shares issued and outstanding at September 30, 2024 and 2023, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl_ab5b77" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl_ab5b77" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_b58664" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_b58664" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_687dc2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl_687dc2" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_34" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl_34" xml:lang="en-US">[Equity, Attributable to Parent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_9b1df6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_9b1df6" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_35" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_35" xml:lang="en-US">[Liabilities and Equity]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_552403" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_552403" xml:lang="en-US">Common stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_78616b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_78616b" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_778ec9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl_778ec9" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl_fcb4e0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl_fcb4e0" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_12df1e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_12df1e" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl_e02388" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl_e02388" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl_3e7810" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl_3e7810" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_e33952" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_e33952" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl_ceb617" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl_ceb617" xml:lang="en-US">STATEMENTS OF OPERATIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl_f2f383" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl_f2f383" xml:lang="en-US">Operating expenses:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl_6957a0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl_6957a0" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl_900e04" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl_900e04" xml:lang="en-US">General &amp; administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_84f61e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl_84f61e" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl_5" xml:lang="en-US">[Operating Expenses]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_e51e91" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl_e51e91" xml:lang="en-US">Operating loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl_6" xml:lang="en-US">[Operating Income (Loss)]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl_ecdcb5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl_ecdcb5" xml:lang="en-US">Interest expense, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl_7" xml:lang="en-US">[Interest Expense, Operating and Nonoperating]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl_d31b71" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl_d31b71" xml:lang="en-US">Other income (expense)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_36fd0e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl_36fd0e" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl_9" xml:lang="en-US">[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ModificationOfWarrants" xlink:label="cvm_ModificationOfWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ModificationOfWarrants" xlink:to="cvm_ModificationOfWarrants_lbl_137e29" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ModificationOfWarrants_lbl_137e29" xml:lang="en-US">Modification of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_7a2571" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_7a2571" xml:lang="en-US">Net loss available to common shareholders</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl_11" xml:lang="en-US">[Net Income (Loss) Attributable to Parent]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl_b0174b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl_b0174b" xml:lang="en-US">Net loss per common share - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl_aab546" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl_aab546" xml:lang="en-US">Weighted average common shares outstanding - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl_b2bfe3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl_b2bfe3" xml:lang="en-US">STATEMENTS OF STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl_e53fdd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl_e53fdd" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl_3c464f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl_3c464f" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl_753b14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl_753b14" xml:lang="en-US">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl_c6331d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl_c6331d" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl_ba6aae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl_ba6aae" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl_52c3ab" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl_52c3ab" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_42c35d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl_42c35d" xml:lang="en-US">Balance, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl_2" xml:lang="en-US">[Shares, Issued]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_1479b9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl_1479b9" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl_454176" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl_454176" xml:lang="en-US">Warrant exercises, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="cvm_StockIssuedDuringPeriodValueStockWarrantsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:to="cvm_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl_abce4f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl_abce4f" xml:lang="en-US">Warrant exercises, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl_979a38" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_lbl_979a38" xml:lang="en-US">401(k) contributions paid in common stock, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl_152c55" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl_152c55" xml:lang="en-US">401(k) contributions paid in common stock, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_be4716" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_be4716" xml:lang="en-US">Stock issued to nonemployees for service, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl_66f216" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl_66f216" xml:lang="en-US">Stock issued to nonemployees for service, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl_46af15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl_46af15" xml:lang="en-US">Proceeds from the sale of common stock, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_4fb2ee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_4fb2ee" xml:lang="en-US">Proceeds from the sale of common stock, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IncentiveStockForfeitedShares" xlink:label="cvm_IncentiveStockForfeitedShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockForfeitedShares" xlink:to="cvm_IncentiveStockForfeitedShares_lbl_a8370b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockForfeitedShares_lbl_a8370b" xml:lang="en-US">2014 Incentive Stock Forfeited, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IncentiveStockForfeitedAmount" xlink:label="cvm_IncentiveStockForfeitedAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockForfeitedAmount" xlink:to="cvm_IncentiveStockForfeitedAmount_lbl_43e0e6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockForfeitedAmount_lbl_43e0e6" xml:lang="en-US">2014 Incentive Stock Forfeited, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl_f44e9e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl_f44e9e" xml:lang="en-US">Equity based compensation - employees</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_CostIncurredInIssuanceOfStock" xlink:label="cvm_CostIncurredInIssuanceOfStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CostIncurredInIssuanceOfStock" xlink:to="cvm_CostIncurredInIssuanceOfStock_lbl_932d05" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CostIncurredInIssuanceOfStock_lbl_932d05" xml:lang="en-US">Share issuance costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_364c4b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl_364c4b" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsShares" xlink:label="cvm_ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsShares" xlink:to="cvm_ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsShares_lbl_a91e7a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsShares_lbl_a91e7a" xml:lang="en-US">Proceeds from the sale of common stock and pre-funded warrants, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount" xlink:label="cvm_ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount" xlink:to="cvm_ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount_lbl_e586d8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount_lbl_e586d8" xml:lang="en-US">Proceeds from the sale of common stock and pre-funded warrants, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ExerciseOfPreFundedWarrantsShares" xlink:label="cvm_ExerciseOfPreFundedWarrantsShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExerciseOfPreFundedWarrantsShares" xlink:to="cvm_ExerciseOfPreFundedWarrantsShares_lbl_bbf934" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExerciseOfPreFundedWarrantsShares_lbl_bbf934" xml:lang="en-US">Exercise of pre-funded warrants, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ExerciseOfPreFundedWarrantsAmount" xlink:label="cvm_ExerciseOfPreFundedWarrantsAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExerciseOfPreFundedWarrantsAmount" xlink:to="cvm_ExerciseOfPreFundedWarrantsAmount_lbl_bb152e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExerciseOfPreFundedWarrantsAmount_lbl_bb152e" xml:lang="en-US">Exercise of pre-funded warrants, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_PurchaseOfStockByOfficersAndDirectorsShares" xlink:label="cvm_PurchaseOfStockByOfficersAndDirectorsShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PurchaseOfStockByOfficersAndDirectorsShares" xlink:to="cvm_PurchaseOfStockByOfficersAndDirectorsShares_lbl_5e02bd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PurchaseOfStockByOfficersAndDirectorsShares_lbl_5e02bd" xml:lang="en-US">Purchase of stock by officers and directors, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_PurchaseOfStockByOfficersAndDirectorsAmount" xlink:label="cvm_PurchaseOfStockByOfficersAndDirectorsAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PurchaseOfStockByOfficersAndDirectorsAmount" xlink:to="cvm_PurchaseOfStockByOfficersAndDirectorsAmount_lbl_403472" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PurchaseOfStockByOfficersAndDirectorsAmount_lbl_403472" xml:lang="en-US">Purchase of stock by officers and directors, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_a95582" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl_a95582" xml:lang="en-US">Balance, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_dc6561" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl_dc6561" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl_09242f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl_09242f" xml:lang="en-US">STATEMENTS OF CASH FLOWS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_54bd52" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl_54bd52" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl_e684b4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl_e684b4" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_49cfda" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl_49cfda" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl_0acd92" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl_0acd92" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl_d69b97" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl_d69b97" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_9782cb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl_9782cb" xml:lang="en-US">Share-based payments for services</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl_6cdd6b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl_6cdd6b" xml:lang="en-US">Equity based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="cvm_CommonStockContributedToEmployeeBenefitPlan" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:to="cvm_CommonStockContributedToEmployeeBenefitPlan_lbl_56a232" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CommonStockContributedToEmployeeBenefitPlan_lbl_56a232" xml:lang="en-US">Common stock contributed to 401(k) plan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl_7f86b8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl_7f86b8" xml:lang="en-US">(Increase)/decrease in assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_a19d78" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_a19d78" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl_11" xml:lang="en-US">[Increase (Decrease) in Prepaid Expense]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl_ca6c05" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl_ca6c05" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl_12" xml:lang="en-US">[Increase (Decrease) in Inventories]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl_6120e0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl_6120e0" xml:lang="en-US">Deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl_13" xml:lang="en-US">[Increase (Decrease) in Deposit Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl_b8a5b5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl_b8a5b5" xml:lang="en-US">Increase/(decrease) in liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_ea9639" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_ea9639" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_15" xml:lang="en-US">[Increase (Decrease) in Accounts Payable]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_c0cbf0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_c0cbf0" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_16" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl_16" xml:lang="en-US">[Increase (Decrease) in Accrued Liabilities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_5903ee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_5903ee" xml:lang="en-US">Due to employees</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl_17" xml:lang="en-US">[Increase (Decrease) in Employee Related Liabilities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_fd4bc5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_fd4bc5" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_18" xml:lang="en-US">[Net Cash Provided by (Used in) Operating Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_0abbed" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_0abbed" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_0c18b6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_0c18b6" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl_20" xml:lang="en-US">[Payments to Acquire Property, Plant, and Equipment]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_da5475" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_da5475" xml:lang="en-US">Expenditures for patent costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl_21" xml:lang="en-US">[Payments to Acquire Intangible Assets]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_63852a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_63852a" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_22" xml:lang="en-US">[Net Cash Provided by (Used in) Investing Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_621175" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_621175" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_3fbeca" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_3fbeca" xml:lang="en-US">Proceeds from issuance of common stock and pre-funded warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl_ddc7a5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl_ddc7a5" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl_25" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl_25" xml:lang="en-US">[Payments of Stock Issuance Costs]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl_4e1f54" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl_4e1f54" xml:lang="en-US">Proceeds from the purchase of stock by officers and directors</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl_c232ca" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl_c232ca" xml:lang="en-US">Proceeds from the exercise of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_23a7d6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_23a7d6" xml:lang="en-US">Payments on obligations under finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_28" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_28" xml:lang="en-US">[Repayments of Debt and Lease Obligation]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl_e075b9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl_e075b9" xml:lang="en-US">Proceeds from related party loans</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl_095216" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl_095216" xml:lang="en-US">Payments of related party loans</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl_30" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl_30" xml:lang="en-US">[Repayments of Related Party Debt]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_f7b4c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_f7b4c9" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_31" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_31" xml:lang="en-US">[Net Cash Provided by (Used in) Financing Activities]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_83d075" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_83d075" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_32" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl_32" xml:lang="en-US">[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_768410" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_768410" xml:lang="en-US">CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_5a2334" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl_5a2334" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF YEAR</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl_06b8a1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl_06b8a1" xml:lang="en-US">SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" xlink:label="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" xlink:to="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities_lbl_4b9dad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities_lbl_4b9dad" xml:lang="en-US">Property and equipment purchases included in current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_CapitalizedIntangibleAssetsCostsIncludedInCurrentLiabilities" xlink:label="cvm_CapitalizedIntangibleAssetsCostsIncludedInCurrentLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CapitalizedIntangibleAssetsCostsIncludedInCurrentLiabilities" xlink:to="cvm_CapitalizedIntangibleAssetsCostsIncludedInCurrentLiabilities_lbl_993a04" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CapitalizedIntangibleAssetsCostsIncludedInCurrentLiabilities_lbl_993a04" xml:lang="en-US">Capitalized patent costs included in current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_PurchaseOfAssetsUnderFinanceLeases" xlink:label="cvm_PurchaseOfAssetsUnderFinanceLeases" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PurchaseOfAssetsUnderFinanceLeases" xlink:to="cvm_PurchaseOfAssetsUnderFinanceLeases_lbl_023449" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PurchaseOfAssetsUnderFinanceLeases_lbl_023449" xml:lang="en-US">Assets purchased under finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_FinanceLeaseObligationIncludedInAccountsPayable" xlink:label="cvm_FinanceLeaseObligationIncludedInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseObligationIncludedInAccountsPayable" xlink:to="cvm_FinanceLeaseObligationIncludedInAccountsPayable_lbl_f9338d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseObligationIncludedInAccountsPayable_lbl_f9338d" xml:lang="en-US">Finance lease obligation included in accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ConsultingServicesPaidWithIssuanceOfCommonStock" xlink:label="cvm_ConsultingServicesPaidWithIssuanceOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultingServicesPaidWithIssuanceOfCommonStock" xlink:to="cvm_ConsultingServicesPaidWithIssuanceOfCommonStock_lbl_f5d31a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultingServicesPaidWithIssuanceOfCommonStock_lbl_f5d31a" xml:lang="en-US">Consulting services paid with issuance of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_FinancingCostsIncludedInCurrentLiabilities" xlink:label="cvm_FinancingCostsIncludedInCurrentLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinancingCostsIncludedInCurrentLiabilities" xlink:to="cvm_FinancingCostsIncludedInCurrentLiabilities_lbl_d08064" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinancingCostsIncludedInCurrentLiabilities_lbl_d08064" xml:lang="en-US">Financing costs included in current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_AccruedConsultingServicesToBePaidUnderShareBasedPaymentArrangement" xlink:label="cvm_AccruedConsultingServicesToBePaidUnderShareBasedPaymentArrangement" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AccruedConsultingServicesToBePaidUnderShareBasedPaymentArrangement" xlink:to="cvm_AccruedConsultingServicesToBePaidUnderShareBasedPaymentArrangement_lbl_f4ff5c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AccruedConsultingServicesToBePaidUnderShareBasedPaymentArrangement_lbl_f4ff5c" xml:lang="en-US">Accrued consulting services to be paid with common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl_a67383" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl_a67383" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOWS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl_fdf153" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl_fdf153" xml:lang="en-US">Cash paid for interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_450229" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_450229" xml:lang="en-US">ORGANIZATION</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_19f968" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_19f968" xml:lang="en-US">ORGANIZATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_2" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_LIQUIDITYAbstract" xlink:label="cvm_LIQUIDITYAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LIQUIDITYAbstract" xlink:to="cvm_LIQUIDITYAbstract_lbl_c196b9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LIQUIDITYAbstract_lbl_c196b9" xml:lang="en-US">LIQUIDITY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LiquidityDisclosureTextblock" xlink:to="cvm_LiquidityDisclosureTextblock_lbl_210515" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_LiquidityDisclosureTextblock_lbl_210515" xml:lang="en-US">LIQUIDITY</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_LiquidityDisclosureTextblock" xlink:label="cvm_LiquidityDisclosureTextblock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LiquidityDisclosureTextblock" xlink:to="cvm_LiquidityDisclosureTextblock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LiquidityDisclosureTextblock_lbl_2" xml:lang="en-US">[LIQUIDITY]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl_8b2d5d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl_8b2d5d" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_fa79e1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_fa79e1" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl_2" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WarrantsAndNonemployeeOptionsAbstract" xlink:label="cvm_WarrantsAndNonemployeeOptionsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantsAndNonemployeeOptionsAbstract" xlink:to="cvm_WarrantsAndNonemployeeOptionsAbstract_lbl_08d0ec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantsAndNonemployeeOptionsAbstract_lbl_08d0ec" xml:lang="en-US">WARRANTS AND NONEMPLOYEE OPTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WarrantsAndNonEmployeeOptionsDisclosureTextBlock" xlink:label="cvm_WarrantsAndNonEmployeeOptionsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantsAndNonEmployeeOptionsDisclosureTextBlock" xlink:to="cvm_WarrantsAndNonEmployeeOptionsDisclosureTextBlock_lbl_da921b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantsAndNonEmployeeOptionsDisclosureTextBlock_lbl_da921b" xml:lang="en-US">WARRANTS AND NON-EMPLOYEE OPTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl_7407e7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl_7407e7" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_fffb53" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_fffb53" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl_2" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl_23a50c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl_23a50c" xml:lang="en-US">PATENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_865218" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_865218" xml:lang="en-US">PATENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl_2" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl_2d1923" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl_2d1923" xml:lang="en-US">INCOME TAXES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl_8d764f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl_8d764f" xml:lang="en-US">INCOME TAXES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl_2" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl_68b12f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl_68b12f" xml:lang="en-US">EQUITY-BASED COMPENSATION</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl_07dc7e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl_07dc7e" xml:lang="en-US">EQUITY-BASED COMPENSATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl_2" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract_lbl_f366a2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract_lbl_f366a2" xml:lang="en-US">EMPLOYEE BENEFIT PLAN</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl_3ab8f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl_3ab8f4" xml:lang="en-US">EMPLOYEE BENEFIT PLAN</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl_2" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_0848bc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl_0848bc" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_276396" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_276396" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl_2" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl_5d54e7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl_5d54e7" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_0def1b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_0def1b" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_2" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl_91f685" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl_91f685" xml:lang="en-US">STOCKHOLDERS EQUITY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_e61e0d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_e61e0d" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_2" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl_3210e2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl_3210e2" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl_8c5713" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl_8c5713" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl_2" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl_cce7e8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl_cce7e8" xml:lang="en-US">NET LOSS PER COMMON SHARE</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl_44c54b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl_44c54b" xml:lang="en-US">NET LOSS PER COMMON SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl_2" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl_5b465e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl_5b465e" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_4fe042" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_4fe042" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_2" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl_d7deb0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl_d7deb0" xml:lang="en-US">Basis of Presentation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_e5de24" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl_e5de24" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_514243" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl_514243" xml:lang="en-US">Property and Equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl_86b12f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl_86b12f" xml:lang="en-US">Supplies used for R&amp;D and manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl_5" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl_f7771c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl_f7771c" xml:lang="en-US">Patents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl_28e970" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl_28e970" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_db1f64" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl_db1f64" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_09359a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl_09359a" xml:lang="en-US">Research and Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl_f8cdcb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl_f8cdcb" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl_bc27f8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl_bc27f8" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl_72c8b6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl_72c8b6" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl_aafd99" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl_aafd99" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl_10ec79" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl_10ec79" xml:lang="en-US">Use of Estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_RecentlyAdoptedAccountingStandardsPolicyPolicyTextBlock" xlink:label="cvm_RecentlyAdoptedAccountingStandardsPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RecentlyAdoptedAccountingStandardsPolicyPolicyTextBlock" xlink:to="cvm_RecentlyAdoptedAccountingStandardsPolicyPolicyTextBlock_lbl_e8580f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_RecentlyAdoptedAccountingStandardsPolicyPolicyTextBlock_lbl_e8580f" xml:lang="en-US">Recently Adopted Accounting Standards</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_f4d47e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl_f4d47e" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl_472ffd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl_472ffd" xml:lang="en-US">Schedule of warrants and non-employee options</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock" xlink:label="cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock" xlink:to="cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock_lbl_e01166" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock_lbl_e01166" xml:lang="en-US">Schedule of equity warrants were exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl_4c3f39" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl_4c3f39" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl_fd596d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl_fd596d" xml:lang="en-US">Schedule of patents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl_fb8350" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl_fb8350" xml:lang="en-US">Schedule of total estimated future amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl_5c473c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl_5c473c" xml:lang="en-US">Schedule of components of the Company's deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl_08139a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl_08139a" xml:lang="en-US">Schedule of federal or state current or deferred tax expense or benefit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl_d23397" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl_d23397" xml:lang="en-US">Schedule of expenses for options issued or vested and restricted stock awarded</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl_044ec2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl_044ec2" xml:lang="en-US">Schedule of assumptions used for fair value of each option granted</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock" xlink:label="cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock" xlink:to="cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock_lbl_eeab8d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock_lbl_eeab8d" xml:lang="en-US">Schedule of non-qualified and incentive stock option plans</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl_f86b5b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl_f86b5b" xml:lang="en-US">Schedule of restricted common stock issued from the incentive stock bonus plan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl_3dd65a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl_3dd65a" xml:lang="en-US">Schedule of non vested options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl_ae21d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl_ae21d3" xml:lang="en-US">Schedule of future minimum payments under finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl_fc821b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl_fc821b" xml:lang="en-US">Schedule of future minimum payments under operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl_ff5ae4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl_ff5ae4" xml:lang="en-US">Schedule of fair value measurements using significant unobservable inputs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl_6cffd0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl_6cffd0" xml:lang="en-US">Schedule of earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl_879665" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl_879665" xml:lang="en-US">Schedule of anti-dilutive securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl_34cca4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl_34cca4" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl_e6dee7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl_e6dee7" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_FiniteLivedIntangibleAssetsUsefulLife" xlink:label="cvm_FiniteLivedIntangibleAssetsUsefulLife" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FiniteLivedIntangibleAssetsUsefulLife" xlink:to="cvm_FiniteLivedIntangibleAssetsUsefulLife_lbl_afa3c3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FiniteLivedIntangibleAssetsUsefulLife_lbl_afa3c3" xml:lang="en-US">Patent Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl_d30e65" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl_d30e65" xml:lang="en-US">Fully insured amount of non-interest bearing cash balances</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl_a6597b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl_a6597b" xml:lang="en-US">Derivative Instrument Risk Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_53890d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_53890d" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl_c09776" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl_c09776" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesYMember" xlink:label="cvm_SeriesYMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesYMember" xlink:to="cvm_SeriesYMember_lbl_60a702" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesYMember_lbl_60a702" xml:lang="en-US">Series Y [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesMMMember" xlink:label="cvm_SeriesMMMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesMMMember" xlink:to="cvm_SeriesMMMember_lbl_1e4828" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesMMMember_lbl_1e4828" xml:lang="en-US">Series MM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesNNMember" xlink:label="cvm_SeriesNNMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesNNMember" xlink:to="cvm_SeriesNNMember_lbl_a5d61f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesNNMember_lbl_a5d61f" xml:lang="en-US">Series NN [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesRRMember" xlink:label="cvm_SeriesRRMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesRRMember" xlink:to="cvm_SeriesRRMember_lbl_3438ff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesRRMember_lbl_3438ff" xml:lang="en-US">Series RR [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ConsultantsMember" xlink:label="cvm_ConsultantsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsMember" xlink:to="cvm_ConsultantsMember_lbl_94c5e4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultantsMember_lbl_94c5e4" xml:lang="en-US">Consultants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesNMember" xlink:label="cvm_SeriesNMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesNMember" xlink:to="cvm_SeriesNMember_lbl_307fbd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesNMember_lbl_307fbd" xml:lang="en-US">Series N [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesUUMember" xlink:label="cvm_SeriesUUMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesUUMember" xlink:to="cvm_SeriesUUMember_lbl_04f0fa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesUUMember_lbl_04f0fa" xml:lang="en-US">Series UU [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesXMember" xlink:label="cvm_SeriesXMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesXMember" xlink:to="cvm_SeriesXMember_lbl_691ac2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesXMember_lbl_691ac2" xml:lang="en-US">Series X [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_BottomMember" xlink:label="cvm_BottomMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_BottomMember" xlink:to="cvm_BottomMember_lbl_553b12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_BottomMember_lbl_553b12" xml:lang="en-US">Minimum</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ConsultantsOneMember" xlink:label="cvm_ConsultantsOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsOneMember" xlink:to="cvm_ConsultantsOneMember_lbl_331c80" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultantsOneMember_lbl_331c80" xml:lang="en-US">Consultants 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_TopMember" xlink:label="cvm_TopMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_TopMember" xlink:to="cvm_TopMember_lbl_e2cb81" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_TopMember_lbl_e2cb81" xml:lang="en-US">Maximum</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_Issuedate2" xlink:label="cvm_Issuedate2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_Issuedate2" xlink:to="cvm_Issuedate2_lbl_93a4eb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_Issuedate2_lbl_93a4eb" xml:lang="en-US">Issue Date</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SharesIssuableUponExerciseOfwarrant" xlink:label="cvm_SharesIssuableUponExerciseOfwarrant" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SharesIssuableUponExerciseOfwarrant" xlink:to="cvm_SharesIssuableUponExerciseOfwarrant_lbl_5fde06" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SharesIssuableUponExerciseOfwarrant_lbl_5fde06" xml:lang="en-US">Shares Issuable upon Exercise of Warrant</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ExercisePrice" xlink:label="cvm_ExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExercisePrice" xlink:to="cvm_ExercisePrice_lbl_f2f26c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExercisePrice_lbl_f2f26c" xml:lang="en-US">Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ExpirationDate1" xlink:label="cvm_ExpirationDate1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExpirationDate1" xlink:to="cvm_ExpirationDate1_lbl_b3f11f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExpirationDate1_lbl_b3f11f" xml:lang="en-US">Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesSSMember" xlink:label="cvm_SeriesSSMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesSSMember" xlink:to="cvm_SeriesSSMember_lbl_eaa887" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesSSMember_lbl_eaa887" xml:lang="en-US">Series SS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_EquityWarrantsExercised" xlink:label="cvm_EquityWarrantsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EquityWarrantsExercised" xlink:to="cvm_EquityWarrantsExercised_lbl_1a3796" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_EquityWarrantsExercised_lbl_1a3796" xml:lang="en-US">Equity Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ProceedsFromEquityWarrantsExercised" xlink:label="cvm_ProceedsFromEquityWarrantsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ProceedsFromEquityWarrantsExercised" xlink:to="cvm_ProceedsFromEquityWarrantsExercised_lbl_2c877c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ProceedsFromEquityWarrantsExercised_lbl_2c877c" xml:lang="en-US">Proceeds from Equity Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_EquityWarrantsExercisePrice" xlink:label="cvm_EquityWarrantsExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EquityWarrantsExercisePrice" xlink:to="cvm_EquityWarrantsExercisePrice_lbl_0b49dc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_EquityWarrantsExercisePrice_lbl_0b49dc" xml:lang="en-US">Equity Warrants Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl_df3c83" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl_df3c83" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl_d89286" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl_d89286" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl_86fbeb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl_86fbeb" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ConsultingAgreementsMember" xlink:label="cvm_ConsultingAgreementsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultingAgreementsMember" xlink:to="cvm_ConsultingAgreementsMember_lbl_58ea77" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultingAgreementsMember_lbl_58ea77" xml:lang="en-US">Consulting Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="cvm_NonQualifiedStockOptionsPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonQualifiedStockOptionsPlansMember" xlink:to="cvm_NonQualifiedStockOptionsPlansMember_lbl_de4bdd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NonQualifiedStockOptionsPlansMember_lbl_de4bdd" xml:lang="en-US">Non Qualified Stock Options Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ConsultantMember" xlink:label="cvm_ConsultantMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantMember" xlink:to="cvm_ConsultantMember_lbl_556dc8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ConsultantMember_lbl_556dc8" xml:lang="en-US">Consultant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_TwoSeptemberTwoThousendTwentyFourMember" xlink:label="cvm_TwoSeptemberTwoThousendTwentyFourMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_TwoSeptemberTwoThousendTwentyFourMember" xlink:to="cvm_TwoSeptemberTwoThousendTwentyFourMember_lbl_ad403d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_TwoSeptemberTwoThousendTwentyFourMember_lbl_ad403d" xml:lang="en-US">September 2, 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_TwoSeptemberTwoThousendTwentyFiveMember" xlink:label="cvm_TwoSeptemberTwoThousendTwentyFiveMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_TwoSeptemberTwoThousendTwentyFiveMember" xlink:to="cvm_TwoSeptemberTwoThousendTwentyFiveMember_lbl_ddcac8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_TwoSeptemberTwoThousendTwentyFiveMember_lbl_ddcac8" xml:lang="en-US">September 2, 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_RestrictedStocksMember" xlink:label="cvm_RestrictedStocksMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RestrictedStocksMember" xlink:to="cvm_RestrictedStocksMember_lbl_e38d13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_RestrictedStocksMember_lbl_e38d13" xml:lang="en-US">Restricted Stocks Member</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ConsultantsMember" xlink:to="cvm_ConsultantsMember_lbl_fe4a18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_ConsultantsMember_lbl_fe4a18" xml:lang="en-US">Consultants Member</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_BottomMember" xlink:to="cvm_BottomMember_lbl_6f2031" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_BottomMember_lbl_6f2031" xml:lang="en-US">Minimum</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_TopMember" xlink:to="cvm_TopMember_lbl_e4db7f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_TopMember_lbl_e4db7f" xml:lang="en-US">Maximum</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_StockIssuedDuringPeriodToPurchaseCommonStock" xlink:label="cvm_StockIssuedDuringPeriodToPurchaseCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockIssuedDuringPeriodToPurchaseCommonStock" xlink:to="cvm_StockIssuedDuringPeriodToPurchaseCommonStock_lbl_d377dd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockIssuedDuringPeriodToPurchaseCommonStock_lbl_d377dd" xml:lang="en-US">Issued options to purchase common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_StockOptionExercisePrice" xlink:label="cvm_StockOptionExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockOptionExercisePrice" xlink:to="cvm_StockOptionExercisePrice_lbl_5e2d08" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockOptionExercisePrice_lbl_5e2d08" xml:lang="en-US">Exercise price</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_VestedOptions" xlink:label="cvm_VestedOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_VestedOptions" xlink:to="cvm_VestedOptions_lbl_f2f4da" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_VestedOptions_lbl_f2f4da" xml:lang="en-US">Options vested</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IssuanceOfOptionsForServices" xlink:label="cvm_IssuanceOfOptionsForServices" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IssuanceOfOptionsForServices" xlink:to="cvm_IssuanceOfOptionsForServices_lbl_ee75b5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IssuanceOfOptionsForServices_lbl_ee75b5" xml:lang="en-US">Options issued to consultants for services</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IncrementalCostDeemedDividend" xlink:label="cvm_IncrementalCostDeemedDividend" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncrementalCostDeemedDividend" xlink:to="cvm_IncrementalCostDeemedDividend_lbl_58a1a8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncrementalCostDeemedDividend_lbl_58a1a8" xml:lang="en-US">Incremental cost</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_CommonStockIssuedForServiceShares" xlink:label="cvm_CommonStockIssuedForServiceShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CommonStockIssuedForServiceShares" xlink:to="cvm_CommonStockIssuedForServiceShares_lbl_840273" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CommonStockIssuedForServiceShares_lbl_840273" xml:lang="en-US">Common stock issued for service, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EquityWarrantsExercised" xlink:to="cvm_EquityWarrantsExercised_lbl_c17640" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_EquityWarrantsExercised_lbl_c17640" xml:lang="en-US">Equity Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl_cbfc99" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl_cbfc99" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl_eceaa4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl_eceaa4" xml:lang="en-US">Total expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PrepaidExpenses" xlink:to="cvm_PrepaidExpenses_lbl_d7f6f7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_PrepaidExpenses_lbl_d7f6f7" xml:lang="en-US">Prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_PrepaidExpenses" xlink:label="cvm_PrepaidExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PrepaidExpenses" xlink:to="cvm_PrepaidExpenses_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PrepaidExpenses_lbl_11" xml:lang="en-US">[Prepaid expenses]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl_767f83" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl_767f83" xml:lang="en-US">Stock prices per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FixturesAndEquipmentGross" xlink:label="us-gaap_FixturesAndEquipmentGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FixturesAndEquipmentGross" xlink:to="us-gaap_FixturesAndEquipmentGross_lbl_5c556f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FixturesAndEquipmentGross_lbl_5c556f" xml:lang="en-US">Research equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl_58e92d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl_58e92d" xml:lang="en-US">Furniture and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl_477d39" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl_477d39" xml:lang="en-US">Leasehold improvements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl_728c1d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl_728c1d" xml:lang="en-US">Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_440a45" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_440a45" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl_6" xml:lang="en-US">[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_ba36d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_ba36d3" xml:lang="en-US">Net property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl_3da04a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl_3da04a" xml:lang="en-US">Depreciation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_lbl_505229" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl_505229" xml:lang="en-US">Patents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="us-gaap_FiniteLivedPatentsGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl_2" xml:lang="en-US">[Finite-Lived Patents, Gross]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_AccumulatedAmortization" xlink:label="cvm_AccumulatedAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AccumulatedAmortization" xlink:to="cvm_AccumulatedAmortization_lbl_e8a3c1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AccumulatedAmortization_lbl_e8a3c1" xml:lang="en-US">Accumulated amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="us-gaap_OtherIntangibleAssetsNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsNet" xlink:to="us-gaap_OtherIntangibleAssetsNet_lbl_aa7f36" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl_aa7f36" xml:lang="en-US">Patents, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_562aea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl_562aea" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_6c8941" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl_6c8941" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_980e54" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl_980e54" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_3b228c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl_3b228c" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_5fe9fb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl_5fe9fb" xml:lang="en-US">2029</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_394440" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl_394440" xml:lang="en-US">Thereafter</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_TotalFiniteLivedIntangibleAssetsAmortizationExpense" xlink:to="cvm_TotalFiniteLivedIntangibleAssetsAmortizationExpense_lbl_9d2637" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_TotalFiniteLivedIntangibleAssetsAmortizationExpense_lbl_9d2637" xml:lang="en-US">Total</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_TotalFiniteLivedIntangibleAssetsAmortizationExpense" xlink:label="cvm_TotalFiniteLivedIntangibleAssetsAmortizationExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_TotalFiniteLivedIntangibleAssetsAmortizationExpense" xlink:to="cvm_TotalFiniteLivedIntangibleAssetsAmortizationExpense_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_TotalFiniteLivedIntangibleAssetsAmortizationExpense_lbl_8" xml:lang="en-US">[Total]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_PatentsWeightedAverageAmortizationPeriod" xlink:label="cvm_PatentsWeightedAverageAmortizationPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PatentsWeightedAverageAmortizationPeriod" xlink:to="cvm_PatentsWeightedAverageAmortizationPeriod_lbl_775e88" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PatentsWeightedAverageAmortizationPeriod_lbl_775e88" xml:lang="en-US">Weighted average amortization period for patents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl_3e113e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl_3e113e" xml:lang="en-US">Amortization of patent costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl_083be2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl_083be2" xml:lang="en-US">NOL carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" xlink:label="cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" xlink:to="cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd_lbl_f03c67" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd_lbl_f03c67" xml:lang="en-US">Capitalized R&amp;D</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl_4ce325" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl_4ce325" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_LeaseLiabilities" xlink:label="cvm_LeaseLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LeaseLiabilities" xlink:to="cvm_LeaseLiabilities_lbl_bf20f2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LeaseLiabilities_lbl_bf20f2" xml:lang="en-US">Lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl_c51c2d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl_c51c2d" xml:lang="en-US">R&amp;D credit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl_79fbdc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl_79fbdc" xml:lang="en-US">Vacation and other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl_998b59" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl_998b59" xml:lang="en-US">Fixed assets and intangibles</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl_8" xml:lang="en-US">[Deferred Tax Assets, Property, Plant and Equipment]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl_118878" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl_118878" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_RightOfUseAssets" xlink:label="cvm_RightOfUseAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RightOfUseAssets" xlink:to="cvm_RightOfUseAssets_lbl_7ea520" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_RightOfUseAssets_lbl_7ea520" xml:lang="en-US">Right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl_86ddc4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl_86ddc4" xml:lang="en-US">Fixed assets and intangibles</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl_5f7c3d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl_5f7c3d" xml:lang="en-US">Total deferred tax liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl_12" xml:lang="en-US">[Deferred Tax Liabilities, Net]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl_f58842" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl_f58842" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl_fc06ac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl_fc06ac" xml:lang="en-US">Valuation allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl_14" xml:lang="en-US">[Deferred Tax Assets, Valuation Allowance]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl_24c491" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl_24c491" xml:lang="en-US">Ending Balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl_0e8e3e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl_0e8e3e" xml:lang="en-US">Federal Rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl_a23c80" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl_a23c80" xml:lang="en-US">State tax rate change</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl_1fd144" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl_1fd144" xml:lang="en-US">State tax rate, net of federal benefit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl_113183" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl_113183" xml:lang="en-US">Other adjustments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl_d70a0a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl_d70a0a" xml:lang="en-US">Permanent differences</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl_2677c4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl_2677c4" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl_3640ba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl_3640ba" xml:lang="en-US">Effective tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl_8" xml:lang="en-US">[Effective Income Tax Rate Reconciliation, Percent]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl_b9ed77" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl_b9ed77" xml:lang="en-US">Tax Credit Carryforward Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IncomeTaxMember" xlink:label="cvm_IncomeTaxMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncomeTaxMember" xlink:to="cvm_IncomeTaxMember_lbl_121078" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncomeTaxMember_lbl_121078" xml:lang="en-US">Income Tax [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ResearchAndDevelopmentCredit" xlink:label="cvm_ResearchAndDevelopmentCredit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ResearchAndDevelopmentCredit" xlink:to="cvm_ResearchAndDevelopmentCredit_lbl_d37a45" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ResearchAndDevelopmentCredit_lbl_d37a45" xml:lang="en-US">Research and development credit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl_0c22bd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl_0c22bd" xml:lang="en-US">NOL carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ResearchAndDevelopmentCreditDescription" xlink:label="cvm_ResearchAndDevelopmentCreditDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ResearchAndDevelopmentCreditDescription" xlink:to="cvm_ResearchAndDevelopmentCreditDescription_lbl_d2623d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ResearchAndDevelopmentCreditDescription_lbl_d2623d" xml:lang="en-US">Research and development credit, description</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_CumulativeChangeInOwnershipPercentage" xlink:label="cvm_CumulativeChangeInOwnershipPercentage" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CumulativeChangeInOwnershipPercentage" xlink:to="cvm_CumulativeChangeInOwnershipPercentage_lbl_42429b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CumulativeChangeInOwnershipPercentage_lbl_42429b" xml:lang="en-US">Cumulative change in ownership percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="us-gaap_TaxCreditCarryforwardDescription" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl_2ece08" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl_2ece08" xml:lang="en-US">Net operating loss carryforwards, description</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl_e408d8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl_e408d8" xml:lang="en-US">Deferred tax asset</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl_d4221e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl_d4221e" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_NonEmployeesMember" xlink:label="cvm_NonEmployeesMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonEmployeesMember" xlink:to="cvm_NonEmployeesMember_lbl_bbafba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NonEmployeesMember_lbl_bbafba" xml:lang="en-US">Non Employees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_EmployeesMember" xlink:label="cvm_EmployeesMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EmployeesMember" xlink:to="cvm_EmployeesMember_lbl_202e7b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_EmployeesMember_lbl_202e7b" xml:lang="en-US">Employees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl_a6140d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl_a6140d" xml:lang="en-US">Stock Based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl_50100c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl_50100c" xml:lang="en-US">Expected stock price volatility, min</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl_279427" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl_279427" xml:lang="en-US">Expected stock price volatility, max</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl_0c727f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl_0c727f" xml:lang="en-US">Risk-free interest rate, min</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl_b80014" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl_b80014" xml:lang="en-US">Risk-free interest rate, max</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ExpectedLifeOfOptionsMin1" xlink:label="cvm_ExpectedLifeOfOptionsMin1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExpectedLifeOfOptionsMin1" xlink:to="cvm_ExpectedLifeOfOptionsMin1_lbl_d0826e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExpectedLifeOfOptionsMin1_lbl_d0826e" xml:lang="en-US">Expected life of options, min</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ExpectedLifeOfOptionsMax" xlink:label="cvm_ExpectedLifeOfOptionsMax" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExpectedLifeOfOptionsMax" xlink:to="cvm_ExpectedLifeOfOptionsMax_lbl_7c48ac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExpectedLifeOfOptionsMax_lbl_7c48ac" xml:lang="en-US">Expected life of options, max</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl_f1a869" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl_f1a869" xml:lang="en-US">Expected dividend yield</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl_f4ccc9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl_f4ccc9" xml:lang="en-US">Option Indexed To Issuers Equity Equity Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_OutstandingMember" xlink:label="cvm_OutstandingMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OutstandingMember" xlink:to="cvm_OutstandingMember_lbl_aa7c55" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OutstandingMember_lbl_aa7c55" xml:lang="en-US">Outstanding [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ExercisableMember" xlink:label="cvm_ExercisableMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ExercisableMember" xlink:to="cvm_ExercisableMember_lbl_4661e1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ExercisableMember_lbl_4661e1" xml:lang="en-US">Exercisable [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_9fcb9c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_9fcb9c" xml:lang="en-US">Number of Options Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_2" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_a889fd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl_a889fd" xml:lang="en-US">Number of Options Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_cb22ac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl_cb22ac" xml:lang="en-US">Number of Options Exercised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_0407e8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_0407e8" xml:lang="en-US">Number of Options Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl_5" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_81af62" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl_81af62" xml:lang="en-US">Number of Options Outstanding, Ending</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_344d07" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_344d07" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_7" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_e22ff4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl_e22ff4" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_67c752" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl_67c752" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl_f7922d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl_f7922d" xml:lang="en-US">Weighted Average Exercise Price Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl_6c8dac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl_6c8dac" xml:lang="en-US">Weighted Average Exercise Price Expired</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_dda12a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl_dda12a" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl_cfd5da" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl_cfd5da" xml:lang="en-US">Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl_13e246" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl_13e246" xml:lang="en-US">Weighted Average Remaining Contractual Life Term (Years) Outstanding, Ending</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl_14" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl_17bf37" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl_17bf37" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl_15" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl_4a2d5f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl_4a2d5f" xml:lang="en-US">Aggregate Intrinsic Value Outstanding, Ending</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NumberOfOptionsVested" xlink:to="cvm_NumberOfOptionsVested_lbl_1fc028" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="cvm_NumberOfOptionsVested_lbl_1fc028" xml:lang="en-US">Number of Options Vested</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_NumberOfOptionsVested" xlink:label="cvm_NumberOfOptionsVested" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NumberOfOptionsVested" xlink:to="cvm_NumberOfOptionsVested_lbl_17" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NumberOfOptionsVested_lbl_17" xml:lang="en-US">[Number of Options Vested]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NumberOfOptionsExercised" xlink:to="cvm_NumberOfOptionsExercised_lbl_7b7fdb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_NumberOfOptionsExercised_lbl_7b7fdb" xml:lang="en-US">Number of Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_NumberOfOptionsExercised" xlink:label="cvm_NumberOfOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NumberOfOptionsExercised" xlink:to="cvm_NumberOfOptionsExercised_lbl_18" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NumberOfOptionsExercised_lbl_18" xml:lang="en-US">[Number of Options Exercised]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NumberOfOptions" xlink:to="cvm_NumberOfOptions_lbl_34bdfa" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_NumberOfOptions_lbl_34bdfa" xml:lang="en-US">Number of Options Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_NumberOfOptions" xlink:label="cvm_NumberOfOptions" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NumberOfOptions" xlink:to="cvm_NumberOfOptions_lbl_19" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NumberOfOptions_lbl_19" xml:lang="en-US">[Number of Options Expired]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageExercisePriceVested" xlink:to="cvm_WeightedAverageExercisePriceVested_lbl_8c9991" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="cvm_WeightedAverageExercisePriceVested_lbl_8c9991" xml:lang="en-US">Weighted Average Exercise Price Vested</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WeightedAverageExercisePriceVested" xlink:label="cvm_WeightedAverageExercisePriceVested" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageExercisePriceVested" xlink:to="cvm_WeightedAverageExercisePriceVested_lbl_20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageExercisePriceVested_lbl_20" xml:lang="en-US">[Weighted Average Exercise Price Vested]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageExercisePriceExpired" xlink:to="cvm_WeightedAverageExercisePriceExpired_lbl_9099cf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_WeightedAverageExercisePriceExpired_lbl_9099cf" xml:lang="en-US">Weighted Average Exercise Price Expired</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WeightedAverageExercisePriceExpired" xlink:label="cvm_WeightedAverageExercisePriceExpired" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageExercisePriceExpired" xlink:to="cvm_WeightedAverageExercisePriceExpired_lbl_21" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageExercisePriceExpired_lbl_21" xml:lang="en-US">[Weighted Average Exercise Price Expired]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" xlink:to="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning_lbl_708605" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning_lbl_708605" xml:lang="en-US">Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" xlink:label="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" xlink:to="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning_lbl_22" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning_lbl_22" xml:lang="en-US">[Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" xlink:label="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" xlink:to="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding_lbl_4cdd06" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding_lbl_4cdd06" xml:lang="en-US">Weighted Average Remaining Contractual Life Term (Years) Outstanding, Ending</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl_0e0433" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl_0e0433" xml:lang="en-US">Number of unvested options, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl_2" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl_236937" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl_236937" xml:lang="en-US">Vested options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl_3" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl_cb2a67" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl_cb2a67" xml:lang="en-US">Granted options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl_7d0e48" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl_7d0e48" xml:lang="en-US">Forfeited options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl_5" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl_10a447" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl_10a447" xml:lang="en-US">Number of unvested options, Ending</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl_c9927e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl_c9927e" xml:lang="en-US">Weighted Average Grant Date Fair Value, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl_7" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl_907f29" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl_907f29" xml:lang="en-US">Weighted Average Grant Date Fair Value, vested</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl_d6cc68" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl_d6cc68" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl_65c39a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl_65c39a" xml:lang="en-US">Weighted Average Grant Date Fair Value, Forfeited</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl_ce243e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl_ce243e" xml:lang="en-US">Weighted Average Grant Date Fair Value, Ending</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_RestrictedStockAwardsMember" xlink:label="cvm_RestrictedStockAwardsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RestrictedStockAwardsMember" xlink:to="cvm_RestrictedStockAwardsMember_lbl_a532b5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_RestrictedStockAwardsMember_lbl_a532b5" xml:lang="en-US">Restricted Stock Awards [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl_7792e7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl_7792e7" xml:lang="en-US">Number of unvested shares, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl_2" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl_e21bfe" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl_e21bfe" xml:lang="en-US">Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl_3" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl_3cac57" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl_3cac57" xml:lang="en-US">Vested shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl_1e66ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl_1e66ad" xml:lang="en-US">Number of unvested shares, Ending</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl_a0d1ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl_a0d1ad" xml:lang="en-US">Weighted Average Grant Date Fair Value, Beginning</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl_6" xml:lang="en-US">[Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl_0e70ae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl_0e70ae" xml:lang="en-US">Weighted Average Grant Date Fair Value, Ending</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl_8597db" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl_8597db" xml:lang="en-US">Class Of Warrant Or Right Axis</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_StockBonusPlansMember" xlink:label="cvm_StockBonusPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockBonusPlansMember" xlink:to="cvm_StockBonusPlansMember_lbl_1c1aeb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockBonusPlansMember_lbl_1c1aeb" xml:lang="en-US">Stock Bonus Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_StockCompensationPlansMember" xlink:label="cvm_StockCompensationPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_StockCompensationPlansMember" xlink:to="cvm_StockCompensationPlansMember_lbl_7f5073" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_StockCompensationPlansMember_lbl_7f5073" xml:lang="en-US">Stock Compensation Plans [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonQualifiedStockOptionsPlansMember" xlink:to="cvm_NonQualifiedStockOptionsPlansMember_lbl_1af946" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_NonQualifiedStockOptionsPlansMember_lbl_1af946" xml:lang="en-US">Non-Qualified Stock Options Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IncentiveStockOptionPlansMember" xlink:label="cvm_IncentiveStockOptionPlansMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockOptionPlansMember" xlink:to="cvm_IncentiveStockOptionPlansMember_lbl_6ca53c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockOptionPlansMember_lbl_6ca53c" xml:lang="en-US">Incentive Stock Option Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IncentiveStockBonusPlanMember" xlink:label="cvm_IncentiveStockBonusPlanMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncentiveStockBonusPlanMember" xlink:to="cvm_IncentiveStockBonusPlanMember_lbl_693056" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncentiveStockBonusPlanMember_lbl_693056" xml:lang="en-US">Incentive Stock Bonus Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_NonVestedOptionsMember" xlink:label="cvm_NonVestedOptionsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NonVestedOptionsMember" xlink:to="cvm_NonVestedOptionsMember_lbl_3c8886" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NonVestedOptionsMember_lbl_3c8886" xml:lang="en-US">Non Vested Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl_021226" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl_021226" xml:lang="en-US">Total compensation cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl_6a34bd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl_6a34bd" xml:lang="en-US">Weighted-average period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_dbfc4a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl_dbfc4a" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_fa16a4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_fa16a4" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl_5edd80" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl_5edd80" xml:lang="en-US">Issuance of common stock options authorized shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_PerformanceBasedStockOptionsSharesGranted" xlink:label="cvm_PerformanceBasedStockOptionsSharesGranted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PerformanceBasedStockOptionsSharesGranted" xlink:to="cvm_PerformanceBasedStockOptionsSharesGranted_lbl_e12f5d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PerformanceBasedStockOptionsSharesGranted_lbl_e12f5d" xml:lang="en-US">Performance based stock options shares granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:to="us-gaap_OptionIndexedToIssuersEquityStrikePrice1_lbl_9a7a26" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1_lbl_9a7a26" xml:lang="en-US">Stock price</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_RemainingOutstandingFairValueOfShares" xlink:label="cvm_RemainingOutstandingFairValueOfShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RemainingOutstandingFairValueOfShares" xlink:to="cvm_RemainingOutstandingFairValueOfShares_lbl_6773fc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_RemainingOutstandingFairValueOfShares_lbl_6773fc" xml:lang="en-US">Grant date fair value remaining outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_VestedShares" xlink:to="cvm_VestedShares_lbl_8c2096" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvm_VestedShares_lbl_8c2096" xml:lang="en-US">Vested shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_VestedShares" xlink:label="cvm_VestedShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_VestedShares" xlink:to="cvm_VestedShares_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_VestedShares_lbl_11" xml:lang="en-US">[Vested shares]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationEquity" xlink:label="us-gaap_DeferredCompensationEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationEquity" xlink:to="us-gaap_DeferredCompensationEquity_lbl_ec7593" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationEquity_lbl_ec7593" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl_dc4f27" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl_dc4f27" xml:lang="en-US">Expense for Company's contribution to employee benefit plan</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_EmployeeContributionsToDefinedContributionPlans" xlink:label="cvm_EmployeeContributionsToDefinedContributionPlans" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EmployeeContributionsToDefinedContributionPlans" xlink:to="cvm_EmployeeContributionsToDefinedContributionPlans_lbl_4f2d79" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_EmployeeContributionsToDefinedContributionPlans_lbl_4f2d79" xml:lang="en-US">Employee Contributions to Defined Contribution Plans</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_PercentageOfEmployeeContributionsToDefinedContributionPlans" xlink:label="cvm_PercentageOfEmployeeContributionsToDefinedContributionPlans" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PercentageOfEmployeeContributionsToDefinedContributionPlans" xlink:to="cvm_PercentageOfEmployeeContributionsToDefinedContributionPlans_lbl_4016e7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PercentageOfEmployeeContributionsToDefinedContributionPlans_lbl_4016e7" xml:lang="en-US">Percentage of employee Contributions to Defined Contribution Plans</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl_d80ac1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl_d80ac1" xml:lang="en-US">Shares issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_5f1474" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_5f1474" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_2" xml:lang="en-US">[Finance Lease, Liability, to be Paid, Year One]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_8ba2ad" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_8ba2ad" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl_3" xml:lang="en-US">[Finance Lease, Liability, to be Paid, Year Two]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_560f1e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_560f1e" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl_4" xml:lang="en-US">[Finance Lease, Liability, to be Paid, Year Three]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_0d9567" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_0d9567" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_lbl_5" xml:lang="en-US">[Finance Lease, Liability, to be Paid, Year Four]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_619216" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_619216" xml:lang="en-US">2029</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_lbl_6" xml:lang="en-US">[Finance Lease, Liability, to be Paid, Year Five]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_f0b2b3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl_f0b2b3" xml:lang="en-US">Total Future Minimum Lease Obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_1ae4a1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_1ae4a1" xml:lang="en-US">Less: Imputed Interest On Financing Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl_8" xml:lang="en-US">[Finance Lease, Liability, Undiscounted Excess Amount]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl_c53ba0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl_c53ba0" xml:lang="en-US">Net present value of finance lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_FinanceLeaseLiabilityCurrentPortion" xlink:label="cvm_FinanceLeaseLiabilityCurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseLiabilityCurrentPortion" xlink:to="cvm_FinanceLeaseLiabilityCurrentPortion_lbl_f1e449" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseLiabilityCurrentPortion_lbl_f1e449" xml:lang="en-US">Net present value of lease finance lease obligations - current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_FinanceLeaseLiabilityNoncurrentPortion" xlink:label="cvm_FinanceLeaseLiabilityNoncurrentPortion" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseLiabilityNoncurrentPortion" xlink:to="cvm_FinanceLeaseLiabilityNoncurrentPortion_lbl_74b971" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseLiabilityNoncurrentPortion_lbl_74b971" xml:lang="en-US">Net present value of lease finance lease obligations - non-current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_b7dd06" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_b7dd06" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl_2" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year One]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_ba1b47" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_ba1b47" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl_3" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Two]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_b21367" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_b21367" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl_4" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Three]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_f2a42e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_f2a42e" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl_5" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Four]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_d75636" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_d75636" xml:lang="en-US">2029</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl_6" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, Year Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_18eff0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_18eff0" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl_7" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid, after Year Five]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_254c7d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_254c7d" xml:lang="en-US">Total Future Minimum Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl_8" xml:lang="en-US">[Lessee, Operating Lease, Liability, to be Paid]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_84051c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_84051c" xml:lang="en-US">Less Imputed Interest On Operating Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl_9" xml:lang="en-US">[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl_daa783" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl_daa783" xml:lang="en-US">Net present value of operating lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_OperatingLeaseObligationyCurrent" xlink:label="cvm_OperatingLeaseObligationyCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OperatingLeaseObligationyCurrent" xlink:to="cvm_OperatingLeaseObligationyCurrent_lbl_024d49" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OperatingLeaseObligationyCurrent_lbl_024d49" xml:lang="en-US">Net present value of operating lease obligation - current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_OperatingLeaseObligationyNoncurrent" xlink:label="cvm_OperatingLeaseObligationyNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OperatingLeaseObligationyNoncurrent" xlink:to="cvm_OperatingLeaseObligationyNoncurrent_lbl_426e2c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OperatingLeaseObligationyNoncurrent_lbl_426e2c" xml:lang="en-US">Net present value of operating lease obligation - non-current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl_453c0d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl_453c0d" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl_1d6d09" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl_1d6d09" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ErgomedMember" xlink:label="cvm_ErgomedMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ErgomedMember" xlink:to="cvm_ErgomedMember_lbl_184a8c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ErgomedMember_lbl_184a8c" xml:lang="en-US">Ergomed [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_LandlordMember" xlink:label="cvm_LandlordMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_LandlordMember" xlink:to="cvm_LandlordMember_lbl_7da5a1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_LandlordMember_lbl_7da5a1" xml:lang="en-US">Landlord [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAgreementsMember" xlink:to="us-gaap_LeaseAgreementsMember_lbl_fc0ede" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAgreementsMember_lbl_fc0ede" xml:lang="en-US">Lease Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenseMember" xlink:to="us-gaap_OperatingExpenseMember_lbl_1eb06a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenseMember_lbl_1eb06a" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl_9eb970" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl_9eb970" xml:lang="en-US">Research and development expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_FinanceLeaseCosts" xlink:label="cvm_FinanceLeaseCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FinanceLeaseCosts" xlink:to="cvm_FinanceLeaseCosts_lbl_582a3f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FinanceLeaseCosts_lbl_582a3f" xml:lang="en-US">Total Finance lease costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl_e8be98" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl_e8be98" xml:lang="en-US">Finance Lease, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl_f6aeb0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestPaymentOnLiability_lbl_f6aeb0" xml:lang="en-US">Interest payment to lease liability</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WeightedAverageMaturityYear" xlink:label="cvm_WeightedAverageMaturityYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageMaturityYear" xlink:to="cvm_WeightedAverageMaturityYear_lbl_0b24b1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageMaturityYear_lbl_0b24b1" xml:lang="en-US">Weighted average maturity year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl_475172" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl_475172" xml:lang="en-US">Finance lease right of use assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl_21feac" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl_21feac" xml:lang="en-US">Finance lease liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl_6b0d1c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl_6b0d1c" xml:lang="en-US">Finance lease liability, current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl_9a2e83" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl_9a2e83" xml:lang="en-US">Depreciation expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl_a75cf9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl_a75cf9" xml:lang="en-US">Cash paid related to finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:label="us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:to="us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_lbl_17c230" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_lbl_17c230" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl_40df2d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl_40df2d" xml:lang="en-US">cash paid related to operating leases</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WeightedAverageOperatingLeaseDiscountRate" xlink:label="cvm_WeightedAverageOperatingLeaseDiscountRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageOperatingLeaseDiscountRate" xlink:to="cvm_WeightedAverageOperatingLeaseDiscountRate_lbl_3e0e48" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageOperatingLeaseDiscountRate_lbl_3e0e48" xml:lang="en-US">Weighted average operating lease discount rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl_d9f4e2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl_d9f4e2" xml:lang="en-US">Operating lease liability, current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl_ca520a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl_ca520a" xml:lang="en-US">Operating lease liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_6b1967" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_6b1967" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WeightedAverageOperatingLeaseMaturityYear" xlink:label="cvm_WeightedAverageOperatingLeaseMaturityYear" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WeightedAverageOperatingLeaseMaturityYear" xlink:to="cvm_WeightedAverageOperatingLeaseMaturityYear_lbl_f8f349" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WeightedAverageOperatingLeaseMaturityYear_lbl_f8f349" xml:lang="en-US">Weighted average operating lease maturity year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl_e52493" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl_e52493" xml:lang="en-US">Lease expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_PaymentsMadeToLandlord" xlink:label="cvm_PaymentsMadeToLandlord" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_PaymentsMadeToLandlord" xlink:to="cvm_PaymentsMadeToLandlord_lbl_780a7a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_PaymentsMadeToLandlord_lbl_780a7a" xml:lang="en-US">Payments Made to Landlord</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_OfficerAndDirectorMember" xlink:label="cvm_OfficerAndDirectorMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OfficerAndDirectorMember" xlink:to="cvm_OfficerAndDirectorMember_lbl_669db5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OfficerAndDirectorMember_lbl_669db5" xml:lang="en-US">Officer and Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_CEOMember" xlink:label="cvm_CEOMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CEOMember" xlink:to="cvm_CEOMember_lbl_4b1f9e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CEOMember_lbl_4b1f9e" xml:lang="en-US">CEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesRRWarrantMember" xlink:label="cvm_SeriesRRWarrantMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_SeriesRRWarrantMember" xlink:to="cvm_SeriesRRWarrantMember_lbl_ddb2f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_SeriesRRWarrantMember_lbl_ddb2f5" xml:lang="en-US">Series RR Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ProceedsFromAdditionalDebtFromRelatedParty" xlink:label="cvm_ProceedsFromAdditionalDebtFromRelatedParty" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ProceedsFromAdditionalDebtFromRelatedParty" xlink:to="cvm_ProceedsFromAdditionalDebtFromRelatedParty_lbl_263e3d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ProceedsFromAdditionalDebtFromRelatedParty_lbl_263e3d" xml:lang="en-US">Additional debt from CEO</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_RestrictedCommonStockSharesIssued" xlink:label="cvm_RestrictedCommonStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_RestrictedCommonStockSharesIssued" xlink:to="cvm_RestrictedCommonStockSharesIssued_lbl_b27ab9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_RestrictedCommonStockSharesIssued_lbl_b27ab9" xml:lang="en-US">Issuance of restricted common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_161af8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_161af8" xml:lang="en-US">Proceeds from issuance of restricted common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl_30a11a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl_30a11a" xml:lang="en-US">Maturity date of debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl_35de5c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl_35de5c" xml:lang="en-US">Proceeds from loan from CEO</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_DescriptionOfModificationOfWarrants" xlink:label="cvm_DescriptionOfModificationOfWarrants" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_DescriptionOfModificationOfWarrants" xlink:to="cvm_DescriptionOfModificationOfWarrants_lbl_fba8d3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_DescriptionOfModificationOfWarrants_lbl_fba8d3" xml:lang="en-US">Description of modification of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IncrementalCostOfWarrantsExtension" xlink:label="cvm_IncrementalCostOfWarrantsExtension" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IncrementalCostOfWarrantsExtension" xlink:to="cvm_IncrementalCostOfWarrantsExtension_lbl_7a6d4c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IncrementalCostOfWarrantsExtension_lbl_7a6d4c" xml:lang="en-US">Incremental cost of warrants extension</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeAxis" xlink:label="us-gaap_TradingActivityByTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradingActivityByTypeAxis" xlink:to="us-gaap_TradingActivityByTypeAxis_lbl_601777" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradingActivityByTypeAxis_lbl_601777" xml:lang="en-US">Trading Activity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_EquityProceedsFromSaleCommonStockMember" xlink:label="cvm_EquityProceedsFromSaleCommonStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EquityProceedsFromSaleCommonStockMember" xlink:to="cvm_EquityProceedsFromSaleCommonStockMember_lbl_31b7d6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_EquityProceedsFromSaleCommonStockMember_lbl_31b7d6" xml:lang="en-US">Equity Proceeds From Sale Common Stock Member</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_13155d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl_13155d" xml:lang="en-US">Common stock shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ProceedFromIssuanceOrSaleOfEquity" xlink:label="cvm_ProceedFromIssuanceOrSaleOfEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ProceedFromIssuanceOrSaleOfEquity" xlink:to="cvm_ProceedFromIssuanceOrSaleOfEquity_lbl_6d43bd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ProceedFromIssuanceOrSaleOfEquity_lbl_6d43bd" xml:lang="en-US">Proceeds from issuance of warrant</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_56862e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl_56862e" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_NetIssuanceCosts" xlink:label="cvm_NetIssuanceCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_NetIssuanceCosts" xlink:to="cvm_NetIssuanceCosts_lbl_516503" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_NetIssuanceCosts_lbl_516503" xml:lang="en-US">Net of issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IssuanceCostOfCommonStock" xlink:label="cvm_IssuanceCostOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_IssuanceCostOfCommonStock" xlink:to="cvm_IssuanceCostOfCommonStock_lbl_63b8cf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_IssuanceCostOfCommonStock_lbl_63b8cf" xml:lang="en-US">Issuance cost of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl_2b6311" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl_2b6311" xml:lang="en-US">Purchase shares of common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_EquityWarrantsExercised" xlink:to="cvm_EquityWarrantsExercised_lbl_75e2dd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvm_EquityWarrantsExercised_lbl_75e2dd" xml:lang="en-US">Equity Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_AdditionalPurchaseOfCommonStock" xlink:label="cvm_AdditionalPurchaseOfCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_AdditionalPurchaseOfCommonStock" xlink:to="cvm_AdditionalPurchaseOfCommonStock_lbl_d09e50" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_AdditionalPurchaseOfCommonStock_lbl_d09e50" xml:lang="en-US">Additional purchase of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl_64204b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl_64204b" xml:lang="en-US">Public offering price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl_923c42" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl_923c42" xml:lang="en-US">Sale of common stock at a public offering price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl_36afe9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl_36afe9" xml:lang="en-US">Warrants exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostAxis" xlink:label="us-gaap_CapitalizedContractCostAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostAxis" xlink:to="us-gaap_CapitalizedContractCostAxis_lbl_971366" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedContractCostAxis_lbl_971366" xml:lang="en-US">Capitalized Contract Cost [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_FairValueMember" xlink:label="cvm_FairValueMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_FairValueMember" xlink:to="cvm_FairValueMember_lbl_166036" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_FairValueMember_lbl_166036" xml:lang="en-US">Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_CostMember" xlink:label="cvm_CostMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_CostMember" xlink:to="cvm_CostMember_lbl_71cc2d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_CostMember_lbl_71cc2d" xml:lang="en-US">Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl_02639f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl_02639f" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_MoneyMarketFundsIncludedInCashAndCashEquivalents" xlink:label="cvm_MoneyMarketFundsIncludedInCashAndCashEquivalents" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_MoneyMarketFundsIncludedInCashAndCashEquivalents" xlink:to="cvm_MoneyMarketFundsIncludedInCashAndCashEquivalents_lbl_e1c88d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_MoneyMarketFundsIncludedInCashAndCashEquivalents_lbl_e1c88d" xml:lang="en-US">Money market funds included in cash and cash equivalents (Note 2)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_ce8db4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_ce8db4" xml:lang="en-US">Total cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ProfitLossPerShareBasicAndDilutedAbstract" xlink:label="cvm_ProfitLossPerShareBasicAndDilutedAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ProfitLossPerShareBasicAndDilutedAbstract" xlink:to="cvm_ProfitLossPerShareBasicAndDilutedAbstract_lbl_c3e285" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ProfitLossPerShareBasicAndDilutedAbstract_lbl_c3e285" xml:lang="en-US">Loss per share - basic and diluted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_c4933a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_c4933a" xml:lang="en-US">Net loss available to common shareholders - basic and diluted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl_28aabd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl_28aabd" xml:lang="en-US">Weighted average shares outstanding - basic and diluted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl_825791" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl_825791" xml:lang="en-US">Basic and diluted loss per common share</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_OptionsMember" xlink:label="cvm_OptionsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_OptionsMember" xlink:to="cvm_OptionsMember_lbl_fea77a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_OptionsMember_lbl_fea77a" xml:lang="en-US">Options and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="cvm_UnvestedRestrictedStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_UnvestedRestrictedStockMember" xlink:to="cvm_UnvestedRestrictedStockMember_lbl_20a845" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_UnvestedRestrictedStockMember_lbl_20a845" xml:lang="en-US">Unvested Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_6a59f1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl_6a59f1" xml:lang="en-US">Antidilutive securities</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WarrantsUsedForCalculationOfEarningPerShare" xlink:label="cvm_WarrantsUsedForCalculationOfEarningPerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantsUsedForCalculationOfEarningPerShare" xlink:to="cvm_WarrantsUsedForCalculationOfEarningPerShare_lbl_81da1b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantsUsedForCalculationOfEarningPerShare_lbl_81da1b" xml:lang="en-US">Prefunded warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl_73205c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl_73205c" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl_9be0ff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl_9be0ff" xml:lang="en-US">Subsequent Event Member</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ErgomedGroupMember" xlink:label="cvm_ErgomedGroupMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_ErgomedGroupMember" xlink:to="cvm_ErgomedGroupMember_lbl_470142" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_ErgomedGroupMember_lbl_470142" xml:lang="en-US">Ergomed Group [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_d2ea78" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl_d2ea78" xml:lang="en-US">Public offering price</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WarrantsOfferingPrice" xlink:label="cvm_WarrantsOfferingPrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantsOfferingPrice" xlink:to="cvm_WarrantsOfferingPrice_lbl_4792e0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantsOfferingPrice_lbl_4792e0" xml:lang="en-US">Pre funded warrants offering price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl_084bdd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl_084bdd" xml:lang="en-US">Sale of common stock at a public offering price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_f06858" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl_f06858" xml:lang="en-US">Stock issued for services</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_274858" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl_274858" xml:lang="en-US">Proceeds from newly issued shares</link:label>
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WarrantsToPurchaseCommonStock" xlink:label="cvm_WarrantsToPurchaseCommonStock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvm_WarrantsToPurchaseCommonStock" xlink:to="cvm_WarrantsToPurchaseCommonStock_lbl_7a88c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvm_WarrantsToPurchaseCommonStock_lbl_7a88c9" xml:lang="en-US">Pre-funded warrants to purchase common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="cvm_CommonStockIssuedForServiceShares" xlink:to="cvm_CommonStockIssuedForServiceShares_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="cvm_CommonStockIssuedForServiceShares_d">Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>cvm-20240930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 01/12/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20240930.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BalanceSheets" xlink:href="cvm-20240930.xsd#BalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BalanceSheetsParenthetical" xlink:href="cvm-20240930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfOperations" xlink:href="cvm-20240930.xsd#StatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfStockholdersEquity" xlink:href="cvm-20240930.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfCashFlows" xlink:href="cvm-20240930.xsd#StatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/ORGANIZATION" xlink:href="cvm-20240930.xsd#ORGANIZATION" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LIQUIDITY" xlink:href="cvm-20240930.xsd#LIQUIDITY" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="cvm-20240930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptions" xlink:href="cvm-20240930.xsd#WarrantsAndNonemployeeOptions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipment" xlink:href="cvm-20240930.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20240930.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxes" xlink:href="cvm-20240930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensation" xlink:href="cvm-20240930.xsd#EquityBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EmployeeBenefitPlan" xlink:href="cvm-20240930.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20240930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20240930.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20240930.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurements" xlink:href="cvm-20240930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShare" xlink:href="cvm-20240930.xsd#NetLossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20240930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20240930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsTables" xlink:href="cvm-20240930.xsd#WarrantsAndNonemployeeOptionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipmentTables" xlink:href="cvm-20240930.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20240930.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesTables" xlink:href="cvm-20240930.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationTables" xlink:href="cvm-20240930.xsd#EquityBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20240930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsTables" xlink:href="cvm-20240930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareTables" xlink:href="cvm-20240930.xsd#NetLossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="cvm-20240930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" xlink:href="cvm-20240930.xsd#WarrantsAndNonemployeeOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1" xlink:href="cvm-20240930.xsd#WarrantsAndNonemployeeOptionsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative" xlink:href="cvm-20240930.xsd#WarrantsAndNonemployeeOptionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipmentDetails" xlink:href="cvm-20240930.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="cvm-20240930.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20240930.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails1" xlink:href="cvm-20240930.xsd#PatentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20240930.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetails" xlink:href="cvm-20240930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetails1" xlink:href="cvm-20240930.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetailsNarrative" xlink:href="cvm-20240930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails" xlink:href="cvm-20240930.xsd#EquityBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails1" xlink:href="cvm-20240930.xsd#EquityBasedCompensationDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails2" xlink:href="cvm-20240930.xsd#EquityBasedCompensationDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails3" xlink:href="cvm-20240930.xsd#EquityBasedCompensationDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails4" xlink:href="cvm-20240930.xsd#EquityBasedCompensationDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetailsNarrative" xlink:href="cvm-20240930.xsd#EquityBasedCompensationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" xlink:href="cvm-20240930.xsd#EmployeeBenefitPlanDetailNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20240930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20240930.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20240930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cvm-20240930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20240930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsDetails" xlink:href="cvm-20240930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareDetails" xlink:href="cvm-20240930.xsd#NetLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareDetails1" xlink:href="cvm-20240930.xsd#NetLossPerCommonShareDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareDetailsNarrative" xlink:href="cvm-20240930.xsd#NetLossPerCommonShareDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:href="cvm-20240930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/BalanceSheets" xlink:title="000002 - Statement - BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaapInventoryNoncurrent" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapInventoryNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_AmountsDueToEmployeesCurrent" xlink:label="loc_cvmAmountsDueToEmployeesCurrent" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_cvmAmountsDueToEmployeesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
    <link:calculationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/BalanceSheetsParenthetical" xlink:title="000003 - Statement - BALANCE SHEETS (Parenthetical)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfOperations" xlink:title="000004 - Statement - STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ModificationOfWarrants" xlink:label="loc_cvmModificationOfWarrants" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_cvmModificationOfWarrants" xlink:type="arc" weight="1" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfStockholdersEquity" xlink:title="000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfCashFlows" xlink:title="000006 - Statement - STATEMENTS OF CASH FLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="loc_cvmCommonStockContributedToEmployeeBenefitPlan" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_cvmCommonStockContributedToEmployeeBenefitPlan" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInDepositOtherAssets" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDepositOtherAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaapProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
    <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/ORGANIZATION" xlink:title="000007 - Disclosure - ORGANIZATION" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/LIQUIDITY" xlink:title="000008 - Disclosure - LIQUIDITY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptions" xlink:title="000010 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipment" xlink:title="000011 - Disclosure - PROPERTY AND EQUIPMENT" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="000012 - Disclosure - PATENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxes" xlink:title="000013 - Disclosure - INCOME TAXES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensation" xlink:title="000014 - Disclosure - EQUITY-BASED COMPENSATION" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/EmployeeBenefitPlan" xlink:title="000015 - Disclosure - EMPLOYEE BENEFIT PLAN" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="000016 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="000017 - Disclosure - RELATED PARTY TRANSACTIONS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="000018 - Disclosure - STOCKHOLDERS EQUITY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurements" xlink:title="000019 - Disclosure - FAIR VALUE MEASUREMENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShare" xlink:title="000020 - Disclosure - NET LOSS PER COMMON SHARE" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="000021 - Disclosure - SUBSEQUENT EVENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsTables" xlink:title="000023 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipmentTables" xlink:title="000024 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="000025 - Disclosure - PATENTS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesTables" xlink:title="000026 - Disclosure - INCOME TAXES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationTables" xlink:title="000027 - Disclosure - EQUITY-BASED COMPENSATION (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsTables" xlink:title="000029 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareTables" xlink:title="000030 - Disclosure - NET LOSS PER COMMON SHARE (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" xlink:title="000032 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1" xlink:title="000033 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative" xlink:title="000034 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipmentDetails" xlink:title="000035 - Disclosure - PROPERTY AND EQUIPMENT (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="000036 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="000037 - Disclosure - PATENTS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails1" xlink:title="000038 - Disclosure - PATENTS (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="000039 - Disclosure - PATENTS (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetails" xlink:title="000040 - Disclosure - INCOME TAXES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetails1" xlink:title="000041 - Disclosure - INCOME TAXES (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetailsNarrative" xlink:title="000042 - Disclosure - INCOME TAXES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails" xlink:title="000043 - Disclosure - EQUITY-BASED COMPENSATION (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails1" xlink:title="000044 - Disclosure - EQUITY-BASED COMPENSATION (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails2" xlink:title="000045 - Disclosure - EQUITY-BASED COMPENSATION (Details 2)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails3" xlink:title="000046 - Disclosure - EQUITY-BASED COMPENSATION (Details 3)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails4" xlink:title="000047 - Disclosure - EQUITY-BASED COMPENSATION (Details 4)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetailsNarrative" xlink:title="000048 - Disclosure - EQUITY-BASED COMPENSATION (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" xlink:title="000049 - Disclosure - EMPLOYEE BENEFIT PLAN (Detail Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="000050 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000051 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000052 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000053 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="000054 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsDetails" xlink:title="000055 - Disclosure - FAIR VALUE MEASUREMENTS (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareDetails" xlink:title="000056 - Disclosure - NET LOSS PER COMMON SHARE (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareDetails1" xlink:title="000057 - Disclosure - NET LOSS PER COMMON SHARE (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareDetailsNarrative" xlink:title="000058 - Disclosure - NET LOSS PER COMMON SHARE (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:title="000059 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>cvm-20240930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 01/12/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20240930.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BalanceSheets" xlink:href="cvm-20240930.xsd#BalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BalanceSheetsParenthetical" xlink:href="cvm-20240930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfOperations" xlink:href="cvm-20240930.xsd#StatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfStockholdersEquity" xlink:href="cvm-20240930.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfCashFlows" xlink:href="cvm-20240930.xsd#StatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/ORGANIZATION" xlink:href="cvm-20240930.xsd#ORGANIZATION" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LIQUIDITY" xlink:href="cvm-20240930.xsd#LIQUIDITY" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="cvm-20240930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptions" xlink:href="cvm-20240930.xsd#WarrantsAndNonemployeeOptions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipment" xlink:href="cvm-20240930.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20240930.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxes" xlink:href="cvm-20240930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensation" xlink:href="cvm-20240930.xsd#EquityBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EmployeeBenefitPlan" xlink:href="cvm-20240930.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20240930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20240930.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20240930.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurements" xlink:href="cvm-20240930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShare" xlink:href="cvm-20240930.xsd#NetLossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20240930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20240930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsTables" xlink:href="cvm-20240930.xsd#WarrantsAndNonemployeeOptionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipmentTables" xlink:href="cvm-20240930.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20240930.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesTables" xlink:href="cvm-20240930.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationTables" xlink:href="cvm-20240930.xsd#EquityBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20240930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsTables" xlink:href="cvm-20240930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareTables" xlink:href="cvm-20240930.xsd#NetLossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="cvm-20240930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" xlink:href="cvm-20240930.xsd#WarrantsAndNonemployeeOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1" xlink:href="cvm-20240930.xsd#WarrantsAndNonemployeeOptionsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative" xlink:href="cvm-20240930.xsd#WarrantsAndNonemployeeOptionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipmentDetails" xlink:href="cvm-20240930.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="cvm-20240930.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20240930.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails1" xlink:href="cvm-20240930.xsd#PatentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20240930.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetails" xlink:href="cvm-20240930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetails1" xlink:href="cvm-20240930.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetailsNarrative" xlink:href="cvm-20240930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails" xlink:href="cvm-20240930.xsd#EquityBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails1" xlink:href="cvm-20240930.xsd#EquityBasedCompensationDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails2" xlink:href="cvm-20240930.xsd#EquityBasedCompensationDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails3" xlink:href="cvm-20240930.xsd#EquityBasedCompensationDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails4" xlink:href="cvm-20240930.xsd#EquityBasedCompensationDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetailsNarrative" xlink:href="cvm-20240930.xsd#EquityBasedCompensationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" xlink:href="cvm-20240930.xsd#EmployeeBenefitPlanDetailNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20240930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20240930.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20240930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cvm-20240930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20240930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsDetails" xlink:href="cvm-20240930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareDetails" xlink:href="cvm-20240930.xsd#NetLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareDetails1" xlink:href="cvm-20240930.xsd#NetLossPerCommonShareDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareDetailsNarrative" xlink:href="cvm-20240930.xsd#NetLossPerCommonShareDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:href="cvm-20240930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/BalanceSheets" xlink:title="000002 - Statement - BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_33e79a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_us-gaapAssetsAbstract_33e79a" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_34a05b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_us-gaapAssetsCurrentAbstract_34a05b" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_78e19d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_78e19d" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_606142" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_us-gaapPrepaidExpenseCurrent_606142" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_df53ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_us-gaapInventoryNet_df53ba" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent_0a19ff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_us-gaapDepositsAssetsCurrent_0a19ff" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_e95897" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_us-gaapAssetsCurrent_e95897" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset_d311b9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset_d311b9" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_738262" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_738262" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_fbccf6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_fbccf6" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_c99118" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_c99118" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent_56f41a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_us-gaapDepositsAssetsNoncurrent_56f41a" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaapInventoryNoncurrent_c3563f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_us-gaapInventoryNoncurrent_c3563f" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_b95646" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_us-gaapAssets_b95646" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_5adf39" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_5adf39" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_d08b41" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_d08b41" order="16" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_cecc1e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_d08b41" xlink:to="loc_us-gaapAccountsPayableCurrent_cecc1e" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_ed35cd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_d08b41" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_ed35cd" order="18" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_AmountsDueToEmployeesCurrent" xlink:label="loc_cvmAmountsDueToEmployeesCurrent_6db2ac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_d08b41" xlink:to="loc_cvmAmountsDueToEmployeesCurrent_6db2ac" order="19" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent_79bf98" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_d08b41" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent_79bf98" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_40e684" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_40e684" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_05886f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_us-gaapLiabilitiesCurrent_05886f" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent_18fb8d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent_18fb8d" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_289883" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_289883" order="24" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent_027513" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent_027513" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_312834" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_us-gaapLiabilities_312834" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_CommitmentsAndContingenciesDisclosuresAbstract" xlink:label="loc_cvmCommitmentsAndContingenciesDisclosuresAbstract_de700c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_cvmCommitmentsAndContingenciesDisclosuresAbstract_de700c" order="27" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_55b8bc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_us-gaapStockholdersEquityAbstract_55b8bc" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_1bcc35" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_55b8bc" xlink:to="loc_us-gaapPreferredStockValue_1bcc35" order="29" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_ca364f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_55b8bc" xlink:to="loc_us-gaapCommonStockValue_ca364f" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_64e9f1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_55b8bc" xlink:to="loc_us-gaapAdditionalPaidInCapital_64e9f1" order="31" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_55aa5c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_55b8bc" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_55aa5c" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_340917" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_55b8bc" xlink:to="loc_us-gaapStockholdersEquity_340917" order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_2ea0a6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_eb522c" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_2ea0a6" order="34" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/BalanceSheetsParenthetical" xlink:title="000003 - Statement - BALANCE SHEETS (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_5991c6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_050899" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_5991c6" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_050899" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_0a129b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_5991c6" xlink:to="loc_us-gaapCommonStockSharesAuthorized_0a129b" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_d8bcda" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_5991c6" xlink:to="loc_us-gaapCommonStockSharesIssued_d8bcda" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_3d5e40" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_5991c6" xlink:to="loc_us-gaapCommonStockSharesOutstanding_3d5e40" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_99fd2a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_5991c6" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_99fd2a" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_13e140" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_5991c6" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_13e140" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_5b6d3a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_5991c6" xlink:to="loc_us-gaapPreferredStockSharesIssued_5b6d3a" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_c2e2f1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_5991c6" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_c2e2f1" order="8" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfOperations" xlink:title="000004 - Statement - STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract_0b5b8c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_f1b3ac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_0b5b8c" xlink:to="loc_us-gaapOperatingExpensesAbstract_f1b3ac" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_a89032" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_f1b3ac" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_a89032" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_d4d324" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_f1b3ac" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_d4d324" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_ffe58f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_f1b3ac" xlink:to="loc_us-gaapOperatingExpenses_ffe58f" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_b66b4d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_f1b3ac" xlink:to="loc_us-gaapOperatingIncomeLoss_b66b4d" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_16975b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_f1b3ac" xlink:to="loc_us-gaapInterestExpense_16975b" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_f83740" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_f1b3ac" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_f83740" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_c5176e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_f1b3ac" xlink:to="loc_us-gaapProfitLoss_c5176e" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ModificationOfWarrants" xlink:label="loc_cvmModificationOfWarrants_bd3873" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_f1b3ac" xlink:to="loc_cvmModificationOfWarrants_bd3873" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_1a9a4a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_0b5b8c" xlink:to="loc_us-gaapNetIncomeLoss_1a9a4a" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_98ad5c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_0b5b8c" xlink:to="loc_us-gaapEarningsPerShareDiluted_98ad5c" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_5c369b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_0b5b8c" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_5c369b" order="12" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfStockholdersEquity" xlink:title="000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract_c236c2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_a90748" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract_c236c2" xlink:to="loc_us-gaapStatementTable_a90748" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_008937" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_a90748" xlink:to="loc_us-gaapStatementLineItems_008937" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis_4e8394" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_a90748" xlink:to="loc_us-gaapStatementEquityComponentsAxis_4e8394" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_d6d986" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis_4e8394" xlink:to="loc_us-gaapEquityComponentDomain_d6d986" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_9acaa3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_d6d986" xlink:to="loc_us-gaapCommonStockMember_9acaa3" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_3b97a9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_d6d986" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_3b97a9" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_6058a9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_d6d986" xlink:to="loc_us-gaapRetainedEarningsMember_6058a9" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_f14e2e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_008937" xlink:to="loc_us-gaapSharesIssued_f14e2e" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_c343eb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_008937" xlink:to="loc_us-gaapStockholdersEquity_c343eb" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="loc_cvmStockIssuedDuringPeriodSharesStockWarrantsExercised_d44225" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_008937" xlink:to="loc_cvmStockIssuedDuringPeriodSharesStockWarrantsExercised_d44225" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="loc_cvmStockIssuedDuringPeriodValueStockWarrantsExercised_9468b6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_008937" xlink:to="loc_cvmStockIssuedDuringPeriodValueStockWarrantsExercised_9468b6" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_a38a47" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_008937" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan_a38a47" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_6dc61d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_008937" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan_6dc61d" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_7373ae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_008937" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_7373ae" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_ee4b90" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_008937" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_ee4b90" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_0ae01e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_008937" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_0ae01e" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_95bdc0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_008937" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_95bdc0" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IncentiveStockForfeitedShares" xlink:label="loc_cvmIncentiveStockForfeitedShares_98c83e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_008937" xlink:to="loc_cvmIncentiveStockForfeitedShares_98c83e" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IncentiveStockForfeitedAmount" xlink:label="loc_cvmIncentiveStockForfeitedAmount_afe2a8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_008937" xlink:to="loc_cvmIncentiveStockForfeitedAmount_afe2a8" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_f5ccf9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_008937" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_f5ccf9" order="13" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_CostIncurredInIssuanceOfStock" xlink:label="loc_cvmCostIncurredInIssuanceOfStock_c49e6c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_008937" xlink:to="loc_cvmCostIncurredInIssuanceOfStock_c49e6c" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_71e2ea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_008937" xlink:to="loc_us-gaapProfitLoss_71e2ea" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsShares" xlink:label="loc_cvmProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsShares_f5734c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_008937" xlink:to="loc_cvmProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsShares_f5734c" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount" xlink:label="loc_cvmProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount_af54e1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_008937" xlink:to="loc_cvmProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount_af54e1" order="17" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ExerciseOfPreFundedWarrantsShares" xlink:label="loc_cvmExerciseOfPreFundedWarrantsShares_eb6ca9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_008937" xlink:to="loc_cvmExerciseOfPreFundedWarrantsShares_eb6ca9" order="18" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ExerciseOfPreFundedWarrantsAmount" xlink:label="loc_cvmExerciseOfPreFundedWarrantsAmount_f51363" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_008937" xlink:to="loc_cvmExerciseOfPreFundedWarrantsAmount_f51363" order="19" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_PurchaseOfStockByOfficersAndDirectorsShares" xlink:label="loc_cvmPurchaseOfStockByOfficersAndDirectorsShares_8a12e7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_008937" xlink:to="loc_cvmPurchaseOfStockByOfficersAndDirectorsShares_8a12e7" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_PurchaseOfStockByOfficersAndDirectorsAmount" xlink:label="loc_cvmPurchaseOfStockByOfficersAndDirectorsAmount_87e6db" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_008937" xlink:to="loc_cvmPurchaseOfStockByOfficersAndDirectorsAmount_87e6db" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_108898" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_008937" xlink:to="loc_us-gaapSharesIssued_108898" order="22" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_6b722f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_008937" xlink:to="loc_us-gaapStockholdersEquity_6b722f" order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfCashFlows" xlink:title="000006 - Statement - STATEMENTS OF CASH FLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract_e3d506" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_7d9fc4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e3d506" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_7d9fc4" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_1c2470" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_7d9fc4" xlink:to="loc_us-gaapProfitLoss_1c2470" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314da8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_7d9fc4" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314da8" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_54197e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314da8" xlink:to="loc_us-gaapDepreciationAndAmortization_54197e" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense_9b5d6f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314da8" xlink:to="loc_us-gaapOtherNoncashExpense_9b5d6f" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_4d69f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314da8" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_4d69f4" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_c5a8a8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314da8" xlink:to="loc_us-gaapShareBasedCompensation_c5a8a8" order="7" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_CommonStockContributedToEmployeeBenefitPlan" xlink:label="loc_cvmCommonStockContributedToEmployeeBenefitPlan_ea376f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314da8" xlink:to="loc_cvmCommonStockContributedToEmployeeBenefitPlan_ea376f" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_152b31" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314da8" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_152b31" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense_c55ec3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_152b31" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense_c55ec3" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories_fe59ef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_152b31" xlink:to="loc_us-gaapIncreaseDecreaseInInventories_fe59ef" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInDepositOtherAssets_a656a2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_152b31" xlink:to="loc_us-gaapIncreaseDecreaseInDepositOtherAssets_a656a2" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_ed4389" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract_152b31" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_ed4389" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable_67a0f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_ed4389" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable_67a0f2" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_31c8a6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_ed4389" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_31c8a6" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities_3d61a5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_ed4389" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities_3d61a5" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_fbff03" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract_ed4389" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_fbff03" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_9947ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e3d506" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_9947ec" order="18" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_67709a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_9947ec" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_67709a" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets_64d0cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_9947ec" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets_64d0cc" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_f1006b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_9947ec" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_f1006b" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_c5a507" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e3d506" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_c5a507" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_1493ee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_c5a507" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_1493ee" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_7be7e8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_c5a507" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_7be7e8" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaapProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_bd3587" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_c5a507" xlink:to="loc_us-gaapProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_bd3587" order="25" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_468db8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_c5a507" xlink:to="loc_us-gaapProceedsFromWarrantExercises_468db8" order="26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations_e79c8d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e3d506" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations_e79c8d" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt_537ff4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e3d506" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt_537ff4" order="28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt_ad83c2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e3d506" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt_ad83c2" order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_cd258b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e3d506" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_cd258b" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_532805" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e3d506" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_532805" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5031a3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e3d506" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5031a3" order="32" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9a928c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e3d506" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9a928c" order="33" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a44f8a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e3d506" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a44f8a" order="34" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities" xlink:label="loc_cvmPropertyAndEquipmentPurchasesIncludedInCurrentLiabilities_bed22d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a44f8a" xlink:to="loc_cvmPropertyAndEquipmentPurchasesIncludedInCurrentLiabilities_bed22d" order="35" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_CapitalizedIntangibleAssetsCostsIncludedInCurrentLiabilities" xlink:label="loc_cvmCapitalizedIntangibleAssetsCostsIncludedInCurrentLiabilities_12275f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a44f8a" xlink:to="loc_cvmCapitalizedIntangibleAssetsCostsIncludedInCurrentLiabilities_12275f" order="36" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_PurchaseOfAssetsUnderFinanceLeases" xlink:label="loc_cvmPurchaseOfAssetsUnderFinanceLeases_92b03c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a44f8a" xlink:to="loc_cvmPurchaseOfAssetsUnderFinanceLeases_92b03c" order="37" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_FinanceLeaseObligationIncludedInAccountsPayable" xlink:label="loc_cvmFinanceLeaseObligationIncludedInAccountsPayable_71ba81" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a44f8a" xlink:to="loc_cvmFinanceLeaseObligationIncludedInAccountsPayable_71ba81" order="38" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ConsultingServicesPaidWithIssuanceOfCommonStock" xlink:label="loc_cvmConsultingServicesPaidWithIssuanceOfCommonStock_97ae5a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a44f8a" xlink:to="loc_cvmConsultingServicesPaidWithIssuanceOfCommonStock_97ae5a" order="39" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_FinancingCostsIncludedInCurrentLiabilities" xlink:label="loc_cvmFinancingCostsIncludedInCurrentLiabilities_282cbc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a44f8a" xlink:to="loc_cvmFinancingCostsIncludedInCurrentLiabilities_282cbc" order="40" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_AccruedConsultingServicesToBePaidUnderShareBasedPaymentArrangement" xlink:label="loc_cvmAccruedConsultingServicesToBePaidUnderShareBasedPaymentArrangement_213cc3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a44f8a" xlink:to="loc_cvmAccruedConsultingServicesToBePaidUnderShareBasedPaymentArrangement_213cc3" order="41" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract_387fa4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_e3d506" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract_387fa4" order="42" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet_b7f01d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_387fa4" xlink:to="loc_us-gaapInterestPaidNet_b7f01d" order="43" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/ORGANIZATION" xlink:title="000007 - Disclosure - ORGANIZATION">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2cee8d" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b7c5a6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2cee8d" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b7c5a6" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/LIQUIDITY" xlink:title="000008 - Disclosure - LIQUIDITY">
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_LIQUIDITYAbstract" xlink:label="loc_cvmLIQUIDITYAbstract_eeb830" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_LiquidityDisclosureTextblock" xlink:label="loc_cvmLiquidityDisclosureTextblock_001add" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmLIQUIDITYAbstract_eeb830" xlink:to="loc_cvmLiquidityDisclosureTextblock_001add" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_d6d61c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock_25abfa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_d6d61c" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock_25abfa" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptions" xlink:title="000010 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS">
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WarrantsAndNonemployeeOptionsAbstract" xlink:label="loc_cvmWarrantsAndNonemployeeOptionsAbstract_742f66" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WarrantsAndNonEmployeeOptionsDisclosureTextBlock" xlink:label="loc_cvmWarrantsAndNonEmployeeOptionsDisclosureTextBlock_2c2754" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmWarrantsAndNonemployeeOptionsAbstract_742f66" xlink:to="loc_cvmWarrantsAndNonEmployeeOptionsDisclosureTextBlock_2c2754" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipment" xlink:title="000011 - Disclosure - PROPERTY AND EQUIPMENT">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_900036" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock_581a32" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_900036" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock_581a32" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="000012 - Disclosure - PATENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_cf89da" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock_b797e5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_cf89da" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock_b797e5" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxes" xlink:title="000013 - Disclosure - INCOME TAXES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_16e765" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock_50b316" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_16e765" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock_50b316" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensation" xlink:title="000014 - Disclosure - EQUITY-BASED COMPENSATION">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19d7a4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f51a98" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_19d7a4" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f51a98" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/EmployeeBenefitPlan" xlink:title="000015 - Disclosure - EMPLOYEE BENEFIT PLAN">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationAbstract_aa4758" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock_ee886a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationAbstract_aa4758" xlink:to="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock_ee886a" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="000016 - Disclosure - COMMITMENTS AND CONTINGENCIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_970c08" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_440454" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_970c08" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock_440454" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="000017 - Disclosure - RELATED PARTY TRANSACTIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_99664c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_c5c3e5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_99664c" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_c5c3e5" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="000018 - Disclosure - STOCKHOLDERS EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_bf4563" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_684533" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_bf4563" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_684533" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurements" xlink:title="000019 - Disclosure - FAIR VALUE MEASUREMENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_5dd5d7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock_7983f7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_5dd5d7" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock_7983f7" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShare" xlink:title="000020 - Disclosure - NET LOSS PER COMMON SHARE">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_b97d94" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock_d5ec91" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_b97d94" xlink:to="loc_us-gaapEarningsPerShareTextBlock_d5ec91" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="000021 - Disclosure - SUBSEQUENT EVENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_1b4d28" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock_ca674e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_1b4d28" xlink:to="loc_us-gaapSubsequentEventsTextBlock_ca674e" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_c1f1ab" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock_20b60e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c1f1ab" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock_20b60e" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_b1b7e7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c1f1ab" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock_b1b7e7" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_9869d3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c1f1ab" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock_9869d3" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock_6d6896" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c1f1ab" xlink:to="loc_us-gaapInventoryPolicyTextBlock_6d6896" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy_44620a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c1f1ab" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy_44620a" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock_ebd1cf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c1f1ab" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock_ebd1cf" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_5152bc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c1f1ab" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy_5152bc" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy_8cd597" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c1f1ab" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy_8cd597" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock_d35152" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c1f1ab" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock_d35152" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk_a055bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c1f1ab" xlink:to="loc_us-gaapConcentrationRiskCreditRisk_a055bf" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock_6de744" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c1f1ab" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock_6de744" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_968bc9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c1f1ab" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_968bc9" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates_7ef1dc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c1f1ab" xlink:to="loc_us-gaapUseOfEstimates_7ef1dc" order="13" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_RecentlyAdoptedAccountingStandardsPolicyPolicyTextBlock" xlink:label="loc_cvmRecentlyAdoptedAccountingStandardsPolicyPolicyTextBlock_ebbc44" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c1f1ab" xlink:to="loc_cvmRecentlyAdoptedAccountingStandardsPolicyPolicyTextBlock_ebbc44" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_37e185" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_c1f1ab" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock_37e185" order="15" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsTables" xlink:title="000023 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Tables)">
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WarrantsAndNonemployeeOptionsAbstract" xlink:label="loc_cvmWarrantsAndNonemployeeOptionsAbstract_1c3382" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_03f8ff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmWarrantsAndNonemployeeOptionsAbstract_1c3382" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_03f8ff" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock" xlink:label="loc_cvmScheduleOfEquityWarrantsWereExercisedTableTextBlock_021230" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmWarrantsAndNonemployeeOptionsAbstract_1c3382" xlink:to="loc_cvmScheduleOfEquityWarrantsWereExercisedTableTextBlock_021230" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipmentTables" xlink:title="000024 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_c3f00e" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock_d16cb2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_c3f00e" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock_d16cb2" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="000025 - Disclosure - PATENTS (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_9a30a0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_0a4811" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_9a30a0" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_0a4811" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_f3a017" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_9a30a0" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_f3a017" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesTables" xlink:title="000026 - Disclosure - INCOME TAXES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_5933f3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_466a99" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_5933f3" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_466a99" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3c80d8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_5933f3" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3c80d8" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationTables" xlink:title="000027 - Disclosure - EQUITY-BASED COMPENSATION (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2d2bad" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_467df5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2d2bad" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_467df5" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_412a85" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2d2bad" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_412a85" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock" xlink:label="loc_cvmScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock_1c8d1e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2d2bad" xlink:to="loc_cvmScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock_1c8d1e" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_7990a0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2d2bad" xlink:to="loc_us-gaapScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_7990a0" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_37c7d4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2d2bad" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_37c7d4" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_945e55" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock_8fb649" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_945e55" xlink:to="loc_us-gaapFinanceLeaseLiabilityMaturityTableTextBlock_8fb649" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock_332ea8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_945e55" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock_332ea8" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsTables" xlink:title="000029 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_8f7633" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_b283da" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_8f7633" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_b283da" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareTables" xlink:title="000030 - Disclosure - NET LOSS PER COMMON SHARE (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_632cdb" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_63567a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_632cdb" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_63567a" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5d0b8c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_632cdb" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5d0b8c" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract_d1bee9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_f0e095" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract_d1bee9" xlink:to="loc_us-gaapStatementTable_f0e095" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_8fa0ef" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f0e095" xlink:to="loc_us-gaapStatementLineItems_8fa0ef" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_a533b5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_f0e095" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_a533b5" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_69b948" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_a533b5" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_69b948" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_331d48" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_69b948" xlink:to="loc_us-gaapPatentsMember_331d48" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_FiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_cvmFiniteLivedIntangibleAssetsUsefulLife_35fd48" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8fa0ef" xlink:to="loc_cvmFiniteLivedIntangibleAssetsUsefulLife_35fd48" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_4e08db" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8fa0ef" xlink:to="loc_us-gaapCashFDICInsuredAmount_4e08db" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" xlink:title="000032 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WarrantsAndNonemployeeOptionsAbstract" xlink:label="loc_cvmWarrantsAndNonemployeeOptionsAbstract_ea259e" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_eb9465" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmWarrantsAndNonemployeeOptionsAbstract_ea259e" xlink:to="loc_us-gaapStatementTable_eb9465" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_216805" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_eb9465" xlink:to="loc_us-gaapStatementLineItems_216805" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis_b76606" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_eb9465" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis_b76606" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_4d8ac3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis_b76606" xlink:to="loc_us-gaapDerivativeContractTypeDomain_4d8ac3" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_b62ca1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_eb9465" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_b62ca1" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_4bd3d8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_b62ca1" xlink:to="loc_us-gaapRelatedPartyDomain_4bd3d8" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_adcc3a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_eb9465" xlink:to="loc_us-gaapPlanNameAxis_adcc3a" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_3143ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_adcc3a" xlink:to="loc_us-gaapPlanNameDomain_3143ce" order="60" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesYMember" xlink:label="loc_cvmSeriesYMember_5a9ef8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_4d8ac3" xlink:to="loc_cvmSeriesYMember_5a9ef8" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesMMMember" xlink:label="loc_cvmSeriesMMMember_f6350a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_4d8ac3" xlink:to="loc_cvmSeriesMMMember_f6350a" order="62" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesNNMember" xlink:label="loc_cvmSeriesNNMember_1ff115" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_4d8ac3" xlink:to="loc_cvmSeriesNNMember_1ff115" order="63" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember_48eb25" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_4d8ac3" xlink:to="loc_cvmSeriesRRMember_48eb25" order="64" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember_0b6dcc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_4bd3d8" xlink:to="loc_cvmConsultantsMember_0b6dcc" order="65" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesNMember" xlink:label="loc_cvmSeriesNMember_f83085" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_4d8ac3" xlink:to="loc_cvmSeriesNMember_f83085" order="66" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesUUMember" xlink:label="loc_cvmSeriesUUMember_da0a08" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_4d8ac3" xlink:to="loc_cvmSeriesUUMember_da0a08" order="67" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesXMember" xlink:label="loc_cvmSeriesXMember_f6938d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_4d8ac3" xlink:to="loc_cvmSeriesXMember_f6938d" order="68" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_BottomMember" xlink:label="loc_cvmBottomMember_9cd092" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_3143ce" xlink:to="loc_cvmBottomMember_9cd092" order="69" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ConsultantsOneMember" xlink:label="loc_cvmConsultantsOneMember_138981" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_4bd3d8" xlink:to="loc_cvmConsultantsOneMember_138981" order="70" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_TopMember" xlink:label="loc_cvmTopMember_3e9af2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_3143ce" xlink:to="loc_cvmTopMember_3e9af2" order="71" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_Issuedate2" xlink:label="loc_cvmIssuedate2_0c2769" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_216805" xlink:to="loc_cvmIssuedate2_0c2769" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SharesIssuableUponExerciseOfwarrant" xlink:label="loc_cvmSharesIssuableUponExerciseOfwarrant_9e1320" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_216805" xlink:to="loc_cvmSharesIssuableUponExerciseOfwarrant_9e1320" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ExercisePrice" xlink:label="loc_cvmExercisePrice_9229dc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_216805" xlink:to="loc_cvmExercisePrice_9229dc" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ExpirationDate1" xlink:label="loc_cvmExpirationDate1_6529aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_216805" xlink:to="loc_cvmExpirationDate1_6529aa" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1" xlink:title="000033 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details 1)">
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WarrantsAndNonemployeeOptionsAbstract" xlink:label="loc_cvmWarrantsAndNonemployeeOptionsAbstract_7efe67" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_c337ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmWarrantsAndNonemployeeOptionsAbstract_7efe67" xlink:to="loc_us-gaapStatementTable_c337ce" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_76aaa6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c337ce" xlink:to="loc_us-gaapStatementLineItems_76aaa6" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis_044224" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c337ce" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis_044224" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_05433e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis_044224" xlink:to="loc_us-gaapDerivativeContractTypeDomain_05433e" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember_27cb20" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_05433e" xlink:to="loc_cvmSeriesRRMember_27cb20" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesSSMember" xlink:label="loc_cvmSeriesSSMember_cd5db1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_05433e" xlink:to="loc_cvmSeriesSSMember_cd5db1" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_EquityWarrantsExercised" xlink:label="loc_cvmEquityWarrantsExercised_be58cd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_76aaa6" xlink:to="loc_cvmEquityWarrantsExercised_be58cd" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ProceedsFromEquityWarrantsExercised" xlink:label="loc_cvmProceedsFromEquityWarrantsExercised_216f7b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_76aaa6" xlink:to="loc_cvmProceedsFromEquityWarrantsExercised_216f7b" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_EquityWarrantsExercisePrice" xlink:label="loc_cvmEquityWarrantsExercisePrice_d97192" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_76aaa6" xlink:to="loc_cvmEquityWarrantsExercisePrice_d97192" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative" xlink:title="000034 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WarrantsAndNonemployeeOptionsAbstract" xlink:label="loc_cvmWarrantsAndNonemployeeOptionsAbstract_038996" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_5ab5d1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cvmWarrantsAndNonemployeeOptionsAbstract_038996" xlink:to="loc_us-gaapStatementTable_5ab5d1" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_aa2c5c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5ab5d1" xlink:to="loc_us-gaapStatementLineItems_aa2c5c" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis_b314c6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5ab5d1" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis_b314c6" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_efc103" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis_b314c6" xlink:to="loc_us-gaapDerivativeContractTypeDomain_efc103" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_61f864" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5ab5d1" xlink:to="loc_us-gaapPlanNameAxis_61f864" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_1bba32" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_61f864" xlink:to="loc_us-gaapPlanNameDomain_1bba32" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_5c4239" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5ab5d1" xlink:to="loc_us-gaapAwardTypeAxis_5c4239" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d536aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_5c4239" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d536aa" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_f954fc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5ab5d1" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_f954fc" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_e6c779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_f954fc" xlink:to="loc_us-gaapRelatedPartyDomain_e6c779" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis_28c379" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5ab5d1" xlink:to="loc_us-gaapAwardDateAxis_28c379" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_5d029a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis_28c379" xlink:to="loc_us-gaapAwardDateDomain_5d029a" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7a1735" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5ab5d1" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7a1735" order="90" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_bf2822" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7a1735" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_bf2822" order="90" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember_894434" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain_efc103" xlink:to="loc_cvmSeriesRRMember_894434" order="91" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ConsultingAgreementsMember" xlink:label="loc_cvmConsultingAgreementsMember_dcc068" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_1bba32" xlink:to="loc_cvmConsultingAgreementsMember_dcc068" order="92" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="loc_cvmNonQualifiedStockOptionsPlansMember_2a0a01" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d536aa" xlink:to="loc_cvmNonQualifiedStockOptionsPlansMember_2a0a01" order="93" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ConsultantMember" xlink:label="loc_cvmConsultantMember_c73c2a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_e6c779" xlink:to="loc_cvmConsultantMember_c73c2a" order="94" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_TwoSeptemberTwoThousendTwentyFourMember" xlink:label="loc_cvmTwoSeptemberTwoThousendTwentyFourMember_f04c50" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_5d029a" xlink:to="loc_cvmTwoSeptemberTwoThousendTwentyFourMember_f04c50" order="95" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_TwoSeptemberTwoThousendTwentyFiveMember" xlink:label="loc_cvmTwoSeptemberTwoThousendTwentyFiveMember_0a70bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain_5d029a" xlink:to="loc_cvmTwoSeptemberTwoThousendTwentyFiveMember_0a70bf" order="96" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_RestrictedStocksMember" xlink:label="loc_cvmRestrictedStocksMember_d90af5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_bf2822" xlink:to="loc_cvmRestrictedStocksMember_d90af5" order="97" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember_4063f8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_e6c779" xlink:to="loc_cvmConsultantsMember_4063f8" order="98" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_BottomMember" xlink:label="loc_cvmBottomMember_451859" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_1bba32" xlink:to="loc_cvmBottomMember_451859" order="99" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_TopMember" xlink:label="loc_cvmTopMember_dc2668" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_1bba32" xlink:to="loc_cvmTopMember_dc2668" order="100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_StockIssuedDuringPeriodToPurchaseCommonStock" xlink:label="loc_cvmStockIssuedDuringPeriodToPurchaseCommonStock_b9e4c1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_aa2c5c" xlink:to="loc_cvmStockIssuedDuringPeriodToPurchaseCommonStock_b9e4c1" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_StockOptionExercisePrice" xlink:label="loc_cvmStockOptionExercisePrice_fe1ec6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_aa2c5c" xlink:to="loc_cvmStockOptionExercisePrice_fe1ec6" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_VestedOptions" xlink:label="loc_cvmVestedOptions_3f46df" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_aa2c5c" xlink:to="loc_cvmVestedOptions_3f46df" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IssuanceOfOptionsForServices" xlink:label="loc_cvmIssuanceOfOptionsForServices_5fb530" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_aa2c5c" xlink:to="loc_cvmIssuanceOfOptionsForServices_5fb530" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IncrementalCostDeemedDividend" xlink:label="loc_cvmIncrementalCostDeemedDividend_7b70d4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_aa2c5c" xlink:to="loc_cvmIncrementalCostDeemedDividend_7b70d4" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_CommonStockIssuedForServiceShares" xlink:label="loc_cvmCommonStockIssuedForServiceShares_967870" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_aa2c5c" xlink:to="loc_cvmCommonStockIssuedForServiceShares_967870" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_EquityWarrantsExercised" xlink:label="loc_cvmEquityWarrantsExercised_cedc3e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_aa2c5c" xlink:to="loc_cvmEquityWarrantsExercised_cedc3e" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c9e93e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_aa2c5c" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c9e93e" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses_f29b49" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_aa2c5c" xlink:to="loc_us-gaapCostsAndExpenses_f29b49" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_PrepaidExpenses" xlink:label="loc_cvmPrepaidExpenses_76c38a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_aa2c5c" xlink:to="loc_cvmPrepaidExpenses_76c38a" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_4cd5a5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_aa2c5c" xlink:to="loc_us-gaapSharePrice_4cd5a5" order="11" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipmentDetails" xlink:title="000035 - Disclosure - PROPERTY AND EQUIPMENT (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_c226b0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FixturesAndEquipmentGross" xlink:label="loc_us-gaapFixturesAndEquipmentGross_a41c25" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_c226b0" xlink:to="loc_us-gaapFixturesAndEquipmentGross_a41c25" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross_abf53f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_c226b0" xlink:to="loc_us-gaapFurnitureAndFixturesGross_abf53f" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross_2e1668" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_c226b0" xlink:to="loc_us-gaapLeaseholdImprovementsGross_2e1668" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_49a7a3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_c226b0" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_49a7a3" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8c68ab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_c226b0" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8c68ab" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_1cf7b8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_c226b0" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_1cf7b8" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="000036 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_193915" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization_2b9fe4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_193915" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization_2b9fe4" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="000037 - Disclosure - PATENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_4af841" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="loc_us-gaapFiniteLivedPatentsGross_682edc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_4af841" xlink:to="loc_us-gaapFiniteLivedPatentsGross_682edc" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_AccumulatedAmortization" xlink:label="loc_cvmAccumulatedAmortization_c08bf5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_4af841" xlink:to="loc_cvmAccumulatedAmortization_c08bf5" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaapOtherIntangibleAssetsNet_a36236" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_4af841" xlink:to="loc_us-gaapOtherIntangibleAssetsNet_a36236" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails1" xlink:title="000038 - Disclosure - PATENTS (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_c61a7c" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_59f6aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_c61a7c" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_59f6aa" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a58ae3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_c61a7c" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a58ae3" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_ecaa59" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_c61a7c" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_ecaa59" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8c4e12" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_c61a7c" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8c4e12" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0fd12d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_c61a7c" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0fd12d" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_216f8f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_c61a7c" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_216f8f" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_TotalFiniteLivedIntangibleAssetsAmortizationExpense" xlink:label="loc_cvmTotalFiniteLivedIntangibleAssetsAmortizationExpense_d0f56c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_c61a7c" xlink:to="loc_cvmTotalFiniteLivedIntangibleAssetsAmortizationExpense_d0f56c" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="000039 - Disclosure - PATENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_904773" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_PatentsWeightedAverageAmortizationPeriod" xlink:label="loc_cvmPatentsWeightedAverageAmortizationPeriod_ecf6fa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_904773" xlink:to="loc_cvmPatentsWeightedAverageAmortizationPeriod_ecf6fa" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_c03da2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_904773" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_c03da2" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetails" xlink:title="000040 - Disclosure - INCOME TAXES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_d07f52" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_b0cd6a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_d07f52" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_b0cd6a" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd" xlink:label="loc_cvmDeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd_d37dcd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_d07f52" xlink:to="loc_cvmDeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd_d37dcd" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c1f2df" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_d07f52" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c1f2df" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_LeaseLiabilities" xlink:label="loc_cvmLeaseLiabilities_cc20f1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_d07f52" xlink:to="loc_cvmLeaseLiabilities_cc20f1" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_7968e5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_d07f52" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_7968e5" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_e68325" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_d07f52" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_e68325" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment_33fcc7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_d07f52" xlink:to="loc_us-gaapDeferredTaxAssetsPropertyPlantAndEquipment_33fcc7" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross_519d33" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_d07f52" xlink:to="loc_us-gaapDeferredTaxAssetsGross_519d33" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_RightOfUseAssets" xlink:label="loc_cvmRightOfUseAssets_8aa5ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_d07f52" xlink:to="loc_cvmRightOfUseAssets_8aa5ec" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment_4e71d3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_d07f52" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment_4e71d3" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities_dc9ada" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_d07f52" xlink:to="loc_us-gaapDeferredTaxLiabilities_dc9ada" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet_6b5b84" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_d07f52" xlink:to="loc_us-gaapDeferredTaxAssetsNet_6b5b84" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_a6fd34" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_d07f52" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_a6fd34" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet_ab7f03" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_d07f52" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet_ab7f03" order="14" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetails1" xlink:title="000041 - Disclosure - INCOME TAXES (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_b66332" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_fe4223" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_b66332" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_fe4223" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_3da8af" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_b66332" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_3da8af" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_c3bf18" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_b66332" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_c3bf18" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments_c01839" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_b66332" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments_c01839" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense_e63a98" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_b66332" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense_e63a98" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6faedb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_b66332" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6faedb" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_eb828e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_b66332" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_eb828e" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetailsNarrative" xlink:title="000042 - Disclosure - INCOME TAXES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_b08192" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_b6e62a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract_b08192" xlink:to="loc_us-gaapStatementTable_b6e62a" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_fdb20e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_b6e62a" xlink:to="loc_us-gaapStatementLineItems_fdb20e" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis_5112d3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_b6e62a" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis_5112d3" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain_5a05fd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis_5112d3" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain_5a05fd" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IncomeTaxMember" xlink:label="loc_cvmIncomeTaxMember_a5f722" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain_5a05fd" xlink:to="loc_cvmIncomeTaxMember_a5f722" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ResearchAndDevelopmentCredit" xlink:label="loc_cvmResearchAndDevelopmentCredit_d6ad34" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fdb20e" xlink:to="loc_cvmResearchAndDevelopmentCredit_d6ad34" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_9a1dba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fdb20e" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards_9a1dba" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ResearchAndDevelopmentCreditDescription" xlink:label="loc_cvmResearchAndDevelopmentCreditDescription_f1de15" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fdb20e" xlink:to="loc_cvmResearchAndDevelopmentCreditDescription_f1de15" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_CumulativeChangeInOwnershipPercentage" xlink:label="loc_cvmCumulativeChangeInOwnershipPercentage_43a021" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fdb20e" xlink:to="loc_cvmCumulativeChangeInOwnershipPercentage_43a021" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="loc_us-gaapTaxCreditCarryforwardDescription_82a29b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fdb20e" xlink:to="loc_us-gaapTaxCreditCarryforwardDescription_82a29b" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet_e70360" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_fdb20e" xlink:to="loc_us-gaapDeferredTaxAssetsNet_e70360" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails" xlink:title="000043 - Disclosure - EQUITY-BASED COMPENSATION (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4c69e4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_86acda" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4c69e4" xlink:to="loc_us-gaapStatementTable_86acda" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_8dc7ac" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_86acda" xlink:to="loc_us-gaapStatementLineItems_8dc7ac" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis_2d38bd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_86acda" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis_2d38bd" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_5a0df2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis_2d38bd" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_5a0df2" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_NonEmployeesMember" xlink:label="loc_cvmNonEmployeesMember_48a26b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain_5a0df2" xlink:to="loc_cvmNonEmployeesMember_48a26b" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_EmployeesMember" xlink:label="loc_cvmEmployeesMember_6f97d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain_5a0df2" xlink:to="loc_cvmEmployeesMember_6f97d0" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_8f566f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8dc7ac" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_8f566f" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails1" xlink:title="000044 - Disclosure - EQUITY-BASED COMPENSATION (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e25c66" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6c0455" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e25c66" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_6c0455" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_b1b7b4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e25c66" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_b1b7b4" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_303bd2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e25c66" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_303bd2" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_6776fd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e25c66" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_6776fd" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ExpectedLifeOfOptionsMin1" xlink:label="loc_cvmExpectedLifeOfOptionsMin1_9a86b5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e25c66" xlink:to="loc_cvmExpectedLifeOfOptionsMin1_9a86b5" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ExpectedLifeOfOptionsMax" xlink:label="loc_cvmExpectedLifeOfOptionsMax_a3331f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e25c66" xlink:to="loc_cvmExpectedLifeOfOptionsMax_a3331f" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_fecf98" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e25c66" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_fecf98" order="7" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails2" xlink:title="000045 - Disclosure - EQUITY-BASED COMPENSATION (Details 2)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e88025" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_2a8f37" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e88025" xlink:to="loc_us-gaapStatementTable_2a8f37" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_9a5ed7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_2a8f37" xlink:to="loc_us-gaapStatementLineItems_9a5ed7" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis_3a1447" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_2a8f37" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis_3a1447" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_e563b9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis_3a1447" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_e563b9" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis_7dcf59" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_2a8f37" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis_7dcf59" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_fec91a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis_7dcf59" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_fec91a" order="30" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_OutstandingMember" xlink:label="loc_cvmOutstandingMember_4ac142" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_e563b9" xlink:to="loc_cvmOutstandingMember_4ac142" order="31" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ExercisableMember" xlink:label="loc_cvmExercisableMember_3abc3c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain_fec91a" xlink:to="loc_cvmExercisableMember_3abc3c" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9563d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9a5ed7" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9563d6" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_401a01" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9a5ed7" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_401a01" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_796e21" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9a5ed7" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_796e21" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_f04133" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9a5ed7" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_f04133" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0e6eb4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9a5ed7" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0e6eb4" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b4845c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9a5ed7" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b4845c" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_df192b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9a5ed7" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_df192b" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ecb390" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9a5ed7" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ecb390" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b471a4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9a5ed7" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b471a4" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_b1c23d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9a5ed7" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_b1c23d" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7be838" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9a5ed7" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7be838" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9173f7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9a5ed7" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9173f7" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e27bb6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9a5ed7" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e27bb6" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_41563a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9a5ed7" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_41563a" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_87b203" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9a5ed7" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_87b203" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_NumberOfOptionsVested" xlink:label="loc_cvmNumberOfOptionsVested_1121a7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9a5ed7" xlink:to="loc_cvmNumberOfOptionsVested_1121a7" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_NumberOfOptionsExercised" xlink:label="loc_cvmNumberOfOptionsExercised_f2d64c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9a5ed7" xlink:to="loc_cvmNumberOfOptionsExercised_f2d64c" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_NumberOfOptions" xlink:label="loc_cvmNumberOfOptions_bd70c5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9a5ed7" xlink:to="loc_cvmNumberOfOptions_bd70c5" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WeightedAverageExercisePriceVested" xlink:label="loc_cvmWeightedAverageExercisePriceVested_4d617e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9a5ed7" xlink:to="loc_cvmWeightedAverageExercisePriceVested_4d617e" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WeightedAverageExercisePriceExpired" xlink:label="loc_cvmWeightedAverageExercisePriceExpired_cf38c5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9a5ed7" xlink:to="loc_cvmWeightedAverageExercisePriceExpired_cf38c5" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" xlink:label="loc_cvmWeightedAverageRemainingContractualLifeInYearsOutstandingBeginning_7cabbb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9a5ed7" xlink:to="loc_cvmWeightedAverageRemainingContractualLifeInYearsOutstandingBeginning_7cabbb" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" xlink:label="loc_cvmWeightedAverageRemainingContractualLifeInYearsOutstandingEnding_c1d79b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_9a5ed7" xlink:to="loc_cvmWeightedAverageRemainingContractualLifeInYearsOutstandingEnding_c1d79b" order="22" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails3" xlink:title="000046 - Disclosure - EQUITY-BASED COMPENSATION (Details 3)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd79dd" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6f19cc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd79dd" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6f19cc" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6f00dc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd79dd" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6f00dc" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d4814e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd79dd" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d4814e" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a18780" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd79dd" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a18780" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4c38c7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd79dd" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4c38c7" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4b2155" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd79dd" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4b2155" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1459e2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd79dd" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1459e2" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d6b4e4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd79dd" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d6b4e4" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_09f0d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd79dd" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_09f0d6" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a93b2a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd79dd" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a93b2a" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails4" xlink:title="000047 - Disclosure - EQUITY-BASED COMPENSATION (Details 4)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_81f267" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_ce0e1d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_81f267" xlink:to="loc_us-gaapStatementTable_ce0e1d" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_8173d5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ce0e1d" xlink:to="loc_us-gaapStatementLineItems_8173d5" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_3edfa1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ce0e1d" xlink:to="loc_us-gaapAwardTypeAxis_3edfa1" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d427c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_3edfa1" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d427c" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_RestrictedStockAwardsMember" xlink:label="loc_cvmRestrictedStockAwardsMember_9acaaa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d427c" xlink:to="loc_cvmRestrictedStockAwardsMember_9acaaa" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_3721f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8173d5" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_3721f0" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_e0b276" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8173d5" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_e0b276" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_f425bb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8173d5" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_f425bb" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0e76e1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8173d5" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0e76e1" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_e13133" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8173d5" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_e13133" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_9f8d5a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_8173d5" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_9f8d5a" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetailsNarrative" xlink:title="000048 - Disclosure - EQUITY-BASED COMPENSATION (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2c0b1e" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_ca64f2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2c0b1e" xlink:to="loc_us-gaapStatementTable_ca64f2" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_756a87" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ca64f2" xlink:to="loc_us-gaapStatementLineItems_756a87" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis_6ea3f5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ca64f2" xlink:to="loc_us-gaapAwardTypeAxis_6ea3f5" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_093172" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis_6ea3f5" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_093172" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis_12df2c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ca64f2" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis_12df2c" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_7cf0d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis_12df2c" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_7cf0d6" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_540877" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ca64f2" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_540877" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_f5ed55" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_540877" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_f5ed55" order="40" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_RestrictedStockAwardsMember" xlink:label="loc_cvmRestrictedStockAwardsMember_f6eb26" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_093172" xlink:to="loc_cvmRestrictedStockAwardsMember_f6eb26" order="41" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_StockBonusPlansMember" xlink:label="loc_cvmStockBonusPlansMember_b28c50" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_7cf0d6" xlink:to="loc_cvmStockBonusPlansMember_b28c50" order="42" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_StockCompensationPlansMember" xlink:label="loc_cvmStockCompensationPlansMember_4b06a1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_f5ed55" xlink:to="loc_cvmStockCompensationPlansMember_4b06a1" order="43" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="loc_cvmNonQualifiedStockOptionsPlansMember_6713f6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_7cf0d6" xlink:to="loc_cvmNonQualifiedStockOptionsPlansMember_6713f6" order="44" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IncentiveStockOptionPlansMember" xlink:label="loc_cvmIncentiveStockOptionPlansMember_4f81c4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_7cf0d6" xlink:to="loc_cvmIncentiveStockOptionPlansMember_4f81c4" order="45" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IncentiveStockBonusPlanMember" xlink:label="loc_cvmIncentiveStockBonusPlanMember_de1b7c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_7cf0d6" xlink:to="loc_cvmIncentiveStockBonusPlanMember_de1b7c" order="46" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_NonVestedOptionsMember" xlink:label="loc_cvmNonVestedOptionsMember_5e335d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_093172" xlink:to="loc_cvmNonVestedOptionsMember_5e335d" order="47" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_9bc0c3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_756a87" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_9bc0c3" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_c65d24" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_756a87" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_c65d24" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_09c830" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_756a87" xlink:to="loc_us-gaapCommonStockSharesIssued_09c830" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_ae12b3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_756a87" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_ae12b3" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_5e2d89" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_756a87" xlink:to="loc_us-gaapCommonStockSharesAuthorized_5e2d89" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2ae574" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_756a87" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2ae574" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_PerformanceBasedStockOptionsSharesGranted" xlink:label="loc_cvmPerformanceBasedStockOptionsSharesGranted_24a221" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_756a87" xlink:to="loc_cvmPerformanceBasedStockOptionsSharesGranted_24a221" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityStrikePrice1_52d246" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_756a87" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityStrikePrice1_52d246" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_RemainingOutstandingFairValueOfShares" xlink:label="loc_cvmRemainingOutstandingFairValueOfShares_69ed16" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_756a87" xlink:to="loc_cvmRemainingOutstandingFairValueOfShares_69ed16" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_VestedShares" xlink:label="loc_cvmVestedShares_afe9fa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_756a87" xlink:to="loc_cvmVestedShares_afe9fa" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationEquity" xlink:label="loc_us-gaapDeferredCompensationEquity_274714" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_756a87" xlink:to="loc_us-gaapDeferredCompensationEquity_274714" order="11" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" xlink:title="000049 - Disclosure - EMPLOYEE BENEFIT PLAN (Detail Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationAbstract_fa6274" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount_721326" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationAbstract_fa6274" xlink:to="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount_721326" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_EmployeeContributionsToDefinedContributionPlans" xlink:label="loc_cvmEmployeeContributionsToDefinedContributionPlans_f662bd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationAbstract_fa6274" xlink:to="loc_cvmEmployeeContributionsToDefinedContributionPlans_f662bd" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_PercentageOfEmployeeContributionsToDefinedContributionPlans" xlink:label="loc_cvmPercentageOfEmployeeContributionsToDefinedContributionPlans_a690a6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationAbstract_fa6274" xlink:to="loc_cvmPercentageOfEmployeeContributionsToDefinedContributionPlans_a690a6" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_fa75e4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeBenefitsAndShareBasedCompensationAbstract_fa6274" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_fa75e4" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="000050 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_98e2b3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_a9aaba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_98e2b3" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_a9aaba" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_61a8ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_98e2b3" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearTwo_61a8ce" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree_7b58f8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_98e2b3" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearThree_7b58f8" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour_c9bf7c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_98e2b3" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFour_c9bf7c" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive_78e38e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_98e2b3" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDueYearFive_78e38e" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_772071" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_98e2b3" xlink:to="loc_us-gaapFinanceLeaseLiabilityPaymentsDue_772071" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount_63c56a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_98e2b3" xlink:to="loc_us-gaapFinanceLeaseLiabilityUndiscountedExcessAmount_63c56a" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability_a29229" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_98e2b3" xlink:to="loc_us-gaapFinanceLeaseLiability_a29229" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_FinanceLeaseLiabilityCurrentPortion" xlink:label="loc_cvmFinanceLeaseLiabilityCurrentPortion_f20c64" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_98e2b3" xlink:to="loc_cvmFinanceLeaseLiabilityCurrentPortion_f20c64" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_FinanceLeaseLiabilityNoncurrentPortion" xlink:label="loc_cvmFinanceLeaseLiabilityNoncurrentPortion_f097c2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_98e2b3" xlink:to="loc_cvmFinanceLeaseLiabilityNoncurrentPortion_f097c2" order="10" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000051 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_4fa7b1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b6908d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_4fa7b1" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b6908d" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_724e76" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_4fa7b1" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_724e76" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_73bf90" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_4fa7b1" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree_73bf90" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour_71591b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_4fa7b1" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour_71591b" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive_de3749" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_4fa7b1" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive_de3749" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4743ff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_4fa7b1" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4743ff" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_7b343e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_4fa7b1" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_7b343e" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6dbb89" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_4fa7b1" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6dbb89" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_a1e329" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_4fa7b1" xlink:to="loc_us-gaapOperatingLeaseLiability_a1e329" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_OperatingLeaseObligationyCurrent" xlink:label="loc_cvmOperatingLeaseObligationyCurrent_5d203f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_4fa7b1" xlink:to="loc_cvmOperatingLeaseObligationyCurrent_5d203f" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_OperatingLeaseObligationyNoncurrent" xlink:label="loc_cvmOperatingLeaseObligationyNoncurrent_9f5e2a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_4fa7b1" xlink:to="loc_cvmOperatingLeaseObligationyNoncurrent_9f5e2a" order="11" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000052 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_43ea52" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_36b8e1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract_43ea52" xlink:to="loc_us-gaapStatementTable_36b8e1" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_658542" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_36b8e1" xlink:to="loc_us-gaapStatementLineItems_658542" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_4e7f2f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_36b8e1" xlink:to="loc_us-gaapPlanNameAxis_4e7f2f" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_fa542e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_4e7f2f" xlink:to="loc_us-gaapPlanNameDomain_fa542e" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis_d262d1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_36b8e1" xlink:to="loc_srtTitleOfIndividualAxis_d262d1" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_593020" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis_d262d1" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_593020" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_07c8a0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_36b8e1" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_07c8a0" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_118315" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_07c8a0" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_118315" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis_656719" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_36b8e1" xlink:to="loc_us-gaapIncomeStatementLocationAxis_656719" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_dcc4b6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis_656719" xlink:to="loc_us-gaapIncomeStatementLocationDomain_dcc4b6" order="60" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember_776639" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_fa542e" xlink:to="loc_cvmErgomedMember_776639" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_LandlordMember" xlink:label="loc_cvmLandlordMember_b13449" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_593020" xlink:to="loc_cvmLandlordMember_b13449" order="62" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaapLeaseAgreementsMember_3fdf81" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_118315" xlink:to="loc_us-gaapLeaseAgreementsMember_3fdf81" order="63" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaapOperatingExpenseMember_8bf98b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain_dcc4b6" xlink:to="loc_us-gaapOperatingExpenseMember_8bf98b" order="64" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_422016" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_658542" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_422016" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_FinanceLeaseCosts" xlink:label="loc_cvmFinanceLeaseCosts_9f3ddb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_658542" xlink:to="loc_cvmFinanceLeaseCosts_9f3ddb" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization_50ba07" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_658542" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization_50ba07" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="loc_us-gaapFinanceLeaseInterestPaymentOnLiability_b289ed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_658542" xlink:to="loc_us-gaapFinanceLeaseInterestPaymentOnLiability_b289ed" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WeightedAverageMaturityYear" xlink:label="loc_cvmWeightedAverageMaturityYear_939c6b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_658542" xlink:to="loc_cvmWeightedAverageMaturityYear_939c6b" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset_460c02" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_658542" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset_460c02" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability_d5e02d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_658542" xlink:to="loc_us-gaapFinanceLeaseLiability_d5e02d" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent_4974ea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_658542" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent_4974ea" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_f2d69d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_658542" xlink:to="loc_us-gaapDepreciation_f2d69d" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments_b668df" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_658542" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments_b668df" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:label="loc_us-gaapLongTermDebtWeightedAverageInterestRateOverTime_3b6f69" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_658542" xlink:to="loc_us-gaapLongTermDebtWeightedAverageInterestRateOverTime_3b6f69" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_1357ba" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_658542" xlink:to="loc_us-gaapOperatingLeasePayments_1357ba" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WeightedAverageOperatingLeaseDiscountRate" xlink:label="loc_cvmWeightedAverageOperatingLeaseDiscountRate_854535" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_658542" xlink:to="loc_cvmWeightedAverageOperatingLeaseDiscountRate_854535" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_d8d02b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_658542" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_d8d02b" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_6e93da" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_658542" xlink:to="loc_us-gaapOperatingLeaseLiability_6e93da" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_3f4176" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_658542" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_3f4176" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WeightedAverageOperatingLeaseMaturityYear" xlink:label="loc_cvmWeightedAverageOperatingLeaseMaturityYear_fcec95" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_658542" xlink:to="loc_cvmWeightedAverageOperatingLeaseMaturityYear_fcec95" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses_55cf96" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_658542" xlink:to="loc_us-gaapOtherExpenses_55cf96" order="18" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_PaymentsMadeToLandlord" xlink:label="loc_cvmPaymentsMadeToLandlord_b696d5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_658542" xlink:to="loc_cvmPaymentsMadeToLandlord_b696d5" order="19" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000053 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_9a564f" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_95f31a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_9a564f" xlink:to="loc_us-gaapStatementTable_95f31a" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_59f929" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_95f31a" xlink:to="loc_us-gaapStatementLineItems_59f929" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_f66cff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_95f31a" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_f66cff" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_2368ab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_f66cff" xlink:to="loc_us-gaapRelatedPartyDomain_2368ab" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis_ac6f27" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_95f31a" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis_ac6f27" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_f87043" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis_ac6f27" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_f87043" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_OfficerAndDirectorMember" xlink:label="loc_cvmOfficerAndDirectorMember_993ad9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_2368ab" xlink:to="loc_cvmOfficerAndDirectorMember_993ad9" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_CEOMember" xlink:label="loc_cvmCEOMember_e54e0f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_2368ab" xlink:to="loc_cvmCEOMember_e54e0f" order="22" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesRRWarrantMember" xlink:label="loc_cvmSeriesRRWarrantMember_56aa12" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain_f87043" xlink:to="loc_cvmSeriesRRWarrantMember_56aa12" order="23" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ProceedsFromAdditionalDebtFromRelatedParty" xlink:label="loc_cvmProceedsFromAdditionalDebtFromRelatedParty_4e4e27" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_59f929" xlink:to="loc_cvmProceedsFromAdditionalDebtFromRelatedParty_4e4e27" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_RestrictedCommonStockSharesIssued" xlink:label="loc_cvmRestrictedCommonStockSharesIssued_d356de" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_59f929" xlink:to="loc_cvmRestrictedCommonStockSharesIssued_d356de" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_7cec3f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_59f929" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_7cec3f" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_dff978" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_59f929" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_dff978" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt_84c771" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_59f929" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt_84c771" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_DescriptionOfModificationOfWarrants" xlink:label="loc_cvmDescriptionOfModificationOfWarrants_6f382d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_59f929" xlink:to="loc_cvmDescriptionOfModificationOfWarrants_6f382d" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IncrementalCostOfWarrantsExtension" xlink:label="loc_cvmIncrementalCostOfWarrantsExtension_a170bf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_59f929" xlink:to="loc_cvmIncrementalCostOfWarrantsExtension_a170bf" order="7" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="000054 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_8bf435" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_3ffaa2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_8bf435" xlink:to="loc_us-gaapStatementTable_3ffaa2" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_c2a0fe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_3ffaa2" xlink:to="loc_us-gaapStatementLineItems_c2a0fe" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeAxis" xlink:label="loc_us-gaapTradingActivityByTypeAxis_01af06" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_3ffaa2" xlink:to="loc_us-gaapTradingActivityByTypeAxis_01af06" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeDomain" xlink:label="loc_us-gaapTradingActivityByTypeDomain_090b3f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivityByTypeAxis_01af06" xlink:to="loc_us-gaapTradingActivityByTypeDomain_090b3f" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_EquityProceedsFromSaleCommonStockMember" xlink:label="loc_cvmEquityProceedsFromSaleCommonStockMember_7b9516" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTradingActivityByTypeDomain_090b3f" xlink:to="loc_cvmEquityProceedsFromSaleCommonStockMember_7b9516" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_9551be" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c2a0fe" xlink:to="loc_us-gaapCommonStockSharesIssued_9551be" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ProceedFromIssuanceOrSaleOfEquity" xlink:label="loc_cvmProceedFromIssuanceOrSaleOfEquity_1879b5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c2a0fe" xlink:to="loc_cvmProceedFromIssuanceOrSaleOfEquity_1879b5" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_9f67b1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c2a0fe" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_9f67b1" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_NetIssuanceCosts" xlink:label="loc_cvmNetIssuanceCosts_9bf4e1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c2a0fe" xlink:to="loc_cvmNetIssuanceCosts_9bf4e1" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IssuanceCostOfCommonStock" xlink:label="loc_cvmIssuanceCostOfCommonStock_067e35" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c2a0fe" xlink:to="loc_cvmIssuanceCostOfCommonStock_067e35" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_63e949" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c2a0fe" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_63e949" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_EquityWarrantsExercised" xlink:label="loc_cvmEquityWarrantsExercised_cfa35a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c2a0fe" xlink:to="loc_cvmEquityWarrantsExercised_cfa35a" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_AdditionalPurchaseOfCommonStock" xlink:label="loc_cvmAdditionalPurchaseOfCommonStock_26614f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c2a0fe" xlink:to="loc_cvmAdditionalPurchaseOfCommonStock_26614f" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_f60a19" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c2a0fe" xlink:to="loc_us-gaapSaleOfStockPricePerShare_f60a19" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_ea9a73" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c2a0fe" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_ea9a73" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_39b527" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_c2a0fe" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_39b527" order="11" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsDetails" xlink:title="000055 - Disclosure - FAIR VALUE MEASUREMENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract_5b4425" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_851f68" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract_5b4425" xlink:to="loc_us-gaapStatementTable_851f68" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_37b7a0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_851f68" xlink:to="loc_us-gaapStatementLineItems_37b7a0" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis_6aece0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_851f68" xlink:to="loc_us-gaapPlanNameAxis_6aece0" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_e6c6f6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis_6aece0" xlink:to="loc_us-gaapPlanNameDomain_e6c6f6" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostAxis" xlink:label="loc_us-gaapCapitalizedContractCostAxis_dd7081" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_851f68" xlink:to="loc_us-gaapCapitalizedContractCostAxis_dd7081" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostDomain" xlink:label="loc_us-gaapCapitalizedContractCostDomain_4219d7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCapitalizedContractCostAxis_dd7081" xlink:to="loc_us-gaapCapitalizedContractCostDomain_4219d7" order="30" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_FairValueMember" xlink:label="loc_cvmFairValueMember_15c286" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain_e6c6f6" xlink:to="loc_cvmFairValueMember_15c286" order="31" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_CostMember" xlink:label="loc_cvmCostMember_b6bc0d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCapitalizedContractCostDomain_4219d7" xlink:to="loc_cvmCostMember_b6bc0d" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_6a1341" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_37b7a0" xlink:to="loc_us-gaapCash_6a1341" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_MoneyMarketFundsIncludedInCashAndCashEquivalents" xlink:label="loc_cvmMoneyMarketFundsIncludedInCashAndCashEquivalents_d2a66a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_37b7a0" xlink:to="loc_cvmMoneyMarketFundsIncludedInCashAndCashEquivalents_d2a66a" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_4ecee3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_37b7a0" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_4ecee3" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareDetails" xlink:title="000056 - Disclosure - NET LOSS PER COMMON SHARE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_f38797" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ProfitLossPerShareBasicAndDilutedAbstract" xlink:label="loc_cvmProfitLossPerShareBasicAndDilutedAbstract_f13aa3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_f38797" xlink:to="loc_cvmProfitLossPerShareBasicAndDilutedAbstract_f13aa3" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_c329e0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_f38797" xlink:to="loc_us-gaapNetIncomeLoss_c329e0" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_5c00c7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_f38797" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_5c00c7" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_ea5061" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_f38797" xlink:to="loc_us-gaapEarningsPerShareDiluted_ea5061" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareDetails1" xlink:title="000057 - Disclosure - NET LOSS PER COMMON SHARE (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_9845aa" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_c9c1b1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_9845aa" xlink:to="loc_us-gaapStatementTable_c9c1b1" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_aaf89b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c9c1b1" xlink:to="loc_us-gaapStatementLineItems_aaf89b" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d9e1d1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c9c1b1" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d9e1d1" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_3dff3c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d9e1d1" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_3dff3c" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_OptionsMember" xlink:label="loc_cvmOptionsMember_7df070" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_3dff3c" xlink:to="loc_cvmOptionsMember_7df070" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="loc_cvmUnvestedRestrictedStockMember_15e389" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain_3dff3c" xlink:to="loc_cvmUnvestedRestrictedStockMember_15e389" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_df4f16" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_aaf89b" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_df4f16" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareDetailsNarrative" xlink:title="000058 - Disclosure - NET LOSS PER COMMON SHARE (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_fd547d" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WarrantsUsedForCalculationOfEarningPerShare" xlink:label="loc_cvmWarrantsUsedForCalculationOfEarningPerShare_c440e8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract_fd547d" xlink:to="loc_cvmWarrantsUsedForCalculationOfEarningPerShare_c440e8" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:title="000059 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_ead2ae" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_8941d8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_ead2ae" xlink:to="loc_us-gaapStatementTable_8941d8" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_0cebb2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_8941d8" xlink:to="loc_us-gaapStatementLineItems_0cebb2" order="2000" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis_a0f568" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_8941d8" xlink:to="loc_us-gaapSubsequentEventTypeAxis_a0f568" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_e3829b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis_a0f568" xlink:to="loc_us-gaapSubsequentEventTypeDomain_e3829b" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_894ae9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_8941d8" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_894ae9" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_0af813" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_894ae9" xlink:to="loc_us-gaapRelatedPartyDomain_0af813" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_b624c6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain_e3829b" xlink:to="loc_us-gaapSubsequentEventMember_b624c6" order="31" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ErgomedGroupMember" xlink:label="loc_cvmErgomedGroupMember_70af92" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_0af813" xlink:to="loc_cvmErgomedGroupMember_70af92" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_885353" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0cebb2" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_885353" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WarrantsOfferingPrice" xlink:label="loc_cvmWarrantsOfferingPrice_557db1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0cebb2" xlink:to="loc_cvmWarrantsOfferingPrice_557db1" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_da001a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0cebb2" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_da001a" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_bb5d66" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0cebb2" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_bb5d66" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_06afff" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0cebb2" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_06afff" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WarrantsToPurchaseCommonStock" xlink:label="loc_cvmWarrantsToPurchaseCommonStock_c2639e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0cebb2" xlink:to="loc_cvmWarrantsToPurchaseCommonStock_c2639e" order="6" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>cvm-20240930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 01/12/2025-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2025 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cvm.com/role/Cover" xlink:href="cvm-20240930.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BalanceSheets" xlink:href="cvm-20240930.xsd#BalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/BalanceSheetsParenthetical" xlink:href="cvm-20240930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfOperations" xlink:href="cvm-20240930.xsd#StatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfStockholdersEquity" xlink:href="cvm-20240930.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StatementsOfCashFlows" xlink:href="cvm-20240930.xsd#StatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/ORGANIZATION" xlink:href="cvm-20240930.xsd#ORGANIZATION" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/LIQUIDITY" xlink:href="cvm-20240930.xsd#LIQUIDITY" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="cvm-20240930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptions" xlink:href="cvm-20240930.xsd#WarrantsAndNonemployeeOptions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipment" xlink:href="cvm-20240930.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PATENTS" xlink:href="cvm-20240930.xsd#PATENTS" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxes" xlink:href="cvm-20240930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensation" xlink:href="cvm-20240930.xsd#EquityBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EmployeeBenefitPlan" xlink:href="cvm-20240930.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingencies" xlink:href="cvm-20240930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactions" xlink:href="cvm-20240930.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquity" xlink:href="cvm-20240930.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurements" xlink:href="cvm-20240930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShare" xlink:href="cvm-20240930.xsd#NetLossPerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEvents" xlink:href="cvm-20240930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20240930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsTables" xlink:href="cvm-20240930.xsd#WarrantsAndNonemployeeOptionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipmentTables" xlink:href="cvm-20240930.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsTables" xlink:href="cvm-20240930.xsd#PatentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesTables" xlink:href="cvm-20240930.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationTables" xlink:href="cvm-20240930.xsd#EquityBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:href="cvm-20240930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsTables" xlink:href="cvm-20240930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareTables" xlink:href="cvm-20240930.xsd#NetLossPerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="cvm-20240930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" xlink:href="cvm-20240930.xsd#WarrantsAndNonemployeeOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1" xlink:href="cvm-20240930.xsd#WarrantsAndNonemployeeOptionsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative" xlink:href="cvm-20240930.xsd#WarrantsAndNonemployeeOptionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipmentDetails" xlink:href="cvm-20240930.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="cvm-20240930.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails" xlink:href="cvm-20240930.xsd#PatentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetails1" xlink:href="cvm-20240930.xsd#PatentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/PatentsDetailsNarrative" xlink:href="cvm-20240930.xsd#PatentsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetails" xlink:href="cvm-20240930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetails1" xlink:href="cvm-20240930.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/IncomeTaxesDetailsNarrative" xlink:href="cvm-20240930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails" xlink:href="cvm-20240930.xsd#EquityBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails1" xlink:href="cvm-20240930.xsd#EquityBasedCompensationDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails2" xlink:href="cvm-20240930.xsd#EquityBasedCompensationDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails3" xlink:href="cvm-20240930.xsd#EquityBasedCompensationDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetails4" xlink:href="cvm-20240930.xsd#EquityBasedCompensationDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EquityBasedCompensationDetailsNarrative" xlink:href="cvm-20240930.xsd#EquityBasedCompensationDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" xlink:href="cvm-20240930.xsd#EmployeeBenefitPlanDetailNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:href="cvm-20240930.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:href="cvm-20240930.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20240930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="cvm-20240930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:href="cvm-20240930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/FairValueMeasurementsDetails" xlink:href="cvm-20240930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareDetails" xlink:href="cvm-20240930.xsd#NetLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareDetails1" xlink:href="cvm-20240930.xsd#NetLossPerCommonShareDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/NetLossPerCommonShareDetailsNarrative" xlink:href="cvm-20240930.xsd#NetLossPerCommonShareDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:href="cvm-20240930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/BalanceSheets" xlink:title="000002 - Statement - BALANCE SHEETS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/BalanceSheetsParenthetical" xlink:title="000003 - Statement - BALANCE SHEETS (Parenthetical)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfOperations" xlink:title="000004 - Statement - STATEMENTS OF OPERATIONS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfStockholdersEquity" xlink:title="000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="loc_cvmStockIssuedDuringPeriodSharesStockWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmStockIssuedDuringPeriodSharesStockWarrantsExercised" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="loc_cvmStockIssuedDuringPeriodValueStockWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmStockIssuedDuringPeriodValueStockWarrantsExercised" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeBenefitPlan" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" order="10" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IncentiveStockForfeitedShares" xlink:label="loc_cvmIncentiveStockForfeitedShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIncentiveStockForfeitedShares" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IncentiveStockForfeitedAmount" xlink:label="loc_cvmIncentiveStockForfeitedAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIncentiveStockForfeitedAmount" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" order="13" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_CostIncurredInIssuanceOfStock" xlink:label="loc_cvmCostIncurredInIssuanceOfStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmCostIncurredInIssuanceOfStock" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" order="15" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsShares" xlink:label="loc_cvmProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsShares" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount" xlink:label="loc_cvmProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount" order="17" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ExerciseOfPreFundedWarrantsShares" xlink:label="loc_cvmExerciseOfPreFundedWarrantsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExerciseOfPreFundedWarrantsShares" order="18" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ExerciseOfPreFundedWarrantsAmount" xlink:label="loc_cvmExerciseOfPreFundedWarrantsAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExerciseOfPreFundedWarrantsAmount" order="19" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_PurchaseOfStockByOfficersAndDirectorsShares" xlink:label="loc_cvmPurchaseOfStockByOfficersAndDirectorsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmPurchaseOfStockByOfficersAndDirectorsShares" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_PurchaseOfStockByOfficersAndDirectorsAmount" xlink:label="loc_cvmPurchaseOfStockByOfficersAndDirectorsAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmPurchaseOfStockByOfficersAndDirectorsAmount" order="21" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StatementsOfCashFlows" xlink:title="000006 - Statement - STATEMENTS OF CASH FLOWS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/ORGANIZATION" xlink:title="000007 - Disclosure - ORGANIZATION" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/LIQUIDITY" xlink:title="000008 - Disclosure - LIQUIDITY" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptions" xlink:title="000010 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipment" xlink:title="000011 - Disclosure - PROPERTY AND EQUIPMENT" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PATENTS" xlink:title="000012 - Disclosure - PATENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxes" xlink:title="000013 - Disclosure - INCOME TAXES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensation" xlink:title="000014 - Disclosure - EQUITY-BASED COMPENSATION" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/EmployeeBenefitPlan" xlink:title="000015 - Disclosure - EMPLOYEE BENEFIT PLAN" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingencies" xlink:title="000016 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactions" xlink:title="000017 - Disclosure - RELATED PARTY TRANSACTIONS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquity" xlink:title="000018 - Disclosure - STOCKHOLDERS EQUITY" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurements" xlink:title="000019 - Disclosure - FAIR VALUE MEASUREMENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShare" xlink:title="000020 - Disclosure - NET LOSS PER COMMON SHARE" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEvents" xlink:title="000021 - Disclosure - SUBSEQUENT EVENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsTables" xlink:title="000023 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipmentTables" xlink:title="000024 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsTables" xlink:title="000025 - Disclosure - PATENTS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesTables" xlink:title="000026 - Disclosure - INCOME TAXES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationTables" xlink:title="000027 - Disclosure - EQUITY-BASED COMPENSATION (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesTables" xlink:title="000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsTables" xlink:title="000029 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareTables" xlink:title="000030 - Disclosure - NET LOSS PER COMMON SHARE (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_FiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_cvmFiniteLivedIntangibleAssetsUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmFiniteLivedIntangibleAssetsUsefulLife" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" order="2" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails" xlink:title="000032 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesYMember" xlink:label="loc_cvmSeriesYMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesYMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesMMMember" xlink:label="loc_cvmSeriesMMMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesMMMember" order="62" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesNNMember" xlink:label="loc_cvmSeriesNNMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesNNMember" order="63" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesRRMember" order="64" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsMember" order="65" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesNMember" xlink:label="loc_cvmSeriesNMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesNMember" order="66" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesUUMember" xlink:label="loc_cvmSeriesUUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesUUMember" order="67" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesXMember" xlink:label="loc_cvmSeriesXMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesXMember" order="68" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_BottomMember" xlink:label="loc_cvmBottomMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmBottomMember" order="69" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ConsultantsOneMember" xlink:label="loc_cvmConsultantsOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsOneMember" order="70" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_TopMember" xlink:label="loc_cvmTopMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmTopMember" order="71" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_Issuedate2" xlink:label="loc_cvmIssuedate2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIssuedate2" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SharesIssuableUponExerciseOfwarrant" xlink:label="loc_cvmSharesIssuableUponExerciseOfwarrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmSharesIssuableUponExerciseOfwarrant" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ExercisePrice" xlink:label="loc_cvmExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExercisePrice" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ExpirationDate1" xlink:label="loc_cvmExpirationDate1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmExpirationDate1" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1" xlink:title="000033 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesRRMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesSSMember" xlink:label="loc_cvmSeriesSSMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesSSMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_EquityWarrantsExercised" xlink:label="loc_cvmEquityWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmEquityWarrantsExercised" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ProceedsFromEquityWarrantsExercised" xlink:label="loc_cvmProceedsFromEquityWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmProceedsFromEquityWarrantsExercised" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_EquityWarrantsExercisePrice" xlink:label="loc_cvmEquityWarrantsExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmEquityWarrantsExercisePrice" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative" xlink:title="000034 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="70" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="80" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" order="90" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="90" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="100" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="110" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesRRMember" xlink:label="loc_cvmSeriesRRMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_cvmSeriesRRMember" order="91" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ConsultingAgreementsMember" xlink:label="loc_cvmConsultingAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmConsultingAgreementsMember" order="92" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="loc_cvmNonQualifiedStockOptionsPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmNonQualifiedStockOptionsPlansMember" order="93" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ConsultantMember" xlink:label="loc_cvmConsultantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantMember" order="94" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_TwoSeptemberTwoThousendTwentyFourMember" xlink:label="loc_cvmTwoSeptemberTwoThousendTwentyFourMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_cvmTwoSeptemberTwoThousendTwentyFourMember" order="95" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_TwoSeptemberTwoThousendTwentyFiveMember" xlink:label="loc_cvmTwoSeptemberTwoThousendTwentyFiveMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_cvmTwoSeptemberTwoThousendTwentyFiveMember" order="96" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_RestrictedStocksMember" xlink:label="loc_cvmRestrictedStocksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmRestrictedStocksMember" order="97" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ConsultantsMember" xlink:label="loc_cvmConsultantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmConsultantsMember" order="98" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_BottomMember" xlink:label="loc_cvmBottomMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmBottomMember" order="99" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_TopMember" xlink:label="loc_cvmTopMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmTopMember" order="100" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_StockIssuedDuringPeriodToPurchaseCommonStock" xlink:label="loc_cvmStockIssuedDuringPeriodToPurchaseCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmStockIssuedDuringPeriodToPurchaseCommonStock" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_StockOptionExercisePrice" xlink:label="loc_cvmStockOptionExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmStockOptionExercisePrice" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_VestedOptions" xlink:label="loc_cvmVestedOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmVestedOptions" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IssuanceOfOptionsForServices" xlink:label="loc_cvmIssuanceOfOptionsForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIssuanceOfOptionsForServices" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IncrementalCostDeemedDividend" xlink:label="loc_cvmIncrementalCostDeemedDividend" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIncrementalCostDeemedDividend" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_CommonStockIssuedForServiceShares" xlink:label="loc_cvmCommonStockIssuedForServiceShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmCommonStockIssuedForServiceShares" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_EquityWarrantsExercised" xlink:label="loc_cvmEquityWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmEquityWarrantsExercised" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaapCostsAndExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostsAndExpenses" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_PrepaidExpenses" xlink:label="loc_cvmPrepaidExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmPrepaidExpenses" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" order="11" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipmentDetails" xlink:title="000035 - Disclosure - PROPERTY AND EQUIPMENT (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="000036 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails" xlink:title="000037 - Disclosure - PATENTS (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetails1" xlink:title="000038 - Disclosure - PATENTS (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/PatentsDetailsNarrative" xlink:title="000039 - Disclosure - PATENTS (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetails" xlink:title="000040 - Disclosure - INCOME TAXES (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetails1" xlink:title="000041 - Disclosure - INCOME TAXES (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/IncomeTaxesDetailsNarrative" xlink:title="000042 - Disclosure - INCOME TAXES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IncomeTaxMember" xlink:label="loc_cvmIncomeTaxMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_cvmIncomeTaxMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ResearchAndDevelopmentCredit" xlink:label="loc_cvmResearchAndDevelopmentCredit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmResearchAndDevelopmentCredit" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" order="2" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ResearchAndDevelopmentCreditDescription" xlink:label="loc_cvmResearchAndDevelopmentCreditDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmResearchAndDevelopmentCreditDescription" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_CumulativeChangeInOwnershipPercentage" xlink:label="loc_cvmCumulativeChangeInOwnershipPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmCumulativeChangeInOwnershipPercentage" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="loc_us-gaapTaxCreditCarryforwardDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardDescription" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsNet" order="6" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails" xlink:title="000043 - Disclosure - EQUITY-BASED COMPENSATION (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_NonEmployeesMember" xlink:label="loc_cvmNonEmployeesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_cvmNonEmployeesMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_EmployeesMember" xlink:label="loc_cvmEmployeesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_cvmEmployeesMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails1" xlink:title="000044 - Disclosure - EQUITY-BASED COMPENSATION (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails2" xlink:title="000045 - Disclosure - EQUITY-BASED COMPENSATION (Details 2)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_OutstandingMember" xlink:label="loc_cvmOutstandingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_cvmOutstandingMember" order="31" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ExercisableMember" xlink:label="loc_cvmExercisableMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_cvmExercisableMember" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="14" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_NumberOfOptionsVested" xlink:label="loc_cvmNumberOfOptionsVested" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNumberOfOptionsVested" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_NumberOfOptionsExercised" xlink:label="loc_cvmNumberOfOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNumberOfOptionsExercised" order="17" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_NumberOfOptions" xlink:label="loc_cvmNumberOfOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNumberOfOptions" order="18" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WeightedAverageExercisePriceVested" xlink:label="loc_cvmWeightedAverageExercisePriceVested" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageExercisePriceVested" order="19" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WeightedAverageExercisePriceExpired" xlink:label="loc_cvmWeightedAverageExercisePriceExpired" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageExercisePriceExpired" order="20" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" xlink:label="loc_cvmWeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageRemainingContractualLifeInYearsOutstandingBeginning" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding" xlink:label="loc_cvmWeightedAverageRemainingContractualLifeInYearsOutstandingEnding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageRemainingContractualLifeInYearsOutstandingEnding" order="22" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails3" xlink:title="000046 - Disclosure - EQUITY-BASED COMPENSATION (Details 3)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetails4" xlink:title="000047 - Disclosure - EQUITY-BASED COMPENSATION (Details 4)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_RestrictedStockAwardsMember" xlink:label="loc_cvmRestrictedStockAwardsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmRestrictedStockAwardsMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/EquityBasedCompensationDetailsNarrative" xlink:title="000048 - Disclosure - EQUITY-BASED COMPENSATION (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_RestrictedStockAwardsMember" xlink:label="loc_cvmRestrictedStockAwardsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmRestrictedStockAwardsMember" order="41" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_StockBonusPlansMember" xlink:label="loc_cvmStockBonusPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_cvmStockBonusPlansMember" order="42" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_StockCompensationPlansMember" xlink:label="loc_cvmStockCompensationPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmStockCompensationPlansMember" order="43" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_NonQualifiedStockOptionsPlansMember" xlink:label="loc_cvmNonQualifiedStockOptionsPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_cvmNonQualifiedStockOptionsPlansMember" order="44" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IncentiveStockOptionPlansMember" xlink:label="loc_cvmIncentiveStockOptionPlansMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_cvmIncentiveStockOptionPlansMember" order="45" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IncentiveStockBonusPlanMember" xlink:label="loc_cvmIncentiveStockBonusPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_cvmIncentiveStockBonusPlanMember" order="46" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_NonVestedOptionsMember" xlink:label="loc_cvmNonVestedOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_cvmNonVestedOptionsMember" order="47" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_PerformanceBasedStockOptionsSharesGranted" xlink:label="loc_cvmPerformanceBasedStockOptionsSharesGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmPerformanceBasedStockOptionsSharesGranted" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityStrikePrice1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityStrikePrice1" order="8" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_RemainingOutstandingFairValueOfShares" xlink:label="loc_cvmRemainingOutstandingFairValueOfShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmRemainingOutstandingFairValueOfShares" order="9" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_VestedShares" xlink:label="loc_cvmVestedShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmVestedShares" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationEquity" xlink:label="loc_us-gaapDeferredCompensationEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredCompensationEquity" order="11" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/EmployeeBenefitPlanDetailNarrative" xlink:title="000049 - Disclosure - EMPLOYEE BENEFIT PLAN (Detail Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails" xlink:title="000050 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetails1" xlink:title="000051 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="000052 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="50" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="60" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="70" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" order="80" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ErgomedMember" xlink:label="loc_cvmErgomedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmErgomedMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_LandlordMember" xlink:label="loc_cvmLandlordMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_cvmLandlordMember" order="62" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaapLeaseAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLeaseAgreementsMember" order="63" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaapOperatingExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapOperatingExpenseMember" order="64" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_FinanceLeaseCosts" xlink:label="loc_cvmFinanceLeaseCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmFinanceLeaseCosts" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAssetAmortization" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:label="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseInterestPaymentOnLiability" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WeightedAverageMaturityYear" xlink:label="loc_cvmWeightedAverageMaturityYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageMaturityYear" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" order="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaapFinanceLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiability" order="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciation" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaapFinanceLeasePrincipalPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinanceLeasePrincipalPayments" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:label="loc_us-gaapLongTermDebtWeightedAverageInterestRateOverTime" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLongTermDebtWeightedAverageInterestRateOverTime" order="11" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" order="12" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WeightedAverageOperatingLeaseDiscountRate" xlink:label="loc_cvmWeightedAverageOperatingLeaseDiscountRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageOperatingLeaseDiscountRate" order="13" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" order="14" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" order="15" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" order="16" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WeightedAverageOperatingLeaseMaturityYear" xlink:label="loc_cvmWeightedAverageOperatingLeaseMaturityYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWeightedAverageOperatingLeaseMaturityYear" order="17" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherExpenses" order="18" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_PaymentsMadeToLandlord" xlink:label="loc_cvmPaymentsMadeToLandlord" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmPaymentsMadeToLandlord" order="19" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000053 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_OfficerAndDirectorMember" xlink:label="loc_cvmOfficerAndDirectorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmOfficerAndDirectorMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_CEOMember" xlink:label="loc_cvmCEOMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmCEOMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_SeriesRRWarrantMember" xlink:label="loc_cvmSeriesRRWarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_cvmSeriesRRWarrantMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ProceedsFromAdditionalDebtFromRelatedParty" xlink:label="loc_cvmProceedsFromAdditionalDebtFromRelatedParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmProceedsFromAdditionalDebtFromRelatedParty" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_RestrictedCommonStockSharesIssued" xlink:label="loc_cvmRestrictedCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmRestrictedCommonStockSharesIssued" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_DescriptionOfModificationOfWarrants" xlink:label="loc_cvmDescriptionOfModificationOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmDescriptionOfModificationOfWarrants" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IncrementalCostOfWarrantsExtension" xlink:label="loc_cvmIncrementalCostOfWarrantsExtension" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIncrementalCostOfWarrantsExtension" order="7" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/StockholdersEquityDetailsNarrative" xlink:title="000054 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeAxis" xlink:label="loc_us-gaapTradingActivityByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTradingActivityByTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeDomain" xlink:label="loc_us-gaapTradingActivityByTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTradingActivityByTypeAxis" xlink:to="loc_us-gaapTradingActivityByTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradingActivityByTypeDomain" xlink:label="loc_us-gaapTradingActivityByTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapTradingActivityByTypeAxis" xlink:to="loc_us-gaapTradingActivityByTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_EquityProceedsFromSaleCommonStockMember" xlink:label="loc_cvmEquityProceedsFromSaleCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTradingActivityByTypeDomain" xlink:to="loc_cvmEquityProceedsFromSaleCommonStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ProceedFromIssuanceOrSaleOfEquity" xlink:label="loc_cvmProceedFromIssuanceOrSaleOfEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmProceedFromIssuanceOrSaleOfEquity" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" order="3" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_NetIssuanceCosts" xlink:label="loc_cvmNetIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmNetIssuanceCosts" order="4" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_IssuanceCostOfCommonStock" xlink:label="loc_cvmIssuanceCostOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmIssuanceCostOfCommonStock" order="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" order="6" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_EquityWarrantsExercised" xlink:label="loc_cvmEquityWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmEquityWarrantsExercised" order="7" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_AdditionalPurchaseOfCommonStock" xlink:label="loc_cvmAdditionalPurchaseOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmAdditionalPurchaseOfCommonStock" order="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" order="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="11" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/FairValueMeasurementsDetails" xlink:title="000055 - Disclosure - FAIR VALUE MEASUREMENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostAxis" xlink:label="loc_us-gaapCapitalizedContractCostAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCapitalizedContractCostAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostDomain" xlink:label="loc_us-gaapCapitalizedContractCostDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCapitalizedContractCostAxis" xlink:to="loc_us-gaapCapitalizedContractCostDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedContractCostDomain" xlink:label="loc_us-gaapCapitalizedContractCostDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapCapitalizedContractCostAxis" xlink:to="loc_us-gaapCapitalizedContractCostDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_FairValueMember" xlink:label="loc_cvmFairValueMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_cvmFairValueMember" order="31" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_CostMember" xlink:label="loc_cvmCostMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCapitalizedContractCostDomain" xlink:to="loc_cvmCostMember" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_MoneyMarketFundsIncludedInCashAndCashEquivalents" xlink:label="loc_cvmMoneyMarketFundsIncludedInCashAndCashEquivalents" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmMoneyMarketFundsIncludedInCashAndCashEquivalents" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareDetails" xlink:title="000056 - Disclosure - NET LOSS PER COMMON SHARE (Details)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareDetails1" xlink:title="000057 - Disclosure - NET LOSS PER COMMON SHARE (Details 1)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_OptionsMember" xlink:label="loc_cvmOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmOptionsMember" order="11" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_UnvestedRestrictedStockMember" xlink:label="loc_cvmUnvestedRestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_cvmUnvestedRestrictedStockMember" order="12" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/NetLossPerCommonShareDetailsNarrative" xlink:title="000058 - Disclosure - NET LOSS PER COMMON SHARE (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cvm.com/role/SubsequentEventsDetailsNarrative" xlink:title="000059 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" order="31" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_ErgomedGroupMember" xlink:label="loc_cvmErgomedGroupMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_cvmErgomedGroupMember" order="32" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WarrantsOfferingPrice" xlink:label="loc_cvmWarrantsOfferingPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantsOfferingPrice" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" order="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" order="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" order="5" />
    <link:loc xlink:type="locator" xlink:href="cvm-20240930.xsd#cvm_WarrantsToPurchaseCommonStock" xlink:label="loc_cvmWarrantsToPurchaseCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_cvmWarrantsToPurchaseCommonStock" order="6" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>cvm_10kimg14.jpg
<TEXT>
begin 644 cvm_10kimg14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" '; ?8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[+JNUQ;K*
M(6GC60]$+#)_"K%?)7CWPOJGB_X__$'2](\)1:_?_P!DV2VUS-J1M!I<C1D"
M9>Y.><#^[[T ?6(D1G9 X+#J >14E?(U]?\ C[P/X@^(6I:=XHMY+_PUH.D2
M7[7-KY_V^1(BK $L-@;YB6P2>*W_ !U\9O%>D:[?W6AZA:FSTK^S5N+ VJ;2
M]P%9U>1W#$X;Y?+!QCF@#Z:HKY]N/B?XPT_XUQZ3J6H6B>'+G6$TNU%I!'<1
ML63(BD97\V.?=ZKLQ67X'^+GCSQ!XVTAK]+1-)U75;K3GL'6&-K98RP4H0YE
M9QM&X,H'/&.* /I,LHQD@9X&>],DDCAC,DKJB+U9C@#\:^;_ -H.'PW<+K=]
M'K"2>*-*TV.3[)=:D]M]@@W,WVBU08$DQ(QC/. ..AU?B[;V?B/P7\/]_B>Q
MM9)I([JWL?$8D2UUC]R#Y=P4X5L'/)QDF@#WU661 Z,&5AD$'((J2OCB/Q!J
M$?P_T>'PCJ3^"K>P\;1Z;?I'=?;[-7?!W0S,0# /^>?3GK7=^*/C!KFAZ?\
M$.!=:TY=4T76=/LM-BD1 \D,OD^8=F<MD/(<]OPH ^B'=(UW2.%7U8X%25\D
M?$[QMX@UZQ\96MUXDL=.T[1O$EII,.B>4%N;A%DC;SQ)N#?-DD #;@&N_M?B
M)XTD^)D/PSEF@.MQ:\\L\XMQM;1A%YJOCH&)98]W]X&@#W!IX$D6)YD61NBE
M@"?PJQ7RS\6/#FI^+/V@M0T72?#T6MWTGA&/[,T]\;5=/D-RZBY4]2R^@YJS
MJ'C[Q[X9UB^TV7Q5;RS>%[K1])_LI[=&DUOSDC$TVYOWF268C;P-ASWH ^G:
M82%!9C@#G)[5\XZ;\2?&C>.+3S/%=K>03>-;CPZVB"UB5UM0K,LNX?/E<#GI
MCKFLC3?BEXF\3>$?#NGWNO6]W<:KH>OR:I#%%&LA>$NL.0HS'A1VQF@#ZD5E
MD4,I#*>01R#0[I&A>1@BCJ6. *^5-2^)6K>'OA/X:C\+^))DO].\)1:K+!%!
M!)"^"J RRRDDC(9?+0;LG.>U5/%6L:Y:VGQPO+OQ +[R8M(GATZ[AC>)1*D#
M;@A'W5W;>.">3EN: /KJBOG/Q%\1O&%E\0=8-KK]M;VVD^(;#18?#QMXR][#
M,J;Y=Q_>9^<D%> $/O3/#?CKQU<>.-"EOO$<5YI6I^*-2T-M/^PQH$BA21D?
MS!\Q8;0/3% 'T3YD>]DWKN4989Y ]Z59(V175U96^Z0>#]*^7/'FHZUX>^//
MCKQE8S3S:7I&CV5OJME&2=]M/'*IE4?WHW5&^FZN&U&XL[CP5H4?B#5YK.WT
MWX;1:CHQ%VT/_$P\X@NF"-\@ 08YX/3F@#[?)"@EC@#N:KB]LV!*W4)P,G$@
MX%<WX7U*VU[PG::=JEU!<ZK_ &=;C5;3>#)$\D(++(HY7.3UKY>UKPKX>TCX
M;?'"\TS2XK:YTW6OL%HZ,P,,!\@^4ISPI)/YT ?9'VBW\GSO.C\K^_N&W\Z7
MSH?*$WFIY9_CW#'YU\B^*?!NJ>'/ 6LWNM:5;>&O#VL:YI"P:'%?F>*!58+-
M(7X"[\\@<<<U6\8/I.D:=\4-'\#WP;P=:QZ3.1!<F2VM;MKA=ZQOD@90 L <
M#':@#[)[45X'\>K[2==^!^HZKIGC9H8;-,K'IM^@CO)<KB-V4DMM^]M!';-=
MQK6L>)H_A;8:AX#M[?6+]H8.=PDQ%@"1T&X"1QV4L,GO0!Z)32RC&2!G@>]?
M,WQ&:/5/V<-;U27Q[XB^UVDLLD\=\!I\L]SA/]':/:N$7A@B'!SG)K%^)VH:
M9JFIQ_VUKS1Z=8^ 9=1T:2*],:/?JZKYB%6 >08  Y[\4 ?6M%<[X/N=0O/
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MU\L5JLICQ)<88+&S_.40D]5+$8R,T >F-H^DR75Y=2Z;:/-?1B&ZD:%2UQ&
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MB1YVF+##%VD)+9'')Z<5GV?P_P#"=A;/:PZ23%(\$A$MQ+*1Y+AXE4LQ*JC
M$*,+[5V%% ')WG@GPO?W3W5QIA6Y>Z-XTT,\D4AE*"-CN1@<% %*]"!R*=8^
M"?"NG6_V>ST6&*'["=-,>693;;BWEX)/&68^O-=510!Q<'P[\&P0W5J-'\U+
MNWCM9C/<2RNT4;%HUW,Q(VDDJ001VZ5-%X'\,PV=M8IIS[+:\^WQR-<RF;S\
M8,AE+;V)'!R2".#QQ7744 <C%X!\(PO>F/2?DNX9K>2)KB4Q+'*<RJB%ML88
M]=@%27W@WP[?AEN-+#%K6.SW+*Z,L4;;XP"&!!5N01S[UU5% ')P^"?#-K#9
M+#IKEK*[:^AE^T2F7SV&&=I-VYRPX.XD$<'BH+CX<^#[JTL[.31]L%G&T$:1
M7$L8,3-O:-]K#>A;G:V1[5V=% '+/X*\.OJ[:PMB1>ES,I,TAB64Q^7YHBW;
M-^WC=C..]16O@O18_!%KX,O89+_3K>)(P9Y&\PE3D-O!W!@1D$'(XYKKJ* .
M*_X5_P"%8[.2QCTUT26Z%\TJW4PF^T;=GFB7?O#;1@D'D9SUJY;^#?#-O;?9
M8M)18VL7TU@9'):W=BSH23DY)))ZY/6NIHH Y:Z\%^&;R"6&XTA)%EM(K%@6
M;_4QMNC4<\%6Y##D'G-<YKGPSL[BUTR/08;6);.ZENI8=0::874CIL\QY0_F
M%P.A+'@X[#'IE% '"Z+X%TW3_#\EAJW_ !-KNYLOL%[<W#,WGP[G(CY8G:OF
M,!DYQC)JKK'PM\.WVEFRL86MVGNK*:[FFGEGDN([>4.L9=G+#C(!SQFO1**
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M\*^T/_G_ /$/_A07W_QZNMHH Y+_ (5]H?\ S_\ B'_PH+[_ ./4?\*^T/\
MY_\ Q#_X4%]_\>KK:* .2_X5]H?_ #_^(?\ PH+[_P"/4?\ "OM#_P"?_P 0
M_P#A07W_ ,>KK:* .2_X5]H?_/\ ^(?_  H+[_X]1_PK[0_^?_Q#_P"%!??_
M !ZNMHH Y+_A7VA_\_\ XA_\*"^_^/4?\*^T/_G_ /$/_A07W_QZNMHH Y+_
M (5]H?\ S_\ B'_PH+[_ ./4?\*^T/\ Y_\ Q#_X4%]_\>KK:* .2_X5]H?_
M #_^(?\ PH+[_P"/4?\ "OM#_P"?_P 0_P#A07W_ ,>KK:* .2_X5]H?_/\
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M)(YKZ4^'LFGR?#G0I--N-2N+ VJ_9Y=5S]I>/^$R9YSC'7MB@ _X5]H?_/\
M^(?_  H+[_X]1_PK[0_^?_Q#_P"%!??_ !ZNMHH X\> _#[.R+J6OEEZJ/$-
M]D?^1J%\!^'V9E74M?8KPP'B&^)'U_?5\W>';RWTGQS?V_A6\B\2Z]J-OK!L
MM2M9IX=1MYU5V"7]N_RLH?:L;<=!@<U8\(3:3#J?P]F^&-T]SXJNM'O'\2(D
MSR.T@M<YN@Q.'%SPN<'/'2@#Z)7P'X?9V1=2U\LOW@/$-]D?^1J&\!^'U=4;
M4M?#-]T'Q#?9/_D:O%_A"_PY:\\$W%EJ6H/X_N;68ZJEO,[R22A?WWVY23M
M?[N<8/ K$^($V@MKGQ5G\7WTEOXRM'B_X153,Z3*GDKY'V50>=TV0VT'G.:
M/H;_ (5]H?\ S_\ B'_PH+[_ ./4B^ -!8974/$!'J/$%]_\>KQVZ\<^/[/Q
MA)]H\0"*WT[6=$TN?33;1E9/M4">?N?&X$,21@\&N8T?QUXJ\*^#],T_0]0\
MUM8NM2T6")HQ(]IJAO\ ]UNSR,Q2,<'CY10!]%?\*^T/_G_\0_\ A07W_P >
MH'P_T-2"+[Q!QZZ_?'_VM710H\=O'')(9750K.1@N0.3^-6Z "BBB@ HHHH
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M,<9?L<$#@UA:+J_C;5I;'18=>U^+2KCQ3:P?:H)9GD%K)8L\BB:1 Q7S!R2
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MHHH **** "BBB@""2..:)HYHUD1N&5AD'\*CD@@FV-)"CE,A25!VYX.*MT4
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M_P"2*["B@#C_ .R/B%_T.^E?^")O_DBC^R/B%_T.^E?^")O_ )(KL** ./\
M[(^(7_0[Z5_X(F_^2*/[(^(7_0[Z5_X(F_\ DBNPHH X_P#LCXA?]#OI7_@B
M;_Y(H_LCXA?]#OI7_@B;_P"2*["B@#C_ .R/B%_T.^E?^")O_DBC^R/B%_T.
M^E?^")O_ )(KL** ./\ [(^(7_0[Z5_X(F_^2*/[(^(7_0[Z5_X(F_\ DBNP
MHH X_P#LCXA?]#OI7_@B;_Y(H_LCXA?]#OI7_@B;_P"2*["B@#C_ .R/B%_T
M.^E?^")O_DBC^R/B%_T.^E?^")O_ )(KL** ./\ [(^(7_0[Z5_X(F_^2*/[
M(^(7_0[Z5_X(F_\ DBNPHH X_P#LCXA?]#OI7_@B;_Y(H_LCXA?]#OI7_@B;
M_P"2*["B@#C_ .R/B%_T.^E?^")O_DBC^R/B%_T.^E?^")O_ )(KL** ./\
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MU7PEXPUJP^PZMXJT:\M3(DABDT)BI9&#*2/M'.& /X5H_P!D_$/_ *';2O\
MP1-_\D5V%% ''_V1\0O^AWTK_P $3?\ R10-(^(61N\:Z41W']AM_P#)%=A1
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC_M'Q._Z!'A?_P &-Q_\8H^T?$[_ *!'A?\ \&-Q_P#&*["B@#C_ +1\3O\
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M-Q_\8KL** ./^T?$[_H$>%__  8W'_QBC[1\3O\ H$>%_P#P8W'_ ,8KL**
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M* .+_P"%@1_]"?XJ_P#!2_\ C1_PL"/_ *$_Q5_X*7_QKM** .+_ .%@1_\
M0G^*O_!2_P#C1_PL"/\ Z$_Q5_X*7_QKM** .+_X6!'_ -"?XJ_\%+_XT?\
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M*WUC6([99+F1V@-LK*LD&XB.3#<C<H#8]"*ZZ@#B_P#A8$?_ $)_BK_P4O\
MXT?\+ C_ .A/\5?^"E_\:[2B@#B_^%@1_P#0G^*O_!2_^-'_  L"/_H3_%7_
M (*7_P :[2B@#S77O%%KX@\/ZCHEQX3\5QQ7MN\!==)<E-PP&'/4'G\*P+A=
M$U*[CO\ 5O"?C.2ZE2#[=#!9S1VU[)&!M:2/.&P1W[ 9S7M-<EXX\07/A;P?
M=ZS:QPM)')%'NGR4B5Y%0R$+\S!0Q;:.3C H XJQF\.Z?X@76H?"/C626)Y9
M+>":SFD@M7DSYC1(3A2V3^9QC-)KC^'=>U.6^O\ PGXTB>XB6"ZCM[.:*.\C
M4DJDJJ<.!EOP)'2J-U\6-6A\.V%V6TV!9[R[MCJ+PS/%*(%RI6%?WBE\$<\#
M!]177ZUXSU"R^'FB>(%M+:TN=5:UCD:Y<M!8^<!N=V7JJYQU&21R* ,"%O#M
MOXF;Q!'X/\8+<F5[E+<V,OV9)V38TPBSM#E>"?<^M:?AGQ+%X=\-VFD'POXI
MN)(@SRS#2'7S)'8N[8SQEF8UL>!?%3^*-*U!IY+26YL+V2REGLF)@GV@,'3/
M(!##(R<'/-=M0!Q?_"P(_P#H3_%7_@I?_&A?'\3,%_X1#Q4,]SI3X_G7:44
M%%%% !1110 4444 %<=??$#P;I]]<:??:N8IX6,<J?9YCM/<9"X_*NQHH \
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M  %F_P#B*/\ A:7@7_H.'_P%F_\ B*[.B@#C/^%I>!?^@X?_  %F_P#B*/\
MA:7@7_H.'_P%F_\ B*[.B@#C/^%I>!?^@X?_  %F_P#B*/\ A:7@7_H.'_P%
MF_\ B*[.B@#C/^%I>!?^@X?_  %F_P#B*/\ A:7@7_H.'_P%F_\ B*[.B@#C
M/^%I>!?^@X?_  %F_P#B*/\ A:7@7_H.'_P%F_\ B*[.B@#C/^%I>!?^@X?_
M  %F_P#B*/\ A:7@7_H.'_P%F_\ B*[.B@#C/^%I>!?^@X?_  %F_P#B*/\
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M\"_]!P_^ LW_ ,11_P +2\"_]!P_^ LW_P 179T4 <9_PM+P+_T'#_X"S?\
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MX6EX%_Z#A_\  6;_ .(H_P"%I>!?^@X?_ 6;_P"(KLZ* .,_X6EX%_Z#A_\
M 6;_ .(H_P"%I>!?^@X?_ 6;_P"(KLZ* .,_X6EX%_Z#A_\  6;_ .(KG_$O
MC'P#XDTJ.SD\23V<L%Q%=6]S#:2EH9HV#(V&C(/(Z$$&O4Z* /!TF\$V]XFK
MV?Q"U*#7C+-)/J0L-QF$H164QF'8!B*/&!D;>^35^+5O ]GH":'I?CS4[*S@
MMX(+=5M&<1&,DEB&B(??G#*V0>P%=JWC2:'Q7I^@WOAC4[5M0FDBM[AFB9&"
M*69R%<D+@=2.X]:L^)/&&E^&-3T:QOO-ENM7O([."*%=Q7<P7S&]$!903ZD4
M <QX:\7?#_PWITUO'XEN+RXNIWNKFZFM)0TTC=3A8PJ@       "M_\ X6EX
M%_Z#A_\  6;_ .(KLZ* .,_X6EX%_P"@X?\ P%F_^(H7XH>!68*-;.3P/]%F
M_P#B*[.B@ HHHH **** "BBB@ HHHH \7TGX4ZMX?L]-N-#O+*TUI;6]M;VX
M=I)8Y!+EHV56! *OMR %!!;KP*=9_#WQ;:ZJ->DDL9]0AN;2YBM9[V259C'#
M)$X>4QC:?GW+A"!C&.]>S44 >1ZY\/=<UC48]0N8--E-YIPL+VRBNYK>WB_>
ME\J%4F12&((.S)&<C/'K2C:H4=!Q3J* "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#A_%?@>Q\1:E:W;0I"_(N9]S;V4*P10H^4\MR3SMRH^]QAV_@7Q
M$OPXUOPP+RTM)]5D2-FAE=DB@*1QS,I*YWN%D?&,!I.IZUTE]XRTO3_$C:+>
M1S(J+^]NSCRHW\IY0AYSDQQNW3'&.]3ZIXHMM+\!3^+IK.X:WAMOM/V?@2$'
MH.N >1]* ..F^&NJ6;ZG#8W7]LV-S/;7L/\ :%])#<V]Q&C1L\<L:'8=OEX.
M#T8$<YH3P/XXM[<W"ZU:3ZC);:=!<NKF%IQ!).T@#A#L)$J8<+D[6X7-;-O\
M1+>:=K.^T>[L+^._MK"6W=D<*TXW1N'4D$8'/<>E;\?BKPY-->V\.M6;26"-
M)<#SA^Z53AF)] >">QZT >>V'PSUR'3=0@N+JP,UUI&I6"_O'?;)<W;SJ2Q7
M)4*P!/7(Z5ZMI]NUOI=I:R,&>&%(V(Z$A0#7-KX\\.RW.G+9W\5U;7SSI]JC
MD'EPF*/S&WD_=^7G\:MW/C#2;>\DCWM);PZ6VKRW"<HD.<+]2V'(_P!PT =/
M17G\GQ(TN/X8KXX.G7IB8B/^SPH^T^;YGEF+;G&X'.>>@)KM;.ZM]0L+>^M)
M!);W$:S1..C*PR#^1H MT444 %%%% !1110 4444 %%%% !1110 4444 <AX
MPT74-:L-.FTEH?M^F:A#J$,=PQ2.8ID%&8 E<JS<X.#CBD\%Z#?:%I-Y_:DD
M3:AJ%_<:A<+;DM'&\K[MBD@$A1@9(&<9Q3=/\;6M]XEAT:32-2L?M8G-G<74
M01+D0D"0@9W*.01N W#D4W5_&UOHNL?8;G1]2>U26&";4$B'DQ22D!!R07Y(
MR5!QD9[X .THHHH **** "BBB@ HHHH Y"/0]2_X3/5O$5T]O-,+5;/2H=S;
M88\;G+G'#/)C.,_*B^]<MKWP]\4ZUJ<&N1^*DL]0EN+":YMOL\<L,"P.KLD+
MLF_&X,P!QD]:[WQ%K]KX;T5]4NXY9@'2&.&!=TDTCL%1%'J215?PWXA@\16-
MU<0V\]G/:7#VES:W  D@E7!*G!(/#*00<$$4 =&.GK1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M '"^*_ MCXDU*UO/)CA?D7,^]M[*$8(H4?*>6Y)YVY4?>XP5\!Z[)\+/$?AB
M3[%'=:H-L,?G.T*D1QH2S;<C>R,YP#@N>O6NIO?&.FV'B5M%O(YD"+^\NCCR
MHW\MY0A.<Y,<;MTQQCO4VH>++/3/"MOXDN;.Y%G*T(9=H#Q+*ZH&89X W GT
M% '"Z?\ #O7K6YFOK6QTC2$_M"QO(])MKJ22%FA8^9(9#&"'92!@+CY!GUJM
M-\,_&&K&\.LZI9M,^FW-FLXF9UD=[F&9"(PBB./$6TJ"3SU-=A-\1M&BN_$U
MJ+6Z>;P_-!!(H4?Z2\NT*(^>?F<*?>I-/^('AW4M,U"XM;V$W=E'<2RV3S(L
MH6%BK$Y. ..IZ C- '.>*O 7B7QM%I\FI+I>C36MS+<>7:2/,K_NU$8E)1?-
M!9<,N -G'-6=2\$^(M>T;68KZZL[&]UVZM8[MK25B+>RB"Y2)BH.XD.1D8^<
MUT5OX\\*74FKQ?VM#&^CO''>>:V!&SJ"H!_BSG''4\59OO%^BV=OI5S'=)=V
M^IR,L,T+AD"+&TCR$Y^ZJH2: .%'PTUH^)A9MXFN?^$<2_;5UF%Q_IQN6A\L
MJ3LV;!RWK\W3O7:>"="U+PSX3MM!U"Z6[^PM)#;S!BS/ &/E;\@?,%(!QQQ5
M+2/'BZI=V+S>']2T_3-2C::RU"=5\N10N[+@$F+*\C=C(]#Q6U9>*/#^I0K-
M8ZS:7$;S+;J8Y0<R,,JOU(Y'J.10!T%%<Y>^*O#>GQ0S7FO6-O'/*\,;23*
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MGCN([A([B>2W(*GJDJ9:-QV;!'8C!J/_ (5;\/\ _H5[3_Q[_&C_ (5;\/\
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M ![_ !H_X5;\/_\ H5[3_P >_P : .RKD?&.BW&N>'GLK:QM;R4313+%<3/
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M_P#0KVG_ (]_C0!V5%<;_P *M^'_ /T*]I_X]_C0OPO^'ZL&7PO: CD'YO\
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M5C:1KNCZ_:O=Z+J$&H01N8V>!PP5@ 2I]^16S0 4444 %%%% !1110 4444
M%%%<G?>'_$5Q?S7%MX\U.SAD8LEO':6C+&/[H+0EB/J2: .LHKR:SU*WU!KP
MV?QJNY191///BVL1LC3AWY@Y4$<D<"M-K>^4:8S?%J^"ZLP6Q/V6Q_TDE2XV
M?N?F^4$_2@#T:BN$L=&UK5+**_T_XI:I<VLPW1RQV=B58=.#Y%7/^$7\4?\
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M*BJX3N5V]Q5G^P'NO$FEZI'HNM-X;L=?BDLHIH[CS8%:UVN_EM^\$?G;?O#
M^8_=->C_ /"+^*/^BE:O_P" 5C_\8H_X1?Q1_P!%*U?_ , K'_XQ0!PGC_PS
MXHU;Q3XLFTEYXK27P_%"T(M1(NHD/*6@5SRK$''R\C<#Z55LK/Q)_P )G=7U
MU_:=AMGEEMT%K/L%C]F_=Q/(6\I0#U&-X<?C7HO_  B_BC_HI6K_ /@%8_\
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M **5J_\ X!6/_P 8H Z^BN0_X1?Q1_T4K5__  "L?_C%'_"+^*/^BE:O_P"
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MQ'KQSS7HE8^DZ/I^BZ9%I^DV:6EM&25C0=R<DDGDDGDD\FMB@ HHHH ****
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MR_$K_H/>&?\ P4W'_P DT?9?B5_T'O#/_@IN/_DF@#KJ*Y'[+\2O^@]X9_\
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M>S!A)<IX?D$DF[[V6%QDY[YZU:;1?';06]LVH>%##;,K0QG1)ML17[I4?:<
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M;E3"G]BS;8BO"[1]IXQVQTH L>";B5O^$DL&D9X=/UJX@@+'.$94EVY] TK
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M9'B.<_*3<97GTH X31=:O?\ A.XM8U97:>Z\17&FA$U*1;B%,-Y:O;GY/)"
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD)4J>G4%200>#WK)M_ /A.UTNZTV'14%K=[!*&D=FPG,85BQ90I^Z%(V]L4
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M/FX/'-:-_P"/H].\0Z5ID^GQ^5?O;PETO8WE1Y@=O[M<DJ" "V1G.1G%2_\
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M/WO_ ,:H_P"$_P!*_P"@-XE_\)^]_P#C5 '6T5R7_"?Z5_T!O$O_ (3][_\
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MUE4.)$+* =R..&4A@<_4=JZFO/-(\3:3H]BUO]E\8WS.[2/->:+>22,3](@
M/8 "M;_A/]*_Z WB7_PG[W_XU0!UM%<E_P )_I7_ $!O$O\ X3][_P#&J/\
MA/\ 2O\ H#>)?_"?O?\ XU0!UM%<E_PG^E?] ;Q+_P"$_>__ !JC_A/]*_Z
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M][_\:H ZVBN2_P"$_P!*_P"@-XE_\)^]_P#C5(/'VED@?V/XEY]= O!_[2H
MZZBBB@ HHHH **** "BBB@#QCP;\4-0\0:U!:WR:?<+/9W5V\-@L@GM/)D"!
M6#$B0L#QMY!'3FNH;XF:+'#(TMEJ$5ZEY'8_87C42F21/,0?>VC*^IZC'6L:
M#X1LNG1Z;?>*+RXM+2"ZAL1!;I!);F<$,Q=>7(#$#H/6K=O\-3:Z;J-O'K$
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M%E0D<@$\D5T=<SX/\/77A7PI9Z#<:L=4%FOEQSM L1V#H"%XS[UTU !1110
M4444 %%%% !1110 445FMK6CJQ5M6LU8'!!G3(_6@#2HK/\ [<T7_H,67_@0
MG^-']N:+_P!!BR_\"$_QH T**S_[<T7_ *#%E_X$)_C1_;FB_P#08LO_  (3
M_&@#0HK/_MS1?^@Q9?\ @0G^-']N:+_T&++_ ,"$_P : -"BL_\ MS1?^@Q9
M?^!"?XT?VYHO_08LO_ A/\: -"BL_P#MS1?^@Q9?^!"?XT?VYHO_ $&++_P(
M3_&@#0HK/_MS1?\ H,67_@0G^-']N:+_ -!BR_\  A/\: -"BL_^W-%_Z#%E
M_P"!"?XT?VYHO_08LO\ P(3_ !H T**S_P"W-%_Z#%E_X$)_C1_;FB_]!BR_
M\"$_QH T**S_ .W-%_Z#%E_X$)_C1_;FB_\ 08LO_ A/\: .:U3QU9Z3XG?2
M[NW=+2%0)KS>,)(89)E7;U(*1-SZX'>GZEXPATWX=W/C![)YD@@\UK:*1693
MD#:S#@8)^;^[@^E4?$VB^%?$FI6=U<:CI<9C#":;>AFD7:=BAL\*&.X^N,="
M:S-#T>31_!VJZ;:>+M)MM4NI$DAFAVO#'LCCC&Y&/.\1Y?W=L4 7H_B,MC96
M,WB'26@&H7\=C:SZ=,+VWN-ZEA(KJ =HP0<C.>F1S6VWC;PVMW>VK:HL+V,<
MDTIEC9%V1L%D*L1AMI(!QGDBO/K'PE);27&I1^(/#=A>R:I:Z@ME9$I9)Y2L
MC<;L[W#DDC'*KUYK-USPKJ"V6J:A-XDT_7+I;&\MHE6X+3SB:1&5B'?8NQ5X
M5 ,XXYQ0!Z/_ ,+(\*^3/,]U<Q)#<&V^>UD#.X0.^U<;B%5@2<8&15CQ!XP3
M1[32+C3;+^U_[79UM1%*%$F('F7!P<[@F!_O"O*M.\/S:PPOY-2TT7-C/+MN
M]0N)HO[3$T2+(\B[Q(K)Y:*.BD \=Z[V33=)D@\'PQZ]I5O%H%PLS)$ZA) (
M'CVH-QVC+YY)X% %N/XAZ7<2Z.]O&WV2^TEM8FN"<_98?E"Y !+$LQ&!_=-=
M#H^N:;X@M);K2YS*D4K0R!HV1XY%ZJRL 01D5YC8>#8]+TKQ/#I_C:RBN;^5
M$TUUD"?8K19C*+<E6W<EY%++@@$8Y%=/X)L['PS::I'>^(-+FEU"_>]Q!/\
M+&&51MR[%F^[U/K0!Z#16?\ VYHO_08LO_ A/\:/[<T7_H,67_@0G^- &A16
M?_;FB_\ 08LO_ A/\:/[<T7_ *#%E_X$)_C0!H45G_VYHO\ T&++_P "$_QH
M_MS1?^@Q9?\ @0G^- &A16?_ &YHO_08LO\ P(3_ !H_MS1?^@Q9?^!"?XT
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M_;FB_P#08LO_  (3_&C^W-%_Z#%E_P"!"?XT :%%9_\ ;FB_]!BR_P# A/\
M&C^W-%_Z#%E_X$)_C0!H5B:[J5UI6E-=66DW&JW1D2**U@(!9F8*"6/"J,Y+
M'H :M_VYHO\ T&++_P "$_QKF_%5_=7WARYL_"OBC2=-U*4A5N;EPZQKGYL
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MNA_^"Z'_ .)H_P"$$\#_ /0FZ'_X+H?_ (FNBHH YW_A!/ __0FZ'_X+H?\
MXFC_ (03P/\ ]";H?_@NA_\ B:Z*B@#G?^$$\#_]";H?_@NA_P#B:/\ A!/
M_P#T)NA_^"Z'_P")KHJ* .=_X03P/_T)NA_^"Z'_ .)H_P"$$\#_ /0FZ'_X
M+H?_ (FNBHH YW_A!/ __0FZ'_X+H?\ XFC_ (03P/\ ]";H?_@NA_\ B:Z*
MB@#G?^$$\#_]";H?_@NA_P#B:/\ A!/ _P#T)NA_^"Z'_P")KHJ* .=_X03P
M/_T)NA_^"Z'_ .)H_P"$$\#_ /0FZ'_X+H?_ (FNBHH YW_A!/ __0FZ'_X+
MH?\ XFC_ (03P/\ ]";H?_@NA_\ B:Z*B@#G?^$$\#_]";H?_@NA_P#B:/\
MA!/ _P#T)NA_^"Z'_P")KHJ* .=_X03P/_T)NA_^"Z'_ .)H_P"$$\#_ /0F
MZ'_X+H?_ (FNBHH YW_A!?!'_0FZ'_X+X?\ XFC_ (03P/\ ]";H?_@NA_\
MB:Z*B@#G?^$$\#_]";H?_@NA_P#B:/\ A!/ _P#T)NA_^"Z'_P")KHJ* .=_
MX03P/_T)NA_^"Z'_ .)H_P"$$\#_ /0FZ'_X+H?_ (FNBHH YW_A!/ __0FZ
M'_X+H?\ XFC_ (03P/\ ]";H?_@NA_\ B:Z*B@#G?^$$\#_]";H?_@NA_P#B
M:/\ A!/ _P#T)NA_^"Z'_P")KHJ* .=_X03P/_T)NA_^"Z'_ .)H_P"$$\#_
M /0FZ'_X+H?_ (FNBHH YW_A!/ __0FZ'_X+H?\ XFC_ (03P/\ ]";H?_@N
MA_\ B:Z*B@#G?^$$\#_]";H?_@NA_P#B:/\ A!/ _P#T)NA_^"Z'_P")KHJ*
M .=_X03P/_T)NA_^"Z'_ .)H_P"$$\#_ /0FZ'_X+H?_ (FNBHH YW_A!/ _
M_0FZ'_X+H?\ XFC_ (03P/\ ]";H?_@NA_\ B:Z*B@#G?^$$\#_]";H?_@NA
M_P#B:/\ A!/ _P#T)NA_^"Z'_P")KHJ* .=_X03P/_T)NA_^"Z'_ .)H_P"$
M$\#_ /0FZ'_X+H?_ (FNBHH YW_A!/ __0FZ'_X+H?\ XFC_ (03P/\ ]";H
M?_@NA_\ B:Z*B@#G?^$$\#_]";H?_@NA_P#B:/\ A!/ _P#T)NA_^"Z'_P")
MKHJ* .=_X03P/_T)NA_^"Z'_ .)H_P"$$\#_ /0FZ'_X+H?_ (FNBHH YW_A
M!/ __0FZ'_X+H?\ XFC_ (03P/\ ]";H?_@NA_\ B:Z*B@#G?^$$\#_]";H?
M_@NA_P#B:0>!?!*D$>#M#!'<:?#_ /$UT=% !1110 4444 %%%% !113695'
MS,!]: '4444 %%%)D9QGF@!:**0D#J<4 +1110 44A( R>!31)&>CJ?H: 'T
M444 %%%% !1110 4444 %%%% !1110 4444 %%%'?WH **** "BBB@ HHHH
M**** "BBB@ HHHH **3(QG/'K2T %%%% !1110 4444 %%%% !1110 4444
M%%'>B@ HHHH **** "BBB@ HHHH *^=]4T_0?&OQ_P#&6B_$K4GBT[1["T?1
MK&2]:UB,<B$RW PR[F#\;NW3M7T17+^(O _A'Q<8'\4>&=/UA[?/E-=VZR%
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3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>cvm_10kimg18.jpg
<TEXT>
begin 644 cvm_10kimg18.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" $7 BX# 2(  A$! Q$!_\0
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M*H)X+QMM<>YY%-RY4KH.:R3DK7^9Z#149=5*J6 )Z GDU)6AJ%%%% !1110
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M.5D5H6W%1O!PP['.,<^E:^>*S/[%L-H4QR,,8.9&.?KS4?\ 9<\)S:WTL?\
MLL=PKTVH/X7;U.12J+XE?T-GM2=JHP_;$A3SPLL@!W%#C/TS_P#6J=KB./'F
M[H_=AQ^?2H>ANM2Q7!Z]HVJR>(M1O+*U^U6^IZ-)I[,&4-;RKO9,Y(^5MY''
M0@9X.1W"LKH'1@RD9!'0BI*!GC=I\,=5N?#ML+JXM=(NHK*Q@-G8@^5,8&WG
MSCCYB3\O . /XNE;&C_#I;'6+;4IGM_W,=V!"2TP229HR'0L %QY9X"CD_7/
MIE% 'E=Q\/=0M/"\\,=Q]MO8-"M;&U$ V.+JW=Y(Y06.!\[*>3V/K4<WPM-U
MI30WEQ;7-W/HMU93S30;BUY<.))+@>GSYX'(&,'BO6** /(M2\ ZA#?VDVDV
M>GWENVIV=R]K*OEPQB*VDC=V'.2693P,],]*&^%<DEMJ$,UQ9R276ESV<1-O
M\MI+).\V8QGY47> H'/R]J]=HH \P;P'JDGC:VUR>^M9%@OOM/F!7622$PM'
MY)4$(>6SN.XMCG%16_PUO(]!TK1_MUI8II]M=V8N+.(K)*LL/E+*1QAQU/)^
MM>J44 >:7'AO6/[$L/#L>EZ9!'+>6S3W6GKY2110,KEV!Y+L4"J!G&>3Q7I=
M%% !1110!CZ[IZZMX?U'2V"$75O)#\_3+*1S^=5/"NF7>B^$-+TF^F6>XM+9
M())$)*L5&.,\UA:\GB36?&-CHNFM<:9I%NR75YJ*-M:?!R((_K_$?3]>YYVU
ME&TI.5MM#&/O2<K;:>I/1116IL%%%% !1110 4444 %%%% !1110 4444 -[
M44M<QXG\6:/X5L3=:E<8<@^5"G,DI] /ZGBL93C"+E)V0FTM6;TTT=O$TDTB
MQQJ,LS'  ]2:\C\6_&;3[%I+/PW&M_..#</_ *I?H.K?H/K7FOC#XB:UXLF:
M%Y#9Z<&^2VB8X/NQ_B/Z>U<='')-(L<:%W8X55&237@XG,92]VCHNYQ5,0WI
M U-:\1:SX@O3=:M?2W#_ ,(8X5!Z*!P/PIVA^&=;\1W7D:3I\DY!&YP,(GU8
M\"O3/!/P=DN#'J7B96AB^\EBIPS?[Y_A^@Y^E>X6.GV.FVB6MA:QVT"?=CB4
M*!^5*A@:E;]Y6=K_ 'BA1E+61Y%X?^!]G"%F\17S7,G>"V.U![%CR?P KK=7
MNO ?POT%=6U"UATRR,R0>=%;-*Y=NF2 6/0\]L5WM<-\0-%OM<B\-1V%J+H6
MNNVEU<J64!8%+;R<]1@].]>U1PM*E\,?\SKC3C'9&[%XBTB?7(-#ANA+>SV7
M]H1JBDJ\&X+O#=.K#O6LDT,C.L<B.R'#!6!*GT/I7AUM\/\ QMIOB?Q#I6DL
M+72(O#ESI^@:J9AN@,LH=(&&=P\H@A6Q]W;W%9?A7X<^+;2:Y^PV=[X:U'^Q
MKFP-REO96\#S.@",[P.TDQ5QN#LH(R3WQ76:'T*MQ;L7"S1DQG:X##Y3Z'TI
MC75LJ-(UQ$$5MK,7& ?0^]>&7/@F:^^&>J>'])^%9\/ZM):6UO/<>=;_ .FL
ML\;.!(CEI.%9M[X/XFMKQ3X"L[#Q)I-W8^ [;Q!X7@MITFT2U6%!'=NR8NC'
M(525BJE"2=PSD9YH ]>FFAA3?-,L2?WG8 ?K6<E_"VJOI<:3><D*W!D,3>65
M)( #XP3QTSG%>&ZA\/\ Q GA3P]#?>';[4+NR%YY%DGV34K6SBEEW1P21W+J
M'*)M42J<@!AT(K7NO!?B:^&H'5M#DACNO"-GILL&AW21;;A)Y&>* R'@!6'W
MOE(^7)H ]JBFAF3=#*DJYQN1@1G\*;<VMK>0F&ZMXIXSU25 P/X&O-?A3H>M
M:&NLPWWAVTT:Q=XC;,EG;V=Q.0I#F6*W9HL#@*P()YR.!7JE39,#S;7/A#X3
MU96>UMVTR<]&MS\O_?!X_+%>0>)_A?XD\/A[B&/^TK->?-@!+*/]I>H_4>]?
M4PI/O5Y]?!4ZFRL_(PG1C+R/B)))(9 \;,CJ<@@X(->O^ _B]<6LD.E>*)#/
M;GY4O3R\?IO_ +P]^OUKH?B-\,[?5+.;6]#MQ#J$8,DL48PMP.IP.S?S^M?/
MI!!P>M>')5L'4T?^3.-J5&1]K0SPW4"3P2"2)U#*ZG(8'H0:MBO#/@MXMEE,
MOA>^D+A5,MJ6.<#^)/ZC\:]SKZ7#5XUZ:DCT(3YXW%HHHKI+"BBB@#A]=\$V
MNJZS#KNGW4VCZS#@"\M  TB]TD4_+(/KTJ]X@\36'A:"VN-4ANS;R,5>YAMV
MDC@P/O2%1\H/KBNF'3FAE5E^89J.6UW'1LRY+7<=&S)TO6-,UFS6\TF_@O+<
M])() Z_3CH?:M8_+S679Z3IVF^<NFV,%EYSF23R(U3>Y&-QP.3Q7+0Z?\1M+
MU"-5UJPUS3VD&_[7 ;:>-"><-'E6P/4"IYI12YE?T!RE%+F5_0[[YMM SMYK
MG_$7B33O#=M#<ZG'=F&1BID@MGF$?'5M@) HT#Q1H/B."630]3AOEB($@C;+
M1D]-P/(Z'KZ57-'FY;ZE<T>:U]>QT=%)N7^\*6K+"BBB@ HHHH YOPCXCC\5
M^&QK2VC6J&XN+?RW<,1Y4SQ$Y'KLS^-5=)^('@_7-:_L?2?$%O=7OS[(UW 3
M;#A_+8@+)COM)Q7+^&_"/CS0M.D\,R76@3Z%+=7+R2KYZW7E3S.[8_A#@.0#
MTXJ'2?AWXD4^&])UW5M-ET+PON6R-E;/'<W/[EH4\PDE4PCDG;G<<=.E '66
M7Q$\'ZE?W5AI^M)=SVR22/Y44C(PC^_L<+M<CT4DU4?XC>';K0-<O]$O!>W>
MDV,M^UG,DEN[JJL0<2*#M)7&X @&L32_!GCS3_!\G@N'Q-IUEIEMI[6-AJ=G
M;R)>I@;8F8;M@('4KR3R-N:Q-*^#^KV^HZMJ%Q<:/:RZAX?NM'*VGVF4F24J
M1*\DSLS=.1P>>IH ]:T/46UCPYIFK-"(6O;6*Y,8.0A= V,]\9K-\.^(W\0W
MFLM#:"/3K*\:QM[K?DW+H )6 Q@*'R@.3DJ:IS6NO:'\,(M-T.)+[6[33XK.
MW(PJ>:$6/S#N/W0?F(ZX&.M;'AO0[7PSX8T[0K0EHK*%8]YZR-U9S[LQ)/N:
M .*U[XF:II.K>*(K7PB;W2_#"1RZA>?VA'$^QH1*2D;+\Q"GH6&2,5T&J?$3
MPAHJV;:KJZVC7=NMVD;1NSI$>CN%!V+[M@<'GBN8UCX.Z7KWBGQ+X@U*91>Z
MC):RZ=<Q E[-H8U4;D8[)!N7.U@01P:S-7^%OB;4]<N/$4FI6$^I:G9Q6NI6
MXN[ZTMV,890Z>1(I*LK<HX;!SAN30!W>N?$#P?X<>WCU37H(9)X/M4:QJTQ,
M/_/4[ <)_M' /K3XO&FDS:H8A>VBV']DIK NWN-O[AF(#E2!A,#.XG\*\O\
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MG/Z5V&EZ))8ZOJ^K7&J7%V^HR1^7$['R[:)$"JB+DC).YBW4EO85;_L/3_\
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M!589/S(R.I/<;3@<U!9?#W1=/O;2ZLY]0@-GO6TC6Z;9:QNVYXT7H%8@9ZG
M ! %7M$T.ZLO$.M^(=4E2XO]1=(HUA4A(+://EQC/).6=F/<MP, 4 =71110
M QONU\A^.K>&U\>:S! H6,73D < 9.2*^MYIHX87ED8*B*69CV ZU\<^)-2_
MMCQ/J6I*<K<7#R+D8^4L<?IBO S9KDBNMSDQ.R-7X>S20_$31&C8J3<*AQW#
M<']":^MJ^6_A/HTNJ>/K2X"GR+',\C8X&/NC_OK'Y&OJ7TK3*DU1;?5CP_PL
M=1117MG4%%%% !1110 4444 )@?W:K+;PQN\D<*(\F-S*H!;Z^M6J* .%O/A
MUHMYJ$^HVM]J^E7EPYDDEL=0ECW,>IVDE?TK;OK/4FT)K'2=0^RWJQJD=W/&
M)B",<LN1N) Y^M;>T9H[UFHI7LK7,^1*]E:_8Y'0[?QU;ZB%US4M'O=/VG+V
M]O)%-GMP6*XIVNZMXHL+N-=%\+KK%L8\N_VU('5L] &'(QWS75CIZTC9["ER
M6CRILGDM'EBVOQ9B:%J.I:CIGVC5-'ETFYWE?L[S)*<#HVY.,&L/_A8++=?9
MY/!?B9?GV;Q8!DZXSD-TKN!T%)QWI\LK))CY962YOPW,C6M;M]"L#?75O=SH
M&"[+2W:9\G_94$XJAH?C+3?$%Z;.SL]3@D2,R'[58RP+@$#&6 &>>E=/MX_Q
MH XXIVE>]]!VES7OIZ',:UXVTG1=0_L^[MM2DEVA]UO8RS)@_P"TJD5?TO6K
M?5M(&IV<-RL+;L)- T4GRD@_(P![<>M:Y'^SQ28!'%)*5]]/0$I7;;T]#AK?
MXA0W5W';Q>%?$N)'">8VF.B+DXR22, =S6_KVK7FDV,<UGH]WK$COL,-J4#*
M,$[CO(&.,?C6[C_9K$U[7;'P]HDVJ:@^V&(< ?>=CT4>YIQC-^[>[?D3[RB^
M:7SML4-!UC7M4EF75/"]QHL**#&\]Q%(9#W&U"<56U63X@-JTL.A6^AI8C'E
MSW<LK.W'.44 #G/>O)=>\=:IJTK&]FD"L<I90R&.*,=MY'+FO+M2^(\VDZPR
MZ2;BTN(6P9K:=D /<8.<_C7=5P?LJ:G4ERW_ *L30HUL1)TZ47)K5NZ6A]?Q
MP:Q-X?$%S>10ZJT)5[BUCRB.?XE5\]/0UD:7X/O+75(-2U/QCK>I3PMN\IY4
MB@;C^)$4 CZUQ7PI^+G_  ETL?A_7E$6L^69;:95VK>(.O'0..XZ'!(Z5[1W
M;=7%*"NN;7L:.%I6DG=:6?1HRM4\.:'K5Q;W&J:3:7TMMGR6N(5D\O.,XS]!
M5^WMX+6(0VT*1(.BHH4#\!5K^&EIV5[V*48IWMJ.HHHIE!1110 4444 %%%%
M !1110 VF,WH:HK=PW'VB*TN(Y;B'AXPX)1B,@-CD5R.E:'XPO-5AU;Q-X@%
MLL+;TTS2_E@^DCL-TGTX%9N5FDE<SE-IKE5[FMX@\::'X:GAM-0N':\G7=#:
MP0O--*,XX503UJYH>K3:UI/V[^R[S3&8L%@OXQ')QT8J"< _G6QY<9<2%06Q
MC..<4]>!3M+FO?0$I<S;>G8X*WL_B7=7T4U_K&B6-LCAGAM+229G7/*[G88R
M.X%;6O:9?ZI81V^GZ[<Z/,LFYIK9$9F&"-OS@C'?\*Z/N*3_ (#@5*II7U>O
MF2H))IMN_FSF-#\/ZCH\L\EYXHU#5Q* %2\\O"8[C:HJMJFA>*KK4Y;S2O&T
MVG0/C%H]C%-&F!@X)PW/7K78GY10OS"CV<;6U^]CY(\O+K][,4V^N1^%Y+<W
MD5WJX@95N GDH\F#@X^;:.GK7B]C\.Y+S6TM_$7AO6X)KECNO8+Z"Y@!Y)9C
MM##/N.]?0?S45E6PT*UN;H3*GS6U>AX^_P (_ T-XEC-K%W'=RJ7C@:XB#N!
MU(7;DBNQ\)^"M%\)P3+I:O)+,?GFF(9R.RY &!5_7?">@^)HU36M+AN63_5R
M\K+'_NN,,OX&HK/3Y/"_AB6"S:_UB2!7>-+B</-)W"!VP/89J*>&ITY<T8)>
M?42CRR;Y5;OU.D^;TIW:N2\.>,])\2-+:V_FV6I0<7&GW:^7/"?=3U'^T,BN
MMKK335XNYK&49*\7=#J***HL**** (RW->7_ !)^+&D_#V:UM9+.6_OKA2\<
M$3!0J XW,3TYX'!Z&O3ROS5YU\0/A=X>^(26[ZI)<6UW; K'<6[ ,%)R5(((
M(_E657FY'[/<Z<*Z*K1]LFX];$WPZ^)&E_$32Y[C3X);6YMG"3P2D$IG.T@C
MJ#@^G0UWJ]/FKB/ ?P^T3X>Z=+9Z.LLKSL'GN)V!DD(&!G   '. !W-=RW2G
M2Y^1<VY.)=)U)>Q3Y;Z7W):***T, HHI#T- '"-\0M%M?&MUX9OY/LTL3*J3
MNW[MV*@[2?X3S]*[7>NW=N&W&<]L5\A>,+[[?XVUB\!.'NI-I]@Q _0"HI/%
M7B*71$T635[@V"](M_&/3U(]CQ7SRS'EE)25]78XUB+-W1ZI\3?B1:M93>']
M!N1,\N4N;B,Y55[HI[Y[G\/IX_I.DZAK.I0V&FV[W%S*<*JC]3Z#WK=\&^!]
M4\97KK:S106T)'G32,"5SZ+U/\O>OH/0_#/A_P  Z%=7%O&<0PM+<W+C,CJH
M+'\.#P*PA1JXVI[2>D?ZV(4)5GS2V'>!?"-OX1T!+-2);N7$ES+C[S>@]AV_
M$]ZC\<:Y>:-H4-MI/F-K.I3K9V2Q1K(ZD\O*$) ;8@9\'C@#O6/-\1=5M]>\
M*>'W\-QOJGB2TN;V)'O/+2W2)0P1VV$ERK#.!@'/;FJVG_&3P/>:%9:I?32V
M%[*]S";"6/?/"\!VS_=R" <<@\Y&.>*^DIPC3BH16B.Y))60NB>-/$$UII.@
MS0Q'Q#_:$VEWLE^AB(V0M-'/Y:?\]$"-@$#+$9XINE^--<UKQ+H69K#3[*\L
M;LS6\H)\V>&Z$+>4_') ) .>#R#5^X^+GPYM]]XVI.T<=C!J<EREE*52VE;9
M'*S;>!G(P>1Z53\5?%'P_IFIZ;INCZ;'K<XUZUT>X<1E8;.6;DXDVE3( 0=H
M]>2*T&9]O\3-6C\'17S?8EGMM"75Y9-2EVF\9O,Q''M"C(\ODXXW+QWK8C\?
M:I<>+WTF'1XQ;PW<%I()9 DCB1%8S(68#:-_ P2VTX.>*P=>\9?#OQ!+I<L-
MF^HQG4AHX-S;W<,#MO97BCVILDDRAX/!'4XJ?3?C!X1UA?#FO7%G#H^GW]O>
MSB;5862:*.VSN:,JK)@'.<L.O&3Q0!M^&_&^K:IJ7AY+^PM8K;7H;J2'[/(Q
M>$P,!\V1@A@>V,'UZU2\5:MXP?QYJ&B^&;J\-Q!I5O<V<,4<1@\YYI%)G9QG
M80@Z'. <<UVVA:QI^NV*7UC9W4,(59(FN;1H"RN,AEW <$?_ %ZP]0\:>7\1
M'\':'HO]I:O#IXU"[DEF%O%!$6*HI?:Q9F;/ & .2: ,J]\?:Y:Z;=ZDVFVC
MPKK#Z/$(R[>6RR%?.D)P ORGY?4K\PS56^^)6LV-E!=76GV,$:K<//,9A+E8
MG4 K$C%P&!)XWE2,$'(K5U/XH>"M$N9-+\27"V-\D<+ZA9A//%H9CA1(4!!R
M3U&>.3@5PVD_'#P\^MWMEXBT"PT;1M)2^F^VAO,$9@NE@7:@3JY8'COQSUH
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MUT'AOQIH>JZ<MY<:2;"^NK>:Z>(6K'[0L4FURC[1YA!VD_[P^M6X?&G@[5K
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MY[W\IF<US/?)Y-%9MM[GSE7$5:KO*39L2^)M9D&U+D6Z^D*!/Y51DU+4)O\
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MBK.XS_\ A!=!D(-\MYJ)];N[DDS^&<5I6GAGP[8@&UT.QB8?Q"!<_GC-;-%
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M@9]S4U*V(510C%.-][ZV[BC3H.CS2D^;M;J=#=76BZ*$DG\BU(!5-J -CJ0
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M>,K[P/X(GUC3K-;JY\Q(D\P$I&6_C;'88_,BO//@O\6O$WC/Q-<:'KT<5P!
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ME['<:UX;TW7 K7<965!A9$.& ]*IZ3X,TG2[E;I?,GF0Y1I2#M/J  *H^/\
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MEE!A$80[>=LAV[AUYKT3G.DU[P.UY<O>Z;*J/(2S1OP,GJ<BL$>!?$&['EQ
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MFMUT^^;Y8YU/^CW)_P!ACT/^R>:ZFO,.@**** "BBB@ HHHH **** "BBB@
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MQ+--YD<:.[%=L<8,F6// S[5M:\OPIGUG2-!\01Z#-J%NB+I]K<K&SQK_ J
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MN.E6J4)6_ Z)0C41Z@M+7"Z;KEQ9XCD_>P_W3V^E=59:E:7R Q28;^ZW!_\
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M'J* )Z^;OBKI,>E^-WEB4*+U/.*CL<XS7TC7SE\6-4BU+Q?&L>/]&B,9P?\
M:.#^/7\J ,/P-K#:'XUTZ]!/EM)Y,H'=&X/]#^%?5-?&T+M'.DB?>5@1]:^P
M[=F>UA=OO,H)_*@":BBB@ HHHH **** "BBB@ HHHH **** *\RNT96.0QL>
MC  X_.N7UC3]3C5YGN#/$.2<]/P[?A76DA023@#O7':YK'VIS:V[?NE/)_O&
MO/Q?)R>\]>AM1YN;0P223EB2?>KFEW!MM0AD[!AGZ=_TS2Z;I\FH7:Q+PO\
M$WH*V+KPR\9\RTDWXYVMP?\ #^5>;2I5'^\BMCLE.*]V3.L[4E5;%G:RB\U2
MLBC:V1CD<5<KZ".J3/.V"BBBJ$%%%% !1110!S'C7P_/XH\'7VAVUTEK+<&,
MK*ZE@NR17Z#_ '<5@3?#?2X==L-2T5OL6S5Y-4O VYS*7@DBVH2?D ,A8 <
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!A0Z;I=OJ%UK%O:I'=7:I)/,@PTH7
MA=WJ0#C/7'%;M%% '+R>$_"]QX@7Q/-HEM+J>X.MTR[F5@-H8 \ @=\9K5DM
MX)K^W26%9)8"9XV=03&Q!!(/8X)''8FBB@#3HHHH *QM0TG3M4A@;4+2.YCM
MYUNHUD&0LB\JV/4'D>_-%% &S1110 4444 %%%% !1110 4444 %%%% !111
<0 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cvm_10kimg17.jpg
<TEXT>
begin 644 cvm_10kimg17.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" $7 E4# 2(  A$! Q$!_\0
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M6_VOJO\ T$;G_OX:/[7U7_H(W/\ W\-']ET>[_KY!]=J=D?:7_"T/"GKJ/\
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MI[B=ML<:RG+'T'-0?VQJA&1J5S_W\-/^RZ/=_>@^MU.R/M/_ (6AX4]=1_\
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M *"-S_W\-']E4^[#Z[4[(^TO^%H>%/[VH_\ @OF_^)H_X6AX4_O:C_X+YO\
MXFOBW^U]5_Z"-S_W\-']KZK_ -!&Y_[^&C^RJ?=A]=J=D?:7_"T/"G][4?\
MP7S?_$T?\+0\*?WM1_\ !?-_\37Q;_:^J_\ 01N?^_AH_M?5?^@C<_\ ?PT?
MV53[L/KM3LC[2_X6AX4_O:C_ ."^;_XFC_A:'A3^]J/_ (+YO_B:^+?[7U7_
M *"-S_W\-']KZK_T$;G_ +^&C^RJ?=A]=J=D?:7_  M#PI_>U'_P7S?_ !-'
M_"T/"G][4?\ P7S?_$U\6_VOJO\ T$;G_OX:/[7U7_H(W/\ W\-']E4^[#Z[
M4[(^TO\ A:'A3^]J/_@OF_\ B:/^%H>%/[VH_P#@OF_^)KXM_M?5?^@C<_\
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M2X=/9;>%S>V$\R17+H79(8GP=A4!@S] 0 35[6(;70](\;6>GZ?:?9Y8M*N
MDD#-Y1F7<0N_YE +$J#R*X:W\0Z[:W5U=6^L723W9!GD,A8RD="V<Y(['J.U
M+%XBU^"YEN8=:O4GFA%O))YQ+21CHA/<#MZ53I2[_P!:?Y#YX]CNY6TW4/&6
MF>';K1;26.[T6W66ZD#-<!Q8AD=&S\FTJO '/.<YXX_PK:VL]OK&I7%DFH3:
M;8?:H;.3)21C(BEV P65%8L1WP,\9K+74M16]COEOIA=1((XY@YW(H78%!]
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M2Q/+@NI5?OIE5."0>O/)JI:^$]5NK*SNDFTZ)+X%K9;B_BB>8!RF55F!^\I
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M)):%.BBBNL@**** "BBB@#Z9^ O_ "3JZ_["4O\ Z!'11\!?^2=77_82E_\
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M(=%OI+:*,3/*L#%50KN#9QTV\_3FLRN_L]?MU\<^"YY]67[!IVG6MO(Y<^7
M?)(E4^G)(/K7GZ#"*.F!713E)[F<DEL+3DDDCW>7(R;U*-M8C<IZ@^H]J;17
M42/CDDAE66&1HY%Y5T8J1]"*9110 4444 %%%% !1110!+-<7%QY?VBXEF\I
M!''YCEMB#HHST ]!Q45%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#_T [_\ \!G_ ,*^_=J_W11M7^Z*?]IR_E_$?U%?S'P%_P (SXA_Z =__P"
MS_X4?\(SXA_Z =__ . S_P"%??VVF[?:E_:DOY?Q%]17<^ _^$9\0_\ 0#O_
M /P&?_"C_A&?$/\ T [_ /\  9_\*^_ME&RC^TY?R?B'U%=SX!_X1GQ#_P!
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M'%9UO!/=W,5M:PO//,P2.*-2S.QX  '4T_JN'[(/;UNY]%?\+WU#_H*Z-_X
M3?\ QVE_X7MJ'_04T;_P F_^.UXG=>$M1TWP[J6IZM;S6<MK-!%&AVLDGF%P
MWS D978..HSS5&^\.:[IME]LO]+GMX 55F;&8RWW0X!RA/;<!FDL+AW]E ZU
M5=6>\_\ "^+_ /Z"FC?^ $W_ ,=I?^%[ZA_T%M&_\ )O_CM>&R>#O%44+32>
M'[P*L@B8!,L&+;1E1S@MP#C&>]5Y_#>O6VK6VDS:3<"^NE#P0HH<RJ<\J5)!
M'!R0>,'/2J6$P[V2#VU7NSWC_A>^H?\ 05T?_P  )O\ X[1_PO?4/^@KH_\
MX 3?_':\'N/#>O6NHVVGSZ5.MU=*6@1<.)@,YV,I(;&#G!XI;SPUX@T^*UDO
M-'N85NY/*ARN2\G'R8&2&Y'RG!YZ4OJN'[(7M:O=GO/_  O;4/\ H+:-_P"
M$W_QVD_X7QJ'_04T;_P F_\ CM>-Z7X$UZ]\0V6DWEJ]D+KS=LI9' *(6(X;
M&> ",Y&<XK(3P_KCVMQ=+I<S06V\32KADC* %P6!QQN7OSGC-'U7#O3E0_;5
M>[/>_P#A>^H?]!71O_ ";_X[1_PO?4/^@KHW_@!-_P#':\&OO#FO:;I_]H7V
ME3P6V5!=L?(6^Z& .4SVW 9K3\0>"M8T?4-5^SV-S<:982LOVIE )C!QYA4'
M.W/&[&WWH^JX?L@]M5[L]D_X7MJ'_06T;_P F_\ CM/_ .%\7_\ T%-&_P#
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M08/?Y@1CKQ4?5</V0>VJ=V>__P#"]M0_Z"VC?^ $W_QVD_X7OJ'_ $%=&_\
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MAV(5)+/\W(Z8*X/6CZOA[VLBO;5M[GO7_"^+_P#Z"FC?^ $W_P =H_X7Q?\
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MV?F\D'VO1;C56PH^5X_-P@]CY0YZ\FH>&PZ^RBE6JOJ>S_\ "];[_H+:-_X
M3?\ QVD_X7MJ'_06T;_P F_^.U\]6-E>:E>Q66GVLEU<R\)%$NYFXR?R')/:
MMN'PGJ$4M_%K%O-8F#39M0A/RLL_EE1@,"01D\D'BK>$P\=XHE5JSV9[9_PO
M;4/^@MHW_@!-_P#':/\ A>VH?]!;1O\ P F_^.UX7_PCFIW3VZZ5I=]<%K6&
M>3=&./,SAA@_ZLX.&..ASBFRZ#?6#ZE;ZM87=O<6EHMT%1590K.H#L<X\LAN
M&7/./>E]5PW9#]M5[L]U_P"%[:A_T%M'_P# ";_X[1_PO;4/^@MH_P#X 3?_
M !VO"+CPSXAM=*_M2XT>XBLPJR-(5&45ONLRYW*IR,$@ Y%)?>&]>TRS6\U#
M2YK>W+*A=L'86Z!@#E">P8#-+ZKA^R%[:KW9[S_PO;4/^@IHW_@!-_\ ':3_
M (7OJ'_04T;_ , )O_CM>"^(-+71O$^IZ-;R-<+:7+VZ.^%+X. 3V%:6L^"M
M:TOQ'+HMM:3:A*D,<P\E0S,K!,G:I.,,X7]>E'U7#Z>ZM2O;5NY[1_PO;4/^
M@MHW_@!-_P#':3_A>VH?]!;1O_ ";_X[7AK>&]28V5K;:;>/?S>>)$95V?NW
MVDJP/1?XB< &I+?PS>+>:E::M#-8S6FFRZ@BX!$H7&W!&05.3R">E;?5,-_*
M@]M6[GMW_"][[_H*Z-_X 3?_ !VG?\+UU#_H*Z-_X 3?_':\$'AW7&TC^UAI
MDOV+R_-\W*Y*9QOVYW%<_P 6,>]9=)8*@]HH7MZJZGT?_P +UU#_ *"VC?\
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M$H3!$;[=N5)ZY(QD5@>(;^#^QK'1K7^R3'%-)<LFF+*4B=@%QYDC'=D*"0H
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MT@^TVYC>/:0#A3M<_,.<@53A4>^NGXV&I1(K/PNM]<^'!;WA^QZM$S2SNO\
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MVB3=&KYQV'S5T4&H0Z_ILO\ :G]ASM]LN+F.&_NY+5[/S6WL P_UL1)SM'S
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MELDI7!D5OOA?XMF.IQNQ3X/'&GPRFX5-61)-.>P;38ID2T@W0&(N@_BY^;!
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M>E +,%49). !WKMK/1=%O(?!^C_8Q'>Z\=MQJ#2M^Z'VIXP8TSC<54#+9'3
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M0VMM;Z'>R+!?VD:P^6YQYRJ,"1,_>! !XZ'@\UU7>FU9DQV/&?VA?^1#L/\
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M>TY9"FX$*"@^4\<5P>IZM+?Z?#IMMIT.GV$4K7'DQ,\C22LH4N[N2S': !V
M[<UE%)FV[MS;1A<G.!Z#TH6NKT&SN?MUUXD\1Z[X7G\G-[))%I<2(L:07$4C
M-$BXZ!P70^I<$US_ (IFM_[:73;)E:TTJ%;&-U'^L*9\R3WW2%S],57T74I]
M#U+^TH+.*>ZC1A;O+NQ!(1@2@ \L.<9R,X/:LT1.!]T_C5QGRR\B'JAE%/\
M+?\ NFCRW_NFO1]I$BPRBG^6_P#=-'EO_=-7[:(#**?Y;_W31Y;_ -TT>VB
MRBG^6_\ =-'EO_=-'MH@,HI_EO\ W31Y;_W31SQ 913_ "W_ +IH\M_[IJ?;
M1 913_+?^Z:/+?\ NFJ]M$!E%/\ +?\ NFCRW_NFH]O !E%/\M_[IH\M_P"Z
M:/;P 913_+?^Z:/+?^Z:/;P 913_ "W_ +IH\M_[IH]O +#**?Y;_P!TT>6_
M]TT>W@ RBG^6_P#=-'EO_=-'MX ,HI_EO_=-'EO_ '33]M$!E%/\M_[IH\M_
M[IJN>(#**?Y;_P!TT>6_]TT<\0&44_RW_NFCRW_NFI]M$!E%/\M_[IH\M_[I
MJO;1 913_+?^Z:/+?^Z:/;1 913_ "W_ +IH\M_[IJ/:Q ^DO@/_ ,D[NO\
ML)2_^@1T59_9_P!J_#R]5F 8:E)D>G[N.BOGYU/>9WP^%'O5%%%>0>N%%%%
M!1110 4444 %%%% %2ZL;2^C\F\M8KB/KME0.,_C2V]O!:6B0VL20PH,*J#
M4>PHHH J7FGV.H0B/4+*"[B!\P)/&LB@^N".O)JM_P (GX9_Z%W2_P#P#C_P
MHHK.-27<EQ0O_")^&O\ H7M,_P# ./\ PH_X1/PU_P!"]IG_ (!Q_P"%%%/V
MDNX>SCV#_A$_#7_0O:9_X!Q_X4?\(GX:_P"A>TS_ , X_P#"BBCVDNX>SCV%
M_P"$4\-?]"]IG_@''_A1_P (IX:_Z%[3/_ ./_"BBI]I+N'LX]@_X13PU_T+
MVF?^ <?^%'_"*^&O^A>TS_P#C_PHHH]I+N'LX]A/^$3\-?\ 0OZ9_P" <?\
MA1_PB?AK_H7],_\  ./_  HHJO:2[A[./8/^$3\-?]"]IG_@''_A1_PB?AK_
M *%[3/\ P#C_ ,***/:2[A[./8/^$3\-?]"]IG_@''_A1_PB?AK_ *%[3/\
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M_P# ./\ PHHH]I+N'LX]@_X1/PU_T+VF?^ <?^%'_")^&O\ H7M,_P# ./\
MPHHH]I+N'LX]@_X1/PU_T+VF?^ <?^%'_")^&O\ H7M,_P# ./\ PHHH]I+N
M'LX]A?\ A%/#/_0O:9_X!Q_X4?\ "*>&?^A>TS_P#C_PHHJ_:2[A[./8/^$4
M\,_]"]IG_@''_A1_PBGAG_H7M,_\ X_\***/:2[A[./83_A$_#7_ $+VF?\
M@''_ (4?\(GX:_Z%[3/_  #C_P ***CVDNX>SCV#_A$_#7_0O:9_X!Q_X4?\
M(GX:_P"A>TS_ , X_P#"BBCVDNX>SCV#_A$_#7_0O:9_X!Q_X4?\(GX:_P"A
M>TS_ , X_P#"BBCVDNX>SCV#_A$_#7_0O:9_X!Q_X4?\(GX:_P"A>TS_ , X
I_P#"BBCVDNX>SCV$@T30;,NMKH^G1;L;A':JF<=,X'-%%%:78<J/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cvm_10kimg16.jpg
<TEXT>
begin 644 cvm_10kimg16.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %$ D # 2(  A$! Q$!_\0
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MM_=_$/\ 5O\ O?@?-%%?2_E0_P#/!?\ OD4>5#_SP7_OD4?VM_=_$/\ 5O\
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M5F=04444 %%%% !1110 4444 %%%% !1110 E9^L?\>/_ Q6AZ5GZQ_QX_\
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MV[+7)E:0!E S)"(6Q\O]U1^-/W2?>+4^K:):R,+B\M8GBX.['R_,!@'UW,O
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M:1=XFSJ6C27-M96MK.T=M;[E>/S"I=2N =P!^8'G\>U4DT#4(5WP748E+.9
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M)$L8[RT95904:=8]Y^H+?*:CT_PW+>26HDNTB\Y(9V7:21#)*(MP/0G)Z?\
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M19M-NUO-,G'VSN84"2 YYP?F9>F?TKWG_A6/B'_GXL?^_C?_ !-'_"L?$/\
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M_P!HX?\ F0O["Q'\C.#XHXKO/^%5^)O^>UG_ -_&_P#B:/\ A5?B;_GM9_\
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M<JO9R_IHCVD7_P ,SI<T9KFO^$DUG_H2=5_[^V__ ,<H_P"$DUG_ *$G5?\
MO[;_ /QRCV<OZ:#VD?Z3.ES1FN:_X236?^A)U7_O[;__ !RC_A)-9_Z$G5?^
M_MO_ /'*/9R_IH/:1_I,Z7-&:YK_ (236?\ H2=5_P"_MO\ _'*/^$DUG_H2
M=5_[^V__ ,<H]G+^F@]I'^DSI<T9KFO^$DUG_H2=5_[^V_\ \<H_X236?^A)
MU7_O[;__ !RCV<OZ:#VD?Z3.ES1FN:_X236?^A)U7_O[;_\ QRC_ (236?\
MH2=5_P"_MO\ _'*/9R_IH/:1_I,Z7-+FN9_X236?^A)U7_O[;_\ QRC_ (23
M6?\ H2=5_P"_MO\ _'*/9R_IH/:1_I,Z7-+FN9_X236?^A)U7_O[;_\ QRC_
M (236?\ H2=5_P"_MO\ _'*/9R_IH/:1_I,Z7-&:YK_A)-9_Z$G5?^_MO_\
M'*/^$DUG_H2=5_[^V_\ \<H]G+^F@]I'^DSI<T9KFO\ A)-9_P"A)U7_ +^V
M_P#\<H_X236?^A)U7_O[;_\ QRCV<OZ:#VD?Z3.ES1FN:_X236?^A)U7_O[;
M_P#QRC_A)-9_Z$G5?^_MO_\ '*/9R_IH/:1_I,Z7-&:YK_A)-9_Z$G5?^_MO
M_P#'*/\ A)-9_P"A)U7_ +^V_P#\<H]G+^F@]I'^DSI<T9KFO^$DUG_H2=5_
M[^V__P <H_X236?^A)U7_O[;_P#QRCDE_30<\?Z3.EW45S/_  DFL?\ 0DZK
M_P!_;?\ ^.5SFE^,M8NM4BC:WBOI)Q*9M,MTV7&G;#@>8S-@YZ'..3\N10J<
MG_PY,JL8[_DST;YJ3!]:P_[<U7_H5K__ +[A_P#BZ/[<U7_H5K__ +^0_P#Q
M=/V<OZ:)YH^?W,W-O^U2?\"K$_MS5?\ H5K_ /[^0_\ Q=']N:K_ -"M?_\
M?R'_ .+H]G+^F@YH>?W,VL?[5&/]NL7^W-5_Z%:__P"_D/\ \71_;FJ_]"M?
M_P#?R'_XNCDE_30KQ\_N9M8_VZ,?[=8O]N:K_P!"M?\ _?R'_P"+H_MS5?\
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M5E6VLZ1>RFWL]5M+F89S'#.KL,=> <\5)?:A8Z9;&ZU"\AM+<$*99I B@DX
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MO**@ANWN":Z_2_$OA&&UCL=-OH;>V@B8I&5:-8U1MK*-P&"I(!7J,CBJVO\
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M^QQB9 H5@,8VY"]/0,1]#BMGFBB[[BY8]C"_X1W1Q$(_[/CV>6L('/RHK;E
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MZ^M[IMU-=:8]U<7-W8W5JGF6S/N)>&3@DER/E^;Y6/(VXI>\KH-'9BZ+\/\
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M-)MYEFM]+M(95^ZZ0*K#Z$"M*BD 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cvm_10kimg15.jpg
<TEXT>
begin 644 cvm_10kimg15.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" &U <T# 2(  A$! Q$!_\0
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MW!^E5+/XT:OJUI\3(-0T75?#\'AI[E8-5MK&.7R$C4'$BR2%6F.<A<;2.XH
M^@:*^>KCXQ2>&_'VF?\ "0:\S^%F\$PZRPDM8TN+NZ>554JJ_P ;@X\M3M!/
MH,UV$GCP?\+&T2RN+C6-+CN] FU9]&N+"'.U"?FDDWETD XV#(]2#0!ZK17C
M_A7X^>#/%VO:#H]OINO6#Z['(]A<W]@8;>=D!+HK[B&( /(RO;.>*DTGX^>
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M@CIM[T :GAWX/Q^'];\&:FOB![@^&=$DT94^S!?M ?\ Y:9W';CTY^M8&D?
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MF#CG%;/A6%=*^)?C#1+7Y-/ECM-66%1A89IO-27'IN,*N1_>9CWH ]!HHHH
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M7"Q_,2_WR!T!;^(@ GOFNIHH S]/T^RTG3;;3=/MDMK.UB6&&%!A8T48"CV
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M;_GUG_[Y'^-6:* *WVIO^?6?_OD?XT?:F_Y]9_\ OD?XU9HH K?:F_Y]9_\
MOD?XT?:F_P"?6?\ [Y'^-6:* *WVIO\ GUG_ .^1_C1]J;_GUG_[Y'^-6:*
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M-_SZS_\ ?(_QJS10,K?:F_Y]9_\ OD?XT?:F_P"?6?\ [Y'^-6:* *WVIO\
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M12U\@?2%"\_X_M-_Z[-_Z*>KWK5&\_X_M-_Z[-_Z*>KWK0^@D+1110,****
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M<"@#;.=IP,GTJM'$21+,P=^V/NK]/\:M44 %%%% !114$DBQKN=L#I[D^@H
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M (U\.?2D-[_Q_:;_ -=F_P#13U=[UE7EPWV[3?\ 19O]<W9?^>3^]7OM#?\
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MDD2)-TC;12MG:=HR>P-5HX?F$LS;Y.WHOT_QH ;Y;W/,V4B[1]V_WO\ "K@
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M/_A%]!.J_P!KG2;<WN_S?,*_Q_W\=-W^UC--;P[HK:X-8;383?[@WG%>=P&
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MO_/)_>KWG2?\^LO_ ([_ (U!>_\ ']IO_79O_13U=_B-#Z"74B\Z3_GUE_\
M'?\ &CSI/^?67_QW_&IZ*!D'G2?\^LO_ ([_ (T>=)_SZR_^._XU/10!!YTG
M_/K+_P"._P"-'G2?\^LO_CO^-3T4 0>=)_SZR_\ CO\ C0)I"0/LL@]SM_QJ
M>B@ HHHH **** "BBB@ HHR,X[TW<N<;AGTH =11GG%% !1144DB1)ND; Z?
M4T 2U1,TEQ\L!Q'WE_\ B?7Z]*=MDN/FF^2+M'W/^]_A5OH..!0!#'$D*;5^
MI)Y)/J:GHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYOXE_P">3^]7O.G_ .?5_P#OI?\ &H+W_C^TW_KLW_HIZN_Q&A]!+J1>=/\
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M35OPA/)-\0= +GC^T(, =!^\6N<9F9BS')/<UO>#"1X]T A=Q^WP<9QG]XM
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M'Q=X3DC75=874+7[3;R0O>Z;;VYB6Q69<PJK?=?"X!P!711S:%2:A).+??\
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MBUSQ:M_P.?\ BXGAW_L(V_\ Z,6@#[=\ZX_Y]#_WV*/.N/\ GT/_ 'V*L44
M5_.N/^?0_P#?8H\ZX_Y]#_WV*L44 5_.N/\ GT/_ 'V*!+<$C-J0/7>*L44
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MQZ/KEIJJZCJTBSZ>(T,UN6W&1PRG< A7G<,8_"O3:JK;6Z7#W"6\:S.,-(%
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M?3_R(*!EBBJ_FW7_ #Z?^1!1YMU_SZ?^1!0!8HJOYMU_SZ?^1!1YMU_SZ?\
MD04 6**K^;=?\^G_ )$%'FW7_/I_Y$% $W>N:\=?\DX\1_\ 8-N/_1;5O>;<
M_P#/I_Y$%<WXXDG/P[\1AK? _LVXY\P?\\VJZ?QQ]41/X6?"1/)HS29YI,U^
ME4OA/D9#LT9IN:,U8#LU=TD_\3NR_P"NR_SJAFKNDG_B=67_ %V7^=85_P"%
M+T?Y%TOC7J>H[J-U0[J-U?FQ]<3;J-U0[J-U $VZJ6KM_P 26\_ZY&I]U4M6
M;_B2WG_7,T <"370>!3_ ,7&\-_]A*W_ /1BUS9-;_@9F_X6-X;VKN/]I6_&
M<9_>+0!]Z457\VZ_Y]/_ "(*/-NO^?3_ ,B"@"Q15?S;K_GT_P#(@H\VZ_Y]
M/_(@H L457\VZ_Y]/_(@I!+<$C-K@>OF"@"S1110 4444 %%%% !1110 444
M4 %%%% !1368*I9B !U)[53\R2X^X3'#_?Z,WT]![T /DF8L88%#OW)^ZGU_
MPI8X5C)9F+R-]YSU_P#K"IXXTC0)&H51V%/H HZI_P @N[_ZXO\ ^@FOSU9O
MF-?>?BKQ%IVBZ+=M=3J&,+@+GG.TU\$,WS&OJ,B^W\CQLQWC\_T'[J-U,W4;
MJ^HN>,/W4;J9NHW47 61OW3_ .Z?Y5R6>*ZF1OW3_P"Z?Y5R+2!1SU]*\W&S
M4;2D]#KP\6[I$\$RPW,4K_=1PQ_.OOKPU\5+#Q1I']JZ#H=_=6>\PI(QCB\Z
M0#)2,.P+D 'A<U^>LCLP)/Y5]!>"+[1=>\$?"MH_$VDZ3+X,UB:ZU:&^NTMY
M!&7+B1%;[^0,<9^]]:^/Q>(5:2Y5HCWJ%)TUKU/8W_:4\"1WC6<EOJ*W*R>2
M83 =X?.-N.N<\8KJ?$'Q0L_"^CG5]<\/ZC;6B.L<K*8Y# S %5D5&)0G(QN
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MS$N,U[U_IGK#^M'^F>L/ZTGC*[5G)C6'I+511XY_PHN7_H9/_)=:/^%%R_\
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M:O=(6DV*68@. S(VPG''X5!INDZEJ&@2OH=K]BCDBU:*WVR*JQ&2X0HH920
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MVBB@"E:V%G8^9]BLX+;S&W/Y,83>?4X')J[110 4444 %%%% !1110 4444
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MEHM+M8VNP1<%85!F!ZA^/FZGK6DJK&@1%"JHP !@ 4 24444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+ %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>cvm_10kimg10.jpg
<TEXT>
begin 644 cvm_10kimg10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %W 9T# 2(  A$! Q$!_\0
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MY'7OQ6!??$'Q;KFHV7BG3[Q=.OKSX;WNJ"".1_L\4RS [PN3\P4'!.><9XH
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MU@VE^%].LSI[3M:F*$+Y!F4++M]-R@ ^PI8OA]X)ABL8X?"]A&EE;2V=L%B
M\J"7/F1C_9;<<CW-==10!S$?@;P?#L\OP[9+LTTZ,N(AQ9'DV_\ N>U4]4^&
M7P]UJSTZQU;P;I5[;Z;"+>S6:V5O(C'1%/4+[=*[.B@#A_$VB?#O5CH7@_Q9
MINE7"S,_]E:=<H K&*/YA&O3Y4/0=!2:1X?^'.HMJ%KH^FZ5<MI]HWAN[2%
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M#KM^;_CW,9!'.T#'2@#T/5M-\(SZ1I_@76-/M)=.OT%O:Z;)$6C=85#A0,8
M4(",^E:NK:'HVO:3_9&LZ;!?6&Y&^SS+N3*$,IQ[$ CZ5XR^@>([R=/[#TW6
MK?3OM&I?V2M\TJS6J/IWE@L9"7C5KC>4#$$9[ @58OKCQOK-A>2:%IWB"RDB
M\/V-NPNX982\JW.;E4!929/*W#<I!/&UNAH [WQEX=^'^NSZ9_PG&@Z=J$DL
MXM+.6\MMY$C9(CWX^7=C@$@$X'4@5U$>FV$>C+I4=C;IIRP_9UM1&!$(MNW9
MMZ;<<8Z8KQAK?4;;X1>)+.\FNW^U7MO%I-O/:7-N8YV:(1K$+EVE8>: _. #
MNQP*](\>0:K_ ,(TFK:''=3ZCH]Q'J,=K;,0UXJ']Y!C^(O&74 _Q%3VH ;H
M/PY\!^&+R>^\.^$-*TRYF4QR2V]JJL5/50<< ^@XK.;X>_"OPK:7>J2>%]!T
M:W6"6*XN?(2%?*E&V16;CAAQCWP*X;Q!IOBR/1M&U*>WU?4=3N5N=1FT@1W9
M@>>5U>.$RP2 P/&H$:EP8P-QZ\UW_CZQU*]T+0;^VTN74/[*U6UU&ZT^)@\D
ML:9W!<D!V0LL@'<QC'.* .?UKPGX/^*'@W3]!\+:Q86ECH4J".%=.AN1;@(5
M1/*F7*<<@\9QW%=#X/\ AGX5\)Z%X?TNVL1=R^'UG%G>W*AID:<DS,"  -^3
MD 8Q@=JP_%&J7'B)])F31?$8\.0WA75(XK.>VN+A#"_EE47;,T:R%=P ZX/(
M!KGH/#?BG5K%8]8C\0HL/AZ]:T!O)4D27[4QM1(48;IUA\O[V3G.<G- '=6_
MPY^&/V[6K>S\)Z"+B\C$6I116T>61SO"NH^Z"0&[9(![5<M/AC\/['2KO2K/
MP?I<%C>O#)<0)  LS1',98=RIY%>6W/A_6D/C+4FTC6T\3:OX?MI+6[MA. T
MPM=DRY4[$E##A2 >?E[UM^,O#]UI>J36]G9^)KNP?2Y'TPZ;=7$KIJA<YDE8
M-D$CRMK2'RQA\XSR >C3VWAGQ5>A+JTM]2N/#VH*Z^;&2;6Z5%=67(^\%D4Y
M'K63'X9^'NLZMXGL_P"P=-O+JZ:'^VHGM=R3/MW1^9D;6<*=W]X;@3C(H\!V
M.KV<_B9]:MVCNKG48I6DVX29OL5LKNGJN]7'X&N/;[9_PA6M6=C'>&:'Q9-_
M;L5EN6ZDMGN-YV;2'.Z%H?N_,4R%YQ0!UO\ PJ7X:MHBZ*W@G1_[/CF-PL/V
M5<"0@ OGKD@ 9ST ':LS5/@OX(U;QA8:]JFDV=SIVGZ3_95OH[VJ?98P)O,$
M@'8CD8Z8)KE?#NG3:]>Q6%F->'A^+Q3>12QO<W"/';C3P DC%]ZIYO&TD<G&
M >*ECLO$DGQ6M&ATO5-/M%U.6QNHTCNWBFL!;R+'(\[RF+#$1D*B;E.,D'.0
M#O?%7A'X>W4">(?%/AC2[M=&AW)/+8B5K>).< !22J]<8('/%7;CP;X-UNWU
M:6YT'3[V'Q L#W[&,,MZ(P/)+'^(* ,5Q?P]DUJ:[U>Z\4:B[Z9X4BET*.>6
M;,=YL;?+=2=B?+$*$G.&67U-=5\,8IH?A9X<CN$>,_8T,:/PR1'F-3Z80J,4
M 6E^'_@A?%1\5KX5TP:X7\S[=]G7S-^,;\X^]_M=?>H[7X>^!['Q6?%-GX3T
MN'6R[2?;8[55D#,,,P('#$$Y/4Y/K7844 9$V@Z--X@A\03:;;R:K! UK'=L
MF9$B8Y9 ?0GM7.2_"GX:SV%MI\W@G2&M;:22:"%K92L3/C?M'8' R!Q7=44
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MO5OM)L[D7RHMT)8%;SPG*!\CYMO;/2M/[5;_ //Q'_WV*/M5O_S\1_\ ?8H
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M%_*CRT_N+^5.HH ;Y:?W%_*CRT_N+^5.HH ;Y:?W%_*CRT_N+^5.HH ****
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ML4 3T5!YMQ_SZG_OL4>;<?\ /J?^^Q0!/14'FW'_ #ZG_OL4>=<?\^I_[[%
M#ONCI7E_Q$^+FB^!86LXMNHZRP^6U1N(_0R'M].I]AS7%_%+XR:E9W5WX;\)
MVKQ3PLT-S?/C*,."L8]0?XC^'K7SI-;ZA<3O/.LDLLC%F=VRS$]22>IKW,!E
M<ZMJE1.W;N>3B<?&-X0>O<]H_P"&EO%7_0%TO\I/_BZ/^&E_%7_0#TS\I/\
MXNO%/L-W_P \&_2C[#=_\\&_2OH/[)P_\GYGF_7*O\Q[0W[2'B=F1FT'2BR'
M*DK)P<8_O^A-._X:6\5?] 73/RD_^+KQ7[#=_P#/!OTJM=+):!?-C*LWW0>]
M2\JP\5=Q_,:Q=5Z*1[BW[3'BA$W-HNE ?23_ .+KW'X7^,+WQQX$@UZ^M8;:
M:2:2/RX<[0%.!U)-?!CNSMN8YK[-_9YDE7X-V>R'>/M4_.X#^*O"S'#4:5/F
MIQL[GHX2K4G4M-WT/9*J:E_R"[O_ *XO_P"@FG^;<?\ /J?^^Q534)9_[+N\
MVI \E_XQ_=->&CU67;?_ (]HO]T?RJ:J-O+<?98O]%/W!_&/2I_-N/\ GU/_
M 'V*3W!$]%0>;<?\^I_[[%'FW'_/J?\ OL4#)Z*@\VX_Y]3_ -]BCS;C_GU/
M_?8H GHJ#S;C_GU/_?8H\VX_Y]3_ -]B@">B@=/2B@ HHHH **** "BBB@ H
MHHH ***ADF6/ P6<_=0=30!(S*BEF8!1U)JK^^N#W2'\F?\ P'ZT1PL[B2?E
MARJ#[J_XGWJY0 U55%"JH51T IU%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %!Z44'I0!\5>.O^2@Z__P!?\_\ Z,:LRQT?5M6CDDTO3;N^
M2+AV@A9POU(%:?CG_DH.O_\ 7_/_ .C&JW\/=/6361JUYXDBM;'39Q<1Z:U^
MD$EY< #: '8 +TRQ[<#O7W/UB5#"PE'LCXV5-5*SB^[,.QT'7-4CFDTW1[V\
M6 [9##"SB,^AP.#[5'!H^K75E<7UKI=U-:VO^NECA9DC]=QQQ7;>%;>XN/'&
MI^)M:\165L+*^DO$TF#5(T%W<M@@*2P7RQD OSG&/6J6A^,KR'7Y]#U2SM([
MR?4+N1;^.^"6MO\ :%Q,S@96557)7!'.!67]J5[M0BG:W_!]3=8:%ES.USCI
M;6Z@@M[B>WDBBN5+PNRX$J@X)7U&01FN:\0_ZRV^C?TKV>XNO _B+PQ<:FOV
M6'R+6YMK<2W12YM!"56SCCAS\P<99C@\L>17C'B'[]M_NM_2NNCB_K%.7,FF
MO\S#V7LJBUO<PZ^U?V=?^2-6?_7U/_Z%7Q57VK^SK_R1JS_Z^I__ $*O(S7^
M#\U^I[&"_B?(]>JIJ7_(+N_^N+_^@FK=5-2_Y!=W_P!<7_\ 037RZ/99+;_\
M>T7^Z/Y5-4-O_P >T7^Z/Y5-0]P04444#"BBB@ HHHH **** "BBB@ JE=32
M6]M)/';R73HN5BBQN<^@R0/S-7:SM4;4AI5S_8_D?;]A\G[3D1AO5L<XH P?
M^$NA6.X2XTVZBU&&YCM/L6Y&=Y)%#)M8-MP5.2<\8/I4$WC:TM[(3?V==/<1
MM.+FV&S=;B  RDDM@X#*1@G(88JM;^'=87286^SVJ:E;7Z:BTLETTIO9,%7W
MMY:[,J<# (7 &,"KD/A7SM+OFU:SM+O4KFZEO4C8L8HG90JINP"R[54-QSSQ
M0!NV>HKJ%Y=);JQCMG6,R'&UV*AB!WX!&??CL:UJX"W\(:A:^)+&\ANHS% 8
MW>X9F$V0K^:@7&TB1WWDYZYX.!COZ *DDS,YBA 9A]YC]U?\3[5+%"L8+<L[
M?>8]34BJJ*%50H'84Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *#THH[4 ?'GB/0=5USQQXNN-,MOM*Z=>2RSJK?.%:5@-J]6
MZ=JYS5O!>K:3JDUG?:1))<PG#F >:N?+\P@,."0GS'T%;?B;7-<T+QUXQCT2
M]-F][?MNGCXEC,<K$;#VZD'@\54_X3[Q0PG62"PE,J\,\;9C/V?[.67YNICZ
MYSSS7V-+ZTZ4>6*<;*W?9'RLXT>9W;3O^HDWPWUJ":.1K.*2%ITMO/BW2*':
M-9!PJEL8<#('7BHIO!^J++:K);AH9[9;I)T1WC ,9D"DA3\VT$D8X[\<U+'X
MZ\2)=Q736VGR2P745Y"S1-^ZD2%8<C##(** 0<\Y(Q3/^$X\3-8Z?9S0V,B:
M= UM:L83NB1X3"X!W<[E.3GN ?:JC2Q:^RB6J+ZLH_\ "+ZU#-;YT&^22ZSY
M(-NV9/EW'''/!S].:Y7Q3;SVMY%;74+P3Q;E>.12K*>."#TKOH?B%XLAN?.A
M-F-TGF.OEMAA]G6 K][(&Q0>"#GG/:N(\::E=:OJXU*\Q]HN,L^"Q'  ZL23
MP.Y-=L?;.+52*2\N]S-1IJ2<7<Y>OM;]G;_DC-E_U\S_ /H5?%-?:W[.W_)&
MK+_KYG_]"KQ\U_@_-?J>O@OXGR/7:J:E_P @N[_ZXO\ ^@FK=5-2_P"07=_]
M<7_]!-?+H]ADMO\ \>T7^Z/Y5-4-O_Q[1?[H_E4U#W!!1110,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHIDDB1IND; H ?15(>=-\VYH4[*
M,;C]<]/I4WD2?\_4OY+_ (4 3T5!Y$G_ #]2_DO^%'D2?\_4OY+_ (4 3T5!
MY$G_ #]2_DO^%'D2?\_4OY+_ (4 3T5!Y$G_ #]2_DO^%'D2?\_4OY+_ (4
M3T5!Y$G_ #]2_DO^%'D2?\_4OY+_ (4 3T5!Y$G_ #]2_DO^%'D2?\_4OY+_
M (4 3T5!Y$G_ #]2_DO^%'D2?\_4OY+_ (4 3T5!Y$G_ #]2_DO^%'D2?\_4
MOY+_ (4 3T5!Y$G_ #]2_DO^%'D2?\_4OY+_ (4 3T'I4'D2?\_4OY+_ (4>
M1)C_ (^I?R7_  H ^,?'7_)0]?\ ^PA/_P"C#7.5T'CCY?B#X@&XM_Q,)^3W
M_>&N>S7ZGEW^[P]%^1\55^.7JQ:*3-&:] Q%K \0_?MOHW]*WLU@>(3\]O\
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MGBF19(W!5E89!![$=ZR&\,^'V\-2^&VT.Q_L:0,KV'V=?((9MQ&S&.ISTZT
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M^A1]HM_^>\?_ 'T*=Y4?_/-?RH\J/_GFOY4 -^T6_P#SWC_[Z%+Y\'_/:/\
M[Z%+Y4?_ #S7\J7RH_[B_E0 _M1110 4444 >::C?7VE^(M8ET_5+N#3S<++
M>2Q:6DT-J_EH&W.7#'Y0I.%.,UZ6.GK7F&M+')JNM77]FSMIEE(O]HPKJ#0_
M:B(T9F\G;AAM*CEEW[<<]_35*LH*G(]J '452:YMX[=YVN(UA3.Z0L JXX.3
MT&*:]]9+;Q7#W<(AF(6.3S!M<GH >AS0!?HJN)(VE:-6!=<%E!Y&>F?RJQ0
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ML\U^>GU)RZ">'7HM;A9'OXY#-YLJA\N?XL'ODY^M6=-U37+'3I-,^UQO:L)
M&>,-*JR'+J'Z@,>2*Z6*UT":VL(6A1DC>^CGNH[E58M$6\L,/]H $&L^WBT*
M?08-427RB\:S;FN%8++YP7[.4/).WG/X]* .4UW_ )%Z^_ZY&O,J]=\=>2K>
M(%MP@@$D@C$>-H7=QC':O(": /6?@+_R4:?_ *\)/_0TKZ>KY>^ 9_XN1/\
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M>3_9C_\ HV.OKOO7R)^S#_R4;5/^P:__ *-CKZ[[U\7F/\=_(^CPG\,IV?\
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MF:\X)H ];^ +LOQ(N"L9<_V?+P"!_&E?4/FW'_/JW_?:U\O?L]G_ (N9<?\
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M_6N99@!UKS,6_>7H=E!>Z>^?LN*Q^)FK;9"G_$J?H!_SUC]:^QO)E_Y^I/\
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MMGR5_P (_P"(/^@!J7_@*U'_  C_ (@_Z &I?^ K5]<_:A_SQF_[]FC[4/\
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M"%IX]0\.QO,VEMJ=I!8W!E>0*5!C;*CYLNO3/?K6IX3\076O6EQ)<R:8TD3
M8L)W<KD9PZNBLA^HYH W=-LDTW2;/3HW9TM84@5FZL%4*"?RJ_110 4444 %
M%%% !1110 5CW6DQ7>OZ=JYF=9+!)D1!C:_F!0<_3:*C\0:M_8>AS:@;=KET
M*1QPJVWS)'8(BY/3+,.>U<:FN:_I&O:Y>ZY8V[WBVEC%;VEG<LT3O)-*B?,Z
MC:2Q )QT&>>E ';S:5%/XBL]9\V02VMO+ L8QM82%"2>^1L'YUB6?A%=/UHW
MEAJUS!9-.URUB(867>S;FPY0N%)). W<XQ6?+XOUK3&N[76M)M([NT^S3N;6
MX:2-[:67RV<$J"&3!)!&#CK5FU\:7%YJG]GQ:>@EDU(6\!,G$MKM<F<<?],I
M!CV'K0!T]];2WMC+:PWLMG(_W9X@I9#UZ,"#]".E<I'X#MX;"15UJ\34GO$O
MA?1QQ(5E1"@(C5!'C:2#\O.<FH])\9:U?7>E3WVCVD.EZG=2V44D5RS2B1/,
M(8J5 VGRR.N0:Q;SQKK^H^%_$+PPV.EWEO9231VYN)%O+;:<$NC1@9 SRI(R
M .AS0!UFG^#8+&2WEDU2[O)H=2?4C+/MW22-"8B#@ 8P<\ 5S_C+P[KE]J6H
MP^'H=1C36;80W<D=Q;K;,P4H"X<&087&=@^88'O6AJWB?7- T2QDU!M#BU*<
ML6A:XG8.HQCRPL;.QY&>,"F0^,=7UFVT]O#^CVSS3:>FHS_;;DQI$C%E"*54
MEF)1^<  #WH TKWP?:W[W<LEY<Q3SK:^7+#A3;R0%BCIP><L<@Y&.*JW_@F:
M_P#L%Q>>)+ZXO[-Y"ET\%NWR.%#($,>P?=&&QD<\\U7F\52&QTC6FLSYT^@W
M6I>4MPXC!58FV%>C?>QN(R.<=32+XXU73Q<R:]H]O G]F-JENMK<F5F5653&
MV54!B77!&1S0!LZ;X1M=+BT..&\GD_L<SF,OMS)YN<[L#MN[8KJJ\_;Q9XHL
M+B_MM4\/VTEU!IQU"&#3[AY6D^?;L.4'([X!]JU_">O7.O6,\UU)ICR1.%_X
ME\[R 9&<.KHK(?8B@#J:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ K,.EVIUT:QA_M(MS:YW?+L+!NGKD=:TZ* .5LO".GZ
M=JPOK&\U*"(.T@LDO)!:AF))(CSCJ2<=,GI4-KX%T6QU*VOK::^ M9FGMK9K
MMV@@9@P8)&3@ [SQV[8KL** ..L? NBZ?JUMJ%O)>DVLLDUO;O=.T,)<,'"Q
MDX .XU)9^"-%T];F&&2_:QGA>#[#)=R-;Q1O]Y40G"C^7;%=;10!RUKX0TN&
M&TAEDN[U+6.:!/MDYES'*%#*V>HPH ':J]KX#T6WBN8_,OKKS[5[)3=7;RFW
M@<8:./<3M' ]^!SQ78T4 <]<>&["XGCN-US'+%9-8(\4S(RQDJW!'(;*+S3M
M%\.V.@R7,L,]W=W5UM\ZYO)VFE<+G:NX]ADX'N:WZ* "BBB@ HHHH **** "
MBBB@#(U;2[36=,N-+OH_-MIUVNH8J>N001R"" 01T(K$M_!>CQV^H0W+7NH?
MVC%'#<27=V\KL$)*$,3E2"V01C& >M=E10!REKX-TFWT[4K.X:[O#J4?D7-S
M>7#2S.F" NX] -QQCN<]:N6OA?1[._TV^@MR)].M/L5N2V<1\=?4\=?<^M;]
M% '/P^%]+@M=,M(UE\K3;E[J#,AR';?G/J/WC?I5&'P-HRFY-Y/J&I?:+>2T
M_P!-O))O*BDQO5,GY<X'/7@<UUU% ''MX)T]HK$-?:K]HLU>-;I;^19I(V8,
M8W<')7(''; Q61K7@F9+73[7PW:[6MK9K,SOJ<ULWE9R%?RU)D7))P2#Z'DU
MZ/10!R<'A#3QH>G:=>-),UGICZ7YB-L#1NBJYQV)V#'I4^H>&=,NU+26_P!H
M==/DTY899"(WB;:2K8YZHOS#D5TM% 'FOA_P9JD.I7EYK%Q/!YUHMG&(M4FN
M9D ??N\Y@I7L %'KG.:ZS0_#MCH)N7MYKJZN+HJ9KF\G::63:,*"Q[ $X'O6
M]10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 -KA/B-XVG\$:-:W]O9QW)GG\DB1B /E)SQ]*[NN3\8^"])\
M::;!I^KR7"102^<IMW"G=@CG(/'-71E&-2+J*\>IE54G!J#LS"^&_P 0KGQR
MVHBXL8K86@C*^6Q.[=NZY_W:P8?&/B3_ (0>YLVOB=:F@>_M[SRQ\EJH=G)&
M,94QE/\ @:&NS\&?#[0_ S7K:/+=R&\">9]HD#XV[L8PH_O&KEOX6L8/"[>'
MED=HVM);/[257S0DF<X./?Z<"KK2ISJ.5-6CT)H*I&"51W8EIXB/-K-;O)-;
MZ3%J3R[@-^[<"N.Q^0\^]<IX@\6:U#%/JVDAQYFC65W';.R[8VEG(8\C!.TA
M:Z34O!L=Y+#);:YJ&GD68T^?[,4_?Q#.T'<IP02>5P>31<>!].N;%[.2\N0C
M:9#I@9"H95B8LL@X^]G\..E8FYG>(-:U2.QF69;G2]0?1+^Z$,4Z.D3Q[0K$
MA<EAN!!! &3D'C$LWBK[1X2U2^M_M+V=E9C.HV\J!I9@/G6+<"#M[L1C.1S@
MXT[GPJM_"%U#5KJYG^PW.GO.RHK.LQ7+$!0 1M&,#%5Y/!.G_8=1T^UN)[2R
MU&V$$]O%M$>\ +YJC'RL0,''!P"1GF@"MJ7C:ZT_4-1C_P"$?N9].TRXCM[J
M^6:,!-ZH0P0G<V/,&14&H?$S1[/Q-)I+1QM%!<K:32FZB619"0/EA)WNH)&2
M!V.,XK<OO"EG?6&MV<EU.BZQ.D\K+C,9544!>.G[L=?4U5?P>B:W)J-CK-Y8
M0S3_ &BXM8XX721^,D,Z%DSCG:1WZ4 =C7.^*?$#>'[&&Y6)9/,?9AOIFNBK
M"\0>&['Q):16VH23HD3[U\E@#G&.X- &1HWC#^TM(U;46M5"Z=#YQ5#RV%8X
M_P#':KZ#I_B/4+'3?$5]XNN%DNHX[F6RC@B^S!& ;RQ\N_@'&[=GO6OH/A'2
M_#\=W'9O/*ET LBSL&! SQ@ ?WC5+3_!\FERV\-GXFU9=)MF#0Z<6C*( >$W
ME-Y3MM+=.* (]/\ &S7EW8O)H-Y:Z3J<ABL=0>1")FP2NY =R!@IVD]>,XS4
M.C^.+G4KG3!)X;N;.VU59/L=P\\;"21%+%2H.5!"G!/IT%6M/\$6UA?V4G]K
M7\]AI\AELM.E9/)MF((&"%#,%#$*&)QFKMEX3L[*WT"".ZG8:(SM"S;<ON1D
M.[CT<],4 <UHOC;Q ?"EA?ZMX?DGN;R\^R6_DW$>9V)DYQP%"[ .>O6KDWC3
M4+47&?"MU.NF1+)JABN(S]ERN_:N2/-8)ACC'4=^*NV7@N&S2W@&K7LMI:7P
MOK:&39B$_.2@(4$J3(>I)X'-+JW@^+5+V\N%U;4-.AU%%CO[>V9 ET NWDLI
M*G;\I*D9 % $VBZA+?>,=="W#362P6<ENI/RJ'1R2![\5U58FGZ+::=JU]J%
MNS#[5'#%Y7&V-8E(7;^#5MT %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>cvm_10kimg11.jpg
<TEXT>
begin 644 cvm_10kimg11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" $J 7(# 2(  A$! Q$!_\0
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M-&N)KK0-.NKR&>&XFMHY)([F,)(C%02'4<*P/4#@&@#8HHHH **** "BBB@
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MQ6\0PD2!%!] ,"IZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ UA_;6AVUV-/N1=VZR7#;4E"L@8KMPWRNW!R.?6M>,WT4:QQV-NBJ JJ)R
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MI9VP!5?:TW,@*Q_W.[?7_"@!3(TIVP].\AZ#Z>M.^SQXYWD^I<\_K4P   '
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MI+LV^0]6/]/05.B+&NU%P*=0 457>14(4 NYZ*.O_P!84NVY_P">D8]MA/\
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MM7M9]BR!'Q\RMR&!'!!]174^'_\ D"Q_[S?SKFM5U>ZUF[2ZO%172,1!4+D
M D]79CW/>NF\/?\ ($B_WF_F:^>XE<GA5S[W7Y'VO"UE7ER[6?YHN3R1I-:1
MS-MAEN(XY&Z80N WZ9KT35;>QUSQ[=>%PVIZ>\&GB2&:.;9:!, 8V#CO@YSG
M!'%>>W=M'>0-;R_=-7([[6?L']FW&O7,UIL\ORSC)7&-I;&XC'O7Y'1Q-.BI
MPG&]W]_EY'Z+C<-4KRA*$K63^5[:G0Z3?0V/PU\/Q^(+B\AAGU(FSN-*9MP
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MVYTBT_<I_JU_A]JTNU4M+_Y!%I_UR7^5+H'4L?9K?_GBG_?-'V:W_P">*?\
M?-344#(?LUO_ ,\4_P"^:/LUO_SQ3_OFIJ* (?LUO_SQ3_OFC[-;_P#/%/\
MOFIJ* (?LUO_ ,\4_P"^:/LUO_SQ3_OFIJ* (EMX%8,L2 CN!4M%% !1110
M5BZ[]M;1;F+3FC6ZE0QQM+&SHI(ZD+STS^.*VJQ-:L++4-.9=0ABEMXCYS"6
M(2CY0>Q'6@#!\)W&L37-O;WL9M8+:U*B"+39;:-VRO)9^,C!P !]X^E:6I>%
M8[[4KBX^V-';7CPR7< C!,C1$%"K=5Z 'KP.,'FL#PG9P6>KI)]CDM'N[5I(
M-^GVT'FIE<D-$201E?E;'4>G'HU '-+HL\FM1:IJ&H?;&MEE2WB$"IL63&0Q
M!^;@ #H/7)YJCJ7@FUOHF1+@0&1W#!;=2JQ,FS8J]%('1AT)8XY-=G10 @&
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M-'G/_P ^TO\ X[_C4U% $/G/_P ^TO\ X[_C1YS_ //M+_X[_C4U% $/G/\
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M-_Z+:OKL]17R%\$PS?%G3PKE3Y4W(&?^6;5]<>3+_P _+_\ ?*_X5]KD_P#
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MK.IA<%5;:2-IX![?6K]<UXEM]3N-($.EQO+(TT9D2.X\EI(PV64/_#GV[9H
MPO!\FEW=]:S0^(8=0GM;'R8+:.!87AB)3._'WB-JCL!SQS757&NZ79ZM'IMQ
M>HEW(%*Q8).&)"]!QD@]?2LKPO\ \)!#')8ZOIDD$*,[0SR7BW#!"V50GJ2
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M68@ =2: '56:5F8QP@,XZL>B_P#U_:F?O)C\N8X_[W1F^GH*M*JHH55P!V%
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MLLJ0QRJN6,C,,/E6&W';KUJ;Q/>:LGBK20;.^6QAOX4B-NR;)RRMN+_,#QG
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M..@XZGN16Q7':MX7NKW7;?5K75YHF%W#-+$ZH5"1J1M4E21R2<9QEF- %O\
MX2K1O,N5:26..!)9!,T3!)1$<2;#_%M/''X9JS8ZY8ZA)%% )EFE,@,3QE6C
M,9 ;>.W) ]\BL.S\)W/VFVL]1%M)IMD+M8PK,7N%F/1Q@!<*2#@G)P>*JWW@
MW4&65M+GCAD:639FYE4QJ0=DA?EG=7+.0>"6QGY10!Z'5>2;80BKOD/11_,^
M@J<=!GGWIJHJLQ5<%CDGUH C2$[O,D;>_;T7Z5/14<DBQ@9R2>BCJ: '$A06
M8@ =S57]Y-]W,<?][HS?3T%.6-G(>;ZA!T'U]35J@!JJJ*%10JCL*=14/VJW
M_P">R_G0!\:_&P_\7CUS_MC_ .B4KSG->A_&QU?XQZXR-D?N>1_UQ2O.^:_1
M<#_N\/1?D?)5_P"++U8N:,TG-'-=IB+FC-)S1S0 N:[#0C_Q)HO]YOYUQW-=
M=H9_XD\7^\W\Z_/N,-<.O5?D?<\*?[P_1_H:N:,TS-&:_#;'['<?FC-,S1FB
MP[C\T9IF:,T6"YH:2V)+S_?3_P!!K4WUBZ6V);S_ 'E_]!K2WU^H9;_ CZ(_
M*LR_WB?JRQOI0]5M]*'KT3RBSOHWU7WT;Z +&^N)\6M_Q.4_ZXK_ #-==OKB
M_%;?\3A/^N*_S- &$6KU#X"G/Q8MO^O>;_T$UY46KU#X"R*OQ8M2S #[/-U_
MW: /K^BH?M5O_P ]EH^U6_\ SV6@":BH?M5O_P ]EH^U6_\ SV6@":BH?M5O
M_P ]EH^U6_\ SV6@":BH5N(&8*LJDGM4U !1110 4444 %%%<?KFH:II=[87
M$-T%LYKB*!XGM\QJ&<*S/+G*D[OEX^]@'KP =A17G\FK^(+74M0MYEF^VLMT
M^G6K6R>5.$/R;75B2VTJ2#MSD^E):^+KFVDCCUAI1' 93-)]D99'0'*,R=8P
M$!9L]BG]Z@#T&BDSD9'(J!O,D8JN8T'!;N?I_C0 CR98QQ#>_?T7Z_X4J1B,
MEF)>0]6/^>!4R(L:A47 IU !3'=8UW.V!4,D@0A%7?(>BC^OH*1(R6$DQWOV
M]%^G^- !M:;F0%(_[G=OK_A5D  8 P!2T4 ?%?QO/_%YM=_[8_\ HE*\ZKT3
MXX'_ (O1KO\ VQ_]$I7G&:_0\#_N\/1?D?*5_P"++U8^BF9HS7:8CZ*9FC-
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M)[G'84 ?3M%5K.U%I:I#YCR[1RSG)-6: "BBB@ HHHH **** "BBB@ HHHH
M*Q;G0M-O=06^NH9))596V&9_+++RK%,[20>A(K:JHUU;1W*6[W$2S.,K&7 9
MA[#J: *%OH>FVNI'4(H9&N,,%:69Y!&&.6"!B0F2!G&*JW7AO2[Y2MS:;PTK
MS,?,92S,,,"0>5( !4\8 &.*V4NK9I985N(VDB \Q XRF?4=J='<6\T4<D<R
M.DGW&5@0_P!/6@"S1136=8U+.VT#N: '55:1I"5AZ=W/0?3U--VO-]\&.+^[
MW;Z^@]JM !0 HP!V% #$C6,';R3U8\DU+110 4QF5$+NP51R2>U/JK=6EO>0
M&"XCWQGJN2,_E0!\6_&:YAO/C!KD\#;XRT2AAT.(4!KSW!]#7WG)\/\ P7/*
M99_#=E+(W5WCW$_B:;_PKGP+_P!"KI__ 'Y%?14<YC3IQI\FR2W/(J8"4YN7
M-N?!V#Z&C!]#7WC_ ,*X\"?]"KI__?D4O_"N/ G_ $*NG_\ ?D5M_;4/Y']Y
M']G2_F/@W!]#1@^AK[R_X5QX$_Z%73_^_(H_X5QX$_Z%73_^_(I?VS#^1_>'
M]G2_F/@W!]#76:(&_LB/Y3]YNWO7V#_PKGP/M_Y%73_^_(I__" ^"U^5/#=D
MJ^@CP*\#.:W]HTE2BN6S3OOLCW<GE]0K.K+WKIJVQ\F[6_NG\J-K?W3^5?6W
M_" ^#_\ H 6G_?NC_A ?!_\ T +3_OBOB/[%G_,ON/K_ .WJ?\C^\^2=K?W3
M^5&UO[I_*OK?_A ?!_\ T+]I_P!\4G_"O_!__0!M/^^*7]C3_F7W%_ZPT_Y'
M]Y\D[6_NG\J-K?W3^5?6_P#P@/@__H7[3_OBC_A ?!__ $+]I_WQ2_L:?\R^
MX/\ 6*G_ "/[SY+L=WGW7RG[R]O]FKOS?W3^5?5 \!>#U''AVS'T2G?\('X0
M_P"A?M/^^:^HPM%T*<8-WLK'R>*K*O4E42M=W/E7YO[I_*CYO[I_*OJO_A _
M!_\ T+]I_P!\T?\ "!^#_P#H7[3_ +YKI.8^5OF_NG\J/F_NG\J^JO\ A _"
M'_0OVG_?%'_"!^$/^A?M/^^* /E7YO[I_*L&^T/4]>\2Q6>GV[2.8EW$C"H,
MGDGM7V1_P@?A#_H7[3_OBKEAX9T'2WWV&DV]NWJJT >5_#KX.V6BQ1ZAJ:^;
M<D9+L,'Z =A^M>SPPQ6\2Q0H$11@ "I:* "BBB@ HHHH **** "BBB@ HHHH
M **** "N%\16<<^LV"66FRR74=W;R2$61Q,BNISY^/D"#)QGG[N,&NZHH \P
MM-!N+ZXBTN2UN+6X\O4(M1O#"5$@E?Y#O(Q)GA@ 3@#!Q3)+37]#D:YTVV:=
MHIKA(=EF2C.WSD+&#^[1WPF[)P$)S\U>I44 (,X&>M5C#,93)YB-C[H93\OZ
MU:HH AQ=?WXO^^3_ (T8NO[\7_?)_P :FHH AQ=?WXO^^3_C1BZ_OQ?]\G_&
MIJ* (<77]^+_ +Y/^-&+K^_%_P!\G_&IJ* (<77]Z+_OD_XT8NO[T7_?)_QJ
M:B@"'%U_?B_[Y/\ C1BZ_OQ?]\G_ !J:B@"'%U_?B_[Y/^-&+K^_%_WR?\:F
MHH @Q=?WHO\ OD_XT8NO[T7_ 'R?\:GHH AQ=?WXO^^3_C1BZ_OQ?]\G_&IJ
M* (<77]^+_OD_P"-&+K^_%_WR?\ &IJ* (<77]^+_OD_XT8NO[\7_?)_QJ:B
M@"'%U_>B_P"^3_C1BZ_OQ?\ ?)_QJ:B@"'%U_?B_[Y/^-&+K^_%_WR?\:FHH
M AQ=?WXO^^3_ (T8NO[\7_?)_P :FHH AQ=?WXO^^3_C1BZ_OQ?]\G_&IJ*
M(<77]^+_ +Y/^-&+K^_%_P!\G_&IJ* (5%QD;GC(]E/^-3444 %%%% !1110
+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>cvm_10kimg12.jpg
<TEXT>
begin 644 cvm_10kimg12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" $4 98# 2(  A$! Q$!_\0
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MJVT!=TK% 2#TR.O%GP_\5-0L;3P_HESI]UJ5Y+/8VVH37EP#-'/>(UP(EVH
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M;@=5#$#T!XKJZ* ,>VT/2;/5[C5+73[>&\N 1+,D8#N"<G)]SR?7 ]*V***
M"BBB@ HHHH **** "BBB@ I**K?:%X_=R_>V<J?S^GO4MI;@M2UBC%45N%8)
MB.4;F*\H1C'KZ"GK<*P3]W(-V>J$8QZ^E+FCW'8MT546Z5@G[N0;@3RA&,>O
MI31=*<8BE&5+<H>,=OK[4<T>X6+M)50W2JA=HY H0R$E#P/3Z^U8H\:^'2NY
M;YR"@<$6\G(_[YZ^U-.^PGIN=+2US/\ PFGA_G_3)#@ \6\G.>WW>M;C7*JK
M_NY#M /"$YSZ>M#=MP6NQ:Q1BJC7"J'_ '<AVXZ(3G/IZTQKA5W?NY#M8+PA
M.<^GM2YH]QV9>Q1BJWV@#/[N7[^S[A_/Z>]'V@9_U<OW]GW#^?T]Z.:/<+,L
M<4<54%PN0/+E&6*\H>/?Z>](MPK!<1R#<Q7E",8]?04<T>X%W%%5%N%8)^[D
M&[/5",8]?2A;E6"?NY!N!/*$8QZ^E'-'N%BU1507*G'[J494MRAX]OK[4_[0
MO_/.7[F_[A_+Z^U'-'N%F6<4=ZK?:%_YY2\)O^X?R^OM6'XNN)/^$'UWR5G6
M06$K*54@_</ /K1S1?4+&[<;MB!21EU!QQQFN1TOQI87\-Y+/&UG%:S>4SO.
M6'\9].N$)QZ$<UR.FRW=CJ=M>?\ ".ZV_DL&V_8I>?SK9.JZ<6C(\#Z\IB7:
MI6VD!498_H6;'U-5<+'66>LZ;J%W/:0RR"2+# %VRR%5;<?[H^;'/H:@7Q!I
MLVI6-A8O+<R73,-P+J$4*6W<]0>QZ'UKF+'6+'3)Q-9>!]<A?R_*.+23YEP
M W'(XXSTY]:=::Q96,T=Q;^"=?$L0VQLUM(Q1<8"C/10.@Z"F(Z";Q1HUO>S
M6LUTT20J"9V9MK-N92J^N-IR1D#!]*6^\3Z/9PSLLTUQ+$LA,:!_X%#')Q@#
M!!!/!S7-RW^ES3/,_@77R[-N4_9Y/W9R2=O]W)9LX]36SH>CZ'J5A),-"NM.
M$DKAXKAG1VR,-D$YP1_(4 :5YJUO%X<N-6L8IKY80?W*,ZL2&VD$8R,<YX[5
M1/BI?M#PPZ?)<?Z''=1&.X8^?N^\$X^8+W/7VK6FTNQCBND:2>);L[G2*9U.
M[)8LNTY!)/.*Y-M2TNVN_P#1_!_B"1(H?L\?^CS!%3H=JG@9P,D<GO0!U6FZ
ME%J=K!>VP=4D<KM:3<<;<\C/!]JW*\KO[^*:P>RT_P 'ZW:"2<3N?L<A!.",
M<=.O2JNDZ_K'AN5I)-%UN;2"=T\4EG(3;^LB$]NY7\1SP5<H]?HJ-65T5E.5
M(R#ZBI*9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445
M3^V6NUW^U0[4;:Q\P84^A]#0!<HJN)X6)42J6#;" 1D-C./KBK% !1110!7N
MO^/2;_KFW\JP=%4-H=EE<GR4_P#016]=?\>DW_7-OY5Q=S)<0^ HY898HD6!
M/->0-\JD 9!4@@@D'/;%:4W:+.:JKR1OWJJNGW!"X/EM_*MKL*\\\*S74WA"
M^6^FDN;I'??<R*0UP"H*R8).,J0<# 'H*]$["B>J0J*M*7R'4445F=04444
M%%%% !1110 4444 %8WBK_D3]7_Z]9/_ $$ULUC>*O\ D3]7_P"O63_T$T ;
M.:,U'NYI=U9W'8?FC-,W4;J+A821MD;,%+$ G:.IJA;K=-"J_P"I!Y9CRY)Y
M/'05H;J-U.X6(HK>*$EE&6/5V.6/XU8IFZC=1<+#ZR?$AQX3U?\ Z\Y?_0#6
MGNK)\3-_Q26K?]>LG_H-%PL:=L,6L(]$7^535'$,1(/]D5)5B"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "O+6\.ZLME)"-#^T6"W;R1V
M4[0B60O&X+,1\K!78$$_-C)["O4J* /.M+\.ZMH^LV-Q;V*3QG9'<RRS9.\*
M \P&>^6 ZGKTW<>BT44 %%%% %:Z_P"/2?\ W&_E7(-:?;/ RQK<QVS_ &4%
M9I6*QI\@R6P1\N,YKK[K_CTG_P!QOY5P&M1SR_#=%A#E!%&90DL4?R #)+2
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M=4CM;>Q$$<D>+BPT1],BE)4Y&'8ER.,G@#.* /1**** "BBB@ HHHH ****
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M5Y4&Q20Y4 9SGU.",FO2?2B>R%2^.7R'4445D=04444 %%%% !1110 4444
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MO^$9O+B&/4KH)%Y;V5@%9YD9TW$*R-N8*&P,8.2#UR*O@=+=;6]:WN-?F)=
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MU%8!F.#A5/%<O\([O2[ZSU.\TR9K@2B!GD2Z%Q!$2K'[/&P4<(2>N6PZY/8
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M-NM/MX8XHK>.\CBCE9@#YC;8S@*3M(]]W &* /0Z*** "BBB@ HHHH ****
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M(55DAC4B)1[@G)/?&.!71:3:SV6GP6MQ=O>2Q@[II.K9.??ITZ]J -6BBB@
MHHHH **** "BBB@#RG1I]FCPIG[K2+_Y$:K_ -J/]ZN<L9]EL\>?NSS+_P"1
M6JU]H(.">:]B-.\4>+*I[S-K[5[T?:?>L7[00<$XH^T'&<\57LB/:&U]I/\
M>H^T_P"U6+]H-+]I(Z\4>R#VIM?:?>C[3[UB_:,=Z/M7^U1[(/:FU]I]ZRO$
MEQGPIJHSUM9/Y5%]J_VJS=?N,^&=3&[_ )=W_E4NGHRH5=46MU&ZH-]&^O&/
M<)]U&ZH-]&^D,GW4;J@WT;Z )]U&ZH-]+NH FW58TIMWBS0E_P"GLG_R%)5'
M=5K13GQEH _Z>G_]$R4 >QT4451(4444 %%%% !1110 4444 %%%% !1110
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MB>&=2^WZ2L<C9F@^1O<=C_GTK?KS/P[J/]GZQ&SMB&7]V_X]#^=>F4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'F]_=ZM+XHOK-=2NK-AYH=54F.&V
M6)624 =R^5R#GDCM6QX1U*[NH[NTOOM;7MLRK(TZ[5QC  ]\#)]SZ5V%% &7
MK-C<:EIYM()EA#D;R1U'I7.?\(3<_P#/]'_WR:[>B@#B/^$)N?\ G^C_ .^3
M1_PA-S_S_1_]\FNWHH XC_A";G_G^C_[Y-'_  A-S_S_ $?_ 'R:[>B@#B/^
M$)N?^?Z/_ODT?\(3<_\ /]'_ -\FNWHH ^:O$OP+\6:IXKU+4K'4-,^S74HD
M3S7=6'R@<@*>XK*_X9Y\<?\ /_H__?Z3_P"(KZD[TN[\J].GFV(IP4(RT6FQ
MY%3*L/5FYSCJ_,^6?^&>O''_ #_Z/_W^D_\ B*/^&>O''_/_ */_ -_I/_B*
M^J,48K3^V,5_-^!G_8V%_E_$^5_^&>O''_/_ */_ -_I/_B*7_AGKQQ_T$-(
M_P"_TG_Q%?4^*,4?VQBOYOP#^Q\+_+^)\L?\,]^./^?[1_\ O])_\11_PSWX
MX_Y_M'_[_2?_ !%?4^*,4?VQBOYOP#^Q\+_+^)\L?\,]>-O^@AI'_?Z3_P"(
MH/[/OCAA_P A#1^H_P"6TG_Q%?4VVF*.?2LWFF(DFG+\"XY70BU)1V\SR(_#
M[Q=G_5:9_P"!+_\ Q%'_  KWQ=_SRTS_ ,"7_P#B*]DHKS#V#QO_ (5[XN_Y
MY:9_X$O_ /$4?\*]\7?\\M,_\"7_ /B*]DHH \;_ .%>^+O^>6F?^!+_ /Q%
M'_"O?%W_ #RTS_P)?_XBO9** /&_^%>^+O\ GEIG_@2__P 11_PKWQ=_SRTS
M_P "7_\ B*]DHH \;_X5[XN_YY:9_P"!+_\ Q%3Z7\/-?778[S4);&"**!XU
M$4C2%F9E/=1@84UZ[10!Q'_"$W/_ #_1_P#?)H_X0FY_Y_H_^^37;T4 <1_P
MA-S_ ,_T?_?)H_X0FY_Y_H_^^37;T4 <1_PA-S_S_1_]\FC_ (0FY_Y_H_\
MODUV]% '$?\ "$W/_/\ 1_\ ?)KK+*.:"QBAN)!)*B[2X[XJW10 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
64444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>cvm_10kimg13.jpg
<TEXT>
begin 644 cvm_10kimg13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" %G G # 2(  A$! Q$!_\0
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M;GTD=00OXFA)O9";2W.NHJ".6.:-98W#HX#*P.00>A%3YH&%%%-W  G/3K0
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MBSM4\R63:3M'T')I)7T0-V-;BEKE[[Q9H.FV6F7MW?!8=5D2.TPI9IF<97
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MM)TATI8_-1(8P%VS*PP@!.YF)^E5;Y])\0:EXE\Y-0U#7Y+C[%IL</G*J&-
MHE!&$ #[B6]J]VK,TW3;+2[);+3X1# K,X4$GEB6)Y]2334[+83IW/+K[7[C
M1M2\46UY]NFU=K.WL[-4AD<2_N\&4$# &]CD^U)J#7.BRZC<?9WECL;&ST19
MI!(50.-TLIV?,0.,D<U[-BC%'M/(/9ON?/$.G^7X0\7)^_GTB62UML1VLT28
MW R2A&); !Z]_2NENH%LGG;P3:7$=I8:/)<VXB63YY96"Y ;DL$4D#Z5[%BC
M H=1OH)4[=3P]?LMK'?ZQX-34GM$TN2&YGE\W_2[IRJIP_)=2220.,UT/A_P
MK!H/CO2K;3UNH_(TEFOIGFDD%PY*JH;<2"00QKT_M1VI.3:L6HI:G%W^+SXJ
M:79W S#9V$MY"IZ&4N$W?4*3^=<5KVBKK.G>)?$4MO>R:A+J"66F[9)$\D(R
MH'50<#G<<XKU:;2[.XU&UU*>#==6H98I,D%0PPP]P?>M.CFM:PN6][GGGB>Q
M\2/J4/\ 9L.M3QK JM)9:E#;HS#KE74G/O276K2>&_A[<2>((KPW$BR)'%>N
M+R21R/E!,:XQ^%>B4E'/M=;!R:W3//M(UC0]!^$EA=O(9+2.U$6W[.Y\R3!R
MNS;GELCIBLS0[/5-6^$^EV?A34(;.9FS>-/%)'G)+21C !4Y.,BO5*2ES[Z=
M;AR=WTL>7^!8[[1QXEUC7(].L;&.7RD%M&\85(5VY&[^$\X[DYK:\,M/H_P\
MN=3G@=))/M&H"$+EE#LSJN/7&./>N@U#2['5HXH[ZV\^**02B-F.TL.FX=\>
MAXK8IRGS:]PC#E/'['05U-])LM>CNY[33=(-[/&9)$$D\S%BIP1NP >.U=C\
M/K6YM? .E1W?G>88VD"2DED5F)5>>>%('-=@:2AR;5AJ"3N>#6.E:/<^&-8-
MC83Q^(-3U![6ZRDJM"DLV".>/N#J,UJ:II=]X?O/%3>$8KRV2"QMH792\Q+L
M^7E52?F98_2O9:*.=W)]FCROX;Z/:PZS?:IIVO27]NT*Q21I9RP1N^<[R9&.
MY_7'K5NYT[Q!K7Q"UB[TW5AI=M:6T5AYCVOF,^[YW*$D 8R.>:](H%'.W)L%
M!))'BUQX3T]+?Q-+)8W4]IHUDEA8IYDBF20*79_EQN)=QS61XRDO)[4Z/>*_
MV_2K&&.W+V]Q-+<R,@S("A"* W&XY/%?0.*;MHC4:=VANFK61XKK-N)/%NFV
M=P9M=NH(;>V?3Y5N(Y(F &Z:.5<(>N26]*IG3[S7O&,BZMX@N+'64U ^3 NG
MS-)!$K_)LD#;-A4<G'<YKWFFTU.W03IWZF9JFJ6NCZ?)J%\9?(CQO,432$ G
M&<*"<5Q'A>2;6_'MYK2W%QJ>EPP%;2[N;?R1 [-\T<0P-PV@98C/:O2J;ZU$
M9<J>FY3C=H\A\?%;GQA C*^K211+&NC21SIO);/F121_+NQU+<#%5GL]*'B/
MQGJ:Z7<-XDM(\V<967=L2$ ,I^ZV23^5>TT8JE.R2L2X7=SQNSU:34HM'A\/
MK>77]A:1+=%I(9$$MP8PBKE@-Q!+'%0>'K+0=6\7>')M/74+J^ACDO-0O;I9
MAODV8VG?A<AF/ '&*]LQ4$L:S0O&^=KJ5.#@X/O3Y^R#V?=GF/@JWU/6)XK6
M]\Q=*\.7DT4;;R?MTP<[6SW5%/XM]*]6-9VF:?9Z5IT&GZ?"L%M"NU$7L/Z_
M6M&IE+F=T7&/*K!1112*"BBB@ HHHH **** "BBB@ HK'\022PZ!=R0R-%(%
M #H<$9('%/&BQX'_ !,-0_\  EJ -6BLO^QH_P#H(:A_X$-1_8T?_00U#_P(
M:@#4HK+_ +&C_P"@AJ'_ ($-1_8T?_00U#_P(:@#4HK+_L:/_H(:A_X$-1_8
MT?\ T$-0_P# AJ -2BLO^QH_^@AJ'_@0U']C1_\ 00U#_P "&H U**R_[&C_
M .@AJ'_@0U']C1_]!#4/_ AJ -2BLO\ L:/_ *"&H?\ @0U']C1_]!#4/_ A
MJ -2BLO^QH_^@AJ'_@0U']C1_P#00U#_ ,"&H U**R_[&C_Z"&H?^!#4?V-'
M_P!!#4/_  (:@#4HK+_L:/\ Z"&H?^!#4?V-'_T$-0_\"&H U**R_P"QH_\
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M!8- ANM4FDF8JB0S$DX&30!TE%<IM;_GVU__ +^__7HVM_S[:_\ ]_?_ *]
M'5T5RFUO^?;7_P#O[_\ 7HVM_P ^VO\ _?W_ .O0!U=%<IM;_GVU_P#[^_\
MUZ-K?\^VO_\ ?W_Z] '5T5RFUO\ GVU__O[_ /7HVM_S[:__ -_?_KT =717
M*;6_Y]M?_P"_O_UZ-K?\^VO_ /?W_P"O0!U=%<IM;_GVU_\ [^__ %Z-K?\
M/MK_ /W]_P#KT =717)IY/VJ"";^V;<SOL1Y)3MW8SC@^U:/A]IFL)TFFDF,
M5S+&K2-EMH;@$T ;=%%% !1110 4444 %%%% !1110 4444 %%9VHZGI^DV+
MWVIWD5I;(0&EE;:H). /SK,N?&'ANT>[CN-8@C>T95F4DDJ3T'3GWQG'>@"Y
MXD_Y%N[^@_\ 0A6P.E8>O2QS^&+F:%A)&Z*RLIR&!(P16X.E !1110 4444
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MW>=LUGMSQE&SC\Z-NO?\]K+_ +]O_C3VU:W5BOD77!QQ W^%)_;%O_S[W?\
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MKR ULTM5;:Z@NH!-;R"2,Y 8>U6J+-.S ****8!1110 4444 %%%% !1110
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MN[^@_P#0A6P.E<9J5GK$?A&!;S4L316\2W*B,-YC@C<=U=D* %HHHH ****
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M8+4N[^[_ ()L^8O]X4>8O]X5C?\ ",Z+_P ^[?\ ?U_\:/\ A%]%_P"?5O\
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MV_$"O1:*?UBIW*5&"Z$<42PQ+&@PJC J2BBN<V"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *QO#W_'I=_]?DW_ *%6S6-X>_X]+O\ Z_)O_0J
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MJLET7W+_ ""QR-UH?BR6&]6'Q<87E<-"WV-#Y2CJ/QI\&C>*(X+Q)O%QEDE
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MV1^\6!BR ^Q(!-7J "O%;SQ]XJB\0ZQ927$-A;QW311R-;B1;2->C/SG+G
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S/B+_D+:%_U^_\
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MMFO_ /0%B_\  H?X4?;-?_Z L7_@4/\ "@#8HK#DU#6H8VEETJWCC499FNP
MH]2<4D.IZQ=0+-;:;:S1,,K)'>!E;Z$"@#=HK'^V:_\ ] 6+_P "A_A52+7+
MZ>=K>"SLI9E)#1I?*64CKD8H Z.BL?[9K_\ T!8O_ H?X56AU75+A7-OIUM,
M(V*.8[Q6VL.H.!P1Z4 =#17/6^M:A=NR6EG97#+]X17RL1]<"K/VS7_^@+%_
MX%#_  H V**Y_P#M74C<FT&FVYN N\P_;%WA<XW8QG&>]6/MFO\ _0%B_P#
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M<<$2QS.S0!%E!S\\60P*\<X/-7KSQIJTVGV6L6N@PZ#?3-.;@W<"/.8XVP&
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MF"LLV-CV\8?^'/SC/TJEJ_Q!US2]8U'YK&2T662WMHPA9<KCYF=6)4KR65E
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M"T_W3_Z$:XRQ\6:I+XPTJUNY+>+3;VTA"K$%>1[AXRY!&[<B@=."/>NS\/\
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M)V*L#Y"YX8'TJVNCZ*RAETNR8'N(4/\ 2@!_]M:/_P!!:S_[_K_C1_;6C_\
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MLNS.!C_4+_A3('?VUH__ $%K/_O^O^-']M:/_P!!:S_[_K_C2'2-'4$G2[,
M=S O^%4;'P[I-K]HS86<OG3-,O[A?E!Z#I0!?_MK1_\ H+6?_?\ 7_&C^VM'
M_P"@M9_]_P!?\:/[%T?_ *!-G_WX7_"LV30]'DU6"^6UL0L"-&R"%.2V/\*
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MW=]X?O[.PG^SW4T#I%)G&UB.#6I10!Q_@?2;[1]%EM[RW%F'G,D5H)/,$"X
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MI/*?WOG%E\U,?<#*<KDXY]*S_"OAW7M-\47-_J:HJM"5FF24L+MB5*?+_"$
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MI[FKE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9R.U$NEZ;/&8YK&WE1NJO$I!YSZ>O- $UK<+=V<-TBE4FC610PP0",\U;I
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277402952672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jan. 06, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CEL-SCI CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000725363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well Known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,107,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,002,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Fin Stmt Error Correction Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-11889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-0916344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">8229 Boone Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td>
<td class="text">Suite 802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Vienna<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">22182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">Icfr Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">BDO USA, P.C.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Potomac, Maryland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">506-9460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CVM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm Id</a></td>
<td class="text">243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277407245968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,738,173<span></span>
</td>
<td class="nump">$ 4,145,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">294,097<span></span>
</td>
<td class="nump">520,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="nump">1,019,908<span></span>
</td>
<td class="nump">2,248,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">4,245<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">6,055,678<span></span>
</td>
<td class="nump">6,918,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">7,350,364<span></span>
</td>
<td class="nump">9,131,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,495,937<span></span>
</td>
<td class="nump">1,698,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,129,753<span></span>
</td>
<td class="nump">10,188,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patent costs, net</a></td>
<td class="nump">165,492<span></span>
</td>
<td class="nump">197,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">2,319,101<span></span>
</td>
<td class="nump">2,319,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="nump">1,475,441<span></span>
</td>
<td class="nump">74,669<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">26,991,766<span></span>
</td>
<td class="nump">30,528,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,448,467<span></span>
</td>
<td class="nump">2,009,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">566,042<span></span>
</td>
<td class="nump">1,049,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_AmountsDueToEmployeesCurrent', window );">Due to employees</a></td>
<td class="nump">363,306<span></span>
</td>
<td class="nump">557,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligation, current portion</a></td>
<td class="nump">2,010,995<span></span>
</td>
<td class="nump">1,771,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligation, current portion</a></td>
<td class="nump">226,969<span></span>
</td>
<td class="nump">197,431<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,615,779<span></span>
</td>
<td class="nump">5,585,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="nump">7,957,925<span></span>
</td>
<td class="nump">9,949,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">1,425,979<span></span>
</td>
<td class="nump">1,652,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">14,124,683<span></span>
</td>
<td class="nump">17,313,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value; 200,000 shares authorized; 0 shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 600,000,000 shares authorized; 63,787,104 and 47,422,304 shares issued and outstanding at September 30, 2024 and 2023, respectively</a></td>
<td class="nump">637,870<span></span>
</td>
<td class="nump">474,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">526,241,074<span></span>
</td>
<td class="nump">499,832,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(514,011,861)<span></span>
</td>
<td class="num">(487,091,396)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">12,867,083<span></span>
</td>
<td class="nump">13,214,890<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 26,991,766<span></span>
</td>
<td class="nump">$ 30,528,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AmountsDueToEmployeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AmountsDueToEmployeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277406059280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">63,787,104<span></span>
</td>
<td class="nump">47,422,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">63,787,104<span></span>
</td>
<td class="nump">47,422,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277406906016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 18,161,451<span></span>
</td>
<td class="nump">$ 22,471,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General &amp; administrative</a></td>
<td class="nump">8,191,023<span></span>
</td>
<td class="nump">9,004,578<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">26,352,474<span></span>
</td>
<td class="nump">31,476,074<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(26,352,474)<span></span>
</td>
<td class="num">(31,476,074)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="num">(745,673)<span></span>
</td>
<td class="num">(675,416)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">177,682<span></span>
</td>
<td class="num">(42,813)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(26,920,465)<span></span>
</td>
<td class="num">(32,194,303)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ModificationOfWarrants', window );">Modification of warrants</a></td>
<td class="num">(659,456)<span></span>
</td>
<td class="num">(171,552)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss available to common shareholders</a></td>
<td class="num">$ (27,579,921)<span></span>
</td>
<td class="num">$ (32,365,855)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - basic and diluted</a></td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - basic and diluted</a></td>
<td class="nump">54,044,989<span></span>
</td>
<td class="nump">44,479,865<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ModificationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ModificationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277400981408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,448,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2022</a></td>
<td class="nump">$ 32,163,207<span></span>
</td>
<td class="nump">$ 434,484<span></span>
</td>
<td class="nump">$ 486,625,816<span></span>
</td>
<td class="nump">$ 454,897,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Warrant exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_StockIssuedDuringPeriodValueStockWarrantsExercised', window );">Warrant exercises, amount</a></td>
<td class="nump">447,291<span></span>
</td>
<td class="nump">$ 2,177<span></span>
</td>
<td class="nump">445,114<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, amount</a></td>
<td class="nump">207,593<span></span>
</td>
<td class="nump">$ 970<span></span>
</td>
<td class="nump">206,623<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service, amount</a></td>
<td class="nump">565,980<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">563,480<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from the sale of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,413,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from the sale of common stock, amount</a></td>
<td class="nump">6,122,497<span></span>
</td>
<td class="nump">$ 34,132<span></span>
</td>
<td class="nump">6,088,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncentiveStockForfeitedShares', window );">2014 Incentive Stock Forfeited, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncentiveStockForfeitedAmount', window );">2014 Incentive Stock Forfeited, amount</a></td>
<td class="nump">22,200<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">22,160<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees</a></td>
<td class="nump">6,308,431<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,308,431<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CostIncurredInIssuanceOfStock', window );">Share issuance costs</a></td>
<td class="nump">383,606<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">383,606<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(32,194,303)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,194,303<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,422,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2023</a></td>
<td class="nump">13,214,890<span></span>
</td>
<td class="nump">$ 474,223<span></span>
</td>
<td class="nump">499,832,063<span></span>
</td>
<td class="nump">487,091,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">401(k) contributions paid in common stock, amount</a></td>
<td class="nump">218,717<span></span>
</td>
<td class="nump">$ 1,368<span></span>
</td>
<td class="nump">217,349<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to nonemployees for service, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to nonemployees for service, amount</a></td>
<td class="nump">759,901<span></span>
</td>
<td class="nump">$ 4,099<span></span>
</td>
<td class="nump">755,802<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Equity based compensation - employees</a></td>
<td class="nump">4,270,180<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,270,180<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CostIncurredInIssuanceOfStock', window );">Share issuance costs</a></td>
<td class="nump">2,331,760<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,331,760<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(26,920,465)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,920,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsShares', window );">Proceeds from the sale of common stock and pre-funded warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,080,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount', window );">Proceeds from the sale of common stock and pre-funded warrants, amount</a></td>
<td class="nump">23,518,200<span></span>
</td>
<td class="nump">$ 100,800<span></span>
</td>
<td class="nump">23,417,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExerciseOfPreFundedWarrantsShares', window );">Exercise of pre-funded warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,680,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExerciseOfPreFundedWarrantsAmount', window );">Exercise of pre-funded warrants, amount</a></td>
<td class="nump">56,800<span></span>
</td>
<td class="nump">$ 56,800<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PurchaseOfStockByOfficersAndDirectorsShares', window );">Purchase of stock by officers and directors, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PurchaseOfStockByOfficersAndDirectorsAmount', window );">Purchase of stock by officers and directors, amount</a></td>
<td class="nump">80,620<span></span>
</td>
<td class="nump">$ 580<span></span>
</td>
<td class="nump">80,040<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,787,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2024</a></td>
<td class="nump">$ 12,867,083<span></span>
</td>
<td class="nump">$ 637,870<span></span>
</td>
<td class="nump">$ 526,241,074<span></span>
</td>
<td class="nump">$ 514,011,861<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CostIncurredInIssuanceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CostIncurredInIssuanceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExerciseOfPreFundedWarrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExerciseOfPreFundedWarrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExerciseOfPreFundedWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExerciseOfPreFundedWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncentiveStockForfeitedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncentiveStockForfeitedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncentiveStockForfeitedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncentiveStockForfeitedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PurchaseOfStockByOfficersAndDirectorsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PurchaseOfStockByOfficersAndDirectorsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PurchaseOfStockByOfficersAndDirectorsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PurchaseOfStockByOfficersAndDirectorsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_StockIssuedDuringPeriodValueStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_StockIssuedDuringPeriodValueStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277398363216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (26,920,465)<span></span>
</td>
<td class="num">$ (32,194,303)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,969,183<span></span>
</td>
<td class="nump">3,958,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash lease expense</a></td>
<td class="nump">4,873<span></span>
</td>
<td class="nump">15,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Share-based payments for services</a></td>
<td class="nump">858,498<span></span>
</td>
<td class="nump">655,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity based compensation</a></td>
<td class="nump">4,270,180<span></span>
</td>
<td class="nump">6,286,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommonStockContributedToEmployeeBenefitPlan', window );">Common stock contributed to 401(k) plan</a></td>
<td class="nump">218,717<span></span>
</td>
<td class="nump">207,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase)/decrease in assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">72,674<span></span>
</td>
<td class="nump">151,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="num">(172,608)<span></span>
</td>
<td class="num">(156,727)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Deposits</a></td>
<td class="nump">745<span></span>
</td>
<td class="num">(2,323,346)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase/(decrease) in liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(460,576)<span></span>
</td>
<td class="nump">257,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(458,489)<span></span>
</td>
<td class="nump">207,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Due to employees</a></td>
<td class="num">(193,938)<span></span>
</td>
<td class="nump">85,756<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(18,811,206)<span></span>
</td>
<td class="num">(22,848,561)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(94,875)<span></span>
</td>
<td class="num">(361,892)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Expenditures for patent costs</a></td>
<td class="num">(13,211)<span></span>
</td>
<td class="num">(10,370)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(108,086)<span></span>
</td>
<td class="num">(372,262)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and pre-funded warrants</a></td>
<td class="nump">23,575,000<span></span>
</td>
<td class="nump">6,552,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="num">(2,370,513)<span></span>
</td>
<td class="num">(744,913)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from the purchase of stock by officers and directors</a></td>
<td class="nump">80,620<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">447,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Payments on obligations under finance leases</a></td>
<td class="num">(1,773,377)<span></span>
</td>
<td class="num">(1,560,455)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party loans</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payments of related party loans</a></td>
<td class="num">(450,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">19,511,730<span></span>
</td>
<td class="nump">4,694,420<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">592,438<span></span>
</td>
<td class="num">(18,526,403)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</a></td>
<td class="nump">4,145,735<span></span>
</td>
<td class="nump">22,672,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AND CASH EQUIVALENTS, END OF YEAR</a></td>
<td class="nump">4,738,173<span></span>
</td>
<td class="nump">4,145,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities', window );">Property and equipment purchases included in current liabilities</a></td>
<td class="nump">32,954<span></span>
</td>
<td class="nump">51,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CapitalizedIntangibleAssetsCostsIncludedInCurrentLiabilities', window );">Capitalized patent costs included in current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PurchaseOfAssetsUnderFinanceLeases', window );">Assets purchased under finance leases</a></td>
<td class="nump">20,797<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinanceLeaseObligationIncludedInAccountsPayable', window );">Finance lease obligation included in accounts payable</a></td>
<td class="nump">1,320<span></span>
</td>
<td class="nump">1,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ConsultingServicesPaidWithIssuanceOfCommonStock', window );">Consulting services paid with issuance of common stock</a></td>
<td class="nump">759,901<span></span>
</td>
<td class="nump">565,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinancingCostsIncludedInCurrentLiabilities', window );">Financing costs included in current liabilities</a></td>
<td class="nump">38,950<span></span>
</td>
<td class="nump">77,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_AccruedConsultingServicesToBePaidUnderShareBasedPaymentArrangement', window );">Accrued consulting services to be paid with common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 923,807<span></span>
</td>
<td class="nump">$ 1,062,564<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AccruedConsultingServicesToBePaidUnderShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AccruedConsultingServicesToBePaidUnderShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CapitalizedIntangibleAssetsCostsIncludedInCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CapitalizedIntangibleAssetsCostsIncludedInCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommonStockContributedToEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommonStockContributedToEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ConsultingServicesPaidWithIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ConsultingServicesPaidWithIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseObligationIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseObligationIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinancingCostsIncludedInCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinancingCostsIncludedInCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PurchaseOfAssetsUnderFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PurchaseOfAssetsUnderFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277403617072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>ORGANIZATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1. ORGANIZATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">CEL-SCI Corporation (the Company) was incorporated on March 22, 1983, in the state of Colorado, to finance research and development in biomedical science and ultimately to engage in marketing and selling products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company has announced results from its Phase III study for its lead investigational therapy, Multikine&#174; (Leukocyte Interleukin, Injection), involving head and neck cancer, for which the Company has received Orphan Drug Status from the United States Food and Drug Administration (FDA). Unlike other immune therapies, Multikine is administered locally at the site of the tumor as a first line treatment right after diagnosis, before surgery and radiation. The goal is to help the intact immune system kill the micro metastases that usually cause recurrence of the cancer to improve outcomes and better overall survival rates for patients suffering from head and neck cancer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">CEL-SCI is also investigating a peptide-based immunotherapy (CEL-4000) as a vaccine for rheumatoid arthritis using its LEAPS technology platform. CEL-SCI is in the process of completing pre-IND studies for CEL-4000.&#160; </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277403465616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_LIQUIDITYAbstract', window );"><strong>LIQUIDITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_LiquidityDisclosureTextblock', window );">LIQUIDITY</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>2</strong><strong>.</strong>&#160; <strong>LIQUIDITY </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and conducting clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine, the Company&#8217;s lead investigational therapy, to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from any regulatory agency for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase III study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Due to the Company&#8217;s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern.&#160; The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LIQUIDITYAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LIQUIDITYAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LiquidityDisclosureTextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LiquidityDisclosureTextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277403406624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>3</strong><strong>. </strong><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Basis of Presentation</em> &#8211; The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Supplies used for R&amp;D and manufacturing</em> &#8211; Supplies are consumable items kept on hand to support the Company&#8217;s R&amp;D and manufacturing operations. Supplies are recorded at the lower of cost or net realizable value and are charged to expense as they are used in operations. The Company regularly reviews the quality and utilization of supplies to determine if future use of these supplies is probable. Due to the generic use of these supplies, they can be used in multiple projects other than those currently being studied. Supplies held less than twelve months are classified as current assets and supplies held longer than twelve months are classified as non-current assets.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Patents</em> &#8211; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Leases</em> &#8211; The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. The incremental borrowing rate reflects the rate of interest that the Company would pay on the lease commencement date to borrow an amount equal to the lease payments on a collateralized basis over a similar term in similar economic environments. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. Operating and finance lease agreements which require payments for lease and non-lease components are accounted for as a single lease component.&#160; Variable lease payments that cannot be determined at the commencement of the lease are not included in the calculation of right of use assets or lease liabilities, and are expensed as incurred.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Share-Based Compensation</em> &#8211; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, Compensation &#8211; Stock Compensation (&#8220;ASC 718&#8221;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate, and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Research and Development Costs</em> - Research and development costs are expensed as incurred.&#160; Management accrues Clinical Research Organization (&#8220;CRO&#8221;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share. Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Concentration of Credit Risk</em> &#8211; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents.&#160; The Company maintains its cash and cash equivalents with high quality financial institutions.&#160; At times, these accounts may exceed federally insured limits.&#160; The Company has not experienced any losses in such bank accounts.&#160; The Company believes it is not exposed to significant credit risk related to cash and cash equivalents.&#160; All non-interest bearing cash balances were fully insured up to $250,000 at September 30, 2024 and 2023. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Income Taxes</em> &#8211; The Company accounts for income taxes in accordance with the provisions of ASC 740, Income Taxes, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards.&#160; Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of September 30, 2024 and 2023.</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Impairment of long-lived assets </em>&#8211; CEL-SCI&#8217;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#8217;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, share-based compensation, useful lives for depreciation and amortization of long-lived assets, right-of-use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year.&#160; Additionally, in calculating the right-of-use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Recently Adopted Accounting Standards</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2016-13, Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;). ASU 2016-13 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13 had no material impact on the Company&#8217;s financial position, results of operations, or cash flows.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>New Accounting Pronouncements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (&#8220;ASU 2023-07&#8221;), which expands disclosures about a public entity&#8217;s reportable segments and requires more enhanced information about a reportable segment&#8217;s expenses, interim segment profit or loss, and how a public entity&#8217;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is currently evaluating the impact that this change will have on the Company&#8217;s disclosures. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In December 2023, the FASB issued Accounting Standards Update No. 2023-09, Improvements to Income Tax Disclosures, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In March 2024, the SEC issued its final climate disclosure rules, which require the disclosure of climate-related information in annual reports and registration statements. The rules require disclosure in the audited financial statements of certain effects of severe weather events and other natural conditions above certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates, if material. Under the rules as originally issued, disclosure requirements begin phasing in for fiscal years beginning on or after January 1, 2027. However, on April 4, 2024, the SEC determined to voluntarily stay the final rules pending certain legal challenges. We are currently evaluating the impact of the new rules and continue to monitor the status of the related legal challenges.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2024, the FASB issued Accounting Standards Update No. 2024-03, Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;). ASU 2024-03 will require more detailed information about the types of expenses in commonly presented income statement captions such as &#8220;Cost of sales&#8221; and &#8220;Selling, general and administrative expenses&#8221;. The new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027 with early adoption permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277403519696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS AND NONEMPLOYEE OPTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantsAndNonemployeeOptionsAbstract', window );"><strong>WARRANTS AND NONEMPLOYEE OPTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantsAndNonEmployeeOptionsDisclosureTextBlock', window );">WARRANTS AND NON-EMPLOYEE OPTIONS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>4. WARRANTS AND NON-EMPLOYEE OPTIONS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following warrants and non-employee options are outstanding at September 30, 2024:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrant/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares Issuable</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of Warrants/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2026&#160; </p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/11/2018</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">93,603</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.80</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/30/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1/13/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">120,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9.25</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/13/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/15/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">26,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">12.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/15/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">333,432</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.86</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">200,087</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.52</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">234,009</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.65</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/28/2017 &#8211; 9/2/2023 </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">110,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;&#160; $1.39 - $2.18 </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/27/2027 &#8211; 9/1/2028</p></td><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following warrants and non-employee options are outstanding at September 30, 2023:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrant/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares Issuable</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of Warrants/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2024&#160; </p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/11/2018</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">93,603</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.80</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/30/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1/13/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">120,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9.25</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/13/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/15/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">26,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">12.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/15/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">333,432</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.86</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">200,087</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.52</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">234,009</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.65</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/28/2017 &#8211; 9/2/2023 </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">110,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;">$</td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;&#160; 1.39 - $2.18 </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/27/2027 &#8211; 9/1/2028</p></td><td>&#160;</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>A. Equity Warrants</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Changes in Equity Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the fiscal year ended September 30, 2024, 5,680,000 pre-funded warrants were exercised. The following equity warrants were exercised during the year ended September 30, 2023:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Proceeds</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,752</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,291</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">418,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">217,752</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">447,291</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">No warrants recorded as equity expired during the fiscal year ended September 30, 2024. On February 5, 2023, 600 Series TT warrants, with an exercise price of $2.24, expired.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On May 4, 2024, the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates.&#160; The incremental cost of this extension was approximately $659,455, which was recorded as a deemed dividend. The Series N, X, MM, NN, RR and UU warrants are held by current Officers of the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><strong>B.</strong> <strong>Options and Shares Issued to Consultants</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company typically enters into consulting arrangements in exchange for common stock or stock options. During the years ended September 30, 2024 and 2023, the Company issued 409,932 and 249,997 shares, respectively, of common stock to consultants, all of which were restricted shares. Under these arrangements, during the periods presented, the common stock was issued with stock prices ranging from $1.08 to $3.47 per share. The weighted average grant price was $1.69 and $1.83, respectively, for stock issued during the years ended September 30, 2024 and 2023.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the years ended September 30, 2024 and 2023, the Company recorded total expense of approximately $681,000 and $656,000, respectively, relating to these consulting agreements, which are included in general and administrative expense on the accompanying statements of operations. At September 30, 2024 and 2023, costs of approximately $52,000 and $205,000, respectively, are included in prepaid expenses.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">No options were issued to consultants during the year ended September 30, 2024. During the year ended September 30, 2023, the Company issued 100,000 options to a consultant to purchase common stock with an exercise price of $1.39. These options vest 50% on September 2, 2024 and 50% on September 2, 2025 and expire on September 1, 2028. As of September 30, 2024, 110,000 options issued to consultants as payment for services remained outstanding, all of which were issued from the Non-Qualified Stock Option Plan.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantsAndNonEmployeeOptionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantsAndNonEmployeeOptionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantsAndNonemployeeOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantsAndNonemployeeOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277407594080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>5</strong><strong>. </strong><strong>PROPERTY AND </strong><strong>EQUIPMENT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px">Property and equipment consisted of the following at September 30:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,167,828</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,109,070</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Furniture and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">104,593</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">99,296</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Leasehold improvements</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13,924,724</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13,924,724</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,197,145</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,133,090</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: Accumulated depreciation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(10,067,392</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,944,964</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8,129,753</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10,188,126</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Depreciation expense for the years ended September 30, 2024 and 2023 totaled approximately $2,135,000 and $2,114,000, respectively, and is included in operating expenses on the accompanying statements of operations.&#160; </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277403830944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">PATENTS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>6</strong><strong>. PATENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Patents consist of the following at September 30:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">829,716</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">853,445</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: Accumulated amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(664,224</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(655,741</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patents, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">165,492</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">197,704</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">During the years ended September 30, 2024 and 2023, there was no impairment of patent costs.&#160; The weighted average remaining amortization period for patents is approximately 8 years. For the years ended September 30, 2024 and 2023, amortization of patent costs totaled approximately $32,000 and $38,000, respectively, and is included in general and administrative expense on the accompanying statements of operations.&#160; The total estimated future amortization is as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="4" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Years ending September 30, </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">54,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">165,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277403866240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>7</strong><strong>. INCOME TAXES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">At September 30, 2024 and 2023, the Company had net deferred tax assets of $62.5 million and $60.0 million, respectively. Due to uncertainties surrounding the Company&#8217;s ability to generate future taxable income to realize these assets, a full valuation allowance has been established to offset the net deferred tax assets. In assessing the realization of deferred tax assets, management considered whether it was more likely than not that some, or all, of the deferred tax assets will be realized.&#160; The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income.&#160; Management has considered the history of the Company&#8217;s operating losses and believes that the realization of the benefit of the deferred tax assets cannot be reasonably assured.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Pursuant to Section 382 of the Internal Revenue Code, or IRC, annual use of the Company&#8217;s net operating loss (NOL) carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. Such ownership change could result in annual limitations on the utilization of tax attributes, including NOL carryforwards and tax credits. The Company performed an estimated analysis to determine if any additional ownership changes occurred during the year ended September 30, 2024 and no such changes were identified. If changes in ownership occur after year end, NOL and tax credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company had federal NOL carryforwards of approximately $146.4 million and $123.1 million at September 30, 2024 and 2023, respectively. Approximately $19.2 million of the NOL carryforwards begin to expire during the year ended September 30, 2024 and become fully expired by 2038 and approximately $127.2 million of NOL carryforwards, which were generated after the enactment of Tax Cuts and Jobs Act, have an indefinite life.&#160; In addition, the Company has a general business credit as a result of the credit for increasing research activities (&#8220;R&amp;D credit&#8221;) of approximately $0.9 million and&#160;$1.2 million at September 30, 2024 and 2023, respectively.&#160;The R&amp;D credit expires during the fiscal year ended 2029.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Significant components of the Company&#8217;s deferred tax assets and liabilities as of September 30, 2024 and 2023 are listed below:&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">NOL carryforwards</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">34,673,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,829,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Capitalized R&amp;D</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,062,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,196,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,645,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,579,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,752,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,400,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">R&amp;D credit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">932,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,221,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vacation and other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">188,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">298,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fixed assets and intangibles</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">347,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">168,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total deferred tax assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,599,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">62,691,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Right-of-use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,095,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,713,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fixed assets and intangibles</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total deferred tax liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,095,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,713,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net deferred tax asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">62,504,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">59,978,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(62,504,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(59,978,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ending balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has no federal or state current or deferred tax expense or benefit.&#160; The Company&#8217;s effective tax rate differs from the applicable federal statutory tax rate.&#160; The reconciliation of these rates is as follows for the years ended September 30:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Federal rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">State rate change </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(11.97</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1.58</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">State tax rate, net of federal benefit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.68</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.05</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other adjustments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2.32</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1.62</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Permanent differences</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Change in valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(9.39</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(21.85</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effective tax rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company applies the provisions of ASC 740, <em>Accounting for Uncertainty in Income Taxes,</em> which requires financial statement benefits to be recognized for positions taken for tax return purposes when it is more likely than not that the position will be sustained.&#160; The Company has elected to reflect any tax penalties or interest resulting from tax assessments on uncertain tax positions as a component of tax expense.&#160; The Company has generated federal net operating losses in tax years ending September 30, 1999 through 2024.&#160;&#160;The Company files income tax returns in the U.S. federal jurisdiction and various states. With few exceptions, the Company is no longer subject to U.S. federal and state income tax examinations by tax authorities for years before September 30, 2021. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277501465040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>EQUITY-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">EQUITY-BASED COMPENSATION</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>8</strong><strong>.</strong> <strong>EQUITY-BASED</strong><strong> COMPENSATION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company recognized the following expenses for options issued or vested and restricted stock awarded during the year:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Year Ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,270,180</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,286,231</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">680,768</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">655,740</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of September 30, 2024, the total compensation cost related to non-vested options and restricted stock awarded to employees and non-employees not yet recognized was approximately $4.5 million and $0.1 million, respectively, and the weighted-average period over which it is expected to be recognized is 1.9 and 0.54 years, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the years ended September 30, 2024 and 2023, the fair value of each option grant was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected stock price volatility</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">100.89 &#8211; 101.66%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">99.18 &#8211; 100.18%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3.77 &#8211; 4.58%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3.41 &#8211; 4.25%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected life of options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">9.61 &#8211; 9.64 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">9.63 &#8211; 9.66 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Non-Qualified Stock Option Plan</span><span style="text-decoration:underline">s</span>&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the year ended September 30, 2024, the Company adopted the 2024 Non-Qualified Stock Option Plan, which provides for the issuance of up to 2,000,000 options to purchase shares of common stock. On April 19, 2024, the Company granted 1,962,000 options to purchase shares of common stock from the 2024 Non-Qualified Stock Option Plan to officers, directors and employees. Each option entitles the holder to purchase one share of the Company&#8217;s common stock at a price of $1.50 per share, vests in three equal annual installments commencing one year after the grant date and expires on April 18, 2034.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the year ended September 30, 2023, the Company adopted the 2023 Non-Qualified Stock Option Plan, which provides for the issuance of up to 2,000,000 options to purchase shares of common stock. On August 8, 2023, the Company granted 1,958,500 options to purchase shares of common stock from the 2023 Non-Qualified Stock Option Plan to officers, directors and employees. Each option entitles the holder to purchase one share of the Company&#8217;s common stock at a price of $1.36 per share, vests in three equal annual installments commencing one year after the grant date and expires on August 7, 2033.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">At September 30, 2024, the Company has collectively authorized the issuance of 17,787,200 options to purchase shares of common stock under its Non-Qualified Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms of the options were determined by the Company&#8217;s Compensation Committee which administers the plans. The Company&#8217;s employees, directors, officers, and consultants or advisors are eligible to be granted options under the Non-Qualified Stock Option Plans.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Incentive Stock Option Plan</span><span style="text-decoration:underline">s</span> &#8211; At September 30, 2024, the Company had collectively authorized the issuance of 138,400 options to purchase shares of common stock under its Incentive Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms of the options were determined by the Company&#8217;s Compensation Committee which administers the Plans. Only the Company&#8217;s employees are eligible to be granted options under the Incentive Stock Option Plans.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Activity in the Company&#8217;s Non-Qualified and Incentive Stock Option Plans for the two years ended September 30, 2024 is summarized as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span style="text-decoration:underline">Non-Qualified and Incentive Stock Option Plans</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Outstanding</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercisable</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Remaining Contractual Term (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Remaining Contractual Term (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">12,964,014</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9.06</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,866,240</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7,067,617</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.21</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.21</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,866,105</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">952,256</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">8.41</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Granted (a)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,065,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1.37</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(213,165</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9.19</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(58,791</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">61.05</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(58,791</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">61.05</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">14,757,558</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.78</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.81</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">7,961,082</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.07</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.60</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,501,583</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.24</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Granted (b)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,969,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(406,333</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">10.01</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(62,145</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">27.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(62,145</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">27.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">16,258,080</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.88</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">9,400,520</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.64</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.19</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(a)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Includes 1,965,500 performance based options issued to officers and directors, 100,000 options issued to consultants. The weighted average grant date fair value was $1.22.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">(b)</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The weighted average grant date fair value was $1.36.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">A summary of the status of the Company&#8217;s unvested options for the two years ended September 30, 2024 is presented below:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Options</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Grant Date Fair Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,896,397</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.63</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(952,256</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7.30</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,065,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.22</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(213,165</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.02</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,796,476</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,501,583</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.73</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,969,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.36</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(406,333</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.94</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6,857,560</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.69</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Incentive Stock Bonus Plan</span> &#8211; On September 30, 2024, 610,500 of the shares granted under the 2014 Incentive Stock Bonus Plan remain outstanding, of which 463,250 shares are fully vested.&#160; During the year ended September 30, 2024 and 2023, there were 0 and 4,000 unvested shares that were forfeited, respectively. The shares are being earned upon the achievement of certain milestones leading to the commercialization of the Company&#8217;s Multikine technology, or specified increases in the market price of the Company&#8217;s stock.&#160; The fair value of the shares on the grant date was calculated using the market value on the grant-date for issuances where the attainment of performance criteria is likely and using a Monte Carlo Simulation for issuances where the attainment of performance criteria is uncertain.&#160; The grant date fair value of shares issued that remain outstanding as of September 30, 2024 was approximately $8.6 million.&#160; The total value of the shares, if earned, is being expensed over the requisite service periods for each milestone, provided the requisite service periods are rendered, regardless of whether the market conditions are met.&#160; No compensation cost is recognized for awards where the requisite service period is not rendered.&#160; During the years ended September 30, 2024 and 2023, the Company recorded expense relating to the issuance of restricted stock pursuant to the plan of approximately $0 and $(22,000), respectively.&#160; As of September 30, 2023, all compensation expense related to the 2014 Incentive Stock Bonus Plan has been fully recognized. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">A summary of the status of the Company&#8217;s restricted common stock issued from the Incentive Stock Bonus Plan for the two years ended September 30, 2024 is presented below: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number of</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Grant Date Fair Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unvested at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">151,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unvested at September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unvested at September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Stock Bonus Plans</span><span style="text-decoration:underline"> </span>&#8211; As of September 30, 2024, the Company authorized to issue up to 1,283,760 shares of common stock from the Stock Bonus Plans and has issued a total of 649,840 shares of common stock under its Stock Bonus Plans.&#160; All employees, directors, officers, consultants, and advisors are eligible to be granted shares.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><span style="text-decoration:underline">Stock Compensation Plans</span> &#8211; On September 30, 2024, 634,000 shares were authorized for issuance pursuant to the Company&#8217;s Stock Compensation Plans, of which 153,195 shares were issued and outstanding.&#160; No shares were issued from the Stock Compensation Plans during the years ended September 30, 2024 and 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277403026176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract', window );"><strong>EMPLOYEE BENEFIT PLAN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">EMPLOYEE BENEFIT PLAN</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>9</strong><strong>. EMPLOYEE BENEFIT PLAN</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company maintains a defined contribution retirement plan, qualifying under Section 401(k) of the Internal Revenue Code, subject to the Employee Retirement Income Security Act of 1974, as amended, and covering substantially all Company employees. Each participant&#8217;s contribution is matched by the Company with shares of common stock that have a value equal to 100% of the participant&#8217;s contribution, not to exceed the lesser of $10,000 or 6% of the participant&#8217;s total compensation. The Company&#8217;s contribution of common stock is valued each quarter based upon the closing bid price of the Company&#8217;s common stock. During the year ended September 30, 2024, 136,868 shares were issued to the Company&#8217;s 401(k) plan for a cost of approximately $219,000. During the year ended September 30, 2023, 97,004 shares were issued to the Company&#8217;s 401(k) plan for a cost of approximately $208,000.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277402729264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>10</strong><strong>. COMMITMENTS AND CONTINGENCIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Clinical Research Agreements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In August 2024 the Company entered into an agreement, pursuant to which the Company engaged Ergomed Clinical Research, Inc. to provide clinical development services related to the Company&#8217;s upcoming confirmatory registration study in exchange for fees. Since the Company entered into this agreement it has incurred research and development expenses of approximately $0.4 million as of September 30, 2024.&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Lease Agreements</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#8217;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#8217;s Phase III clinical trial and sales of the drug if approved by the FDA or regulators in Canada, the UK or Europe. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. &#160;The renewal options are not included in the calculation of the right-of-use asset and lease liability because exercise of those options is not reasonably certain.&#160;&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of September 30, 2024 and 2023, respectively, the net book value of the finance lease right-of-use asset is approximately $7.4 million and $9.1 million and the balance of the finance lease liability is approximately $10.0 million and $11.7 million, of which approximately $2.0 million and $1.8 million is current. These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment. During the years ended September 30, 2024 and 2023, the finance right of use assets are being depreciated using a straight-line method over the underlying lease terms and depreciation expense totaled approximately $1.8 million in both periods, which is included in research and development expense on the accompanying statements of operations. Total cash paid related to finance leases during the years ended September 30, 2024 and 2023, respectively, was approximately $2.7 million and $2.6 million, of which approximately $0.9 million and $1.1 million was for interest. The total cash paid related to finance lease principal payments is included in cash flows from financing activities on the accompanying statements of cash flows. The total cash paid related to finance lease interest expense is included in cash flows from operating activities on the accompanying statements of cash flows. The weighted average discount rate of the Company&#8217;s finance leases is 8.46% and the weighted average remaining lease term is 4.09 years. During the years ended September 30, 2024 and 2023, total finance lease costs were approximately $2.7 million and $2.9 million, consisting of approximately $1.8 million of lease asset amortization in both periods, and approximately $0.9 million and $1.1 million of interest on the finance lease liabilities, respectively. Variable lease expenses, such as maintenance costs, utilities, and real property taxes are not included in right of use assets or lease liabilities but rather are expensed as incurred. During the year ended September 30, 2024, there were approximately $0.9 million of variable finance lease costs, which are included in research and development expense on the accompanying statements of operations. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On January 11, 2023, the Company was required to deposit approximately $2.3 million to its landlord, equivalent to one year&#8217;s rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Approximate future minimum lease payments under finance leases as of September 30, 2024 are as follows:&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,747,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,838,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,929,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,021,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">255,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,790,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,821,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,969,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of finance lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,011,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of finance lease obligations &#8211; non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,958,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company leases two facilities under operating leases.&#160; The lease for the Company&#8217;s office headquarters will expire on November 30, 2025.&#160; The lease for its research and development laboratory and will expire on February 29, 2032. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of September 30, 2024 and 2023, respectively, the net book value of the operating lease right-of-use asset is approximately $1.5 million and $1.7 million and the balance of the operating lease liability is approximately $1.7 million and $1.9 million, of which approximately $0.2 million is current in both periods. During the years ended September 30, 2024 and 2023, the Company incurred lease expense under operating leases of approximately $0.4 million in both periods, which is included in general and administrative expense on the accompanying statements of operations. Total cash paid related to operating leases during the years ended September 30, 2024 and 2023 was approximately $0.4 million and $0.3 million, respectively. The total cash paid related to operating leases is included in cash flows from operating activities on the accompanying statements of cash flows. The weighted average discount rate of the Company&#8217;s operating leases is 9.0% and the weighted average the remaining lease term is 6.98 years. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of September 30, 2024, future minimum lease payments on operating leases are as follows: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">366,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">287,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">277,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">285,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">294,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">746,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,255,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(602,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,653,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">227,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations &#8211; non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,426,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277402547248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1</strong><strong>1</strong><strong>. </strong><strong>RELATED PARTY TRANSACTIONS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the year ended September 30, 2024, certain officers and directors purchased 58,000 shares of restricted common stock at an aggregated fair market value of approximately $81,000. During the year ended September 30, 2023, no restricted shares of the Company&#8217;s common stock were purchased by related parties.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On July 11, 2024, Geert Kersten, the Company&#8217;s Chief Executive Officer and a director, loaned the Company $200,000. On July 18, 2024, Mr. Kersten loaned the Company an additional $250,000. These amounts were repaid on July 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On May 4, 2024, the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates. The incremental cost of this extension was approximately $0.7 million, which was recorded as a deemed dividend in the financial statements for the three months ended June 30, 2024. The Series N, X, MM, NN, RR and UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company&#8217;s CEO, Geert Kersten, is a beneficiary.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024 (Note C). The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277506381040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1</strong><strong>2</strong><strong>.</strong> <strong>STOCKHOLDERS&#8217; EQUITY</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Exercise of Warrants</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the year ended September 30, 2024, 5,680,000 pre-funded warrants were exercised. During the year ended September 30, 2023, the Company received proceeds of approximately $0.4 million from the exercise of warrants, as detailed in Note 4. Upon exercise, 217,752 shares of common stock were issued during the year ended September 30, 2023. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Proceeds from the Sale of Common Stock</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On July 29, 2024, the Company sold 3,715,000 shares of common stock at an offering price of $1.00 per share, and pre-funded warrants to purchase up to 7,130,000 shares of common stock, at an offering price of $0.99 per pre-funded warrant, for proceeds of approximately $9.7 million, net of issuance costs of approximately $1.1 million. Holders of the pre-funded warrants have exercised 5,680,000 of the pre-funded warrants as of September 30, 2024. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company determined that the pre-funded warrants sold in the July 26, 2024 offering are freestanding financial instruments because they are both legally detachable and separately exercisable from the common stock sold in the offering. As such, the Company evaluated the pre-funded warrants to determine whether they represent instruments that require liability classification pursuant to the guidance in ASC 480. However, the Company concluded that the pre-funded warrants are not a liability within the scope of ASC 480 due to their characteristics. Further, the Company determined that the pre-funded warrants do not meet the definition of a derivative under ASC 815. Accordingly, the Company assessed the pre-funded warrants relative to the guidance in ASC No. 815-40, Contracts in Entity&#8217;s Own Equity, to determine the appropriate treatment. The Company concluded that the pre-funded warrants are both indexed to its own stock and meet all other conditions for equity classification. Accordingly, the Company has classified the pre-funded warrants as permanent equity and recorded them as a component of additional paid-in capital upon the closing of the transaction in July 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In February 2024, the Company sold 3,875,000 shares of common stock at a public offering price of $2.00 per share and received proceeds of approximately $7.0 million, net of issuance costs of approximately $0.7 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2023, the Company sold 2,490,000 shares of common stock at a public offering price of $2.00 per share and received proceeds of approximately $4.5 million, net of issuance costs of approximately $0.5 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In April 2023, the Company sold 794,117 shares of common stock at a public offering price of $1.70 per share and received proceeds of approximately $1.4 million. The Company granted the underwriters a 30-day option to purchase up to 119,117 additional shares of common stock to cover over-allotments. The underwriter fully exercised this option in May 2023, resulting in additional proceeds to the Company of approximately $200,000. The Company incurred issuance costs of approximately $0.2 million related to this offering.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277402458672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1</strong><strong>3</strong><strong>. FAIR VALUE MEASUREMENTS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In accordance with the provisions of ASC 820, &#8220;Fair Value Measurements,&#8221; the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160; The Company generally applies the income approach to determine fair value.&#160; This method uses valuation techniques to convert future amounts to a single present amount.&#160; The measurement is based on the value indicated by current market expectations with respect to the future amounts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value.&#160; The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&#160; The Company classifies fair value balances based on the observability of those inputs.&#160; The three levels of the fair value hierarchy are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Level 1 &#8211; Observable inputs such as quoted prices in active markets for identical assets or liabilities</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Level 2 &#8211; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs other than quoted prices that are observable for the asset or liability are observable in active markets</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Level 3 &#8211; Unobservable inputs that reflect management&#8217;s assumptions</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement.&#160; The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company&#8217;s money market funds included in cash equivalents are measured at fair value on a recurring basis. The following tables summarize the Company&#8217;s fair value measurements and the level of inputs within the fair value hierarchy utilized to determine such fair value as of September 30:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30, 2024</strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Description</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Level</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Cost</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fair Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,258,173</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Money market funds included in cash and cash equivalents (Note 2)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,480,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,480,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Total cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,480,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,738,173</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="13" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30, 2023</strong></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Description</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Level</strong></p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Cost</strong></p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Fair Value</strong></p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,895,735</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Money market funds included in cash and cash equivalents (Note 2)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,250,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,250,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Total cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,250,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,145,735</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277501450672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER COMMON SHARE</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1</strong><strong>4</strong><strong>. NET LOSS PER COMMON SHARE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed using the treasury stock method. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, common stock warrants and restricted stock&#160;are not included in the computation of diluted net loss per share&#160;if their effect&#160;would be anti-dilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The calculation of basis and diluted net loss per share includes 1,450,000 of the pre-funded warrants that remain outstanding as of September 30, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The following table provides a reconciliation of the numerators and denominators of the basic and diluted per-share computations: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Year ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Loss per share &#8211; basic and diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common shareholders &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(27,579,921</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(32,365,855</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">54,044,989</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">44,479,865</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Basic and diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.51</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.73</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In accordance with the contingently issuable shares guidance of ASC 260, <em>Earnings Per Share</em>, the calculation of diluted net loss per share excludes the following dilutive securities because their inclusion would have been anti-dilutive as of September 30: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options and warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,350,550</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,850,028</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested restricted stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">17,497,800</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,997,278</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277403864960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>15.&#160; SUBSEQUENT EVENTS </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On October 18, 2024, the Company entered into a Securities Purchase Agreement with Ergomed Group Limited pursuant to which the Company issued 1 million shares of common stock in exchange for services. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On December 31, 2024, the Company sold&#160;7,552,500&#160;shares of common stock at an offering price of $0.31&#160;per share, and pre-funded warrants to purchase up to&#160;8,577,500&#160;shares of common stock, at an offering price of $0.3099&#160;per pre-funded warrant, for gross proceeds of approximately $5&#160;million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277407077072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Basis of Presentation</em> &#8211; The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Cash and Cash Equivalents </em>&#8211; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Property and Equipment</em> &#8211; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Supplies used for R&amp;D and manufacturing</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Supplies used for R&amp;D and manufacturing</em> &#8211; Supplies are consumable items kept on hand to support the Company&#8217;s R&amp;D and manufacturing operations. Supplies are recorded at the lower of cost or net realizable value and are charged to expense as they are used in operations. The Company regularly reviews the quality and utilization of supplies to determine if future use of these supplies is probable. Due to the generic use of these supplies, they can be used in multiple projects other than those currently being studied. Supplies held less than twelve months are classified as current assets and supplies held longer than twelve months are classified as non-current assets.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patents</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Patents</em> &#8211; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Leases</em> &#8211; The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. The incremental borrowing rate reflects the rate of interest that the Company would pay on the lease commencement date to borrow an amount equal to the lease payments on a collateralized basis over a similar term in similar economic environments. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. Operating and finance lease agreements which require payments for lease and non-lease components are accounted for as a single lease component.&#160; Variable lease payments that cannot be determined at the commencement of the lease are not included in the calculation of right of use assets or lease liabilities, and are expensed as incurred.&#160; </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Share-Based Compensation</em> &#8211; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, Compensation &#8211; Stock Compensation (&#8220;ASC 718&#8221;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate, and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#8217;s stockholders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company&#8217;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Research and Development Costs</em> - Research and development costs are expensed as incurred.&#160; Management accrues Clinical Research Organization (&#8220;CRO&#8221;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Net Loss Per Common Share</em> &#8211; The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share. Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#8217;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Concentration of Credit Risk</em> &#8211; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents.&#160; The Company maintains its cash and cash equivalents with high quality financial institutions.&#160; At times, these accounts may exceed federally insured limits.&#160; The Company has not experienced any losses in such bank accounts.&#160; The Company believes it is not exposed to significant credit risk related to cash and cash equivalents.&#160; All non-interest bearing cash balances were fully insured up to $250,000 at September 30, 2024 and 2023. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Income Taxes</em> &#8211; The Company accounts for income taxes in accordance with the provisions of ASC 740, Income Taxes, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards.&#160; Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of September 30, 2024 and 2023.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Impairment of long-lived assets </em>&#8211; CEL-SCI&#8217;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#8217;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Use of Estimates</em> &#8211; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#8217;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, share-based compensation, useful lives for depreciation and amortization of long-lived assets, right-of-use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year.&#160; Additionally, in calculating the right-of-use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_RecentlyAdoptedAccountingStandardsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update No. 2016-13, Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;). ASU 2016-13 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13 had no material impact on the Company&#8217;s financial position, results of operations, or cash flows.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (&#8220;ASU 2023-07&#8221;), which expands disclosures about a public entity&#8217;s reportable segments and requires more enhanced information about a reportable segment&#8217;s expenses, interim segment profit or loss, and how a public entity&#8217;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is currently evaluating the impact that this change will have on the Company&#8217;s disclosures. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In December 2023, the FASB issued Accounting Standards Update No. 2023-09, Improvements to Income Tax Disclosures, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In March 2024, the SEC issued its final climate disclosure rules, which require the disclosure of climate-related information in annual reports and registration statements. The rules require disclosure in the audited financial statements of certain effects of severe weather events and other natural conditions above certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates, if material. Under the rules as originally issued, disclosure requirements begin phasing in for fiscal years beginning on or after January 1, 2027. However, on April 4, 2024, the SEC determined to voluntarily stay the final rules pending certain legal challenges. We are currently evaluating the impact of the new rules and continue to monitor the status of the related legal challenges.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In November 2024, the FASB issued Accounting Standards Update No. 2024-03, Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses (&#8220;ASU 2024-03&#8221;). ASU 2024-03 will require more detailed information about the types of expenses in commonly presented income statement captions such as &#8220;Cost of sales&#8221; and &#8220;Selling, general and administrative expenses&#8221;. The new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027 with early adoption permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_RecentlyAdoptedAccountingStandardsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_RecentlyAdoptedAccountingStandardsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277403871472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS AND NONEMPLOYEE OPTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantsAndNonemployeeOptionsAbstract', window );"><strong>WARRANTS AND NONEMPLOYEE OPTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants and non-employee options</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrant/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares Issuable</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of Warrants/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2026&#160; </p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/11/2018</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">93,603</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.80</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/30/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1/13/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">120,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9.25</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/13/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/15/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">26,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">12.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/15/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">333,432</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.86</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">200,087</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.52</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">234,009</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.65</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2026</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/28/2017 &#8211; 9/2/2023 </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">110,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;&#160; $1.39 - $2.18 </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/27/2027 &#8211; 9/1/2028</p></td><td>&#160;</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrant/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Issue Date</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares Issuable</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">upon Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">of Warrants/</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Options</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Expiration Date</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series N</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2008</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">85,339</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">3.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/18/2024&#160; </p></td><td style="width:1%;">&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series UU</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/11/2018</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">93,603</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.80</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/30/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series X</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1/13/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">120,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9.25</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/13/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series Y</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2/15/2016</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">26,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">12.00</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">8/15/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series MM</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">333,432</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.86</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6/22/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series NN</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">200,087</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.52</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/24/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2017</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">234,009</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.65</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10/30/2024</p></td><td>&#160;</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Consultant Options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/28/2017 &#8211; 9/2/2023 </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">110,000</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;">$</td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;&#160; 1.39 - $2.18 </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7/27/2027 &#8211; 9/1/2028</p></td><td>&#160;</td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock', window );">Schedule of equity warrants were exercised</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Warrants Exercised</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Proceeds</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series RR</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,752</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,291</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Series SS</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">200,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.09</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">418,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">217,752</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">447,291</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantsAndNonemployeeOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantsAndNonemployeeOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277507570592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,167,828</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,109,070</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Furniture and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">104,593</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">99,296</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Leasehold improvements</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13,924,724</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13,924,724</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,197,145</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,133,090</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: Accumulated depreciation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(10,067,392</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(7,944,964</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8,129,753</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">10,188,126</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277403464320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of patents</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2024</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">829,716</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">853,445</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: Accumulated amortization</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(664,224</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(655,741</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patents, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">165,492</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">197,704</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of total estimated future amortization</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="4" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Years ending September 30, </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">29,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">54,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">165,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277403615184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of components of the Company's deferred tax assets</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">NOL carryforwards</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">34,673,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,829,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Capitalized R&amp;D</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,062,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,196,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stock-based compensation </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,645,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,579,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,752,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,400,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">R&amp;D credit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">932,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,221,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vacation and other</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">188,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">298,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fixed assets and intangibles</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">347,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">168,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total deferred tax assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,599,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">62,691,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Right-of-use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,095,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,713,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Fixed assets and intangibles</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total deferred tax liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,095,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,713,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net deferred tax asset</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">62,504,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">59,978,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(62,504,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(59,978,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ending balance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of federal or state current or deferred tax expense or benefit</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Federal rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21.00</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">State rate change </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(11.97</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1.58</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">State tax rate, net of federal benefit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.68</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.05</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other adjustments</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2.32</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1.62</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Permanent differences</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Change in valuation allowance</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(9.39</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(21.85</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effective tax rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.00</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277403609104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>EQUITY-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of expenses for options issued or vested and restricted stock awarded</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Year Ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,270,180</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,286,231</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-employees</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">680,768</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">655,740</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used for fair value of each option granted</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected stock price volatility</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">100.89 &#8211; 101.66%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">99.18 &#8211; 100.18%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3.77 &#8211; 4.58%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3.41 &#8211; 4.25%</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected life of options</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">9.61 &#8211; 9.64 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">9.63 &#8211; 9.66 years</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">-</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock', window );">Schedule of non-qualified and incentive stock option plans</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Outstanding</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercisable</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Remaining Contractual Term (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Remaining Contractual Term (Years)</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Aggregate Intrinsic Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">12,964,014</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9.06</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,866,240</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7,067,617</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.21</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.21</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,866,105</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">952,256</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">8.41</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Granted (a)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">2,065,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1.37</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(213,165</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">9.19</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(58,791</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">61.05</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(58,791</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">61.05</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">14,757,558</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">7.78</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.81</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">7,961,082</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.07</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.60</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,501,583</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">4.24</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Granted (b)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1,969,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">1.50</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(406,333</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">10.01</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(62,145</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">27.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">(62,145</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">27.35</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">16,258,080</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.88</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">6.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">9,400,520</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.64</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">5.19</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Schedule of restricted common stock issued from the incentive stock bonus plan</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Number of</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted Average Grant Date Fair Value</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unvested at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">151,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unvested at September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unvested at September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13.75</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of non vested options</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number of</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Options</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Weighted Average Grant Date Fair Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,896,397</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.63</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(952,256</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7.30</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,065,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.22</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(213,165</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.02</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,796,476</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.25</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Vested</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,501,583</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.73</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,969,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.36</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Forfeited</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(406,333</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.94</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested at September 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6,857,560</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.69</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277510508416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum payments under finance leases</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,747,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,838,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,929,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,021,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">255,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,790,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,821,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of finance lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,969,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of finance lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,011,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of finance lease obligations &#8211; non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,958,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum payments under operating leases</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Year ending September 30,</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2025</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">366,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2026</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">287,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2027</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">277,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2028</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">285,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2029</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">294,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Thereafter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">746,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total future minimum lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,255,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less imputed interest on operating lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(602,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,653,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations &#8211; current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">227,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net present value of operating lease obligations &#8211; non-current portion</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,426,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277403595184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of fair value measurements using significant unobservable inputs</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30, 2024</strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Description</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Level</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Cost</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fair Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,258,173</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Money market funds included in cash and cash equivalents (Note 2)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,480,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,480,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Total cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3,480,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,738,173</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="13" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30, 2023</strong></p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Description</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Level</strong></p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Cost</strong></p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Fair Value</strong></p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,895,735</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;">Money market funds included in cash and cash equivalents (Note 2)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,250,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,250,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Total cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,250,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,145,735</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277403832976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of earnings per share</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Year ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Loss per share &#8211; basic and diluted</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss available to common shareholders &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(27,579,921</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(32,365,855</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">54,044,989</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">44,479,865</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Basic and diluted loss per common share</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.51</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.73</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti-dilutive securities</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2024</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options and warrants</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">17,350,550</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,850,028</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Unvested restricted stock</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">147,250</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">17,497,800</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">15,997,278</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277403594128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Fully insured amount of non-interest bearing cash balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FiniteLivedIntangibleAssetsUsefulLife', window );">Patent Useful Life</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FiniteLivedIntangibleAssetsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FiniteLivedIntangibleAssetsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277402990672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS AND NONEMPLOYEE OPTIONS (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember', window );">Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember', window );">Consultants [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">7/28/2017<span></span>
</td>
<td class="text">7/28/2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.39<span></span>
</td>
<td class="nump">$ 1.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">7/27/2027<span></span>
</td>
<td class="text">7/27/2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOneMember', window );">Consultants 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOneMember', window );">Consultants 1 [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">9/2/2023<span></span>
</td>
<td class="text">9/2/2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.18<span></span>
</td>
<td class="nump">$ 2.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">9/1/2028<span></span>
</td>
<td class="text">9/1/2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesYMember', window );">Series Y [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">2/15/2016<span></span>
</td>
<td class="text">2/15/2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">26,000<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">8/15/2026<span></span>
</td>
<td class="text">8/15/2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesMMMember', window );">Series MM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">6/22/2017<span></span>
</td>
<td class="text">6/22/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">333,432<span></span>
</td>
<td class="nump">333,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.86<span></span>
</td>
<td class="nump">$ 1.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">6/22/2026<span></span>
</td>
<td class="text">6/22/2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNNMember', window );">Series NN [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">7/24/2017<span></span>
</td>
<td class="text">7/24/2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">200,087<span></span>
</td>
<td class="nump">200,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.52<span></span>
</td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">7/24/2026<span></span>
</td>
<td class="text">7/24/2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesRRMember', window );">Series RR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">10/30/2017<span></span>
</td>
<td class="text">10/30/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">234,009<span></span>
</td>
<td class="nump">234,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="nump">$ 1.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">10/30/2026<span></span>
</td>
<td class="text">10/30/2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNMember', window );">Series N [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">8/18/2008<span></span>
</td>
<td class="text">8/18/2008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">85,339<span></span>
</td>
<td class="nump">85,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">8/18/2026<span></span>
</td>
<td class="text">8/18/2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesUUMember', window );">Series UU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">6/11/2018<span></span>
</td>
<td class="text">6/11/2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">93,603<span></span>
</td>
<td class="nump">93,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.80<span></span>
</td>
<td class="nump">$ 2.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">6/30/2026<span></span>
</td>
<td class="text">6/30/2024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesXMember', window );">Series X [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_Issuedate2', window );">Issue Date</a></td>
<td class="text">1/13/2016<span></span>
</td>
<td class="text">1/13/2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 9.25<span></span>
</td>
<td class="nump">$ 9.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpirationDate1', window );">Expiration Date</a></td>
<td class="text">7/13/2026<span></span>
</td>
<td class="text">7/13/2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_Issuedate2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_Issuedate2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_SharesIssuableUponExerciseOfwarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_SharesIssuableUponExerciseOfwarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_BottomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_BottomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_TopMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_TopMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesMMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesMMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesRRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesRRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesUUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesUUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277399345408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS AND NONEMPLOYEE OPTIONS (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised</a></td>
<td class="nump">5,680,000<span></span>
</td>
<td class="nump">217,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds from Equity Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 447,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesRRMember', window );">Series RR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds from Equity Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercisePrice', window );">Equity Warrants Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesSSMember', window );">Series SS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedsFromEquityWarrantsExercised', window );">Proceeds from Equity Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 418,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercisePrice', window );">Equity Warrants Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.09<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_EquityWarrantsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_EquityWarrantsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_EquityWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_EquityWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ProceedsFromEquityWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ProceedsFromEquityWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesRRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesRRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesSSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesSSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277402883984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANTS AND NONEMPLOYEE OPTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CommonStockIssuedForServiceShares', window );">Common stock issued for service, shares</a></td>
<td class="nump">409,932<span></span>
</td>
<td class="nump">249,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised</a></td>
<td class="nump">5,680,000<span></span>
</td>
<td class="nump">217,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember', window );">Consultants Member | Restricted Stocks Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 2.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember', window );">Non Qualified Stock Options Plans [Member] | Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_StockIssuedDuringPeriodToPurchaseCommonStock', window );">Issued options to purchase common stock</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_StockOptionExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 1.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssuanceOfOptionsForServices', window );">Options issued to consultants for services</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember', window );">Non Qualified Stock Options Plans [Member] | Consultant [Member] | September 2, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_VestedOptions', window );">Options vested</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember', window );">Non Qualified Stock Options Plans [Member] | Consultant [Member] | September 2, 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_VestedOptions', window );">Options vested</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember', window );">Consulting Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expense</a></td>
<td class="nump">$ 681,000<span></span>
</td>
<td class="nump">$ 656,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_BottomMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock prices per share</a></td>
<td class="nump">$ 1.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_TopMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock prices per share</a></td>
<td class="nump">3.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_TopMember', window );">Maximum | Consultants Member | Restricted Stocks Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 1.69<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesRRMember', window );">Series RR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncrementalCostDeemedDividend', window );">Incremental cost</a></td>
<td class="nump">$ 659,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CommonStockIssuedForServiceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CommonStockIssuedForServiceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_EquityWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_EquityWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncrementalCostDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncrementalCostDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IssuanceOfOptionsForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IssuanceOfOptionsForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_StockIssuedDuringPeriodToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_StockIssuedDuringPeriodToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_StockOptionExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_StockOptionExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_VestedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_VestedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_RestrictedStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_NonQualifiedStockOptionsPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cvm_TwoSeptemberTwoThousendTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cvm_TwoSeptemberTwoThousendTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=cvm_TwoSeptemberTwoThousendTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=cvm_TwoSeptemberTwoThousendTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_BottomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_BottomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_TopMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_TopMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesRRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=cvm_SeriesRRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277501257792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FixturesAndEquipmentGross', window );">Research equipment</a></td>
<td class="nump">$ 4,167,828<span></span>
</td>
<td class="nump">$ 4,109,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and equipment</a></td>
<td class="nump">104,593<span></span>
</td>
<td class="nump">99,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">13,924,724<span></span>
</td>
<td class="nump">13,924,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross</a></td>
<td class="nump">18,197,145<span></span>
</td>
<td class="nump">18,133,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(10,067,392)<span></span>
</td>
<td class="num">(7,944,964)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net property and equipment</a></td>
<td class="nump">$ 8,129,753<span></span>
</td>
<td class="nump">$ 10,188,126<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FixturesAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FixturesAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277501426832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">$ 2,135,000<span></span>
</td>
<td class="nump">$ 2,114,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277509508592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PATENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedPatentsGross', window );">Patents</a></td>
<td class="nump">$ 829,716<span></span>
</td>
<td class="nump">$ 853,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_AccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(664,224)<span></span>
</td>
<td class="num">(655,741)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">$ 165,492<span></span>
</td>
<td class="nump">$ 197,704<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedPatentsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedPatentsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277402920960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PATENTS (Details 1)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 29,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">22,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">19,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">54,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_TotalFiniteLivedIntangibleAssetsAmortizationExpense', window );">Total</a></td>
<td class="nump">$ 165,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_TotalFiniteLivedIntangibleAssetsAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_TotalFiniteLivedIntangibleAssetsAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277404119792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PATENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>PATENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PatentsWeightedAverageAmortizationPeriod', window );">Weighted average amortization period for patents</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of patent costs</a></td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="nump">$ 38,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PatentsWeightedAverageAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PatentsWeightedAverageAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277402031456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 34,673,000<span></span>
</td>
<td class="nump">$ 30,829,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd', window );">Capitalized R&amp;D</a></td>
<td class="nump">14,062,000<span></span>
</td>
<td class="nump">15,196,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">11,645,000<span></span>
</td>
<td class="nump">11,579,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">2,752,000<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D credit</a></td>
<td class="nump">932,000<span></span>
</td>
<td class="nump">1,221,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences', window );">Vacation and other</a></td>
<td class="nump">188,000<span></span>
</td>
<td class="nump">298,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets and intangibles</a></td>
<td class="nump">347,000<span></span>
</td>
<td class="nump">168,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">64,599,000<span></span>
</td>
<td class="nump">62,691,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_RightOfUseAssets', window );">Right of use assets</a></td>
<td class="num">(2,095,000)<span></span>
</td>
<td class="num">(2,713,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets and intangibles</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liability</a></td>
<td class="num">(2,095,000)<span></span>
</td>
<td class="num">(2,713,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">62,504,000<span></span>
</td>
<td class="nump">59,978,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(62,504,000)<span></span>
</td>
<td class="num">(59,978,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Ending Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_RightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_RightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277403014560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details 1)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal Rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">State tax rate change</a></td>
<td class="num">(11.97%)<span></span>
</td>
<td class="num">(1.58%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">State tax rate, net of federal benefit</a></td>
<td class="nump">2.68%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other adjustments</a></td>
<td class="num">(2.32%)<span></span>
</td>
<td class="num">(1.62%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(9.39%)<span></span>
</td>
<td class="num">(21.85%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277406033280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 34,673,000<span></span>
</td>
<td class="nump">$ 30,829,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">62,504,000<span></span>
</td>
<td class="nump">59,978,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=cvm_IncomeTaxMember', window );">Income Tax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ResearchAndDevelopmentCredit', window );">Research and development credit</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 146,400,000<span></span>
</td>
<td class="nump">123,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ResearchAndDevelopmentCreditDescription', window );">Research and development credit, description</a></td>
<td class="text">The R&D credit expires during the fiscal year ended 2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_CumulativeChangeInOwnershipPercentage', window );">Cumulative change in ownership percentage</a></td>
<td class="text">net operating loss (NOL) carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Net operating loss carryforwards, description</a></td>
<td class="text">Approximately $19.2 million of the NOL carryforwards begin to expire during the year ended September 30, 2024 and become fully expired by 2038 and approximately $127.2 million of NOL carryforwards<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">$ 62,500,000<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_CumulativeChangeInOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_CumulativeChangeInOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ResearchAndDevelopmentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ResearchAndDevelopmentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ResearchAndDevelopmentCreditDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ResearchAndDevelopmentCreditDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the origin, nature, and characteristics of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=cvm_IncomeTaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=cvm_IncomeTaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277403615184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cvm_NonEmployeesMember', window );">Non Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock Based Compensation Expense</a></td>
<td class="nump">$ 680,768<span></span>
</td>
<td class="nump">$ 655,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cvm_EmployeesMember', window );">Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock Based Compensation Expense</a></td>
<td class="nump">$ 4,270,180<span></span>
</td>
<td class="nump">$ 6,286,231<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cvm_NonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cvm_NonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cvm_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cvm_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277406036672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION (Details 1)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>EQUITY-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility, min</a></td>
<td class="nump">100.89%<span></span>
</td>
<td class="nump">99.18%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility, max</a></td>
<td class="nump">101.66%<span></span>
</td>
<td class="nump">100.18%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, min</a></td>
<td class="nump">3.77%<span></span>
</td>
<td class="nump">3.41%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, max</a></td>
<td class="nump">4.58%<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpectedLifeOfOptionsMin1', window );">Expected life of options, min</a></td>
<td class="text">9 years 7 months 9 days<span></span>
</td>
<td class="text">9 years 7 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ExpectedLifeOfOptionsMax', window );">Expected life of options, max</a></td>
<td class="text">9 years 7 months 28 days<span></span>
</td>
<td class="text">9 years 7 months 20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExpectedLifeOfOptionsMax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExpectedLifeOfOptionsMax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ExpectedLifeOfOptionsMin1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ExpectedLifeOfOptionsMin1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277402934800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cvm_ExercisableMember', window );">Exercisable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Beginning</a></td>
<td class="nump">7,961,082<span></span>
</td>
<td class="nump">7,067,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Ending</a></td>
<td class="nump">9,400,520<span></span>
</td>
<td class="nump">7,961,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Beginning</a></td>
<td class="nump">$ 6.07<span></span>
</td>
<td class="nump">$ 6.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending</a></td>
<td class="nump">$ 5.64<span></span>
</td>
<td class="nump">$ 6.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value Outstanding, Beginning</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,866,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value Outstanding, Ending</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NumberOfOptionsVested', window );">Number of Options Vested</a></td>
<td class="nump">1,501,583<span></span>
</td>
<td class="nump">952,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NumberOfOptions', window );">Number of Options Expired</a></td>
<td class="num">(62,145)<span></span>
</td>
<td class="num">(58,791)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WeightedAverageExercisePriceVested', window );">Weighted Average Exercise Price Vested</a></td>
<td class="nump">$ 4.24<span></span>
</td>
<td class="nump">$ 8.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WeightedAverageExercisePriceExpired', window );">Weighted Average Exercise Price Expired</a></td>
<td class="nump">$ 27.35<span></span>
</td>
<td class="nump">$ 61.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning', window );">Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 2 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding', window );">Weighted Average Remaining Contractual Life Term (Years) Outstanding, Ending</a></td>
<td class="text">5 years 2 months 8 days<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_OutstandingMember', window );">Outstanding [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Beginning</a></td>
<td class="nump">14,757,558<span></span>
</td>
<td class="nump">12,964,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Granted</a></td>
<td class="nump">1,969,000<span></span>
</td>
<td class="nump">2,065,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Options Expired</a></td>
<td class="num">(62,145)<span></span>
</td>
<td class="num">(58,791)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Ending</a></td>
<td class="nump">16,258,080<span></span>
</td>
<td class="nump">14,757,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Beginning</a></td>
<td class="nump">$ 7.78<span></span>
</td>
<td class="nump">$ 9.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">1.50<span></span>
</td>
<td class="nump">1.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
<td class="nump">10.01<span></span>
</td>
<td class="nump">9.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Expired</a></td>
<td class="nump">27.35<span></span>
</td>
<td class="nump">61.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding, Ending</a></td>
<td class="nump">$ 6.88<span></span>
</td>
<td class="nump">$ 7.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life Term (Years) Outstanding, Ending</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 9 months 21 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value Outstanding, Beginning</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,866,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value Outstanding, Ending</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NumberOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NumberOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NumberOfOptionsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NumberOfOptionsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageExercisePriceExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageExercisePriceExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageExercisePriceVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageExercisePriceVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cvm_ExercisableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cvm_ExercisableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_OutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_OutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277404044592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION (Details 3) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>EQUITY-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of unvested options, Beginning</a></td>
<td class="nump">6,796,476<span></span>
</td>
<td class="nump">5,896,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested options</a></td>
<td class="num">(1,501,583)<span></span>
</td>
<td class="num">(952,256)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted options</a></td>
<td class="nump">1,969,000<span></span>
</td>
<td class="nump">2,065,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited options</a></td>
<td class="num">(406,333)<span></span>
</td>
<td class="num">(213,165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of unvested options, Ending</a></td>
<td class="nump">6,857,560<span></span>
</td>
<td class="nump">6,796,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning</a></td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="nump">$ 3.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, vested</a></td>
<td class="nump">3.73<span></span>
</td>
<td class="nump">7.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="nump">1.36<span></span>
</td>
<td class="nump">1.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited</a></td>
<td class="nump">1.94<span></span>
</td>
<td class="nump">8.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending</a></td>
<td class="nump">$ 1.69<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277407581264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION (Details 4) - Restricted Stock Awards [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of unvested shares, Beginning</a></td>
<td class="nump">147,250<span></span>
</td>
<td class="nump">151,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of unvested shares, Ending</a></td>
<td class="nump">147,250<span></span>
</td>
<td class="nump">147,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning</a></td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending</a></td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="nump">$ 13.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277406216048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY-BASED COMPENSATION (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jul. 29, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">63,787,104<span></span>
</td>
<td class="nump">47,422,304<span></span>
</td>
<td class="nump">3,715,000<span></span>
</td>
<td class="nump">3,875,000<span></span>
</td>
<td class="nump">2,490,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_StockCompensationPlansMember', window );">Stock Compensation Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">153,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">634,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_StockBonusPlansMember', window );">Stock Bonus Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">649,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,283,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_NonQualifiedStockOptionsPlansMember', window );">Non-Qualified Stock Options Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">17,787,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Issuance of common stock options authorized shares</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PerformanceBasedStockOptionsSharesGranted', window );">Performance based stock options shares granted</a></td>
<td class="nump">1,962,000<span></span>
</td>
<td class="nump">1,958,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityStrikePrice1', window );">Stock price</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="nump">$ 1.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_IncentiveStockOptionPlansMember', window );">Incentive Stock Option Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">138,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_IncentiveStockBonusPlanMember', window );">Incentive Stock Bonus Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">610,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_RemainingOutstandingFairValueOfShares', window );">Grant date fair value remaining outstanding</a></td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_VestedShares', window );">Vested shares</a></td>
<td class="nump">463,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationEquity', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_RestrictedStockAwardsMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total compensation cost</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average period</a></td>
<td class="text">6 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cvm_NonVestedOptionsMember', window );">Non Vested Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total compensation cost</a></td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average period</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PerformanceBasedStockOptionsSharesGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PerformanceBasedStockOptionsSharesGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_RemainingOutstandingFairValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_RemainingOutstandingFairValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_VestedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_VestedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityStrikePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481648/480-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)(2)<br> -SubTopic 40<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityStrikePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_StockCompensationPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_StockCompensationPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_StockBonusPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_StockBonusPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_NonQualifiedStockOptionsPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_NonQualifiedStockOptionsPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_IncentiveStockOptionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_IncentiveStockOptionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_IncentiveStockBonusPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=cvm_IncentiveStockBonusPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_RestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_RestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cvm_NonVestedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cvm_NonVestedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277398376816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLAN (Detail Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract', window );"><strong>EMPLOYEE BENEFIT PLAN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Expense for Company's contribution to employee benefit plan</a></td>
<td class="nump">$ 219,000<span></span>
</td>
<td class="nump">$ 208,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EmployeeContributionsToDefinedContributionPlans', window );">Employee Contributions to Defined Contribution Plans</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PercentageOfEmployeeContributionsToDefinedContributionPlans', window );">Percentage of employee Contributions to Defined Contribution Plans</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued</a></td>
<td class="nump">136,868<span></span>
</td>
<td class="nump">97,004<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_EmployeeContributionsToDefinedContributionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_EmployeeContributionsToDefinedContributionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PercentageOfEmployeeContributionsToDefinedContributionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PercentageOfEmployeeContributionsToDefinedContributionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277402544160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 2,747,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">2,838,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">2,929,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">3,021,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">255,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total Future Minimum Lease Obligation</a></td>
<td class="nump">11,790,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed Interest On Financing Lease Obligation</a></td>
<td class="num">(1,821,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Net present value of finance lease obligations</a></td>
<td class="nump">9,969,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinanceLeaseLiabilityCurrentPortion', window );">Net present value of lease finance lease obligations - current portion</a></td>
<td class="nump">2,011,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinanceLeaseLiabilityNoncurrentPortion', window );">Net present value of lease finance lease obligations - non-current portion</a></td>
<td class="nump">$ 7,958,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseLiabilityCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseLiabilityCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseLiabilityNoncurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseLiabilityNoncurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277406030048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details 1)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 366,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">287,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">277,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">285,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">294,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">746,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total Future Minimum Lease Obligation</a></td>
<td class="nump">2,255,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less Imputed Interest On Operating Lease Obligation</a></td>
<td class="num">(602,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Net present value of operating lease obligations</a></td>
<td class="nump">1,653,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_OperatingLeaseObligationyCurrent', window );">Net present value of operating lease obligation - current portion</a></td>
<td class="nump">227,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_OperatingLeaseObligationyNoncurrent', window );">Net present value of operating lease obligation - non-current portion</a></td>
<td class="nump">$ 1,426,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_OperatingLeaseObligationyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_OperatingLeaseObligationyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_OperatingLeaseObligationyNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_OperatingLeaseObligationyNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277406090736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 11, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Interest payment to lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,350,364<span></span>
</td>
<td class="nump">9,131,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,969,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,010,995<span></span>
</td>
<td class="nump">1,771,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,969<span></span>
</td>
<td class="nump">197,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,653,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495,937<span></span>
</td>
<td class="nump">1,698,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">cash paid related to operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WeightedAverageOperatingLeaseDiscountRate', window );">Weighted average operating lease discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">200,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WeightedAverageOperatingLeaseMaturityYear', window );">Weighted average operating lease maturity year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Lease expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">400,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_FinanceLeaseCosts', window );">Total Finance lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Finance Lease, Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">1,800,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Interest payment to lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WeightedAverageMaturityYear', window );">Weighted average maturity year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="nump">9,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="nump">11,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">1,800,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Cash paid related to finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime', window );">Weighted average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvm_LandlordMember', window );">Landlord [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_PaymentsMadeToLandlord', window );">Payments Made to Landlord</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_ErgomedMember', window );">Ergomed [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_FinanceLeaseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_FinanceLeaseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_PaymentsMadeToLandlord">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_PaymentsMadeToLandlord</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageMaturityYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageMaturityYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WeightedAverageOperatingLeaseMaturityYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WeightedAverageOperatingLeaseMaturityYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated over time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtWeightedAverageInterestRateOverTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvm_LandlordMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvm_LandlordMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_ErgomedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_ErgomedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277402898944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative ) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 11, 2024</div></th>
<th class="th"><div>May 04, 2024</div></th>
<th class="th"><div>Jul. 29, 2024</div></th>
<th class="th"><div>Jul. 18, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="nump">$ 23,575,000<span></span>
</td>
<td class="nump">$ 6,552,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from loan from CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_DescriptionOfModificationOfWarrants', window );">Description of modification of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates. The incremental cost of this extension was approximately $0.7 million, which was recorded as a deemed dividend<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRWarrantMember', window );">Series RR Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IncrementalCostOfWarrantsExtension', window );">Incremental cost of warrants extension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_OfficerAndDirectorMember', window );">Officer and Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_RestrictedCommonStockSharesIssued', window );">Issuance of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_CEOMember', window );">CEO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedsFromAdditionalDebtFromRelatedParty', window );">Additional debt from CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date of debt</a></td>
<td class="text">Jul. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from loan from CEO</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_DescriptionOfModificationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_DescriptionOfModificationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IncrementalCostOfWarrantsExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IncrementalCostOfWarrantsExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ProceedsFromAdditionalDebtFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ProceedsFromAdditionalDebtFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_RestrictedCommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_RestrictedCommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cvm_SeriesRRWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_OfficerAndDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_OfficerAndDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_CEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_CEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277407182320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 29, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">3,715,000<span></span>
</td>
<td class="nump">3,875,000<span></span>
</td>
<td class="nump">2,490,000<span></span>
</td>
<td class="nump">63,787,104<span></span>
</td>
<td class="nump">47,422,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 9,700,000<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="nump">$ 23,575,000<span></span>
</td>
<td class="nump">$ 6,552,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_NetIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_EquityWarrantsExercised', window );">Equity Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,680,000<span></span>
</td>
<td class="nump">217,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price per share</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingActivityByTypeAxis=cvm_EquityProceedsFromSaleCommonStockMember', window );">Equity Proceeds From Sale Common Stock Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProceedFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_IssuanceCostOfCommonStock', window );">Issuance cost of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_AdditionalPurchaseOfCommonStock', window );">Additional purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock at a public offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">794,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_AdditionalPurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_AdditionalPurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_EquityWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_EquityWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_IssuanceCostOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_IssuanceCostOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_NetIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_NetIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ProceedFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ProceedFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingActivityByTypeAxis=cvm_EquityProceedsFromSaleCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingActivityByTypeAxis=cvm_EquityProceedsFromSaleCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277406903248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAxis=cvm_CostMember', window );">Cost [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_MoneyMarketFundsIncludedInCashAndCashEquivalents', window );">Money market funds included in cash and cash equivalents (Note 2)</a></td>
<td class="nump">3,480,000<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents</a></td>
<td class="nump">3,480,000<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cvm_FairValueMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">1,258,173<span></span>
</td>
<td class="nump">1,895,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_MoneyMarketFundsIncludedInCashAndCashEquivalents', window );">Money market funds included in cash and cash equivalents (Note 2)</a></td>
<td class="nump">3,480,000<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents</a></td>
<td class="nump">$ 4,738,173<span></span>
</td>
<td class="nump">$ 4,145,735<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_MoneyMarketFundsIncludedInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_MoneyMarketFundsIncludedInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAxis=cvm_CostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAxis=cvm_CostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cvm_FairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cvm_FairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277403311104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_ProfitLossPerShareBasicAndDilutedAbstract', window );"><strong>Loss per share - basic and diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss available to common shareholders - basic and diluted</a></td>
<td class="num">$ (27,579,921)<span></span>
</td>
<td class="num">$ (32,365,855)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - basic and diluted</a></td>
<td class="nump">54,044,989<span></span>
</td>
<td class="nump">44,479,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic and diluted loss per common share</a></td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_ProfitLossPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_ProfitLossPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277398525088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">17,497,800<span></span>
</td>
<td class="nump">15,997,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember', window );">Options and Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">17,350,550<span></span>
</td>
<td class="nump">15,850,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember', window );">Unvested Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">147,250<span></span>
</td>
<td class="nump">147,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cvm_UnvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277401235792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER COMMON SHARE (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantsUsedForCalculationOfEarningPerShare', window );">Prefunded warrants</a></td>
<td class="nump">1,450,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantsUsedForCalculationOfEarningPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantsUsedForCalculationOfEarningPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46277402534064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Oct. 18, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from newly issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,122,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Public offering price</a></td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantsOfferingPrice', window );">Pre funded warrants offering price</a></td>
<td class="nump">$ 0.3099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock at a public offering price</a></td>
<td class="nump">7,552,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from newly issued shares</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvm_WarrantsToPurchaseCommonStock', window );">Pre-funded warrants to purchase common stock</a></td>
<td class="nump">8,577,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event Member | Ergomed Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantsOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantsOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvm_WarrantsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvm_WarrantsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ErgomedGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cvm_ErgomedGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>80
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M0[%:D'Q9O%4PXU*%B.+K@I*("KV!^OV9<[E9T#LHWV09_ ]02P,$%     @
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MQ-D27+)5$B=\"#(5?.](QSO2<8-*1U#?1FF4Q^PEJ-91R2H0<;!@FU> P)<
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MYXA9G>V T,5SC;$)XQL@4ZN8#40$D)RL=AUQS_%8(\VHL ^CC^+DCNJU37>
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MS'*122A+P,YCF2-L]*45,D</W!5B!C.*6:HCV\W;.B-K&P\9XGC?F.!CYY-
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MDV0$TE[+V!<M&G,5<B>T%I5Y7'&&390$<'XAA.Y>:('^;NSD3U!+ P04
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;)U8;6_;.!+^*X0W6Z2
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M+W=O<FMS:&5E=',O<VAE970Q-BYX;6S-66UOVS@2_BN$M[O8!51%EIW8;I,
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M#*11.#KN^>;1W%A5NL^$P#>K<G=);5YH.H#W,Z5L<T,"UM^-S_\+4$L#!!0
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M/0V/!0IR-PO0]X6A(W:[X TV_V$X_P=02P,$%     @ #8(M6H=\2>#L!0
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M]$"TJCE3)\C4OQYILC4"&2MO:\W1XC/4^M3Z"2^CK^_D#:-19_0B6-(@;SA
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M,[S:R? $C*<:TIL&&^C^#W#\+U!+ P04    "  -@BU:P>ANMS$$  #D"0
M&0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6RM5MMNXS80_96!MEBT@&)=
M+/F2V :2;!:[P.:".-M%'VF)LHA0I$I2]N;O.Z1DQ6YMHP7Z(O$R<^;,<&;(
MV5:J5UU2:N!GQ86>>Z4Q]640Z*RD%=$#65.!.X54%3$X5>M UXJ2W"E5/(C#
M<!14A EO,7-K3VHQDXWA3- G!;JI*J+>;BB7V[D7>;N%9[8NC5T(%K.:K.F2
MFN_UD\)9T*/DK*)",RE T6+N74>7-XF5=P*_,[K5>V.PGJRD?+63K_G<"RTA
MRFEF+ +!WX;>4LXM$-+XL\/T>I-6<7^\0__L?$=?5D336\E_L-R4<V_B04X+
MTG#S++=?:.=/:O$RR;7[PK:5C4<>9(TVLNJ4D4'%1/LG/[LX["E,PA,*<:<0
M.]ZM(<?R$S%D,5-R"\I*(YH=.%>=-I)CPA[*TBC<9:AG%@]W+_#M<;F$I[MG
MN'V\OW]\@.67Z^>[66 0W@H%60=UTT+%)Z"B&.ZE,*6&.Y'3_! @0%X]N7A'
M[B8^B[BD]0"&H0]Q&"=G\(:]LT.'-_P_G&VADN-0ME8N=4TR.O>P&#15&^HM
M/GZ(1N'5&:))3S0YA_[?B)Z%.DXT@@0&<-(*W!#-,N!2:Z@IEG!)% 6F(9-5
MW1B:P^H-<K9A.1-K$-@ZG"C9$,;)BE,PTHI66'5.M90\ITI;+5-2V+I2012R
MH0HK'T13K=",+ ZT-& 3T88(9R5OE/U9?:3$9#Z 3XP[,I0H@7NGN#9ZIVBP
M;>E&O0&65?8*%36EQ7G!K5N4)N+MXX=)'(VO$$H:*@PCG%M/T0[VCHZ6#]N2
M924PD?$FIP<L=_P=OJQMXT'Y@]4M48H(@^$2.;8U;13++,UVUY(7TNS <QPX
MZJTWQ'4RC%/>N=['?L_UPBHP!;0HL/5A5VPX'AA%>X9=['QIO<X(SQK>HV)[
M8RVO<_@M,PV1GZ2A'X:A577GHNA%T=C:?W?2E,2@E_9Z. @4T58+"]Q0=_:[
M*F]Y%9+C;>&.S>53K20F&]HDB)5)D3'.>M;6-&80II*1JJ-/A<1FV2YT(BN7
MT_O.H4\7K4][T=67\ <F%%#GQS\)VL\0OAW&Q*5-='7$QL._+H[3&+_ K_'8
M3\=3?QI'\)N=#V-_.$K]29KB_,??Z^E(^9Q&3Q,_3!)_.ID"_A*T,AFE70?8
ME^O38)^\Y1(.THY5.!@/<?357K:95#D1&58[,V67PIB 8HUEA37%M&Y<-#JN
MZX:UXGA:U\M;B$<8[[M=83^AV:6S]WX$CVUU.8Y]ND5C?XA)F:8A1#8\F)_Q
M!+Z+#=89/5)N43+V8RO<_5^D(=RB)-.Q/PD=RA2'\7@"Q_IZL'?S8@:NW?O"
M]IY&F/82[E?[)\QU>W._B[?OGWNBU@S]X;1 50QEZH%JWQ3MQ,C:W>,K:?!5
MX(8E/L.HL@*X7TCL6=W$&N@?=HN_ %!+ P04    "  -@BU:GM#$J^ "  "%
M!@  &0   'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6RE56UOVC 0_BNGK-HG
M1EZ 0CM *BU[D=:5E;7[;)(CL1K;F>T4^N]W=B"C:HLF[4OB.]\]]SP7^S+>
M*/U@"D0+6U%*,PD*:ZOS,#1I@8*9KJI0TLY::<$LF3H/3:6193Y)E&$21:>A
M8%P&T['W+?1TK&I;<HD+#:86@NFG&99J,PGB8.^XY7EAG2.<CBN6XQ+M7;70
M9(4M2L8%2L.5!(WK27 1G\_Z+MX'W'/<F(,U."4KI1Z<\36;!)$CA"6FUB$P
M>CWB)9:E R(:OW>805O2)1ZN]^B?O';2LF(&+U7YBV>VF 2C #)<L[JTMVKS
M!7=Z!@XO5:7Q3]@TL3$%I[6Q2NR2B8'@LGFS[:X/!PFCZ(V$9)>0>-Y-(<_R
MBEDV'6NU >VB"<TMO%2?3>2X=!]E:37M<LJST^7=;#G_<3?__A/F]_1<CD-+
ML&XS3'<0LP8B>0,B3N!:25L8F,L,L^< (?%I225[4K/D*.(2JR[TH@XD4=(_
M@M=K1?8\7N]_1#80_=<AW-TX-Q5+<1+0X3>H'S&8OG\7GT8?CQ#LMP3[Q]#_
MC>!QB'C0A1<P<"/A)K5JA1KB4=//#M@"X5*)BLDG0&E18P9<6@4,EIC6FEN.
M!A:U3@LZ[W"1:T2ZAY:.IBU@KG,E*..S5G4%W[C@EJRJUJ9F%$,PFX*GQ;,J
MW)B:@F(ZP67I+J,I&'41U!I2)81S6)4^$ O +565.0(-''!]YBF:KA-RA2D*
MIZ07OZ;$J#*#86<P2#J#*'JK K/ )'G7J+G,H=($[X).HFXOAHK0?6*'HDB4
MQ@_KVAUJV#"M29YQ^JI]9T@_F:/.8#@\4K-SM&AT=N;+OJS5\2W(M3*&=E6*
MF'EL5I&UY321L'R"D\&^J=W7#F)X,!H$ZMP/0$/\:FF;*=%ZVQE[T8R6O^'-
M@+YF.N?20(EK2HVZPT$ NAEZC6%5Y0?-2ED:6WY9T'\"M0N@_;52=F^X NV?
M9_H'4$L#!!0    (  V"+5HS%DN9(@P  %PE   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;+U:;7/;-A+^*QAUII?,R+8D.[:;%\_83M*ZTS@^*[[.
M?81(2,29)%@ M*+[]??L B1%65;:)+V93B-1P&*Q+\\^N^;KI;'W+E/*B\]%
M7KHW@\S[ZN7!@4LR54BW;RI5XI>YL87T^&H7!ZZR2J:\J<@/)J/1\4$A=3DX
M>\W/;NS9:U/[7)?JQ@I7%X6TJPN5F^6;P7C0/+C5B\S3@X.SUY5<J*GR=]6-
MQ;>#5DJJ"U4Z;4IAU?S-X'S\\F)\2AMXQ;^T6KJUSX*N,C/FGKY<I6\&(])(
MY2KQ)$+BGP=UJ?*<)$&//Z+007LF;5S_W$A_SY?'96;2J4N3_ZY3G[T9G Y$
MJN:RSOVM6?ZBXH5>D+S$Y([_+Y9A[8NC@4AJYTT1-T.#0I?A7_DY&F)MP^GH
MB0V3N&'">H>#6,NWTLNSU]8LA:75D$8?^*J\&\KIDKPR]1:_:NSS9].[#Q_.
M;_\M/KX7TZN?KZ_>7UV>7W\2YY>7'^^N/UU=_RQN/OYV=7GU;BJ>W9A<)UJY
MYZ\//(XF 0=)/.8B'#-YXICQ1'PPI<^<>%>F*NT+.(#.K>*31O&+R4Z)4U7M
MB\/14$Q&DZ,=\@Y;0QRRO,-O-L2VVP?91]ME4V:]=)5,U)L!4L<I^Z &9S_^
M,#X>O=JA^5&K^=$NZ6<7TFDGS%S<D.S22PKW;4I^LYB>>B]:]5[LE'LI729D
MF0K^\.Z/6C_('/+=-A5WBMINQR?EBQW*'[?*'^]4_L8"_ZQ?\0$DNP(B^6V:
M?[N<GH(GK8(G.P5/ZZK*D9.B=BH50&EQ^Z,LJE=O^:1"EO4<P%=;72ZV:?TW
M">]=Y;2]RNEN&TG_5%A\Q<:>"C^U*ORT4])O"@"_58._OJ^GP'C4X?%HM\TS
M:=4>DA$6OS0%JJ][,J&_4I3XE"E^(,N5R*035V4" Z(ZBJDWR;WX6/&RFUR6
M;BBN3;GWSUKF>JXA:-N*\*QW1.^7"U/6+CSBR)'EHR.[)?NDGE/-<JL$:AP7
M\0>5KX@)*&NAB#<"JGM<9<!+!_OB/,_CMDQ"\DPIE/VJLN8!ZV<K7ASO_>,/
MIY/QR2LG'!V?F3Q5UNVO6Z:_0AB^<5"H-%YXBW.@BISE:LBW(NF4#C(70*!:
M$9;2L_Y^GTE/!E!%E9N54D@CNA3,^U_(T7/\MAJ"!. JJ8(]4P%KDACU.5'.
M-4)!H>[!V2JK$]6L2)$']+OZK&RB84+<V\:]\0FOWQ<@-*U"VKD:YEEJGPF"
M5!*8F#+5X6=3YM#';T3,C(-* V0EMA<A&@@@PF6#6@\F1S#D&K 7-7R05LLR
M82U3J>'.)#<.\!%VM+?;ZH+@':O=_=[<PG"Z] I5P M+]U[30S?ZQ5/O]J?8
M"QN[VJ[B:M^SV +.],$$]!AR"Z'^($\BRH(!*T0@1"(+6L<&"[(UYTH#!U4(
M#YDDIBY]A,QEIE@-&"%):AMNT<KCHR"O\89552B_(;11-+1)0] T2UA9;*6C
M.CD&X2Y NYU'+))%*239590%J:*#@ ]I9QI)_\E\%<M^IF%E> &7;L-EII!(
MVD#I*P[,YN:=L6-MT,'2%[E,[O>F"?()MBA,JG*19+)<( OTH@2")-"= LHQ
M-@5=DG7@H!N5.)I,5X+4RZ6TJ>,L2?4<"8>/N(N6.:(G'CNOR?AB;DT13&55
M8FS:Z06[6]@TFG-?W")L<%4R7 C8QJ8UV&E(F:<!BBV[Z8QNXY?@DOWFZME_
MX#AR6\RY(2G'71;E1ZBOG.)KN<A/J57C.^7P EN495/>@U<0Q6"+-3 :[;=$
MJF OI0"%CA=SJ6V#4\%((0DH)<BI'$),VI&.TN905!=U+MM,)]P@71U%.(1S
M7'B/1I"H#>FS?J'$:O8:)6>-!Y86AESPQB/F>D&0&.<#!LY4$Q'I&IPYKRD*
M4C@:=W80W4)7=/&N6KS6&XUW%E"$B9(V"?3RK4+],<S;@$]N.U'YC@+[.D\Z
MG2<[C[A&>/QF4"AN8"S@: %S,A'8JNYWD=77M&NXQCN[HK-+PREFV_B]1&AJ
M+VZ!\%N5_5[B^OIV;=9X=X,$1#"%$I_DY^T4\:NW]_7I^JKQ[L;J"C52VR;9
M<E,N]G)-3 >XH)X(SZ_HK[YPS*XN:]RU6>/=_=&=XZKZ+B;V=N6_141?KZZ[
M&N_N@&X5Q10JS7D*Q,>EST-M)W2<4J4E<-VJ[&ZY5Z7XM2Z5F(S&QX%=O=<E
M@!)E;>L1*#_X1SPC1C09O7I_/KW@C^-7SQL"MW7;7<44Y]KL\U%[X\/AVDE7
M)<I@73#;8*XU?M5D#:4]H/W9)U/I1!Q.CI^_%!]"^6A"H;\2.;==<*/S^?2N
MT:%1'8R]>QBPG#F4F+>2.,C$,]0;B0)EZHI.WOC9/>]5-ED8Z\&FTU!&9CS7
M"/PH<JNPCJQ>*EX/NVU2J=ATJ#04*8G+I.%"X!1]M2NPGE#_=,E, S214%-W
MF5,HGYG4Y&;!I*7A(\Q,?SX_OPG<4_;6128S)S5<IUX2S)X'LU,A:0T'JN T
M>$@+@5+,K)'$3"R3,#PB&FQ*ZEIXKT.+#W/Q=UV&*2^3VO4K+D$C%;@7]V!<
M_*?O+N&%'#W3D!J3O&;*Z0JP,CI,D4QZDC"1UPK+:-M<.^*7*Q1!(J8+79;,
M,^;@!JB'B2IF^#!^05.]\4]#LF<4S61?%[&\.[87DSM#7'%-+#2G"'I*E8U>
MAFY6$3/VT?.2\CR&QE*XF$A_6?G)Y"N5?]>:^6/B#0MD>8=]O64#1VM>:C@;
M:'?@GE9Y:UP5Y7'#RD0R1ED,[#1068J-=6F93-'GMF2;@QF$-7+%S0:MR\C*
MA$.&.-[5N7>ANXE!B3B )1.:U,USLW0[>5HW.!KO'@!=PU5K\'=C36F(9!9/
MS9.^( _H? VRR?[L;$^@^^?!=G*X-SH9BJE:, #<MG$8(75R.@*DHKC2="(
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M>4G78)V@16>;VE)H;)%VNL%O$I!& ?=70NA7P3@8OG)F_P!02P,$%     @
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M9KU5-)$/<B(P!Q^ER"=PB'\=,+(61O9J&$O,FY]+CA;+)MUE.1:E)?<FH@V
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MU0Z*/>:\PXS?P(QBN)6-J33<-"66_P4(B&#/,CZPG,>#B MLSR$)?8C#.!W
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M"A.@WR><J\W$;%!W^. /4$L#!!0    (  V"+5J9<VL=]P4  !TI   9
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;+5:_6_J-A3]5RPV39NTD=@. 3I
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MM$0F2(8ZMTO]:HN>G/K2<4C9)&NH*/&D(X UYC5:^JSWLJ5/3GFQM);8Q %
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M6,5GAMNO:J8M)YF:L+3)F_)D"*S&4[_@J:_E:28FGC]V*"!K<A0;>$CD\LS
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MXQ;*$?*<C\AU7+]'T.KOX=Z '*_MFV?XO.&^]76F!OK]0#V5<U'B&$)+C9T
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M3.E3 :41H/=S(?33PAQ0?WR,OP)02P,$%     @ #8(M6H%&YT62 @  10<
M !D   !X;"]W;W)K<VAE971S+W-H965T-#,N>&ULK55K;]HP%/TK5C9-K;22
M)P&Q$(G7U'Z@94V[:9KVP207$C6.,]M ^^]G.R$#"JB3^H7X<<_Q.??BZV!#
MV1-/ 01Z)GG!^T8J1-DS31ZG0#!OT1(*N;.@C& AIVQI\I(!3C2(Y*9C6;Y)
M<%888:#79BP,Z$KD60$SAOB*$,Q>AI#33=^PC>W"?;9,A5HPPZ#$2XA /)8S
M)F=FPY)D! J>T0(Q6/2-@=T;^2I>!WS/8,-WQD@YF5/ZI"8W2=^PE"#((1:*
M <O/&D:0YXI(ROA3<QK-D0JX.]ZR?]7>I9<YYC"B^8\L$6G?Z!HH@05>Y>*>
M;JZA]M-6?#'-N?Y%FRK6\PT4K[B@I 9+!20KJB]^KO.P [!/ 9P:X!P"O!,
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MH7PCJI;^CZ9Z8*:8+;."HQP6DM)J=63.6=6TJXF@I>Y[<RID%]7#5+YSP%2
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MVFEQY%,\L&29GYH\)XPE47Z[(/Z4T,R _S]+$K9YR#JH#MX&_P-02P,$%
M  @ #8(M6J95WKQZ P  #0P  !D   !X;"]W;W)K<VAE971S+W-H965T-#8N
M>&ULK9=M<YLX$,>_BH:[N>G-- :$$29G,V,[:2\ODN;J-IV^5.RUS100E62[
M]^U/$H08D)U>)V]B)';_^]M%#YOQ@?%O8@L@T8\\*\3$V4I97KJN6&XAIV+
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M4D<*KWK/:B!9:=JW1R95,V@>MZI?!ZX-U/LU8_)IH ,T_P$D_P%02P,$%
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MI^.@):Q(GJA'OOL.^X("DV_!$VE_T:Z8&WD.6N12\70?K U2RHHC>=XOQ$$
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M%*U;18N.:=UV+:U3TCJ-M-D&=$M=*1!5S,X1,VK7/RO=DMEM9G)%$G27JUP
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MKK"HFF:.SQX('8#S"\[5KJ,7:![2Y ]02P,$%     @ #8(M6N4/\(&P @
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M!/K7UX$;])O (ZU>H]4[JW56ZJ<C$*8I>L"<8RI;A9YET77E1I0X@8&E"H<
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M 6D=S/E1"'TQ;(#A8DK^ %!+ P04    "  -@BU:=2+=6J,#  !D#P  &0
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MEM*D9-B9 G?[G*6D'[\G@7,W51E+R?W9VQ]+9:[>!.Y^\N[DI'=_?G5H/VN
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M1%'S'CQX'X6;]U2X_8UK\AM02P,$%     @ #8(M6I>*NQS     $P(   L
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M36MY718/]RK_UEQ&W\40W$;;#X?/KA,OR__3C<5VJ]9R6JP?]C*ONWXL9=8
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MZNX]GPU_LER] E!+ 0(4 Q0    (  V"+5H'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ #8(M6H&;
M\XON    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ #8(M6IE<G",0!@  G"<  !,              ( !S $
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  -@BU:+CLX.X4'  #5
M,@  &               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ #8(M6E^:\59^!@  )QH  !@              ("!R \
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (  V"+5H(IH-)
MN (  + )   8              " @7P6  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    "  -@BU:EB$;TO(#  "/#   &
M@(%J&0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ #8(M
M6GS7 B!/!P  ,2L  !@              ("!DAT  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    (  V"+5I5QJ1KJ@@  )HE   8
M      " @1<E  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M"  -@BU:28(BN7($  !F"0  &               @('W+0  >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ #8(M6H;5D9+C!0  *PT  !@
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M970Q,BYX;6Q02P$"% ,4    "  -@BU:@\T@_L$'  #Z$@  &0
M    @($L4@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M  V"+5HUVI^?10@  )X8   9              " @21:  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ #8(M6IXNJ#"$ P  2 @  !D
M             ("!H&(  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    "  -@BU:)97C8(X)  !#'@  &0              @(%;9@  >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (  V"+5IV0^NO4 0
M "X*   9              " @2!P  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ #8(M6L9L6.SK!0  ;1   !D              ("!
MIW0  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  -@BU:
MAWQ)X.P%   3$   &0              @(')>@  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    (  V"+5K!Z&ZW,00  .0)   9
M      " @>R   !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ #8(M6I[0Q*O@ @  A08  !D              ("!5(4  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  -@BU:,Q9+F2(,  !<)0
M&0              @(%KB   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    (  V"+5HA?R/0F@,  !\*   9              " @<24  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ #8(M6H C>]6M
M @  R@4  !D              ("!E9@  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    "  -@BU:!Y/U%Z4"   Y!@  &0
M@(%YFP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (  V"
M+5JYQZ-QU@,  /$(   9              " @56>  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ #8(M6GYORP]?!0  " \  !D
M         ("!8J(  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M    "  -@BU:,)&XJS<#   >"0  &0              @('XIP  >&PO=V]R
M:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (  V"+5IY^$^MPP(  -@&
M   9              " @6:K  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
M4$L! A0#%     @ #8(M6G@$SC 3 P  )P<  !D              ("!8*X
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  -@BU:<K'X
MYK4"  #M!P  &0              @(&JL0  >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;%!+ 0(4 Q0    (  V"+5J9<VL=]P4  !TI   9
M  " @9:T  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
M#8(M6E3"/1D@ P  ? P  !D              ("!Q+H  'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    "  -@BU:=DG?48P%  #0(   &0
M            @($;O@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    (  V"+5I(;83#W@(  $@(   9              " @=[#  !X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ #8(M6BYG8.), @
MH 4  !D              ("!\\8  'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    "  -@BU:B,UR?4<"   ,!@  &0              @(%V
MR0  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (  V"+5K^
M?P=>/ (  '(&   9              " @?3+  !X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ #8(M6OTOL>MK @  ?P8  !D
M     ("!9\X  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  V"+5H_D%A)#@,  $,*   9              "
M@1[?  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ #8(M
M6L%[=3QG!0  A!L  !D              ("!8^(  'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6Q02P$"% ,4    "  -@BU:IE7>O'H#   -#   &0
M        @($!Z   >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0
M   (  V"+5J,AQ@5SP(  ,H'   9              " @;+K  !X;"]W;W)K
M<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ #8(M6O:NGGVN!@  ;#8
M !D              ("!N.X  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q0
M2P$"% ,4    "  -@BU:%S171]H"   9"   &0              @(&=]0
M>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (  V"+5H(2V&Z
M[0(  /T(   9              " @:[X  !X;"]W;W)K<VAE971S+W-H965T
M-3 N>&UL4$L! A0#%     @ #8(M6J.QYEKT @  9@D  !D
M ("!TOL  'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    "  -
M@BU:KA^=KC4&  !E)@  &0              @(']_@  >&PO=V]R:W-H965T
M<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    (  V"+5HD-3U$L04  (<G   9
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M970U-RYX;6Q02P$"% ,4    "  -@BU:P;I?@"$"  "D!   &0
M    @(&;&0$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (
M  V"+5IU(MU:HP,  &0/   9              " @?,; 0!X;"]W;W)K<VAE
M971S+W-H965T-3DN>&UL4$L! A0#%     @ #8(M6LU.+64Q P  \!(   T
M             ( !S1\! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  -@BU:
MEXJ[',     3 @  "P              @ $I(P$ 7W)E;',O+G)E;'-02P$"
M% ,4    "  -@BU:*B'Z[Z\$  #E)@  #P              @ $2) $ >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ #8(M6EEV ?CU 0  .",  !H
M         ( ![B@! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ #8(M6A?(S!O; 0  T2(  !,              ( !&RL! %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     $, 0P!,$@  )RT!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>147</ContextCount>
  <ElementCount>348</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>48</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000002 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/BalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000003 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000004 - Statement - STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StatementsOfOperations</Role>
      <ShortName>STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000006 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000007 - Disclosure - ORGANIZATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/ORGANIZATION</Role>
      <ShortName>ORGANIZATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000008 - Disclosure - LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/LIQUIDITY</Role>
      <ShortName>LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000010 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/WarrantsAndNonemployeeOptions</Role>
      <ShortName>WARRANTS AND NONEMPLOYEE OPTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000011 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000012 - Disclosure - PATENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PATENTS</Role>
      <ShortName>PATENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000013 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000014 - Disclosure - EQUITY-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/EquityBasedCompensation</Role>
      <ShortName>EQUITY-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000015 - Disclosure - EMPLOYEE BENEFIT PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/EmployeeBenefitPlan</Role>
      <ShortName>EMPLOYEE BENEFIT PLAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000016 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000017 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000018 - Disclosure - STOCKHOLDERS EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000019 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000020 - Disclosure - NET LOSS PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/NetLossPerCommonShare</Role>
      <ShortName>NET LOSS PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000021 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000023 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/WarrantsAndNonemployeeOptionsTables</Role>
      <ShortName>WARRANTS AND NONEMPLOYEE OPTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/WarrantsAndNonemployeeOptions</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000024 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/PropertyAndEquipment</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000025 - Disclosure - PATENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsTables</Role>
      <ShortName>PATENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/PATENTS</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000026 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/IncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>000027 - Disclosure - EQUITY-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/EquityBasedCompensationTables</Role>
      <ShortName>EQUITY-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/EquityBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>000029 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/FairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/FairValueMeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>000030 - Disclosure - NET LOSS PER COMMON SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/NetLossPerCommonShareTables</Role>
      <ShortName>NET LOSS PER COMMON SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cvm.com/role/NetLossPerCommonShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>000032 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails</Role>
      <ShortName>WARRANTS AND NONEMPLOYEE OPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/WarrantsAndNonemployeeOptionsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>000033 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1</Role>
      <ShortName>WARRANTS AND NONEMPLOYEE OPTIONS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/WarrantsAndNonemployeeOptionsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>000034 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative</Role>
      <ShortName>WARRANTS AND NONEMPLOYEE OPTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/WarrantsAndNonemployeeOptionsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>000035 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>000036 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>000037 - Disclosure - PATENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsDetails</Role>
      <ShortName>PATENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PatentsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>000038 - Disclosure - PATENTS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsDetails1</Role>
      <ShortName>PATENTS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PatentsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>000039 - Disclosure - PATENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/PatentsDetailsNarrative</Role>
      <ShortName>PATENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/PatentsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>000040 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/IncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/IncomeTaxesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>000041 - Disclosure - INCOME TAXES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/IncomeTaxesDetails1</Role>
      <ShortName>INCOME TAXES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/IncomeTaxesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>000042 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/IncomeTaxesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>000043 - Disclosure - EQUITY-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/EquityBasedCompensationDetails</Role>
      <ShortName>EQUITY-BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/EquityBasedCompensationTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>000044 - Disclosure - EQUITY-BASED COMPENSATION (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/EquityBasedCompensationDetails1</Role>
      <ShortName>EQUITY-BASED COMPENSATION (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/EquityBasedCompensationTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>000045 - Disclosure - EQUITY-BASED COMPENSATION (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/EquityBasedCompensationDetails2</Role>
      <ShortName>EQUITY-BASED COMPENSATION (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/EquityBasedCompensationTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>000046 - Disclosure - EQUITY-BASED COMPENSATION (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/EquityBasedCompensationDetails3</Role>
      <ShortName>EQUITY-BASED COMPENSATION (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/EquityBasedCompensationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>000047 - Disclosure - EQUITY-BASED COMPENSATION (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/EquityBasedCompensationDetails4</Role>
      <ShortName>EQUITY-BASED COMPENSATION (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/EquityBasedCompensationTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>000048 - Disclosure - EQUITY-BASED COMPENSATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/EquityBasedCompensationDetailsNarrative</Role>
      <ShortName>EQUITY-BASED COMPENSATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/EquityBasedCompensationTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>000049 - Disclosure - EMPLOYEE BENEFIT PLAN (Detail Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/EmployeeBenefitPlanDetailNarrative</Role>
      <ShortName>EMPLOYEE BENEFIT PLAN (Detail Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>000050 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>000051 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>000052 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>000053 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative )</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/RelatedPartyTransactions</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>000054 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/StockholdersEquity</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>000055 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>000056 - Disclosure - NET LOSS PER COMMON SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/NetLossPerCommonShareDetails</Role>
      <ShortName>NET LOSS PER COMMON SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/NetLossPerCommonShareTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>000057 - Disclosure - NET LOSS PER COMMON SHARE (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/NetLossPerCommonShareDetails1</Role>
      <ShortName>NET LOSS PER COMMON SHARE (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/NetLossPerCommonShareTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>000058 - Disclosure - NET LOSS PER COMMON SHARE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/NetLossPerCommonShareDetailsNarrative</Role>
      <ShortName>NET LOSS PER COMMON SHARE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/NetLossPerCommonShareTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="cvm_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>000059 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cvm.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cvm.com/role/SubsequentEvents</ParentRole>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cvm-20240930.xsd</File>
    <File>cvm-20240930_cal.xml</File>
    <File>cvm-20240930_def.xml</File>
    <File>cvm-20240930_lab.xml</File>
    <File>cvm-20240930_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="cvm_10k.htm">cvm_10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cvm_10kimg10.jpg</File>
    <File>cvm_10kimg11.jpg</File>
    <File>cvm_10kimg12.jpg</File>
    <File>cvm_10kimg13.jpg</File>
    <File>cvm_10kimg14.jpg</File>
    <File>cvm_10kimg15.jpg</File>
    <File>cvm_10kimg16.jpg</File>
    <File>cvm_10kimg17.jpg</File>
    <File>cvm_10kimg18.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="500">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>87
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cvm_10k.htm": {
   "nsprefix": "cvm",
   "nsuri": "http://cvm.com/20240930",
   "dts": {
    "schema": {
     "local": [
      "cvm-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cvm-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cvm-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cvm-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cvm-20240930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "cvm_10k.htm"
     ]
    }
   },
   "keyStandard": 264,
   "keyCustom": 84,
   "axisStandard": 17,
   "axisCustom": 0,
   "memberStandard": 7,
   "memberCustom": 40,
   "hidden": {
    "total": 29,
    "http://fasb.org/us-gaap/2024": 19,
    "http://xbrl.sec.gov/dei/2024": 8,
    "http://cvm.com/20240930": 2
   },
   "contextCount": 147,
   "entityCount": 1,
   "segmentCount": 48,
   "elementCount": 470,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 500,
    "http://xbrl.sec.gov/dei/2024": 38
   },
   "report": {
    "R1": {
     "role": "http://cvm.com/role/Cover",
     "longName": "000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://cvm.com/role/BalanceSheets",
     "longName": "000002 - Statement - BALANCE SHEETS",
     "shortName": "BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://cvm.com/role/BalanceSheetsParenthetical",
     "longName": "000003 - Statement - BALANCE SHEETS (Parenthetical)",
     "shortName": "BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://cvm.com/role/StatementsOfOperations",
     "longName": "000004 - Statement - STATEMENTS OF OPERATIONS",
     "shortName": "STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://cvm.com/role/StatementsOfStockholdersEquity",
     "longName": "000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-09-30_us-gaap_CommonStockMember",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-09-30_us-gaap_CommonStockMember",
      "name": "us-gaap:SharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://cvm.com/role/StatementsOfCashFlows",
     "longName": "000006 - Statement - STATEMENTS OF CASH FLOWS",
     "shortName": "STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://cvm.com/role/ORGANIZATION",
     "longName": "000007 - Disclosure - ORGANIZATION",
     "shortName": "ORGANIZATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://cvm.com/role/LIQUIDITY",
     "longName": "000008 - Disclosure - LIQUIDITY",
     "shortName": "LIQUIDITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "cvm:LiquidityDisclosureTextblock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "cvm:LiquidityDisclosureTextblock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://cvm.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://cvm.com/role/WarrantsAndNonemployeeOptions",
     "longName": "000010 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS",
     "shortName": "WARRANTS AND NONEMPLOYEE OPTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "cvm:WarrantsAndNonEmployeeOptionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "cvm:WarrantsAndNonEmployeeOptionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://cvm.com/role/PropertyAndEquipment",
     "longName": "000011 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://cvm.com/role/PATENTS",
     "longName": "000012 - Disclosure - PATENTS",
     "shortName": "PATENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://cvm.com/role/IncomeTaxes",
     "longName": "000013 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://cvm.com/role/EquityBasedCompensation",
     "longName": "000014 - Disclosure - EQUITY-BASED COMPENSATION",
     "shortName": "EQUITY-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://cvm.com/role/EmployeeBenefitPlan",
     "longName": "000015 - Disclosure - EMPLOYEE BENEFIT PLAN",
     "shortName": "EMPLOYEE BENEFIT PLAN",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://cvm.com/role/CommitmentsAndContingencies",
     "longName": "000016 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://cvm.com/role/RelatedPartyTransactions",
     "longName": "000017 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://cvm.com/role/StockholdersEquity",
     "longName": "000018 - Disclosure - STOCKHOLDERS EQUITY",
     "shortName": "STOCKHOLDERS EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://cvm.com/role/FairValueMeasurements",
     "longName": "000019 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://cvm.com/role/NetLossPerCommonShare",
     "longName": "000020 - Disclosure - NET LOSS PER COMMON SHARE",
     "shortName": "NET LOSS PER COMMON SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://cvm.com/role/SubsequentEvents",
     "longName": "000021 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://cvm.com/role/WarrantsAndNonemployeeOptionsTables",
     "longName": "000023 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Tables)",
     "shortName": "WARRANTS AND NONEMPLOYEE OPTIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cvm:WarrantsAndNonEmployeeOptionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cvm:WarrantsAndNonEmployeeOptionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://cvm.com/role/PropertyAndEquipmentTables",
     "longName": "000024 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://cvm.com/role/PatentsTables",
     "longName": "000025 - Disclosure - PATENTS (Tables)",
     "shortName": "PATENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://cvm.com/role/IncomeTaxesTables",
     "longName": "000026 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://cvm.com/role/EquityBasedCompensationTables",
     "longName": "000027 - Disclosure - EQUITY-BASED COMPENSATION (Tables)",
     "shortName": "EQUITY-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesTables",
     "longName": "000028 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://cvm.com/role/FairValueMeasurementsTables",
     "longName": "000029 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://cvm.com/role/NetLossPerCommonShareTables",
     "longName": "000030 - Disclosure - NET LOSS PER COMMON SHARE (Tables)",
     "shortName": "NET LOSS PER COMMON SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "000031 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
     "longName": "000032 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details)",
     "shortName": "WARRANTS AND NONEMPLOYEE OPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30_cvm_ConsultantsMember",
      "name": "cvm:SharesIssuableUponExerciseOfwarrant",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "cvm:WarrantsAndNonEmployeeOptionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30_cvm_ConsultantsMember",
      "name": "cvm:SharesIssuableUponExerciseOfwarrant",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "cvm:WarrantsAndNonEmployeeOptionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1",
     "longName": "000033 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details 1)",
     "shortName": "WARRANTS AND NONEMPLOYEE OPTIONS (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "cvm:EquityWarrantsExercised",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "cvm:ProceedsFromEquityWarrantsExercised",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfEquityWarrantsWereExercisedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative",
     "longName": "000034 - Disclosure - WARRANTS AND NONEMPLOYEE OPTIONS (Details Narrative)",
     "shortName": "WARRANTS AND NONEMPLOYEE OPTIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "cvm:CommonStockIssuedForServiceShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "cvm:CommonStockIssuedForServiceShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://cvm.com/role/PropertyAndEquipmentDetails",
     "longName": "000035 - Disclosure - PROPERTY AND EQUIPMENT (Details)",
     "shortName": "PROPERTY AND EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:FixturesAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:FixturesAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://cvm.com/role/PropertyAndEquipmentDetailsNarrative",
     "longName": "000036 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)",
     "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://cvm.com/role/PatentsDetails",
     "longName": "000037 - Disclosure - PATENTS (Details)",
     "shortName": "PATENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:FiniteLivedPatentsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:FiniteLivedPatentsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://cvm.com/role/PatentsDetails1",
     "longName": "000038 - Disclosure - PATENTS (Details 1)",
     "shortName": "PATENTS (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://cvm.com/role/PatentsDetailsNarrative",
     "longName": "000039 - Disclosure - PATENTS (Details Narrative)",
     "shortName": "PATENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "cvm:PatentsWeightedAverageAmortizationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "cvm:PatentsWeightedAverageAmortizationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://cvm.com/role/IncomeTaxesDetails",
     "longName": "000040 - Disclosure - INCOME TAXES (Details)",
     "shortName": "INCOME TAXES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "cvm:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://cvm.com/role/IncomeTaxesDetails1",
     "longName": "000041 - Disclosure - INCOME TAXES (Details 1)",
     "shortName": "INCOME TAXES (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://cvm.com/role/IncomeTaxesDetailsNarrative",
     "longName": "000042 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30_cvm_IncomeTaxMember",
      "name": "cvm:ResearchAndDevelopmentCredit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://cvm.com/role/EquityBasedCompensationDetails",
     "longName": "000043 - Disclosure - EQUITY-BASED COMPENSATION (Details)",
     "shortName": "EQUITY-BASED COMPENSATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30_cvm_NonEmployeesMember",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30_cvm_NonEmployeesMember",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://cvm.com/role/EquityBasedCompensationDetails1",
     "longName": "000044 - Disclosure - EQUITY-BASED COMPENSATION (Details 1)",
     "shortName": "EQUITY-BASED COMPENSATION (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://cvm.com/role/EquityBasedCompensationDetails2",
     "longName": "000045 - Disclosure - EQUITY-BASED COMPENSATION (Details 2)",
     "shortName": "EQUITY-BASED COMPENSATION (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30_cvm_ExercisableMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-09-30_cvm_ExercisableMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "cvm:ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://cvm.com/role/EquityBasedCompensationDetails3",
     "longName": "000046 - Disclosure - EQUITY-BASED COMPENSATION (Details 3)",
     "shortName": "EQUITY-BASED COMPENSATION (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://cvm.com/role/EquityBasedCompensationDetails4",
     "longName": "000047 - Disclosure - EQUITY-BASED COMPENSATION (Details 4)",
     "shortName": "EQUITY-BASED COMPENSATION (Details 4)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30_cvm_RestrictedStockAwardsMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-09-30_cvm_RestrictedStockAwardsMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://cvm.com/role/EquityBasedCompensationDetailsNarrative",
     "longName": "000048 - Disclosure - EQUITY-BASED COMPENSATION (Details Narrative)",
     "shortName": "EQUITY-BASED COMPENSATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30_cvm_StockCompensationPlansMember",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://cvm.com/role/EmployeeBenefitPlanDetailNarrative",
     "longName": "000049 - Disclosure - EMPLOYEE BENEFIT PLAN (Detail Narrative)",
     "shortName": "EMPLOYEE BENEFIT PLAN (Detail Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetails",
     "longName": "000050 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetails1",
     "longName": "000051 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 1)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "000052 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:FinanceLeaseInterestPaymentOnLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:FinanceLeaseInterestPaymentOnLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "000053 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative )",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative )",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "From2024-07-01to2024-07-29",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-05-01to2024-05-04",
      "name": "cvm:DescriptionOfModificationOfWarrants",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://cvm.com/role/StockholdersEquityDetailsNarrative",
     "longName": "000054 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)",
     "shortName": "STOCKHOLDERS EQUITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2024-07-29",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "cvm:ProceedFromIssuanceOrSaleOfEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://cvm.com/role/FairValueMeasurementsDetails",
     "longName": "000055 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30_cvm_CostMember",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30_cvm_CostMember",
      "name": "us-gaap:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://cvm.com/role/NetLossPerCommonShareDetails",
     "longName": "000056 - Disclosure - NET LOSS PER COMMON SHARE (Details)",
     "shortName": "NET LOSS PER COMMON SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R57": {
     "role": "http://cvm.com/role/NetLossPerCommonShareDetails1",
     "longName": "000057 - Disclosure - NET LOSS PER COMMON SHARE (Details 1)",
     "shortName": "NET LOSS PER COMMON SHARE (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://cvm.com/role/NetLossPerCommonShareDetailsNarrative",
     "longName": "000058 - Disclosure - NET LOSS PER COMMON SHARE (Details Narrative)",
     "shortName": "NET LOSS PER COMMON SHARE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "cvm:WarrantsUsedForCalculationOfEarningPerShare",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-01to2024-09-30",
      "name": "cvm:WarrantsUsedForCalculationOfEarningPerShare",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://cvm.com/role/SubsequentEventsDetailsNarrative",
     "longName": "000059 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "From2022-10-01to2023-09-30",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_SubsequentEventMember",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cvm_10k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r501"
     ]
    },
    "cvm_AccruedConsultingServicesToBePaidUnderShareBasedPaymentArrangement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "AccruedConsultingServicesToBePaidUnderShareBasedPaymentArrangement",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued consulting services to be paid with common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "cvm_AccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "AccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated depreciation and amortization",
        "label": "[Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment]",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r110",
      "r383"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r501",
      "r609"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r531",
      "r532",
      "r533",
      "r534",
      "r589",
      "r610"
     ]
    },
    "cvm_AdditionalPurchaseOfCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "AdditionalPurchaseOfCommonStock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional purchase of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total compensation cost",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r263"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of patent costs",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r180",
      "r186",
      "r490"
     ]
    },
    "cvm_AmountsDueToEmployeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "AmountsDueToEmployeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due to employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails1",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails1",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "[Assets]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r92",
      "r111",
      "r132",
      "r160",
      "r162",
      "r166",
      "r167",
      "r169",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r302",
      "r306",
      "r331",
      "r374",
      "r433",
      "r488",
      "r489",
      "r501",
      "r512",
      "r556",
      "r557",
      "r604"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "[Assets, Current]",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r116",
      "r132",
      "r169",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r302",
      "r306",
      "r331",
      "r501",
      "r556",
      "r557",
      "r604"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm Id",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r516",
      "r517",
      "r518"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r516",
      "r517",
      "r518"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r516",
      "r517",
      "r518"
     ]
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails4",
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_BottomMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "BottomMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_CEOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "CEOMember",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CEO [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedContractCostAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedContractCostAxis",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost [Axis]",
        "documentation": "Information by cost capitalized in obtaining or fulfilling contract with customer."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_CapitalizedContractCostDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedContractCostDomain",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost capitalized in obtaining and fulfilling contract with customer."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "cvm_CapitalizedIntangibleAssetsCostsIncludedInCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "CapitalizedIntangibleAssetsCostsIncludedInCurrentLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized patent costs included in current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r376",
      "r409",
      "r428",
      "r501",
      "r512",
      "r523"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r108",
      "r479"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets",
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF YEAR",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r65",
      "r129"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS",
        "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r65"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fully insured amount of non-interest bearing cash balances",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative",
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Axis",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative",
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public offering price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r196",
      "r197",
      "r476",
      "r554",
      "r555"
     ]
    },
    "cvm_CommitmentsAndContingenciesDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "CommitmentsAndContingenciesDisclosuresAbstract",
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_CommonStockContributedToEmployeeBenefitPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "CommonStockContributedToEmployeeBenefitPlan",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock contributed to 401(k) plan"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_CommonStockIssuedForServiceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "CommonStockIssuedForServiceShares",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for service, shares",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r503",
      "r504",
      "r506",
      "r507",
      "r508",
      "r509",
      "r531",
      "r532",
      "r534",
      "r589",
      "r608",
      "r610"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://cvm.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://cvm.com/role/BalanceSheetsParenthetical",
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "verboseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r420"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://cvm.com/role/BalanceSheetsParenthetical",
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "verboseLabel": "Common stock, shares issued",
        "terseLabel": "Common stock shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://cvm.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r52",
      "r420",
      "r439",
      "r610",
      "r611"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.01 par value; 600,000,000 shares authorized; 63,787,104 and 47,422,304 shares issued and outstanding at September 30, 2024 and 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r378",
      "r501"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://cvm.com/role/EmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "EMPLOYEE BENEFIT PLAN",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r79"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r97"
     ]
    },
    "cvm_ConsultantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ConsultantMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ConsultantsMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultants [Member]",
        "verboseLabel": "Consultants Member"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultantsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ConsultantsOneMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consultants 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ConsultingAgreementsMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ConsultingServicesPaidWithIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ConsultingServicesPaidWithIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting services paid with issuance of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://cvm.com/role/EmployeeBenefitPlanDetailNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "cvm_CostIncurredInIssuanceOfStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "CostIncurredInIssuanceOfStock",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_CostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "CostMember",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total expense",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_CumulativeChangeInOwnershipPercentage": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "CumulativeChangeInOwnershipPercentage",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative change in ownership percentage"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity date of debt",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r491",
      "r590",
      "r591"
     ]
    },
    "us-gaap_DeferredCompensationEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationEquity",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation expense",
        "documentation": "Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r55"
     ]
    },
    "cvm_DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized R&amp;D"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ending Balance",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails",
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net deferred tax asset",
        "verboseLabel": "Deferred tax asset",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails",
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NOL carryforwards",
        "verboseLabel": "NOL carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fixed assets and intangibles",
        "label": "[Deferred Tax Assets, Property, Plant and Equipment]",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "R&amp;D credit",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vacation and other",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days)."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "[Deferred Tax Assets, Valuation Allowance]",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Total deferred tax liability",
        "label": "[Deferred Tax Liabilities, Net]",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed assets and intangibles",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/EmployeeBenefitPlanDetailNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense for Company's contribution to employee benefit plan",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deposits",
        "label": "[Deposits Assets, Noncurrent]",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expenses",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r27"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r27"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r160",
      "r164",
      "r167",
      "r488",
      "r489"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r412",
      "r425",
      "r426",
      "r427",
      "r429",
      "r430",
      "r431",
      "r432",
      "r434",
      "r435",
      "r436",
      "r437",
      "r449",
      "r450",
      "r451",
      "r452",
      "r455",
      "r456",
      "r457",
      "r458",
      "r469",
      "r470",
      "r471",
      "r472",
      "r502",
      "r504",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument Risk Axis",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r85",
      "r411",
      "r412",
      "r425",
      "r426",
      "r427",
      "r429",
      "r430",
      "r431",
      "r432",
      "r434",
      "r435",
      "r436",
      "r437",
      "r449",
      "r450",
      "r451",
      "r452",
      "r455",
      "r456",
      "r457",
      "r458",
      "r469",
      "r470",
      "r471",
      "r472",
      "r482",
      "r502",
      "r504",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599"
     ]
    },
    "cvm_DescriptionOfModificationOfWarrants": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "DescriptionOfModificationOfWarrants",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of modification of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "EQUITY-BASED COMPENSATION",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r256",
      "r257",
      "r258",
      "r492"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "EQUITY-BASED COMPENSATION"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r517",
      "r518"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fin Stmt Error Correction Flag",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r517",
      "r518",
      "r520"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER COMMON SHARE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails",
      "http://cvm.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per common share - basic and diluted",
        "verboseLabel": "Basic and diluted loss per common share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r150",
      "r152",
      "r153",
      "r154",
      "r159",
      "r297",
      "r300",
      "r316",
      "r317",
      "r371",
      "r388",
      "r485"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Common Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r156"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "NET LOSS PER COMMON SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r155",
      "r157",
      "r158"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://cvm.com/role/IncomeTaxesDetails1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "[Effective Income Tax Rate Reconciliation, Percent]",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r494"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://cvm.com/role/IncomeTaxesDetails1": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r269",
      "r289",
      "r494"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://cvm.com/role/IncomeTaxesDetails1": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r494",
      "r530",
      "r585"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://cvm.com/role/IncomeTaxesDetails1": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State tax rate, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r272",
      "r494",
      "r530",
      "r585"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://cvm.com/role/IncomeTaxesDetails1": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent differences",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r530",
      "r585"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://cvm.com/role/IncomeTaxesDetails1": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other adjustments",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r530",
      "r585",
      "r586"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://cvm.com/role/IncomeTaxesDetails1": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State tax rate change",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeBenefitsAndShareBasedCompensationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "EMPLOYEE BENEFIT PLAN"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_EmployeeContributionsToDefinedContributionPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "EmployeeContributionsToDefinedContributionPlans",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/EmployeeBenefitPlanDetailNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Contributions to Defined Contribution Plans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation Expense",
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "cvm_EmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "EmployeesMember",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 2",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well Known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r103",
      "r120",
      "r121",
      "r122",
      "r134",
      "r135",
      "r136",
      "r138",
      "r143",
      "r145",
      "r147",
      "r161",
      "r170",
      "r171",
      "r192",
      "r221",
      "r287",
      "r288",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r340",
      "r341",
      "r353",
      "r387",
      "r391",
      "r392",
      "r393",
      "r408",
      "r461"
     ]
    },
    "cvm_EquityProceedsFromSaleCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "EquityProceedsFromSaleCommonStockMember",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Proceeds From Sale Common Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_EquityWarrantsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "EquityWarrantsExercisePrice",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Warrants Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_EquityWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "EquityWarrantsExercised",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Warrants Exercised",
        "verboseLabel": "Equity Warrants Exercised",
        "terseLabel": "Equity Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ErgomedGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ErgomedGroupMember",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ergomed Group [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ErgomedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ErgomedMember",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ergomed [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ExercisableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ExercisableMember",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ExerciseOfPreFundedWarrantsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ExerciseOfPreFundedWarrantsAmount",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of pre-funded warrants, amount"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ExerciseOfPreFundedWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ExerciseOfPreFundedWarrantsShares",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of pre-funded warrants, shares"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ExercisePrice",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ExpectedLifeOfOptionsMax": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ExpectedLifeOfOptionsMax",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life of options, max"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ExpectedLifeOfOptionsMin1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ExpectedLifeOfOptionsMin1",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life of options, min"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ExpirationDate1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ExpirationDate1",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r322",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r370",
      "r497",
      "r499"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value measurements using significant unobservable inputs",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r321",
      "r325"
     ]
    },
    "cvm_FairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "FairValueMember",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_FinanceLeaseCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "FinanceLeaseCosts",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Finance lease costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest payment to lease liability",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r350"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails",
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of finance lease obligations",
        "verboseLabel": "Finance lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r351"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets",
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligation, current portion",
        "verboseLabel": "Finance lease liability, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "cvm_FinanceLeaseLiabilityCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "FinanceLeaseLiabilityCurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of lease finance lease obligations - current portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of future minimum payments under finance leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease liabilities, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "cvm_FinanceLeaseLiabilityNoncurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "FinanceLeaseLiabilityNoncurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of lease finance lease obligations - non-current portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Future Minimum Lease Obligation",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "[Finance Lease, Liability, to be Paid, Year One]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2029",
        "label": "[Finance Lease, Liability, to be Paid, Year Five]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "[Finance Lease, Liability, to be Paid, Year Four]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "[Finance Lease, Liability, to be Paid, Year Three]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "[Finance Lease, Liability, to be Paid, Year Two]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Imputed Interest On Financing Lease Obligation",
        "label": "[Finance Lease, Liability, Undiscounted Excess Amount]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "cvm_FinanceLeaseObligationIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "FinanceLeaseObligationIncludedInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease obligation included in accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid related to finance leases",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r350"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets",
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance lease right-of-use assets",
        "verboseLabel": "Finance lease right of use assets",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r349",
      "r500"
     ]
    },
    "cvm_FinancingCostsIncludedInCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "FinancingCostsIncludedInCurrentLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing costs included in current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r478",
      "r490"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r478",
      "r490"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r478",
      "r490"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r478",
      "r490"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r478",
      "r490"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r188",
      "r189",
      "r368",
      "r369",
      "r478"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r188",
      "r189",
      "r478"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent costs, net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r550"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "PATENTS"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_FiniteLivedIntangibleAssetsUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "FiniteLivedIntangibleAssetsUsefulLife",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent Useful Life"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedPatentsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedPatentsGross",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Patents",
        "label": "[Finite-Lived Patents, Gross]",
        "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights."
       }
      }
     },
     "auth_ref": [
      "r524",
      "r550"
     ]
    },
    "us-gaap_FixturesAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FixturesAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research equipment",
        "documentation": "Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesGross",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and equipment",
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General &amp; administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r443"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r516",
      "r517",
      "r518"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of long-lived assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r72"
     ]
    },
    "cvm_IncentiveStockBonusPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "IncentiveStockBonusPlanMember",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Stock Bonus Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncentiveStockForfeitedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "IncentiveStockForfeitedAmount",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2014 Incentive Stock Forfeited, amount"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncentiveStockForfeitedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "IncentiveStockForfeitedShares",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2014 Incentive Stock Forfeited, shares"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncentiveStockOptionPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "IncentiveStockOptionPlansMember",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Stock Option Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r195",
      "r319",
      "r321",
      "r325",
      "r389",
      "r390",
      "r446",
      "r478",
      "r498",
      "r607"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r319",
      "r321",
      "r325",
      "r389",
      "r390",
      "r446",
      "r478",
      "r498",
      "r607"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r266",
      "r269",
      "r276",
      "r277",
      "r278",
      "r279",
      "r284",
      "r290",
      "r291",
      "r292",
      "r293",
      "r403",
      "r494"
     ]
    },
    "cvm_IncomeTaxMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "IncomeTaxMember",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r267",
      "r268",
      "r279",
      "r280",
      "r283",
      "r286",
      "r399"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "[Increase (Decrease) in Accounts Payable]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "[Increase (Decrease) in Accrued Liabilities]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInDepositOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDepositOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deposits",
        "label": "[Increase (Decrease) in Deposit Assets]",
        "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Due to employees",
        "label": "[Increase (Decrease) in Employee Related Liabilities]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Supplies used for R&amp;D and manufacturing",
        "label": "[Increase (Decrease) in Inventories]",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Increase)/decrease in assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase/(decrease) in liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "[Increase (Decrease) in Prepaid Expense]",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "cvm_IncrementalCostDeemedDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "IncrementalCostDeemedDividend",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental cost"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IncrementalCostOfWarrantsExtension": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "IncrementalCostOfWarrantsExtension",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental cost of warrants extension"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/PATENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "PATENTS",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r190",
      "r191",
      "r477",
      "r478"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r368",
      "r483",
      "r543"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense, net",
        "label": "[Interest Expense, Operating and Nonoperating]",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r162",
      "r163",
      "r165",
      "r167",
      "r339",
      "r488",
      "r489"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r127",
      "r128"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplies used for R&amp;D and manufacturing",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r480",
      "r501"
     ]
    },
    "us-gaap_InventoryNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Supplies used for R&amp;D and manufacturing",
        "label": "[Inventory, Noncurrent]",
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Supplies used for R&amp;D and manufacturing",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r107",
      "r113",
      "r172",
      "r173",
      "r174",
      "r363",
      "r484"
     ]
    },
    "cvm_IssuanceCostOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "IssuanceCostOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance cost of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_IssuanceOfOptionsForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "IssuanceOfOptionsForServices",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options issued to consultants for services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payments for services",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "cvm_Issuedate2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "Issuedate2",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue Date"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_LIQUIDITYAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "LIQUIDITYAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LIQUIDITY"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_LandlordMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "LandlordMember",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Landlord [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseAgreementsMember",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Agreement [Member]",
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r550",
      "r552",
      "r553"
     ]
    },
    "cvm_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsGross",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold improvements",
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of future minimum payments under operating leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total Future Minimum Lease Obligation",
        "label": "[Lessee, Operating Lease, Liability, to be Paid]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Thereafter",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, after Year Five]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year One]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2029",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Five]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Four]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Three]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "[Lessee, Operating Lease, Liability, to be Paid, Year Two]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less Imputed Interest On Operating Lease Obligation",
        "label": "[Lessee, Operating Lease, Liability, Undiscounted Excess Amount]",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "[Liabilities]",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r132",
      "r169",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r303",
      "r306",
      "r307",
      "r331",
      "r419",
      "r486",
      "r512",
      "r556",
      "r604",
      "r605"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "[Liabilities and Equity]",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r89",
      "r380",
      "r501",
      "r529",
      "r542",
      "r600"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "[Liabilities, Current]",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r106",
      "r132",
      "r169",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r303",
      "r306",
      "r307",
      "r331",
      "r501",
      "r556",
      "r604",
      "r605"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_LiquidityDisclosureTextblock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "LiquidityDisclosureTextblock",
     "presentation": [
      "http://cvm.com/role/LIQUIDITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIQUIDITY",
        "label": "[LIQUIDITY]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtWeightedAverageInterestRateOverTime",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average discount rate",
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ModificationOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ModificationOfWarrants",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Modification of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_MoneyMarketFundsIncludedInCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "MoneyMarketFundsIncludedInCashAndCashEquivalents",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money market funds included in cash and cash equivalents (Note 2)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "[Net Cash Provided by (Used in) Financing Activities]",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "[Net Cash Provided by (Used in) Investing Activities]",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "[Net Cash Provided by (Used in) Operating Activities]",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r67"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails",
      "http://cvm.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss available to common shareholders",
        "label": "[Net Income (Loss) Attributable to Parent]",
        "verboseLabel": "Net loss available to common shareholders - basic and diluted",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r67",
      "r90",
      "r104",
      "r117",
      "r118",
      "r122",
      "r132",
      "r137",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r146",
      "r147",
      "r151",
      "r169",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r297",
      "r300",
      "r317",
      "r331",
      "r386",
      "r441",
      "r459",
      "r460",
      "r510",
      "r556"
     ]
    },
    "cvm_NetIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "NetIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NonEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "NonEmployeesMember",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Employees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NonQualifiedStockOptionsPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "NonQualifiedStockOptionsPlansMember",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Qualified Stock Options Plans [Member]",
        "verboseLabel": "Non-Qualified Stock Options Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NonVestedOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "NonVestedOptionsMember",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Vested Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NumberOfOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "NumberOfOptions",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of Options Expired",
        "label": "[Number of Options Expired]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NumberOfOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "NumberOfOptionsExercised",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of Options Exercised",
        "label": "[Number of Options Exercised]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_NumberOfOptionsVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "NumberOfOptionsVested",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Options Vested",
        "label": "[Number of Options Vested]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_OfficerAndDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "OfficerAndDirectorMember",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer and Director [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenseMember",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expense [Member]",
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "[Operating Expenses]",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://cvm.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "[Operating Income (Loss)]",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r487",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1",
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of operating lease obligations",
        "verboseLabel": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets",
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease obligation, current portion",
        "verboseLabel": "Operating lease liability, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "cvm_OperatingLeaseObligationyCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "OperatingLeaseObligationyCurrent",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of operating lease obligation - current portion"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_OperatingLeaseObligationyNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "OperatingLeaseObligationyNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net present value of operating lease obligation - non-current portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "cash paid related to operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r350"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets",
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease right of use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r342"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityEquityAxis",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2",
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed To Issuers Equity Equity Axis",
        "documentation": "Information by type of options indexed to an issuer's equity."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r39",
      "r40",
      "r87"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityStrikePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityStrikePrice1",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock price",
        "documentation": "Exercise or strike price stated in the contract for options indexed to the issuer's equity shares."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r13"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2",
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_OptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "OptionsMember",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options and Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/ORGANIZATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ORGANIZATION",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r84",
      "r396",
      "r397"
     ]
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease expenses",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60"
     ]
    },
    "us-gaap_OtherIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents, net",
        "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_OtherNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash lease expense",
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "cvm_OutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "OutstandingMember",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PatentsMember",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r550",
      "r552",
      "r553"
     ]
    },
    "cvm_PatentsWeightedAverageAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "PatentsWeightedAverageAmortizationPeriod",
     "presentation": [
      "http://cvm.com/role/PatentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average amortization period for patents"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_PaymentsMadeToLandlord": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "PaymentsMadeToLandlord",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments Made to Landlord"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of stock issuance costs",
        "label": "[Payments of Stock Issuance Costs]",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expenditures for patent costs",
        "label": "[Payments to Acquire Intangible Assets]",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "[Payments to Acquire Property, Plant, and Equipment]",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "cvm_PercentageOfEmployeeContributionsToDefinedContributionPlans": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "PercentageOfEmployeeContributionsToDefinedContributionPlans",
     "presentation": [
      "http://cvm.com/role/EmployeeBenefitPlanDetailNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of employee Contributions to Defined Contribution Plans"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_PerformanceBasedStockOptionsSharesGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "PerformanceBasedStockOptionsSharesGranted",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance based stock options shares granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/FairValueMeasurementsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/FairValueMeasurementsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://cvm.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r208"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://cvm.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r420"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://cvm.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r208"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://cvm.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r420",
      "r439",
      "r610",
      "r611"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $0.01 par value; 200,000 shares authorized; 0 shares issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r377",
      "r501"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r175",
      "r176",
      "r481"
     ]
    },
    "cvm_PrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "PrepaidExpenses",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses",
        "label": "[Prepaid expenses]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ProceedFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ProceedFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of warrant"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ProceedsFromAdditionalDebtFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ProceedsFromAdditionalDebtFromRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional debt from CEO"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ProceedsFromEquityWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ProceedsFromEquityWarrantsExercised",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Equity Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StatementsOfCashFlows",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock and pre-funded warrants",
        "verboseLabel": "Proceeds from issuance of restricted common stock",
        "terseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the purchase of stock by officers and directors",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r11"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from related party loans",
        "verboseLabel": "Proceeds from loan from CEO",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "cvm_ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock and pre-funded warrants, amount"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsShares",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock and pre-funded warrants, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://cvm.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows",
      "http://cvm.com/role/StatementsOfOperations",
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]",
        "verboseLabel": "Net loss",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r117",
      "r118",
      "r125",
      "r132",
      "r137",
      "r143",
      "r146",
      "r147",
      "r169",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r297",
      "r300",
      "r301",
      "r304",
      "r305",
      "r317",
      "r331",
      "r372",
      "r385",
      "r407",
      "r441",
      "r459",
      "r460",
      "r495",
      "r496",
      "r511",
      "r527",
      "r556"
     ]
    },
    "cvm_ProfitLossPerShareBasicAndDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ProfitLossPerShareBasicAndDilutedAbstract",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share - basic and diluted"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment purchases included in current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "PROPERTY AND EQUIPMENT",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r98",
      "r101",
      "r102"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r109",
      "r384"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets",
      "http://cvm.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "verboseLabel": "Net property and equipment",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r352",
      "r373",
      "r384",
      "r501"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r98",
      "r101",
      "r382"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://cvm.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of property and equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "cvm_PurchaseOfAssetsUnderFinanceLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "PurchaseOfAssetsUnderFinanceLeases",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets purchased under finance leases"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_PurchaseOfStockByOfficersAndDirectorsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "PurchaseOfStockByOfficersAndDirectorsAmount",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of stock by officers and directors, amount"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_PurchaseOfStockByOfficersAndDirectorsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "PurchaseOfStockByOfficersAndDirectorsShares",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of stock by officers and directors, shares"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_RecentlyAdoptedAccountingStandardsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "RecentlyAdoptedAccountingStandardsPolicyPolicyTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Adopted Accounting Standards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r222",
      "r357",
      "r358",
      "r375",
      "r381",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r438",
      "r440",
      "r468"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r222",
      "r357",
      "r358",
      "r375",
      "r381",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r438",
      "r440",
      "r468",
      "r603"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r358",
      "r359",
      "r404",
      "r405",
      "r406",
      "r444",
      "r445",
      "r446",
      "r465",
      "r467"
     ]
    },
    "cvm_RemainingOutstandingFairValueOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "RemainingOutstandingFairValueOfShares",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant date fair value remaining outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on obligations under finance leases",
        "label": "[Repayments of Debt and Lease Obligation]",
        "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of related party loans",
        "label": "[Repayments of Related Party Debt]",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "cvm_ResearchAndDevelopmentCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ResearchAndDevelopmentCredit",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credit"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_ResearchAndDevelopmentCreditDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ResearchAndDevelopmentCreditDescription",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credit, description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r478",
      "r488",
      "r606"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "cvm_RestrictedCommonStockSharesIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "RestrictedCommonStockSharesIssued",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of restricted common stock"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_RestrictedStockAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "RestrictedStockAwardsMember",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails4",
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Awards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_RestrictedStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "RestrictedStocksMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stocks Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r75",
      "r379",
      "r394",
      "r395",
      "r402",
      "r421",
      "r501"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r134",
      "r135",
      "r136",
      "r138",
      "r143",
      "r145",
      "r147",
      "r170",
      "r171",
      "r192",
      "r287",
      "r288",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r308",
      "r310",
      "r311",
      "r313",
      "r315",
      "r340",
      "r341",
      "r391",
      "r393",
      "r408",
      "r610"
     ]
    },
    "cvm_RightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "RightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails",
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of common stock at a public offering price",
        "verboseLabel": "Sale of common stock at a public offering price",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public offering price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of anti-dilutive securities",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of components of the Company's deferred tax assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of earnings per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of federal or state current or deferred tax expense or benefit",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r494",
      "r585"
     ]
    },
    "cvm_ScheduleOfEquityWarrantsWereExercisedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ScheduleOfEquityWarrantsWereExercisedTableTextBlock",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of equity warrants were exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://cvm.com/role/PatentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of patents",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r549"
     ]
    },
    "cvm_ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of non-qualified and incentive stock option plans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of expenses for options issued or vested and restricted stock awarded",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of non vested options",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r80"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of assumptions used for fair value of each option granted",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrants and non-employee options",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of restricted common stock issued from the incentive stock bonus plan",
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://cvm.com/role/PatentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of total estimated future amortization",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r551"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "cvm_SeriesMMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "SeriesMMMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series MM [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesNMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "SeriesNMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series N [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesNNMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "SeriesNNMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series NN [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesRRMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "SeriesRRMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series RR [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesRRWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "SeriesRRWarrantMember",
     "presentation": [
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series RR Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesSSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "SeriesSSMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series SS [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesUUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "SeriesUUMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series UU [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesXMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "SeriesXMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series X [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_SeriesYMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "SeriesYMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series Y [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://cvm.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited options",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period]",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted options",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of unvested options, Beginning",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number]",
        "periodEndLabel": "Number of unvested options, Ending",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value]",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested options",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period]",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected stock price volatility, max",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected stock price volatility, min",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate, max",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate, min",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock options authorized shares",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options Expired",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period]",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Options Outstanding, Beginning",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number]",
        "periodEndLabel": "Number of Options Outstanding, Ending",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price]",
        "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails4",
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Forfeited",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r228",
      "r247",
      "r248",
      "r249",
      "r250",
      "r253",
      "r259",
      "r260",
      "r261",
      "r262"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock prices per share",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value Outstanding, Beginning",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding]",
        "periodEndLabel": "Aggregate Intrinsic Value Outstanding, Ending",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Remaining Contractual Life Term (Years) Outstanding, Ending",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term]",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of unvested shares, Beginning",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares]",
        "periodEndLabel": "Number of unvested shares, Ending",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails4",
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares]",
        "documentation": "Number of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning",
        "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price]",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average period",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "cvm_SharesIssuableUponExerciseOfwarrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "SharesIssuableUponExerciseOfwarrant",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issuable upon Exercise of Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "label": "[Shares, Issued]",
        "periodEndLabel": "Balance, shares",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r130"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r52",
      "r55",
      "r56",
      "r103",
      "r120",
      "r121",
      "r122",
      "r134",
      "r135",
      "r136",
      "r138",
      "r143",
      "r145",
      "r147",
      "r161",
      "r170",
      "r171",
      "r192",
      "r221",
      "r287",
      "r288",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r340",
      "r341",
      "r353",
      "r387",
      "r391",
      "r392",
      "r393",
      "r408",
      "r461"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/EquityBasedCompensationDetails",
      "http://cvm.com/role/EquityBasedCompensationDetails2",
      "http://cvm.com/role/EquityBasedCompensationDetails4",
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative",
      "http://cvm.com/role/FairValueMeasurementsDetails",
      "http://cvm.com/role/IncomeTaxesDetailsNarrative",
      "http://cvm.com/role/NetLossPerCommonShareDetails1",
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StatementsOfStockholdersEquity",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative",
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r161",
      "r341",
      "r367",
      "r398",
      "r410",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r429",
      "r430",
      "r431",
      "r432",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r440",
      "r442",
      "r443",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r461",
      "r505"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://cvm.com/role/EquityBasedCompensationDetails",
      "http://cvm.com/role/EquityBasedCompensationDetails2",
      "http://cvm.com/role/EquityBasedCompensationDetails4",
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative",
      "http://cvm.com/role/FairValueMeasurementsDetails",
      "http://cvm.com/role/IncomeTaxesDetailsNarrative",
      "http://cvm.com/role/NetLossPerCommonShareDetails1",
      "http://cvm.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://cvm.com/role/StatementsOfStockholdersEquity",
      "http://cvm.com/role/StockholdersEquityDetailsNarrative",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative",
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails1",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r161",
      "r168",
      "r341",
      "r367",
      "r398",
      "r410",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r429",
      "r430",
      "r431",
      "r432",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r440",
      "r442",
      "r443",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r461",
      "r505"
     ]
    },
    "cvm_StockBonusPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "StockBonusPlansMember",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Bonus Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_StockCompensationPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "StockCompensationPlansMember",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Compensation Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "401(k) contributions paid in common stock, shares",
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued to nonemployees for service, shares",
        "verboseLabel": "Stock issued for services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock, shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r51",
      "r52",
      "r75",
      "r400",
      "r461",
      "r473"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r51",
      "r52",
      "r75",
      "r234"
     ]
    },
    "cvm_StockIssuedDuringPeriodSharesStockWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "StockIssuedDuringPeriodSharesStockWarrantsExercised",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercises, shares"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_StockIssuedDuringPeriodToPurchaseCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "StockIssuedDuringPeriodToPurchaseCommonStock",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued options to purchase common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "401(k) contributions paid in common stock, amount",
        "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued to nonemployees for service, amount",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity",
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock, amount",
        "verboseLabel": "Proceeds from newly issued shares",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r51",
      "r52",
      "r75",
      "r408",
      "r461",
      "r473",
      "r511"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity based compensation - employees",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r51",
      "r52",
      "r75"
     ]
    },
    "cvm_StockIssuedDuringPeriodValueStockWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "StockIssuedDuringPeriodValueStockWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercises, amount"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_StockOptionExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "StockOptionExercisePrice",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase shares of common stock",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r51",
      "r52",
      "r75",
      "r401",
      "r461",
      "r474"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cvm.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://cvm.com/role/BalanceSheets",
      "http://cvm.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "label": "[Equity, Attributable to Parent]",
        "periodStartLabel": "Balance, amount",
        "periodEndLabel": "Balance, amount",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r55",
      "r56",
      "r69",
      "r422",
      "r439",
      "r462",
      "r463",
      "r501",
      "r512",
      "r529",
      "r542",
      "r600",
      "r610"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://cvm.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "STOCKHOLDERS' EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r131",
      "r207",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r314",
      "r464",
      "r466",
      "r475"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Member",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r361"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r361"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r361"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://cvm.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r362"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails",
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://cvm.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOWS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward Axis",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_TaxCreditCarryforwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardDescription",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards, description",
        "documentation": "A description of the origin, nature, and characteristics of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://cvm.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r541",
      "r602"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "auth_ref": []
    },
    "cvm_TopMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "TopMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetails",
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_TotalFiniteLivedIntangibleAssetsAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "TotalFiniteLivedIntangibleAssetsAmortizationExpense",
     "crdr": "debit",
     "presentation": [
      "http://cvm.com/role/PatentsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "[Total]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradingActivityByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradingActivityByTypeAxis",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Activity [Axis]",
        "documentation": "Information by type of trading activity."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_TradingActivityByTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradingActivityByTypeDomain",
     "presentation": [
      "http://cvm.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gains and losses on trading activities (including both derivative and nonderivative instruments) recognized in the statement of financial performance, separately by major types of items (such as fixed income/interest rates, foreign exchange, equity, commodity, and credit)."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cvm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "cvm_TwoSeptemberTwoThousendTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "TwoSeptemberTwoThousendTwentyFiveMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "September 2, 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_TwoSeptemberTwoThousendTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "TwoSeptemberTwoThousendTwentyFourMember",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "September 2, 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_UnvestedRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "UnvestedRestrictedStockMember",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested Restricted Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://cvm.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r95",
      "r96",
      "r99",
      "r100"
     ]
    },
    "cvm_VestedOptions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "VestedOptions",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options vested"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_VestedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "VestedShares",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested shares",
        "label": "[Vested shares]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WarrantsAndNonEmployeeOptionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "WarrantsAndNonEmployeeOptionsDisclosureTextBlock",
     "presentation": [
      "http://cvm.com/role/WarrantsAndNonemployeeOptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WARRANTS AND NON-EMPLOYEE OPTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WarrantsAndNonemployeeOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "WarrantsAndNonemployeeOptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "WARRANTS AND NONEMPLOYEE OPTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WarrantsOfferingPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "WarrantsOfferingPrice",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre funded warrants offering price"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WarrantsToPurchaseCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "WarrantsToPurchaseCommonStock",
     "presentation": [
      "http://cvm.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-funded warrants to purchase common stock"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WarrantsUsedForCalculationOfEarningPerShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "WarrantsUsedForCalculationOfEarningPerShare",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prefunded warrants"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WeightedAverageExercisePriceExpired": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "WeightedAverageExercisePriceExpired",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Exercise Price Expired",
        "label": "[Weighted Average Exercise Price Expired]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WeightedAverageExercisePriceVested": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "WeightedAverageExercisePriceVested",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price Vested",
        "label": "[Weighted Average Exercise Price Vested]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WeightedAverageMaturityYear": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "WeightedAverageMaturityYear",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average maturity year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://cvm.com/role/NetLossPerCommonShareDetails",
      "http://cvm.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average common shares outstanding - basic and diluted",
        "verboseLabel": "Weighted average shares outstanding - basic and diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r154"
     ]
    },
    "cvm_WeightedAverageOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "WeightedAverageOperatingLeaseDiscountRate",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average operating lease discount rate"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WeightedAverageOperatingLeaseMaturityYear": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "WeightedAverageOperatingLeaseMaturityYear",
     "presentation": [
      "http://cvm.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average operating lease maturity year"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning",
        "label": "[Weighted Average Remaining Contractual Life Term (Years) Outstanding, Beginning]"
       }
      }
     },
     "auth_ref": []
    },
    "cvm_WeightedAverageRemainingContractualLifeInYearsOutstandingEnding": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cvm.com/20240930",
     "localname": "WeightedAverageRemainingContractualLifeInYearsOutstandingEnding",
     "presentation": [
      "http://cvm.com/role/EquityBasedCompensationDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life Term (Years) Outstanding, Ending"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481648/480-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)(2)",
   "SubTopic": "40",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "63",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-63"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>88
<FILENAME>0001654954-25-000288-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-25-000288-xbrl.zip
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MF\\V;*I<Q',%IH.(?/#^_?L^JXU(.<KLQ*+5#["ZXIZA%I?08YNN="-#;^9
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MCSF5DGA;_<%"*JF\D% *'A>!RQ)ZV@]!UQU@99F]-$XE]5)XN"!=G.7K0.%
M@< #UD8&ATR15/5<>!ZF_CI=E^0 T_KFBZ4ZYZ+P=#ZP4[QB8C -0CF)%! N
M#B],$G;H5$A8I1&2DTE1XJ+UTN15AY12 )_&J(Q BHYJ,-_AHA35IW$I(Y#A
M<J,>X7?(U(L[Q\C3L446-%#Q\".J$G]R;:5X"M(&ZG%H.)P6C]=AK120AGI3
MB$@C2BF.7#Y!'I*&?7>85<%LH [:0(Y:C41"M.8&'6Y5<,N9TVI-I#AR&0=U
M'#O;J90;RIC,,@(I5GR*HB [U-E'=5QRRTN)4HH4E]B0(-6MI<*47G;Y9,ND
M.'#YC#BIURV14G4/1/I6< NXU$1>X=WN7Z3RO"$JJ)1"P.4?. @Z8U.6T\X8
M'$&Y#( W7*(AF]7N+(]4]X,BY<LMT!LN+2#4?F>&RO2?,T5E!%(\N/!>C$=G
MDU0?]V3LDX1&B@X7QI<\\.D,5R6 !BH(*1@T]8/[G76K#-*U"DC7<I#XP_UR
MD*X[D-1 NE$!Z48.$A>5*X!TTX&D!M(;%9#>R$&J<@0A NE-!Y(:2#G'3I58
M"AH7]BN UGE\*B^<!=K*XR:GDT+&I0F$KZ-%<'5H53KPD_'1%>AD:+WE<@J2
M(S^=KUX9K($J6G*?_2V7A%"#J_/;JP"6,XI5&D@!Y+(6B@!V9E+YG5$QBLK4
M4@BYU$;Q.Z4"_+0.P.(730L.>LGII*!QR0[!BZC=:JMZMC7CCI122 'B$AV%
MIUL[%T3E>&L&FE(**31<>J/D@&L'3@5P!G)T%'Q"+K$AAZ?S!]4 RFU$:J12
MP+BDA@)@W8XD?4V\Z)2XA$H*E^"+@KG7R/]/8:+_T9L0UFBGL1L4/M"OXG^Z
M(/AXLNA]!ZSLP"[? .1ZT0?B_P727CX?K8B"=E]R@0(#.Z^@<-RH"]TUN%ZX
M"QZ@$W8&#P*W?L3[A=9_+:DL_:&J5- $62T5!R9657%R<[&%0L&DKRI4=IV\
MODP?^^E[$>"O[+T)'T$DQ_4TF[MWH>RJD>">G)ECL(Y*FM"_>E&['BWJ#:Y[
M-X/+9V)&/%9A(9&O&@M1N\HLB.]/41P\:D!'?5MA//'%*J)!25F3Z \V/^L,
MG[V/2&W\=)OXK[H<)/>L* T>D=,?%894N'U%!?!TRT70D +_GDZWP;L7L5*/
MC9H\%%T"I01!3,]^U06!71(4&K_^3C>\'GH^6;JM>XY[OH._U51AN6ZFETG2
MR<N0$=Q;I<I/NM7K,5%!(5&+E\V+]"U<2A,C:1#\K&L2DOO+E(:-R.F/"D,6
M7@Q5.BAW(U,?61Y)^JC+ %W.+V6 ]?%BHYB^5*N($UE+]C>I WUR/9L:]A$]
M^U5'^3ZI 7[ZEJU _U$W-5FH#K^0A:HS0'"_6-W)5T_NU%UE+Q";W9Y8T]@D
M=Z"I;7XA.?W!#QG>?\;2!A U_&MXI.X9&?MHZT0G(\B(>4Q@SBEGGRXD--BR
MZ!O_GRX\UZ=Q";TK\,-#<.<3#.(B$WM1,80(V#&W+) )/'*H"N*:@.#HP*Z@
MN^>IAXZ4#(3V'XB'/79YYF?7\4\1*0:20KG*'FC&>0XRA*Y=MI,'DE9NE9-=
M#VNRND@+;?K!?4M9J:$5#/12F>>.R3X10%LM=]&[KI%LA;5U\1.+\EH L@=B
M4T)\9(Y]JIT5&YJE(PFKC$28/"/7P(3Z/X&D]9H*U:  '>OU=Y*6/6JJ)6QY
MRW9"/H71;9I89'S?.>X. 7V(6R2OC*A1& N8"PRH1(*8J)W@C!SB >?4ZIM3
MFTXXRD]X:5EB/\N)VBG:RG4,A$QRYSK'[0%M= M8#I]^4,9A*UBYZ,ZW361&
MJRD[*5_40Z,SM@[GV>G\HA[:.2$B4[G<27!7(6P4WA(&LRBJ$+83K)7O&@>=
M1%;F]KS<@9N#7.K!C;&+#,]Q\\NU4I-FUZ<*J[D%6:E).:@F>FAFLXG-!W7"
M@TN=S23ZR%PJDKCNZDU:*;7H\QD1F 2V5<LWZ;8:1EXSK#]@"WLXLPW5[J"5
M&AGI)^SI%OXW91N"Q3T&%H>$((]05T-)*2_LHY5Z299X(,@]V&OW#MN4J1FB
M://&H(2RE3*FF5P^6'C/QDK0"C^#1U;ZF3(?"5R]62NE!QM&?(NF'S;(?03S
M#0QC\ROV#HE7G3)YB16LVJR5T@<@@A3*J[Q2BU;*#!,3N#%Y!+?.+:(HLJ7+
MO!+VTAE,8-I^2)VT/3JF\W6OT5,K=33#L*V9]'!TG(W;HF?OP4HM 0E-96_.
M=FS;/W[PH(];VL=+9<A^@VZ2^P9=AN?;M%PUVC4NZQK15(=U'IK.B:8XXB^7
M;F C-G77#*[.. ?_<R+7;]ZXY!OC@$R?AL+!:?X(O:_(17$FCGTIEY.Z7M,6
M20S3\Q<?/*X=!LQL,YOO"B8L=<.)3/S:_32NBSMZF@K-@%?.Y[PG:.=;,[Q+
M>RQ*Q#7CT*CTQ;E-EF/6/70=)S+3)76CY%=Y\A'$ZLS% 1[N3V ?XWS&4[!\
MXNFE1"J51OCPZG5S-BL7&_$DR1=699!.[U.XZ;^<P1,.L!P#^(.$Q7QQHW,B
M:SRYYR;%U:W)QTHD4"-MI1\G9C<[X4M)JEOX5YS_!8_<MDX4; L"LXIMFG\8
M&>RO0FA*ZAO%Y0LBX"6&'G'$;+ZP+H?4]WB-+32(P4-^[APWBLW2FVH)39,;
M$SA@P1N/ND6C[#&"/\PQ?L0FLF.K)"-JI3U*+;Y@C29*SSXY4"%L>/] )XCP
M82]&=CH-R!77Q.%W/;0# 9Y_]-D[[,.CXWKXWZ&>XKQ&074KCR!M'5@#)<Y]
M6H80F$C2>DW;"&GX)=ZO".\/%+='Y.I[E.8_V CCB:I.WW \-$8[1,\Y;/5G
M!LH=?@9^&3P)7.P86?( 8AW+6;MU&T%FR79!4E90WLJ5NJ:3;;F#:#M (,X_
M\>5M5/\:$:2#%TF?[Z)'9#GLP=\HU&642BNE:2<L)3R/$3%<?$IO#^KDC<:E
MHV / [,^.M!\^]1>/MG()0=\6@5N)AB\V-]0)&XVTH8=R !C3?-4L=LZQW8Z
M,U!(T+ 5%[.F/Y>SSNH;YGSA'Q^0&_,4Q#D1VT65388/.9ZX?$9)?:,N=8ZO
M G:;YC+G,64"\^S<4*)L,K]8QB!+,JK)DI VFI7(L;A&1QT<>_J@VF;O"O@Z
M2_!/[>^P>Y&E[U&]FD!PB_;8II0%PM;KJ6&K55N&"?O_Q:J(NVE8#[![[QSW
M2/TK]@P^E5,+3QY^IHG/5+:W0H,FK7P,14KI\5>SEKML.D65N)7N:6 KLP+E
MRIH]^QL>$8B/0]*ILG7&]%L/['1(7,J>HL8>3^5FK4SI)>[Q<E=3$R_KHLE$
M<_H07!1_G\.C4"N:2DFB)C725BY (>L+)WC_1$U0$74K95W"2#H]^I([V'C.
MO:NI0/>_)5^"D%3$#&DKI4S/0790430YHXIVOFZ1\[SFNN>[L)"HGU7@G.5(
MVN6 9B<3/49'CYBM=0\52%/:H$F;7\JG DRE#9KVEH,3JF2NFVCKS,!1M!PW
M]<R@H+:=CDGJV,;0--E7MW1KC!X\6I+^A+/HH(>T12ME7B.:::1YM-0#U.0D
M5A+EJ!"V4L)4@GFY*W\17XVTT8QN[B%^PMCDV4,V27E52I2M1"Q<570)Q6<N
MW.#MU>#L46[YE1*V4L(%\B*&,\Z&H+R5_*>9%+[M4D;03N\I,=_)BUD"P>1D
MC686YJ"-\UQW?T4>?54X_;J-3@[LH34YT+7Q"*LD\PF2RNW:"2.8A!V.OI,<
MO4B##?:"K47?.\U_6*9*@U9]4R8RY_>$G74:)5\_!>NGNW9PDI%)E']11:U)
MLP]-0E:7NQUBAS+3QQR+*AM]-!+R5'K65$;4J,IGTU_NI^/I]GM^B8@J6KD4
M@A>P4/8%K+PTJL2MD##,021W6] GFQ=)UB)?4?L%&].A^?Z7L1E?J)QGDZMH
ME,T-#(/(]SR3N>(6L#B?BWE,REO Y&(A9C(I;P&3Z[68R:2\!4QN-F(FD_)&
MF0Q?6J:F,\^GH*I15E//+/.L"JH:934\%T''S[,JJ&J4U20#%'P]ZHF^YIMG
MNI2HV47&/KGCV#YASP&YM2:N;I[E]!6VQ9P74C4J0/H]X?2Q"*$<2L1-.SCB
M]YP%#D\Y88O$B.=\N1 <6;,6/OAP5NJ[69RA+Z1HEO'PG&J>VVQQLUN2NP=O
MW63DW)XDJ&O6*YDL.6\D*6J!5[=>AP%GD0>:JVZ#CP?.T7#OHN .Q0)G3TC3
M!N8%JN9K&F5T^^1LT,ECK,#O[<'Q";+-[1.0G.\<G[-ER@U:+!;L(]7$2C5H
M5*Q[^Y$='<QYMGEA)&0ML$1%@7J+6+R_%_.8E+> R6]B'K^U@L7<])/%9^VP
MW,'#VO1A"OH0-Y4:Y]P0U09M<*0*?*A6L!@=R<GSF"]OE,E;Q_.<8Y[%;&FS
M.Y_#.<JIHI8X161I<SNPN+;IE$%\DXD@0\#5-;O"BSAM%YOT% 8//6F'-PR@
M9KX$(P!=6/_?9/IC/[C@YZ?_ %!+ P04    "  .@BU:M"\Y3T00  "&Q
M%    &-V;2TR,#(T,#DS,%]C86PN>&ULW5UM<]LV$OY^,_<?<+X/36=.MB7;
M;9-IVJ$E.M&<+*F2G#;]TJ$IR.:5(EV"\LO]^@-(2:&$MZ5)",QUIFUB8\%G
M]UE@@>4"_/'GYV6('G%"@CAZ?]0^/CU"./+C>1#=O3]:D99'_" X0B3UHKD7
MQA%^?_2"R='//_W];S_^H]7Z[7(R0+W87RUQE*)N@KT4S]%3D-XC]JMKCZ0X
M:;76K3_ESWF'.L=GQZ<_;']^Z1$J%4>9#/UE>_N;'NT/Q0ODLYXST=/V2;MS
MTCGM7&P;3>-%^N0E&'F)?Q^DV$]7B1>B.2;!780H<)0K] XYW_BH=^\E2^\A
MP4LO8DHAYS$]WO;5C1]>DN#N/D5O_&\1>PSJMX;N#%VN2!!A0M T#E<,"OD7
MZD?^,7+"$$V8!$$33'#RB.?K[L(@^O,=^\\MU0]10T?DW3,)WA_=I^G#NY.3
MIZ>GXZ>SXSBYH_I0O7Z['DS]>XJK%43,X#X^VDBQ7D1R[;=OWYYDO]TTY5H^
MWR;AYAEG)QLXM#D)WI'L<8/8SXP+$$/2%NQOK4VS%OM1J]UIG;6/G\G\B%H#
MH=P>21SB"5X@]O^;27_[3/]Q>>S'RQ/V\Y-N3%V20LPD[A.\>']$?T][[9R?
MOCT[97W^<Z=-^O) /9,$RX>0JG92]GF77LC,/;W'."6:YPK;UOG\,77E*+W'
M:>![81DP0L&*R*8I'8%L<)/18O2 D\Q1="92"]6(:)K&_I_W<3BG$XO[URI(
M7TH@DPO7B+#KD?NK,'XJ8S).IB*>T>2#,^S_[LSZHZ$&AJAIQ:</^K_<]'O]
MV6?-H[EV55E8+9=>\D)YIE$@6- Q$:6.[\>K**6Q8!R'@1]@+2VE.JF(^%<O
M26C_Q(GF0QII:2_Q"\:C!\B0 \E6Q#=.8CJ8TQ?Z##9>'IB[:F"I1*JB<6;N
M<#;5 =AM5?&9-.#'2SSSGK6.(VA9\=GY%)4ME;KQ\@%'))M6-3@T4E4QK?WL
M$D=X$:1C&HQT>.02%;%0]99!FDVAU-NZ<39"Z5I6/\@!DA6Q37#(%L8T0*<O
M,SI.B>=#!K5.K'*<*AT]#47,*R](/GGA"E]CCZR2/!!JP"AE*N(9XG00$S+&
M"?.-.)K2/0/6X%'*5(YEMP3_M:(:NH\ T\B:'R2BUAI9#QEA9]YMJ(5=H@<#
MT18$42]8%1F=E*@)8&!$;>N+PB ,TO9F(C(($TC67$0$803+FYC]00@!DB8B
M 0@;0/(@\W$/IUX0DB&;N-+@41?&JG5J<GY>/[/*!+W7Q0'0MFN VSX@7JB;
MO*HO Q$1YA0 27/8H"8MTT4]$1QH/&'C6A'H1HFD=:T8P#2II>I;V\#8D0O4
MCD3'DD*B=BQ0M@"29E:!,/9@PD81ZE@%2AO%V*F$L7,0C&>5,)X=!.-Y)8SG
M!\$('=DE>ZD_TYD_"0P7W(&Y71]L3H)W8!RI;FXJT8-QK%!'>$5/AK+/)8&7
M[:;V['39G2RX Q/Y"]A8@XB:R&# T$%$#:+3C7Z0K$%\4$<LU4?-;PI*9W]@
MXG*4OA?ZJS +Q0/Z]YWV^)ENG>9XONF%(084 *5!RMJ=YO^T4>M+Q5GACZS.
MRZ63:?J"^M$B3I;K%YWU@Q-7 !5 =BBN;4$'_?.E,W"&71=-/[KN;)I70VT@
MA;&_ R-DQ5CQ7O$30T$HC*SD:N&1VZSN:D5:=Y[WP(KASD]PF)+-3S).,S[7
M/_C#(81B[:Z2I/ "/O1N<9@]\8]UN[UF)Q:0LN(7]B^;L1^]D#GA!),T"7P:
M>]@O:-#<_4&AI5RSBMWN6J+@1D[BHSBA(>;]T7:;X27^CO/PQ7+K%B>$)5M9
M-ZV .LM&?I'$2Q4M:Q+B.A4L$DO1':$GS&H:WQ^U[;C!.,$/7C!WG]G"'FL=
M5](<0MN95=J4>C:'CG[$PD&<O-!8)F=AMQ7$^.=6C2_2JCDV[^&'F 1TEP";
MNR7-(2Q<6&5!J6=SZ,CAZ6(GS.#?&3:XQ-(-M_!5$+%UU8!NA7!643]:W!"<
M@9:;72D$X>)[.UP E&T.,^LB[NBN'#<:,0@[/]AA!Z1P<_C9O#ID6<6T^/Y0
M&:[54A!VWMIA!Z)N<\BA(YVJ.J"[YWD_2KWH+K@-<T<B2GIT<A""VJ?69C>
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M==5!$.+4U*H0391 ZJ5A,?JPA2;\/ 2M.*;X&JQ &!;\*LG\HIL:5A\=9"!
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MP1H5^\\O>P*)_NTI0AX?RCZ*?B+\/P7HD2@:^<R:?&:\()_Y?](_7\,=VO\
M".67NRNA5.M"6RG33XI0FS5^BR(_="^#["L]"5IN5A5\KY^_3V"4M.KR*K]F
M 1["!.Y;0<]S:@9]@]KU]HE/=R]CJX_:]7*.<P#0215PXZ[E]>F>_.D:_ZL
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M/^Z?(.Z4[2&AV9#8\1&[55(FK;ZJ OR2QRKAL$"5E$&*O%?*"2@K8+P@QVQ
MPVX/N[WO?-J'D)=\PZ'1J3\<<$5UR1%8HQU53 )E8(2 4AI9>C9!<(![MI.2
MV,TBF=Y%AP>QO.+D:2S0 @DLX5K#:---K9GDBP@&L4\2L6OUH4JJ.2E# +62
MH%&BLT@W!-#$B1M'>I,Z\LG'B]YS<AE%870>1A%R"")!:H<*DVX'M@Y^U9<5
M<5BD2[4@)1XN<46>$T!YP8G95!X)V;G?')YWDB/@/(GNP$D16C5JPGZW0#4$
MD"3Q$L (#8SY5>"$$39I]!(0B>6B\_ 0)!'VLEUQEG -ET[-4!*@J"Q2%FOT
M1P6E0*4*K#1"CT#*# BW 3U[@-^N7&SU?,]G%\YJ#(V07J=NU8 N:I6 V!I]
MDN,3:!)F D4N<Z9JX[JX5^+T?Z[] (V%PG)I=:J.!&Q1;3B$UJB,&)M 75+*
MX_\2%C"V0E<F#:2<F-:5B:JN3"S6E4D+79F8TY5S_,]M]!!^#>IDS%,:T),J
M4*Z6G,ALTY$*LAH-(?1@&P'"84X_J!NUC6ZC\-4/'+%O+"(WH"D"R%QU*=':
MIC-\>#6*PSQ?K#D9FSGMN0WC!.[_M_\BW5?QB0UH#A<N5V\*E+9I#0]<C<XP
M%H!Y]&^5B*';1 @*=*3XLZ9+&AQ(QXL9N=\L&'D.G,H%##K2F$;_V%XY7K0Y
MN#YN9Y,D""N9)'HK(]8S[O5P,RT04UJ@$[7@RAI"&$#* 7(L^F.R*0C!;?W"
MKYHN;E8!':]MGGZR8-"K:"I7-M,!UG[_/OUP5G5)#/Y$H75PR\!* YS];,\@
MEQ")!CHCTSK8Y*/[VZ<P$)^J5$GT#+<(6C;>Y=\M&' !I/*(4S) Z4R$*N^1
M<XBPES&>[![\9,\SW542/6,N@I:->?EW"\9< *D\YAD9P'2 $FH=\X<(DO2Q
M^[?G7<B3HO2[GM'F@LJ&NO"C!>/,PU,>Y)0&,"(CD_KRF_.$(2&!3\8GTSNY
M>1#+$SQ/8\'@2V ))WI&:ZJ"TE60(%+)RW]%%S"!Z;4HR5DNGUSO0;D,<OF$
MG$=K@:XHP!.>B1]YR/4DF%UE,^'^?_*CYRN7(U[I=ZVN?Q%4R?%G/UJ@ #P\
M(J>?$($KM\<1]F"\HT /\8='"%_8,*-]$F=_.8UW^H>_TR T2?C:>I_\  :.
MC]W8D*43"@HO-F,=7DO:B$(4J D?&<N_SU?KQ<(UJ&+M$9>5\./F>G-S?@GN
M_W)Y^7!O6 <W<8R2N$;;RD3Z](H/+Z]!10K:\^/1=#U?6: K,FP5TW1_;XLV
MI.N?DE)4:'7KA@!L545*A'0T1JOU9#JQ1E.D$$4EHR!E_:-AS3F'\1/YO\M_
M'OQ7N,? XCN$Q?"=!+GDATW@%O^0HQ1T2L<V]6EB+\+G-;93@U1MUDMGN5M8
MH-D]BE*9 9B8/>1 _H%.;(;GPFV$7J#O7GY[04&,^#O &EI]NBL%F]=)+B$=
MH!7RYF// EU3@%C6H90%(,9C6G6N@E<,.8S>;I!(8XHD^A2%!RVO'_G?:9]/
MG?$80@O40HRL$D4ZO+SL?12# WEZQL,[Q;M_@\\O?[J@9N89!@</DG=D^KT2
MW$91+M +V73$!<=!(+^ 5I_J2,'F=8A+2(?,17 Z=2Q0)@6(E7M=*8M8971Y
MR;7>,9L>\_G:66KJZR3W9DJ]:US$5SD((&T!I^ 8V[2C4I'0V Y*33?LV5:7
M4965X3=&=I:%<_M\6J.-)K!H$;I&,$;T9;"M]R5&%*1 3BF'/BU1 )[7&0DY
M':O%SIGG,@;-J9$RT+)FI8Q@3S@!?1?N0^A]P#Z#'39G^X+(!;_@L8&NU?#H
MTS8E\'E]DS+0@403SUN-+-"X!E#+.G=DM5;K;J,08TS>;C'N!&_JR3;^A03*
MQ5L9.8O./7 ]].)66$S/UB.X7D]F%FB<.M+JQIAQTIT/RMC.0(#Z/!AMN9#Z
M";KV7Y%[%208L[_;LRD4BU6MCDGK<JH O[2B2CCH,"Y7WG0VM4#AFF"MJ!Q,
MB-_NA#%QVZ2*IFVS>H,95/>K)UHJ)X3>9*TK+/:*HEUX?!918><J MM\\VH@
MWE$=%459S44].BC2V(:)78^PL@'+6$"V$SMQ239C6D*8TL'@D#'G#"X64UT!
M384)78OS_88W)2-5WPEFHN*M5&IL@Y,H!5>9U4=J\_.9V15QX(H=H"-OO=C9
M%<TL N.',:W8U!5[F"N+_H!ES8"/YQ;,J3(>0732=%#RVH<[?^\G>%' NT-:
M_O8IW+LHBLE.,7FKR0%29]>G(TU%RFN1*B^+#ZY6#K3!-6N'NG(]ZFKS\>KZ
MZN'J\AYL;B[ _</V_#__LKV^N+R[_QVX_.N7JX=?[=%6M1PU&8,1C53(5A-3
M,VLR7DR\M5U:)\4IREO+\9M.7MLX#JF!%]_"-[C;UV3LB(@UKH)2N(55D4O)
M[, :+9$NMTBZ4BI@K"3+ICS@A3&9UY_H@-SJC!"++*+7JD5RT"5%XA.G&P6X
MFMMPI*<(DZ-.A*VG)##G]9FJR&@]'5$UP7_X^^:9*NS% 3V$E\\O^_ -B;2D
MGGQX)5&%3'2DCI;V_62T],8F\U&;H:Q$00\()"% &9/Y(Y#CT76F[&]RFR-G
M,9--(((N2B<HT[-9[4Z@9X/Q44<J3R@(=WO_D=:D.#OF,M$W]7HM4M$]L4!1
M\>J83*46J"B?G(,.ZFZ^]G8V1!R:8*W++FBE@EIW4&H[)RJUMQZ/I[KBK+4!
MP#J0\IS&_8G;NKVXLL!F]]X--&=B672G@JT25<P16YGX>#1+M><ZM5R&71;Y
M>4\-"[/&H]T:V7!%JQ%8N>^RS^M?@!(0>N_#AZG51P4^XYZ,7"=KF5A"V'CD
M(1LN<S6$6^?2O /-3)Y0E#/@]2HI8="HB[6P"THHI&9GHI/QW+/AFH\JSHK:
M$3XU-TV/UU/C[K",/ BAH\O7:>(A%]'Q76,K7>)ZT0PYP2KJ,-%U]TO1[3V!
MDOF['=U<;M26/ OK)R3QF9RLGH<!65!0X.#/7?BQLP_C Y9;< C9I@$]D=UV
M8F6QWF;<++O4FTVAZ>AO%]R50\Q36ZP"0;XUXV6E&F9QV)&WT2Q3HR;+8>J,
MI\B&NXJJ."NIFO9E7]SB9A!V@5B&R<]P?RB7NI12:BUI(0):*FA1)F/WN-=P
MM;1A!U0+D%/,@C& F'"<@?]W].-H#%Y@!%X)]Y\ _O#9:#0",7OB'!Z2IS#R
M_X7</X'C'_TX)H>AQ*R%@SR!WJJ^T.EI=YGF5<DT5@$20"P4]BG1,-=F-Q_M
M;*A")4?'6P/#0*AJ"Z9J(G5;3,^6J^79>#2CFC9;GLTFD[,I_D^I&@*8@'L\
M$(C4[P;3T1D@JD*I\#^F9P"SOB!:S'/_9CHMQ'5I64"XOX6^>Q6<PQ<?[UA$
MN0LB:HTI(7+ A800/BGSFG;SW=*&/802R$HRR)$)D,I '_P .(S/L#K=H03Z
M 7(O813@F1!O'.?P?-C#!+D7R/,=7^3?J3#J4S)U,?+Z5L^5GG"N%@L;[E0T
MQ<M)2<KH@<L8C$22JOZKFC>>YAHO74?7PE8;5ZH#R0\OQ3FNW]&+T(GI=44\
M)K42F]W0-5 =;0?VS39O)VR54!0C."-/0T7^[I"0O%22,W8+S5V0JKL94!,-
MY/*PFHR[L>OI"N@TB1@K0*[,\^W#YAJ\K^L/TM%LV#LV7<YIK9!3&U*PU)'*
M MET,\,83*=NY#:$V(QM(UK\W*5[PUL4W9.-6OU64LQI9&]>)XA@NRYB8[7>
MYY/9R(9DH<: Y9OZXW;>'CVD,L2;8R2AOB.J'$;T3@1<H&]E\K1TRF*L[2ZS
MHI[)@<KUJQ(7LDW/KF@02K43,FJ#^E4$+-4M1LJ&:[E"C@V7"I5 *ND4"Q_:
MID_;4R13M0<*+ 8UBP-=JEXY>I;A[.QFR(8J?.I(E13-GC.2XGE10X=-E=G4
M,5X3MTV-D]W)F;C>V(;;0VTPUY[_V>*_%853=.'JF$QIHHHC)^=@59I&D^G*
MAA2%)EAK-<XVCXXGG-2IDS&8U3BQ:R>F9A$'M%R-;5AY57&J:ID5/AY/J'HW
MKY;+K*[5.'LU+,QF3*?KN0U9#8W JJJ>/5[?5>"$S^CX+&%-KI^06F?)/"G@
M8MD\+BD=,@?M%F,;L@R40%;S^S8/EY\O;Q[NP?83V-Y>WFT>KK8WIA\ /-Z:
M2=]0JGL94D)OX#:4"#3W%E29F&W])MYT94,@5Q&F^-935LO$=&VE.Q0CW(/D
MF;<+](KV(:TCGDHE3)Z0\NC,55$ 7TQ3D3"D-8WF2VB#,]8 :EG+,E9Z4N6>
MF VKVI]1@+5_CP7:N,]^X),)0Q(!Y<I6RZ5/W10%R"M<#0L[^1Z-T,B&?(I&
M8,M*ES(#6K$8P$(#1I(K*B9::;EAMU9GWD);U*DV?:(&(S\O*JRL-+:Y+JK2
M&G55U'7&A@0',;)*0L/)$\EHS:1 '7$P-_TZC.5]?B)C&\/Y&*W'ULU4$4K)
M+7A,:\L,K0Y%O9Q&9FD[G;&AIH<,FV2N,FKP>T+_!U./-"0(]X;,RRZ1L"G@
MN,[P=;C6K.<#]$B.9F1358JQ/ (9<;:6VO#,DF <Y&+JC2.U4A0[0D9\7)S'
M%E+%N,P4XS17R>;K)@R.CICI9$%:^B(/B!D3N?[4,6FN8U(+OU++1,C!KFI.
MQ[NE+O=!NAXTP,JO:>*G2T-JHOY@9'&XC4+/3T0+\NE7=IZT\-R1-;LL$;AR
M;]^@Q 9GK=K30GDT/]6HK@ V9+1Q(%6L/!GR@N=U1OYS?Z 77F]9<:K*O1)2
MD2@,$@Q@SSPWME(,40;E<^CZGN_0@J!;[Q<813"HO HC(]13UD0.,RM?PJ=*
MGS%;HHE)I5'%5]:@/ \I;/8UY3)BH[$VR_=-!8*TQ--DKFV9K+74$GPB8PW@
M*_3WV=1TTCQ!<E2<7@ Q;,VY8R(36Z=-;Z$P8QM\*@&L>O/>_(Z@%B7)[BIG
MR887_OZ0"!.EA-3Z%*<&<%Z%!*1I;=/Q<F;#K0HED$(3A#W[@N4!'\ .QK[#
M3NE84X8U[!=$GBU'[N85[T(>T<V!5/'8>JF<JKE3C5O1IY$M!<QK:L,FTM=[
M=_.9#6''3N#+FITUAA=7VEI!NPLI6!:J^C$?:.NU*,BFQ*OS*G\#88JW^Q48
MF7V;[#QD0^9-"\CRY"X+;Y(?97P@'DA=1Z1$!M2M (^K5Y0B/0.;>JYKDP)Q
ML%4T):,%OU%JTR[@$<^U'Z K_$_19H%':$!!*C"Y2G*D2FLNSA8S&^K[U>&3
M* OA )3%&HUA!O(\?'X) UIC]9M?JSQ\'@-Z) //52D> PL5S*<[*U[U;@!5
MK&B,%YR8P6^$W;32Y:YP?J:5  5]P*$S<H.V"%)P;981L;3QQ70ZMF$MJX$G
MN"!+Z>TLOBA5EQH>XX48Q6HD96#.*EQ :,-%UP90):49">^'JP"<6UF:4:IE
M(F)S)1C%>L6G9%E_$V<*;8B:J6"4E5>\,%E>L>9F9^6.Y Q+-->U,KR@R ]=
M[ U$B>R\1 RRW.T?X9X\%I7=HC/MNM;?!C9U_[>Q7MAPT9(+JG(:PJC. *,S
MDV/8J33E>+9<[W2=$JM.P1JHPHD(Z9/( ^0,4$1LC"\.$;;+MTP2.OKTQ^QH
M^_(;BAP_KLS!UJWHR3;H(&"6BM"B"69?Y[/QTO1S*IW!5\+]C!R@E#SN9YEH
MHIVTUDI7Y90V8E0W%<2K44U)"VE5=0<9C:WU@5U!,?LPF_W4@1;-P.Q]^X\H
MP/YM<HLEDJT=C9K17$.ZA8B59;Q!&RQ/;[F&4QNJ\W1#7U;EV6C\^W_\@3Y7
M11-0\&8ZIL\< /+, :>\F9TJ3J=R9PT7MV)<P>L$5-!O41/,,<0[X[D--PH[
M@>^@W?8;</;W3V%TCZ)7WQ'>9VW:B''=KA%/V7176F#!0S1;CFU(A>F"O7H@
M@]O*7D1*0A"$ 4HG1PR\, (Q:^8=6.V.:BUJP[A6RX53M==\O5@LO(G-.JT"
MO;U*VV^J;]!7^E,K$YUC-J[$ G&43?*1D^WT%] ;6^QD2#%7"\&%#D(NUDW<
MD2!Y0B"&>T1?D7]?;G-+92WS&M=5OC"JAK8TZMYN@FPX'&T!N:VB#A;YO<(C
M&I"J/%08O"!XR#\F_W+"-37T>B)F2J"SX)B4F,625M/ER.3A:$.8926:C,8S
M<.1G"1W@V,* @5D!Y@U55G49,WJCRE,$7:,\C)A-[2D:(=/A_08PFRJ/S0X=
M"Q(3[?X(8^22Q#<4Q/1B90N3+6K(CL53+J;J2LIOA96IG,W0VO9E505_6</3
MM,@=X2++ZI$-? #'7<P UO$\C,F5PP,I2'P5$('(*6YZ48$SB6OH]5A')="9
M=902L]CV=.*.3.XJ&L*L;'SIW3P_9<':$QNZI]VPEL;,T79'\A5%NS!&LH0'
M$;QAJFEP)V/F:'_"O?KPA.ZQE[WU<@FSF\"]C="G0^ B-SMQ%#K!71K3,XV[
MBYO-\?8M,:=U/49+:-@ ]"5#N]T;O>?X$J$/'OW L=[#@(YY&X&%7GN7QNS5
M=KZ_W[ZE].K8:N&:/(CN4X:^M7VP&$:6&;+UU$VX H\>W54&GZEH+0,[G=IY
M:Z//<K> 6G'<4W:B8GKMIP2XT$PJ\!C7*+[1JV5(AVD\GYC<'[: VEBC!K-1
MM[@'GF"<[3H^OFT]SW=01-Z>OO CY.!F) YG$VY-:VYS@8Z+K#HKNQB"1I.=
MR0MVG4!7EM&T(:*#;,7<O>%_L\;2FAAI<T-ZB"KBB%W")MP6Z:/ Z5-G9;'4
MT72V-'F'HQ/H3OI89Q^'#(XVO64#U_/Y2M<PL:L?EX&TS+088NN[5T-'H]O>
MNW&=Q7RAJ^Z;6N?7 !WTUDV?%8K.8?ST:1]^K7ON2\YBI!Z1$+J@#%&%G@[9
M:#V93:RJ"5*+5%YTZ'QS_Q?PZ7K[B^D7Y6Y00@3!._U7'SO&']^^Q"1D?BQC
MOG$2_]5/_-JGYMHTI+6&94LQ2X4N&[;"',/9SK7BJ<VN^"OU)(Y:##[=;3]G
M[R3>_!ELSA^N?KYZN+J\ESQP9\OA"5JL9CM=D9,$+T9-CDZ.X"PM1+YQ_^L0
M)\0DQ@_A'2)CX^]1H?;J0]B/B1GF4SK+A@S75<5J(_U_A^THUH[GFCS:T2=A
MM;;)\8LD'3K*ODE>@F'U74F2-/ZW@[\*#B3QP ]RK[#!X_=,O_AY@5XP>I_F
M0Y"G_IY) ?M_R5)HI!SZIH\"\/PLD) S3PTZ[MJ&55D9:%DG\XQTVPYSK):\
M-D.F@]H3,P5*_>_*<(#R'I/)D;'-Y&*]6]OP9E$MP(K_$ 8?J+':(Q(+2M^-
M,?VJ53%5!T^'+-B?N[FRC<[WT!?6OFS8AL87L=H(5W@OJTD#Z4WCU<2QH0I4
M!^C<#*T/++GO!;ZQ-3EW)<FT1]PL/=5\"JIZFJDX%7/AN.["!CU3P:B<+CI(
MBN@Q*^,\NP>-W(>P_K9\8VY=Z:.-!3HEDRJSLCC$ DZFID]A6H,6%.-D!S#.
MJ2FRD4AORK]@!M,+<N!$Q#^X0.Q_\UNH.$9)W9Z] ;_.IRD;"E5\M%*1F17Q
M]5:+G0V%2EK"+FOM[[-V_O"3F[9$-KJ0-F$FUE>5[#9"I*R$].51.0\[JQNO
MW>7@8]?DS=HFH*O)?)36EO?@54>M81^8-2,]*9X5SV>I(^4\BYM:AM]GS'\@
M1B+3P+0!4^]7E\6Z"E[Q%B*,?/XU92D#J[<-%\[P5UZZV DAXLK>ZO#RLL=4
M+())-E5W_P:?7_YT0>-+SS X>'B)H'>TK+,?G'%LTC%F+4=G)1S;$,I4A*EJ
M,'+,MAB+"_02QGY"HVW,;U(;KBH?VY..)R,TLMETU 'G!*4)O7WNA7CD6O2!
M66/1LQ*.;7C7JQE:50N2M@$8O^EW421[L&L?[OR]RBEXTT:LV%9+Q%/<6W-:
M8)G_*SC?V5#%J OVLCIG;?WT>S>OS?M3.[9LM3>.0W(EXUOX)GH,KI:)Y;G
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M)4W=W^V0#0]%=\5?=_/OZN;GRWL[;OZE&<$/X<;YY\&/$)89S[[DC63D)9O
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MGZG=;C6=VY!"-9QDL@F5A G< Y2& %W@T0\ F/N")9-MZUT@#T41\=J^L=[
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M@XO<3UAOR!;LP(KR5CM(?3;T]R$3$Z7O;N+/H;Z^PDI4+M>+A0V%#H>63WH
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MP";"SG/6:PNR@(P*7[8"&3N C)\]9@W(O=3<ZT"FRTACKR/>!.[E-])=%6]
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MQKMFL'F]B85#2],>IQ18Y7"HYR'N?CB4 KI'T:OO('[U/G*<Z:2%BLDYP6-
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M'5T!C)H5N3'FWI,E![$'I1%J)K -%J&CBDU,%\]M!+2Q4;#%2^"=,I,DDZN
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M@GY$;\89TMI:7,QI7J\G2Z15H6TX)6O8.;7GP+0!0%H I(GLKN__08=IRM/
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MGZ# P@+).[AR388L6X&M)A\>&R!3_CG7!/GOKVDC ^C65>!$]+XXW).;>2?
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M4F-DPS=%DY7I"\<M(5<*C> &3A%@\ 'L2"OL?2+6CI&\))*A01_^)/AX]J%
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M.7J>XR3@FAM'SXOLQ]=H#:-5=D\VKG7TWG2,]1OTG/OS[IM]-NB3(2XP6W6
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MZ&FA2X%KVN3'R3[++_[[E^GM]/YJ-GGZRVRV?.H;KQ;"S,N)O,E^?(;P;2L
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M@%>J%4PWZY<DC?YU6,1,AIYV(@%AFCNF:'!>1M8B%1P3?CK#O(Y>&^9M.X
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M_4!Q9<G?2'\25&A)!5"0LILK6]/YM8@1YQ&V;PE4W7$=291,'4^Q*IBBDM2
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MH*VK;HX_<*:15,<NQ"*D_W@&(# <U9!$OS!.Z:\AZ$BC$1OA[GPVQ6[AE4D
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MEY.'V^D^1D-PB,8)Q&P:UVAOFZ,R6@\%0FAIU:OSQ=8@EM @5]5%WJ;0^^U
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M.%G\%3*S814D[V9;HBM:TL1'*,AN\/2G01 1&L$5L1V3GY0EI$;YPMT?&,A
MTAV]U5='52'3'N+PL0F/"#]M(W^=U\=^3>)*G6LZ>QJ[@4 WK4"2)"5MN,*/
M3&PL0UEZR,2(U\TB+,VY_G;4V!78/O)E22W(S;S6Z,:;0I]L$O,8"^J&$*8P
M85S3'2KVWG-U?4 0AJXM267>MNSF@-4KHF'0A7IT,\(3YUNCI[V 8_BV+!4M
M^RS/6F#"4LI3S\AKE/EI]$;HN@CODB#"[P"X_=?N/E43T<?1$5BA[DCL15][
M3K;!UJL"*94E\]A/\YG"%0DP/'QS1LQ.66UMN^9^ *JVXHWM[&L'[1#?<&%3
M7W[^OB0K_/EL]L\-V:@YC'S&J9'O:;FX^NM?%K?7L\>GR>QO7^?+WV5)O;I%
MU6S*.VY'(LB-JA^CU(8[/0PAE.1-7$--'C-= 6/D9CI?@THHVW/KF,*\9KH"
MBG SW3*%010_3WV\FV#Q^O*QQ!]C&PAJNP!%A:$BFWL.!X.:$0DV$% GV&0@
M8'0"BJMXLCQ^FZG/S[03>&<P$&RWX?(-_PFN4.GIS<QTQ=<9V)YKRI*&A(?.
ME8M:6Z#]S J#))/GTPL6"NH:O9EKFJHGVQ%5/7;H%K<&3%WKPJ[Q17CHY^I.
MLH[T7RD1L46X%3VFQKV^&U =V_7D]7RD,[ 5LD^LTG5#BU+86G+FM4;75:5[
MCG5XC];%9!E9GTY; 1<_7F0I2M%FE=4"&3ZA3/D[30N$:$;JF@/%LI'$X8.U
MM&Y&)#:53#Z71_2V2?T7F*'@>I/B:](#2J,DV)Z?K,=M4U]@Z<@5GK:SXU[6
M M[P:M/M<7=0#*+4C[(Z&V]-8^"'4#<E\=ANLVB:\'3-^G*.L^/@#_"P$Q2.
M?:ZA$] L2ZU&!\C/.%Y<AT0N0O:\_$*9S^@AC7R$EW2^GAD[74T/$%H*E"X+
M.N_^U@1*;,*6TO3N-^29C?]1>M#-XY*O,Q?G&D<!"+K0EL3AM <W^8$*]NO.
M)_B%G*UXDR AA3L:XYD^Y]B_?!R:[*+BIM]@&MPG\2(W:&Y/BH-7 ?.D+"AU
MQJ\"';].)79Q8XO0)0@CKL#D#8S27^%J@^X0).;);77JK2V29LPT3XV9-]/Y
MX^37Z>W7V>1N-GWZ^CC;5I<L#)I"S)A[5(>I<L0GLGH!TS,,;5PF3L=40TL2
MOR@NVO(8/ M0(S=XZK9G2UKJJ: PK\&S@"+<X-FA'*0%D8]&R 8JB'&6@T26
M;X62&,2H9&4RX 2$Z)A ^!:MX2KZ%\I+\)+-E>C8&J("ZSN!(+ 56:J6M%D?
M/)@$5Q>LF6)C;""K&S TU0TDN6GS\* -\TX@]F,?O=+%X3)<;^@_:014T]<<
MR?:ODUVIHI*JPU#0=,@00,PY9@S@_O? LSQ?D<27F$\&*X2EH"EH*L@J>P6S
M%]9NDKW@@T[5#=DV^>K]LF:O* $8/K[L+HG1QQU,_X'6-YLXR.:QO]H$1'-$
M/DPJW>/_D ?^.URA6D?ZMJ. 0(.6):^-@LZ1/D#%>B[0)S==7\$T_8CBYWRK
M9"^BQN[ P+=))*\>M7&5\2,\+:ES,676/5K?)EGV@-*=?84HYAC*+.M4F74_
M6TYN%T]/DX?9X^1J<7>WN)\\_67Z.!.KSIK!-,94S@IC!(=_?DT/$.J.[7;+
M"UCGK15&!=4+16CDYUD&5AN2M;!^KEO?)K[N(%1U""59/HW4K6R,[7'V.LMZ
M2QSQALGK#)(IUXO943/@ZYHKBS*E)8N8> Z'T]@";4]2AQ8VL)W,;4UAB\TZ
M6\.8. +7,[KE0,#T%<67Y!W:312Z(AYO5/8IG790^0^970> H*E4*R./B?E-
MR X^@?V9+,7M2*5=C^SVUZ.).O8+DNL8)JP\O:2V\_FNK\KB&]U(5QX;7P%H
MY#8^"$/'E20?8@V%>6U\!13A-KYIO(X"LAM'[^@)^21;1H2RV?>MGH%XV!,W
MC<UZ%\M_*HY?/N@#L"TD9_PH"%RD!I(LWC9"<@F:"+:FT6?(8^)LZ@GT( QU
M7PZN7X*3+42(0J5^<D!/!IF[9F7,#)#E)L .0L66Y''+3;B*'H*.J5^-,RI]
MO\;O*,-7YD,^LL8(6F87H)I(=R1Q*NY.?SZ,_4J:B3YCIZ^D^M?93M/M\" (
MC5"6.&K&A>D<9^<)!4XUA5(\*)D9<9P.#TO!>7$&U, 'IF%7K-S==]HB(NAK
MAD4G2:_@RM^LCB6'$<M!Z@OQ#P!\PU"0)"ZEC12N[+Y=D I;74\;+T/_W."1
M9N\EIVSFPG(KJ::^?GF:_>WK['XYF?UZY)<M>$&=HFM>4'4] (*!!BN)&:36
MV#BNH0:2+*-&NO)H; I (]?8*#[R/$F2@M50F%=C4T 1KK$YD:_F)%0U'0!4
M0E.6<(96S&G (S@!%65Z3>J-VBX OU\T:52>#73G9=8)-,'LNG#Q)2S9$$GR
M[&ZSZ#I %.P/WK/XDH(?G-7JVN(K:' 2OY&))S %,^MDFZA5:]%WE;V'L&;X
MLJ@P&O<]GNWR!-@9W,EGZ7/RBH)?TF3SQDS'5VD';"P[KB27.X9D5UZM#"BB
M?<MIM5R*Z.8\?<(AC?/NMP=/ \ZR5TW# <<Q=5.2C8]Q#Z<NGWZ(AW=WWW\K
M#%&>UX=,@:TU.FH*3-,.9'%%X&9&(QJQWND"<GX$4%%DJ6K;=DUU CI>K[T<
MZ!9:-1?7]N<W2?J$TG<LT4UYR[C' 9YG!I8L=Y>V$M(-ZI!.?U+(2!ZU<8^^
MY;]I+QK'W8%BP5"Z,KW])*(&H5SE78JC:YD4Z<4:,ZTQNP!?LW17WD3'C6<X
M&]5I5L)Z>\[N-^0/#P_VO_]_4$L#!!0    (  Z"+5IJ',=S6$8" "K:%P +
M    8W9M7S$P:RYH=&WLO6ESVTB6+OS]_15XW9L405(BM5JN]@2MQ>:4MA'E
MJNZY<:,#))(DRB# 1@*2V+_^GB4SD0!!;99DDL;$O5T6221R.7GV\YQ?_NMN
M'#@W(I9^%/[];\W&YM\<$?8CSP^'?_];NWO8Z?SMOS[^?[^,$O@9_#24!_[=
MW]^-DF1RL+%Q>WO;N.O%02.*AQNMS>;6AA\&?BC^\>GJ])WY>5+^^^RG&TGL
MAG(0Q6,W@6G@2#OUS5:]M6L-4I>BGQL(_FX,HYL'Q]FO;S7U./TTCF%Y4S,0
MS4:/I+^%!UO;ZI'<*V^W:.;-]^_?;]SAENAQ[Z1?]L/6YF9SXQ]GI]W^2(S=
MNA_*Q W[PCP%$_\V_P7XK?[IS"^M;=_<VL"O>Z[,1H9O_7M^/S,3^-9+\KNB
M?KRSP5_F?NJ7_G27?^KKGWK"+]]H^,+>XX,P'9=/UDOBC60Z$1OP"Q'[??-
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M9J=6..&]=Q]W-]7_?>_L+M($-314PTNGM_WTZ0$GWMW:V]]K;FZ_]NR>L7G
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MV[__2(VU7QWC=QPCQZB3DI/1WSS[LLT3_E_#&U"'A)<I1:1 +/9)M6$$SP_
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M"(,H$XR4 WG,)XM,\*F1%665_!+>.18B 7;FRR3/DZQWFBA]17"K0'!S9-=
M>&CEUEC9GT=_=B5%10[+3@ZDKX"YZDY$"B\&"S,4 U^I+3/Y()446ETJD.Y
M@*B XZ4Z*SS_6 1D(;D>3$AJ!TI%"*M+" 5U!)Y*T7N%ZH!,,<'")XN8[&DB
M!&/5.DH;8>=7B::!Z@JZO4"]*=5R(\3%&2CU!AVX*JOP/KL["*);\DYQ4>",
MCE11Y$I0)'F?.:\T%H@@3'D[?3A^MZ=0,UE@!7Z?W3N:<\'/N*C)N'-J.:+&
M:CR7T6 JEK:Z!)13>%VR>I21D^7V6:[RFO83.@$2CJ8MT'L]9(RJ*59%&JM
M&I:THQ1$,'R(T; <XQPX%#84O'&996 ,IV>XBK*:I0@HRU3Q$.L)'M>G+$4>
MNV(U*TE/62@7JR0P%LO!@Q&6;(5#(;7R8\*A*D6O.ONE/_L"+W&3!#/.:J")
MD$</Z6 <)9S[\$U0(K*,PE $U=&OV-'KE ;*)'&&$==H8I9 2.D-U7FOP'D;
M;;#QV+K"[TH%*$E<?X&T7\Z1\$/,:3K8)K)K!\%]N2^HSJB\D6#J_#N%K='-
M7$!?\K&77>+'Z$>B2BX$1W%35+M=CB+P.)1D<]]K5,*9'CC+1 /CS\4<<GBY
MJ_/4_5A;A:A@D2K5P-PN,4FT_4>UBU9-2H]<!& M4@8)!EJ5OTO#O<B:<RNX
MH"UQOPDGQ-!,H$.T6!4YP1<]G 4&/]5E1W@"?LA)SC[VY=3NM$(.DL-U2':U
M4M3O$V +I]FGH:UH\"@-IQ,"40+_4+LB58(2+2R7H\19W<4YJ\F0OI*;C2=D
M/_9[LV>!6C#F_M#DN.XPE\WD4(J9RE*R\Y8H6XFKB>R%6%E(?OA0%E+#:??[
M$<4M@FG-F48IJ]I,;5GUZB1P^W20*54#^9P)%3YX<&^9^+VLR<:%M.H>;/4W
M"Y35F4E&+LNT;3U5%%8YRH4<Y<OVU;736=9\Y#DZ04FK-OJE)_K*XW= W!E,
M;O'N8^?Z^,QI-IQ/7[N=\^-NM[1YVE+NR?W=Z^[9$M5BSA1A75Y=''T]O'8.
MV^='G:/V]?&R;])C$]E-KSVKQ9*"X$J$"4/4@?4/A=/SP3+OC\(HB(934P'I
M"2ZA]%@N<Y(@23P[3]#S8P9.<!,49-2M1"6$ ;=*=*%]'T50;"4*>SZ"A K*
M&$^E?L8?C],0I,)4@D1BD8TLRIQGZ"9I#,+6$P/R5/(/&XY>+JI>#/*&$C?J
MIS*KK[-GK=+BLUC*O'02O2V@050YOLN<X]M<7P0CR@0."?+.#V^P]H#U:Z!J
MHOZ($Q.F"EC"IEJ#X&D<:?D[QMJN,Q(N5_J%6/?,-T\NLA'^&KQQZP=,X%%O
M6ZB=_U'WH+40M_&T<=QH-RXQ[7#M%*XA7)GCB0^O%4X;[M=0A,XE"KY0H<IT
M2=JL9U(!;#"XDJ?'[<MNC8,<$D%9,:XV*T^>?)_CD4C!@(Q\N,UQ,L+Z+?EH
MQ\LK$<\+&HB/566R9(NU4Y%^B_I3T& (V36 /_VP!G_\P25OZZ@ D&!/@\#T
MXB7SO<AK%9>M<<\*SKN09(GW_02QHU0QE4*A+7@!7)GE@#2L=!#U^B1V/4&
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MLF@#Q3L7\=%5M*K %MOY=Y(@AZ%5R$N1J8SJBG9O(RS<I@5+8"8(DFNBR?A
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MQ#"-1<#NX8CAV$&7Q0Z%60C$RA(H<SCG(R3:SFV/18QWS=BYI2[ M7;W\(*
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MP#0=*R@**\DOT(&$+CP7>_ .H?X=NA8MYS2E"".G>!$DX_!/:&O"ID%LD&1
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MY6%Q%62T*,G\V.S40_?MM\.NO8'+;QH+P(C'F>_[A>72?+C)4[?^9-Y(3Q-
MDA&^'W+8V;!.%5>IE*I62:V*-F8H26?:3@7_7P C$?A!E#4';G>F70.!:X/G
MLNUW5#RKV<$8X*B)9S2ZOD-#!;M7WM+2D?*"'Q<?I.ZTMJ!<*&OT_1]8RDRS
M7.0<=][S]5'/'1F&V*<[7.UJN^I\%P(#,U(I+B8GLVJ;SF!WF,8(R#?I,,PQ
M1M'0F0N&SQ_;9CAY:#^'2#DUI;YNRXUF ]^X<K?NVXX/##TD_,E^[@?Y%3*7
M*&#D[2[?P/6VC);<YVO[C/W2$>.1DI;1BBS;X@FG@#8RSE*N,\-+)9#XO7U^
MI&9MI?49;_W<<'E1-B0>YIG0TA3!/-Q"^"/N1[E$"9:#UO:>-NUU7@M?<E"[
M/XR?BPDZ-Y1D1N\OM317E:NO8[61:CQ,BY/ON'%=T\Y/1@*)ZA4ES?:=G-B#
MI)5M[::6<C3J'H[,;M6)" L'(G;Q2F#,U*?5,5;ATJI_O+VRFG(F-]5AG.(X
MU;30O<F.Z&)PI"\*@T+/SEW274*&8SK%AKRFJ&W+&I@>6T.:)F6V\1-Q/B*D
M>;@DT*5:UTS80ZLJN8V?'>3UP)E#WV+E5B5$XC?9QO9I)A)R[P;3(]'0<*%=
M#$R0>:)8OP48.;+Z3%CYCH@7[$ (\:+DCY328R\DZ)4P/SXV"_\^N(MQ]0@4
MV5MQ-W_V;FA7:.M5WL85()U7-_FMBXR A@RI(CZ)*@^#:EPCIDP'YU)CR7S,
M%NR.W<'MH$J7'V5=<OY3&.R'VTOM[.0LAPD]7JPN@46 M.<1,! Q?,'2SA35
MG'<WH.B3Q?J:M4$@/'-0WM50P5""^S^.WLZ2LAV06V3I49835YH/\S-)\#.A
M7VGDQ474Q6\TD0C+H9<,BSE1J(!A3@\T[W'UI*>+=,6:^+NX6$&J6][UWS:;
M7F.4S@E50Q<D/_&#] SD:6)TPR[_F?ATS((0X5K*FBXEP(]4 OQJ*0'^5N]8
M@_ W(=%R[@[PRS3W8X%ETQ@&/6TGTE,YPXC8&=8#QEZ1O=N$V^@0L91&HXP!
M!4,BJZ&7HPZ@?R]R" *[RTW3=.I%P</AX)@X1^JC<0WZ QUT&DNFN 4X4,-D
M-K^?4ND0ZS%+O^@_%00*'XDQ6JO*+QY6;^-LNBT,67HF+M EI5A^B"3/$$>0
MG4)V)6U=4H6 TM8L80J+$5_JE=T2O^0U(6"\99]YN\?F))W<Z"_?OGBU^N(;
M[W:^O/J/U7>7S]_^^.;JW/<Z5A,$AR+4<>W(A1;/BQ&; Q6A5D!\0X=,$(O=
MH=F\.ZNU ;&H[\"BMKKJ=_XP.I[[RE#32;Z>CW[[%HK!QOFM&@@9=R5XJH$9
M)?2$UC4BKTNG5%I\0%A:,%QXZJI:PZ<CPX>,<.*$:4L)66M"B7JO]P:05R!8
MA11L;P6M'MLZ?-_Y"<K"99MR@!LUHDV^+P^<!?6G!@V1_W_-WK6!@MUDN>74
M ?(ODB7K)4#'2WD+9 /(1# 6W43<T+O,&$)#N6A2-$6;%# >095EE(D0,S+D
M;!WIQ6DH<JXS^U9R92.9N--#E5!=JP\%-( **5/.NQ-] ?JV^FL@=;HA_;D
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M5\]_I'WS+%N]N'H5_OG\^__$O[^D/[]]$__]2O_Y\MMOK]YBQ^&B^LE7]TJ
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M;MO<Q]\]*$@?3-;\FZSZ:BFR/OO+4F3]D#G:1F-3+CCN;"JC,K$[T&WB4#[
MGYQ N0B''UTGA,K6591P&6WO78I@-J"V))0"(\VJ1=\H5=],SWE,2-@^;1$
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M[T^719&7F&K,6_3/2-.;Y"@B@)FPA#BI6<[PNG7\U4]U+2V[>-G%CV$7C[*
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M ZYTCY3Y&JPH;6(K_3L4Y,ICO5@YX0_:*@90$/U\HE$)[;D8"5U9W,'[@9_
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M^#4 B=T5))$$+,Q+]B#%BOR,M;FE3K1#_BZ1<-_E!077-=(66:!*V3>U:HL
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MM+T.^3LJ6).2'FOTEMU8=#2JO%RLKG!WLWJ8L: JWQ'SET#V:C#(W%HADY.
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M;\$C,IAIN7*XL/9WN5H6XU1)?7Z]?48F8(!F7D=><ZAZ4(X&34=WF$I=%EW
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MS03="T4QG'E_K,7]O'.]7RVYW@],)3)T_M1ZH3=@W.@CSJQZAN1FG<("QE]
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MU!RR-\BD=0JS9Z])S[MII.[%ZI7_*ITV6<*G.)K'$PLBT6<3(;03,VY?W4^
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M=?FW7JDDF K4E&X"&@K!F,!U G-<A.F(/36!TS@\5MS>>3AF]_"2Q\5/+BX
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M_:.[N+[(%'G&])8$//NG;'Z =VOW][]7$E)U!W]7X^7R0ZRFGR)>I%EWAU8
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MQP13?3_26 &\M&\E[[\@<I9*[D/2MCXNB8E;L6;9RMMM&&+NH@&-$T$3REO
MQC6F9$08XI>A%SZSUY?\RJ\H%)HXGP<W#*=I>\K9"TV98@CH[+_;$[7-U*RE
M^<>^TYP!IY#=&(:?"I<EZ;(%(_31,4)?+ABAY63YI(P5UG&S'0AX1^EX(!-0
M'N0FMX$]L[1I^UA<7[$BBRD;6FB1\">S,'OD)D,  OEXM !V7&T4_Y^R<DOJ
M^;VGN">XB0\F7"U]?8AS)(P8X8:2L))UD0 GIU!BRDNP'9'GFJ$>:0W&1.:]
M ;=M0 SZ4\;S9YFGV.YNB,I-&#X4E!Z*>THS?*)A.)>U4,X%SJHE& P;G0@M
M%OIBIMJVY#)@,AB'J2)IYUHN=B-@[D)S4Q"K?%1)T(?DR<>=5E&^>H*( +)0
MDD5[WK1M[P_!UX'TXU(TGK4G&1R6:RHVBYXD_K#AWRGQ4 363*#&@T(B*A><
M#\**DC]H;HQ=QL\F74T93^D.%-0>_<6_>,,\4GTAHP@VW#H7G<^J"0@E&(!C
M.GS^O\I#R>K301O47,ST?,8\XB@S>;&*G:0/SM#^MLPL-+?;DLA533)VU?0'
M0$X%/3%XRLL.K<E4'#O1=_C;=@.,UW?/7U]F\_NB:2>WQ8@2I^V%S^#!FX7;
MN>CV4N&IH'(D&HE&W9"U1/#/ZZ!R*%VS,,W2ZD?-N9P(/4(^*7"'AH/BE"@P
M2@-(-EN20;2,<VMLT(TOZZV_*/>;R<<L]!1X74"U&KDX)(<0B6'"BX.U)'!]
MBT!)PBW+)0G2 G%NOUHWS3OE4"*E>&7UIF2I'U.A?]CF)35"MVY;82D0-H<(
M546.2E><O\"^,157R,3<EA(!1P(1T_+7'3L(,&YUZU:0K.]K84Q#-_3GU)8^
MNS-+8OC.;TO,P[606@J V4], WN&.D27M$9B7'.CL**J-;+4D@Z!\$>:D8GU
M2W8DV$K1^MQ%ABC3YTWK89*,Z.[&@K+693/LCJ>O.Q_I-,= 1%RVB>R8PK95
M_)/S+C.7,IM/29"^CF,V-H4%:]^$8HOK7'Q>:04V-T:),YK(:,2,^A#MS(O5
M&[?ADBO]Z>K%<USI6T<>I#:>_R]:!AO'=0@_*V"Y40IW[&]7HQ;"?!;15@_)
M(/Q8H"A)Y![24#)#-ZW5K!)E8*D<4N+25'='B72>'>B,7#NA1]5B&9UD<E;3
MBHHG"RAD)JC=B.0^Y84:<KH-^!C()O-!#/Z.T#7,\?$O ;VC+&87J_]2EK,N
M_61$'L>U+3XE:6T+N5A4U5+:J2# )V.3K>2(\=,GC%MQD& ;JZ:;Z=@4,=J2
M>>&,['A,1)+Z=$LA]D84LE"14MZVJ=.;R GD85UA-V80B@@_-RQ=0:56 #,X
M.E6R1A"R"$0F7B.>1I<:=]S&<>>1E3K*Z-+O@WN>AW;0X5B#C@$IBN@RQ+*E
M4:-B!CE<N77[7HGE(+?>0KF!_AE<1>M8&BIPKBGQ=\U3YP=L!EE@/(>Z($(5
M,"*9 C8I4] 28Q6 9,()/(8ZG55X9F3M*W===I)\@I'>D6X<$3*Q3SI"C3T8
M,2:S,<:'G3_PY\4O/M(PTC!$0K*']+>,JC_/Z@!O#-&0.3R'')MK(KEF<(3P
ML]#^V@-*Y<]HIG2#2!P!!<QM;8?) QB)AO5P)4Q"9K1\YZKR!I+>-6KVL+S,
M3N8O/_GXL5#L8ZC.,56@;/.P]MCW'I .LA<5G/])G K]"B?=$&;7$;<4\ 2*
M9,N+?,]TAQA[V&P7Y\D<!()]R8MFKT8;"V+P'9U0I:$Q=P?EAMPW..)F4N(9
MD$)YJ@;>^Q2/ (^CD*]@4VJ7NQBX@-Y3@!>UJ_@5R1Q:3,(!@_D1+=GG7=OZ
MZMQK6Q\W\SRQ_S-!NV$_K"FGS[Z'T/IQK<;2OMC33O)1(#HZ1?P7#%AT5.'P
M*#%5 *L#_W17W^4M+','5N8FD+EO7++7K:@+IY4)+35'PY>@R_P3O,I]3+1Z
M]O2+I]Z"^).T!4&R7_:B8?9:NGA>1QYV"-Z2 U5@5SZG-T06B=02=E34"$HT
MHA'V7+EX7X0N$Q]6-34YT/R?FH6BC+WBA-D#G[P39Y*\>YWC;LE0RR >;EH0
M! :%,7R["TD.@A.,?&KM1F8Y0HJ1 ];-<DS"Z4YZ"Z1E6?N,]6BXG^!/%-QB
M7?!>20E.&UT^O]25UB4K$R$[L^ER,,C^U0,>P1)+D@">X6[]$XZRZ"XHS0&R
M&OY;2MNU$S&"8=P:KJ4,S1(ET\&$>ZM*![\]:P",M,AQ93CYWFW8A?B>#]=(
MC@E'0C0H&VR+H  2+FDY2]E[\BN^ZT2UW&&[I2HE.!QW%,]IXN+D@Q@"4WXG
M1?<:YR8R&!M6JBGJ:C_E^2_J55MGYPX9:W;GA.7<<3N=W]'_S%/F*D3!7'RB
M[KQ?A*_[:&"9A<E[T-+:2F941>HI_2,48,$/D=U1G-@::_^L=<VH6'JDOX(A
M,?=6YTC_^2\B_,([7<T/^[#?] 5U$?Z(V)R>M-SEZK5F22\G78BO$'=!7S,9
MK&0N-"E#=NG+U8YZ%IE:FIX)0_V7]*_/_@76D1(8%D&O8WG27,0-2@4%I'9Q
MI)A\T\]^LCDLO"&Y2&\K,##?>@..-^!7RH,9X((#MG%/PU7^7_;>O+EM[$H?
M_BJH_B4S<A7$UKZT,ZF7EN2VTM824>Y,YC^0N!31!@$V%JF93_^>[2Y8J,4M
M6:3(J4EB20#N=N[9SW,HSUF_"Z2(K*Z@3L_.)DA_D )4Q41-<^U>]S6:O,RR
M3#!3N(B*4LR'B..H>,4S1#;IJT%0Y@@=BX=KI 2<'1R\R(D6KFDXD9:N=URT
M$,,'$-?1ZP,#D/8_Z(M/:A0 E$KW47 QN6\<E\HQT6ONQ=D6=QWO4NX]Z+J*
M7*0N,CCA:1*N)>H1OED^*OF%#=:9+4 /E_CF@.<NCRN[2H=;6XY>8%@-2GGC
M["(;9P#J-<5S0FMIZ&[R0<X728[J(QA^[$5%SG\Q3B*P]$$A(.Z&P=DU:>;Y
M\?CBJBN=.]_Y(N[Q?#\>=ZW/R2$/'P$]=2#(H^ /$ 'F\F'0/(QT.D:8!7<\
MOP%(+_10H$/*HQH3PJJ0:C@'VC1-AA&BBY#55<4Y)7\H,HD0U)D;4X6N>U_5
M7N9W^M)Q]0ZS>[(HI8 2;%8BJ?ZM&[K$\13=.]'HY'0^()V5@[GD&.3$$M2-
M5"<Z%G,,/^>#8&(4:F&QNET1)_A6PM$$^NI&4"K:OPZFB>:?I3&7JCB:FVGS
MP'8 ERN0BLVB0D3=D;Q>TZ5U;:2%KZ'>Y*8CV=9?60?C::!*KU6(M7Y9D,C6
M>L0[I]UCZ@1W6!!NLR8;$=]#*4^>#58?M38-#&$?*#<FMYS=D"KCEK 5\G;@
MN8F.552EH:,!BJUE@8XEUH6_=]0EW3.WW8/3:$8._XA(RQ']FK%]3>^7:OO/
M%+N]MS6B<K6M4&&$3DJAJ-:'[+=*6V@,GCKC^:Y^C,??0)EF=;'>?CE3MQ&C
M)$A*7YI0&^&^*NYP]PQF,T5HK9YJ41>,;HG)@ZC*Q'A9R-84SWHP(2=^0U7G
MW4'VA9NMM6<"1A4==H9V[\ME(T;>U'-K9L=8 >,.R=R0S]-6L(88VKK@&R8J
MYS[5P?D=W<-IXIPIA\9 ORB)UOI1J(]<\WZ*=^O2-\)P;\0DJXTL6*N0AMJ9
M;9)0@YF*LN9).R6(K:;=:2(NN_OS0OPZ1GY2,8)UPW(.T^>8=C*MM:SI3R70
M(N5-% ZVH1<)9;)62 6<J(4/5,1!5@0MP/L%GZMNC0/17?$T-+'7-?O!5D<6
M^@N)DWM<\_T3]5"T7[H.Y/!&V%^\+!3>JR#KF-86L/V&AS<L%+TSNG5D<SLU
M,S=.E_R>04<E[!\J&LLGHFTC(O(/-)IG.639%A:J^<*RZ";-4FK!)R8D7!^*
M&,E-=Z7. TXR[>@V*.2SRI)GHD)'U/AA!C:TSLZEN*F1P%X#89\"%48F&UV@
MQ0]0VY# 9&)5OFY$.#=+DA8HNKG)=:M?BR2/N(N$^<H9M+6@XG/BZ4ADR'@<
M:="^(MDC@8EZSQX?3<Y&M,"K;=[,3B&KJ,+WB2KLKJ(*S\@-/[LF0=7D8.V2
M=!+4?FV,0;=99\,6>T7 =[7Q7(D22@2<I:!-CL>,R+2P2K<DD9";M))*I(55
M(RQ+F:+HFADI;K;1;N1HRTIK.N((()>]?A6,\FKVCVE13[Y$()@)IE186=_F
M:]8#\(!Z '%M E\+.(F%T^-E4L+T6R#3[VT$0! YO@3%:UJG3>("]0U4P&2J
M(QIDVQF'B/9HN/X(?8 !MSPC#]CZ./AJM$[T--.P58V,(^[4CX59;EO3##"A
M[A ]);"]:)S&1R1"D4J2&^6T5] PIYZA,OOI0N4&78 %@4MX;RI91>= .WF1
MTA"8#&K>.=UJW"2QNG58#_85M#6AE3#YVTY2,?D*V!(N%+P@]=7).#!= ?$R
MQBH(!4DANM$*NM'$W.3YA-O:-6W]P&EY_5N913FFEE!"D)N]P7D->:6OD9MH
MUOJ%6DE0-9.>D]OKV8=D[2']5#XD=CM>L=2NBO@,.:'UZ+/:5XF3H]ZPJFE1
MNEV+%JT]%2W <&5DK#.CE)J5YOH8VXZ/JT583%1?J"8Z?X]^6%4OL=A'H1IC
MK(7491>)VN*J(/H(56H:% $J8-&&E04K%7O;]MBZI\66M6J>WE;+L8B^0T\M
MO:-.OM7\I"&]O(QRV)<3A;!IURJYC;)4[J2O_1I.%X+V1&P+^\>H-=11R>$6
ME##-$ G2R9F5-L3><9)7-/X?&/%N(NSR2+@*BTU*,&;15_&-AV*=#BP^F-WB
MSZ9'\]3U4^JT%6 '84R^90K*YO <L$S?L@:-,$I6!U[A4?"?( MQJCK]5AR9
M08[B5!OPH8[\:LW<<2U3(PK.>)\VK B38L",']'XR>D ^V'#Y4A/P*NG[$)@
M,62FHT63QZKO/6^S?X2F@]_!Z98,]]RR2G>3LR",TH!9JMV&,K?+QG)N2H>R
M^]^\.G"\U/J86[P;7"H]*=/@7)^6M"_58>I(NT/X>^J/ 6*KR>AIF0W<W%FR
M%TT*/MS%2E]VKCJO%9J;SMNF^('O-JG^YG(/)<HI[:)=#D.F51O!OBD^6P$%
MH"=#+*2CE?Y$P1C$1?CA[U>$%'>EN&X+MNH4E%Q*4<-HPR7J9EDQ-=@!B\D&
M'X54VH+IZ4AF6R58A;27.*4+O6C<$G54R;K_4RQWT" 406?8%V$M),/PPI4)
M9A+"OP=</9_V\S16Q?)464<.DB$= '!OW>9R&"&S8D>X!!FY^!H5OE"J?2U+
MJ1X-^U?8I3P)N*VBU!M4HO V58&?=? 3G-.5W,0Z'H(6!D0VF):4<W*7$([Q
M<[';Q#>!:,.KN<2&4TY-51>R95LX34-S(U95@8?FPBS2]1MXC;4 H!/#EQ(\
MWR3H4^PA[%146-/6=(*<E5(B@X)=#HGD$59W7/2OY@[1F2+)X'>"?$37"1=(
MA7XK=_EW<I?OK=SES]G&F\/-NL =K=>[-/LJ&*Z<$^&F6PRD2(AT7+P= Y5U
MO#-!7#&HGO(Y<K&;VCO?,@OVR1J>I$/?#LPPJV"Z&R1"UJ(^=(/#:BR)1M4C
MI@]CZCD"U,3*)&&3UNFR5TQ\7,=$ RLC$7J4RY+ZTQKV;+(^2DM*7Y;)WP#G
MFQ"7Z!-'&7.MO8&X@36C\DRV K$P9EBZ?+KFXL['F#V:N8> Z<QILL[6M8G^
M,Q?..-.)L@+LE%P?%Q^*A&G)_X"J.)@AZ$B7R&0%!MC+1Q01=5T,4C(U"SZG
M@77,+CK.L2'@6&.*A/BH%BRXUUCA+&?/VHB !;H>*8O.1:GSZ$T/A@PQW.:4
MJ5)"K[7@PL*,D+^'A(!GQ1LA#[;7>-/X6"N-R2N)SKWA_25YKTNGG4PW,M;@
MWY2[4V^H9J0./P^*%=R/22PCL2M<X9=U0$#2P,H$+P8J&#4\$EP1;!U0NO0_
ME#IW!Z512ST;;Y)*0&.PZ-KU&GTVT*&^)NF=#C:M$%U7N'OW(+I2ICDE=T99
M7ACX%,Y31QXIM>VW&GM/!0QT32#/H,YA;H@0KAC.G#3&MU=P#^@K*Q37YSF@
M812KMOW5"/*Y>W2K37_2I@LNDE3"&.!!BCFS/-2)1FA6N)W1:M9)6/+!* UU
M5U>%W!=6A_2TIII&E;V/W>CT;.,CJ3"KU99_\Y8+M]<:)6DUW-9!-)I8K7;W
MR;NKMU7(%/B\"<YSKF\5H5,Z>L@QZ-Q<&Y"GJ,JTXF%TNFIKT$5.'^+2.*E$
M=C _5Z?X;0);=E;[?HTE91/&9OIJC3'%Y+"Z2]^$)UW')*0347]@/FUN!#)U
M&"F"HJ3@88;;F3O7SJFG<L(8$PEC\$&A:B:GJVTT9]1A2;+I/=RVU1$^Y0C=
M@+F F@XI4:\B?XR;V;U,<HP:5#-?*$#H)\'[ZFT8XXH]Q@TBW DB;">AE<(&
MCF?'M_BB ZSSKD>M&'TJF5IYX2%-5YQ#F,2B8DF4G-9\0=5&670[EB7"9$ZG
MI=,;,2&V*$R]O,!PNV!PXFIS9(5K73M';("4:HZR2N9K[>LV]JCA2=NYV\1"
MF.BV9*Z8\EO]C8P'/:UW^VBO0;1!3B?3K WI7,\TGLX@\+;)L(.O.@^_0L&2
M.Z5E-.5%9*;D$2<\9C<=O$U_2M2-MN9:E:H*V>,=JI;44R;0O;!M=7P]B1A7
M$[C(-:Q!MMN3(S7XA-XMR9VKLTBI1J=6]QI/S"!^T6_A-F#/.* BDJ>,88PS
M=5>J$AI851,N8#S8V#&=O:8EW<Y7#<5FJP>M96)1(_&RTT@TU<?F4D3+IXCU
ME8D&/D;H#@:VJ':82Y-X:F K>"ND(&IV5'TFU;7= (.VPTHV6TP5)W!<D6N!
MZS^/I^;:8H%[CD6T(7;!&V3J6=/.Y[Z*3KOU&6CB(:=*?=>)B-UT:-GP&<YT
M*L%V$$)P]FU>!O% 5%%F*<Y-!1VZ/V3--6%B9MJ!84(/PIC0R6>JV(6>:@X-
M\M'"0%PX(FV,]9H^EAERUS$A !>M4PL,$\#0:UCHF!\BN4MDSN)83>O.7M8[
M H*<TIO6\8ZC?%(64K3!Z(.Z#MMD:FG.GSLSX)18_),)DIA@I57T].*PC)#X
M2*[J7@D-TIC>ZIZ$G%[6[/+(FX+YV;#=S3.KLQS*+; R5EO0H5*868=R(,KQ
M'OL<X,LR@FEA$"<]69@Y_ :>MDD.1K<EDZ&.SNM4_E,.F\^E+T(PHT 2Z=PP
M+3IB$#T8&0O^T:EY"?JP;NK[V>!='>]"=&FND60,:,%6QX!:-0NS3"(L[Q!(
M7P./R$1;]TD[#S"< 1&2S[E0TP<TGIDJ/A*.4[7EP&P!C\>$&I+9W-=RZMAU
M5IA(3HKM%!S<29#5M!61F?@>PD/,IM/JL[I<2J<U4D4IB89:^W5Z399#-?AC
MFWJ3ZN#?*FOE.V6M[*^R5OZLC7I6<FSP<2Z4*-<BID6O$<#U810*8@W&M-='
MZ9TOB63(Q>C&+8MM:2J(:DII9=<$@+"R<\AZRH0W"W9:;Z1 =3H)=FFU5,'3
MQ\G!X%8[D56R5K]9-2&^ F'B&W@41Y>SZH^IMHT*DSHNTG(HJ!J4C$3]S-5]
M1-2V'7K]TK^XF$X4=^? /"'I'=7XLN!5"1R((U-="R2,<@3!=S+%C<LEQTZH
M)IE$ZU6YU( Y+XKZAZC,8\ZEQ#PCLO6IFWQW@$U,"*;%YX0K.2!JV\(_1/?<
M.-M+K9Q(-; CD9R%4?,4LK3K.VHIR-W7)3)$KE/'N)Y!0KI[@G.T:-A-^.KR
M,_UIE4@:+CY$NZ93*TS+&W;]V,X+I-/&>'_Y!].A@G'.02F5QDLDY[A7DWML
ME(Y4Z]UD-*5/Z9VB?"P7JP26J+*G34&)PP6A)@M.3"!-391H:DVG=TK7YCDW
MUMW7^L42_)E9Z]'L1 ?(W,X\6+@=FNI14TU3\1>XQS><.:N.=Y)H?3M ?28:
M2R3'\31,+7HXK!DY@>F7GC/BDO\$[E5I9.^WV3? \EF#1![*CJ-FSMD#6T=H
M2.1%J92.$BRG_7F)KGX-^D"*70/J8VF!+(RHYHJUBO'O)D\ZM:PFMY(+._BN
M$U)PA0)I/$H]B8WEZR@#%9H\->8G3M I&T7IAB6_H06SP#"E>__<*\>77MVD
ME3+?P*G!UOA8]8X MC+5*6IOS]O_JAQ,K28K3 G+M$PLDAG+.\*&*+&!RA(1
MX4=;CF8[IAG7_A-X"#_J^'G8__  =D.OM6[)3=^M.]IG9%*5_1RE!EOM2/)P
MI@+&T4;1DH$^9?]&O5K$70;G71.\H5P2=&@3=58[EO+V4?*Y->&=+U67PKO#
M?3_PHU),2:\^0>]<,#/ET25O50 (DH*Y22_1G) S$V$W$:(1/7MWF,5"/P@
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ME8Y;A_BU[:TE(H#3Q.N6-]AS:6MC8]^Z6^3H K@444QJ58( M"T'[ZWAUO>
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MZ3VN>W[I[^>,L94.ASG<2]S)Q*!<MHR]X2P,QM8FRXRSHJDM6:CJ]0![MU>
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M?DT*#[ -JY8__2!&?I%7T\2M=D;-HN#MDMLW6=S06C,H&!HF33GQ<)3P!Y@
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M>&@J)DV-I;*3$!9+EM&P]96:%41SI@Y(2P\$\T3%_[\E^#/$H :YS;E'#U.
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M(5&&:(J1FW&A=N+;/%2#(,M0]<9L2/0GF&WR'2T]+R>H,.8Z7&_=N90)@ U
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M ;[TV& ZNI9S<44LSZ#BZ&%]!DW1:)"ES#79YK*90K/T_(NB".Y@1\S_PDX
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MV!KBOV>570!JQ@B; KL<6[P!(;\#0T?G:*)UB6[<^J;(&9 &^8OW0:?MZ$2
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M9)D;[!J!]6%/2FP?)2W+3:*G"DM]^]> J-P\5GRNZL+Y5Y2CAH )KD$)8B+
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MAIP$"80]T/5!4>ZV:V_(KYX#O><D5AKK4<I,+-9-!8 /S0R\3/"_&-Z@ XE
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M)<KS$OX>Y-JS\]\YF+$)*+C]$AM/>?#_?34*XB$2$KZ8@$4?:L>3=S=*O4F
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M%,N!.;6P\3W< ;XH?^8]6\_LURXLEP<TG[%;*O1K;)Z02LP=B)Q7\*2#^(O
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MTF?Q&0=_+3EDLU"4T^O]D>9/5":6;;E5I)SB(6%;@.64TORU/VE9SIB6P9_
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M=J_(P^/MY=]^N;V^ZM[#1QX?X>/A)/BRJZ$W)WHIX0"M*SK@\[/T^?RL>!4
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M?5@@,2(]6,$4/0*P8??TR4)E#DNZF_7![P)[-  ?G#E>7RUOLOR:1_84*F,
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MW#'SL,2+C]Z,*8JM)V4*X=F\P=5/_J?W1@[<P _V&SC0/OFR<@7)\N@! 1W
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MI9$Q?T=DF9QN#X?_4,\=FOYX8]+\5+A2FHI2S@%>[VC0M^&U]F"FH/ 2,Z;
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MH%RE?J6*4LY>)35W.CO;627MKVPT75=J F;OQ3PSTU6M1GH.SINUGBF_^X1
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M9C/P>>LS90,VL[]71U6: MY1)11E8;%42P%+<A!@GL[NU[CNC,W37G)VS<$
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MQ5TZYJ>X*.B:G_YX I$/:GF?<A"->I=SZ_]">UC49('7VJUR_WP%MLQ;Z:)
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M-_SH$G9AB@*)O])V;IQ[V*)K_H/T-V9> DT:SXR^Q'R^SX;E_=VPPVS;;M'
MX@?F!W H>-]CX(Z^JUF(6XZ@7VKYQ>4K$;GI$I@U=<K%R2:& 0)^-=ZTMLS[
M0M1%M#"<-VWJFM;8 LS%#P/F37W$M6AHAJ[]4]=^U[5;7?OZ%?YS2\-K'QYB
M2ADB902,#ZS%E[!XBAG6;] 3P2O@U]O%V T][:=F^V=8U@DFOC:& ^&/+$\;
MA9X'#Z5^+D&$N5R6,_((>X'H1JX?X%:#B>7S'?CXFU<@6&,V\]P?@ 4!L]^6
MTDVR+"9^^Q6\_!.#/\Q/UHMEPNDVPO!\G-C=SD!O=])1$F 2$VLTH:.J?,J
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MY+(L9+DNN4P\MG0 W=8$DVU:'1HPI94O_9*@[2D33".CY>.F!(.S&@KQCI^
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MWF7YV%L2TXI@U^%,I(X(:(C?9H)$+OHU/C1>N')P?-'$\@/7>Y,[F$> N%\
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M 65I%-H&,4I?TKM86+Q%^=T%[^4#V\9^2=AXR0?VB/=.MQ?@;<G+4[LSC3P
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M O]N>!8YT?F3<9C+#U$+]A-!,.*J>ASPTD7T+A5/RPP;91GJKI?>HC8,21-
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M(^X1!Y:5,F[><*"5:C:QX-B;--<I[/3U6G.=MC/S!8K;MX6)]"+9#C=1V+9
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M?+5?;'+;=^GY2Q,]@UY#Z2>BK># *GHHG<I'Y4."V%D=D=]=$VJ->\*J094
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MG/-72"MEF='/+F^;\(XDB%.'=9U3_M=7,>LVPPQ[H3F7,.''H>L4..-8-RQ
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M@$833Q3$!L[?_0KWX6Z%J<J-E&-\&?^2/H'=8QD%N3%GCM%CE#CA[(.Y%7E
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MC=]C7,,6"7J_MX !(@YE OY.ZFKTQ(3.KV$YY@0UMB)1]]N2\53["RRUIC%
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M $0Q;%49U8$L.L32U$SPN4[#'I59)//S$=CZH3.2"(+FC?MB/W]T+H'& V$
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M..&^\SQBH5WWO+]I"@NO@D0S,0X)5<WO"-TTY_W9;5^0GTJ\8@]EF3IB?YX
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MDO; 3I% FP7)9DEYC*6^]AVI]@<*J_B3J^=!DDZ3A^O#-?_\^P4^^G8):JH
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M>Q-79EUCO3^B:5+UJX;'5\!)0 ;\N'*HY .=>'&31Z$H3U3M23'%(19X=S)
MY?6] W9-R)Q"GN6LVJBIQNY^SW2E[5!IA<%<DP*^IT65ZX:X7DU4B:2I*V*@
M;=C+XU""NO/M0^Y$/7Z3S@='N;TV58/<G\7.FS[A'9-^ILI8\2Y<VUWX[C07
ME=R9QQW;R3AWR+EG7UP+9QOTG>CQ@;Z7=%W*N+8YP<@PY+>K.+ TEC;4S9K"
M\IE5Y T+X>F^?4P"E$NTJU^LX(3TEE=QQXALW@SRR[J1&ELG[2.C@%+6V(K&
M:^/]NUPM!6D@QV7 ;<<:?SL,9U3:RZ#V<'/BC2&Z 5:%,2$)$K3[,1;@!M]K
MF4G0O%Y,[:32]80A\PJIT*P7GPDR;MF1<?/ -F7A-"#9/FMRB\H#89,4=>C)
M7Q)6SE3<<7/LM05SU.>?4BUAYW#M ]WU#UC ]H;#EK&IU,[KRCGI9]/I&?=[
M'MZ<><?-(A/]9F)MM_W5M)\RLI#O/6]VS%[?8*B^O9*RN/3DL6Z(B+ +RPS4
MQ^3=EH'P'M .^(LH>"^T)DMJ>A_TM^HC'"IX"PMM$YS-XNU8JH0;EK1>3/]P
MFHE2%Y,"76GR0=HL@N\H';204DF8()^.7%Z[Z-^"JPG,VHJ_BWW<$Z?B6.61
M5!%3F<"<1?\,?R>%:UEL]X04J9T.&3Y>N#EMTI;@XZ-4MI%P-KX9@ 5>1U"O
MA#D8O7Z5/,A(RI:FK_G<?7D@],*Q3=644Q3%58H%; RIW28S4^!/WTY87C\=
M)G=.ONDIP#KV+"NP#_"W4?#"Q,/YR+HO)>:\ZK=&S.S-N+P_RQO*.=+=E*OO
M(&>^_BSHZY4<"7^_=27D!X2YW@$JP7EKF"01H9CZI;D0"UB6Y.\D$C^):.V)
M-.#H["5SWIX/E,YE8>?N!-Q9D^D_<-NQO"Z+X*=Y*DMQ>)H%AWT M8[7\S:4
MF$Y/WU W'-ZOZA*494F4([PR)?DUHG!MSS&)3\*)6$S(KBU!_",ZR&V;_?5>
MT[3@KI1:HW-M(L0ZG!EPH+>2GLHDS6<O_]2HMBAEW"I]J]%4[F*F53P@ITS!
MUR[+6,&ST$:#Q2G^P:R@;=EMO?-^*H=%T B#Q;"#^=([C.B!]1!*@&&MND;O
M0-Z3)^W7JN*]S\S/7D8R'&@:7+>X>WT0-%FIWW7HE;.L_A8#WNA4KQLM.9ZJ
M8I SYK)+U4_4BE._"7L5:620JX'D]E )>5Y#8!%=(&CWH:SRAOC6(<U2;<JT
M&$O4VH-89@J"4,V6KU(RB[3 9'88._!?"GZO0Q.K<$;1?.G:V]W\5F]W"_KJ
M"2;C#R_?$GV&.5?ZY6D&WHL6[:+I$Y)F,84$OT1<V:S7.1 <_R@S7C^M1N:]
M:H#@>H\%//2]V$(80ZJ/%P@VZ]7FZXJ,SC7M:$O;1G!&0&+=>^ ($%Z7G2VN
MI&<D=38$'Q3O[I4Y[ O9/Z9K^%53>91"0KP8IE-3>R?8JT/^^X-F2S;@ "0&
MU.6B%(<=CH>$\ZXGZ%ON^0K55.O_N)/DW*0<H:S:@7^]:1!O<7%\X;U[H6"X
M!-XKN]/B7<4]"0D#PS .RU\"#YOOZ5+,(N)J&+8_C6(H9N8V]W,GMV O1O26
M5786+YDD-N>?T;4W!H:$WT@PH>==?B"C(<YWQT8\8MQ':#PV8,@W9[[3I:(7
MU9]*RT%>L=$A1AV$7L3%')H 5IL7##Z4[]L+-D?F6PFN?_/V9)VC.?W@\?JZ
MKJH]P4<\45&AAN?+NXQ;+</+=N]";-9#^K);&1)O/_KV_GM4@!Y(BBLC=:DQ
M,6ZAU7V9(U6MMKX!%C)F'_-$8("NPZ#)I2=;Z9Z3&#,+G'P%Z3&TY3',"Q.P
M&3*3+9#*JI%[F2+A'K1_<JVGR$F<_B@H#!BM0XQ_E@XO-/?RPSD5$P-C]->9
M;RJDTW<)]KP,$V]?H:C^MJKRLZO?SD/-K$.*0BB:W_#U_/UD(VHSO5>O[>_=
MHA3K6KQVM M9*IFG&*QBE^0?G]!W-<"A:RJ99Y@J1/BN8\)3U5UJ%J"A^KB[
MS]VHYIW%J.154/ S6,(XEUM-Y/V96M'WA21,*XZ*,R$F$6\5  5G!&GSZ;CP
MQ#?;J!>UAE,>1D_VLBE)A%>(#84IZ6KPHDXHRQ'X2A5CW&XS-)!*A[)R'IZT
M1U$6'ZR>5Z7(Y.';2[R-O4I]0J&DC'2URYVF9AY-"@G5?/>^-);<O*K184;3
M2^/+ ^!L+2=TJ;=Z@C+&&!GE-K+<\+TI973FGH"Z([US$*RHF)LC_@0$ I'C
M.78P"J>V7'SZV)[=Z4M8ELI;[,XU3WQ-@8[P'IX6P_GB[9QJ[]QA/[_IA;"R
MRF(&\5%Y&Z?3HP]5A%&(*V5/,BRY/K^#@SR4[\(IB@N\($KCDA8VRVJ/QTFF
M>'AHIZD=[JI0"O-SG8<9T#^8B>*2/FH6L)WG^3[N;F_(^_QKP^6K7#L+>M='
M/V\56((?RM8B M7EE/ME!"H=WP^;&&Q,)[ZOU!FJG#,;*MMUU#M0IR5\WZME
MDOW)D<<0]MXO/PTNE9!8;+ M[FIFF-S&Z62T/*_J.DB_&Z,3\_:F<Y!)0/S!
M\MJ(ZD@E6KLMNE VU_#'E\_@2;CR,@]9>%_,TR6N=]R-J%K+<V^X=HLTE?GU
MS40?.W.A64]MFNLVX'@"(-,T1JFNFN]7+-YE6[I &! RLTP4FTY7.2'4(>XG
MGI@J]4F5/J[KM+@K>8P\GN[:=\8PZBNN1IK(@=9=;]]7-T8G[A@R=8M65::X
MRW1]X^M]+\M=E@NHB,&%?DUY@8WBY(9+7X[?C"G<%':USMXB5TG8Z@XCM"\]
MHW\/%\-07G_P<SP<)545W7(!"]VIX@JW=IR?RA&=6^4FD[^=XR)23$RTJ#Q+
M$TH.H"TZS/!')27'IZNFZK^.ZBU350N[-GP-O_+*>DPDRR1BY8KXB*"I^A(L
M*$(<%(H9>)$8V\K*O;L2PZCZED!115?Y.A;@%:E6[GRM(T[:JFI*-JY\PM1[
MXX@\;.Q>A']QSRP%53#)ZG72 #LJS"TPF<W%>'+NQE'=8(*_\-:I-ZKTFU3F
M!Y=,ORW#9Q'VS33K3BNW;O:HT]B<#9HW+U6;JFI7AZADU<2\#)& \5371FDU
MF!"=J_(N7J4I_K6LQJ1^P\ K3#7'T2+@*W5NC#K1BV+JUU8.AJ.N/]E2X,?1
MH?:+$S]&_?BK)Q(U9]0HWMV1J>CZHGB=(&XE-O/-X/4W_<N$;A^1B@,8BDI&
MDH:/OQSJ?28;,Y_%WG%,DKH9\'S#688THR,=_!8UB:Y7V7OT36[(V%A5@DOI
M>R\+4QIG\BW*R\RT.^D<[@-DIC87'9^S;<0U1D^,CQ->1JX=,H6QGX;&+-C=
MXM_()&1).":(LCQ;\IFS3A%.1-=Q=N>'VKCC.X3L&>8Z'0[09X:$*?K%191#
MW!;U5<J\/+9U1DN$(B$Z<2IC;B<)[.MD5[64<V>:Q&[!G>Z3A1#?+5@ON'N+
M+T*P0657\(<W['N5][N 5]_V/M^UH<]]OJH[V=#5LC?3D$FS7+@%OM/(895K
MFWAZ)C#?]-G>V>5YV+2NS3N>;YHTK_!ZJO&:1;O8\%/>;B^AVU=G9DV1L=X6
M3<)]14JG;N;5@J1-_+G0(@:*0!!G3E8WOXF?<%7]T-*(Y1BOL))]H3&5CD8O
M']@5_.+'#]]!HAROLU:NAR%VFYGQ]L$KQ5)I0^CT.[#;JG6@!%A#@#&#5+LL
M:;1@PZZ%4L6PITGI[FC"R'E%-T%"N_WTJUZ'K*9G1/Q$LEU]^E "J+71MM-V
M2FZBR[:/GS 5?S-QD&/BVM+@RT7,65;7N5(9AR 6P.LC?5_:J%*X_<U6O,13
MVB^6Q/T#BZ;# 1,AP2Z@W/M4A24]" #LS+R"=N:YU2B>RQ((JQ>8F_;QME6'
MW]>NN?_>M1L@GIDN4$+0-1_.]+D)J6B)JM4Z\O>[6:Q_Y[ZO^Y'RINY7G5O.
MFMOI-(VCC?+>;/'K-N+CT:SQ >%WHY0K&CMZE,6Z$A2D0VU6+.MV\9L#V$<=
M\T<;#;T&'W_;[+MB_[ZK96@%FOKK7,:"E_^F%QO^7>!F7:--9KLG1<F1Z4R?
MH*)!VZD(V0<@HDM7]2YARQ4/TM2@3J+,L48["YOL@4(;'LH"^]=+8ZQAPO>:
MVE8P)T\?/!WST!6=JZ%W+QE ZG.(1,,1]ATE RSZ"XY18CPQJ_(K@JSW'IZ_
M,[!O!JBE7 U3U -/U,!+I["<29EB_W(3-<K[2>*31A+4<)F%M@HYER*)%4]<
MZICKPE)1$O/UY3,: [>[HV.$C60ST^V.MUH>O2$'RSS@] '8L\/^]TK!2KP%
MOABW#_N637*]Y,Y[7TK)@$]X4A2D%^JYT.0<--LPI'>08%0'LBD=@[&,/LY0
MQ@(",G<T-;! [H72>0IDV)\9U0>H*<ACXC;!:]980.4X^D@03^C_GQ+D8#9=
ML\R=?G>T-? 4R/]3&99[:[!X<RV003=%SJ"3^#J\< =F?O EP3>Z[E/TY=S,
MYN9),7LX+:'"-.BYS*W<%_P&L7L^%=M88)SBQ;]QS=Q]!<W&.CNOF)R(QWU,
M'45]E2_3W)NS)P9OFB^+1,"6" _"MLG:;7AZSZK'']Q?[9Q:6N N2DU_PA!6
M9/BA4Z$$"UQ#'FDC0*UT,*J:4+.U-9HRYK<3CQ/[365??,SNQA=5ZT)VL5R/
M;JFIBKRYT';C.;HJ:\8T4GK%=*8D\4;5_6M=U&6S(CV[S5WKXU5PD2'%BDX+
MA[!,SH*T0&!'^K$'69<750=M8IA;I+Y&;;1ZV-ID8+U:W:?9J>IAOX;HAQK[
M;$/ XF*-T1$L&$I196^L&=^HOQQ.,B=U[&LJM^S(*^$V[&A9ZQ70\OALR0G,
MEU%0[C$7<-7QZ\P>,\'Y.AL6H"_*>.7_K?Q4*N$^5%AVS6E_POE<3/*F]5>P
MI"G*##&6GK6L8N].8J]U2&+OO"!/V=V@>,E2E' HO? YJ)A2HI\.Z<1QA@7(
M))_Y,1?UY?H]'N;E<2M]]BAEM2TA(6.Z>L'"T(Q=51%!<UN_DZ2+6G*MZ;U!
M&7.M[_OC&=T4&8+8JT[]H">?DX7(OFG;)N3+C_225:^\_SJ=7R8S%6C]_4I^
MT E7I%VS.&4%WS3JUPRU _6\8D5?@HS+5B:[@S> MVDJI'54Q7=^%(0%KI#B
M^J'TN1 ZD 9&WH(BP[CY=RE4^T=AZ_VD*&((2H'1(P\+2#M!%V6QP#+[5RKK
M(K/_<>5_"%((;%#X?Q!-.,V9^&_?_4L[ITN6:J>^]\K,N*9955%>&2/75+[R
MSV6[_Z5P)=<BA"++BL9ORSOMTCV*>QRS)DJK7?V@4^P\2AP_XB@,V"PHT\;<
M+KUOM)1[^<BI)4XYKA+*LLS\0;+)15FZ5>H;9U_H>QYWDMIG873OXGNSEF,>
M#"9UW8"EW53N$$@;!"DH4)BNG4<X\Y[M;\", -^NBC<-A1L@EE%5.F7YOI%*
MB\R+BQ0#.+'J=\>/)Q9H*4)#7*_LZCOR/G\EU)\><;W+!3Z3J)E L>,]B>28
M(7UZR!BTN?WT4M)KW5LZ;P!2^@0 \'XR!/, \J?6:'/,I2,B9V?H H8^78!K
M:\K<0J= ]+% TPS*^E(PH!P+^-<@1T<U","6T6C8Y2ZLH\!6&$&\BW1$(J.1
M V=-5<6&%XD7Q="+\V@L()=;(_>J_+O2UL+9##22;RKG!/J[R9?LI*Z /G Q
M%EBPQPCZ__,!MK;L5\"XREC@=VW< \:PP'XU%J!-"0-"_]DEI;^%E%,@?1&^
M>HC.Z!F5FN_#>X*>QILD4RK,ZB\^#JS*.? +XS_XQ1F4=OTXD_3EWUT?^J>.
MY:)UB,3WB<M2L)"]8R1*(H\N.(IN>^-EQJ6^Y$YP3IOSG9&SR(8AKFAD,CR:
MRAIR6S$U=UO+H%+OPBU%+_[4S7WB?LI.N].[;PD2S,TM%%R?.\. ,^A_ZOV!
M>3CT=GF)T;SZ=>17&P^-R:W7B1HRL>AR[6KVBLF,AP9^O284U):=H+ \TC8^
M&A6$@N#V[JN=<EK4=-_2B"/C+U_2G27(3+C]0MM*Y$P8HH8FDS0+\[\.GUV[
M-!$RM4U\K/,]CAK<\@K'W$XNN3V)2]JF9I6$WI5LM2<P?7VDVT&T*E$1O^)Y
M1@L$=4>#VW'#DH$H\C$A^\PT$H(%]& =_M)5>=.%-M!#XDHL4*:**CRFTNK\
MY[!'_ZVBFL*]C__%."#_TE[ZGQT5$B+'(_U/4@ 9'KC>=9&7T$IH1_Z_15*N
MX+%&/M\"K_Q+%<OJSF3\3J?+=Z?9 @F/\$/TULL>&)PL-Q2QXW_X?E#:8F9L
MO%!5.:W[L<[ PK1]S3!:B> 9H982P7HY V?5V5N'5Q^PP'?+M[.5Y56J79*Y
MG'*B=U=S];A1!ZKI7D0-%^QX(, UPT<FR[42+]TK7U.&4-^;X"4[X8H4.32=
M4"C7ACI7JI;7AS2_L# GT@)$PW)B,3I(P$'S@B5I+^"GFWD^<JR(DX;%X"?/
MZ &PDI$'*"MKJ-+CS8Y"K+6'7C*/*CK9A..PJO8/K-;(W/+/@C2PH2\=#W)V
M2=#=D/T9:+"J24V8GWD6$J)LKVKTXU+2Y/V@*TLI>M1L_9@!\<B"0XBZN)IU
M5'=J")T'_:OM%W011.5/6S\[>'1$$R="+Q\+W+[\%4FE]B$ZCK"D-PHZ[6%"
M*3T'VO(F13YI-,<"\GH56.#-,!9 Z.Z.=&_U</2H"/0E2%^=XLKP]\^&[,%^
M"RZ:H+,TZ'AI&LN=L36Y#A(M#X(M\2.@Z!M&G1B0*A9HU\0"5Q/#L<"&[3CD
M0-P<PUEMR#(Q8^X,GGZ(T=[/J.0[,\>@:Y!::)S$;BP0,(/B6C3_OW= !]KR
M:AD+7-!61:-N)F*!L)S+F]#^ID7,4/1AAA\Z[Q\CE.^?+8#B!U]:+BR9X]5$
M^AF%US7J%[_! N9_M-@TQT-I+O-8+)?HU8?4%9C.^"=8'N;7>Y-_)+IYE:G.
M;C4V1ZVOV]I.G;9(12G1=1M2R8<ZBOO=.\W38"R0[@)=P)GIM?2P0])''4TQ
MN>G38R]3R%,##F,.9<S2@G3=_$G5!]WL3,&*EPK!P=^(E]ZRZ]NR;X@]P;@7
M>F*!>ZK@2QLLD#DV;3_%Y%F7L8I3%S(!.UN%(,/DZ6*IY^=CQ>]<<\8"47J?
MR4T\^!L3.E$!9A82L%$V<_.ZIX<9$DTSO@W4 [')G6B$D9NF4T52A7ATPBE"
M*3,8A.G6W6-)G[NMT%@/G>_(,[O?3/A3BMQ#J$KGA ]Y&HUI4, ".93O]MK&
MW\W[P/=^X49Z *DKQ;L$_68/\>2[J,(""5;#E0VZ/'P86<J,DVYH/ -H-&.7
M! M(KF !F#V&W#\+NIZ6<;8+:\G/_M@E/0@[ZE>_/%U84IJFPGC_-76</NQ7
M2/_;J %!_TU:X#W#L23>;B)_C;"4?Z-I9=K&<5JA!B.+(^[>+U(.7^E6'<)?
MDGVAU6<IV[&'E\^_.BDK*T"'3%PJ;S$:7*I$=Q])O.MW/L>-]*8,O5]*XOM=
MOA,2XP^\TG/\<]*I>%%W"(I"V?'Y!FHYM$,ZO MV_72]K3AY*TX3PA;Z;8QW
M?C[NDGYEI7DFG-\[N;[V5*S=;;S^9JI5@726HU7UTMF-G9T9>?JO&BK7KJ[
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M)I%C'>W8W3=I3N*N<3(,"A0=2G! WR#6V!?*]>3H+-LTR*E%F"N.<:B2WGW
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M$4RX[<7."<4A5?.#/H25^K55]7B1NU88PRI_YQ5<0(#PX>)[.5)_>@4+_ R
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M(O1F,#]P]'A0S=O&]GCAC3RTW?AY72*:T;$>.H4#2#L%Z106V&R$G8V!K;#
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M(3$I>14GO@6#ILXP]A*R_[\) %!+ P04    "  .@BU:VM"=W% P  #2-
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MB2_$67II%\FJ=NZ1[FBQ[CO>G_7?\ZS&2NS>R?]-@PC4+7:]"075@>X>F&$
MOLGKC1CUA^HHJ.-WB6I(Q_!U%CM<PVL1&DPA_[=U94/'V@7?P  Z'%HXUJ;\
M\13^A;>Q_FP"Z6\9TEWNL6)UI#D4Y1UY!N*Z3TBM'K338$ 0%PSH@3,HYE7O
MZJ]A.-U_3X4!&VSS+%7/+O$H84"8[\;)S78A:$T9!L#7U-5VZGE_-B4!@1=]
MUU&72BQ(?3!@W?BZ!>IMDW5-  /N96DA57Y&,$"T;NP> P1]TI88!9QV7.NT
M<\* 3'TK*'('W!CY>[954M 8!P\,0#3Y[0#SW$!11RCQ273';LJ?J]*\->D>
M\7>?.^'#>&<:Q4+#AZ\P26)I(39M^D;%YX@(H>>O7O]GH,PZR@+.M/\,L;Q_
MA G?XH0DU3\#S!H&A#+M0D%P%[6K>)RKH>'_3R%VR)Z7CD66TQ2OR,HYN=G.
MNOS_7,;^_P@";/Y_ %!+ P04    "  .@BU:[P.<"*II   "=P  $    &-V
M;5\Q,&MI;6<Q,RYJ<&?LN@547,VV/W@(%L&#:PCN[IX$:0C!M9$DA" =(+BG
M"0DDP25 D$"PX!"D<0GN$!P:=Y=&&^N>SG?MNV_N_;_W_F]FUIHU<UB[%^><
M.E7[M_>N+56%GD0O "3J*B 5  L+"WB*^0/0T\!# !<'<V'__L7#Q<6[27CS
M)C[^39([!+<([Y*0WR4C(2,CIV*@(:>DIR0CHV6AI6=D8F9F)J=AY6"]Q\YP
MC_G>[TZP</'P;N+?)+YYD_@>!1G%O?_VA?X)D-[$LKGQ&AOK/G"#% N;% O=
M!C ! !8NUA\7\-<+ZP8V#BX>_LU;M^]@&L!(@!M8V-@W,/QC &#>^F/> SBD
MN&3,0DIX=W6>X=]W)A=^&YU^D^5!:3.%[M !J\ASE\!;MRFIJ&EHV=@Y.+FX
M1<7$)22EI!\^4E9150.IZ^D;&!H9FYA:O;!^:6-K9^_JYN[AZ>7M\^Y]4/"'
MCY]"8F(_Q\4G?$E,RLC,ROZ>DYN77U9> :NLJJZI;6EM:^_H[.KN&1X9'1N?
MF)R"+RXMKZRNK6]L;B$.CXY/3L^0YQ>_<6$!V%A_N_XE+E(,KAL8M>#@_\:%
M=</S=P-2'%QF(3PR)1W\9\YW[PN_O4G^(#J]M/D6BXCN <5SEZ';E*RBBVR(
MW]#^0/9? Q;XOX7L[\#^@0L.$&!C892'30HH )?\8=H\//ICKXZ]6*H;DWLB
M0+H4,AID>Z\SL>?>EV1@Z\:7.IPT2&^;IH&JOO2[OTK_?C.KT&2C<!;;U[TH
M9>AE%4F%H6-V+MC.QV \VZ5-"4*GP:P3&R#LO*\+-^,;2Y%0*RP0Y@TI%OQ)
MFJI:)&/WNL8CA#-+\/M2S:Y">RUC#F,>6]%%A8]9/^%TE/ZC'F&?$\:E8MO:
M\;02V\J+C@2AI(%%#55FW;I@YQ1&7SV[HB%NT$Z_#W=0^XK@'!C>E+AFAL=M
M<$NGXL7*,5.X99;VYQ3="3;H\B"!G6>,Z>P6<2W>M&QTRZ&JHS^K.X[ DBVH
M(2I9P[4XXUN$\5JX=7AK9D#/SQ42'U*]M;=!Y'J>P*W!)Q5 4Q!3D*LI-+3B
MJZZ#-)VE;&-&N:Q,+!.O)NS+T<]!+=,T4P1CPK=.TE%':MFVCQDAXC&@F]LP
M<C)GK;BY<8Y$TS.)/)]Q_LAB8TBE@WM.11U%I7#_G4=;<T'&V&"Y/-&1<EI/
MRI#'8P*5+?#HTAM:HJIKZ\^FPI;WW09AV (ZJO9=XV*^YL1J:0:-\Z=> "^+
M>9^+(D"TSOZ^F'T',J3O)%"T(SH%N].-(W[081T]C=0G2$I/W]8H-J9K']E_
MI5U)ZKAT.-6I_?/%@1W&MMU]Z2J<?W<*"R7$5ZD=.P%=A<KH'['%VLFH_G*Q
M8_,GD; "AYBN[M>;?-NL-+7>G3TP=C<ADWG,]3(QQ?HU,(@TTFJ7$:OF<+8M
M=D61.3"XRTQS%<O&E\=3LWKCD73?Z[F?NGYEKZEA63JT6)=T-G#+[I5CEG58
MW"21(/&#N:E^?J-)LZ[YC++5T:>1ZJAAM\^/6,@^Z_,B62XS4XY,;R]^EE!L
M#3NPF\Q0YRR\W.Z5$Y^9M31CJV>.\ZSYV2V)C6"/7[#54;']=B.$$T.9UKDF
M6X+UE9ZW7D=W#8DP=Q'E$"A@&^5._N4U#Z.__3@QB>E&T9K8;)^ ]*Y9KO)/
MUM29:.5BGLG)C/P9<[ )'.3N+MR.PVT!HE[@9 #E=^K!T,"#R4'N.320YS5:
M%EWE 6+ DTGR>.;Z!&.M0M)#PV5B#A8CCT9,3Q%?OC&3LI@/LJ3>R-UK.RWX
MU;O62A\63FJ-;W5B=BI_;#)IQ*>CK%];6UD*B]D[7)+Q]>I8CU>YG2\'$B6
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M#.KS2I7UE;]@O;T:,EZK9'[(YR./L0_S]:TX:-JU&V.6VQC%RJJ#3$>T:3/
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M&\KJGQ-:X!P)I<F,G[*Z:;OXIG'PF!J@B#R%'VY-YZ=.EQ<8<U<7]9?2Y_P
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M9>'J]+%4\'<_<Y);9S3?DPRO4:)#CO&Y7H3_#7/<+VF+:84E?>Z^F2\?5#I
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MU8^\J*AH4<:97WQ9UR \\,2KQ"QK4EW;CV?F%@V#Q8%'D';DF-:Y3_AIRH.
ML,Q)$ K4[%'HWM&&>TQ7D CJ<V-\?L7>,A8DPT?.J50 A(%G2-%T$=+/)]D^
MP<U#ANJV?GI*CCC?B1RFSWV%T=A'4'ZHST BS).:ZP99..H$Z!>8,[M:<<(!
MZY\9;*Y"@U=%:O?EED$;!E2)O)T_7L"13)';DB*%GUELFLK;5QE^[S]G$%)L
M@.1J/56<)_ : Z8YVS=D!TBL=]Y1H\B3UO3:9IB4 ^M?2!0Y6U*\]OA-*0$)
M((Z?$UQ"<D[JCR9>\ LX,&&&0^;7F3^)EDQK D-^2:%?!-LTD;3,SIX)41>V
M),ZJS/=?KJZP>\2(=F4T#FRU3H:SH<,EM'[> \CM3 6F3[F$IE7L72S.="S<
M*\G@3_%N?Y])O]A]8]]PZ)'JGW\AKC%URG)T\#3:@OMV R_-\F3TY50@HJF)
M#7VLC=G+TQ1%'O\1*^+8&"XJGB)31*Z(\84^3X.)-AJ<VFG(=9!<M#N7E/(N
MQ6=XB/+13]7ZAPIY:M2SBCGMA)*NI#D[@$]"P5HJ9S5=<7#./UT"[]OF0%6U
MDM6^J?JJ$]H%7!TE%%MD9VK432QN?DSQ\;NWJ QTVZ5?^@7<>*Y!2X:X<BG/
M&Q#ITEGQK.60(5RBQ,?H,4ZUFO1">6ZSE3W)E-.QZ.80Z]!^RAG[/[DI!2FT
MN3*9UJOK&F'Y(:";_9Y7*00M57J?ERL:/("2#G%7VP=?:U=!RLO*N<Q4RDQ_
M%8]5FXQ0 D,P?<XKE!\6I;FSC0R5'[^.[2[IHU777$GM GNEYS?NNYK Z\6,
M%[2,,LWY^^T/6L0:OH_&X6R(:]ENY-KD@KQT8LC\QD\ T!2FN-B'I,V4K9S-
M;3<2-Y$U*.OM/UI I1WZH/0DE%9'>'H-F5.D:G"';)DXJG,2F(OZ-W0)B@Y7
MNL5@4=$6+G2#1CO83/7AHI4-E'MI&X>B>S*/BWUEQVN7Q56GF0PJ0# 1TS5@
MM)V5("#^.&$;"-V8Z47= T*-U-5FIHEG(F4G],F_*#OG75[ZW;(K'II&"":$
MY$WSN--!6A(K+WN$B/L('1O0@3 +^&%!5XDU2UKL0X$!IWT=IY[V!=01!V25
M'!- 0\(9U4E4:!P5T;Y'K>47>]3MV=KB5P\P9S-CTRL.\=(7-)9\_S_]$0?:
M@+TI::KN- ]WO";1;3:'5]<^JU,2]Q'X?,>XZX:Y!B)OM-QM[U+-+$PD7R=;
M__F( %R'RLP#YY&B;5'K=4M7WDC/MO!S]=:DOP)(*7I]#P"PZ)]WL%*6F-(=
M"HY"UJI*55SLF&2?T;]B^?B]GX*#Z<G@<RFM*(Z)!R-FJ;^P*)H?\W.W*%Z0
MY5_F&FGY+$_:;\7<.'H@3X\&)V.\>?$A6Q Z$R<INQ'M_MOE0Z2LD J%\6KH
MY^0*W0>:^+R]D!9<$JI:W,-FK L2,/(V?\[_%)/J:H/D!RW89T[6XJ=1*T]'
M4]U70<SFAN80,MHBK48F'<!&1IZ_X0DU&_J@U86U=Y&ZX DB;N&VWO<8X>T3
M-.RRF18\.O;#9P.L!>RJB]?$?[@]KM)/Z)MEC2/C2R--OIG)G2+ R5;#<,"1
MO?^7'5IU)U>7CQ*^_;2+OONLL9M8%AD>ATI@ZQL.O[<:8M-U];IS^$6+M_'F
M6< MCB8]*^8-P!N@X>D@VR-L\R/0>H2+$Y?<@>0;+';P_\7_'DINLVGWCW-&
M]W\L29T7S"%*];[N9>+[&KBLV8\8J4R702$PV1(Y"-.CY\8\^8 7L:<":+\K
M7/ ^1,9E[_?M#V/Q3PF<QE(FZ&%$6J*G6>=YE?WIO@=\I4ZX/<AS*91)$C[K
M>_QDGR46ZR9 <4F((@ \FU?QY3.3 J\5BN35N#SU*_.DQYP1 09S3NQZTCQV
M@-/![*O$3,J8 3_'(*8ZN<G">3]"">KC?=Q.I!B(?5::R&OV2+S9_KR!RW$0
MZ?91>5[%-%D4'?;AO1=A3X23N=LMH9Q:"1%*LEM5S=11E][^4:ZEM>=(?,8%
ME- R:HT*^J2;3X68BJ 4)_:T4$^S:CZ.:P-+U,C2@=E8'(R>H>[,VG$^DKNH
M9.O* DDS-$Y4DCL.6]CP$%V:9!O58&5J+!5_'Y9RPKBE4KLLMBO^0[U%Z)P$
M;V<[>N51,5EJ%!2]8[L, +XR7AP07X1+. EX(<,[JF^5[&I,O7_^P=DUQ#\A
M7MDY>]):K%Q1^HUR"9DH.H3G?CH@-?/+#:#CG1^*9!+L*2+AT?/  :[9]3K?
M XA:A/W7( 2(*0V'%@H5<;FQ*BL <9 R4Y!L)^U:@-AF0ZB2UWHRW11-@CY)
MXTZF*LS4Y<$TL'>O"!HY$<&&L1NU( F,@V8KLX[JC$#>=^X_Y[S=<8T-QO ^
M>3LQ.Q2O7ZA0C@ 8D0N-:(Y9H%$+RAC:RMWV]W:-IDPY-_PH\HS$B8$SI7<Q
M;!Y)/&AXI8YH.,+\("8Z&4EU'W? V[BCV1?THMQ92A#/IMH LO?:XH3@ZE(J
M^1<8]+)T>P,W!C]-_/5G825E0C0V:^T0$@N6OJTFG;X90!%Q0N?I0R( NSV$
M#=^'G.R+G0]=*[3@TER^2NBG^P;%/38V6LP><!&3*^V4]<!Y+ F4W)E8DN=7
MCAV.$U"'=56R$&:=" Y<K'>?(Y_53<5K!-*O(=9'HO32H/6^9BKU&%*BEV_8
MD[I7L'>19'Y:[B^ROQNK-*B6-6XY5/$]"8S</DA;GPV0Q(A!8PT03\DC.TWK
M$PS=I:*64<6((>EPAY>S2VHCU5KICV8%"([E4"'<FK21%LX;?O8C;D[H>XD4
M=_3^OQ>QS:<*^#C;/"[-PC"\,?8QK^((E"1=9>@;#?8+]?LL24SE0ADQ G.U
M*C.2MR-G0[RQ2GZV?C*1-TJ9DZ]J#-9J6)HP-G%"JG2F>_(,=HK@?.(?>V#_
M50E+;PL/]8B 2VV8'= ,-U-V3\OV[!Y@,<4%(E/E?,G\P:">. "+?V7/N")"
M0KIP3^KI. Q?BC)X7EG?N*7'^VEL\[G7LR-H%#1R'.A06I9>2D! 0"BO4>[4
MU?3$R_]-<Q6BY ER1$*UW A[/S;.>T1M#22L-2LAZI._ PX[\YOI<C *IK^%
MGE+V[_+Q+PJ@%=:3_V'[Q@I)*S_,"F0!6]-GG#JV!'?= PA]%7(N<F3;4K86
MN$[V--@] VNVB?+D (H_6X(^FS^FZK.?^_4H=TYWO$3@G+BG"-([ST:UDS93
MGH-H>:M_8;$VM*^FWY9J4#>=>+3%\46N3064-:-3T^@!_1 8Y3(_5Z$OS]*6
M#G+B9U(C58W4_*""#D2OA.*J,SY#6WZ7D2PRHH0WOO3J>7WR<TB3&*^9/[&I
MZ[H&^D5\3P8K;+K4??Y#=2A2'[-&4?Z5*5_I8,?1&YD-9XZLP^=A?JLK.+WY
M*[DO^ZOY.5V(/%[\P@6@,_CB ':3$][5$ $VXL??F2O/AQB0QC4'  M/K_3X
MU\N [U#27RH$3%C?JCTN,"D=#?D2$:7Y,PCME"QDE0'+*UX!Y6-OV%<%\L-+
M,=;U8?J:]2TFDOU(<6),\HTWE%"U>,M&\0^2#2'CJ(1Q,B+933G/!#(G>$S5
M64%^#PAYO^[$MY.+DDSO&BA1*"*:_2TU/E3/>0\0QC!;!;M!"1T+J95GNFH
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MI1'.DRJ/,TNT;++[UM#8D!/T]&7/MD_)!G$(>N&N_>1N\:)13I@RDZYQC%R
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MP\G>@0%B.BG_VY\B___<[A?^&U!+ P04    "  .@BU:">+/?3R8  !JMP
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M?.'S\@^QXC/.2I/O\.'#;0US'\9?FX(I)G2H:),;7+FWE<3$6!(\U\\JOD<
M&Q6M%*OI_:PA:XI*Y/J*93KD=F?\]=N33EU:ZT_7Z9T,-IO@OW_#9E[%RH9,
ML]8T)^_JN&"FF;@P?Q_AWR#<I #E<KN+[O/O?-' POV&I%"=N)%A#2E' 8_
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M&\^IFFRE@^&K_'3REH]84X2;(E7SQP_JP'/40DVZ87&7^4$L@4]Q$G\O$'&
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MNJTO)M((JLMQD9RS,UTW1DRN:Y3B@H^UUXY9?*#?>ESF2W\/&*FTO0?$0*(
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MLM\4'N.3]C?EPG^&'T!OZ"OU#61!H!,<3?\G7YB<>]^;D9$Z >CD'T'_CB?
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M>ZL](3EAU&$<W]<VO =L8 /VG_\#$:-+S 5'U>IRY(W#RN8C?!BU:E.GSI3
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M-*NH /:#$,%DQB.6!=?/DI1S(5V#8!-@X8ZPJ.M2+TM^N_8+*V)YD/-&Z4W
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M_=OIN=E R:NZ$56Z@$JX?O\_T[C:2=*#QL=GH5D1'WY\UQFN&W$D5[B=^*J
M>9R-[Z4:JK]V0SL&TQ4?<%Y;5%*)7^-EJR-]G6/+8CDDS2EL':_I :TD!N=I
MCOL^V;EC@,6__N3./OE59K/Z=_GG.<'//Z)17V,1"%:HTU*O?D=J<^';T5&>
M\-?8HW$;S ^7@+UV;0_6G?V+[R1?BL1X-3@3!,PKA  #5$\2"PI*#:#I[E=\
M:S@"@?'Q7:+I;.GIZ327I"B3WF+3?'B?.C6,[-39$SH]^1"M\:9QH]388V]4
MS%V$*T<N*]::ACNO-@-6Y_4.#GX-DQOVNXH8+A@NVGC$L)_RHU@]8Q &O (
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M_ E]6]&)C6[K!Q2J$XX?SD5 >_PP?X-$SYRV>H59K7" BZ=EC^20"QNG1(@
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M]<9C+KA"S"<W4D'<@VY<1X\-,5 T VFYY< 5ERK')H&\7ZT?\+J4]2&AP[X
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MR>Q:08(E^Z22]0EPK@4*DQ2?>S"4/NQ2+#37(5'#S\RU!U!^^"3>L9#Q@X)
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M[OG@7V\-.;QM<^!Y8FSR-)(]R/7S=C<V4>;G;P"9H5S_G8(3W^\^C59"-V&
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MQ(!.&.EHZ@ :DHY5(F&H[:,4WZ5+?%_H%,O1!F0[$YO'+KFB+O4N\;UM[4[
ML(S]!=^)KMCRH[0S$,OYK@@ZPFKPEQ:0Z43_^EHB2^^W')(D^%^^%6*8JTUC
MQ%)E203-98 MEHAKJ_S7*YJ_[6<6>/,@S8XSDSR3N(^0WIQ=9://+8JO,NF)
MDZ/"D^PNO3D/BWX,#<)6S$9@VXN0%*<E2!"_PAG]KS?97BIBIC'+'A0B%B,,
MG^[<],VKE+N]SUMU7)+<ZN@>\@SYJF1J1G]&B:*;MIP8IS5WI^P9J/?!Z&$H
MJE]ALNU[Y/B63OB07A^[\MBP\%W(-8$GBJ\31&*YS&(H][]FW/3-=BZ):G[N
M'LOT^CM#CXJ1C;B<J:4#Y=(P=:OM?:[%1KMGI#*+&.!&IXG#Y3O.:3[^K%&^
M*^I3M\[H_>+N9IPMX WXWI7^/HE62S3U,-LEC[QZU/=Z&W8 -/[2?PUW!Y2'
MCY,5!3>2MK:F5>ML!*7R&5[:)Z_4^)+C(YE$<>OGC0SK;F?Z!>!'!"\.'HZ_
MD:RK1E%C #:T'Y8]$4*.7O[:%N#! .TP[(^X()3!KL2--^")__"%!VZA$GU_
MF6 H4\O=[(-FEV:4W+UY79@%,9X;\(V[7F:-_%YIR5Q-R<,SYVE86)U4YQ2;
M?NT.GVFT5 OGOFP%/B=QVHL'^P9':^W/3MWBL"R+!L5Q=34@"L+LN=N)L#F
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M';J?*NO B.@=#9+X;@#.??C_%'.=84ULW3IT!12D(R(H 90FTCL*THST*E5
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MSN2HT9#AZS**2-B RH\#0+!:!2J]\PHX5N D7Y5JR#DH@(.Z%A0_@*$5<E)
M^%*R  %94'(R?P8ZN5SB\[W!W.2-C<D>,5"<BN^=KSWT&<A\__J);=!\7-<N
M/_?"/H9H*\-%(8'?Y(5S6QG@:BV/# %#+C'-TWCI*>FOU;V[1J^#COC.:YIC
MS7S=ICF2W>AJ5@B 8R!A&=$>H];R8><ROC>$_Z]=B(M=T7U2G0"T"YG&F?YQ
MB\Y*YPW MY@7 ./L,]!@D3&[O"?C_[AI=QF FCL M8&_H(: S1>;GU>QUPI_
M5K'SKK+/[#OE<[@> A8?4I39H ?Y)I?W^!@3^)7[Z(L>B0MZ*4CO2I4"T]]
M;TA?C"3+@%$/>H-XIB4N QV2M5NBB7131Z1/R:^COYWLV8W8YP)#'[8I+9?
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M!DZ\&R\R9XXZIOV$&-T"EUY#_CH#I9S3H^^L-6.-J_6-0(Z-[<7^1IW&J!K
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MQ^/?Z]8[%N,/KXGJ=0@RLPR?":QT.72;DVD-]E /)=>K8M]A$%F*/Q>*C[J
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M=C*7VD_6K(5YKRJ%#R:)=K:CP@D;@%KG!<DVW[MU O8N$VE.MV&0"YR<6;>
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MZ#Y0(6NS3S,'BROR\_N4:#2IE#FG7VB;5\R6=.G7>LTJ4-]J]56N8 I& 58
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MW4BP8KZ[63#8G6CQ7>2M[)4W]KX^%;EY;A\K*#AHQ2!E!021EXKES,X:^KD
MZOOIN0+V7@;LKEVB>CV,#"J>Z_Z6Y^P)'Z@(R9<I<#8[2?5/WR=S+2F$27@O
M)UJ8O8*G1G@U&K'*S!=G*@J$G=;OXXU'9@2F3KD\J%#8N[T\Z:<'.HB4/?.<
M;.QAJS^H*)4;9MT-[%!A4:E>%OG5X4%9!@S-@JK"W\$&8B*GM93+$X&L?!2J
MG3+]D([8\D)$<I "R=6O-?$XOU)R$X)T1\Z1:-H,%U+&AUJQ?*U8#06E\F+O
M0[% (B?8584('79!&'Z==ZKQ1[5UASK_4&&*F6Q?8/:/;-A%AX5)A5EEQ/CL
M^S&M 7%WW&ZY9=_F)CS7U-'"86 @\^MMAF3?[J4EBC458F%NFN1'MY1(/9R%
M0=$\A6M:SD=3+9(MOS)R13JQ"V%;8=:F[F!@HG3OD&)]][/+>]1"U%%UQ146
M5<%%E!93Q-K&BCTA+2&/WKS\]I-5AF#&E7KE)&M50\CT6CN:TF7L6Z3.K)3Y
M69?UBIQX*\&9/O["+:TM#.!WG0394>O=K"2P0]++$.J((P/Y5PL1U[,-6_VY
MA5GIF0V?7/S'\&$&K!F?4F8I4ZF4:TT<.^3RT>LK]A=7XWC,L6D1777$J^;6
MVX$=K[-G108NAM<+P4=?TY6NRN*)%+H+2D3POV>PT)5,T):G483.R?E+<=JO
M[HJ5G6P;$+N5+"M*^X^V//+K<@J+UOCV? CG-N>"W12#!$0APNWCB Y4+9)X
MK[($)EI#N+:KH:9GMR[FDS[^630>WA3$27)R'MI95A_VQKSRR]W!KH=D8J/$
M=X&!H.@7QE^DU\GG>S:;+&&7)T61\^TJK:[F3M->!6<6FH_)F*R2Q;NY[T@$
MO4X\D[#\<E$D5Y\IZ..D^LB(7EX^-,)^_986.0I@OGFI#E=HZKJ([E*^#'4O
MA_WBV%EWDR?[&,^HHO@E&X>!5*_[:XH]WF?MW=LLS9)^<[6/#P7R#/3D*H4X
M*]->$\5L._J[WX[KGWGS)M2XT6.(*3AT%\]1MYM#Q0 [6.30CX_/QI";PO4-
MM8].5IXF4L4N&]'!L?IY+ P%F,Q2&=F5F8X3F4G]<-I_9RGA3*0=[7\GR.3(
MY[WO0.@7R0^AZ^/E&1/&L3HUC6"M*7OS,QEL@V&FO19;?&C#D=]%Q,NQBBEG
M/5 9OS7Y\8N ]5_O7T2$AN\>F22K67W-@^<6J^E;;NUOF+D_V-4\>CS=K:/4
MZHNC)M&P<5_I)ZGO<P(Y.D+AE:5:/0@I# 8FWC)6^IYAID/\I.9Z1O8B6F:^
M=O[;SYQ=<3V!AE)8N1IONRV>2HE=!U-8$%[J1TR)#C$"M\Q=5B?HDA8[Z-M:
M?N:!44BQ.-F2186<J[S51?@> #+>F7Q]QQF]25D+>6AFMM46I:M+$ )9XG 9
MD1TQGG5T@#^3((($07]0CPM_:U%?W16L3$]EZ4AS.M_P; HKIP(16?RX:'UF
MFOCM1:CQ^D (Q0"\!U'*UG/E/7VZZW&L? %9\%3&W]A%1JU^2QN86]_OACRX
M3+8Z EV"X=TKW=]E7V4?9&=[ B7:B+)Q<UN7K8X4P2C MV[FM(;E)=__A>]
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MYJ:[QL5-\5@K"&:%Y]43W>&V\BZK^K!\,,7B9(.1]ED-@<V/T#0@?XZ8SP'
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M6U3VDV!+D/.:7!E/QX$"*X3?!LN4O'CP:#6B#"\#M/<+R4ZJ'S%([,VLH/G
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MB8ROA:%HQ=\O?[@K@-/^"V5_,G?F=I-&;,?P@Z]@@*H"_"=E4G^R]0=TB?S
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M9=:EY (? /V\D >ZXD< <^X L!-$)-OUJ.?+A*XN7@[@KM,ITI)G^G>FH&!
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M)".) :!'$(\%]U-M_;@;"T3LDS+V5#X$I;_^9441BIFC%Z&N(X4,H5.DSJA
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M!G'JF*?^L$)(I9R*F^A2;Z/;HS')J=,LMD&0&)OT-A\!J_@SS5&"ZE -L-(
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MA%571\AK(4;AXT2RWG6+'=1PV05?IC^3AL=+0<Y=O3.?Z1$.89JRM9-V!1_
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M[&@3)[[1'HYIP'(@H-7F7:%YR6QG9F_6CM![]_"DNFL]HSS7,'O(M+WF(2/
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M&QI$@?< LM#*M74EP58]\LC:@F\X*=7W@,?PG<5JS3"G77;L7&@''+5I(ZE
M3SONV:)L_L6W:!\ZV:%/S#]%7BS-&ZQ,M8L1P((^C, T\W>*188@2Z>(8FU"
M::!(LL]7ENCO78J*$@#&UO(ZAF\X22+,RZ*/5U=<.FV0=BFQ&JIL<.6IJ\=I
M1H\?Z513IU4A!?PZ:C5'_7S ^ DUKVEEB#)<LI.O)-93=$Q\F3BL?HX6=DJL
MP)5AR$BC>G?1Y(53"-HMLKA(MDHD(LPZ(/(? K\(T6I_Q$^#K1YHCP/4NL,X
MT@A8LL'Q-K;@''SAEKX#*GO%-6#'?;M-ZW#Q=<EACP$Y*_DY#SOAA4*?ICTY
MUV:=:+A]OD3&FZ^[?*=*Q;#75=WN=U9]&9UK]=?Y5.W#9SV[^FF2_'\<!4PW
MZ6NY^B)9.,6U[,7'XW>9(T&VTA+%!/'+0[\('#/^.""X6'+N^>KO_H>QNW^V
M2907!>^*PXGNY&Z#_NR(R"$#R:P-*K/.'2\CTM;-E;7J$ Q>[F8SK!AT15 X
M1)]I.T!Y=URG<]W#!@-)RNAE69?=\AS\(WA9?GH!R)-EC9)7U ,7Z).E!W%Y
M6;J1Z7WVL!PS<+2#.EIP*BLT=+])4$@\=2N+_#'2N<*.KW59K!3\$A9,1]J9
M(XE$4;KV:!VP399.C-.P.1+@KLYT(K==*;B*#:8$PW-\T0_,Y3TL3-)!V+@"
MXU6<9P![<(GOHN1H4&!U8SBJD\;$_L>Z]*7^EWV>&TRX6#D,C&'V9"Q/1.Q4
M7-^-7=.OODH+XZ<$58W3!= K7X2@(;6\GQ2#;U?7$-$5K!)HSRCC5W$^!9#0
MIG]6S0W1HG,U"\]*X&/:VE&/BWA"?<:[Q6</TKC06'Q>.M#0;]]3<^7:QK'S
M=D5ZYAX@,FRFOI\HM6<9%,E2FBW455)XET@?S(OA$E<AJ/ZDCW.LF/.\9/+E
MB7+MC< <2YG=KHVP3K_C]T8)/*9>!BHFPL%A):NEU2W02M]1B@]"KLHJ<^,Q
M%^8[64#MMWZ&S7%-NQ4,#'TBR6/3^*:"$&)KQP0.65VR\,9&Y$$W8]<A]ZJ5
MW.IQ3\/5X/1!!MJ*JN#AUD%^P034N=:*7G@',%^1BUM]_WSV:EB0Q6VMII;#
M0#0.<2+E&+E>S9(CU&Q7':F'R!O G+S U9U[.Z* AQ_#3VSRT5:"X@OO-B77
M" M$1*[($M-X_,#&J:7JIU'<_IBD@*E&MS:%@]^%)J:@==QYOS>.JSL:3(PJ
M4J7>"_RA9M9))%TKD/$9X,WW5]\[3#)4[-UYORC"K?D5ITY$[D+.O"3;22G]
MG>3C(5RO>=WV(&.:=?' 0(8)/9SYDT&7"#EBC%1<U]9Q1U%<?6/3,4^I/&V=
M7\JRN!MR7YDKUT>(I>69TL->]]"4TU6'N_8;ZY$*NG_ X% GH5U"6F@$BQ))
MP8+:KL2G.UP:CF?M"GA*KS,1^6'$8P)SZJ_[31Q;!Q6$=H;:*R4\*JK!@OOZ
M!C^U](98?KXM:E;+[$*GSDA9;\>1##'4TH2VE/I%IZH=*8 =6*$_E3"/.>5H
M[ *ER9_)&#.BV/,H,'5U\5)S!PBKI7].GVF["7=IZ&RJ%F,\-B@MT $I06XK
M1&$.EO8#U77&/T.B3A2?QG0'])P7DZXW!04YXI""^!(T3G59[])'1'[N]= &
MR@#XI)W7EJ+GUBC[=\E LV=4]$D;Y[0< PYV%$TP)9[1[[*K$@G.] "DN5B#
M4.^'12(FJ.'G F5C_<AJ;2!UN1LB:6 KJHML $YDI!?EC!3>=#H@E=V=O=4L
M?%06R,/3D*SYO=[C'B#8,43;2(M%C&:>T%BS"AH<B\%YYQH (?IZF]Y0-42B
MK57\B)C\F0=I-&0S!J[K'[#PY%U)#&I?IM4^"F(06RR^<?F6;4KKN+ZJ&5?.
MBG3#[:7_\L;S[-[UPCU=:^Y#73@SZ([VJ*S0W"9/=ZO%<KRZWSP!+F/A*Q*#
M%+7WR2AVT.VL,,W (*V%\#W08<C79QA)7O\@-^?2:U9CS.BN!YH\Y:Z-(9^T
MW@!21Y38!^J7&&8*Z)=("ZRD>&=O8V6Z!G*;YT@46-BR= D+'M!&<?V,[B4O
MN0?0^-6M%1+31#!Z&3%;B$G;>0-A='8([2KK=)/6S,>O>LA2ADT3RPO."X1"
MSL-U$)TWX-5>MNJ>,([MYX>!:":G@]?&_!6T$;;8G*WG&_7': %K"F@ZS=]K
MQXQ:H(TR_CP#8,37#"NK:;K70;9S2"*1;RQ7=:Z@MSJKCGL7=^7 H*R:&SFS
MR=J:T5 ,,BWKC[@=5X[[K$VM<VH-A+01$JA*;W >53"7L2?I]19;X"M+??C+
MIO3_%Q?5^YN_)NKLO_9.]YR[HW.67)9I&9$B6$D?_M<=]&JJ]X#NZI:#C'65
M\7_\?$UR]]>#X^,3_WJPO(PR:R39;:;XVIM_?H'+<UY>TF*A].M9]3]W"=):
M=[F=E6?UM_@W::^N-+_L#-]?2/'&N@W;1QW':A D*LHP %U9YWKGZ-^6OV^,
M&?5FS5HD6<O&Y,KX(*4U[)@P!9/(W]JV3=CWX/BB0-W7G;%",Q:2C(-E&7O9
MYLF\7O)0Y5MP<)K]>H;]WO\>8,L^E'%P:A!K-R&VZ-,35RN1?YG=0:KNJ[5]
ME=*&HALF_K)*HO'0S4K"XG011) &]'+)6^ST @I+.*"SDA=/R*%0-G=,E()E
MZD:<A*\9T6.8A>M9[D8+- 0I< 2&:K"%EL96AP]TWXY#T0EE\RICX)Q6(VFC
MOV9KHK=_^ ILVA;J);387M3LF79YULI$KIM0%U)4C-9 ;M17,+1M3()4(1=C
M7GGVQ]D'*1D+6*W[GY1^UHF,7PT%V#A2J*J,G7,*R8&LJ[IVK6;->A4W#PH6
MI%>[I(4G(+J2&0K';+G972:-^D) \BJ9Y\N22+ (6RZ93W4$Y,.)7W6421=H
MITRN75(*Y?@1_G)84\E%=_99^WIKE*^7^!=V!U@W@Z&[9XZP\?2/1QCFK_!Y
MHGU+"+Z06"L+"HHS;$1=>JO5C6]6CI[-7A_%])*;LI(+^PL(&KR+CHZ>CF(J
M38\OLB12T9D&U6JJ=F9P,62:F;1U_P2LI@N60I2\D!=>W<U-A.^?+[=$#160
MSPMV'T8<+46'F7"@4'9E-4WP8LGQ&>K#=C?E[0*[KWJ?</%33/MDY*K'"+Z(
M7T[FBWAK7!*1JRV[\T042Y&%/3S%()3,SS*T*?\Y7Z?^K+TN,;(MS0ZGJ@6K
ME+-A9 =\S\4ET="&J]=S13>:1X[IW6HVOBESG;/ @+G^@K[A@KR;E]VKSI\#
M#7(F@F:\HEV1Q=H2J)V()!<0:AL&>=6;GM+TK[3N#IKE(MQ%,BL4JE)C+ =.
MVCR_%@@]7$DJ";[,O1[D#B&JTL59,-.;JG5H!V'68O>:!0K;C?6I=!X]N0>
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M=V,*S>R=EQ)9S,>,MJQL*II_5^M[ !1Q)?RA5C5TI'&#L)>2?CZ=V/^J#5'
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M]5<>!4D=#Z9<5>@,$Y]T19V-_ =02P,$%     @ #H(M6EW!M$OZA0  "XD
M !    !C=FU?,3!K:6UG,3@N:G!GK+MU5!S!%^\Y!()+<)<$=W=+('B X#)(
MD 0+#.Y.D* ! @0/[A!D&-S==0B#SN#N,/C+[^G^\=Z>W3U[^WS[GZIS;W^Z
MJF_=JG/Z^>_S.N"5JJ**(@ %!07PZ=\%>%X"R ->HOTSU/_<T5^^1,?$P\3$
MP,!\A8.+A4?\BH28Z!41$0DY+24)&0T9$1$5(Q4-'?WKUZ])*)E8F1A8:!E>
M,_S'"<I+='1,#$P"3$P"!E(B4H;_U_;<!2#$1"%_P8.*\@;P@A %E1#EN0]
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MYN:Z(2!1RA6$3_#B3SA5$RQGQE?I[F\XEK[_S%^O$']&$)P6A6ONN]-67YK
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M!.+;B2K96386F!(TZS1NIHWAE79W1]'FAHLK\IAZ22S-#;8XG+$1IEW.2L\
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MMI+$4?["(TO%BRA*BR@..9*SC48\:#=7EJ0Z$>BU\* (=H\-MDN/3."<W-)
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M:!$'"TZ:M%8F#']N;3.:EF1RR,C;1@_-PQ6)_U":@2NDB#=[HF0PX+!HA-]
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M,VJ._^>2AC+\W=]+HR90'0\* S"'&MJOA0W_I Y6(, 5'Q\SQBO"V8PSU+O
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M.7EIQW1]B]6IU2U!>D]QV@.7\X=<LXKR=ZO"Z W$2C0M 'Y&K$NSTZ]WTA5
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MP;^R6?)* C=.$P!R1-%P>$>S\SY231X"1;%_"+8S+Y"I/C2$GP6 HR<7E .
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M8WKW$LN5^.5&(&A%3ITQ&L[_539IIG=#??IC+N^:S5H"'W,KNZ\7,H=D^].
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MLKMU4(#O::>H[M\IX@:.=XP)5 ]5S,CJ<\G ^BW8->BSF^>%B/C:5&!LP#U
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M;(^K%%O)Z%T?*LN9G=TO6Q )28@I@@.0DC6__NUN "1%T?$EV4JL^9"1)1(
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M-![Z&C0HS&X'AG%#.9%AQB.3K\U!T9E=-GL9BH&,8>"^B-3T%1MS0!5AX/T
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M$ !/^5B\6K.GW&A=CZ=U_?14KWV_K\+9P?\#4$L#!!0    (  Z"+5I$MG!
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M!R//6]XLML%B"I-@/7]UG7F(^(7!D4FV*R!,15Z26J6@C@RX"%.9I9(JG@K
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M:;Q&4?NP?-;^JEY_HX,B$6G. B-X+D)66)D.6??-V[/K]]SFPM3KG?9AV=5
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M=P^]WY/0'Y2ZWVCU\75ASU7AV ?PQS>1YSASE//)WNP[GP%02P$"% ,4
M"  .@BU::>B[!943  !?VP  $               @ $     8W9M+3(P,C0P
M.3,P+GAS9%!+ 0(4 Q0    (  Z"+5JT+SE/1!   (;$   4
M  "  <,3  !C=FTM,C R-# Y,S!?8V%L+GAM;%!+ 0(4 Q0    (  Z"+5JZ
M/N-%:",   I( @ 4              "  3DD  !C=FTM,C R-# Y,S!?9&5F
M+GAM;%!+ 0(4 Q0    (  Z"+5KE=-!SLF4  "1\!0 4              "
M =-'  !C=FTM,C R-# Y,S!?;&%B+GAM;%!+ 0(4 Q0    (  Z"+5K)=L:+
M5U   .F$!  4              "  ;>M  !C=FTM,C R-# Y,S!?<')E+GAM
M;%!+ 0(4 Q0    (  Z"+5IJ',=S6$8" "K:%P +              "  4#^
M  !C=FU?,3!K+FAT;5!+ 0(4 Q0    (  Z"+5H@,1BK&DP  &56   0
M          "  <%$ P!C=FU?,3!K:6UG,3 N:G!G4$L! A0#%     @ #H(M
M6D-6O1=-10  SDL  !               ( !"9$# &-V;5\Q,&MI;6<Q,2YJ
M<&=02P$"% ,4    "  .@BU:VM"=W% P  #2-   $               @ &$
MU@, 8W9M7S$P:VEM9S$R+FIP9U!+ 0(4 Q0    (  Z"+5KO YP(JFD   )W
M   0              "  0('! !C=FU?,3!K:6UG,3,N:G!G4$L! A0#%
M  @ #H(M6@GBSWT\F   :K<  !               ( !VG $ &-V;5\Q,&MI
M;6<Q-"YJ<&=02P$"% ,4    "  .@BU:AN'I@Y9>  !%:P  $
M    @ %$"04 8W9M7S$P:VEM9S$U+FIP9U!+ 0(4 Q0    (  Z"+5HY5&<_
MQ&8  &!T   0              "  0AH!0!C=FU?,3!K:6UG,38N:G!G4$L!
M A0#%     @ #H(M6MA&<-!3E@  <*D  !               ( !^LX% &-V
M;5\Q,&MI;6<Q-RYJ<&=02P$"% ,4    "  .@BU:7<&T2_J%   +B0  $
M            @ %[908 8W9M7S$P:VEM9S$X+FIP9U!+ 0(4 Q0    (  Z"
M+5KP)'X$%A@  *JR   ,              "  :/K!@!C=FU?97@Q.2YH=&U0
M2P$"% ,4    "  .@BU:1+9P0+T"  !E!P  #0              @ 'C P<
M8W9M7V5X,C,Q+FAT;5!+ 0(4 Q0    (  Z"+5JG(/,^\ <  +I6   ,
M          "  <L&!P!C=FU?97@S,2YH=&U02P$"% ,4    "  .@BU:)W[@
MA\T#   W$   #               @ 'E#@< 8W9M7V5X,S(N:'1M4$L%!@
0   3 !, E@0  -P2!P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>cvm_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cvm="http://cvm.com/20240930"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cvm-20240930.xsd" xlink:type="simple"/>
    <context id="From2023-10-01to2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-10-01to2024-10-18_us-gaap_SubsequentEventMember_cvm_ErgomedGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ErgomedGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-18</endDate>
        </period>
    </context>
    <context id="From2024-12-01to2024-12-31_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_UnvestedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_UnvestedRestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_CostMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">cvm:CostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_CostMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">cvm:CostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_CostMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">cvm:CostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_CostMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">cvm:CostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_FairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:FairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_FairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:FairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_FairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:FairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_FairValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:FairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_EquityProceedsFromSaleCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">cvm:EquityProceedsFromSaleCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-02-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="AsOf2023-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="From2024-07-01to2024-07-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-29</endDate>
        </period>
    </context>
    <context id="From2023-11-01to2023-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="From2024-02-01to2024-02-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_EquityProceedsFromSaleCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TradingActivityByTypeAxis">cvm:EquityProceedsFromSaleCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2024-07-29</instant>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_SeriesRRWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:SeriesRRWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-05-01to2024-05-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-04</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-07-11_cvm_CEOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:CEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-11</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_OfficerAndDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:OfficerAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_OfficerAndDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:OfficerAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-01to2024-07-18_cvm_CEOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:CEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-18</endDate>
        </period>
    </context>
    <context id="From2023-01-01to2023-01-11_cvm_LandlordMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvm:LandlordMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-11</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_us-gaap_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_us-gaap_LeaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_ErgomedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ErgomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_NonQualifiedStockOptionsPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_NonQualifiedStockOptionsPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_NonQualifiedStockOptionsPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_IncentiveStockBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:IncentiveStockBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_IncentiveStockOptionPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:IncentiveStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_NonQualifiedStockOptionsPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_StockCompensationPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cvm:StockCompensationPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_IncentiveStockBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:IncentiveStockBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_IncentiveStockBonusPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:IncentiveStockBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_StockBonusPlansMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:StockBonusPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_NonVestedOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonVestedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_cvm_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_RestrictedStockAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:RestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_ExercisableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_ExercisableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_ExercisableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_ExercisableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_cvm_ExercisableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:ExercisableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_OutstandingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_OutstandingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_OutstandingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_OutstandingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_cvm_OutstandingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">cvm:OutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_NonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_NonEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:NonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cvm:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_IncomeTaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">cvm:IncomeTaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_IncomeTaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">cvm:IncomeTaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_IncomeTaxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">cvm:IncomeTaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_TopMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:TopMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_BottomMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:BottomMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember_cvm_TopMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:TopMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember_cvm_TopMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:TopMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cvm:RestrictedStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember_cvm_TwoSeptemberTwoThousendTwentyFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:TwoSeptemberTwoThousendTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember_cvm_TwoSeptemberTwoThousendTwentyFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">cvm:TwoSeptemberTwoThousendTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cvm:NonQualifiedStockOptionsPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_SeriesSSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesSSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_ConsultantsMember_cvm_BottomMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:BottomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_ConsultantsOneMember_cvm_TopMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:TopMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_ConsultantsOneMember_cvm_TopMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:TopMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_ConsultantsMember_cvm_BottomMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:BottomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_ConsultantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_SeriesNNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_SeriesMMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesMMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_SeriesUUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesUUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_cvm_SeriesNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_ConsultantsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_SeriesNNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_SeriesMMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesMMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_SeriesUUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesUUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_cvm_SeriesNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_ConsultantsMember_cvm_BottomMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:BottomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_SeriesNNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_SeriesMMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesMMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_ConsultantsOneMember_cvm_TopMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:TopMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_ConsultantsOneMember_cvm_TopMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:TopMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_SeriesUUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesUUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_SeriesNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_ConsultantsMember_cvm_BottomMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cvm:BottomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cvm:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_SeriesRRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesRRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_SeriesNNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_SeriesMMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesMMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_SeriesYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_SeriesXMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_cvm_SeriesUUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesUUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_cvm_SeriesNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">cvm:SeriesNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-01to2022-09-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-10-01to2024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2022-10-01to2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-01-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2025-01-06</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000725363</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-10-01to2024-09-30" id="ixv-16398">0000725363</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-10-01to2024-09-30" id="ixv-16399">false</dei:AmendmentFlag>
    <dei:EntityVoluntaryFilers contextRef="From2023-10-01to2024-09-30" id="ixv-16400">No</dei:EntityVoluntaryFilers>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-10-01to2024-09-30" id="ixv-16401">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2023-10-01to2024-09-30" id="ixv-16402">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-10-01to2024-09-30" id="ixv-16403">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2023-10-01to2024-09-30" id="ixv-16404">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2023-10-01to2024-09-30" id="ixv-16405">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="ixv-16406"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="ixv-16407"
      unitRef="Shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="ixv-16408"
      unitRef="Shares">63787104</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="ixv-16409"
      unitRef="Shares">47422304</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="ixv-16410"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="ixv-16411"
      unitRef="Shares">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="ixv-16412"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="ixv-16413"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="ixv-16414"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="ixv-16415"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="ixv-16416"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="ixv-16417"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-10-01to2024-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="ixv-16418"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-10-01to2024-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="ixv-16419"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <cvm:EmployeeContributionsToDefinedContributionPlans
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="ixv-16420"
      unitRef="USD">10000</cvm:EmployeeContributionsToDefinedContributionPlans>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2022-10-01to2023-09-30_us-gaap_LeaseAgreementsMember"
      decimals="0"
      id="ixv-16421"
      unitRef="USD">1800000.0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:Depreciation
      contextRef="From2022-10-01to2023-09-30_us-gaap_LeaseAgreementsMember"
      decimals="0"
      id="ixv-16422"
      unitRef="USD">1800000.0</us-gaap:Depreciation>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-09-30_us-gaap_OperatingExpenseMember"
      decimals="0"
      id="ixv-16423"
      unitRef="USD">200000.0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherExpenses
      contextRef="From2022-10-01to2023-09-30_us-gaap_OperatingExpenseMember"
      decimals="0"
      id="ixv-16424"
      unitRef="USD">400000.0</us-gaap:OtherExpenses>
    <cvm:RestrictedCommonStockSharesIssued
      contextRef="From2022-10-01to2023-09-30_cvm_OfficerAndDirectorMember"
      decimals="0"
      id="ixv-16425"
      unitRef="USD">0</cvm:RestrictedCommonStockSharesIssued>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-10-01to2023-09-30_cvm_OfficerAndDirectorMember"
      decimals="0"
      id="ixv-16426"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <dei:DocumentType contextRef="From2023-10-01to2024-09-30" id="ixv-17541">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2023-10-01to2024-09-30" id="ixv-17542">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-10-01to2024-09-30" id="ixv-17543">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2023-10-01to2024-09-30" id="ixv-17544">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-10-01to2024-09-30" id="ixv-17545">1-11889</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-10-01to2024-09-30" id="ixv-17546">CEL-SCI CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-10-01to2024-09-30" id="ixv-17547">CO</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-10-01to2024-09-30" id="ixv-17548">84-0916344</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-10-01to2024-09-30" id="ixv-17549">8229 Boone Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-10-01to2024-09-30" id="ixv-17550">Suite 802</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-10-01to2024-09-30" id="ixv-17551">Vienna</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-10-01to2024-09-30" id="ixv-17552">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-10-01to2024-09-30" id="ixv-17553">22182</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-10-01to2024-09-30" id="ixv-17554">703</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-10-01to2024-09-30" id="ixv-17555">506-9460</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-10-01to2024-09-30" id="ixv-17556">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-10-01to2024-09-30" id="ixv-17557">CVM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-10-01to2024-09-30" id="ixv-17558">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2023-10-01to2024-09-30" id="ixv-17559">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-10-01to2024-09-30" id="ixv-17560">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-10-01to2024-09-30" id="ixv-17561">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-10-01to2024-09-30" id="ixv-17562">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-10-01to2024-09-30" id="ixv-17563">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2023-10-01to2024-09-30" id="ixv-17564">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="From2023-10-01to2024-09-30" id="ixv-17565">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2024-03-31"
      decimals="0"
      id="ixv-17566"
      unitRef="USD">100002189</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-01-06"
      decimals="INF"
      id="ixv-17567"
      unitRef="Shares">74107041</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="From2023-10-01to2024-09-30" id="ixv-17568">243</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2023-10-01to2024-09-30" id="ixv-17569">BDO USA, P.C.</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2023-10-01to2024-09-30" id="ixv-17570">Potomac, Maryland</dei:AuditorLocation>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2088"
      unitRef="USD">4738173</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2089"
      unitRef="USD">4145735</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2090"
      unitRef="USD">294097</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2091"
      unitRef="USD">520368</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2092"
      unitRef="USD">1019908</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2093"
      unitRef="USD">2248072</us-gaap:InventoryNet>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2094"
      unitRef="USD">3500</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2095"
      unitRef="USD">4245</us-gaap:DepositsAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2096"
      unitRef="USD">6055678</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2097"
      unitRef="USD">6918420</us-gaap:AssetsCurrent>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2098"
      unitRef="USD">7350364</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2099"
      unitRef="USD">9131987</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2100"
      unitRef="USD">1495937</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2101"
      unitRef="USD">1698243</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2102"
      unitRef="USD">8129753</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2103"
      unitRef="USD">10188126</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2104"
      unitRef="USD">165492</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2105"
      unitRef="USD">197704</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2106"
      unitRef="USD">2319101</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2107"
      unitRef="USD">2319101</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2108"
      unitRef="USD">1475441</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2109"
      unitRef="USD">74669</us-gaap:InventoryNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2110"
      unitRef="USD">26991766</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2111"
      unitRef="USD">30528250</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2114"
      unitRef="USD">1448467</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2115"
      unitRef="USD">2009786</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2116"
      unitRef="USD">566042</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2117"
      unitRef="USD">1049581</us-gaap:AccruedLiabilitiesCurrent>
    <cvm:AmountsDueToEmployeesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2118"
      unitRef="USD">363306</cvm:AmountsDueToEmployeesCurrent>
    <cvm:AmountsDueToEmployeesCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2119"
      unitRef="USD">557244</cvm:AmountsDueToEmployeesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2120"
      unitRef="USD">2010995</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2121"
      unitRef="USD">1771804</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2122"
      unitRef="USD">226969</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2123"
      unitRef="USD">197431</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2124"
      unitRef="USD">4615779</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2125"
      unitRef="USD">5585846</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2126"
      unitRef="USD">7957925</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2127"
      unitRef="USD">9949565</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2128"
      unitRef="USD">1425979</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2129"
      unitRef="USD">1652949</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2130"
      unitRef="USD">125000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2131"
      unitRef="USD">125000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2132"
      unitRef="USD">14124683</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2133"
      unitRef="USD">17313360</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="fid_1456"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1457"
      unitRef="Shares">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1458"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2136"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2137"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="fid_1443"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1445"
      unitRef="Shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1446"
      unitRef="Shares">63787104</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1447"
      unitRef="Shares">47422304</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2335"
      unitRef="USD">637870</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2336"
      unitRef="USD">474223</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2138"
      unitRef="USD">526241074</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2139"
      unitRef="USD">499832063</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2140"
      unitRef="USD">-514011861</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2141"
      unitRef="USD">-487091396</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2142"
      unitRef="USD">12867083</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2143"
      unitRef="USD">13214890</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2144"
      unitRef="USD">26991766</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2145"
      unitRef="USD">30528250</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2147"
      unitRef="USD">18161451</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2148"
      unitRef="USD">22471496</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2149"
      unitRef="USD">8191023</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2150"
      unitRef="USD">9004578</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2151"
      unitRef="USD">26352474</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2152"
      unitRef="USD">31476074</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2153"
      unitRef="USD">-26352474</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2154"
      unitRef="USD">-31476074</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2155"
      unitRef="USD">745673</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2156"
      unitRef="USD">675416</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2157"
      unitRef="USD">177682</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2158"
      unitRef="USD">-42813</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2159"
      unitRef="USD">-26920465</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2160"
      unitRef="USD">-32194303</us-gaap:ProfitLoss>
    <cvm:ModificationOfWarrants
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2161"
      unitRef="USD">-659456</cvm:ModificationOfWarrants>
    <cvm:ModificationOfWarrants
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2162"
      unitRef="USD">-171552</cvm:ModificationOfWarrants>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2163"
      unitRef="USD">-27579921</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2164"
      unitRef="USD">-32365855</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="fid_2165"
      unitRef="USDPShares">-0.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_2166"
      unitRef="USDPShares">-0.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2167"
      unitRef="Shares">54044989</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2168"
      unitRef="Shares">44479865</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2246"
      unitRef="Shares">43448317</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2247"
      unitRef="USD">434484</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2248"
      unitRef="USD">486625816</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2249"
      unitRef="USD">454897093</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_2250"
      unitRef="USD">32163207</us-gaap:StockholdersEquity>
    <cvm:StockIssuedDuringPeriodSharesStockWarrantsExercised
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2251"
      unitRef="Shares">217752</cvm:StockIssuedDuringPeriodSharesStockWarrantsExercised>
    <cvm:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2252"
      unitRef="USD">2177</cvm:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <cvm:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2253"
      unitRef="USD">445114</cvm:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <cvm:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2254"
      unitRef="USD">0</cvm:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <cvm:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2255"
      unitRef="USD">447291</cvm:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2256"
      unitRef="Shares">97004</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2257"
      unitRef="USD">970</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2258"
      unitRef="USD">206623</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2259"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2260"
      unitRef="USD">207593</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2261"
      unitRef="Shares">249997</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2262"
      unitRef="USD">2500</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2263"
      unitRef="USD">563480</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2264"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2265"
      unitRef="USD">565980</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2266"
      unitRef="Shares">3413234</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2267"
      unitRef="USD">34132</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2268"
      unitRef="USD">6088365</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2270"
      unitRef="USD">6122497</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <cvm:IncentiveStockForfeitedShares
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2271"
      unitRef="Shares">4000</cvm:IncentiveStockForfeitedShares>
    <cvm:IncentiveStockForfeitedAmount
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2272"
      unitRef="USD">40</cvm:IncentiveStockForfeitedAmount>
    <cvm:IncentiveStockForfeitedAmount
      contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2273"
      unitRef="USD">22160</cvm:IncentiveStockForfeitedAmount>
    <cvm:IncentiveStockForfeitedAmount
      contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2274"
      unitRef="USD">0</cvm:IncentiveStockForfeitedAmount>
    <cvm:IncentiveStockForfeitedAmount
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2275"
      unitRef="USD">22200</cvm:IncentiveStockForfeitedAmount>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2276"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2277"
      unitRef="USD">6308431</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2278"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2279"
      unitRef="USD">6308431</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2280"
      unitRef="USD">0</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2281"
      unitRef="USD">383606</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2282"
      unitRef="USD">0</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2283"
      unitRef="USD">383606</cvm:CostIncurredInIssuanceOfStock>
    <us-gaap:ProfitLoss
      contextRef="From2022-10-01to2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2284"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-10-01to2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2285"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-10-01to2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2286"
      unitRef="USD">32194303</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2287"
      unitRef="USD">-32194303</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2288"
      unitRef="Shares">47422304</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2289"
      unitRef="USD">474223</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2290"
      unitRef="USD">499832063</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2291"
      unitRef="USD">487091396</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2292"
      unitRef="USD">13214890</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2293"
      unitRef="Shares">136868</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2294"
      unitRef="USD">1368</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2295"
      unitRef="USD">217349</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2296"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2297"
      unitRef="USD">218717</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2298"
      unitRef="Shares">409932</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2299"
      unitRef="USD">4099</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2300"
      unitRef="USD">755802</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-01to2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2301"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2302"
      unitRef="USD">759901</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <cvm:ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsShares
      contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2303"
      unitRef="Shares">10080000</cvm:ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsShares>
    <cvm:ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount
      contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2304"
      unitRef="USD">100800</cvm:ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount>
    <cvm:ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount
      contextRef="From2023-10-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2305"
      unitRef="USD">23417400</cvm:ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount>
    <cvm:ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount
      contextRef="From2023-10-01to2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2306"
      unitRef="USD">0</cvm:ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount>
    <cvm:ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2307"
      unitRef="USD">23518200</cvm:ProceedsFromTheSaleOfCommonStockAndPreFundedWarrantsAmount>
    <cvm:ExerciseOfPreFundedWarrantsShares
      contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2308"
      unitRef="Shares">5680000</cvm:ExerciseOfPreFundedWarrantsShares>
    <cvm:ExerciseOfPreFundedWarrantsAmount
      contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2309"
      unitRef="USD">56800</cvm:ExerciseOfPreFundedWarrantsAmount>
    <cvm:ExerciseOfPreFundedWarrantsAmount
      contextRef="From2023-10-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2310"
      unitRef="USD">0</cvm:ExerciseOfPreFundedWarrantsAmount>
    <cvm:ExerciseOfPreFundedWarrantsAmount
      contextRef="From2023-10-01to2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2311"
      unitRef="USD">0</cvm:ExerciseOfPreFundedWarrantsAmount>
    <cvm:ExerciseOfPreFundedWarrantsAmount
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2312"
      unitRef="USD">56800</cvm:ExerciseOfPreFundedWarrantsAmount>
    <cvm:PurchaseOfStockByOfficersAndDirectorsShares
      contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2313"
      unitRef="Shares">58000</cvm:PurchaseOfStockByOfficersAndDirectorsShares>
    <cvm:PurchaseOfStockByOfficersAndDirectorsAmount
      contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2314"
      unitRef="USD">580</cvm:PurchaseOfStockByOfficersAndDirectorsAmount>
    <cvm:PurchaseOfStockByOfficersAndDirectorsAmount
      contextRef="From2023-10-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2315"
      unitRef="USD">80040</cvm:PurchaseOfStockByOfficersAndDirectorsAmount>
    <cvm:PurchaseOfStockByOfficersAndDirectorsAmount
      contextRef="From2023-10-01to2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2316"
      unitRef="USD">0</cvm:PurchaseOfStockByOfficersAndDirectorsAmount>
    <cvm:PurchaseOfStockByOfficersAndDirectorsAmount
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2317"
      unitRef="USD">80620</cvm:PurchaseOfStockByOfficersAndDirectorsAmount>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2318"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2319"
      unitRef="USD">4270180</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2320"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2321"
      unitRef="USD">4270180</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2322"
      unitRef="USD">0</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2023-10-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2323"
      unitRef="USD">2331760</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2023-10-01to2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2324"
      unitRef="USD">0</cvm:CostIncurredInIssuanceOfStock>
    <cvm:CostIncurredInIssuanceOfStock
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2325"
      unitRef="USD">2331760</cvm:CostIncurredInIssuanceOfStock>
    <us-gaap:ProfitLoss
      contextRef="From2023-10-01to2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2326"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-10-01to2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2327"
      unitRef="USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-10-01to2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2328"
      unitRef="USD">26920465</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2329"
      unitRef="USD">-26920465</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2330"
      unitRef="Shares">63787104</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_2331"
      unitRef="USD">637870</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_2332"
      unitRef="USD">526241074</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_2333"
      unitRef="USD">514011861</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2334"
      unitRef="USD">12867083</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2170"
      unitRef="USD">-26920465</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2171"
      unitRef="USD">-32194303</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2173"
      unitRef="USD">3969183</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2174"
      unitRef="USD">3958334</us-gaap:DepreciationAndAmortization>
    <us-gaap:OtherNoncashExpense
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2175"
      unitRef="USD">4873</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2176"
      unitRef="USD">15292</us-gaap:OtherNoncashExpense>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2177"
      unitRef="USD">858498</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2178"
      unitRef="USD">655740</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2179"
      unitRef="USD">4270180</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2180"
      unitRef="USD">6286231</us-gaap:ShareBasedCompensation>
    <cvm:CommonStockContributedToEmployeeBenefitPlan
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2181"
      unitRef="USD">218717</cvm:CommonStockContributedToEmployeeBenefitPlan>
    <cvm:CommonStockContributedToEmployeeBenefitPlan
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2182"
      unitRef="USD">207593</cvm:CommonStockContributedToEmployeeBenefitPlan>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2184"
      unitRef="USD">-72674</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2185"
      unitRef="USD">-151935</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2186"
      unitRef="USD">172608</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2187"
      unitRef="USD">156727</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2188"
      unitRef="USD">-745</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2189"
      unitRef="USD">2323346</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2191"
      unitRef="USD">-460576</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2192"
      unitRef="USD">257845</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2193"
      unitRef="USD">-458489</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2194"
      unitRef="USD">207089</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2195"
      unitRef="USD">-193938</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2196"
      unitRef="USD">85756</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2197"
      unitRef="USD">-18811206</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2198"
      unitRef="USD">-22848561</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2200"
      unitRef="USD">94875</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2201"
      unitRef="USD">361892</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2202"
      unitRef="USD">13211</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2203"
      unitRef="USD">10370</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2204"
      unitRef="USD">-108086</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2205"
      unitRef="USD">-372262</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2207"
      unitRef="USD">23575000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2208"
      unitRef="USD">6552497</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2209"
      unitRef="USD">2370513</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2210"
      unitRef="USD">744913</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2211"
      unitRef="USD">80620</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2212"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2213"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2214"
      unitRef="USD">447291</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2215"
      unitRef="USD">1773377</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2216"
      unitRef="USD">1560455</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2217"
      unitRef="USD">450000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2218"
      unitRef="USD">0</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2219"
      unitRef="USD">450000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2220"
      unitRef="USD">0</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2221"
      unitRef="USD">19511730</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2222"
      unitRef="USD">4694420</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2223"
      unitRef="USD">592438</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2224"
      unitRef="USD">-18526403</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2225"
      unitRef="USD">4145735</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_2226"
      unitRef="USD">22672138</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2227"
      unitRef="USD">4738173</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_2228"
      unitRef="USD">4145735</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2229"
      unitRef="USD">32954</cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities>
    <cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2230"
      unitRef="USD">51650</cvm:PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities>
    <cvm:CapitalizedIntangibleAssetsCostsIncludedInCurrentLiabilities
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2231"
      unitRef="USD">0</cvm:CapitalizedIntangibleAssetsCostsIncludedInCurrentLiabilities>
    <cvm:CapitalizedIntangibleAssetsCostsIncludedInCurrentLiabilities
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2232"
      unitRef="USD">13211</cvm:CapitalizedIntangibleAssetsCostsIncludedInCurrentLiabilities>
    <cvm:PurchaseOfAssetsUnderFinanceLeases
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2233"
      unitRef="USD">20797</cvm:PurchaseOfAssetsUnderFinanceLeases>
    <cvm:PurchaseOfAssetsUnderFinanceLeases
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2234"
      unitRef="USD">0</cvm:PurchaseOfAssetsUnderFinanceLeases>
    <cvm:FinanceLeaseObligationIncludedInAccountsPayable
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2235"
      unitRef="USD">1320</cvm:FinanceLeaseObligationIncludedInAccountsPayable>
    <cvm:FinanceLeaseObligationIncludedInAccountsPayable
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2236"
      unitRef="USD">1451</cvm:FinanceLeaseObligationIncludedInAccountsPayable>
    <cvm:ConsultingServicesPaidWithIssuanceOfCommonStock
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2237"
      unitRef="USD">759901</cvm:ConsultingServicesPaidWithIssuanceOfCommonStock>
    <cvm:ConsultingServicesPaidWithIssuanceOfCommonStock
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2238"
      unitRef="USD">565980</cvm:ConsultingServicesPaidWithIssuanceOfCommonStock>
    <cvm:FinancingCostsIncludedInCurrentLiabilities
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2239"
      unitRef="USD">38950</cvm:FinancingCostsIncludedInCurrentLiabilities>
    <cvm:FinancingCostsIncludedInCurrentLiabilities
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2240"
      unitRef="USD">77703</cvm:FinancingCostsIncludedInCurrentLiabilities>
    <cvm:AccruedConsultingServicesToBePaidUnderShareBasedPaymentArrangement
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2241"
      unitRef="USD">0</cvm:AccruedConsultingServicesToBePaidUnderShareBasedPaymentArrangement>
    <cvm:AccruedConsultingServicesToBePaidUnderShareBasedPaymentArrangement
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2242"
      unitRef="USD">55000</cvm:AccruedConsultingServicesToBePaidUnderShareBasedPaymentArrangement>
    <us-gaap:InterestPaidNet
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2244"
      unitRef="USD">923807</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2245"
      unitRef="USD">1062564</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1563">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;1. ORGANIZATION&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;CEL-SCI Corporation (the Company) was incorporated on March 22, 1983, in the state of Colorado, to finance research and development in biomedical science and ultimately to engage in marketing and selling products.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company has announced results from its Phase III study for its lead investigational therapy, Multikine&#xae; (Leukocyte Interleukin, Injection), involving head and neck cancer, for which the Company has received Orphan Drug Status from the United States Food and Drug Administration (FDA). Unlike other immune therapies, Multikine is administered locally at the site of the tumor as a first line treatment right after diagnosis, before surgery and radiation. The goal is to help the intact immune system kill the micro metastases that usually cause recurrence of the cancer to improve outcomes and better overall survival rates for patients suffering from head and neck cancer.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;CEL-SCI is also investigating a peptide-based immunotherapy (CEL-4000) as a vaccine for rheumatoid arthritis using its LEAPS technology platform. CEL-SCI is in the process of completing pre-IND studies for CEL-4000.&#160; &lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <cvm:LiquidityDisclosureTextblock contextRef="From2023-10-01to2024-09-30" id="fid_1549">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;2&lt;/strong&gt;&lt;strong&gt;.&lt;/strong&gt;&#160; &lt;strong&gt;LIQUIDITY &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company has incurred significant costs since its inception for the acquisition of certain proprietary technology and scientific knowledge relating to the human immunological defense system, patent applications, research and development, administrative costs, construction and expansion of manufacturing and laboratory facilities and conducting clinical trials. The Company has funded such costs primarily with proceeds from loans and the public and private sale of its securities. The Company will be required to raise additional capital or find additional long-term financing to continue with its efforts to bring Multikine, the Company&#x2019;s lead investigational therapy, to market. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to obtain approval from any regulatory agency for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;To finance the Company through marketing approval, the Company plans to raise additional capital in the form of corporate partnerships, and debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past and because Multikine showed great survival benefit in the Phase III study in one of the two treatment arms for advanced primary head and neck cancer. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Due to the Company&#x2019;s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern.&#160; The financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;</cvm:LiquidityDisclosureTextblock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1550">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;3&lt;/strong&gt;&lt;strong&gt;. &lt;/strong&gt;&lt;strong&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Basis of Presentation&lt;/em&gt; &#x2013; The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;).&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Cash and Cash Equivalents &lt;/em&gt;&#x2013; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Property and Equipment&lt;/em&gt; &#x2013; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Supplies used for R&amp;amp;D and manufacturing&lt;/em&gt; &#x2013; Supplies are consumable items kept on hand to support the Company&#x2019;s R&amp;amp;D and manufacturing operations. Supplies are recorded at the lower of cost or net realizable value and are charged to expense as they are used in operations. The Company regularly reviews the quality and utilization of supplies to determine if future use of these supplies is probable. Due to the generic use of these supplies, they can be used in multiple projects other than those currently being studied. Supplies held less than twelve months are classified as current assets and supplies held longer than twelve months are classified as non-current assets.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Patents&lt;/em&gt; &#x2013; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Leases&lt;/em&gt; &#x2013; The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. The incremental borrowing rate reflects the rate of interest that the Company would pay on the lease commencement date to borrow an amount equal to the lease payments on a collateralized basis over a similar term in similar economic environments. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. Operating and finance lease agreements which require payments for lease and non-lease components are accounted for as a single lease component.&#160; Variable lease payments that cannot be determined at the commencement of the lease are not included in the calculation of right of use assets or lease liabilities, and are expensed as incurred.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Share-Based Compensation&lt;/em&gt; &#x2013; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, Compensation &#x2013; Stock Compensation (&#x201c;ASC 718&#x201d;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate, and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#x2019;s stockholders.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company&#x2019;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#x2019;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Research and Development Costs&lt;/em&gt; - Research and development costs are expensed as incurred.&#160; Management accrues Clinical Research Organization (&#x201c;CRO&#x201d;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Net Loss Per Common Share&lt;/em&gt; &#x2013; The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share. Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Concentration of Credit Risk&lt;/em&gt; &#x2013; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents.&#160; The Company maintains its cash and cash equivalents with high quality financial institutions.&#160; At times, these accounts may exceed federally insured limits.&#160; The Company has not experienced any losses in such bank accounts.&#160; The Company believes it is not exposed to significant credit risk related to cash and cash equivalents.&#160; All non-interest bearing cash balances were fully insured up to $250,000 at September 30, 2024 and 2023. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Income Taxes&lt;/em&gt; &#x2013; The Company accounts for income taxes in accordance with the provisions of ASC 740, Income Taxes, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards.&#160; Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of September 30, 2024 and 2023.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Impairment of long-lived assets &lt;/em&gt;&#x2013; CEL-SCI&#x2019;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#x2019;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Use of Estimates&lt;/em&gt; &#x2013; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#x2019;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, share-based compensation, useful lives for depreciation and amortization of long-lived assets, right-of-use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year.&#160; Additionally, in calculating the right-of-use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Recently Adopted Accounting Standards&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update No. 2016-13, Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;). ASU 2016-13 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13 had no material impact on the Company&#x2019;s financial position, results of operations, or cash flows.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;New Accounting Pronouncements&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In November 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (&#x201c;ASU 2023-07&#x201d;), which expands disclosures about a public entity&#x2019;s reportable segments and requires more enhanced information about a reportable segment&#x2019;s expenses, interim segment profit or loss, and how a public entity&#x2019;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is currently evaluating the impact that this change will have on the Company&#x2019;s disclosures. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In December 2023, the FASB issued Accounting Standards Update No. 2023-09, Improvements to Income Tax Disclosures, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In March 2024, the SEC issued its final climate disclosure rules, which require the disclosure of climate-related information in annual reports and registration statements. The rules require disclosure in the audited financial statements of certain effects of severe weather events and other natural conditions above certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates, if material. Under the rules as originally issued, disclosure requirements begin phasing in for fiscal years beginning on or after January 1, 2027. However, on April 4, 2024, the SEC determined to voluntarily stay the final rules pending certain legal challenges. We are currently evaluating the impact of the new rules and continue to monitor the status of the related legal challenges.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In November 2024, the FASB issued Accounting Standards Update No. 2024-03, Income Statement &#x2013; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses (&#x201c;ASU 2024-03&#x201d;). ASU 2024-03 will require more detailed information about the types of expenses in commonly presented income statement captions such as &#x201c;Cost of sales&#x201d; and &#x201c;Selling, general and administrative expenses&#x201d;. The new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027 with early adoption permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_2338">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Basis of Presentation&lt;/em&gt; &#x2013; The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1564">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Cash and Cash Equivalents &lt;/em&gt;&#x2013; Cash and cash equivalents consist principally of unrestricted cash on deposit and short-term money market funds. The Company considers all highly liquid investments with a maturity when purchased of less than three months to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1567">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Property and Equipment&lt;/em&gt; &#x2013; Property and equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. Property and equipment is reviewed on a quarterly basis to determine if any of the assets are impaired.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1566">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Supplies used for R&amp;amp;D and manufacturing&lt;/em&gt; &#x2013; Supplies are consumable items kept on hand to support the Company&#x2019;s R&amp;amp;D and manufacturing operations. Supplies are recorded at the lower of cost or net realizable value and are charged to expense as they are used in operations. The Company regularly reviews the quality and utilization of supplies to determine if future use of these supplies is probable. Due to the generic use of these supplies, they can be used in multiple projects other than those currently being studied. Supplies held less than twelve months are classified as current assets and supplies held longer than twelve months are classified as non-current assets.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2023-10-01to2024-09-30" id="fid_1568">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Patents&lt;/em&gt; &#x2013; Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustments to the asset value and period of amortization are made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value. &lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <cvm:FiniteLivedIntangibleAssetsUsefulLife
      contextRef="From2021-10-01to2022-09-30_us-gaap_PatentsMember"
      id="fid_1852">P17Y</cvm:FiniteLivedIntangibleAssetsUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1569">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Leases&lt;/em&gt; &#x2013; The Company accounts for contracts that convey the right to control the use of identified property, plant or equipment over a period of time in exchange for consideration as leases upon inception. The Company leases certain real estate, machinery, laboratory equipment and office equipment over varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included in the lease term when it is reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate the lease liabilities is based on the information available at the commencement date, as most of the leases do not provide an implicit borrowing rate. The incremental borrowing rate reflects the rate of interest that the Company would pay on the lease commencement date to borrow an amount equal to the lease payments on a collateralized basis over a similar term in similar economic environments. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the balance sheet. Lease expense for such short-term leases is not material. Operating and finance lease agreements which require payments for lease and non-lease components are accounted for as a single lease component.&#160; Variable lease payments that cannot be determined at the commencement of the lease are not included in the calculation of right of use assets or lease liabilities, and are expensed as incurred.&#160; &lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2023-10-01to2024-09-30" id="fid_1571">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Share-Based Compensation&lt;/em&gt; &#x2013; Compensation cost for all share-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718, Compensation &#x2013; Stock Compensation (&#x201c;ASC 718&#x201d;). The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires five input variables: the strike price of an option, the current stock price, the time to expiration, the risk-free rate, and the volatility. The share-based compensation cost is recognized using the straight-line method as expense over the requisite service or vesting period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, Stock Compensation Plans, Stock Bonus Plans and an Incentive Stock Bonus Plan. These Plans are collectively referred to as the "Plans". All Plans have been approved by the Company&#x2019;s stockholders.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company&#x2019;s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. For options issued with service conditions only, the Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company&#x2019;s stock. The risk-free interest rate assumption is based on the U.S. Treasury rate at the date of grant with the term equal to the expected life of the option. Forfeitures are accounted for when they occur.&#160; The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, share-based compensation expense for new awards may differ materially in the future from that recorded in the current period.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Restricted stock granted under the Incentive Stock Bonus Plan and options granted under the Non-Qualified Stock Option Plans are subject to service, performance and market conditions and meet the classification of equity awards. These awards were measured at fair value on the grant dates using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-10-01to2024-09-30" id="fid_1572">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Research and Development Costs&lt;/em&gt; - Research and development costs are expensed as incurred.&#160; Management accrues Clinical Research Organization (&#x201c;CRO&#x201d;) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company records revisions to estimated expense in the period in which the facts that give rise to the revision become known. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1573">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Net Loss Per Common Share&lt;/em&gt; &#x2013; The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share. Basic and diluted net loss per common share was determined by dividing net loss applicable to common shareholders by the weighted average number of common shares outstanding during the period. The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and common stock warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2023-10-01to2024-09-30" id="fid_1574">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Concentration of Credit Risk&lt;/em&gt; &#x2013; Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents.&#160; The Company maintains its cash and cash equivalents with high quality financial institutions.&#160; At times, these accounts may exceed federally insured limits.&#160; The Company has not experienced any losses in such bank accounts.&#160; The Company believes it is not exposed to significant credit risk related to cash and cash equivalents.&#160; All non-interest bearing cash balances were fully insured up to $250,000 at September 30, 2024 and 2023. &lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1851"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1575">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Income Taxes&lt;/em&gt; &#x2013; The Company accounts for income taxes in accordance with the provisions of ASC 740, Income Taxes, on a tax jurisdiction basis. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards.&#160; Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&#160; The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&#160; The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of September 30, 2024 and 2023.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_2060">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Impairment of long-lived assets &lt;/em&gt;&#x2013; CEL-SCI&#x2019;s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI&#x2019;s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2023-10-01to2024-09-30" id="fid_1576">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Use of Estimates&lt;/em&gt; &#x2013; The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management&#x2019;s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, share-based compensation, useful lives for depreciation and amortization of long-lived assets, right-of-use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year.&#160; Additionally, in calculating the right-of-use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms.&#160; The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant. &lt;/p&gt;</us-gaap:UseOfEstimates>
    <cvm:RecentlyAdoptedAccountingStandardsPolicyPolicyTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_2339">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update No. 2016-13, Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;). ASU 2016-13 requires a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The amendments in ASU 2016-13 replace the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information. ASU 2016-13 was effective for SEC filers, excluding smaller reporting companies, for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. As a smaller reporting company, the Company was permitted to adopt the new standard for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Effective October 1, 2023, the Company adopted ASU 2016-13 using a modified retrospective transition method. The adoption of ASU 2016-13 had no material impact on the Company&#x2019;s financial position, results of operations, or cash flows.&lt;/p&gt;</cvm:RecentlyAdoptedAccountingStandardsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1577">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In November 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (&#x201c;ASU 2023-07&#x201d;), which expands disclosures about a public entity&#x2019;s reportable segments and requires more enhanced information about a reportable segment&#x2019;s expenses, interim segment profit or loss, and how a public entity&#x2019;s chief operating decision maker uses reported segment profit or loss information in assessing segment performance and allocating resources. The update will be effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company is currently evaluating the impact that this change will have on the Company&#x2019;s disclosures. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In December 2023, the FASB issued Accounting Standards Update No. 2023-09, Improvements to Income Tax Disclosures, which require greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid. The update will be effective for annual periods beginning after December 15, 2024. The guidance should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In March 2024, the SEC issued its final climate disclosure rules, which require the disclosure of climate-related information in annual reports and registration statements. The rules require disclosure in the audited financial statements of certain effects of severe weather events and other natural conditions above certain financial thresholds, as well as amounts related to carbon offsets and renewable energy credits or certificates, if material. Under the rules as originally issued, disclosure requirements begin phasing in for fiscal years beginning on or after January 1, 2027. However, on April 4, 2024, the SEC determined to voluntarily stay the final rules pending certain legal challenges. We are currently evaluating the impact of the new rules and continue to monitor the status of the related legal challenges.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In November 2024, the FASB issued Accounting Standards Update No. 2024-03, Income Statement &#x2013; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses (&#x201c;ASU 2024-03&#x201d;). ASU 2024-03 will require more detailed information about the types of expenses in commonly presented income statement captions such as &#x201c;Cost of sales&#x201d; and &#x201c;Selling, general and administrative expenses&#x201d;. The new guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027 with early adoption permitted. The Company is currently evaluating the impact that this change will have on the Company's disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <cvm:WarrantsAndNonEmployeeOptionsDisclosureTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1551">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;4. WARRANTS AND NON-EMPLOYEE OPTIONS&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The following warrants and non-employee options are outstanding at September 30, 2024:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrant/&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Issue Date&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Shares Issuable&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;upon Exercise &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;of Warrants/&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series N&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2008&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;85,339&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2026&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/11/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;93,603&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/30/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series X&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1/13/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;120,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;9.25&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/13/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Y&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/15/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;26,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;12.00&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/15/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;333,432&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;200,087&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;234,009&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Consultant Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/28/2017 &#x2013; 9/2/2023 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;110,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&#160; $1.39 - $2.18 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/27/2027 &#x2013; 9/1/2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The following warrants and non-employee options are outstanding at September 30, 2023:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrant/&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Issue Date&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Shares Issuable&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;upon Exercise &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;of Warrants/&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series N&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2008&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;85,339&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2024&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/11/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;93,603&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/30/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series X&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1/13/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;120,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;9.25&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/13/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Y&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/15/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;26,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;12.00&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/15/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;333,432&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;200,087&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;234,009&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Consultant Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/28/2017 &#x2013; 9/2/2023 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;110,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&#160; 1.39 - $2.18 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/27/2027 &#x2013; 9/1/2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;A. Equity Warrants&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Changes in Equity Warrants&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the fiscal year ended September 30, 2024, 5,680,000 pre-funded warrants were exercised. The following equity warrants were exercised during the year ended September 30, 2023:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrants Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,752&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,291&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series SS&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;200,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.09&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;418,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;217,752&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;447,291&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;No warrants recorded as equity expired during the fiscal year ended September 30, 2024. On February 5, 2023, 600 Series TT warrants, with an exercise price of $2.24, expired.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On May 4, 2024, the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates.&#160; The incremental cost of this extension was approximately $659,455, which was recorded as a deemed dividend. The Series N, X, MM, NN, RR and UU warrants are held by current Officers of the Company.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;strong&gt;B.&lt;/strong&gt; &lt;strong&gt;Options and Shares Issued to Consultants&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company typically enters into consulting arrangements in exchange for common stock or stock options. During the years ended September 30, 2024 and 2023, the Company issued 409,932 and 249,997 shares, respectively, of common stock to consultants, all of which were restricted shares. Under these arrangements, during the periods presented, the common stock was issued with stock prices ranging from $1.08 to $3.47 per share. The weighted average grant price was $1.69 and $1.83, respectively, for stock issued during the years ended September 30, 2024 and 2023.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the years ended September 30, 2024 and 2023, the Company recorded total expense of approximately $681,000 and $656,000, respectively, relating to these consulting agreements, which are included in general and administrative expense on the accompanying statements of operations. At September 30, 2024 and 2023, costs of approximately $52,000 and $205,000, respectively, are included in prepaid expenses.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;No options were issued to consultants during the year ended September 30, 2024. During the year ended September 30, 2023, the Company issued 100,000 options to a consultant to purchase common stock with an exercise price of $1.39. These options vest 50% on September 2, 2024 and 50% on September 2, 2025 and expire on September 1, 2028. As of September 30, 2024, 110,000 options issued to consultants as payment for services remained outstanding, all of which were issued from the Non-Qualified Stock Option Plan.&lt;/p&gt;</cvm:WarrantsAndNonEmployeeOptionsDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1578">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrant/&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Issue Date&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Shares Issuable&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;upon Exercise &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;of Warrants/&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series N&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2008&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;85,339&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2026&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/11/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;93,603&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/30/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series X&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1/13/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;120,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;9.25&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/13/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Y&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/15/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;26,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;12.00&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/15/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;333,432&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;200,087&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;234,009&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2026&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Consultant Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/28/2017 &#x2013; 9/2/2023 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;110,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&#160; $1.39 - $2.18 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/27/2027 &#x2013; 9/1/2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrant/&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Issue Date&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Shares Issuable&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;upon Exercise &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;of Warrants/&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Options&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series N&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2008&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;85,339&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;3.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:12%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/18/2024&#160; &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series UU&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/11/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;93,603&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.80&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/30/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series X&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1/13/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;120,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;9.25&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/13/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series Y&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2/15/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;26,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;12.00&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;8/15/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series MM&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;333,432&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.86&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6/22/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series NN&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;200,087&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;2.52&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/24/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;234,009&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10/30/2024&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Consultant Options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/28/2017 &#x2013; 9/2/2023 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="vertical-align:bottom;text-align:right;"&gt;110,000&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;$&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;&#160; 1.39 - $2.18 &lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7/27/2027 &#x2013; 9/1/2028&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <cvm:Issuedate2
      contextRef="From2023-10-01to2024-09-30_cvm_SeriesNMember"
      id="fid_1864">8/18/2008</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2024-09-30_cvm_SeriesNMember"
      decimals="0"
      id="fid_1881"
      unitRef="Shares">85339</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2024-09-30_cvm_SeriesNMember"
      decimals="INF"
      id="fid_1899"
      unitRef="USDPShares">3.00</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2023-10-01to2024-09-30_cvm_SeriesNMember"
      id="fid_1918">8/18/2026</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2023-10-01to2024-09-30_cvm_SeriesUUMember"
      id="fid_1855">6/11/2018</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2024-09-30_cvm_SeriesUUMember"
      decimals="0"
      id="fid_1882"
      unitRef="Shares">93603</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2024-09-30_cvm_SeriesUUMember"
      decimals="INF"
      id="fid_1900"
      unitRef="USDPShares">2.80</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2023-10-01to2024-09-30_cvm_SeriesUUMember"
      id="fid_1919">6/30/2026</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2023-10-01to2024-09-30_cvm_SeriesXMember"
      id="fid_1867">1/13/2016</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2024-09-30_cvm_SeriesXMember"
      decimals="0"
      id="fid_1883"
      unitRef="Shares">120000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2024-09-30_cvm_SeriesXMember"
      decimals="INF"
      id="fid_1902"
      unitRef="USDPShares">9.25</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2023-10-01to2024-09-30_cvm_SeriesXMember"
      id="fid_1921">7/13/2026</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2023-10-01to2024-09-30_cvm_SeriesYMember"
      id="fid_1868">2/15/2016</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2024-09-30_cvm_SeriesYMember"
      decimals="0"
      id="fid_1884"
      unitRef="Shares">26000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2024-09-30_cvm_SeriesYMember"
      decimals="INF"
      id="fid_1903"
      unitRef="USDPShares">12.00</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2023-10-01to2024-09-30_cvm_SeriesYMember"
      id="fid_1922">8/15/2026</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2023-10-01to2024-09-30_cvm_SeriesMMMember"
      id="fid_1869">6/22/2017</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2024-09-30_cvm_SeriesMMMember"
      decimals="0"
      id="fid_1885"
      unitRef="Shares">333432</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2024-09-30_cvm_SeriesMMMember"
      decimals="INF"
      id="fid_1904"
      unitRef="USDPShares">1.86</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2023-10-01to2024-09-30_cvm_SeriesMMMember"
      id="fid_1923">6/22/2026</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2023-10-01to2024-09-30_cvm_SeriesNNMember"
      id="fid_1870">7/24/2017</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2024-09-30_cvm_SeriesNNMember"
      decimals="0"
      id="fid_1886"
      unitRef="Shares">200087</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2024-09-30_cvm_SeriesNNMember"
      decimals="INF"
      id="fid_1905"
      unitRef="USDPShares">2.52</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2023-10-01to2024-09-30_cvm_SeriesNNMember"
      id="fid_1924">7/24/2026</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2023-10-01to2024-09-30_cvm_SeriesRRMember"
      id="fid_1860">10/30/2017</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2024-09-30_cvm_SeriesRRMember"
      decimals="0"
      id="fid_1887"
      unitRef="Shares">234009</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2024-09-30_cvm_SeriesRRMember"
      decimals="INF"
      id="fid_1906"
      unitRef="USDPShares">1.65</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2023-10-01to2024-09-30_cvm_SeriesRRMember"
      id="fid_1925">10/30/2026</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2023-10-01to2024-09-30_cvm_ConsultantsMember_cvm_BottomMember"
      id="fid_1872">7/28/2017</cvm:Issuedate2>
    <cvm:Issuedate2
      contextRef="From2023-10-01to2024-09-30_cvm_ConsultantsOneMember_cvm_TopMember"
      id="fid_1866">9/2/2023</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2024-09-30_cvm_ConsultantsMember"
      decimals="0"
      id="fid_1890"
      unitRef="Shares">110000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2024-09-30_cvm_ConsultantsMember_cvm_BottomMember"
      decimals="INF"
      id="fid_1909"
      unitRef="USDPShares">1.39</cvm:ExercisePrice>
    <cvm:ExercisePrice
      contextRef="AsOf2024-09-30_cvm_ConsultantsOneMember_cvm_TopMember"
      decimals="INF"
      id="fid_1901"
      unitRef="USDPShares">2.18</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2023-10-01to2024-09-30_cvm_ConsultantsMember_cvm_BottomMember"
      id="fid_1928">7/27/2027</cvm:ExpirationDate1>
    <cvm:ExpirationDate1
      contextRef="From2023-10-01to2024-09-30_cvm_ConsultantsOneMember_cvm_TopMember"
      id="fid_1920">9/1/2028</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesNMember"
      id="fid_1854">8/18/2008</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2023-09-30_cvm_SeriesNMember"
      decimals="0"
      id="fid_1873"
      unitRef="Shares">85339</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2023-09-30_cvm_SeriesNMember"
      decimals="INF"
      id="fid_1891"
      unitRef="USDPShares">3.00</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesNMember"
      id="fid_1910">8/18/2024</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesUUMember"
      id="fid_1865">6/11/2018</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2023-09-30_cvm_SeriesUUMember"
      decimals="0"
      id="fid_1874"
      unitRef="Shares">93603</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2023-09-30_cvm_SeriesUUMember"
      decimals="INF"
      id="fid_1892"
      unitRef="USDPShares">2.80</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesUUMember"
      id="fid_1911">6/30/2024</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesXMember"
      id="fid_1856">1/13/2016</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2023-09-30_cvm_SeriesXMember"
      decimals="0"
      id="fid_1875"
      unitRef="Shares">120000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2023-09-30_cvm_SeriesXMember"
      decimals="INF"
      id="fid_1893"
      unitRef="USDPShares">9.25</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesXMember"
      id="fid_1912">7/13/2024</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesYMember"
      id="fid_1857">2/15/2016</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2023-09-30_cvm_SeriesYMember"
      decimals="0"
      id="fid_1876"
      unitRef="Shares">26000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2023-09-30_cvm_SeriesYMember"
      decimals="INF"
      id="fid_1894"
      unitRef="USDPShares">12.00</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesYMember"
      id="fid_1913">8/15/2024</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesMMMember"
      id="fid_1858">6/22/2017</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2023-09-30_cvm_SeriesMMMember"
      decimals="0"
      id="fid_1877"
      unitRef="Shares">333432</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2023-09-30_cvm_SeriesMMMember"
      decimals="INF"
      id="fid_1895"
      unitRef="USDPShares">1.86</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesMMMember"
      id="fid_1914">6/22/2024</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesNNMember"
      id="fid_1859">7/24/2017</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2023-09-30_cvm_SeriesNNMember"
      decimals="0"
      id="fid_1878"
      unitRef="Shares">200087</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2023-09-30_cvm_SeriesNNMember"
      decimals="INF"
      id="fid_1896"
      unitRef="USDPShares">2.52</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesNNMember"
      id="fid_1915">7/24/2024</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesRRMember"
      id="fid_1871">10/30/2017</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2023-09-30_cvm_SeriesRRMember"
      decimals="0"
      id="fid_1879"
      unitRef="Shares">234009</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2023-09-30_cvm_SeriesRRMember"
      decimals="INF"
      id="fid_1897"
      unitRef="USDPShares">1.65</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesRRMember"
      id="fid_1916">10/30/2024</cvm:ExpirationDate1>
    <cvm:Issuedate2
      contextRef="From2022-10-01to2023-09-30_cvm_ConsultantsMember_cvm_BottomMember"
      id="fid_1863">7/28/2017</cvm:Issuedate2>
    <cvm:Issuedate2
      contextRef="From2022-10-01to2023-09-30_cvm_ConsultantsOneMember_cvm_TopMember"
      id="fid_1929">9/2/2023</cvm:Issuedate2>
    <cvm:SharesIssuableUponExerciseOfwarrant
      contextRef="AsOf2023-09-30_cvm_ConsultantsOneMember"
      decimals="0"
      id="fid_2341"
      unitRef="Shares">110000</cvm:SharesIssuableUponExerciseOfwarrant>
    <cvm:ExercisePrice
      contextRef="AsOf2023-09-30_cvm_ConsultantsMember_cvm_BottomMember"
      decimals="INF"
      id="fid_1898"
      unitRef="USDPShares">1.39</cvm:ExercisePrice>
    <cvm:ExercisePrice
      contextRef="AsOf2023-09-30_cvm_ConsultantsOneMember_cvm_TopMember"
      decimals="INF"
      id="fid_1930"
      unitRef="USDPShares">2.18</cvm:ExercisePrice>
    <cvm:ExpirationDate1
      contextRef="From2022-10-01to2023-09-30_cvm_ConsultantsMember_cvm_BottomMember"
      id="fid_1917">7/27/2027</cvm:ExpirationDate1>
    <cvm:ExpirationDate1
      contextRef="From2022-10-01to2023-09-30_cvm_ConsultantsOneMember_cvm_TopMember"
      id="fid_1931">9/1/2028</cvm:ExpirationDate1>
    <cvm:EquityWarrantsExercised
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2384"
      unitRef="Shares">5680000</cvm:EquityWarrantsExercised>
    <cvm:ScheduleOfEquityWarrantsWereExercisedTableTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1582">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Warrants Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Exercise&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Price&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Proceeds&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series RR&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,752&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,291&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Series SS&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;200,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.09&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;418,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;217,752&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;447,291&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfEquityWarrantsWereExercisedTableTextBlock>
    <cvm:EquityWarrantsExercised
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesRRMember"
      decimals="0"
      id="fid_1951"
      unitRef="Shares">17752</cvm:EquityWarrantsExercised>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesRRMember"
      decimals="INF"
      id="fid_1957"
      unitRef="USDPShares">1.65</cvm:EquityWarrantsExercisePrice>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesRRMember"
      decimals="0"
      id="fid_1954"
      unitRef="USD">29291</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesSSMember"
      decimals="0"
      id="fid_1952"
      unitRef="Shares">200000</cvm:EquityWarrantsExercised>
    <cvm:EquityWarrantsExercisePrice
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesSSMember"
      decimals="INF"
      id="fid_1958"
      unitRef="USDPShares">2.09</cvm:EquityWarrantsExercisePrice>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2022-10-01to2023-09-30_cvm_SeriesSSMember"
      decimals="0"
      id="fid_1955"
      unitRef="USD">418000</cvm:ProceedsFromEquityWarrantsExercised>
    <cvm:EquityWarrantsExercised
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1961"
      unitRef="Shares">217752</cvm:EquityWarrantsExercised>
    <cvm:ProceedsFromEquityWarrantsExercised
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1960"
      unitRef="USD">447291</cvm:ProceedsFromEquityWarrantsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-10-01to2024-09-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember"
      decimals="INF"
      id="fid_2385"
      unitRef="USDPShares">2.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <cvm:IncrementalCostDeemedDividend
      contextRef="From2023-10-01to2024-09-30_cvm_SeriesRRMember"
      decimals="0"
      id="fid_2383"
      unitRef="USD">659455</cvm:IncrementalCostDeemedDividend>
    <cvm:CommonStockIssuedForServiceShares
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2369"
      unitRef="Shares">409932</cvm:CommonStockIssuedForServiceShares>
    <cvm:CommonStockIssuedForServiceShares
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2368"
      unitRef="Shares">249997</cvm:CommonStockIssuedForServiceShares>
    <us-gaap:SharePrice
      contextRef="AsOf2024-09-30_cvm_BottomMember"
      decimals="INF"
      id="fid_2376"
      unitRef="USDPShares">1.08</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2024-09-30_cvm_TopMember"
      decimals="INF"
      id="fid_2377"
      unitRef="USDPShares">3.47</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-10-01to2024-09-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember_cvm_TopMember"
      decimals="INF"
      id="fid_2371"
      unitRef="USDPShares">1.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-10-01to2023-09-30_cvm_RestrictedStocksMember_cvm_ConsultantsMember_cvm_TopMember"
      decimals="INF"
      id="fid_2370"
      unitRef="USDPShares">1.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:CostsAndExpenses
      contextRef="From2023-10-01to2024-09-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_2373"
      unitRef="USD">681000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2022-10-01to2023-09-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_2372"
      unitRef="USD">656000</us-gaap:CostsAndExpenses>
    <cvm:PrepaidExpenses
      contextRef="AsOf2024-09-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_2374"
      unitRef="USD">52000</cvm:PrepaidExpenses>
    <cvm:PrepaidExpenses
      contextRef="AsOf2022-09-30_cvm_ConsultingAgreementsMember"
      decimals="0"
      id="fid_2375"
      unitRef="USD">205000</cvm:PrepaidExpenses>
    <cvm:StockIssuedDuringPeriodToPurchaseCommonStock
      contextRef="From2023-10-01to2024-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember"
      decimals="0"
      id="fid_2378"
      unitRef="Shares">100000</cvm:StockIssuedDuringPeriodToPurchaseCommonStock>
    <cvm:StockOptionExercisePrice
      contextRef="From2023-10-01to2024-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember"
      decimals="INF"
      id="fid_2379"
      unitRef="USDPShares">1.39</cvm:StockOptionExercisePrice>
    <cvm:VestedOptions
      contextRef="From2023-10-01to2024-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember_cvm_TwoSeptemberTwoThousendTwentyFourMember"
      decimals="INF"
      id="fid_2380"
      unitRef="Pure">0.50</cvm:VestedOptions>
    <cvm:VestedOptions
      contextRef="From2023-10-01to2024-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember_cvm_TwoSeptemberTwoThousendTwentyFiveMember"
      decimals="INF"
      id="fid_2381"
      unitRef="Pure">0.50</cvm:VestedOptions>
    <cvm:IssuanceOfOptionsForServices
      contextRef="AsOf2024-09-30_cvm_NonQualifiedStockOptionsPlansMember_cvm_ConsultantMember"
      decimals="0"
      id="fid_2382"
      unitRef="Shares">110000</cvm:IssuanceOfOptionsForServices>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1552">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;5&lt;/strong&gt;&lt;strong&gt;. &lt;/strong&gt;&lt;strong&gt;PROPERTY AND &lt;/strong&gt;&lt;strong&gt;EQUIPMENT&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 45px"&gt;Property and equipment consisted of the following at September 30:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Research equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,167,828&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,109,070&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;104,593&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;99,296&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;13,924,724&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;13,924,724&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;18,197,145&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;18,133,090&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less: Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(10,067,392&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(7,944,964&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;8,129,753&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;10,188,126&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Depreciation expense for the years ended September 30, 2024 and 2023 totaled approximately $2,135,000 and $2,114,000, respectively, and is included in operating expenses on the accompanying statements of operations.&#160; &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1583">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Research equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,167,828&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,109,070&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Furniture and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;104,593&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;99,296&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;13,924,724&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;13,924,724&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;18,197,145&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;18,133,090&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less: Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(10,067,392&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(7,944,964&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;8,129,753&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;10,188,126&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:FixturesAndEquipmentGross
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1599"
      unitRef="USD">4167828</us-gaap:FixturesAndEquipmentGross>
    <us-gaap:FixturesAndEquipmentGross
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1598"
      unitRef="USD">4109070</us-gaap:FixturesAndEquipmentGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1601"
      unitRef="USD">104593</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1600"
      unitRef="USD">99296</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1603"
      unitRef="USD">13924724</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1602"
      unitRef="USD">13924724</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1605"
      unitRef="USD">18197145</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1604"
      unitRef="USD">18133090</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1607"
      unitRef="USD">10067392</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1606"
      unitRef="USD">7944964</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1609"
      unitRef="USD">8129753</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1608"
      unitRef="USD">10188126</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_1611"
      unitRef="USD">2135000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1610"
      unitRef="USD">2114000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1553">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;6&lt;/strong&gt;&lt;strong&gt;. PATENTS&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Patents consist of the following at September 30:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Patents&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;829,716&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;853,445&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less: Accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(664,224&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(655,741&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Patents, net&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;165,492&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;197,704&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;"&gt;During the years ended September 30, 2024 and 2023, there was no impairment of patent costs.&#160; The weighted average remaining amortization period for patents is approximately 8 years. For the years ended September 30, 2024 and 2023, amortization of patent costs totaled approximately $32,000 and $38,000, respectively, and is included in general and administrative expense on the accompanying statements of operations.&#160; The total estimated future amortization is as follows: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="4" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Years ending September 30, &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;22,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;19,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;16,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;54,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;165,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1584">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Patents&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;829,716&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;853,445&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less: Accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(664,224&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(655,741&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Patents, net&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;165,492&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;197,704&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedPatentsGross
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1613"
      unitRef="USD">829716</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:FiniteLivedPatentsGross
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1612"
      unitRef="USD">853445</us-gaap:FiniteLivedPatentsGross>
    <cvm:AccumulatedAmortization
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1614"
      unitRef="USD">-664224</cvm:AccumulatedAmortization>
    <cvm:AccumulatedAmortization
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1615"
      unitRef="USD">-655741</cvm:AccumulatedAmortization>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1616"
      unitRef="USD">165492</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1617"
      unitRef="USD">197704</us-gaap:OtherIntangibleAssetsNet>
    <cvm:PatentsWeightedAverageAmortizationPeriod contextRef="From2023-10-01to2024-09-30" id="fid_2343">P8Y</cvm:PatentsWeightedAverageAmortizationPeriod>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_1626"
      unitRef="USD">32000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1625"
      unitRef="USD">38000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1585">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="4" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Years ending September 30, &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;29,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;25,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;22,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;19,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;16,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;54,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;165,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1620"
      unitRef="USD">29000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1621"
      unitRef="USD">25000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1622"
      unitRef="USD">22000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1618"
      unitRef="USD">19000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1619"
      unitRef="USD">16000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1623"
      unitRef="USD">54000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive>
    <cvm:TotalFiniteLivedIntangibleAssetsAmortizationExpense
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1624"
      unitRef="USD">165000</cvm:TotalFiniteLivedIntangibleAssetsAmortizationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1554">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;7&lt;/strong&gt;&lt;strong&gt;. INCOME TAXES&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;At September 30, 2024 and 2023, the Company had net deferred tax assets of $62.5 million and $60.0 million, respectively. Due to uncertainties surrounding the Company&#x2019;s ability to generate future taxable income to realize these assets, a full valuation allowance has been established to offset the net deferred tax assets. In assessing the realization of deferred tax assets, management considered whether it was more likely than not that some, or all, of the deferred tax assets will be realized.&#160; The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income.&#160; Management has considered the history of the Company&#x2019;s operating losses and believes that the realization of the benefit of the deferred tax assets cannot be reasonably assured.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Pursuant to Section 382 of the Internal Revenue Code, or IRC, annual use of the Company&#x2019;s net operating loss (NOL) carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period. Such ownership change could result in annual limitations on the utilization of tax attributes, including NOL carryforwards and tax credits. The Company performed an estimated analysis to determine if any additional ownership changes occurred during the year ended September 30, 2024 and no such changes were identified. If changes in ownership occur after year end, NOL and tax credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company had federal NOL carryforwards of approximately $146.4 million and $123.1 million at September 30, 2024 and 2023, respectively. Approximately $19.2 million of the NOL carryforwards begin to expire during the year ended September 30, 2024 and become fully expired by 2038 and approximately $127.2 million of NOL carryforwards, which were generated after the enactment of Tax Cuts and Jobs Act, have an indefinite life.&#160; In addition, the Company has a general business credit as a result of the credit for increasing research activities (&#x201c;R&amp;amp;D credit&#x201d;) of approximately $0.9 million and&#160;$1.2 million at September 30, 2024 and 2023, respectively.&#160;The R&amp;amp;D credit expires during the fiscal year ended 2029.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities as of September 30, 2024 and 2023 are listed below:&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;NOL carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;34,673,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;30,829,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Capitalized R&amp;amp;D&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;14,062,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,196,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock-based compensation &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,645,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,579,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,752,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,400,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;R&amp;amp;D credit&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;932,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,221,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Vacation and other&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;188,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;298,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Fixed assets and intangibles&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;347,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;168,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;64,599,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;62,691,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(2,095,000&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(2,713,000&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Fixed assets and intangibles&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,095,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,713,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net deferred tax asset&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;62,504,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;59,978,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(62,504,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(59,978,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company has no federal or state current or deferred tax expense or benefit.&#160; The Company&#x2019;s effective tax rate differs from the applicable federal statutory tax rate.&#160; The reconciliation of these rates is as follows for the years ended September 30:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Federal rate&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;State rate change &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(11.97&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1.58&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;State tax rate, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.68&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.05&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Other adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(2.32&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1.62&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(9.39&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(21.85&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Effective tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company applies the provisions of ASC 740, &lt;em&gt;Accounting for Uncertainty in Income Taxes,&lt;/em&gt; which requires financial statement benefits to be recognized for positions taken for tax return purposes when it is more likely than not that the position will be sustained.&#160; The Company has elected to reflect any tax penalties or interest resulting from tax assessments on uncertain tax positions as a component of tax expense.&#160; The Company has generated federal net operating losses in tax years ending September 30, 1999 through 2024.&#160;&#160;The Company files income tax returns in the U.S. federal jurisdiction and various states. With few exceptions, the Company is no longer subject to U.S. federal and state income tax examinations by tax authorities for years before September 30, 2021. &lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-09-30_cvm_IncomeTaxMember"
      decimals="-5"
      id="fid_1676"
      unitRef="USD">62500000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-09-30_cvm_IncomeTaxMember"
      decimals="-5"
      id="fid_1677"
      unitRef="USD">60000000.0</us-gaap:DeferredTaxAssetsNet>
    <cvm:CumulativeChangeInOwnershipPercentage
      contextRef="From2023-10-01to2024-09-30_cvm_IncomeTaxMember"
      id="fid_1674">net operating loss (NOL) carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period</cvm:CumulativeChangeInOwnershipPercentage>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-09-30_cvm_IncomeTaxMember"
      decimals="-5"
      id="fid_1671"
      unitRef="USD">146400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-09-30_cvm_IncomeTaxMember"
      decimals="-5"
      id="fid_1672"
      unitRef="USD">123100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardDescription
      contextRef="From2023-10-01to2024-09-30_cvm_IncomeTaxMember"
      id="fid_1675">Approximately $19.2 million of the NOL carryforwards begin to expire during the year ended September 30, 2024 and become fully expired by 2038 and approximately $127.2 million of NOL carryforwards</us-gaap:TaxCreditCarryforwardDescription>
    <cvm:ResearchAndDevelopmentCredit
      contextRef="AsOf2024-09-30_cvm_IncomeTaxMember"
      decimals="-5"
      id="fid_1669"
      unitRef="USD">900000</cvm:ResearchAndDevelopmentCredit>
    <cvm:ResearchAndDevelopmentCredit
      contextRef="AsOf2023-09-30_cvm_IncomeTaxMember"
      decimals="-5"
      id="fid_1670"
      unitRef="USD">1200000</cvm:ResearchAndDevelopmentCredit>
    <cvm:ResearchAndDevelopmentCreditDescription
      contextRef="From2023-10-01to2024-09-30_cvm_IncomeTaxMember"
      id="fid_1673">The R&amp;D credit expires during the fiscal year ended 2029</cvm:ResearchAndDevelopmentCreditDescription>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1586">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;NOL carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;34,673,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;30,829,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Capitalized R&amp;amp;D&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;14,062,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,196,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stock-based compensation &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,645,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,579,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,752,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,400,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;R&amp;amp;D credit&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;932,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,221,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Vacation and other&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;188,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;298,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Fixed assets and intangibles&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;347,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;168,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;64,599,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;62,691,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(2,095,000&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(2,713,000&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Fixed assets and intangibles&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,095,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(2,713,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net deferred tax asset&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;62,504,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;59,978,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(62,504,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(59,978,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1628"
      unitRef="USD">34673000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1627"
      unitRef="USD">30829000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <cvm:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1636"
      unitRef="USD">14062000</cvm:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd>
    <cvm:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1635"
      unitRef="USD">15196000</cvm:DeferredTaxAssetFixedAssetsIntangiblesAndCapitalizedRd>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1634"
      unitRef="USD">11645000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1633"
      unitRef="USD">11579000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <cvm:LeaseLiabilities
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1630"
      unitRef="USD">2752000</cvm:LeaseLiabilities>
    <cvm:LeaseLiabilities
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1629"
      unitRef="USD">3400000</cvm:LeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1632"
      unitRef="USD">932000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1631"
      unitRef="USD">1221000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1638"
      unitRef="USD">188000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1637"
      unitRef="USD">298000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1654"
      unitRef="USD">347000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1653"
      unitRef="USD">168000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1640"
      unitRef="USD">64599000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1639"
      unitRef="USD">62691000</us-gaap:DeferredTaxAssetsGross>
    <cvm:RightOfUseAssets
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1642"
      unitRef="USD">-2095000</cvm:RightOfUseAssets>
    <cvm:RightOfUseAssets
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1641"
      unitRef="USD">-2713000</cvm:RightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1644"
      unitRef="USD">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1643"
      unitRef="USD">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1646"
      unitRef="USD">2095000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1645"
      unitRef="USD">2713000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1648"
      unitRef="USD">62504000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1647"
      unitRef="USD">59978000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1650"
      unitRef="USD">62504000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1649"
      unitRef="USD">59978000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1652"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1651"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1587">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Federal rate&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;State rate change &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(11.97&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1.58&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;State tax rate, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.68&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4.05&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Other adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(2.32&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1.62&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(9.39&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(21.85&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Effective tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="fid_1656"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1655"
      unitRef="Pure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="fid_1657"
      unitRef="Pure">-0.1197</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1658"
      unitRef="Pure">-0.0158</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="fid_1659"
      unitRef="Pure">0.0268</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1660"
      unitRef="Pure">0.0405</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="fid_1661"
      unitRef="Pure">-0.0232</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1662"
      unitRef="Pure">-0.0162</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="fid_1663"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1664"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="fid_1665"
      unitRef="Pure">-0.0939</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1666"
      unitRef="Pure">-0.2185</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="fid_1667"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1668"
      unitRef="Pure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1555">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;8&lt;/strong&gt;&lt;strong&gt;.&lt;/strong&gt; &lt;strong&gt;EQUITY-BASED&lt;/strong&gt;&lt;strong&gt; COMPENSATION&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company recognized the following expenses for options issued or vested and restricted stock awarded during the year:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Year Ended September 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,270,180&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,286,231&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;680,768&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;655,740&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;As of September 30, 2024, the total compensation cost related to non-vested options and restricted stock awarded to employees and non-employees not yet recognized was approximately $4.5 million and $0.1 million, respectively, and the weighted-average period over which it is expected to be recognized is 1.9 and 0.54 years, respectively.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the years ended September 30, 2024 and 2023, the fair value of each option grant was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Expected stock price volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;100.89 &#x2013; 101.66%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;99.18 &#x2013; 100.18%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;3.77 &#x2013; 4.58%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;3.41 &#x2013; 4.25%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Expected life of options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;9.61 &#x2013; 9.64 years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;9.63 &#x2013; 9.66 years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Non-Qualified Stock Option Plan&lt;/span&gt;&lt;span style="text-decoration:underline"&gt;s&lt;/span&gt;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the year ended September 30, 2024, the Company adopted the 2024 Non-Qualified Stock Option Plan, which provides for the issuance of up to 2,000,000 options to purchase shares of common stock. On April 19, 2024, the Company granted 1,962,000 options to purchase shares of common stock from the 2024 Non-Qualified Stock Option Plan to officers, directors and employees. Each option entitles the holder to purchase one share of the Company&#x2019;s common stock at a price of $1.50 per share, vests in three equal annual installments commencing one year after the grant date and expires on April 18, 2034.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the year ended September 30, 2023, the Company adopted the 2023 Non-Qualified Stock Option Plan, which provides for the issuance of up to 2,000,000 options to purchase shares of common stock. On August 8, 2023, the Company granted 1,958,500 options to purchase shares of common stock from the 2023 Non-Qualified Stock Option Plan to officers, directors and employees. Each option entitles the holder to purchase one share of the Company&#x2019;s common stock at a price of $1.36 per share, vests in three equal annual installments commencing one year after the grant date and expires on August 7, 2033.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;At September 30, 2024, the Company has collectively authorized the issuance of 17,787,200 options to purchase shares of common stock under its Non-Qualified Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms of the options were determined by the Company&#x2019;s Compensation Committee which administers the plans. The Company&#x2019;s employees, directors, officers, and consultants or advisors are eligible to be granted options under the Non-Qualified Stock Option Plans.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Incentive Stock Option Plan&lt;/span&gt;&lt;span style="text-decoration:underline"&gt;s&lt;/span&gt; &#x2013; At September 30, 2024, the Company had collectively authorized the issuance of 138,400 options to purchase shares of common stock under its Incentive Stock Option Plans. Options typically vest over a three-year period and expire no later than ten years after the grant date. Terms of the options were determined by the Company&#x2019;s Compensation Committee which administers the Plans. Only the Company&#x2019;s employees are eligible to be granted options under the Incentive Stock Option Plans.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Activity in the Company&#x2019;s Non-Qualified and Incentive Stock Option Plans for the two years ended September 30, 2024 is summarized as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;&lt;span style="text-decoration:underline"&gt;Non-Qualified and Incentive Stock Option Plans&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Outstanding&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Exercisable&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Remaining Contractual Term (Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Aggregate Intrinsic Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Remaining Contractual Term (Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Aggregate Intrinsic Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Outstanding at September 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;12,964,014&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;9.06&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;7.35&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1,866,240&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;7,067,617&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.21&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.21&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1,866,105&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;952,256&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;8.41&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Granted (a)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;2,065,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1.37&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;(213,165&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;9.19&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;(58,791&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;61.05&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;(58,791&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;61.05&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Outstanding at September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;14,757,558&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;7.78&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.81&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;7,961,082&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.07&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;5.60&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1,501,583&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;4.24&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Granted (b)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1,969,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1.50&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;(406,333&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;10.01&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;(62,145&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;27.35&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;(62,145&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;27.35&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Outstanding at September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"&gt;16,258,080&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.88&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.25&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"&gt;9,400,520&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;5.64&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;5.19&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;(a)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Includes 1,965,500 performance based options issued to officers and directors, 100,000 options issued to consultants. The weighted average grant date fair value was $1.22.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;(b)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;The weighted average grant date fair value was $1.36.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;A summary of the status of the Company&#x2019;s unvested options for the two years ended September 30, 2024 is presented below:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Grant Date Fair Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested at September 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,896,397&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.63&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(952,256&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7.30&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,065,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.22&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(213,165&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8.02&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested at September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;6,796,476&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.25&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1,501,583&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.73&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,969,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.36&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(406,333&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.94&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested at September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;6,857,560&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.69&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Incentive Stock Bonus Plan&lt;/span&gt; &#x2013; On September 30, 2024, 610,500 of the shares granted under the 2014 Incentive Stock Bonus Plan remain outstanding, of which 463,250 shares are fully vested.&#160; During the year ended September 30, 2024 and 2023, there were 0 and 4,000 unvested shares that were forfeited, respectively. The shares are being earned upon the achievement of certain milestones leading to the commercialization of the Company&#x2019;s Multikine technology, or specified increases in the market price of the Company&#x2019;s stock.&#160; The fair value of the shares on the grant date was calculated using the market value on the grant-date for issuances where the attainment of performance criteria is likely and using a Monte Carlo Simulation for issuances where the attainment of performance criteria is uncertain.&#160; The grant date fair value of shares issued that remain outstanding as of September 30, 2024 was approximately $8.6 million.&#160; The total value of the shares, if earned, is being expensed over the requisite service periods for each milestone, provided the requisite service periods are rendered, regardless of whether the market conditions are met.&#160; No compensation cost is recognized for awards where the requisite service period is not rendered.&#160; During the years ended September 30, 2024 and 2023, the Company recorded expense relating to the issuance of restricted stock pursuant to the plan of approximately $0 and $(22,000), respectively.&#160; As of September 30, 2023, all compensation expense related to the 2014 Incentive Stock Bonus Plan has been fully recognized. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;A summary of the status of the Company&#x2019;s restricted common stock issued from the Incentive Stock Bonus Plan for the two years ended September 30, 2024 is presented below: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Number of&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Weighted Average Grant Date Fair Value&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Unvested at September 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;151,250&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(4,000&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Unvested at September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;147,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Unvested at September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;147,250&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Stock Bonus Plans&lt;/span&gt;&lt;span style="text-decoration:underline"&gt; &lt;/span&gt;&#x2013; As of September 30, 2024, the Company authorized to issue up to 1,283,760 shares of common stock from the Stock Bonus Plans and has issued a total of 649,840 shares of common stock under its Stock Bonus Plans.&#160; All employees, directors, officers, consultants, and advisors are eligible to be granted shares.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;span style="text-decoration:underline"&gt;Stock Compensation Plans&lt;/span&gt; &#x2013; On September 30, 2024, 634,000 shares were authorized for issuance pursuant to the Company&#x2019;s Stock Compensation Plans, of which 153,195 shares were issued and outstanding.&#160; No shares were issued from the Stock Compensation Plans during the years ended September 30, 2024 and 2023.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1588">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Year Ended September 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,270,180&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;6,286,231&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Non-employees&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;680,768&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;655,740&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2023-10-01to2024-09-30_cvm_EmployeesMember"
      decimals="0"
      id="fid_1678"
      unitRef="USD">4270180</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2022-10-01to2023-09-30_cvm_EmployeesMember"
      decimals="0"
      id="fid_1679"
      unitRef="USD">6286231</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2023-10-01to2024-09-30_cvm_NonEmployeesMember"
      decimals="0"
      id="fid_1680"
      unitRef="USD">680768</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="From2022-10-01to2023-09-30_cvm_NonEmployeesMember"
      decimals="0"
      id="fid_1681"
      unitRef="USD">655740</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-10-01to2024-09-30_cvm_NonVestedOptionsMember"
      decimals="-5"
      id="fid_2072"
      unitRef="USD">4500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-10-01to2024-09-30_cvm_RestrictedStockAwardsMember"
      decimals="-5"
      id="fid_2070"
      unitRef="USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2023-10-01to2024-09-30_cvm_NonVestedOptionsMember"
      id="fid_2074">P1Y10M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2023-10-01to2024-09-30_cvm_RestrictedStockAwardsMember"
      id="fid_2073">P0Y6M14D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1589">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Expected stock price volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;100.89 &#x2013; 101.66%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;99.18 &#x2013; 100.18%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;3.77 &#x2013; 4.58%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;3.41 &#x2013; 4.25%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Expected life of options&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;9.61 &#x2013; 9.64 years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;9.63 &#x2013; 9.66 years&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="fid_1682"
      unitRef="Pure">1.0089</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="fid_1684"
      unitRef="Pure">1.0166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1683"
      unitRef="Pure">0.9918</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1685"
      unitRef="Pure">1.0018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="fid_1686"
      unitRef="Pure">0.0377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="fid_1688"
      unitRef="Pure">0.0458</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1687"
      unitRef="Pure">0.0341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_1689"
      unitRef="Pure">0.0425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <cvm:ExpectedLifeOfOptionsMin1 contextRef="From2023-10-01to2024-09-30" id="fid_1690">P9Y7M9D</cvm:ExpectedLifeOfOptionsMin1>
    <cvm:ExpectedLifeOfOptionsMax contextRef="From2022-10-01to2023-09-30" id="fid_1692">P9Y7M20D</cvm:ExpectedLifeOfOptionsMax>
    <cvm:ExpectedLifeOfOptionsMin1 contextRef="From2022-10-01to2023-09-30" id="fid_1691">P9Y7M17D</cvm:ExpectedLifeOfOptionsMin1>
    <cvm:ExpectedLifeOfOptionsMax contextRef="From2023-10-01to2024-09-30" id="fid_1693">P9Y7M28D</cvm:ExpectedLifeOfOptionsMax>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2024-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_1792"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <cvm:PerformanceBasedStockOptionsSharesGranted
      contextRef="AsOf2024-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_1782"
      unitRef="Shares">1962000</cvm:PerformanceBasedStockOptionsSharesGranted>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1
      contextRef="From2023-10-01to2024-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="INF"
      id="fid_1784"
      unitRef="USDPShares">1.50</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2023-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_1791"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <cvm:PerformanceBasedStockOptionsSharesGranted
      contextRef="AsOf2023-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_1788"
      unitRef="Shares">1958500</cvm:PerformanceBasedStockOptionsSharesGranted>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1
      contextRef="From2022-10-01to2023-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="INF"
      id="fid_1783"
      unitRef="USDPShares">1.36</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-09-30_cvm_NonQualifiedStockOptionsPlansMember"
      decimals="0"
      id="fid_1777"
      unitRef="Shares">17787200</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-09-30_cvm_IncentiveStockOptionPlansMember"
      decimals="0"
      id="fid_1778"
      unitRef="Shares">138400</us-gaap:CommonStockSharesAuthorized>
    <cvm:ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1590">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Outstanding&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Exercisable&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Remaining Contractual Term (Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Aggregate Intrinsic Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Remaining Contractual Term (Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Aggregate Intrinsic Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Outstanding at September 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;12,964,014&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;9.06&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;7.35&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1,866,240&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;7,067,617&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.21&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.21&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1,866,105&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;952,256&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;8.41&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Granted (a)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;2,065,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1.37&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;(213,165&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;9.19&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;(58,791&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;61.05&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;(58,791&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;61.05&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Outstanding at September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;14,757,558&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;7.78&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.81&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;7,961,082&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.07&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;5.60&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1,501,583&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;4.24&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Granted (b)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1,969,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;1.50&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;(406,333&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;10.01&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;(62,145&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;27.35&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"&gt;(62,145&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;27.35&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Outstanding at September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"&gt;16,258,080&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.88&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;6.25&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"&gt;9,400,520&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;5.64&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;5.19&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"&gt;0&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</cvm:ScheduleOfNonQualifiedAndIncentiveStockOptionPlansTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1696"
      unitRef="Shares">12964014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1710"
      unitRef="USDPShares">9.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember"
      id="fid_2409">P7Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2022-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_2075"
      unitRef="USD">1866240</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1697"
      unitRef="Shares">7067617</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="fid_1711"
      unitRef="USDPShares">6.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning
      contextRef="From2022-10-01to2023-09-30_cvm_ExercisableMember"
      id="fid_2410">P6Y2M15D</cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingBeginning>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2022-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_2080"
      unitRef="USD">1866105</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <cvm:NumberOfOptionsVested
      contextRef="AsOf2022-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1700"
      unitRef="Shares">952256</cvm:NumberOfOptionsVested>
    <cvm:WeightedAverageExercisePriceVested
      contextRef="AsOf2022-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="fid_1714"
      unitRef="USDPShares">8.41</cvm:WeightedAverageExercisePriceVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1736"
      unitRef="Shares">2065500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1741"
      unitRef="USDPShares">1.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1740"
      unitRef="USDPShares">9.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1705"
      unitRef="Shares">58791</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1717"
      unitRef="USDPShares">61.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <cvm:NumberOfOptions
      contextRef="From2022-10-01to2023-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1706"
      unitRef="Shares">-58791</cvm:NumberOfOptions>
    <cvm:WeightedAverageExercisePriceExpired
      contextRef="From2022-10-01to2023-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="fid_1718"
      unitRef="USDPShares">61.05</cvm:WeightedAverageExercisePriceExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1698"
      unitRef="Shares">14757558</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1712"
      unitRef="USDPShares">7.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2022-10-01to2023-09-30_cvm_OutstandingMember"
      id="fid_1725">P6Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2023-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_2076"
      unitRef="USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1699"
      unitRef="Shares">7961082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="fid_1713"
      unitRef="USDPShares">6.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding
      contextRef="From2022-10-01to2023-09-30_cvm_ExercisableMember"
      id="fid_1726">P5Y7M6D</cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2023-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_2082"
      unitRef="USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <cvm:NumberOfOptionsVested
      contextRef="AsOf2023-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1743"
      unitRef="Shares">1501583</cvm:NumberOfOptionsVested>
    <cvm:WeightedAverageExercisePriceVested
      contextRef="AsOf2023-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="fid_1745"
      unitRef="USDPShares">4.24</cvm:WeightedAverageExercisePriceVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-10-01to2024-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1734"
      unitRef="Shares">1969000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-10-01to2024-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1739"
      unitRef="USDPShares">1.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-10-01to2024-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1738"
      unitRef="USDPShares">10.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-10-01to2024-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1707"
      unitRef="Shares">62145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-10-01to2024-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1719"
      unitRef="USDPShares">27.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <cvm:NumberOfOptions
      contextRef="From2023-10-01to2024-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1708"
      unitRef="Shares">-62145</cvm:NumberOfOptions>
    <cvm:WeightedAverageExercisePriceExpired
      contextRef="From2023-10-01to2024-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="fid_1720"
      unitRef="USDPShares">27.35</cvm:WeightedAverageExercisePriceExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_1732"
      unitRef="Shares">16258080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_cvm_OutstandingMember"
      decimals="INF"
      id="fid_1737"
      unitRef="USDPShares">6.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-10-01to2024-09-30_cvm_OutstandingMember"
      id="fid_1724">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2024-09-30_cvm_OutstandingMember"
      decimals="0"
      id="fid_2078"
      unitRef="USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_1742"
      unitRef="Shares">9400520</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-09-30_cvm_ExercisableMember"
      decimals="INF"
      id="fid_1744"
      unitRef="USDPShares">5.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding
      contextRef="From2023-10-01to2024-09-30_cvm_ExercisableMember"
      id="fid_1723">P5Y2M8D</cvm:WeightedAverageRemainingContractualLifeInYearsOutstandingEnding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2024-09-30_cvm_ExercisableMember"
      decimals="0"
      id="fid_2083"
      unitRef="USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_2061">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Options&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Weighted Average Grant Date Fair Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested at September 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,896,397&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.63&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(952,256&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;7.30&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,065,500&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.22&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(213,165&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;8.02&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested at September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;6,796,476&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2.25&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(1,501,583&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3.73&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,969,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.36&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(406,333&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.94&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested at September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;6,857,560&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1.69&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-09-30"
      decimals="0"
      id="fid_1751"
      unitRef="Shares">5896397</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-09-30"
      decimals="INF"
      id="fid_1760"
      unitRef="USDPShares">3.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1752"
      unitRef="Shares">952256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_2084"
      unitRef="USDPShares">7.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1754"
      unitRef="Shares">2065500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_2414"
      unitRef="USDPShares">1.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1756"
      unitRef="Shares">213165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_2415"
      unitRef="USDPShares">8.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="fid_1750"
      unitRef="Shares">6796476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-09-30"
      decimals="INF"
      id="fid_1761"
      unitRef="USDPShares">2.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_1753"
      unitRef="Shares">1501583</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="fid_2085"
      unitRef="USDPShares">3.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_1755"
      unitRef="Shares">1969000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="fid_2412"
      unitRef="USDPShares">1.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_1757"
      unitRef="Shares">406333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="fid_2413"
      unitRef="USDPShares">1.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1759"
      unitRef="Shares">6857560</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="fid_1763"
      unitRef="USDPShares">1.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-09-30_cvm_IncentiveStockBonusPlanMember"
      decimals="0"
      id="fid_1779"
      unitRef="Shares">610500</us-gaap:CommonStockSharesAuthorized>
    <cvm:VestedShares
      contextRef="From2023-10-01to2024-09-30_cvm_IncentiveStockBonusPlanMember"
      decimals="0"
      id="fid_1786"
      unitRef="Shares">463250</cvm:VestedShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2023-10-01to2024-09-30_cvm_IncentiveStockBonusPlanMember"
      decimals="0"
      id="fid_2417"
      unitRef="Shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2022-10-01to2023-09-30_cvm_IncentiveStockBonusPlanMember"
      decimals="0"
      id="fid_1793"
      unitRef="Shares">4000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <cvm:RemainingOutstandingFairValueOfShares
      contextRef="AsOf2024-09-30_cvm_IncentiveStockBonusPlanMember"
      decimals="-5"
      id="fid_1785"
      unitRef="USD">8600000</cvm:RemainingOutstandingFairValueOfShares>
    <us-gaap:DeferredCompensationEquity
      contextRef="AsOf2024-09-30_cvm_IncentiveStockBonusPlanMember"
      decimals="-3"
      id="fid_1789"
      unitRef="USD">0</us-gaap:DeferredCompensationEquity>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1592">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Number of&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;Weighted Average Grant Date Fair Value&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Unvested at September 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;151,250&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;(4,000&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Unvested at September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;147,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Unvested at September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;147,250&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;13.75&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2022-09-30_cvm_RestrictedStockAwardsMember"
      decimals="0"
      id="fid_1765"
      unitRef="Shares">151250</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-09-30_cvm_RestrictedStockAwardsMember"
      decimals="INF"
      id="fid_2416"
      unitRef="USDPShares">13.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="From2022-10-01to2023-09-30_cvm_RestrictedStockAwardsMember"
      decimals="0"
      id="fid_1766"
      unitRef="Shares">4000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2023-09-30_cvm_RestrictedStockAwardsMember"
      decimals="0"
      id="fid_1764"
      unitRef="Shares">147250</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-09-30_cvm_RestrictedStockAwardsMember"
      decimals="INF"
      id="fid_1772"
      unitRef="USDPShares">13.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2024-09-30_cvm_RestrictedStockAwardsMember"
      decimals="0"
      id="fid_1771"
      unitRef="Shares">147250</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-09-30_cvm_RestrictedStockAwardsMember"
      decimals="INF"
      id="fid_1774"
      unitRef="USDPShares">13.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-09-30_cvm_StockBonusPlansMember"
      decimals="0"
      id="fid_1780"
      unitRef="Shares">1283760</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-09-30_cvm_StockBonusPlansMember"
      decimals="0"
      id="fid_1775"
      unitRef="Shares">649840</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-09-30_cvm_StockCompensationPlansMember"
      decimals="0"
      id="fid_1781"
      unitRef="Shares">634000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-09-30_cvm_StockCompensationPlansMember"
      decimals="0"
      id="fid_1776"
      unitRef="Shares">153195</us-gaap:CommonStockSharesIssued>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1556">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;9&lt;/strong&gt;&lt;strong&gt;. EMPLOYEE BENEFIT PLAN&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company maintains a defined contribution retirement plan, qualifying under Section 401(k) of the Internal Revenue Code, subject to the Employee Retirement Income Security Act of 1974, as amended, and covering substantially all Company employees. Each participant&#x2019;s contribution is matched by the Company with shares of common stock that have a value equal to 100% of the participant&#x2019;s contribution, not to exceed the lesser of $10,000 or 6% of the participant&#x2019;s total compensation. The Company&#x2019;s contribution of common stock is valued each quarter based upon the closing bid price of the Company&#x2019;s common stock. During the year ended September 30, 2024, 136,868 shares were issued to the Company&#x2019;s 401(k) plan for a cost of approximately $219,000. During the year ended September 30, 2023, 97,004 shares were issued to the Company&#x2019;s 401(k) plan for a cost of approximately $208,000.&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <cvm:EmployeeContributionsToDefinedContributionPlans
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2344"
      unitRef="USD">10000</cvm:EmployeeContributionsToDefinedContributionPlans>
    <cvm:PercentageOfEmployeeContributionsToDefinedContributionPlans
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="fid_2345"
      unitRef="Pure">0.06</cvm:PercentageOfEmployeeContributionsToDefinedContributionPlans>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_1986"
      unitRef="Shares">136868</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_1982"
      unitRef="USD">219000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1987"
      unitRef="Shares">97004</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_1983"
      unitRef="USD">208000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1557">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;10&lt;/strong&gt;&lt;strong&gt;. COMMITMENTS AND CONTINGENCIES&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Clinical Research Agreements&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In August 2024 the Company entered into an agreement, pursuant to which the Company engaged Ergomed Clinical Research, Inc. to provide clinical development services related to the Company&#x2019;s upcoming confirmatory registration study in exchange for fees. Since the Company entered into this agreement it has incurred research and development expenses of approximately $0.4 million as of September 30, 2024.&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Lease Agreements&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#x2019;s specifications so that it can be used by the Company to manufacture Multikine for the Company&#x2019;s Phase III clinical trial and sales of the drug if approved by the FDA or regulators in Canada, the UK or Europe. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease, which expires in October 2028. &#160;The renewal options are not included in the calculation of the right-of-use asset and lease liability because exercise of those options is not reasonably certain.&#160;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;As of September 30, 2024 and 2023, respectively, the net book value of the finance lease right-of-use asset is approximately $7.4 million and $9.1 million and the balance of the finance lease liability is approximately $10.0 million and $11.7 million, of which approximately $2.0 million and $1.8 million is current. These amounts include the San Tomas lease as well as several other smaller finance leases for office equipment. During the years ended September 30, 2024 and 2023, the finance right of use assets are being depreciated using a straight-line method over the underlying lease terms and depreciation expense totaled approximately $1.8 million in both periods, which is included in research and development expense on the accompanying statements of operations. Total cash paid related to finance leases during the years ended September 30, 2024 and 2023, respectively, was approximately $2.7 million and $2.6 million, of which approximately $0.9 million and $1.1 million was for interest. The total cash paid related to finance lease principal payments is included in cash flows from financing activities on the accompanying statements of cash flows. The total cash paid related to finance lease interest expense is included in cash flows from operating activities on the accompanying statements of cash flows. The weighted average discount rate of the Company&#x2019;s finance leases is 8.46% and the weighted average remaining lease term is 4.09 years. During the years ended September 30, 2024 and 2023, total finance lease costs were approximately $2.7 million and $2.9 million, consisting of approximately $1.8 million of lease asset amortization in both periods, and approximately $0.9 million and $1.1 million of interest on the finance lease liabilities, respectively. Variable lease expenses, such as maintenance costs, utilities, and real property taxes are not included in right of use assets or lease liabilities but rather are expensed as incurred. During the year ended September 30, 2024, there were approximately $0.9 million of variable finance lease costs, which are included in research and development expense on the accompanying statements of operations. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On January 11, 2023, the Company was required to deposit approximately $2.3 million to its landlord, equivalent to one year&#x2019;s rent, for falling below the stipulated cash threshold in accordance with the San Tomas lease. The amount will be included as an asset on the balance sheet until the Company meets the minimum cash balance required and the deposit is returned.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Approximate future minimum lease payments under finance leases as of September 30, 2024 are as follows:&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,747,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,838,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,929,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,021,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;255,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,790,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,821,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;9,969,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of finance lease obligations &#x2013; current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2,011,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of finance lease obligations &#x2013; non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;7,958,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company leases two facilities under operating leases.&#160; The lease for the Company&#x2019;s office headquarters will expire on November 30, 2025.&#160; The lease for its research and development laboratory and will expire on February 29, 2032. The operating leases include escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the terms of the leases. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;As of September 30, 2024 and 2023, respectively, the net book value of the operating lease right-of-use asset is approximately $1.5 million and $1.7 million and the balance of the operating lease liability is approximately $1.7 million and $1.9 million, of which approximately $0.2 million is current in both periods. During the years ended September 30, 2024 and 2023, the Company incurred lease expense under operating leases of approximately $0.4 million in both periods, which is included in general and administrative expense on the accompanying statements of operations. Total cash paid related to operating leases during the years ended September 30, 2024 and 2023 was approximately $0.4 million and $0.3 million, respectively. The total cash paid related to operating leases is included in cash flows from operating activities on the accompanying statements of cash flows. The weighted average discount rate of the Company&#x2019;s operating leases is 9.0% and the weighted average the remaining lease term is 6.98 years. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;As of September 30, 2024, future minimum lease payments on operating leases are as follows: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;366,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;287,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;277,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;285,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;294,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;746,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,255,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(602,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,653,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligations &#x2013; current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;227,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligations &#x2013; non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,426,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2023-10-01to2024-09-30_cvm_ErgomedMember"
      decimals="-5"
      id="fid_2008"
      unitRef="USD">400000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2018"
      unitRef="USD">7400000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2023-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2019"
      unitRef="USD">9100000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2020"
      unitRef="USD">10000000.0</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2023-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2021"
      unitRef="USD">11700000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2024-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2022"
      unitRef="USD">2000000.0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2023-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2023"
      unitRef="USD">1800000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:Depreciation
      contextRef="From2023-10-01to2024-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2024"
      unitRef="USD">1800000</us-gaap:Depreciation>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2023-10-01to2024-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2027"
      unitRef="USD">2700000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="From2022-10-01to2023-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2028"
      unitRef="USD">2600000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="From2023-10-01to2024-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2026"
      unitRef="USD">900000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="From2022-10-01to2023-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2029"
      unitRef="USD">1100000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="From2023-10-01to2024-09-30_us-gaap_LeaseAgreementsMember"
      decimals="INF"
      id="fid_2030"
      unitRef="Pure">0.0846</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <cvm:WeightedAverageMaturityYear
      contextRef="From2023-10-01to2024-09-30_us-gaap_LeaseAgreementsMember"
      id="fid_2017">P4Y1M2D</cvm:WeightedAverageMaturityYear>
    <cvm:FinanceLeaseCosts
      contextRef="From2023-10-01to2024-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2418"
      unitRef="USD">2700000</cvm:FinanceLeaseCosts>
    <cvm:FinanceLeaseCosts
      contextRef="From2022-10-01to2023-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2419"
      unitRef="USD">2900000</cvm:FinanceLeaseCosts>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="From2023-10-01to2024-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2420"
      unitRef="USD">1800000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="From2023-10-01to2024-09-30"
      decimals="-5"
      id="fid_2422"
      unitRef="USD">900000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="From2022-10-01to2023-09-30"
      decimals="-5"
      id="fid_2423"
      unitRef="USD">1100000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2023-10-01to2024-09-30_us-gaap_LeaseAgreementsMember"
      decimals="-5"
      id="fid_2424"
      unitRef="USD">900000</us-gaap:OtherResearchAndDevelopmentExpense>
    <cvm:PaymentsMadeToLandlord
      contextRef="From2023-01-01to2023-01-11_cvm_LandlordMember"
      decimals="-5"
      id="fid_2033"
      unitRef="USD">2300000</cvm:PaymentsMadeToLandlord>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1593">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,747,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,838,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,929,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,021,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;255,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;11,790,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(1,821,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;9,969,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of finance lease obligations &#x2013; current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2,011,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of finance lease obligations &#x2013; non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;7,958,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1989"
      unitRef="USD">2747000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1990"
      unitRef="USD">2838000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1991"
      unitRef="USD">2929000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1996"
      unitRef="USD">3021000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1988"
      unitRef="USD">255000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1993"
      unitRef="USD">11790000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1994"
      unitRef="USD">1821000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1992"
      unitRef="USD">9969000</us-gaap:FinanceLeaseLiability>
    <cvm:FinanceLeaseLiabilityCurrentPortion
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1995"
      unitRef="USD">2011000</cvm:FinanceLeaseLiabilityCurrentPortion>
    <cvm:FinanceLeaseLiabilityNoncurrentPortion
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1997"
      unitRef="USD">7958000</cvm:FinanceLeaseLiabilityNoncurrentPortion>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-09-30_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="fid_2041"
      unitRef="USD">1500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-09-30_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="fid_2042"
      unitRef="USD">1700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-09-30_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="fid_2039"
      unitRef="USD">1700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-09-30_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="fid_2040"
      unitRef="USD">1900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-09-30_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="fid_2037"
      unitRef="USD">200000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherExpenses
      contextRef="From2023-10-01to2024-09-30_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="fid_2044"
      unitRef="USD">400000</us-gaap:OtherExpenses>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-10-01to2024-09-30_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="fid_2034"
      unitRef="USD">400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-10-01to2023-09-30_us-gaap_OperatingExpenseMember"
      decimals="-5"
      id="fid_2035"
      unitRef="USD">300000</us-gaap:OperatingLeasePayments>
    <cvm:WeightedAverageOperatingLeaseDiscountRate
      contextRef="From2023-10-01to2024-09-30_us-gaap_OperatingExpenseMember"
      decimals="INF"
      id="fid_2036"
      unitRef="Pure">0.090</cvm:WeightedAverageOperatingLeaseDiscountRate>
    <cvm:WeightedAverageOperatingLeaseMaturityYear
      contextRef="From2023-10-01to2024-09-30_us-gaap_OperatingExpenseMember"
      id="fid_2043">P6Y11M23D</cvm:WeightedAverageOperatingLeaseMaturityYear>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1594">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Year ending September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;366,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;287,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;277,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;285,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;294,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;746,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total future minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,255,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Less imputed interest on operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(602,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,653,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligations &#x2013; current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;227,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net present value of operating lease obligations &#x2013; non-current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,426,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1999"
      unitRef="USD">366000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2000"
      unitRef="USD">287000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2001"
      unitRef="USD">277000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2006"
      unitRef="USD">285000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_1998"
      unitRef="USD">294000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2002"
      unitRef="USD">746000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2003"
      unitRef="USD">2255000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2004"
      unitRef="USD">602000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2367"
      unitRef="USD">1653000</us-gaap:OperatingLeaseLiability>
    <cvm:OperatingLeaseObligationyCurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2007"
      unitRef="USD">227000</cvm:OperatingLeaseObligationyCurrent>
    <cvm:OperatingLeaseObligationyNoncurrent
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="fid_2005"
      unitRef="USD">1426000</cvm:OperatingLeaseObligationyNoncurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1558">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;1&lt;/strong&gt;&lt;strong&gt;1&lt;/strong&gt;&lt;strong&gt;. &lt;/strong&gt;&lt;strong&gt;RELATED PARTY TRANSACTIONS&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the year ended September 30, 2024, certain officers and directors purchased 58,000 shares of restricted common stock at an aggregated fair market value of approximately $81,000. During the year ended September 30, 2023, no restricted shares of the Company&#x2019;s common stock were purchased by related parties.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On July 11, 2024, Geert Kersten, the Company&#x2019;s Chief Executive Officer and a director, loaned the Company $200,000. On July 18, 2024, Mr. Kersten loaned the Company an additional $250,000. These amounts were repaid on July 30, 2024.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On May 4, 2024, the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates. The incremental cost of this extension was approximately $0.7 million, which was recorded as a deemed dividend in the financial statements for the three months ended June 30, 2024. The Series N, X, MM, NN, RR and UU warrants are held by Geert Kersten, Patricia Prichep (current Officers of the Company) and the de Clara Trust, of which the Company&#x2019;s CEO, Geert Kersten, is a beneficiary.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On October 28, 2022, the expiration date of the Series RR warrants was extended two years from October 30, 2022 to October 30, 2024 (Note C). The incremental cost of this extension was approximately $172,000, which was recorded as a deemed dividend.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <cvm:RestrictedCommonStockSharesIssued
      contextRef="From2023-10-01to2024-09-30_cvm_OfficerAndDirectorMember"
      decimals="0"
      id="fid_1796"
      unitRef="USD">58000</cvm:RestrictedCommonStockSharesIssued>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-10-01to2024-09-30_cvm_OfficerAndDirectorMember"
      decimals="0"
      id="fid_2354"
      unitRef="USD">81000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2024-07-01to2024-07-11_cvm_CEOMember"
      decimals="0"
      id="fid_2361"
      unitRef="USD">200000</us-gaap:ProceedsFromRelatedPartyDebt>
    <cvm:ProceedsFromAdditionalDebtFromRelatedParty
      contextRef="From2024-07-01to2024-07-18_cvm_CEOMember"
      decimals="0"
      id="fid_2359"
      unitRef="USD">250000</cvm:ProceedsFromAdditionalDebtFromRelatedParty>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-07-01to2024-07-11_cvm_CEOMember"
      id="fid_2363">2024-07-30</us-gaap:DebtInstrumentMaturityDate>
    <cvm:DescriptionOfModificationOfWarrants contextRef="From2024-05-01to2024-05-04" id="fid_2366">the Company modified the terms of Series UU, X, Y, N, MM, NN and RR warrants by extending the expiration dates by twenty-four (24) months from their current expiration dates. The incremental cost of this extension was approximately $0.7 million, which was recorded as a deemed dividend</cvm:DescriptionOfModificationOfWarrants>
    <cvm:IncrementalCostOfWarrantsExtension
      contextRef="From2023-10-01to2024-09-30_cvm_SeriesRRWarrantMember"
      decimals="0"
      id="fid_1795"
      unitRef="USD">172000</cvm:IncrementalCostOfWarrantsExtension>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1559">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;1&lt;/strong&gt;&lt;strong&gt;2&lt;/strong&gt;&lt;strong&gt;.&lt;/strong&gt; &lt;strong&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Exercise of Warrants&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;During the year ended September 30, 2024, 5,680,000 pre-funded warrants were exercised. During the year ended September 30, 2023, the Company received proceeds of approximately $0.4 million from the exercise of warrants, as detailed in Note 4. Upon exercise, 217,752 shares of common stock were issued during the year ended September 30, 2023. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&lt;em&gt;Proceeds from the Sale of Common Stock&lt;/em&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On July 29, 2024, the Company sold 3,715,000 shares of common stock at an offering price of $1.00 per share, and pre-funded warrants to purchase up to 7,130,000 shares of common stock, at an offering price of $0.99 per pre-funded warrant, for proceeds of approximately $9.7 million, net of issuance costs of approximately $1.1 million. Holders of the pre-funded warrants have exercised 5,680,000 of the pre-funded warrants as of September 30, 2024. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company determined that the pre-funded warrants sold in the July 26, 2024 offering are freestanding financial instruments because they are both legally detachable and separately exercisable from the common stock sold in the offering. As such, the Company evaluated the pre-funded warrants to determine whether they represent instruments that require liability classification pursuant to the guidance in ASC 480. However, the Company concluded that the pre-funded warrants are not a liability within the scope of ASC 480 due to their characteristics. Further, the Company determined that the pre-funded warrants do not meet the definition of a derivative under ASC 815. Accordingly, the Company assessed the pre-funded warrants relative to the guidance in ASC No. 815-40, Contracts in Entity&#x2019;s Own Equity, to determine the appropriate treatment. The Company concluded that the pre-funded warrants are both indexed to its own stock and meet all other conditions for equity classification. Accordingly, the Company has classified the pre-funded warrants as permanent equity and recorded them as a component of additional paid-in capital upon the closing of the transaction in July 2024.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In February 2024, the Company sold 3,875,000 shares of common stock at a public offering price of $2.00 per share and received proceeds of approximately $7.0 million, net of issuance costs of approximately $0.7 million.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In November 2023, the Company sold 2,490,000 shares of common stock at a public offering price of $2.00 per share and received proceeds of approximately $4.5 million, net of issuance costs of approximately $0.5 million.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In April 2023, the Company sold 794,117 shares of common stock at a public offering price of $1.70 per share and received proceeds of approximately $1.4 million. The Company granted the underwriters a 30-day option to purchase up to 119,117 additional shares of common stock to cover over-allotments. The underwriter fully exercised this option in May 2023, resulting in additional proceeds to the Company of approximately $200,000. The Company incurred issuance costs of approximately $0.2 million related to this offering.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <cvm:EquityWarrantsExercised
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2390"
      unitRef="Shares">5680000</cvm:EquityWarrantsExercised>
    <cvm:ProceedFromIssuanceOrSaleOfEquity
      contextRef="From2022-10-01to2023-09-30"
      decimals="-5"
      id="fid_2388"
      unitRef="USD">400000</cvm:ProceedFromIssuanceOrSaleOfEquity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2389"
      unitRef="Shares">217752</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-07-29"
      decimals="0"
      id="fid_2386"
      unitRef="Shares">3715000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-07-29"
      decimals="INF"
      id="fid_2387"
      unitRef="USDPShares">1.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2425"
      unitRef="Shares">7130000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="fid_2406"
      unitRef="USDPShares">0.99</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-07-01to2024-07-29"
      decimals="-5"
      id="fid_2407"
      unitRef="USD">9700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cvm:NetIssuanceCosts
      contextRef="From2023-10-01to2024-09-30"
      decimals="-5"
      id="fid_2408"
      unitRef="USD">1100000</cvm:NetIssuanceCosts>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-02-29"
      decimals="0"
      id="fid_2391"
      unitRef="Shares">3875000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-02-29"
      decimals="INF"
      id="fid_2392"
      unitRef="USDPShares">2</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-02-01to2024-02-29"
      decimals="-6"
      id="fid_2393"
      unitRef="USD">7000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cvm:NetIssuanceCosts
      contextRef="From2024-02-01to2024-02-29"
      decimals="-5"
      id="fid_2394"
      unitRef="USD">700000</cvm:NetIssuanceCosts>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-11-30"
      decimals="0"
      id="fid_2395"
      unitRef="Shares">2490000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-11-30"
      decimals="INF"
      id="fid_2396"
      unitRef="USDPShares">2</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-11-01to2023-11-30"
      decimals="-5"
      id="fid_2397"
      unitRef="USD">4500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cvm:NetIssuanceCosts
      contextRef="From2023-11-01to2023-11-30"
      decimals="-5"
      id="fid_2398"
      unitRef="USD">500000</cvm:NetIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-10-01to2024-09-30_cvm_EquityProceedsFromSaleCommonStockMember"
      decimals="0"
      id="fid_2399"
      unitRef="Shares">794117</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2024-09-30_cvm_EquityProceedsFromSaleCommonStockMember"
      decimals="INF"
      id="fid_2400"
      unitRef="USDPShares">1.70</us-gaap:SaleOfStockPricePerShare>
    <cvm:ProceedFromIssuanceOrSaleOfEquity
      contextRef="From2023-10-01to2024-09-30_cvm_EquityProceedsFromSaleCommonStockMember"
      decimals="-5"
      id="fid_2401"
      unitRef="USD">1400000</cvm:ProceedFromIssuanceOrSaleOfEquity>
    <cvm:AdditionalPurchaseOfCommonStock
      contextRef="From2023-10-01to2024-09-30_cvm_EquityProceedsFromSaleCommonStockMember"
      decimals="0"
      id="fid_2402"
      unitRef="Shares">119117</cvm:AdditionalPurchaseOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-10-01to2024-09-30_cvm_EquityProceedsFromSaleCommonStockMember"
      decimals="0"
      id="fid_2403"
      unitRef="USD">200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cvm:IssuanceCostOfCommonStock
      contextRef="From2023-10-01to2024-09-30_cvm_EquityProceedsFromSaleCommonStockMember"
      decimals="-5"
      id="fid_2404"
      unitRef="USD">200000</cvm:IssuanceCostOfCommonStock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1560">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;1&lt;/strong&gt;&lt;strong&gt;3&lt;/strong&gt;&lt;strong&gt;. FAIR VALUE MEASUREMENTS&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In accordance with the provisions of ASC 820, &#x201c;Fair Value Measurements,&#x201d; the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#160; The Company generally applies the income approach to determine fair value.&#160; This method uses valuation techniques to convert future amounts to a single present amount.&#160; The measurement is based on the value indicated by current market expectations with respect to the future amounts.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value.&#160; The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).&#160; The Company classifies fair value balances based on the observability of those inputs.&#160; The three levels of the fair value hierarchy are as follows:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Level 1 &#x2013; Observable inputs such as quoted prices in active markets for identical assets or liabilities&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Level 2 &#x2013; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs other than quoted prices that are observable for the asset or liability are observable in active markets&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Level 3 &#x2013; Unobservable inputs that reflect management&#x2019;s assumptions&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160; &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement.&#160; The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company&#x2019;s money market funds included in cash equivalents are measured at fair value on a recurring basis. The following tables summarize the Company&#x2019;s fair value measurements and the level of inputs within the fair value hierarchy utilized to determine such fair value as of September 30:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="13" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;September 30, 2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Description&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Level&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Cost&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Fair Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Cash&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,258,173&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Money market funds included in cash and cash equivalents (Note 2)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3,480,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3,480,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Total cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;3,480,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;4,738,173&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td colspan="13" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;September 30, 2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Description&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Level&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Cost&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Fair Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"&gt;Cash&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,895,735&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"&gt;Money market funds included in cash and cash equivalents (Note 2)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2,250,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2,250,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Total cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,250,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;4,145,735&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1595">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="13" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;September 30, 2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Description&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Level&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Cost&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Fair Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Cash&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,258,173&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Money market funds included in cash and cash equivalents (Note 2)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3,480,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;3,480,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Total cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;3,480,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;4,738,173&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td colspan="13" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;September 30, 2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Description&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Level&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Cost&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&lt;strong&gt;Fair Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"&gt;Cash&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;-&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;1,895,735&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 15px; text-align:justify;"&gt;Money market funds included in cash and cash equivalents (Note 2)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2,250,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;2,250,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Total cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,250,000&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;4,145,735&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:Cash
      contextRef="AsOf2024-09-30_cvm_CostMember"
      decimals="0"
      id="fid_2439"
      unitRef="USD">0</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2024-09-30_cvm_FairValueMember"
      decimals="0"
      id="fid_2438"
      unitRef="USD">1258173</us-gaap:Cash>
    <cvm:MoneyMarketFundsIncludedInCashAndCashEquivalents
      contextRef="From2023-10-01to2024-09-30_cvm_CostMember"
      decimals="0"
      id="fid_1813"
      unitRef="USD">3480000</cvm:MoneyMarketFundsIncludedInCashAndCashEquivalents>
    <cvm:MoneyMarketFundsIncludedInCashAndCashEquivalents
      contextRef="From2023-10-01to2024-09-30_cvm_FairValueMember"
      decimals="0"
      id="fid_2443"
      unitRef="USD">3480000</cvm:MoneyMarketFundsIncludedInCashAndCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-09-30_cvm_CostMember"
      decimals="0"
      id="fid_2454"
      unitRef="USD">3480000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-09-30_cvm_FairValueMember"
      decimals="0"
      id="fid_2453"
      unitRef="USD">4738173</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Cash
      contextRef="AsOf2023-09-30_cvm_CostMember"
      decimals="0"
      id="fid_2444"
      unitRef="USD">0</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="AsOf2023-09-30_cvm_FairValueMember"
      decimals="0"
      id="fid_2442"
      unitRef="USD">1895735</us-gaap:Cash>
    <cvm:MoneyMarketFundsIncludedInCashAndCashEquivalents
      contextRef="From2022-10-01to2023-09-30_cvm_CostMember"
      decimals="0"
      id="fid_2445"
      unitRef="USD">2250000</cvm:MoneyMarketFundsIncludedInCashAndCashEquivalents>
    <cvm:MoneyMarketFundsIncludedInCashAndCashEquivalents
      contextRef="From2022-10-01to2023-09-30_cvm_FairValueMember"
      decimals="0"
      id="fid_2441"
      unitRef="USD">2250000</cvm:MoneyMarketFundsIncludedInCashAndCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-09-30_cvm_CostMember"
      decimals="0"
      id="fid_2451"
      unitRef="USD">2250000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-09-30_cvm_FairValueMember"
      decimals="0"
      id="fid_2452"
      unitRef="USD">4145735</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1561">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;1&lt;/strong&gt;&lt;strong&gt;4&lt;/strong&gt;&lt;strong&gt;. NET LOSS PER COMMON SHARE&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed using the treasury stock method. The Company&#x2019;s potentially dilutive shares, which include outstanding common stock options, common stock warrants and restricted stock&#160;are not included in the computation of diluted net loss per share&#160;if their effect&#160;would be anti-dilutive.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The calculation of basis and diluted net loss per share includes 1,450,000 of the pre-funded warrants that remain outstanding as of September 30, 2024.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The following table provides a reconciliation of the numerators and denominators of the basic and diluted per-share computations: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Year ended September 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Loss per share &#x2013; basic and diluted&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net loss available to common shareholders &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(27,579,921&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(32,365,855&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Weighted average shares outstanding &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;54,044,989&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;44,479,865&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Basic and diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.51&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.73&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;In accordance with the contingently issuable shares guidance of ASC 260, &lt;em&gt;Earnings Per Share&lt;/em&gt;, the calculation of diluted net loss per share excludes the following dilutive securities because their inclusion would have been anti-dilutive as of September 30: &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options and warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,350,550&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,850,028&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;147,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;147,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;17,497,800&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;15,997,278&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <cvm:WarrantsUsedForCalculationOfEarningPerShare
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2351"
      unitRef="Shares">1450000</cvm:WarrantsUsedForCalculationOfEarningPerShare>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1596">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Year ended September 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Loss per share &#x2013; basic and diluted&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" colspan="2" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Net loss available to common shareholders &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(27,579,921&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;(32,365,855&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Weighted average shares outstanding &#x2013; basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;54,044,989&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;44,479,865&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Basic and diluted loss per common share&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.51&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;$&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;(0.73&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2049"
      unitRef="USD">-27579921</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2048"
      unitRef="USD">-32365855</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2051"
      unitRef="Shares">54044989</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2050"
      unitRef="Shares">44479865</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-10-01to2024-09-30"
      decimals="INF"
      id="fid_2053"
      unitRef="USDPShares">-0.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-10-01to2023-09-30"
      decimals="INF"
      id="fid_2052"
      unitRef="USDPShares">-0.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1597">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Options and warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;17,350,550&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;15,850,028&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Unvested restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;147,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;147,250&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;17,497,800&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;15,997,278&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-10-01to2024-09-30_cvm_OptionsMember"
      decimals="0"
      id="fid_2054"
      unitRef="Shares">17350550</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-10-01to2023-09-30_cvm_OptionsMember"
      decimals="0"
      id="fid_2055"
      unitRef="Shares">15850028</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-10-01to2024-09-30_cvm_UnvestedRestrictedStockMember"
      decimals="0"
      id="fid_2056"
      unitRef="Shares">147250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-10-01to2023-09-30_cvm_UnvestedRestrictedStockMember"
      decimals="0"
      id="fid_2057"
      unitRef="Shares">147250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-10-01to2024-09-30"
      decimals="0"
      id="fid_2059"
      unitRef="Shares">17497800</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-10-01to2023-09-30"
      decimals="0"
      id="fid_2058"
      unitRef="Shares">15997278</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-10-01to2024-09-30" id="fid_1562">&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;15.&#160; SUBSEQUENT EVENTS &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On October 18, 2024, the Company entered into a Securities Purchase Agreement with Ergomed Group Limited pursuant to which the Company issued 1 million shares of common stock in exchange for services. &lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On December 31, 2024, the Company sold&#160;7,552,500&#160;shares of common stock at an offering price of $0.31&#160;per share, and pre-funded warrants to purchase up to&#160;8,577,500&#160;shares of common stock, at an offering price of $0.3099&#160;per pre-funded warrant, for gross proceeds of approximately $5&#160;million.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-10-01to2024-10-18_us-gaap_SubsequentEventMember_cvm_ErgomedGroupMember"
      decimals="-6"
      id="fid_2437"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2024-12-01to2024-12-31_us-gaap_SubsequentEventMember"
      decimals="0"
      id="fid_2428"
      unitRef="Shares">7552500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="fid_2426"
      unitRef="USDPShares">0.31</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cvm:WarrantsToPurchaseCommonStock
      contextRef="From2024-12-01to2024-12-31_us-gaap_SubsequentEventMember"
      decimals="0"
      id="fid_2433"
      unitRef="Shares">8577500</cvm:WarrantsToPurchaseCommonStock>
    <cvm:WarrantsOfferingPrice
      contextRef="AsOf2024-12-31_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="fid_2427"
      unitRef="USDPShares">0.3099</cvm:WarrantsOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-12-01to2024-12-31_us-gaap_SubsequentEventMember"
      decimals="-6"
      id="fid_2432"
      unitRef="USD">5000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
